Display Name,UNII,Status,Record Protection Status,Expr1004,Generic Name,Date Designated,Orphan Designation,Orphan Designation Status,FDA Orphan Approval Status,Approved Labeled Indication,Marketing Approval Date,Exclusivity End Date,Exclusivity Protected Indication * (Shown for approvals from Jan,Sponsor Company,Sponsor Address 1,Sponsor Address 2,Sponsor City,Sponsor State,Sponsor Zip,Sponsor Country,CF Grid Key
STP-705,ZT3VR2T6GY,Designated,Public record,4358,Cotsiranib,6/15/2017,Treatment of primary sclerosing cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Sirnaomics, Inc.",401 Professional Drive,Suite 280,Gaithersburg,Maryland,20879,United States,580717
STP-705,ZT3VR2T6GY,Designated,Public record,4621,cotsiranib,11/29/2017,Treatment of cholangiocarcinoma (CCA),Designated,Not FDA Approved for Orphan Indication,,,,,"Sirnaomics, Inc.",401 Professional Drive,Suite 280,Gaithersburg,Maryland,20879,United States,614817
"""2-OXYGEN, 3-OXYGEN DESULFATED HEPARIN""",,Designated,Public record,4639,"2-O, 3-O, desulfated heparin",12/21/2017,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Chimerix, Inc.",2505 Meridian Park,Suite 100,Durham,North Carolina,27713,United States,477815
NPT520-34,L05II461IJ,Designated,Public record,5197,"4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione",8/8/2019,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuropore Therapies, Inc.","10835 Road to the Cure, Suite 230",,San Diego,California,92121,United States,704119
CTCE-9908 HEXA-ACETATE,AQH30RK500,Designated,Public record,5244,"L-Lysinamide,N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-hexa-acetate salt",9/18/2019,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,TCM Biotech International Corp.,"24F-8, No. 97","Sec. 1, Xintai 5th Rd., Xizhi Dist.",New Taipei City,Taiwan,,Taiwan,703719
Linafexor,US5Q3KD5RD,Designated,Public record,6068,"3-(4-((3-endo)-3-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-2-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one",9/13/2021,Treatment of Primary Sclerosing Cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Cascade Pharmaceuticals, Inc","Building No. 6, Lane 908, Ziping Road,",Pudong New District,Shanghai,,201321,China,836821
HANFERON,G934HY6WHU,Designated,Public record,2667,Hanferon,3/9/2012,Treatment of Behcet's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"HanAll BioPharma Co., Ltd.",Jamsil I-Space Building 6F,138 420,Seoul,,,South Korea,362911
AEM-28,V9526P2UXZ,Designated,Public record,2824,apolipoprotein E mimetic peptide,12/3/2012,Treatment of homozygous familial hypercholesterolemia,Designated,Not FDA Approved for Orphan Indication,,,,,"LipimetiX Development, LLC",5 Commonwealth Road,Suite 2A,Natick,Massachusetts,1760,United States,381712
INN-108 DISODIUM,QS757J8N0F,Designated,Public record,4506,5-(4-carboxymethyl-phenylazo)-2-hydroxybenzoic acid disodium salt,8/31/2017,Treatment of pediatric ulcerative colitis (UC),Designated,Not FDA Approved for Orphan Indication,,,,,"9 Meters Biopharma, Inc.",8480 Honeycutt Road,Suite 120,Raleigh,North Carolina,27615,United States,599917
JTT-251 MONOHYDRATE,0AQV15PQ6M,Designated,Public record,4669,2-{4-[(9R)-9-Hydroxy-2-(3-hydroxy-3-methylbutyloxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl}-2-methylpropanamide monohydrate,1/23/2018,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Akros Pharma Inc.,302 Carnegie Center,Suite 300,Princeton,New Jersey,8540,United States,620017
VMD-928,1JT6DVS51P,Designated,Public record,4762,"4-{[4-Amino-3-(4-cyclohexylpiperazin-1-yl)-9,10-dioxo-9,10-dihydroanthracen-1-yl]amino}benzoic acid",4/11/2018,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"VM Oncology, LLC",45535 Northport Loop East,,Fremont,California,94538,United States,633518
HEC-68498 SODIUM,8PL809KPW4,Designated,Public record,4886,"soidum (5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)((2,4-difluorophenyl)sulfonyl)amide",7/9/2018,Treatment of idiopathic pulmonary fibrosis (IPF),Designated,Not FDA Approved for Orphan Indication,,,,,"Sunshine Lake Pharma Co., Ltd",Northern Industry Road #1,Song Shan Lake,Dongguan,Guangdong,,China,642518
MG-S-2525,I45A327R6A,Designated,Public record,4974,"5-(3,5-Dimethyl-4-hydroxybenzylamino)-3-(4-morpholin-4-yl-phenylamino)-1H-pyrazole-4-carboxylic acid amide",12/7/2018,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Metagone Biotech Inc.,"3F., No. 11, Ln. 77, Xing-Ai Rd",Neihu Dist,Taipei,,,Taiwan,644218
X-165,G24JS5Y1KL,Designated,Public record,5168,"(R)-N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4,5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide",7/18/2019,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"X-Rx, Inc.",100 Beaver Street,,Waltham,Massachusetts,2453,United States,693119
WSD-0922-FU,TTT6PCQ53K,Designated,Public record,5182,"(R)-6-((3,3-difluoro-1-methylpiperidine-4-yl)oxy-N-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine-,fumerate (2:1) (salt)",7/24/2019,Treatment of glioma (including glioblastoma and anaplastic astrocytoma),Designated,Not FDA Approved for Orphan Indication,,,,,Wayshine Biopharm Inc.,"957 Ferndale Dr,",,Corona,California,92881,United States,695019
RZL-012,M8BBT7ORRM,Designated,Public record,5294,"5-(3,6-dibromo-9H-carbazol-9-yl)-N,N,N-trimethylpentan-1-aminium chloride",11/21/2019,Treatment of Dercum’s disease (adiposis dolorosa),Designated,Not FDA Approved for Orphan Indication,,,,,"Raziel Therapeutics, Inc.","High-Tech Village, Givat Ram Campus",Hebrew University,Jerusalem,,,Israel,688219
HEMOPEXIN (HUMAN),5H7PB76DFY,Designated,Public record,5674,Hemopexin (Human),9/23/2020,Treatment of Sickle Cell Disease,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,768120
.ALPHA.1-PROTEINASE INHIBITOR HUMAN RECOMBINANT (MAMMALIAN),Q34EXF8ZZT,Designated,Public record,5718,CHO cell line produced human alpha-1 antitrypsin (CHO-AAT) protein,10/19/2020,treatment of alpha-1 antitrypsin deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Caravella Biopharma SA,Route de l’Ile-aux-Bois 1A,,Monthey,,1870,Switzerland,773920
GENTULIZUMAB,PS8L3VP5HJ,Designated,PUBLIC RECORD,6141,Gentulizumab,10/12/2021,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Changchun GeneScience Pharmaceutical Co., Ltd.",No. 1718 Yueda Road,Changchun High-Tech Dev. Zone,Changchun City,Jilin Province,130012,China,841321
MBS-2320,38E2HYD3AW,Designated,Public record,6418,4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulfonamide,8/15/2022,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Modern Biosciences Ltd,"2nd Floor, 3 Pancras Square",,London,Greater London,,United Kingdom,894922
ASP-8731 PHOSPHATE,ZTQ38HN3AA,Designated,PUBLIC RECORD,6434,"2-[(1,3-Benzoxazol-2-yl)amino]-N-[2-(2-hydroxyethoxy)ethyl]-1-methyl-1H-benzimidazole-5- carboxamide monophosphate",9/1/2022,Treatment of Sickle Cell Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,897122
CN-105,W525NLS74J,Designated,Public record,3447,pentapeptide with sequence Ac-VSRRR-NH2,1/13/2015,Treatment of intracerebral hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,"AegisCN, LLKC",3105 Cone Manor Lane,Suite B,Raleigh,North Carolina,27613,United States,449014
AUT-00206,46P8AHZ243,Designated,Public record,4341,"5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione",6/12/2017,Treatment of fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Autifony Therapeutics Limited,Gunnels Wood Road,Stevenage,,England,,United Kingdom,579217
BHV-5000 FUMARATE,6P4560AP4D,Designated,Public record,4395,[(S)-1-(L-valyl)-N_((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate],6/22/2017,Treatment of Rett Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceutical Holding Company, Ltd.",215 Church Street,,New Haven,Connecticut,6511,United States,582217
NMD-670,U7PP8PY4XB,Designated,Public record,6446,bromophenoxyazole propanoic acid,9/12/2022,Treatment of Myasthenia Gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"NMD Pharma, INCUBA",Palle Juul-Jensens Boulevard 82,,Aarhus,Midtjylland,8200,Denmark,859421
WSD-0628,KTC2HLR3RE,Designated,Public record,6607,"(R)-1-(3,3-difluoro-1-methlypiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one",2/7/2023,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Wayshine Biopharm, INC","957 Ferndale Dr,",,Corona,California,92881,United States,924022
BARASERTIB TRIHYDRATE,WM1NC31680,Designated,Public record,2226,2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate,1/19/2010,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,298509
CENEGERMIN,B6E7K36KT8,Designated,Public record,2982,recombinant human nerve growth factor,8/8/2013,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,Dompe S.p.A.,Via S. Martino 12-12/A,,Milan,,,Italy,402013
CENEGERMIN,B6E7K36KT8,Designated,Public record,3293,cenegermin-bkbj,6/23/2014,Treatment of neurotrophic keratitis,Designated/Approved,,Treatment of neurotrophic keratitis,8/22/2018,8/22/2025,Treatment of neurotrophic keratitis,Dompe S.p.A.,Via S. Martino 12-12/A,,Milan,,,Italy,436214
OMBURTAMAB I-124,D42C24MT3J,Designated,Public record,4034,131-I-8H9 monoclonal antibody,8/29/2016,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Y-mAbs Therapeutics, Inc.",750 3rd Avenue,9th Floor,New York,New York,10017,United States,535716
GANAPLACIDE DIPHOSPHATE,R3ZA37PM4S,Designated,Public record,4302,"2-amino-1-[2-(4-fluoro-phenyl)-3-(4-fluoro-phenyl)amino)-8,8-dimethyl-5,6-dihydro-imidazo[1,2-a]pyrazin-7(8H)-yl)-ethanone diphosphate",5/11/2017,Treatment of malaria.,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,1 Health Plaza,,East Hanover,New Jersey,7936,United States,568216
N-{2-[4-(2-Amino-5-chloropyridin-3-yl)phenoxy]pyrimidin-5-yl}-N'-[2-(methanesulfonyl)-5-(trifluoromethyl)phenyl]urea mono-4-toluenesulfonate,1C01KML96K,Designated,Public record,4525,N-{2-[4-(2-Amino-5-chloropyridin-3-yl)phenoxy]pyrimidin-5-yl}-N'-[2-(methanesulfonyl)-5-(trifluoromethyl)phenyl]urea mono-4-toluenesulfonate,9/13/2017,Treatment of tropomyosin receptor kinase (Trk) gene fusion-positive cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Ono Pharmaceuticals Co. Ltd.,"8-2, Kyutaromachi l-chome",,Chuo-ku,Osaka-fu,,Japan,599717
AC-225-4-PHENYLBUTYRYL-HIS-D-PHE-ARG-TRP-GLY-LYS(EAHX-DOTA)-NH2,KUM3LNY4CP,Designated,Public record,5052,Ac-225-4-PHenylbutyryl-His-D-Phe-Arg-Trp-Gly-Lys(eAhx-DOTA)-NH2,2/28/2019,Treatment of Uveal Melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,Modulation Therapeutics Incorporated,1 Medical Center Drive,MBRCC room 1817,Morgantown,West Virginia,26506,United States,675618
PL-8177,16134B0YTH,Designated,Public record,5127,Ac-Nle-cyclo-(Glu-His-D-Phe-Arg-Dap)-Trp-NH2,6/3/2019,"Treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis",Designated,Not FDA Approved for Orphan Indication,,,,,"Palatin Technologies, Inc.",4b Cedarbrook Drive,,Cranbury Township,New Jersey,8512,United States,670418
IPL-344 ACETATE,RA35FQ7AJE,Designated,Public record,5147,"L-Leucyl-L-prolyl-L-prolyl-L-leucyl-L-prolyl-L-tyrosyl-L-proline, acetate salt",6/19/2019,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunity Pharma, Ltd.","6 Rabbi Binyamin st,",,Jerusalem,,,Israel,689819
FN-1501 DIMALEATE SESQUIHYDRATE,EVI82EH5FG,Designated,Public record,5300,"4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4- methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide, (2Z)-2-butenedioate (1:2), Sesquihydrate",11/26/2019,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Shanghai Fosun Pharmaceutical Development Co., Ltd.",16 Esquire Rd (Breas),,Billerica,Massachusetts,1862,United States,713619
Crozbaciclib fumarate,EA0UN3NLN3,Designated,Public record,5637,"5-fluoro-4-(7''-fluoro-2''-methylspiro[cyclopentane-1,3''-indol]-5''-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine fumarate",9/8/2020,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Gan & Lee Pharmaceuticals USA Corporation,520 US Highway 22 East,Suite 302,Bridgewater,New Jersey,8807,United States,760620
TRE-515,8EK0RD3M21,Designated,Public record,5818,"(R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy) phenyl)-5-methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine",1/7/2021,Treatment of acute disseminated encephalomyelitis,Designated,Not FDA Approved for Orphan Indication,,,,,Trethera Corporation,"13547 Ventura Boulevard, Suite 363",,Sherman Oaks,California,91423,United States,792220
TRE-515,8EK0RD3M21,Designated,Public record,6084,"(R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy) phenyl)-5-methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine",11/9/2021,Treatment of Optic Neuritis,Designated,Not FDA Approved for Orphan Indication,,,,,Trethera Corporation,"13547 Ventura Boulevard, Suite 363",,Sherman Oaks,California,91423,United States,845721
CB-103 HYDROCHLORIDE,37VB9K7MPR,Designated,Public record,6232,6-(4-(tert-butyl)phenoxy)pyridin-3-amine hydrochloride,2/23/2022,Treatment of acute lymphoblastic leukemia (ALL),Designated,Not FDA Approved for Orphan Indication,,,,,Cellestia Biotech AG,Hochbergerstrasse 60C,,Basel,Basel-Stadt,4057,Switzerland,862821
Arginyl-Glutamine Dipeptide,H694N9A9AP,Designated,Public record,6453,Arginyl-Glutamine Dipeptide,9/20/2022,Prevention of Retinopathy of Prematurity,Designated,Not FDA Approved for Orphan Indication,,,,,Infant Bacterial Therapeutics AB,Bryggargatan 10,,Sweden,Stockholm,,Sweden,899822
SPH-4336,9X8U786V5T,Designated,Public record,6650,"N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo[d]imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine maleate",3/21/2023,Treatment of Liposarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Shanghai Pharma Biotherapeutics USA Inc.,"3545 John Hopkins Ct., Ste 160",,San Diego,California,92121,United States,930522
"(R)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a] pyrimidin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)benzamide sulfate hydrate",X2KR249RXD,Designated,Public record,6708,"(R)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a] pyrimidin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)benzamide sulfate hydrate",5/17/2023,Treatment of NTRK fusion-positive solid tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Teligene US LLC,2060 D Avenida De Los Arboles 636,,Thousand Oaks,California,91362,United States,938623
DIAZIQUONE,FQL5EUP13W,Designated/Withdrawn,Public record,1,Diaziquone,11/10/1983,Treatment of primary brain malignancies (grade III and IV astrocytomas).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,"2800 Plymouth Rd., P.O. Box 1047",,Ann Arbor,Michigan,48106,United States,383
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated/Withdrawn,Public record,2,Alpha-1-antitrypsin (recombinant DNA Origin),1/1/1984,As supplementation therapy for alpha-1-antitrypsin deficiency in the ZZ phenotype population.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation,4560 Horton Street,,Emeryville,California,94608,United States,283
ALTRETAMINE,Q8BIH59O7H,Designated/Approved,Public record,3,Altretamine,2/9/1984,Treatment of advanced adenocarcinoma of the ovary.,Designated/Approved,,Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.,12/26/1990,12/26/1997,,"Medimmune Oncology, Inc.",One Tower Bridge,"100 Front Street, Suite 400",West Conshohocken,Pennsylvania,19428,United States,983
LEVOCARNITINE,0G389FZZ9M,Designated/Approved,Public record,4,Levocarnitine,2/28/1984,Treatment of genetic carnitine deficiency.,Designated/Approved,,,4/10/1986,4/10/1993,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,20878,United States,1384
PENTAMIDINE ISETHIONATE,V2P3K60DA2,Designated/Approved,Public record,5,Pentamidine isethionate,2/28/1984,Treatment of Pneumocystis carinii pneumonia.,Designated/Approved,,,10/16/1984,10/16/1991,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,60015,United States,1083
CROMOLYN SODIUM,Q2WXR1I0PK,Designated/Approved,Public record,6,Cromolyn sodium,3/8/1984,Treatment of mastocytosis.,Designated/Approved,,,12/22/1989,12/22/1996,,Fisons Corporation,"755 Jefferson Rd., P.O. Box 1710",,Rochester,New York,14603,United States,1183
Bacitracin,58H6RWO52I,Designated,Public record,7,Bacitracin,3/13/1984,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.",One Executive Drive,P.O. Box 1399,Fort Lee,New Jersey,7024,United States,1284
HEMIN,743LRP9S7N,Designated/Approved,Public record,8,Hemin,3/16/1984,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.",Designated/Approved,,,7/20/1983,7/20/1990,,Abbott Laboratories,Diagnostics Division,,Abbott Park,Illinois,60064,United States,683
BOTULINUM TOXIN TYPE A,E211KPY694,Designated/Approved,Public record,9,Botulinum toxin type A,3/22/1984,Treatment of strabismus and blepharospasms,Designated/Approved,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above),12/30/1989,12/30/1996,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,92713,United States,483
BOTULINUM TOXIN TYPE A,E211KPY694,Designated/Approved,Public record,10,Botulinum toxin type A,3/22/1984,Treatment of strabismus and blepharospasms,Designated/Approved,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above),12/29/1989,12/29/1996,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,92713,United States,483
ETHANOLAMINE OLEATE,U4RY8MRX7C,Designated/Approved,Public record,11,Ethanolamine oleate,3/22/1984,"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.",Designated/Approved,,,12/22/1988,12/22/1995,,QOL Medical,"4445 North Highway A1A, 241",,Vero Beach,Florida,32963,United States,1484
EPOPROSTENOL,DCR9Z582X0,Designated/Withdrawn,Public record,12,Epoprostenol,3/29/1984,Replacement of heparin in patients requiring hemodialysis and who are at risk of hemmorrage,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,783
SUCCIMER,DX1U2629QE,Designated/Approved,Public record,13,Succimer,5/9/1984,Treatment of lead poisoning in children.,Designated/Approved,,,1/30/1991,1/30/1998,,Bock Pharmacal Company,P.O. Box 419056,,Saint Louis,Missouri,63141,United States,1984
PEGADEMASE BOVINE,HW3H7D91F6,Designated/Approved,Public record,14,Pegademase bovine,5/29/1984,For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.,Designated/Approved,,,3/21/1990,3/21/1997,,"Sigma-tau Pharmaceuticals, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,20878,United States,2084
MONOCTANOIN,VFU0OU98LO,Designated/Approved,Public record,15,Monooctanoin,5/30/1984,For dissolution of cholesterol gallstones retained in the common bile duct.,Designated/Approved,,,10/31/1985,10/31/1992,,"Ethitek Pharmaceuticals, Inc.","7855 Gross Point Road, Unit L",,Skokie,Illinois,60077,United States,2484
CLOFAZIMINE,D959AE5USF,Designated/Approved,Public record,16,Clofazimine,6/11/1984,"Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.",Designated/Approved,,,12/15/1986,12/15/1993,,Novartis Pharmaceutical Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,2684
VILOXAZINE HYDROCHLORIDE,OQW30I1332,Designated/Withdrawn,Public record,17,viloxazine HCL,6/11/1984,Treatment of cataplexy and narcolepsy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Stuart Pharmaceuticals,Division of ICI Americas,,Wilmington,Delaware,19897,United States,2384
LEVOCARNITINE,0G389FZZ9M,Designated/Approved,Public record,18,Levocarnitine,7/26/1984,Treatment of primary and secondary carnitine deficiency of genetic origin.,Designated/Approved,,Treatment of primary systemic carnitine deficiency. (approved 12/27/85) Treatment of secondary carnitine deficiency. (approved 12/16/92),12/16/1992,12/16/1999,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,20878,United States,1584
NORCHOLESTENOL IODOMETHYL I-131,HFE9M7UF0L,Designated,Public record,19,Iodine 131 6B-iodomethyl-19-norcholesterol,8/1/1984,For use in adrenal cortical imaging.,Designated,Not FDA Approved for Orphan Indication,,,,,"David E. Kuhl, M.D.",University of Michigan Medical Center/1500 E. Med.,B1G412 /0028 University Hospital,Ann Arbor,Michigan,48109,United States,2184
CHENODIOL,0GEI24LG0J,Designated/Approved,Public record,20,chenodiol,9/21/1984,"For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age",Designated/Approved,,,7/28/1983,7/28/1990,,Solvay,901 Sawyer Road,,Marietta,Georgia,30062,United States,3384
QUINACRINE HYDROCHLORIDE,G6242H2NAA,Designated/Withdrawn,Public record,21,Quinacrine hydrochloride,10/17/1984,For prevention of recurrence of pneumothorax in patients at high risk of recurrence.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Lyphomed, Inc.",,,,,,,4184
SPIRAMYCIN,71ODY0V87H,Designated/Withdrawn,Public record,22,Spiramycin,10/17/1984,For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Rhone-Poulenc Rorer Pharmaceuticals,500 Arcola Road,,Collegeville,Pennsylvania,19426,United States,3684
Cyproterone Acetate,4KM2BN5JHF,Designated/Withdrawn,Public record,23,Cyproterone acetate,10/26/1984,Treatment of severe hirsutism.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",300 Fairfield Road,,Wayne,New Jersey,7470,United States,3884
EPOPROSTENOL,DCR9Z582X0,Designated/Withdrawn,Public record,24,Epoprostenol,10/29/1984,Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Upjohn Company,301 Henrietta Street,,Kalamazoo,Michigan,49001,United States,2884
PENTAMIDINE ISETHIONATE,V2P3K60DA2,Designated,Public record,25,Pentamidine isethionate,10/29/1984,Treatment of Pneumocystis carinii pneumonia.,Designated,Not FDA Approved for Orphan Indication,,,,,Aventis Behring L.L.C.,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,3784
OVINE DIGOXIN IMMUNE FAB,YB12NQZ1YN,Designated/Approved,Public record,26,Digoxin immune FAB (Ovine),11/1/1984,Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.,Designated/Approved,,,4/22/1986,4/22/1993,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,2584
DIGOXIN IMMUNE FAB (OVINE),,Designated/Approved,Public record,26,Digoxin immune FAB (Ovine),11/1/1984,Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.,Designated/Approved,,,4/22/1986,4/22/1993,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,2584
OXITRIPTAN,C1LJO185Q9,Designated,Public record,27,L-5 Hydroxytrytophan,11/1/1984,Treatment of postanoxic intention myoclonus.,Designated,Not FDA Approved for Orphan Indication,,,,,"Watson Laboratories, Inc.",33 Ralph Avenue,P.O. Box 30,Copiaque,New York,11726,United States,3984
POTASSIUM CITRATE,EE90ONI6FF,Designated/Approved,Public record,28,Potassium citrate,11/1/1984,Prevention of uric acid nephrolithiasis.,Designated/Approved,,,8/30/1985,8/30/1992,,University of Texas Health Science Center at Dallas,5323 Harry Hines Blvd,,Dallas,Texas,75235,United States,2784
POTASSIUM CITRATE,EE90ONI6FF,Designated/Approved,Public record,29,Potassium citrate,11/1/1984,1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.,Designated/Approved,,Prevention of recurring calcium conating stines associated with a deficiency in the urine.,8/7/1985,8/7/1992,,University of Texas Health Science Center at Dallas,5323 Harry Hines Blvd,,Dallas,Texas,75235,United States,9685
TENIPOSIDE,957E6438QA,Designated/Approved,Public record,30,Teniposide,11/1/1984,Treatment of refractory childhood acute lymphocytic leukemia.,Designated/Approved,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.,7/14/1992,7/14/1999,,Bristol-Myers Squibb Pharmaceutical Research Institute,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,6492,United States,883
NEPIDERMIN,TZK30RF92W,Designated,Public record,31,Urogastrone,11/1/1984,For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.,Designated,Not FDA Approved for Orphan Indication,,,,,Chiron Vision,500 Iolab Drive,,Claremont,California,91711,United States,1684
SELEGILINE HYDROCHLORIDE,6W731X367Q,Designated/Approved,Public record,32,Selegiline HCl,11/7/1984,"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.",Designated/Approved,,,6/5/1989,6/5/1996,,"Somerset Pharmaceuticals, Inc.","400 Morris Ave., Suite 7s",,Denville,New Jersey,7834,United States,583
IOBENGUANE SULFATE I-131,M575VKV19N,Designated/Approved/Withdrawn,Public record,35,Iobenguane Sulfate I 131,11/14/1984,For use as a diagnostic adjunct in patients with pheochromocytoma.,Designated/Approved/Withdrawn,,Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas.,3/25/1994,3/25/2001,,University of Michigan,UH B1 H410/0028,1500 E. Medical Center Drive,Ann Arbor,Michigan,48109,United States,2284
ANTITHROMBIN III HUMAN,T0LTO7L82X,Designated/Approved,Public record,36,Antithrombin III (human),11/26/1984,For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.,Designated/Approved,,,12/30/1991,12/30/1998,,Bayer Corporation,"Pharmaceutical Division, Biological Products",400 Morgan Lane,New Haven,Connecticut,6516,United States,4084
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated/Approved,Public record,37,Alpha1-proteinase inhibitor (human),12/7/1984,For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.,Designated/Approved,,For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.,12/2/1987,12/2/1994,,Bayer Corporation,"Pharmaceutical Division, Biological Products",400 Morgan Lane,New Haven,Connecticut,6516,United States,3084
AMSACRINE,00DPD30SOY,Designated/Withdrawn,Public record,38,Amsacrine,12/7/1984,Treatment of acute adult leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,2800 Plymouth Road,,Ann Arbor,Michigan,48106,United States,4584
TRIENTINE HYDROCHLORIDE,HC3NX54582,Designated/Approved,Public record,40,Trientine HCl,12/24/1984,"Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine.",Designated/Approved,,,11/8/1985,11/8/1992,,Merck Sharp & Dohme Research,Division Of Merck And Company,,West Point,Pennsylvania,19486,United States,4884
PROTIRELIN,5Y5F15120W,Designated/Withdrawn,Public record,41,Protirelin injection,1/10/1985,Treatment of amyotrophic lateral sclerosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Abbott Laboratories,200 Abbott Park Road,,Abbott Park,Illinois,,United States,5184
FLUMECINOL,JB0YA8LDOW,Designated/Withdrawn,Public record,42,Flumecinol,1/15/1985,Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Farmacon, Inc.","Post House, Suite 213",1720 Post Road East,Westport,Connecticut,6880,United States,2984
FACTOR XIII CONCENTRATE (HUMAN),F7R0FBC1XD,Designated/Approved,Public record,43,factor XIII concentrate (human),1/16/1985,Treatment of congenital factor XIII deficiency,Designated/Approved,,Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.,1/24/2013,1/24/2020,Peri-operative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.,CSL Behring LLC,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,4484
FACTOR XIII CONCENTRATE (HUMAN),F7R0FBC1XD,Designated/Approved,Public record,44,factor XIII concentrate (human),1/16/1985,Treatment of congenital factor XIII deficiency,Designated/Approved,,For the routine prophylactic treatment of congenital factor XIII deficiency,2/17/2011,2/17/2018,,CSL Behring LLC,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,4484
PHYSOSTIGMINE SALICYLATE,2046ZRO9VU,Designated/Withdrawn,Public record,45,physostigmine salicylatephysostigmine salicylate,1/16/1985,Treatment of Friedreich's and other inherited ataxias.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Forest Pharmaceuticals.3-.3-.30 6,150 East 58th Street,,New York,New York,10155,United States,183
OXYBATE,30IW36W5B2,Designated/Withdrawn,Public record,46,Gamma-hydroxybutyric acid,1/22/1985,"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sigma Chemical Company,,,,,,,5384
LEVOMETHADYL ACETATE HYDROCHLORIDE,B54CW5KG52,Designated/Approved,Public record,47,Levomethadyl acetate hydrochloride,1/24/1985,Treatment of heroin addicts suitable for maintenance on opiate agonists.,Designated/Approved,,For the management of opiate dependence.,7/9/1993,7/9/2000,,Biodevelopment Corporation,"8180 Greensboro Drive, Suite 1000",,McLean,Virginia,22102,United States,4784
ASPARAGINASE ERWINIA CHRYSANTHEMI,D733ET3F9O,Designated/Withdrawn,Public record,48,Erwinia L-asparaginase,1/25/1985,For use as an alternative to E. coli asparaginase in those situations where repeat courses of asparaginase therapy for acute lymphoblastic leukemia are required or where allergic reactions force the discontinuance of the E. coli preparation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Lyphomed, Inc.",,,,,,,4684
ANTITHROMBIN III HUMAN,T0LTO7L82X,Designated/Approved,Public record,49,Antithrombin III (human),2/8/1985,For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.,Designated/Approved,,,12/13/1989,12/13/1996,,Pharmacia & Upjohn AB,Lindhagensgatan 133,,Stockholm,,,Sweden,5084
ANTIPYRINE,T3CHA1B51H,Designated/Withdrawn,Public record,50,Antipyrine Test,2/21/1985,For use as an index of hepatic drug-metabolizing capacity.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Upsher-Smith Laboratories, Inc",4905 23rd Avenue North,,Minneapolis,Minnesota,55447,United States,5284
NEPIDERMIN,TZK30RF92W,Designated/Withdrawn,Public record,51,Epidermal growth factor (human),3/6/1985,For promotion of cutaneous wound healing in extreme burn treatment protocols.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Ethicon, Inc.",P.O. Box 151,,Somerville,New Jersey,8876,United States,5485
LEDISMASE,0786H5RV0T,Designated,Public record,52,Superoxide dismutase (human),3/6/1985,"For protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.",Designated,Not FDA Approved for Orphan Indication,,,,,Pharmacia-Chiron Partnership,4560 Horton Street,,Emeryville,California,94608,United States,5985
ALGLUCERASE,27T56C7KK0,Designated/Approved,Public record,53,Alglucerase injection,3/11/1985,For replacement therapy in patients with Gaucher's disease type I.,Designated/Approved,,"Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions: a) moderate-",4/5/1991,4/5/1998,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,5585
OVINE DIGOXIN IMMUNE FAB,YB12NQZ1YN,Designated,Public record,54,Digoxin immune fab(ovine),3/11/1985,"Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.",Designated,Not FDA Approved for Orphan Indication,,,,,Boehringer Mannheim Corp.,1301 Piccard Drive,,Rockville,Maryland,20850,United States,5685
NALTREXONE HYDROCHLORIDE,Z6375YW9SF,Designated/Approved,Public record,55,Naltrexone HCl,3/11/1985,For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.,Designated/Approved,,,11/30/1984,11/30/1991,,DuPont Pharmaceuticals,E.I. Du Pont De Nemours & Co.,,Wilmington,Delaware,19880,United States,6085
OXYMORPHONE,9VXA968E0C,Designated,Public record,56,Oxymorphone,3/19/1985,For relief of severe intractable pain in narcotic-tolerant patients.,Designated,Not FDA Approved for Orphan Indication,,,,,DuPont Merck Pharmaceutical Company,P.O. Box 80027,,Wilmington,Delaware,19880,United States,6185
TRETINOIN,5688UTC01R,Designated,Public record,57,Tretinoin,4/15/1985,Treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hannan Ophthalmic Marketing Services, Inc",34 Sherrill Rd.,,Marshfield,Massachusetts,2050,United States,5785
CALFACTANT,Q4K217VGA9,Designated/Approved,Public record,58,calfactant,6/7/1985,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,Designated/Approved,,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,7/1/1998,,,ONY Biotech Inc.,1576 Sweet Home Road,,Amherst,New York,14228,United States,6285
GANCICLOVIR,P9G3CKZ4P5,Designated/Withdrawn,Public record,59,Gancyclovir,6/7/1985,Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,P.O. Box 12700,Research Triangle Park,North Carolina,27709,United States,5885
ANAGRELIDE,K9X45X0051,Designated,Public record,60,Anagrelide,6/11/1985,Treatment of polycythemia vera.,Designated,Not FDA Approved for Orphan Indication,,,,,Roberts Pharmaceutical Corp.,Meridian Center II,Four Industrial Way West,Eatontown,New Jersey,7724,United States,6985
PREDNIMUSTINE,9403SIO2S8,Designated/Withdrawn,Public record,61,Prednimustine,6/17/1985,Treatment of malignant non-Hodgkin's lymphomas.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmacia Inc.,P.O. Box 16529,,Columbus,Ohio,43216,United States,6685
MIDODRINE HYDROCHLORIDE,59JV96YTXV,Designated/Approved,Public record,62,Midodrine HCl,6/21/1985,Treatment of patients with symptomatic orthostatic hypotension.,Designated/Approved,,Treatment of symptomatic orthostatic hypotension.,9/6/1996,9/6/2003,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,7585
ANTITHROMBIN III HUMAN,T0LTO7L82X,Designated/Withdrawn,Public record,63,Antithrombin III (human) concentrate IV,7/2/1985,For prophylaxis and treatment of thromboembolic episodes in patients with genetic AT-III deficiency.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,7185
DEFIBROTIDE SODIUM,L7CHH2B2J0,Designated,Public record,64,Defibrotide,7/5/1985,Treatment of thrombotic thrombocytopenic purpura.,Designated,Not FDA Approved for Orphan Indication,,,,,Crinos International,Via Belvedere 1,,"Villa Guardia, Italy",,22079,United States,7285
HPA-23,J08H62IZC9,Designated/Withdrawn,Public record,65,ammonium 21-tungsto-9-antimoniate,7/17/1985,Treatment of acquired immunodeficiency syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Rhone-Poulenc Rorer Pharm.,500 Arcola Road,,Collegeville,Pennsylvania,19426,United States,7785
ZIDOVUDINE,4B9XT59T7S,Designated/Approved,Public record,66,zidovudine,7/17/1985,Treatment of AIDS,Designated/Approved,,Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in t,3/19/1987,3/19/1994,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,8185
CROMOLYN SODIUM,Q2WXR1I0PK,Designated/Approved,Public record,67,Cromolyn sodium 4% ophthalmic solution,7/24/1985,Treatment of vernal keratoconjunctivitis.,Designated/Approved,,,10/3/1984,10/3/1991,,Fisons Corporation,755 Jefferson Rd.,P.O. Box 1710,Rochester,New York,14603,United States,8285
TRIMETREXATE GLUCURONATE,L137U4A79K,Designated/Withdrawn,Public record,68,Trimetrexate glucuronate,7/25/1985,Treatment of pancreatic adenocarcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medimmune Oncology, Inc.",One MedImmune Way,,Gaithersburg,Maryland,20878,United States,8385
IFOSFAMIDE,UM20QQM95Y,Designated,Public record,69,ifosfamide,8/7/1985,Treatment of soft tissue and bone sarcomas,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 4000,Mail Stop D12-02,Princeton,New Jersey,8543,United States,8585
PENTOSAN POLYSULFATE SODIUM,914032762Y,Designated/Approved,Public record,70,Pentosan polysulfate sodium,8/7/1985,Treatment of interstitial cystitis.,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis.,9/26/1996,9/26/2003,,Alza Corporation,950 Page Mill Rd.,PO Box 10950,Palo Alto,California,94303,United States,1784
PENTASTARCH,MOQ3RNM0SV,Designated/Approved,Public record,71,Pentastarch,8/28/1985,As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.,Designated/Approved,,,5/19/1987,5/19/1994,,DuPont Pharmaceuticals,E.I. Du Pont De Nemours & Co.,,Wilmington,Delaware,19880,United States,8085
ISONIAZID,V83O1VOZ8L,Designated/Approved,Public record,72,"Rifampin, isoniazid, pyrazinamide",9/12/1985,For the short-course treatment of tuberculosis.,Designated/Approved,,Short-course treatment of tuberculosis.,5/31/1994,5/31/2001,,Hoechst Marion Roussel,P.O. Box 9627,,Kansas City,Missouri,64134,United States,6585
PYRAZINAMIDE,2KNI5N06TI,Designated/Approved,Public record,72,"Rifampin, isoniazid, pyrazinamide",9/12/1985,For the short-course treatment of tuberculosis.,Designated/Approved,,Short-course treatment of tuberculosis.,5/31/1994,5/31/2001,,Hoechst Marion Roussel,P.O. Box 9627,,Kansas City,Missouri,64134,United States,6585
RIFAMPIN,VJT6J7R4TR,Designated/Approved,Public record,72,"Rifampin, isoniazid, pyrazinamide",9/12/1985,For the short-course treatment of tuberculosis.,Designated/Approved,,Short-course treatment of tuberculosis.,5/31/1994,5/31/2001,,Hoechst Marion Roussel,P.O. Box 9627,,Kansas City,Missouri,64134,United States,6585
EPOPROSTENOL,DCR9Z582X0,Designated/Approved,Public record,73,Epoprostenol,9/25/1985,Treatment of primary pulmonary hypertension.,Designated/Approved,,Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.,9/20/1995,9/20/2002,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,8785
HYDROXOCOBALAMIN,Q40X8H422O,Designated/Withdrawn,Public record,74,Hydroxycobalamin/sodium thiosulfate,10/4/1985,Treatment of severe acute cyanide poisoning.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Hall, Alan H., M.D.",Mile 5.0 Pass Creek Road,PO Box 24,Elk Mountain,Wyoming,82324,United States,9585
SODIUM THIOSULFATE,HX1032V43M,Designated/Withdrawn,Public record,74,Hydroxycobalamin/sodium thiosulfate,10/4/1985,Treatment of severe acute cyanide poisoning.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Hall, Alan H., M.D.",Mile 5.0 Pass Creek Road,PO Box 24,Elk Mountain,Wyoming,82324,United States,9585
METHOTREXATE SODIUM,3IG1E710ZN,Designated/Approved,Public record,75,Methotrexate sodium,10/21/1985,Treatment of osteogenic sarcoma.,Designated/Approved,,For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.,4/7/1988,4/7/1995,,Lederle Laboratories,Division of American Cyanamid Company,401 N. Middletown Road,Pearl River,New York,10965,United States,9985
GANCICLOVIR SODIUM,02L083W284,Designated/Approved/Withdrawn,Public record,76,Ganciclovir sodium,10/31/1985,Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.,Designated/Approved/Withdrawn,,,6/23/1989,6/23/1996,,"Syntex (USA), Inc.",3401 Hillview Avenue,,Palo Alto,California,94304,United States,7985
ZINC ACETATE,FM5526K07A,Designated/Approved,Public record,78,Zinc acetate,11/6/1985,Treatment of Wilson's disease.,Designated/Approved,,For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.,1/28/1997,1/28/2004,,Lemmon Company,1510 Delp Drive,,Kulpsville,Pennsylvania,19443,United States,11185
MESNA,NR7O1405Q9,Designated/Approved,Public record,79,Mesna,11/14/1985,For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.,Designated/Approved,,,12/30/1988,12/30/1995,,Degussa Corporation,65 Challenger Road,,Ridgefield Park,New Jersey,7660,United States,8685
TRANEXAMIC ACID,6T84R30KC1,Designated/Approved/Withdrawn,Public record,80,tranexamic acid,12/3/1985,"For use in patients with congenital coagulopathies undergoing surgical procedures, e.g. dental extractions",Designated/Approved/Withdrawn,,Treatment of patients with hemophilia for short term use (2 to 8 days) before and after tooth extraction to reduce or prevent hemorrhage abd reduce the need for replacement therapy,12/30/1986,12/30/1993,,Pharmacia Inc.,P.O. Box 16529,,Columbus,Ohio,43216,United States,8885
ALLOPURINOL RIBOSIDE,WZS8452SEC,Designated/Withdrawn,Public record,81,Allopurinol riboside,12/4/1985,1. Treatment of Chagas' disease 2. Treatment of cutaneous and visceral leishmaniasis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,P.O. Box 12700,Research Triangle Park,North Carolina,27709,United States,10685
Colchicine,SML2Y3J35T,Designated/Withdrawn,Public record,82,Colchicine,12/9/1985,For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmacontrol Corporation,"661 Palisade Ave., P.O. Box 931",,Englewood Cliffs,New Jersey,7632,United States,11085
RIFAMPIN,VJT6J7R4TR,Designated/Approved,Public record,83,Rifampin,12/9/1985,For antituberculosis treatment where use of the oral form of the drug is not feasible.,Designated/Approved,,,5/25/1989,5/25/1996,,Hoechst Marion Roussel,P.O. Box 9627,,Kansas City,Missouri,64134,United States,7685
SOMATREM,CU8D464EDW,Designated/Approved,Public record,84,Somatrem for injection,12/9/1985,"1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000).",Designated/Approved,,,10/17/1985,10/17/1992,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,94080,United States,10785
ANTITHROMBIN III HUMAN,T0LTO7L82X,Designated,Public record,85,Antithrombin III human,1/2/1986,Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.,Designated,Not FDA Approved for Orphan Indication,,,,,American National Red Cross,9312 Old Georgetown Road,,Bethesda,Maryland,20814,United States,11485
FLUNARIZINE,R7PLA2DM0J,Designated,Public record,86,flunarizine,1/6/1986,Treatment of alternating hemiplegia.,Designated,Not FDA Approved for Orphan Indication,,,,,Janssen Research Foundation,,P.O. Box 200,Titusville,New Jersey,8560,United States,9485
GUANETHIDINE MONOSULFATE,5UBY8Y002G,Designated/Withdrawn,Public record,87,Guanethidine monosulfate,1/6/1986,Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,6385
TIOPRONIN,C5W04GO61S,Designated/Approved,Public record,88,Tiopronin,1/17/1986,Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,Designated/Approved,,"THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to the",6/28/2019,6/28/2026,,Mission Pharmacal Company,P.O. Box 786099,,San Antonio,Texas,78278,United States,12386
TIOPRONIN,C5W04GO61S,Designated/Approved,Public record,89,Tiopronin,1/17/1986,Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,Designated/Approved,,"Indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet mo",8/11/1988,8/11/1995,,Mission Pharmacal Company,P.O. Box 786099,,San Antonio,Texas,78278,United States,12386
TIOPRONIN,C5W04GO61S,Designated/Approved,Public record,90,Tiopronin,1/17/1986,Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,Designated/Approved,,"THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these",6/28/2019,6/28/2026,"Indicated in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in pediatric patients between 20 kg and 9 years of age with severe homozygous cystinuria, who are not responsive to these measure",Mission Pharmacal Company,P.O. Box 786099,,San Antonio,Texas,78278,United States,12386
Benzoic acid,8SKN0B0MIM,Designated/Approved,Public record,91,Benzoate and phenylacetate,1/21/1986,"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.",Designated/Approved,,,12/23/1987,12/23/1994,,ImmunexImmunex,2525 McGaw Avenue,P.O. Box 19791,Irvine,California,92623,United States,11385
PHENYL ACETATE,355G9R500Y,Designated/Approved,Public record,91,Benzoate and phenylacetate,1/21/1986,"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.",Designated/Approved,,,12/23/1987,12/23/1994,,ImmunexImmunex,2525 McGaw Avenue,P.O. Box 19791,Irvine,California,92623,United States,11385
Beractant,S866O45PIG,Designated/Approved,Public record,93,Beractant,2/5/1986,Treatment of neonatal respiratory distress syndrome,Designated/Approved,,"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",7/1/1991,7/1/1998,,Ross Laboratories,625 Cleveland Avenue,,Columbus,Ohio,43215,United States,10885
Beractant,S866O45PIG,Designated/Approved,Public record,94,Beractant,2/5/1986,Treatment of neonatal respiratory distress syndrome,Designated/Approved,,Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency,7/2/1991,7/2/1998,,Ross Laboratories,625 Cleveland Avenue,,Columbus,Ohio,43215,United States,10885
POTASSIUM CITRATE,EE90ONI6FF,Designated/Withdrawn,Public record,95,Potassium citrate and citric acid,2/14/1986,For the dissolution and control of uric acid and cysteine calculi in the urinary tract.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Willen Drug Company,,,,,,,9785
CITRIC ACID MONOHYDRATE,2968PHW8QP,Designated/Withdrawn,Public record,95,Potassium citrate and citric acid,2/14/1986,For the dissolution and control of uric acid and cysteine calculi in the urinary tract.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Willen Drug Company,,,,,,,9785
TERLIPRESSIN,7Z5X49W53P,Designated,Public record,96,Terlipressin,3/6/1986,Treatment of bleeding esophageal varices.,Designated,Not FDA Approved for Orphan Indication,,,,,Ferring Pharmaceuticals Inc.,100 Interpace Parkway,,Parsippany-Troy Hills,New Jersey,7054,United States,11785
ETIDRONATE DISODIUM,M16PXG993G,Designated/Approved,Public record,97,Etidronate disodium,3/21/1986,Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.,Designated/Approved,,,4/21/1987,4/21/1994,,"MGI Pharma, Inc.",5775 West Old Shakoppe Rd.,Suite 100,Bloomington,Minnesota,55437,United States,12185
DITIOCARB,99Z2744345,Designated,Public record,98,Diethyldithiocarbamate,4/3/1986,Treatment of AIDS.,Designated,Not FDA Approved for Orphan Indication,,,,,Connaught Laboratories,"Route 611, P.O. Box 187",,Swiftwater,Pennsylvania,18370,United States,13286
EPOETIN ALFA,,Designated/Approved,Public record,99,Epoetin alfa,4/10/1986,Treatment of anemia associated with end stage renal disease.,Designated/Approved,,"Treatment of anemia associated with chronic renal failure, including patients on dialysis (end stage renal disesae) and patients not on dialysis",6/1/1989,6/1/1996,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,91320,United States,12486
EFLORNITHINE HYDROCHLORIDE,4NH22NDW9H,Designated/Withdrawn,Public record,100,Eflornithine HCl,4/18/1986,Treatment of Pneumocystis carinii pneumonia in AIDS patients.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Marion Merrell Dow, Inc.",P.O. Box 9627,,Kansas City,Missouri,64134,United States,13686
EFLORNITHINE HYDROCHLORIDE,4NH22NDW9H,Designated/Approved,Public record,101,Eflornithine HCl,4/23/1986,Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).,Designated/Approved,,,11/28/1990,11/28/1997,,Hoechst Marion Roussel,P.O. Box 9627,,Kansas City,Missouri,64134,United States,13586
CYSTEAMINE,5UX2SD1KE2,Designated,Public record,102,Cysteamine,5/1/1986,Treatment of nephropathic cystinosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Thoene, Jess G., M.D.",University of Michigan Medical School,"300 NIB, 1192 SE",Ann Arbor,Michigan,48109,United States,13986
TRIMETREXATE GLUCURONATE,L137U4A79K,Designated/Approved,Public record,104,Trimetrexate glucuronate,5/15/1986,Treatment of Pneumocystis carinii pneumonia in AIDS patients.,Designated/Approved,,"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.",12/17/1993,12/17/2000,,"Medimmune Oncology, Inc.",One Tower Bridge,"100 Front Street, Suite 400",West Conshohocken,Pennsylvania,19428,United States,14286
Dimethyl sulfoxide,YOW8V9698H,Designated/Withdrawn,Public record,105,Dimethyl sulfoxide,6/6/1986,Treatment of cutaneous manifestations of scleroderma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Research Industries Corp.,,,,,,,14986
SODIUM TETRADECYL SULFATE,Q1SUG5KBD6,Designated,Public record,106,Sodium tetradecyl sulfate,6/10/1986,Treatment of bleeding esophageal varices.,Designated,Not FDA Approved for Orphan Indication,,,,,"Elkins-Sinn, Inc.",2 Esterbrook Lane,,Cherry Hill,New Jersey,8003,United States,12786
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,107,Somatropin for injection,6/12/1986,For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,Designated/Approved,,,3/8/1987,3/8/1994,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,11285
SILIBININ DIHEMISUCCINATE DISODIUM,57LSQ377IE,Designated/Withdrawn,Public record,108,Disodium silibinin dihemisuccinate,7/10/1986,Treatment of hepatic intoxication by Amanita phalloides (mushroom poisoning).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmaquest Corporation,4470 Redwood Highway,,San Rafael,California,94903,United States,15086
ANAGRELIDE,K9X45X0051,Designated,Public record,109,Anagrelide,7/14/1986,Treatment of thrombocytosis in chronic myelogenous leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,Roberts Pharmaceutical Corp.,Meridian Center II,Four Industrial Way West,Eatontown,New Jersey,7724,United States,14586
ASPARAGINASE ERWINIA CHRYSANTHEMI,D733ET3F9O,Designated/Approved,Public record,110,Erwinia L-asparaginase,7/30/1986,Treatment of acute lymphocytic leukemia.,Designated/Approved/Withdrawn,,Treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.,11/18/2011,11/18/2018,,"Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,94304,United States,15186
CHLORHEXIDINE GLUCONATE,MOR84MUD8E,Designated,Public record,111,Chlorhexidine gluconate mouthrinse,8/18/1986,For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.,Designated,Not FDA Approved for Orphan Indication,,,,,Procter & Gamble Company,Sharon Wood Technical Center,11370 Reed Hartman Highway,Cincinnati,Ohio,45241,United States,13086
BOTULINUM TOXIN TYPE A,E211KPY694,Designated/Approved,Public record,112,Botulinum toxin type A,8/20/1986,Treatment of cervical dystonia.,Designated/Approved,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.,12/21/2000,12/21/2007,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,92623,United States,9885
INTERFERON ALFA-N1,41697D4Z5C,Designated/Withdrawn,Public record,113,Interferon alfa-nl,8/25/1986,Treatment of AIDS related Kaposi's sarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,,Research Triangle Pk,North Carolina,27709,United States,12886
NEBACUMAB,908FWN27WK,Designated,Public record,114,Nebacumab,10/1/1986,Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,14186
LEVOCARNITINE,0G389FZZ9M,Designated/Withdrawn,Public record,115,Levocarnitine,11/24/1986,Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,20878,United States,17386
LEUCOVORIN,Q573I9DVLP,Designated/Approved,Public record,116,Leucovorin,12/8/1986,For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,Designated/Approved,,For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.,12/12/1991,12/12/1998,,Immunex Corporation,51 University Street,,Seattle,Washington,98101,United States,16786
MAZINDOL,C56709M5NH,Designated,Public record,117,Mazindol,12/8/1986,Treatment of Duchenne muscular dystrophy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Collipp, Platon J. M.D.",176 Memorial Drive,,Jesup,Georgia,31545,United States,16186
ZALCITABINE,6L3XT8CB3I,Designated,Public record,118,Zalcitabine,12/9/1986,Treatment of AIDS.,Designated,Not FDA Approved for Orphan Indication,,,,,"National Cancer Institute, DCT","NIH, Executive Plaza North, Room 7-18",,Bethesda,Maryland,20892,United States,17586
TERIPARATIDE,10T9CSU89I,Designated/Approved,Public record,119,Teriparatide,1/9/1987,Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.,Designated/Approved,,,12/23/1987,12/23/1994,,"Rhone-Poulenc Rorer Pharmaceuticals, Inc.",500 Arcola Road,,Collegeville,Pennsylvania,19426,United States,14486
CALCITONIN HUMAN,I0IO929019,Designated/Approved,Public record,120,Calcitonin-human for injection,1/20/1987,Treatment of symptomatic Paget's disease (osteitis deformans).,Designated/Approved,,,10/31/1986,10/31/1993,,Novartis Pharmaceutical Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,13186
IFOSFAMIDE,UM20QQM95Y,Designated/Approved,Public record,121,Ifosfamide,1/20/1987,Treatment of testicular cancer.,Designated/Approved,,"In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer.",12/30/1988,12/30/1995,,Bristol-Myers Squibb Pharmaceutical Research Institute,"5 Research Parkway, P.O. Box 5100",,Wallingford,Connecticut,6492,United States,17786
"""24,25-DIHYDROXYCHOLECALCIFEROL""",0AXX2V8L5Z,Designated,Public record,122,"24,25 dihydroxycholecalciferol",2/27/1987,Treatment of uremic osteodystrophy.,Designated,Not FDA Approved for Orphan Indication,,,,,Lemmon Company,1510 Delp Drive,,Kulpsville,Pennsylvania,19443,United States,15786
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,124,Somatropin,3/6/1987,For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,Designated/Approved,,,10/17/1985,10/17/1992,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,94080,United States,12586
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,125,Somatropin (rDNA origin),3/6/1987,Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.,Designated/Approved,,Long term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.,10/8/1996,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,15486
B-TRISACCHARIDE,2P888H42QS,Designated,Public record,127,Trisaccharides A and B,4/12/1987,Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.,Designated,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.","P.O. Box 8050, Station F",T6H 4NP,,,,Canada,18086
A-TRISACCHARIDE,P104QT2V1B,Designated,Public record,127,Trisaccharides A and B,4/12/1987,Treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances A and B.,Designated,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.","P.O. Box 8050, Station F",T6H 4NP,,,,Canada,18086
B-TRISACCHARIDE,2P888H42QS,Designated,Public record,128,Trisaccharides A and B,4/20/1987,"For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.",Designated,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.",P.O. Box 8050,T6H 4NP,,,,Canada,18887
A-TRISACCHARIDE,P104QT2V1B,Designated,Public record,128,Trisaccharides A and B,4/20/1987,"For use in ABO-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.",Designated,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.",P.O. Box 8050,T6H 4NP,,,,Canada,18887
GONADORELIN ACETATE,2RG1XQ1NYJ,Designated/Approved,Public record,129,Gonadorelin acetate,4/22/1987,For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.,Designated/Approved,,,10/10/1989,10/10/1996,,"Ferring Laboratories, Inc.","400 Rella Boulevard, Suite 201",,Suffern,New York,10901,United States,17086
DALFAMPRIDINE,BH3B64OKL9,Designated/Approved,Public record,130,dalfampridine,6/2/1987,Relief of symptoms of multiple sclerosis,Designated/Approved,,Treatment to improve walking in patients with multiple sclerosis,1/22/2010,1/22/2017,,Acorda Therapeutics,15 Skyline Dr.,,Hawthorne,New York,10532,United States,18186
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,132,Interferon alfa-2b (recombinant),6/22/1987,Treatment of metastatic renal cell carcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,19787
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,133,Interferon alfa-2b (recombinant),6/22/1987,Treatment of chronic myelogenous leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,20087
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Approved,Public record,134,Interferon alfa-2b (recombinant),6/24/1987,Treatment of AIDS-related Kaposi's sarcoma.,Designated/Approved,,Treatment of selected patients with AIDS-related Kaposi's sarcoma.,11/21/1988,11/21/1995,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,19187
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,135,somapacitan-beco,7/10/1987,1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome,Designated/Approved,,Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH),4/28/2023,,,Novo Nordisk Pharmaceuticals,100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,13386
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,136,Somatropin (rDNA origin) injection,7/10/1987,1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome,Designated/Approved,,Long-term treatment of children who have growth failure due to inadequate secretion of endogenous growth hormone.,6/20/2000,,,Novo Nordisk Pharmaceuticals,100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,13386
MITOXANTRONE HYDROCHLORIDE,U6USW86RD0,Designated/Approved,Public record,137,Mitoxantrone HCl,7/13/1987,"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",Designated/Approved,,,12/23/1987,12/23/1994,,Lederle Laboratories,Division of American Cyanamid Company,401 N. Middletown Road,Pearl River,New York,10965,United States,19287
DIDEOXYADENOSINE,4Q86AH641A,Designated/Withdrawn,Public record,138,2'-3'-dideoxyadenosine,7/21/1987,Treatment of aquired immunodeficiency syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"National Cancer Institute, Dct","NIH, Exec. Plaza N., Room 7-18",,Bethesda,Maryland,20892,United States,20587
MEFLOQUINE HYDROCHLORIDE,5Y9L3636O3,Designated,Public record,139,Mefloquine HCl,7/22/1987,Treatment and prevention of chloroquine-resistant Falciparummalaria,Designated,Not FDA Approved for Orphan Indication,,,,,Mepha AG,4143 Dornach,,Aesch Basel,,,Switzerland,18687
DECITABINE,776B62CQ27,Designated,Public record,140,5-aza-2'-deoxycytidine,8/3/1987,Treatment of acute leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,20687
HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN,129L90A25N,Designated/Approved,Public record,141,Cytomegalovirus immune globulin (human),8/3/1987,Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.,Designated/Approved,,"#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2) Prophylaxis of CMV disease associated transplantation of kidney (all other), lung,",12/4/1998,12/4/2005,,CSL Behring LLC,1020 First Avenue,P. O. Box 61501,King of Prussia,Pennsylvania,19406,United States,15386
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,142,Interferon alfa-2b (recombinant),8/3/1987,Treatment of ovarian carcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,20187
B-TRISACCHARIDE,2P888H42QS,Designated/Withdrawn,Public record,143,Trisaccharides A and B,8/3/1987,"Treatment of moderate to very severe clinical forms of transfusion reactions arising from ABO incompatible transfusions of blood, blood products, and blood derivatives.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.",P.O. Box 8050,T6H 4NP,,,,Canada,20287
A-TRISACCHARIDE,P104QT2V1B,Designated/Withdrawn,Public record,143,Trisaccharides A and B,8/3/1987,"Treatment of moderate to very severe clinical forms of transfusion reactions arising from ABO incompatible transfusions of blood, blood products, and blood derivatives.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.",P.O. Box 8050,T6H 4NP,,,,Canada,20287
ACETYLCYSTEINE,WYQ7N0BPYC,Designated,Public record,145,Acetylcysteine,8/13/1987,Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 4000,,Princeton,New Jersey,8543,United States,20787
EPOETIN,64FS3BFH5W,Designated,Public record,146,Erythropoietin (recombinant human),8/19/1987,Treatment of anemia associated with end stage renal disease.,Designated,Not FDA Approved for Orphan Indication,,,,,McDonnell Douglas Corp,"P.O. Box 516, 107/2 MS10",,St. Louis,Missouri,63166,United States,17886
EPOETIN ALFA,,Designated,Public record,148,Epoetin alpha,8/27/1987,Treatment of anemia associated with end stage renal disease.,Designated,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute,Route 202 South,P.O. Box 300,Raritan,New Jersey,8869,United States,17186
SOMATROPIN,NQX9KB6PCL,Designated/Withdrawn,Public record,149,Somatropin,9/1/1987,"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Pharmaceuticals,100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,21787
PENTOSTATIN,395575MZO7,Designated/Approved,Public record,150,pentostatin for injection,9/10/1987,Treatment of hairy cell leukemia,Designated/Approved,,Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.,10/11/1991,10/11/1998,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,21287
BENZYLPENILLOIC ACID,F93JSF8762,Designated,Public record,151,"Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid",9/28/1987,Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.,Designated,Not FDA Approved for Orphan Indication,,,,,AllerQuest LLC,836 Farmington Avenue,Suite 207,West Hanford,Connecticut,6119,United States,18787
PENICILLIN G,Q42T66VG0C,Designated,Public record,151,"Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid",9/28/1987,Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.,Designated,Not FDA Approved for Orphan Indication,,,,,AllerQuest LLC,836 Farmington Avenue,Suite 207,West Hanford,Connecticut,6119,United States,18787
PIRACETAM,ZH516LNZ10,Designated/Withdrawn,Public record,152,Piracetam,10/2/1987,Treatment of myoclonus.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"UCB Pharma, Inc.",1950 Lake Park Drive,,Smyrna,Georgia,30080,United States,20987
NEPIDERMIN,TZK30RF92W,Designated,Public record,153,Epidermal growth factor (human),10/5/1987,For acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.,Designated,Not FDA Approved for Orphan Indication,,,,,Chiron Vision,500 Iolab Drive,,Claremont,California,91711,United States,14386
PENTAMIDINE ISETHIONATE,V2P3K60DA2,Designated,Public record,154,Pentamidine isethionate (inhalation),10/5/1987,Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease,Designated,Not FDA Approved for Orphan Indication,,,,,Fisons Corporation,"755 Jefferson Rd., P.O. Box 1710",,Rochester,New York,14603,United States,21187
INTERFERON ALFA-N1,41697D4Z5C,Designated/Withdrawn,Public record,155,Interferon alfa-nl,10/16/1987,Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,12986
EPOETIN BETA,,Designated,Public record,156,Epoetin beta,10/22/1987,Treatment of anemia associated with end stage renal disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Chugai-USA, Inc.",3780 Hawthorn Court,,Waukegan,Illinois,60087,United States,22987
METRONIDAZOLE,140QMO216E,Designated/Approved,Public record,157,Metronidazole (topical),10/22/1987,Treatment of acne rosacea.,Designated/Approved,,,11/22/1988,11/22/1995,,"Galderma Laboratories, Inc.",P.O. Box 331329,,Fort Worth,Texas,76163,United States,21687
VELARESOL,9EQV0XQ79B,Designated/Withdrawn,Public record,158,substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits,10/23/1987,Treatment of sickle cell disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,,Research Triangle Pk,North Carolina,27709,United States,22087
DESLORELIN,TKG3I66TVE,Designated,Public record,160,Deslorelin,11/5/1987,Treatment of central precocious puberty.,Designated,Not FDA Approved for Orphan Indication,,,,,Roberts Pharmaceutical Corp.,Meridian Center II,Four Industrial Way West,Eatontown,New Jersey,7724,United States,16086
ALLOPURINOL SODIUM,428673RC2Z,Designated/Withdrawn,Public record,161,Allopurinol sodium,11/9/1987,Ex-vivo preservation of cadaveric kidneys for transplantation,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,,Research Triangle Pk,North Carolina,27709,United States,22787
AMMONIUM TRICHLOROTELLURATE,708681952A,Designated/Withdrawn,Public record,162,"Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)",11/9/1987,Treatment of acquired immunodeficiency syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"NPDC-AS101, Inc.",783 Jersey Avenue,,New Brunswick,New Jersey,8901,United States,22387
GLATIRAMER ACETATE,5M691HL4BO,Designated/Approved,Public record,163,glatiramer acetate,11/9/1987,Treatment of multiple sclerosis,Designated/Approved,,For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.,12/20/1996,12/20/2003,,Teva Pharmaceuticals USA,1510 Delp Drive,,Kulpsville,Pennsylvania,19443,United States,24087
BACLOFEN,H789N3FKE8,Designated/Approved,Public record,164,baclofen,11/10/1987,"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).",Designated/Approved,,Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.,6/25/1992,6/25/1999,,"Medtronic, Inc.",800 53rd Avenue N.E.,,Minneapolis,Minnesota,55432,United States,23987
MOXISYLYTE HYDROCHLORIDE,WK2KZM9V6X,Designated/Withdrawn,Public record,165,Thymoxamine HCl,11/16/1987,Reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma following mydriasis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Iolab Pharmaceuticals,500 Iolab Drive,,Claremont,California,91711,United States,19887
DEXTRAN SULFATE SODIUM,,Designated,Public record,166,Dextran sulfate sodium,11/19/1987,Treatment of aquired immunodeficiency syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.","2-31 Koraibashi, Higashi-ku",,Osaka 541,,,Japan,23187
EPOETIN,64FS3BFH5W,Designated/Withdrawn,Public record,167,"Erythropoietin (human, recombinant)",11/19/1987,Treatment of anemia associated with end stage renal disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Organon Teknika Corporation,,,,,,,18987
METRONIDAZOLE,140QMO216E,Designated/Withdrawn,Public record,168,Metronidazole (topical),11/24/1987,"Treatment of grade III and IV, anaerobically infected, decubitus ulcers.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Searle,4901 Searle Parkway,,Skokie,Illinois,60077,United States,17486
Urofollitropin,W9BB98U6HP,Designated/Approved,Public record,169,Urofollitropin,11/25/1987,For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.,Designated/Approved,,,9/18/1986,9/18/1993,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,14086
OXYBATE,30IW36W5B2,Designated,Public record,170,Gamma hydroxybutyrate,12/3/1987,"Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.",Designated,Not FDA Approved for Orphan Indication,,,,,"Biocraft Laboratories, Inc.",18-01 River Road,,Fair Lawn,New Jersey,7410,United States,26387
DANTROLENE SODIUM,287M0347EV,Designated/Withdrawn,Public record,171,Dantrolene sodium,12/14/1987,Treatment of the neuroleptic malignant syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Norwich Eaton Pharmaceuticals,P.O. Box 191,,Norwich,New York,13815,United States,23287
INTERFERON ALFA-2A,47RRR83SK7,Designated/Approved,Public record,172,Interferon alfa-2a (recombinant),12/14/1987,Treatment of AIDS related Kaposi's sarcoma.,Designated/Approved,,,11/21/1988,11/21/1995,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,25987
MESNA,NR7O1405Q9,Designated/Withdrawn,Public record,173,Mesna,12/16/1987,Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Asta Medica , Inc.",890 East St.,,Tewksbury,Massachusetts,1876,United States,24887
PENTAMIDINE ISETHIONATE,V2P3K60DA2,Designated/Approved,Public record,174,Pentamidine isethionate,1/12/1988,Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.,Designated/Approved,,,6/15/1989,6/15/1996,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,60015,United States,25887
TRIMETREXATE GLUCURONATE,L137U4A79K,Designated/Withdrawn,Public record,175,Trimetrexate glucuronate,1/13/1988,Treatment of patients with advanced non-small cell carcinoma of the lung.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medimmune Oncology, Inc.",One MedImmune Way,,Gaithersburg,Maryland,20878,United States,14686
AGALSIDASE BETA,RZD65TSM9U,Designated/Approved,Public record,176,agalsidase beta,1/19/1988,Treatment of Fabry's disease.,Designated/Approved,,For use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types,4/24/2003,4/24/2010,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,15286
AGALSIDASE BETA,RZD65TSM9U,Designated/Approved,Public record,177,agalsidase beta,1/19/1988,Treatment of Fabry's disease.,Designated/Approved,,treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease,3/11/2021,3/11/2028,treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,15286
ANAGRELIDE,K9X45X0051,Designated/Approved,Public record,178,Anagrelide,1/27/1988,Treatment of essential thrombocythemia.,Designated/Approved,,Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.,3/14/1997,3/14/2004,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,20887
LEVOCABASTINE HYDROCHLORIDE,124XMA6YEI,Designated/Withdrawn,Public record,179,Levocabastine HCl ophthalmic suspension 0.05%,2/29/1988,Treatment of vernal keratoconjunctivitis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Iolab Pharmaceuticals,500 Iolab Drive,,Claremont,California,91711,United States,24787
HEME ARGINATE,R1B526117P,Designated,Public record,180,Heme arginate,3/10/1988,Treatment of symptomatic stage of acute porphyria.,Designated,Not FDA Approved for Orphan Indication,,,,,Orphan Europe SARL,Immeuble Le Wilson,70 avenue du General de Gaulle,Puteaux,,,France,9185
PROPAMIDINE ISETHIONATE,7T9IJ84C42,Designated/Withdrawn,Public record,181,Propamidine isethionate 0.1% ophthalmic solution,3/10/1988,Treatment of acanthamoeba keratitis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bausch & Lomb,Pharmaceuticals Division,8500 Hidden River Parkway,Tampa,Florida,33637,United States,27288
EDRECOLOMAB,0KYI9U9FSJ,Designated/Withdrawn,Public record,182,Monoclonal antibody 17-1a,4/4/1988,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,27388
MEFLOQUINE HYDROCHLORIDE,5Y9L3636O3,Designated/Approved,Public record,183,mefloquine HCL,4/13/1988,"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs",Designated/Approved,,Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax,5/2/1989,5/2/1996,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,26287
MEFLOQUINE HYDROCHLORIDE,5Y9L3636O3,Designated/Approved,Public record,184,mefloquine HCL,4/13/1988,"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs",Designated/Approved,,Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs,5/3/1989,5/3/1996,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,26287
MEGESTROL ACETATE,TJ2M0FR8ES,Designated/Approved,Public record,185,Megestrol acetate,4/13/1988,"Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.",Designated/Approved,,"Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome.",9/10/1993,9/10/2000,,Bristol-Myers Squibb Pharmaceutical Research Institute,2400 West Lloyd Expressway,,Evansville,Indiana,47721,United States,26187
VITAMIN E POLYETHYLENE GLYCOL SUCCINATE,O03S90U1F2,Designated/Withdrawn,Public record,186,Tocophersolan oral solution (vitamin E-tpgs),4/15/1988,Treatment of vitamin E deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sterling Winthrop,9 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,22687
A-TRISACCHARIDE,P104QT2V1B,Designated,Public record,187,Trisaccharides A and B,4/15/1988,Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.","P.O. Box 8050, Station F",T6H 4NP,,,,Canada,27988
B-TRISACCHARIDE,2P888H42QS,Designated,Public record,187,Trisaccharides A and B,4/15/1988,Prevention of ABO medical hemolytic reactions arising from ABO-incompatible bone marrow transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.","P.O. Box 8050, Station F",T6H 4NP,,,,Canada,27988
INTERFERON ALFA-2A,47RRR83SK7,Designated,Public record,188,Interferon alfa-2a (recombinant),4/18/1988,Treatment of renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,27488
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,189,Interferon alfa-2b (recombinant),4/18/1988,Treatment of invasive carcinoma of the cervix.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,20387
PRAZIQUANTEL,6490C9U457,Designated/Withdrawn,Public record,190,Praziquantel,4/18/1988,Treatment of neurocysticercosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EM Pharmaceuticals, Inc.",,,,,,,19487
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,191,Interferon alfa-2b (recombinant),5/13/1988,Treatment of primary malignant brain tumors.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,21087
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated/Approved,Public record,193,Coagulation factor VIIa (recombinant),6/6/1988,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,Designated/Approved,,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,3/25/1999,3/25/2006,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,26588
PIRITREXIM ISETHIONATE,V77I71FH72,Designated/Withdrawn,Public record,194,Piritrexim isethionate,6/13/1988,"Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,P.O. Box 12700,Research Triangle Park,North Carolina,27709,United States,29188
ACONIAZIDE,8OKQ9NS8MO,Designated/Withdrawn,Public record,195,Aconiazide,6/20/1988,Treatment of tuberculosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Lincoln Diagnostics,P.O. Box 1128,,Decatur,Illinois,62525,United States,28288
SOMATOSTATIN,6E20216Q0L,Designated,Public record,196,Somatostatin,6/20/1988,"Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",Designated,Not FDA Approved for Orphan Indication,,,,,"Ferring Laboratories, Inc.","400 Rella Boulevard, Suite 201",,Suffern,New York,10901,United States,21587
DIDANOSINE,K3GDH6OH08,Designated/Withdrawn,Public record,197,Dideoxyinosine,6/22/1988,Treatment of acquired immunodeficiency syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,2400 West Lloyd Expressway,,Evansville,Indiana,47721,United States,29488
ETHINYL ESTRADIOL,423D2T571U,Designated/Withdrawn,Public record,198,"Ethinyl Estradiol, USP",6/22/1988,Treatment of Turner's syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,8830,United States,28788
LEUCOVORIN CALCIUM,RPR1R4C0P4,Designated/Withdrawn,Public record,199,Leucovorin calcium,6/23/1988,For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Research and Development,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,27709,United States,29288
ZALCITABINE,6L3XT8CB3I,Designated/Approved,Public record,200,Zalcitabine,6/28/1988,Treatment of AIDS.,Designated/Approved,,Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.,6/19/1992,6/19/1999,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,28388
NAFARELIN ACETATE,8ENZ0QJW4H,Designated/Approved,Public record,202,Nafarelin acetate,7/20/1988,Treatment of central precocious puberty.,Designated/Approved,,Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.,2/26/1992,2/26/1999,,"Syntex (USA), Inc.",3401 Hillview Avenue,,Palo Alto,California,94303,United States,29888
EPOETIN ALFA,,Designated/Withdrawn,Public record,203,Epoetin alpha,7/21/1988,Treatment of anemia of prematurity in preterm infants.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,21987
IDARUBICIN HYDROCHLORIDE,5VV3MDU5IE,Designated/Approved,Public record,204,Idarubicin HCl for injection,7/25/1988,"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",Designated/Approved,,,9/27/1990,9/27/1997,,"Adria Laboratories, Inc.",P.O. Box 16529,,Columbus,Ohio,43216,United States,29388
LEUPROLIDE ACETATE,37JNS02E7V,Designated/Approved,Public record,205,leuprolide acetate,7/25/1988,Treatment of central precocious puberty,Designated/Approved,,treatment of pediatric patients with central precocious puberty (CPP),4/14/2023,,,AbbVie Endocrine Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,28688
LEUPROLIDE ACETATE,37JNS02E7V,Designated/Approved,Public record,206,Leuprolide acetate,7/25/1988,Treatment of central precocious puberty,Designated/Approved,,Treatment of children with central precocious puberty,4/16/1993,4/16/2000,,AbbVie Endocrine Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,28688
COLFOSCERIL PALMITATE,319X2NFW0A,Designated,Public record,207,Dipalmitoylphosphatidylcholine /phosphatidylglycerol,7/28/1988,Prevention and treatment of neonatal respiratory distress syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Forum Products, Inc.",33 Flying Point Road,,Southampton,New York,11968,United States,29688
"""DIPALMITOYLPHOSPHATIDYLGLYCEROL, DL-""",VA9U6BR3SB,Designated,Public record,207,Dipalmitoylphosphatidylcholine /phosphatidylglycerol,7/28/1988,Prevention and treatment of neonatal respiratory distress syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Forum Products, Inc.",33 Flying Point Road,,Southampton,New York,11968,United States,29688
HISTRELIN ACETATE,QMG7HLD1ZE,Designated/Approved,Public record,208,Histrelin acetate,8/10/1988,Treatment of central precocious puberty.,Designated/Approved,,Treatment of central precocious puberty.,12/24/1991,12/24/1998,,Roberts Pharmaceutical Corp.,Meridian Center III,6 Industrial Way West,Eatontown,New Jersey,7724,United States,16986
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,209,Interferon alfa-2b (recombinant),8/10/1988,Treatment of carcinoma in situ of the urinary bladder.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,20487
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,210,Interferon alfa-2b (recombinant),8/17/1988,Treatment of laryngeal (respiratory) papillomatosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,21487
LEUCOVORIN,Q573I9DVLP,Designated/Approved,Public record,211,Leucovorin,8/17/1988,For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.,Designated/Approved,,,8/31/1988,8/31/1995,,Immunex Corporation,51 University Street,,Seattle,Washington,98101,United States,30588
LEVOCARNITINE,0G389FZZ9M,Designated/Approved,Public record,213,Levocarnitine,9/6/1988,Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.,Designated/Approved,,Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.,12/15/1999,12/15/2006,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,20878,United States,27888
PHOSPHOCYSTEAMINE,WFH6A9S0V4,Designated/Withdrawn,Public record,215,Phosphocysteamine,9/12/1988,Treatment of cystinosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Medea Research Laboratories,Port Jefferson Business Center,"200 Wilson Street, Building D-6",Port Jefferson,New York,11776,United States,29588
ALDESLEUKIN,M89N0Q7EQR,Designated/Approved,Public record,216,Aldesleukin,9/14/1988,Treatment of metastatic renal cell carcinoma.,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma.,5/5/1992,5/5/1999,,Chiron Corporation,4560 Horton Street,,Emeryville,California,94608,United States,29088
SERMORELIN ACETATE,00IBG87IQW,Designated/Approved,Public record,217,Sermorelin acetate,9/14/1988,Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.,Designated/Approved,,,9/26/1997,9/26/2004,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,24687
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,218,thalidomide,9/19/1988,1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving bone marrow transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Pediatric Pharmaceuticals, Inc.",718 Bradford Avenue,,Westfield,New Jersey,7090,United States,30788
BETHANIDINE SULFATE,J4THI5N7O2,Designated/Withdrawn,Public record,219,Bethanidine sulfate,9/20/1988,Treatment of primary ventricular fibrillation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medco Research, Inc.",8455 Beverly Blvd.,Suite 308,Los Angeles,California,90048,United States,26087
CAFFEINE,3G6A5W338E,Designated/Approved,Public record,220,Caffeine,9/20/1988,Treatment of apnea of prematurity.,Designated/Approved,,Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.,9/21/1999,9/21/2006,,"O.P.R. Development, L.P.",1501 Wakarusa Drive,,Lawrence,Kansas,66047,United States,31288
INOSINE PRANOBEX,W1SO0V223F,Designated,Public record,221,Inosine pranobex,9/20/1988,Treatment of subacute sclerosing panencephalitis.,Designated,Not FDA Approved for Orphan Indication,,,,,Newport Pharmaceuticals,897 West Sixteenth Street,,Newport Beach,California,92663,United States,26888
SOTALOL HYDROCHLORIDE,HEC37C70XX,Designated/Approved,Public record,222,Sotalol HCl,9/23/1988,1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias,Designated/Approved,,Treatment of life-threatening ventricular tachyarrhythmias,10/30/1992,10/30/1999,,"Berlex Laboratories, Inc.",300 Fairfield Road,,Wayne,New Jersey,7470,United States,30088
INTERFERON GAMMA-1B,21K6M2I7AG,Designated/Approved,Public record,223,Interferon gamma 1-b,9/30/1988,Treatment of chronic granulomatous disease.,Designated/Approved,,,12/20/1990,12/20/1997,,Horizon Therapeutic Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin 4,,,Ireland,29788
CLINDAMYCIN,3U02EL437C,Designated,Public record,226,Clindamycin,10/28/1988,Prevention of Pneumocystis carinii pneumonia in AIDS patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,235 East 42nd Street,,New York,New York,10017,United States,27088
CLINDAMYCIN,3U02EL437C,Designated,Public record,227,Clindamycin,10/28/1988,Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,Unit 0633-298-113,Kalamazoo,Michigan,49001,United States,26988
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,230,Cyclosporine ophthalmic,11/9/1988,Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,University Of Georgia,College Of Veterinary Medicine,Department of Small Animal Medicine,Athens,Georgia,30602,United States,29988
INTERFERON BETA-1B,TTD90R31WZ,Designated/Withdrawn,Public record,231,"Interferon beta, recombinant human",11/15/1988,Treatment of acquired immunodeficiency syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",1401 Harbor Bay Parkway,,Alameda,California,94501,United States,31788
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,232,Thalidomide,11/15/1988,Treatment and maintenance of reactional lepromatous leprosy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Pediatric Pharmaceuticals, Inc.",718 Bradford Avenue,,Westfield,New Jersey,7090,United States,32188
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,234,Interferon alfa-2b (recombinant),11/17/1988,Treatment of acute hepatitis B.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,26487
INTERFERON BETA-1B,TTD90R31WZ,Designated/Approved,Public record,235,Interferon beta-1b,11/17/1988,Treatment of multiple sclerosis.,Designated/Approved,,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.,7/23/1993,7/23/2000,,Chiron Corp. & Berlex Laboratories,4560 Horton Street,,Emeryville,California,94608,United States,31888
GALLIUM NITRATE,VRA0C6810N,Designated/Approved/Withdrawn,Public record,238,Gallium nitrate injection,12/5/1988,Treatment of hypercalcemia of malignancy.,Designated/Approved/Withdrawn,,,1/17/1991,1/17/1998,,Solopak Pharmaceutical Co.,1845 Tonne Road,,Elk Grove Village,Illinois,60007,United States,24487
Calcium acetate,Y882YXF34X,Designated/Approved,Public record,240,Calcium acetate,12/22/1988,Treatment of hyperphosphatemia in end stage renal failure.,Designated/Approved,,,12/10/1990,12/10/1997,,Fresenius Medical Care North America,920 Winter Street,,Waltham,Massachusetts,2451,United States,31588
CETIEDIL CITRATE,IE65P4OE02,Designated/Withdrawn,Public record,241,Cetiedil citrate injection,12/22/1988,Treatment of sickle cell disease crisis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Baker Cummins Pharmaceuticals, Inc.",,,,,,,31488
FOMEPIZOLE,83LCM6L2BY,Designated/Approved,Public record,242,fomepizole,12/22/1988,Treatment of methanol or ethylene glycol poisoning.,Designated/Approved,,"Use for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis",12/8/2000,12/8/2007,,"Par Pharmaceuticals, Inc",1 Ram Ridge Road,,Chestnut Ridge,New York,10977,United States,33388
FOMEPIZOLE,83LCM6L2BY,Designated/Approved,Public record,243,fomepizole,12/22/1988,Treatment of methanol or ethylene glycol poisoning.,Designated/Approved,,"As an antidote to ethylene glycol (antifreeze) poisoning, or for use in suspected ethylene glycol ingestion.",12/4/1997,12/4/2004,,"Par Pharmaceuticals, Inc",1 Ram Ridge Road,,Chestnut Ridge,New York,10977,United States,33388
ISOLEUCINE,04Y7590D77,Designated,Public record,244,Branched chain amino acids,12/23/1988,Treatment of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Mount Sinai Medical Center,One Gustave L. Levy Place,,New York,New York,10029,United States,33588
VALINE,HG18B9YRS7,Designated,Public record,244,Branched chain amino acids,12/23/1988,Treatment of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Mount Sinai Medical Center,One Gustave L. Levy Place,,New York,New York,10029,United States,33588
LEUCINE,GMW67QNF9C,Designated,Public record,244,Branched chain amino acids,12/23/1988,Treatment of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Mount Sinai Medical Center,One Gustave L. Levy Place,,New York,New York,10029,United States,33588
MITOLACTOL,LJ2P1SIK8Y,Designated,Public record,246,Mitolactol,1/23/1989,Treatment of invasive carcinoma of the uterine cervix,Designated,Not FDA Approved for Orphan Indication,,,,,"Targent, Inc..",155 Lambert Drive,,Princeton,New Jersey,8540,United States,33188
CLONIDINE,MN3L5RMN02,Designated/Approved,Public record,247,Clonidine,1/24/1989,"For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.",Designated/Approved,,In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.,10/2/1996,10/2/2003,,"Roxane Laboratories, Inc.",PO Box 16532,,Columbus,Ohio,43216,United States,34388
FELBAMATE,X72RBB02N8,Designated/Approved,Public record,248,Felbamate,1/24/1989,Treatment of Lennox-Gastaut syndrome.,Designated/Approved,,As adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children.,7/29/1993,7/29/2000,,Wallace Laboratories,301B College Road East,,Princeton,New Jersey,8540,United States,33488
MOLGRAMOSTIM,B321AL142J,Designated/Withdrawn,Public record,249,Molgramostim,1/24/1989,"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,34188
IMCIROMAB PENTETATE,3U979E1001,Designated,Public record,250,Imciromab pentetate,1/25/1989,Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",244 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,32888
BOTULISM IMMUNE GLOBULIN IV HUMAN,,Designated/Approved,Public record,251,Botulism immune globulin,1/31/1989,Treatment of infant botulism.,Designated/Approved,,Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum.,10/23/2003,10/23/2010,,California Department of Health Services,2151 Berkeley Way,,Berkeley,California,94704,United States,34488
FLUOROURACIL,U3P01618RT,Designated/Withdrawn,Public record,252,Fluorouracil,2/6/1989,For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Lederle Laboratories,Division of American Cyanamid Company,401 N. Middletown Road,Pearl River,New York,10965,United States,32088
THREONINE,2ZD004190S,Designated/Withdrawn,Public record,253,L-threonine,2/6/1989,Treatment of amyotrophic lateral sclerosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Tyson And Associates,12832 Chadron Avenue,,Hawthorne,California,90250,United States,33888
EPOETIN ALFA,,Designated,Public record,254,Epoetin alpha,3/7/1989,Treatment of HIV associated anemia related to HIV infection or HIV treatment.,Designated,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute,"Route 202, P.O. Box 300",,Raritan,New Jersey,8869,United States,32688
CASCARA SAGRADA BARK,,Designated,Public record,255,Cascara sagrada fluid extract,3/21/1989,Treatment of oral drug overdosage to speed lower bowel evacuation.,Designated,Not FDA Approved for Orphan Indication,,,,,Intramed Corporation,102 Tremont Way,,Augusta,Georgia,30907,United States,34288
ALDESLEUKIN,M89N0Q7EQR,Designated,Public record,256,Aldesleukin,3/22/1989,Treatment of primary immunodeficiency disease associated with T-cell defects.,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Melanie-Rose Brown,45 Great Valley Parkway,Malvern,Pennsylvania,19355,United States,28988
ILEPCIMIDE,5ML58O200F,Designated,Public record,257,Antiepilepsirine,3/23/1989,Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.,Designated,Not FDA Approved for Orphan Indication,,,,,Children's Hospital,700 Children's Drive,,Columbus,Ohio,43205,United States,34588
BOTULINUM TOXIN TYPE A,E211KPY694,Designated,Public record,258,Botulinum toxin type A,3/23/1989,Treatment of essential blepharospasm.,Designated,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.","1155 15th Street, N.W., #315",,Washington,District of Columbia,20005,United States,35789
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,260,Somatropin for injection,3/23/1989,Treatment of short stature associated with Turner's syndrome.,Designated/Approved,,Treatment of growth failure associated with Turner syndrome.,12/30/1996,12/30/2003,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,94080,United States,12686
FLUDARABINE PHOSPHATE,1X9VK9O1SC,Designated,Public record,261,Fludarabine phosphate,4/18/1989,Treatment and management of patients with non-Hodgkins lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",15049 San Pablo Avenue,P.O. Box 4099,Richmond,California,94804,United States,35889
FLUDARABINE PHOSPHATE,1X9VK9O1SC,Designated/Approved,Public record,262,Fludarabine phosphate,4/18/1989,"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.",Designated/Approved,,,4/18/1991,4/18/1998,,"Berlex Laboratories, Inc.","15049 San Pablo Avenue, P.O. Box 4099",,Richmond,California,94804,United States,27688
SOMATROPIN,NQX9KB6PCL,Designated,Public record,263,Somatropin (rDNA),5/3/1989,For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,24587
BROMHEXINE,Q1J152VB1P,Designated/Withdrawn,Public record,264,Bromhexine,5/15/1989,Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.","900 Ridgebury Road, Box 368",,Ridgefield,Connecticut,6877,United States,34789
MOLGRAMOSTIM,B321AL142J,Designated/Withdrawn,Public record,265,Granulocyte macrophage-colony stimulating factor,6/6/1989,Treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,27588
INTERFERON ALFA-2A,47RRR83SK7,Designated/Approved,Public record,266,Interferon alfa-2a,6/6/1989,Treatment of chronic myelogenous leukemia.,Designated/Approved,,Treatment of chronic myelogenous leukemia.,10/19/1995,10/19/2002,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,36989
PORFIMER SODIUM,Y3834SIK5F,Designated/Approved,Public record,267,Porfimer sodium,6/6/1989,For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.,Designated/Approved,,"Photodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy.",12/27/1995,12/27/2002,,"QLT Phototherapeutics, Inc.",Lederle Laboratories,401 North Middletown Road,Pearl River,New York,10965,United States,35589
Calcium acetate,Y882YXF34X,Designated,Public record,268,Calcium acetate,6/27/1989,Treatment of hyperphosphatemia in end stage renal disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Pharmedic Company,"28101 Ballard Road, Suite F",,Lake Forest,Illinois,60045,United States,36489
COAGULATION FACTOR IX (HUMAN),,Designated/Approved,Public record,269,Coagulation factor IX,6/27/1989,Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.,Designated/Approved,,"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.",8/20/1992,8/20/1999,,Armour Pharmaceutical Company,"500 Arcola Road, P.O. Box 1200",,Collegeville,Pennsylvania,19426,United States,36189
COAGULATION FACTOR IX HUMAN,6U90Y1795T,Designated/Approved,Public record,269,Coagulation factor IX,6/27/1989,Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.,Designated/Approved,,"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.",8/20/1992,8/20/1999,,Armour Pharmaceutical Company,"500 Arcola Road, P.O. Box 1200",,Collegeville,Pennsylvania,19426,United States,36189
POLOXAMER 188,LQA7B6G8JG,Designated,Public record,270,poloxamer 188 (purified),6/27/1989,Treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease),Designated,Not FDA Approved for Orphan Indication,,,,,Mast Therapeutics Inc.,3611 Valley Centre rive,Suite 500,San Diego,California,92130,United States,38189
ADENOSINE,K72T3FS567,Designated/Withdrawn,Public record,272,Adenosine,8/1/1989,For use in conjunction with BCNU in the treatment of brain tumors.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medco Research, Inc.",8455 Beverly Boulevard,Suite 308,Los Angeles,California,90048,United States,32388
AMIFOSTINE,M487QF2F4V,Designated/Withdrawn,Public record,273,Ethiofos,8/1/1989,Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,U.S. Bioscience,100 Front Street,,West Conshohocken,Pennsylvania,19428,United States,24187
LEVCYCLOSERINE,AK7DRB7FMO,Designated,Public record,274,L-cycloserine,8/1/1989,Treatment of Gaucher's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Lev, Meir M.D.","The City College, City University Of NY Medical Sc",Convent Avenue at 138 Street,New York,New York,10031,United States,38489
ASPIRIN LYSINE,XAN4V337CI,Designated/Withdrawn,Public record,275,Lysine acetylsalicylate injectable,8/1/1989,Treatment of pain and fever secondary to sickle cell disease crisis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,G.D. Searle & Company,4901 Searle Parkway,,Skokie,Illinois,60077,United States,33988
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,279,Somatropin for injection,8/4/1989,Treatment of growth retardation associated with chronic renal failure.,Designated/Approved,,Treatment of children with growth failure associated with chronic renal insufficency.,11/17/1993,11/17/2000,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,94080,United States,34989
MOLGRAMOSTIM,B321AL142J,Designated/Withdrawn,Public record,280,Granulocyte macrophage-colony stimulating factor,8/7/1989,Treatment of myelodysplastic syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,37889
SOMATORELIN,4UR7N9Z9MM,Designated,Public record,281,Growth hormone releasing factor,8/7/1989,For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,Designated,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America,700 Route 202/206,,Bridgewater,New Jersey,8807,United States,37389
INDIUM IN-111 IMCIROMAB PENTETATE,77OCC8FTPV,Designated/Withdrawn,Public record,284,Indium In 111 murine monoclonal antibody FAB to myosin,8/7/1989,To aid in the diagnosis of myocarditis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",244 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,33788
SOMATORELIN,4UR7N9Z9MM,Designated,Public record,286,somatorelin,8/8/1989,Diagnostic measure of the capacity of the pituitary gland to release growth hormone.,Designated,Not FDA Approved for Orphan Indication,,,,,"Ferring Laboratories, Inc.","400 Rella Boulevard, Suite 201",,Suffern,New York,10901,United States,36689
GLUCONOLACTONE,WQ29KQ9POT,Designated/Approved,Public record,287,"Citric acid, glucono-delta-lactone and magnesium carbonate",8/28/1989,Treatment of renal and bladder calculi of the apatite or struvite variety.,Designated/Approved,,,10/2/1990,10/2/1997,,"United-Guardian, Inc.",P.O. Box 2500,,Smithtown,New York,11787,United States,40189
MAGNESIUM CARBONATE,0E53J927NA,Designated/Approved,Public record,287,"Citric acid, glucono-delta-lactone and magnesium carbonate",8/28/1989,Treatment of renal and bladder calculi of the apatite or struvite variety.,Designated/Approved,,,10/2/1990,10/2/1997,,"United-Guardian, Inc.",P.O. Box 2500,,Smithtown,New York,11787,United States,40189
ILOPROST,JED5K35YGL,Designated/Withdrawn,Public record,289,Iloprost solution for infusion,9/21/1989,Treatment of Raynaud's phenomenon secondary to systemic sclerosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",300 Fairfield Road,,Wayne,New Jersey,7470,United States,38789
TROLEANDOMYCIN,C4DZ64560D,Designated/Withdrawn,Public record,290,Troleandomycin,9/21/1989,Treatment of severe steroid-requiring asthma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Szefler, Stanley M. M.D.",National Jewish Center for Immunology and Respirat,1400 Jackson Street,Denver,Colorado,80206,United States,39089
"""ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT""",P89DR4NY54,Designated/Approved,Public record,291,Antihemophilic factor (recombinant),9/25/1989,Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.,Designated/Approved,,Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease),2/25/1993,2/25/2000,,Bayer Corporation,1884 Miles Avenue,,Elkhart,Indiana,46515,United States,39289
MOLGRAMOSTIM,B321AL142J,Designated/Withdrawn,Public record,292,Molgramostim,9/25/1989,Treatment of aplastic anemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,39989
INDIUM IN-111 SATUMOMAB PENDETIDE,7V9926378A,Designated/Approved,Public record,293,Satumomab pendetide,9/25/1989,Detection of ovarian carcinoma.,Designated/Approved,,For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.,12/29/1992,12/29/1999,,Cytogen Corporation,600 College Road East,,Princeton,New Jersey,8540,United States,36789
ANCROD,EL55307L15,Designated,Public record,294,Ancrod,10/20/1989,To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.,Designated,Not FDA Approved for Orphan Indication,,,,,Knoll Pharmaceutical Company,"3000 Continental Dr., North",,Mt. Olive,New Jersey,7828,United States,37189
CETYL ALCOHOL,936JST6JCN,Designated/Approved,Public record,295,"Colfosceril palmitate, cetyl alcohol, tyloxapol",10/20/1989,"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32",Designated/Approved,,"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages",8/2/1990,8/2/1997,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,14886
COLFOSCERIL PALMITATE,319X2NFW0A,Designated/Approved,Public record,295,"Colfosceril palmitate, cetyl alcohol, tyloxapol",10/20/1989,"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32",Designated/Approved,,"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages",8/2/1990,8/2/1997,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,14886
TYLOXAPOL,Y27PUL9H56,Designated/Approved,Public record,295,"Colfosceril palmitate, cetyl alcohol, tyloxapol",10/20/1989,"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32",Designated/Approved,,"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages",8/2/1990,8/2/1997,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,14886
ENISOPROST,J85F4K48Q1,Designated/Withdrawn,Public record,296,enisoprost,10/20/1989,1. For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,G.D. Searle & Company,4901 Searle Parkway,,Skokie,Illinois,60077,United States,37289
PEGASPARGASE,7D96IR0PPM,Designated/Approved,Public record,297,Pegaspargase,10/20/1989,Treatment of acute lymphocytic leukemia.,Designated/Approved,,Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.,2/1/1994,2/1/2001,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,39589
PEGASPARGASE,7D96IR0PPM,Designated/Approved,Public record,298,Pegaspargase,10/20/1989,Treatment of acute lymphocytic leukemia.,Designated/Approved,,ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.,12/20/2018,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,39589
FLUOROURACIL,U3P01618RT,Designated,Public record,299,Fluorouracil,10/27/1989,"For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.",Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,40589
INTERFERON ALFA-2A,47RRR83SK7,Designated,Public record,300,Interferon alfa-2a (recombinant),10/27/1989,For use in combination with fluorouracil for the treatment of esophageal carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,40889
LEVOCARNITINE,0G389FZZ9M,Designated,Public record,301,levocarnitine,11/15/1989,1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in valproic acid toxicity,Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,20878,United States,32488
PORFIMER SODIUM,Y3834SIK5F,Designated,Public record,302,Porfimer sodium,11/15/1989,For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.,Designated,Not FDA Approved for Orphan Indication,,,,,"QLT Phototherapeutics, Inc.",Lederle Laboratories,401 North Middletown Road,Pearl River,New York,10965,United States,39489
NAVURIDINE,PS28W65479,Designated/Withdrawn,Public record,303,"3'-azido-2',3'dideoxyuridine",11/20/1989,Treatment of acquired immunodeficiency syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",1401 Harbor Bay Parkway,,Alameda,California,94501,United States,39889
BETHANIDINE SULFATE,J4THI5N7O2,Designated/Withdrawn,Public record,308,Bethanidine sulfate,11/24/1989,Prevention of recurrence of primary ventricular fibrillation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medco Research, Inc.",8455 Beverly Blvd.,Suite 308,Los Angeles,California,90048,United States,32588
CORTICORELIN OVINE TRIFLUTATE,56X54T817Q,Designated/Approved,Public record,309,Corticorelin ovine triflutate,11/24/1989,For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.,Designated/Approved,,To differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.,5/23/1996,5/23/2003,,"Ferring Laboratories, Inc.","400 Rella Boulevard, Suite 201",,Suffern,New York,10901,United States,35089
PERFOSFAMIDE,U880A4FUDA,Designated/Withdrawn,Public record,310,Perfosfamide,12/4/1989,"For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Scios Nova, Inc.",2450 Bayshore Parkway,,Mountain View,California,94043,United States,37789
MOLGRAMOSTIM,B321AL142J,Designated/Withdrawn,Public record,311,Granulocyte macrophage-colony stimulating factor,12/12/1989,Treatment of neutropenia associated with bone marrow transplants.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,41389
AMINOSALICYLIC ACID,5B2658E0N2,Designated,Public record,313,4-aminosalicylic acid,12/13/1989,Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.,Designated,Not FDA Approved for Orphan Indication,,,,,"Beeken, Warren M.D.",University Of Vermont,Given C-317,Burlington,Vermont,5405,United States,37989
CARBOVIR,05469V2RW8,Designated/Withdrawn,Public record,314,Carbovir,12/13/1989,Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,41189
POLIFEPROSAN 20,S40C40DA21,Designated/Approved,Public record,315,polifeprosan 20 with carmustine,12/13/1989,Treatment of malignant glioma.,Designated/Approved,,As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated,9/23/1996,9/23/2003,,"Guilford Pharmaceuticals, Inc.",6611 Tributary Street,,Baltimore,Maryland,21224,United States,37089
CARMUSTINE,U68WG3173Y,Designated/Approved,Public record,315,polifeprosan 20 with carmustine,12/13/1989,Treatment of malignant glioma.,Designated/Approved,,As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated,9/23/1996,9/23/2003,,"Guilford Pharmaceuticals, Inc.",6611 Tributary Street,,Baltimore,Maryland,21224,United States,37089
POLIFEPROSAN 20,S40C40DA21,Designated/Approved,Public record,316,polifeprosan 20 with carmustine,12/13/1989,Treatment of malignant glioma.,Designated/Approved,,Expanding the indication to include patients with malignant glioma undergoing primary surgical resection.,2/25/2003,2/25/2010,,"Guilford Pharmaceuticals, Inc.",6611 Tributary Street,,Baltimore,Maryland,21224,United States,37089
CARMUSTINE,U68WG3173Y,Designated/Approved,Public record,316,polifeprosan 20 with carmustine,12/13/1989,Treatment of malignant glioma.,Designated/Approved,,Expanding the indication to include patients with malignant glioma undergoing primary surgical resection.,2/25/2003,2/25/2010,,"Guilford Pharmaceuticals, Inc.",6611 Tributary Street,,Baltimore,Maryland,21224,United States,37089
RIFABUTIN,1W306TDA6S,Designated,Public record,317,Rifabutin,12/18/1989,Treatment of disseminated Mycobacterium avium complex disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,235 East 42nd Street,,New York,New York,10017,United States,41889
RIFABUTIN,1W306TDA6S,Designated/Approved,Public record,318,Rifabutin,12/18/1989,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.,Designated/Approved,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.,12/23/1992,12/23/1999,,"Adria Laboratories, Inc.",P.O. Box 16529,,Columbus,Ohio,43216,United States,41989
AMIFAMPRIDINE,RU4S6E2G0J,Designated,Public record,322,Dynamine,2/5/1990,Treatment of Lambert Eaton myasthenic syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Mayo Foundation,200 First Street Southwest,,Rochester,Minnesota,55905,United States,43189
TECELEUKIN,H5ZRB188EI,Designated,Public record,323,Interleukin-2,2/5/1990,Treatment of metastatic renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,36289
TECELEUKIN,H5ZRB188EI,Designated,Public record,325,Interleukin-2,2/6/1990,Treatment of metastatic malignant melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,36389
SERMORELIN ACETATE,00IBG87IQW,Designated/Withdrawn,Public record,326,Sermorelin acetate,2/13/1990,Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,31988
FRUCTOSE,6YSS42VSEV,Designated/Withdrawn,Public record,327,Glyceol,2/22/1990,To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Chugai Pharmaceutical Co., Ltd.",,,,,,,28188
GLYCERIN,PDC6A3C0OX,Designated/Withdrawn,Public record,327,Glyceol,2/22/1990,To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Chugai Pharmaceutical Co., Ltd.",,,,,,,28188
POLOXAMER 188,LQA7B6G8JG,Designated,Public record,328,Poloxamer 188,2/22/1990,Treatment of severe burns requiring hospitalization.,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,154 Technology Parkway,,Norcross,Georgia,30092,United States,40389
DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL,6PHSP9EORV,Designated,Public record,329,Disaccharide tripeptide glycerol dipalmitoyl,3/1/1990,Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunoTherapeutics, Inc.",3505 Riverview Circle,,Moorhead,Minnesota,56560,United States,39789
DEXTRAN 70,7SA290YK68,Designated,Public record,330,Dextran 70,3/5/1990,Treatment of recurrent corneal erosion unresponsive to conventional therapy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Holles Laboratories, Inc.",30 Forest Notch,,Cohasset,Massachusetts,2025,United States,42689
CLODRONATE DISODIUM,N030400H8J,Designated,Public record,331,Disodium clodronate tetrahydrate,3/5/1990,Treatment of increased bone resorption due to malignancy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Anthra Pharmaceuticals, Inc.","103 Carnegie Center, Suite 102",,Princeton,New Jersey,8540,United States,40689
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,332,Thalidomide,3/5/1990,Prevention of graft versus host disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Andrulis Research Corporation,"11800 Baltimore Avenue, Suite 113",,Beltsville,Maryland,20705,United States,43890
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,333,Thalidomide,3/5/1990,Treatment of graft versus host disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Andrulis Research Corporation,"11800 Baltimore Avenue, Suite 113",,Beltsville,Maryland,20705,United States,43790
MDX-11,7SEQ6X57ZH,Designated/Withdrawn,Public record,334,Monoclonal antibodies PM-81 and AML-2-23,3/12/1990,For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medarex, Inc.",67 Beaver Avenue,,Annandale,New Jersey,8801,United States,39689
SUCRALFATE,XX73205DH5,Designated,Public record,335,Sucralfate suspension,3/12/1990,Treatment of oral complications of chemotherapy in bone marrow transplant patients.,Designated,Not FDA Approved for Orphan Indication,,,,,"Darby Pharmaceuticals, Inc.",100 Banks Avenue,,Rockville Centre,New York,11570,United States,41089
ACECAINIDE,910Q707V6F,Designated/Withdrawn,Public record,336,N-acetylprocainamide,3/23/1990,To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medco Research, Inc.",8455 Beverly Blvd.,Suite 308,Los Angeles,California,90048,United States,35989
FLUOROURACIL,U3P01618RT,Designated,Public record,337,Fluorouracil,4/18/1990,"For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.",Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,42289
INTERFERON ALFA-2A,47RRR83SK7,Designated,Public record,340,Interferon alfa-2a (recombinant),5/2/1990,For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,44590
MOLGRAMOSTIM,B321AL142J,Designated/Withdrawn,Public record,342,Granulocyte macrophage-colony stimulating factor,5/3/1990,Treatment of neutropenia due to hairy cell leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,41289
TECELEUKIN,H5ZRB188EI,Designated,Public record,343,Interleukin-2,5/3/1990,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,44490
SARGRAMOSTIM,5TAA004E22,Designated/Approved,Public record,344,sargramostim,5/3/1990,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.",Designated/Approved,,,3/5/1991,3/5/1998,,Immunex Corporation,51 University Street,,Seattle,Washington,98101,United States,44290
MOLGRAMOSTIM,B321AL142J,Designated/Withdrawn,Public record,345,Granulocyte macrophage-colony stimulating factor,5/4/1990,Treatment of chronic lymphocytic leukemia to increase granulocyte count.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,43289
INTERFERON ALFA-2B,43K1W2T1M6,Designated/Withdrawn,Public record,346,Interferon alfa-2b (recombinant),5/4/1990,Treatment of chronic delta hepatitis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,40289
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,348,Somatropin,5/8/1990,Treatment of short stature associated with Turner syndrome.,Designated/Approved,,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.,12/30/1996,12/30/2003,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,45090
INTERFERON ALFA-2A,47RRR83SK7,Designated,Public record,349,Interferon alfa-2a (recombinant),5/11/1990,For the treatment of metastatic malignant melanoma in combination with Teceleukin.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,44690
TECELEUKIN,H5ZRB188EI,Designated,Public record,350,Interleukin-2,5/11/1990,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,44790
ILOPROST,JED5K35YGL,Designated/Withdrawn,Public record,351,Iloprost solution for infusion,5/14/1990,Treatment of heparin-associated thrombocytopenia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",300 Fairfield Road,,Wayne,New Jersey,7470,United States,40089
INTERFERON ALFA-2A,47RRR83SK7,Designated,Public record,352,Interferon alfa-2a (recombinant),5/14/1990,For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,42389
HEXAPEPTIDE-2,4H7N4I6X6A,Designated/Withdrawn,Public record,353,His-D-Trp-Ala-Trp-D-Phe-Lys NH2,5/23/1990,For the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,SmithKline Beecham Pharmaceuticals,One Franklin Plaza,,Philadelphia,Pennsylvania,19101,United States,46190
PENICILLIN G,Q42T66VG0C,Designated/Withdrawn,Public record,354,PR-239 (redox penicillin G),5/23/1990,Treatment of AIDS associated neurosyphilis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmos,2 Innovation Drive,,Alachua,Florida,32615,United States,37689
ACYCLOVIR,X4HES1O11F,Designated/Withdrawn,Public record,355,PR-225 (redox-acyclovir),5/29/1990,Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmos,2 Innovation Drive,,Alachua,Florida,32615,United States,37589
AMIFOSTINE,M487QF2F4V,Designated/Approved,Public record,357,Amifostine,5/30/1990,For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.,Designated/Approved,,To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.,12/8/1995,12/8/2002,,"Medimmune Oncology, Inc.",One Tower Bridge,"100 Front Street, Suite 400",West Conshohocken,Pennsylvania,19428,United States,42789
AMIFOSTINE,M487QF2F4V,Designated,Public record,358,Amifostine,5/30/1990,For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Merav Edan,45 Great Valley Parkway,Malvern,Pennsylvania,19355,United States,42989
AMIFOSTINE,M487QF2F4V,Designated,Public record,359,Amifostine,5/30/1990,For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Merav Edan,45 Great Valley Parkway,Malvern,Pennsylvania,19355,United States,42889
CALCIUM CARBONATE,H0G9379FGK,Designated,Public record,360,Calcium carbonate,6/6/1990,Treatment of hyperphosphatemia in patients with end stage renal disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"R & D Laboratories, Inc.",4204 Glencoe Avenue,,Marina Del Rey,California,90292,United States,42189
Sodium dichloroacetate,42932X67B5,Designated,Public record,361,Sodium dichloroacetate,6/11/1990,Treatment of homozygous familial hypercholesterolemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Stacpoole, Peter W. M.D., Ph.D.",University of Florida,P.O. Box 100277,Gainesville,Florida,32610,United States,45390
Sodium dichloroacetate,42932X67B5,Designated,Public record,362,Sodium dichloroacetate,6/11/1990,Treatment of congenital lactic acidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Stacpoole, Peter W. M.D., Ph.D.",University of Florida,P.O. Box 100277,Gainesville,Florida,32610,United States,45290
COAGULATION FACTOR IX (HUMAN),,Designated/Approved,Public record,363,Coagulation Factor IX (human),7/5/1990,"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.",Designated/Approved,,,12/31/1990,12/31/1997,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,90032,United States,45890
OXANDROLONE,7H6TM3CT4L,Designated/Withdrawn,Public record,364,Oxandrolone,7/5/1990,Treatment of short stature associated with Turner's syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,8830,United States,45590
PHENYTOIN,6158TKW0C5,Designated/Withdrawn,Public record,365,Pr-122 (redox-phenytoin),7/5/1990,"For the emergency rescue treatment of status epilepticus, grand mal type.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmos,2 Innovation Drive,,Alachua,Florida,32615,United States,43490
GENTAMICIN,T6Z9V48IKG,Designated,Public record,366,Gentamicin liposome injection,7/10/1990,Treatment of disseminated Mycobacterium avium-intracellulare infection.,Designated,Not FDA Approved for Orphan Indication,,,,,"Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,8540,United States,47390
MORPHINE SULFATE,X3P646A2J0,Designated/Approved,Public record,367,Morphine sulfate concentrate (preservative free),7/12/1990,For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.,Designated/Approved,,For intrathecal or epidural infusion in the treatment of tractable chronic pain. It was developed for use in continuous microinfusion devices and may require dilution before use as directed.,7/19/1991,7/19/1998,,"Elkins-Sinn, Inc.",2 Esterbrook Lane,,Cherry Hill,New Jersey,8003,United States,18587
"""BACLOFEN, (S)-""",3OHN4989XM,Designated,Public record,368,L-baclofen,7/13/1990,Treatment of trigeminal neuralgia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Fromm, Gerhard M.D.",University Of Pittsburgh School of Medicine,,Pittsburgh,Pennsylvania,15261,United States,45690
AMILORIDE HYDROCHLORIDE,FZJ37245UC,Designated/Withdrawn,Public record,369,Amiloride HCl solution for inhalation,7/18/1990,Treatment of cystic fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Research and Development,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,27709,United States,48190
MAFENIDE ACETATE,RQ6LP6Z0WY,Designated/Approved,Public record,370,Mafenide acetate solution,7/18/1990,For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.,Designated/Approved,,,6/5/1998,6/5/2005,,"Mylan Laboratories, Inc.",781 Chestnut Ridge Road,P.O. Box 4310,Morgantown,West Virginia,26504,United States,47890
AGALSIDASE ALFA,2HLC17MX9G,Designated,Public record,371,Alpha-galactosidase A,7/20/1990,Treatment of Fabry's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Desnick, Robert J. M.D.",The Mount Sinai School Of Medicine,"Fifth Avenue at 100th Street, Box 1203",New York,New York,10029,United States,47190
CLADRIBINE,47M74X9YT5,Designated/Withdrawn,Public record,372,Cladribine,7/20/1990,Treatment of acute myeloid leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,47990
CARBAMAZEPINE,33CM23913M,Designated/Withdrawn,Public record,373,Pr-320 (molecusol-carbamazepine),7/20/1990,"For the emergency rescue treatment of status epilepticus, grand mal type.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmos,2 Innovation Drive,,Alachua,Florida,32615,United States,43590
LIOTHYRONINE SODIUM,GCA9VV7D2N,Designated/Approved,Public record,374,Liothyronine sodium injection,7/30/1990,Treatment of myxedema coma/precoma.,Designated/Approved,,Treatment of myxedema coma/precoma.,12/31/1991,12/31/1998,,SmithKline Beecham Pharmaceuticals,One Franklin Plaza,P.O. Box 7929,Philadelphia,Pennsylvania,19101,United States,46090
TRIPTORELIN PAMOATE,08AN7WA2G0,Designated/Withdrawn,Public record,375,Triptorelin pamoate,8/10/1990,For use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Debio R.A. Inc.,"7929 Westpark Drive, Suite 400",,Mclean,Virginia,22102,United States,34688
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Withdrawn,Public record,376,C1-inhibitor,8/30/1990,Treatment of acute attacks of angioedema.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corp.,Hyland Division (Baxter Hyland),550 North Brand Blvd.,Glendale,California,91203,United States,46490
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Withdrawn,Public record,376,C1-inhibitor,8/30/1990,Treatment of acute attacks of angioedema.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corp.,Hyland Division (Baxter Hyland),550 North Brand Blvd.,Glendale,California,91203,United States,46490
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Withdrawn,Public record,377,C1-inhibitor,8/30/1990,"Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corp.,Hyland Division (Baxter Hyland),550 North Brand Blvd.,Glendale,California,91203,United States,46590
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Withdrawn,Public record,377,C1-inhibitor,8/30/1990,"Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corp.,Hyland Division (Baxter Hyland),550 North Brand Blvd.,Glendale,California,91203,United States,46590
FILGRASTIM,PVI5M0M1GW,Designated/Withdrawn,Public record,378,Filgrastim,8/30/1990,Treatment of myelodysplastic syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,91320,United States,49090
ATOVAQUONE,Y883P1Z2LT,Designated/Approved,Public record,381,Atovaquone,9/10/1990,Treatment of AIDS associated Pneumocystis Carinii Pneumonia.,Designated/Approved,,For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.,11/25/1992,11/25/1999,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,48890
CALCIUM GLUCONATE,SQE6VB453K,Designated,Public record,382,Calcium gluconate gel 2.5%,9/10/1990,Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.,Designated,Not FDA Approved for Orphan Indication,,,,,"Paddock Laboratories, Inc.",3940 Quebec Avenue North,,Minneapolis,Minnesota,55427,United States,46290
SULFAPYRIDINE,Y5V2N1KE8U,Designated,Public record,383,Sulfapyridine,9/10/1990,Treatment of dermatitis herpetiformis.,Designated,Not FDA Approved for Orphan Indication,,,,,Jacobus Pharmaceutical Company,37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,8540,United States,51090
BOS TAURUS COLOSTRUM IMMUNOGLOBULINS,EP5SDKM7A0,Designated/Withdrawn,Public record,384,Lactobin,9/12/1990,Treatment of AIDS-associated diarrhea unresponsive to initial antidiarrheal therapy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Roxane Laboratories, Inc.",PO Box 16532,,Columbus,Ohio,43216,United States,46990
LEUPEPTIN,J97339NR3V,Designated,Public record,385,Leupeptin,9/18/1990,For use as an adjunct to microsurgical peripheral nerve repair.,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuromuscular Adjuncts, Inc.",S.U.N.Y. at Stony Brook,H.S.C. T18-020,Stony Brook,New York,11794,United States,49690
Pilocarpine,01MI4Q9DI3,Designated/Approved,Public record,386,Pilocarpine,9/24/1990,Treatment of xerostomia induced by radiation therapy for head and neck cancer.,Designated/Approved,,Treatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck.,3/22/1994,3/22/2001,,"MGI Pharma, Inc.",5775 West Old Shakoppe Rd.,Suite 100,Bloomington,Minnesota,55437,United States,45990
RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN),78I1W13C3D,Designated/Approved,Public record,387,Respiratory syncytial virus immune globulin (Human),9/27/1990,Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.,Designated/Approved,,For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to 35 weeks gestation).,1/18/1996,1/18/2003,,MedImmune & Massachussetts Public Health Biologics Labs.,35 West Watkins Mill Road,,Gaithersburg,Maryland,20878,United States,51190
RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN),78I1W13C3D,Designated,Public record,388,Respiratory Syncytial Virus Immune Globulin (human),9/27/1990,Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.,Designated,Not FDA Approved for Orphan Indication,,,,,"MedImmune, Inc.",35 West Watkins Mill Road,,Gaithersburg,Maryland,20878,United States,51290
FILGRASTIM,PVI5M0M1GW,Designated/Approved,Public record,389,Filgrastim,10/1/1990,Treatment of neutropenia associated with bone marrow transplants.,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT.,6/15/1994,6/15/2001,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,91320,United States,50090
Hydroxyurea,X6Q56QN5QC,Designated/Approved,Public record,390,Hydroxyurea,10/1/1990,Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.,Designated/Approved,,To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months).,2/25/1998,2/25/2005,,Bristol-Myers Squibb Pharmaceutical Research Institute,P.O. Box 4000,,Princeton,New Jersey,8543,United States,49590
OXANDROLONE,7H6TM3CT4L,Designated/Withdrawn,Public record,392,Oxandrolone,10/5/1990,Treatment of constitutional delay of growth and puberty.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,8830,United States,45790
LAUROCAPRAM,1F3X9DRV9X,Designated,Public record,393,Methotrexate with laurocapram,10/15/1990,Topical treatment of mycosis fungoides.,Designated,Not FDA Approved for Orphan Indication,,,,,"Echo Therapeutics, Ltd.",8 Penn Center,1628 JFK Blvd,Philadelphia,Pennsylvania,19103,United States,43389
METHOTREXATE,YL5FZ2Y5U1,Designated,Public record,393,Methotrexate with laurocapram,10/15/1990,Topical treatment of mycosis fungoides.,Designated,Not FDA Approved for Orphan Indication,,,,,"Echo Therapeutics, Ltd.",8 Penn Center,1628 JFK Blvd,Philadelphia,Pennsylvania,19103,United States,43389
PACLITAXEL,P88XT4IS4D,Designated/Withdrawn,Public record,394,Taxol isolated from Taxus brevifolia,10/15/1990,Treatment of ovarian cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,6492,United States,50190
GOSSYPOL,KAV15B369O,Designated,Public record,395,Gossypol,10/22/1990,Treatment of cancer of the adrenal cortex.,Designated,Not FDA Approved for Orphan Indication,,,,,"Reidenberg, Marcus M. M.D.",The New York Hospital - Cornell Medical Center,"525 East 68th Street, Box 70",New York,New York,10021,United States,46390
TRETINOIN,5688UTC01R,Designated/Approved,Public record,396,Tretinoin,10/24/1990,Treatment of acute promyelocytic leukemia.,Designated/Approved,,Induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens.,11/22/1995,11/22/2002,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,50990
CALCITONIN SALMON,7SFC6U2VI5,Designated/Withdrawn,Public record,397,Calcitonin salmon nasal spray,10/29/1990,Treatment of symptomatic Paget's disease (osteitis deformans).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sandoz Pharmaceuticals Corp.,59 Route 10,,East Hanover,New Jersey,7936,United States,48290
SUCCIMER,DX1U2629QE,Designated,Public record,398,Succimer,11/5/1990,Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sanofi Winthrop, Inc.",90 Park Avenue,,New York,New York,10016,United States,50790
FILGRASTIM,PVI5M0M1GW,Designated/Approved,Public record,399,Filgrastim,11/7/1990,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,Designated/Approved,,Treatment of patients with severe chronic neutropenia.,12/19/1994,12/19/2001,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,91320,United States,49390
CLADRIBINE,47M74X9YT5,Designated/Approved,Public record,401,Cladribine,11/15/1990,Treatment of hairy cell leukemia.,Designated/Approved,,,2/26/1993,2/26/2000,,R. W. Johnson Pharmaceutical Research Institute,"Route 202, P.O. Box 300",,Raritan,New Jersey,8869,United States,51690
BOS TAURUS COLOSTRUM,S256WJ3OFQ,Designated,Public record,403,Bovine colostrum,11/19/1990,Treatment of AIDS-related diarrhea.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hastings, Donald DVM",1030 North Parkview Drive,,Bismarck,North Dakota,58501,United States,55190
AMIFAMPRIDINE,RU4S6E2G0J,Designated/Approved,Public record,404,amifampridine,12/18/1990,Treatment of Lambert-Eaton myasthenic syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 801,Coral Gables,Florida,33134,United States,51590
LEVOLEUCOVORIN,990S25980Y,Designated/Approved,Public record,405,levoleucovorin,12/18/1990,For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum,Designated/Approved,,For use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer,4/29/2011,4/29/2018,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,48590
CLADRIBINE,47M74X9YT5,Designated/Withdrawn,Public record,406,cladribine,12/31/1990,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,54190
DRONABINOL,7J8897W37S,Designated/Approved,Public record,408,Dronabinol,1/15/1991,For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.,Designated/Approved,,Treatment of anorexia associated with weight loss in patients with AIDS.,12/22/1992,12/22/1999,,"Unimed Pharmaceuticals, Inc.",901 Sawyer Rd.,,Marietta,Georgia,30062,United States,54890
DORNASE ALFA,953A26OA1Y,Designated/Approved,Public record,409,Dornase alfa,1/16/1991,To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.,Designated/Approved,,In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function.,12/30/1993,12/30/2000,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,94080,United States,48090
TESTOSTERONE,3XMK78S47O,Designated/Withdrawn,Public record,410,Testosterone sublingual,1/16/1991,Treatment of constitutional delay of growth and puberty in boys.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,8830,United States,52590
DESMOPRESSIN ACETATE,XB13HYU18U,Designated/Approved,Public record,411,Desmopressin acetate,1/22/1991,Treatment of mild hemophilia A and von Willebrand's disease.,Designated/Approved,,Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.,3/7/1994,3/7/2001,,"Ferring Pharmaceuticals, Inc.",100 Interpace Parkway,,Parsippany-Troy Hills,New Jersey,7054,United States,51490
CYSTEAMINE,5UX2SD1KE2,Designated/Approved,Public record,413,Cysteamine,1/25/1991,Treatment of nephropathic cystinosis.,Designated/Approved,,Treatment of nephropathic cystinosis in adults and children.,8/15/1994,8/15/2001,,"Mylan Laboratories, Inc.",781 Chestnut Ridge Road,P.O. Box 4310,Morgantown,West Virginia,26504,United States,55690
HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN,129L90A25N,Designated,Public record,415,Cytomegalovirus immune globulin intravenous (human),1/28/1991,For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Bayer Corporation,"Pharmaceutical Division, Biological Products",400 Morgan Lane,New Haven,Connecticut,6516,United States,52190
PENTOSTATIN,395575MZO7,Designated,Public record,416,Pentostatin,1/29/1991,Treatment of patients with chronic lymphocytic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,50390
GENTAMICIN,T6Z9V48IKG,Designated,Public record,417,Gentamicin impregnated PMMA beads on surgical wire,1/31/1991,"Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.",Designated,Not FDA Approved for Orphan Indication,,,,,"Lipha Pharmaceuticals, Inc.",9 West 57th Street,Suite 3825,New York,New York,10019,United States,52090
IDARUBICIN HYDROCHLORIDE,5VV3MDU5IE,Designated/Withdrawn,Public record,419,Idarubicin HCl for injection,2/12/1991,Treatment of acute lymphoblastic leukemia in pediatric patients.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",235 East 42nd Street,,New York,New York,10017,United States,55890
INTERFERON BETA,V9GU1EM8SF,Designated/Withdrawn,Public record,420,Interferon beta (recombinant),2/12/1991,For the systemic treatment of metastatic renal cell carcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,53890
URSODIOL,724L30Y2QR,Designated/Withdrawn,Public record,421,Ursodiol,2/19/1991,Management of the clinical signs and symptoms associated with primary biliary cirrhosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,55390
SUCRALFATE,XX73205DH5,Designated,Public record,422,Sucralfate suspension,3/4/1991,Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.,Designated,Not FDA Approved for Orphan Indication,,,,,"Darby Pharmaceuticals, Inc.",100 Banks Avenue,,Rockville Centre,New York,11570,United States,47090
DEFEROXAMINE,J06Y7MXW4D,Designated,Public record,423,Dextran and deferoxamine,3/8/1991,Treatment of acute iron poisoning.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biomedical Frontiers, Inc.",1095 10th Avenue S.E.,,Minneapolis,Minnesota,55414,United States,52290
POLOXAMER 331,IS93EQR73R,Designated,Public record,424,Poloxamer 331,3/21/1991,Initial therapy of toxoplasmosis in patients with AIDS.,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,154 Technology Parkway,,Norcross,Georgia,30092,United States,55990
SUCCIMER,DX1U2629QE,Designated,Public record,425,Succimer,3/22/1991,Treatment of mercury intoxication.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sanofi Winthrop, Inc.",90 Park Avenue,,New York,New York,10016,United States,50890
KETOCONAZOLE,R9400W927I,Designated/Withdrawn,Public record,426,Ketoconazole,3/27/1991,For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmedic Company,28101 Ballard Road,,Lake Forest,Illinois,60045,United States,51990
SECRETORY LEUKOCYTE PROTEASE INHIBITOR,909E17P4ZW,Designated/Withdrawn,Public record,427,Recombinant secretory leucocyte protease inhibitor,3/29/1991,Treatment of congenital alpha-1 antitrypsin deficiency.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,3200 Walnut Street,,Boulder,Colorado,80301,United States,55490
SECRETORY LEUKOCYTE PROTEASE INHIBITOR,909E17P4ZW,Designated,Public record,428,Recombinant secretory leucocyte protease inhibitor,3/29/1991,Treatment of cystic fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",3200 Walnut Street,,Boulder,Colorado,80301,United States,55590
INTERFERON BETA-1A,XRO4566Q4R,Designated/Withdrawn,Public record,429,Interferon beta-1a (recombinant),4/3/1991,For the systemic treatment of cutaneous malignant melanoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,53290
RIBAVIRIN,49717AWG6K,Designated,Public record,430,ribavirin,4/12/1991,Treatment of hemorrhagic fever with renal syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals International,3300 Hyland Avenue,,Costa Mesa,California,92626,United States,57491
INTERFERON BETA,V9GU1EM8SF,Designated/Withdrawn,Public record,431,Interferon beta (recombinant),4/18/1991,For the systemic treatment of cutaneous T-cell lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,53390
OFLOXACIN,A4P49JAZ9H,Designated/Approved,Public record,432,Ofloxacin,4/18/1991,Treatment of bacterial corneal ulcers.,Designated/Approved,,Treatment of bacterial corneal ulcers.,5/22/1996,5/22/2003,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,92713,United States,56791
LEDISMASE,0786H5RV0T,Designated/Withdrawn,Public record,433,Recombinant human superoxide dismutase,4/18/1991,Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Savient Pharmaceuticals, Inc.","One Tower Center Boulevard, 12th floor",,East Brunswick,New Jersey,8816,United States,54990
ETIDRONATE DISODIUM,M16PXG993G,Designated/Withdrawn,Public record,434,Etidronate disodium,5/2/1991,Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MGI Pharma, Inc.",6300 West Old Shakoppe Rd.,Suite 110,Bloomington,Minnesota,55438,United States,49890
ETIDRONATE DISODIUM,M16PXG993G,Designated/Withdrawn,Public record,435,Etidronate disodium,5/2/1991,Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MGI Pharma, Inc.",6300 West Old Shakoppe Rd.,Suite 110,Bloomington,Minnesota,55438,United States,49790
HISTRELIN,H50H3S3W74,Designated,Public record,436,Histrelin,5/3/1991,"Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.",Designated,Not FDA Approved for Orphan Indication,,,,,"Anderson, Karl E., M.D.",University of Texas Medical Branch at Galveston,"Route J-09, 700 The Strand",Galveston,Texas,77550,United States,28488
THYMALFASIN,W0B22ISQ1C,Designated,Public record,437,thymalfasin,5/3/1991,Treatment of chronic active hepatitis B,Designated,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",950 Tower Lane,Suite 900,Foster City,California,94404,United States,52990
INTERFERON BETA,V9GU1EM8SF,Designated/Withdrawn,Public record,438,Interferon beta (recombinant),5/9/1991,For the intralesional and/or systemic treatment of AIDS-related Kaposi's sarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,53590
MUPLESTIM,A802907MI4,Designated/Withdrawn,Public record,439,Interleukin-3 human (recombinant),5/20/1991,Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation,51 University Street,,Seattle,Washington,98101,United States,53490
RINTATOLIMOD,94325AJ25N,Designated,Public record,440,Poly I: poly C12U,5/20/1991,Treatment of renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,783 Jersey Avenue,,New Brunswick,New Jersey,8901,United States,57091
CALCIUM GLUCONATE,SQE6VB453K,Designated,Public record,441,Calcium gluconate gel,5/21/1991,For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.,Designated,Not FDA Approved for Orphan Indication,,,,,Calgonate Corporation,3310 South Ocean Blvd,Unit 132,Highland Beach,Florida,33487,United States,6485
FOSPHENYTOIN,B4SF212641,Designated/Approved,Public record,442,Fosphenytoin,6/4/1991,For the acute treatment of patients with status epilepticus of the grand mal type.,Designated/Approved,,For the control of generalized convulsive status epilepticus.,8/5/1996,8/5/2003,,Warner-Lambert Company,2800 Plymouth Road,,Ann Arbor,Michigan,48106,United States,55790
PRILIXIMAB,TW5DE23BLM,Designated/Withdrawn,Public record,443,Chimeric M-T412 (human-murine) IgG monoclonal anti-CD4,6/5/1991,Treatment of multiple sclerosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,54490
NIFEDIPINE,I9ZF7L6G2L,Designated,Public record,444,Nifedipine,6/13/1991,Treatment of interstitial cystitis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Fleischmann, Jonathan M.D.",MetroHealth Medical Center,3395 Scranton Road,Cleveland,Ohio,44109,United States,57991
AGALSIDASE ALFA,2HLC17MX9G,Designated,Public record,445,Alpha-galactosidase A,6/17/1991,Treatment of alpha-galactosidase A deficiency (Fabry's disease).,Designated,Not FDA Approved for Orphan Indication,,,,,"David Calhoun, Ph.D.",Department of Chemistry,Convent Avenue & 138th Street,New York,New York,10031,United States,58691
INTERLEUKIN-1.ALPHA.,8666ZWZ3E1,Designated/Withdrawn,Public record,446,"Interleukin-1 alpha, human recombinant",6/17/1991,For the promotion of early engraftment in bone marrow transplantation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation,51 University Street,,Seattle,Washington,98101,United States,57191
INTERLEUKIN-1.ALPHA.,8666ZWZ3E1,Designated/Withdrawn,Public record,447,"Interleukin-1 alpha, human recombinant",6/17/1991,For hematopoietic potentiation in aplastic anemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation,51 University Street,,Seattle,Washington,98101,United States,57291
TUVIRUMAB,31Z0AB5WNC,Designated/Withdrawn,Public record,448,Monoclonal antibody to hepatitis B virus (human),6/17/1991,Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.",34801 Campus Dr.,,Fremont,California,94555,United States,58391
URSODIOL,724L30Y2QR,Designated/Approved,Public record,449,Ursodiol,6/20/1991,Treatment of patients with primary biliary cirrhosis,Designated/Approved,,,12/10/1997,12/10/2004,,"Aptalis Pharma US, Inc.",100 Somerset corporate Blvd,,Bridgewater,New Jersey,8807,United States,22187
MDX-11,7SEQ6X57ZH,Designated/Withdrawn,Public record,450,Monoclonal antibody -81,6/27/1991,Adjunctive treatment of acute myelogenous leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medarex, Inc.",67 Beaver Avenue,,Annandale,New Jersey,8801,United States,58791
EPOETIN ALFA,,Designated/Approved,Public record,452,Epoetin alfa,7/1/1991,Treatment of anemia associated with HIV infection or HIV treatment.,Designated/Approved,,Treatment of AZT-induced anemia in HIV infected patients.,12/31/1990,12/31/1997,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,91320,United States,56490
Testosterone propionate,WI93Z9138A,Designated,Public record,453,Testosterone propionate ointment 2%,7/31/1991,Treatment of vulvar dystrophies.,Designated,Not FDA Approved for Orphan Indication,,,,,"Star Pharmaceuticals, Inc.",1990 N.W. 44th Street,,Pompano Beach,Florida,33064,United States,57691
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,454,cyclosporine 2% ophthalmic ointment,8/1/1991,Treatment of patients at high risk of graft rejection following penetrating keratoplasty,Designated,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Drive,P. O. Box 19534,Irvine,California,92612,United States,51790
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,455,cyclosporine 2% ophthalmic ointment,8/1/1991,"For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer",Designated,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Drive,P. O. Box 19534,Irvine,California,92612,United States,58991
LEVOLEUCOVORIN,990S25980Y,Designated/Approved,Public record,456,Levoleucovorin,8/1/1991,For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.,Designated/Approved,,Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid,3/7/2008,3/7/2015,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,48490
MECASERMIN,7GR9I2683O,Designated/Withdrawn,Public record,457,mecasermin,8/5/1991,Treatment of amyotrophic lateral sclerosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",41 Moores Road,,Frazer,Pennsylvania,19355,United States,59191
TIRATRICOL,29OQ9EU4R1,Designated,Public record,458,Tiratricol,8/13/1991,For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.,Designated,Not FDA Approved for Orphan Indication,,,,,Laphal Laboratoires,"48 Bis, Rue des Belles-Feuilles",,Paris,,,France,46890
ATOVAQUONE,Y883P1Z2LT,Designated/Approved,Public record,459,Atovaquone,8/14/1991,"Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.",Designated/Approved,,Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.,1/5/1999,1/5/2006,,Glaxo Wellcome Research and Development,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,27709,United States,48990
FILGRASTIM,PVI5M0M1GW,Designated/Withdrawn,Public record,460,Filgrastim,9/3/1991,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Dr.,,Thousand Oaks,California,91320,United States,49990
OXANDROLONE,7H6TM3CT4L,Designated,Public record,461,Oxandrolone,9/6/1991,Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"One Tower Center Boulevard, 12 th floor",,East Brunswick,New Jersey,8816,United States,59091
EXEMESTANE,NY22HMQ4BX,Designated/Approved,Public record,463,Exemestane,9/19/1991,Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.,Designated/Approved,,Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.,10/21/1999,10/21/2006,,Pharmacia & Upjohn,7000 Portage Road,Mail Stop: 0636-298-113,Kalamazoo,Michigan,49001,United States,60191
TOREMIFENE,7NFE54O27T,Designated/Approved,Public record,464,Toremifene,9/19/1991,Hormonal therapy of metastatic carcinoma of the breast.,Designated/Approved,,Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.,5/29/1997,5/29/2004,,Orion Corporation,Orionintie 1,,Espoo,,,Finland,60291
ANAKINRA,9013DUQ28K,Designated,Public record,465,"Interleukin-1 receptor antagonist, human recombinant",9/23/1991,Treatment of juvenile rheumatoid arthritis.,Designated,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ) (SOBI),SE-112 76,,Stockholm,,,Sweden,59991
AMIFAMPRIDINE,RU4S6E2G0J,Designated,Public record,466,Dynamine,10/16/1991,Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).,Designated,Not FDA Approved for Orphan Indication,,,,,Mayo Foundation,200 First Street Southwest,,Rochester,Minnesota,55905,United States,56090
LODOXAMIDE TROMETHAMINE,50LV9A548L,Designated/Approved,Public record,467,Lodoxamide tromethamine,10/16/1991,Treatment of vernal keratoconjunctivitis.,Designated/Approved,,"Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis.",9/23/1993,9/23/2000,,"Alcon Laboratories, Inc.",6201 South Freeway,,Fort Worth,Texas,76134,United States,59791
BOTULINUM TOXIN TYPE F,U1R2P71O7G,Designated,Public record,468,Botulinum toxin type F,10/24/1991,Treatment of spasmodic torticollis (cervical dystonia).,Designated,Not FDA Approved for Orphan Indication,,,,,Ipsen Limited,27 Maple Street,,Milford,Massachusetts,1757,United States,61091
METRONIDAZOLE,140QMO216E,Designated,Public record,469,Metronidazole,10/24/1991,Treatment of perioral dermatitis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Galderma Laboratories, Inc.",P.O. Box 331329,,Fort Worth,Texas,76163,United States,61891
"""16-HYDROXY-9,12,14-OCTADECATRIENOIC ACID, (9Z,12Z,14E)-""",OI8UM3P94Z,Designated,Public record,470,"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid",10/24/1991,Prophylactic treatment of sickle cell disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Omex International, Inc.","6001 Savoy, Suite 110",,Houston,Texas,77036,United States,32288
HALOFANTRINE,Q2OS4303HZ,Designated/Approved,Public record,471,Halofantrine,11/4/1991,Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.,Designated/Approved,,Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax.,7/24/1992,7/24/1999,,SmithKline Beecham Pharmaceuticals,One Franklin Plaza,P.O. Box 7929,Philadelphia,Pennsylvania,19101,United States,61791
PRAMIRACETAM SULFATE,OP7O7MNS9P,Designated/Withdrawn,Public record,472,Pramiracetam Sulfate,11/4/1991,For the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cambridge Neuroscience, Inc.","1 Kendall Square, Bldg. 700",,Cambridge,Massachusetts,2139,United States,61691
IMIGLUCERASE,Q6U6J48BWY,Designated/Approved,Public record,473,Imiglucerase,11/5/1991,"Replacement therapy in patients with types I, II, and III Gaucher's disease.",Designated/Approved,,Enzyme replacement therapy in patients with type I Gaucher's disease.,5/23/1994,5/23/2001,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,62491
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,475,Somatropin for injection,11/15/1991,Treatment of AIDS-associated catabolism/weight loss.,Designated/Approved,,Treatment of AIDS wasting or cachexia.,8/23/1996,8/23/2003,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,60491
Amphotericin B,7XU7A7DROE,Designated/Approved,Public record,477,Amphotericin B lipid complex,12/5/1991,Treatment of invasive fungal infections.,Designated/Approved,,Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.,10/18/1996,10/18/2003,,"Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,8540,United States,57891
ABOBOTULINUMTOXINA,,Designated,Public record,478,Botulinum toxin type A,12/5/1991,Treatment of essential blepharospasm.,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.",106 Allen Road,3rd Floor,Basking Ridge,New Jersey,7920,United States,60891
ILOMASTAT,I0403ML141,Designated,Public record,479,Matrix metalloproteinase inhibitor,12/5/1991,Treatment of corneal ulcers.,Designated,Not FDA Approved for Orphan Indication,,,,,"Glycomed, Inc",860 Atlantic Avenue,,Alameda,California,94501,United States,63991
SERMORELIN ACETATE,00IBG87IQW,Designated/Withdrawn,Public record,480,Sermorelin acetate,12/5/1991,Treatment of AIDS-associated catabolism/weight loss.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,61491
BOTULINUM TOXIN TYPE A,E211KPY694,Designated/Approved,Public record,481,botulinum toxin type A,12/6/1991,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients,Designated/Approved,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.,6/20/2019,6/20/2026,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.",2525 Dupont Drive,T1-2A,Irvine,California,92623,United States,56591
BACLOFEN,H789N3FKE8,Designated/Approved,Public record,482,baclofen,12/16/1991,Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.,Designated/Approved,,"Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. OZOBAX may also be of some value in patients with spinal cord injuries and other spinal cord disea",9/18/2019,,,"Metacel Pharmaceuticals, LLC",244 E Washington Street,,Athens,Georgia,30601,United States,64091
INTERFERON BETA-1A,XRO4566Q4R,Designated/Approved,Public record,483,Interferon beta-1a,12/16/1991,Treatment of multiple sclerosis.,Designated/Approved,,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.,5/17/1996,5/17/2003,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,62791
DEXRAZOXANE,048L81261F,Designated/Approved,Public record,484,Dexrazoxane,12/17/1991,For the prevention of cardiomyopathy associated with doxorubicin administration.,Designated/Approved,,Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2.,5/26/1995,5/26/2002,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,49001,United States,63291
"""BACLOFEN, (S)-""",3OHN4989XM,Designated,Public record,485,L-baclofen,12/17/1991,Treatment of spasticity associated with spinal cord injury or multiple sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Osmotica Pharmaceutical Corp.,1205 Culbreth Dr.,Suite 200,Wilmington,North Carolina,28405,United States,57391
DAPSONE,8W5C518302,Designated,Public record,486,Dapsone USP,12/24/1991,Prophylaxis for Pneumocystis carinii pneumonia.,Designated,Not FDA Approved for Orphan Indication,,,,,Jacobus Pharmaceutical Company,37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,8540,United States,61191
DAPSONE,8W5C518302,Designated,Public record,488,Dapsone USP,1/8/1992,For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.,Designated,Not FDA Approved for Orphan Indication,,,,,Jacobus Pharmaceutical Company,37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,8540,United States,61291
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR,PW7453NX3R,Designated/Withdrawn,Public record,489,Cystic fibrosis transmembrane conductance regulator,1/14/1992,For cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Mountain Road,P.O. Box 9322,Framingham,Massachusetts,1701,United States,63891
RIMABOTULINUMTOXINB,0Y70779M1F,Designated/Approved,Public record,490,Botulinum toxin type B,1/16/1992,Treatment of cervical dystonia.,Designated/Approved,,Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.,12/8/2000,12/8/2007,,"Soltice Neurosciences, LLC",4010 Dupont Circle,Suite L-07,Louisville,Kentucky,40207,United States,64791
COMOSAIN,55MVW171WS,Designated,Public record,491,"Ananain, comosain",1/21/1992,For the enzymatic debridement of severe burns.,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,63091
ANANAIN,K0H66D72UT,Designated,Public record,491,"Ananain, comosain",1/21/1992,For the enzymatic debridement of severe burns.,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,63091
CILIARY NEUROTROPHIC FACTOR,CR102F038W,Designated,Public record,492,Ciliary neurotrophic factor,1/30/1992,Treatment of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc,777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,63691
"""BACLOFEN, (S)-""",3OHN4989XM,Designated,Public record,493,L-baclofen,1/30/1992,Treatment of intractable spasticity in children with cerebral palsy.,Designated,Not FDA Approved for Orphan Indication,,,,,Osmotica Pharmaceutical Corp.,1205 Culbreth Drive,Suite 200,Wilmington,North Carolina,28405,United States,65592
PAPAVERINE,DAA13NKG2Q,Designated/Withdrawn by OPD,Public record,494,Papaverine topical gel,2/6/1992,Treatment of sexual dysfunction in spinal cord injury patients.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmedic Company,417 Harvester Court,,Wheeling,Illinois,60090,United States,64991
AMINOSALICYLIC ACID,5B2658E0N2,Designated/Approved,Public record,495,Aminosalicylic acid,2/19/1992,Treatment of tuberculosis infections,Designated/Approved,,Treatment of tuberculosis,6/30/1994,6/30/2001,,Jacobus Pharmaceutical Company,37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,8540,United States,65792
LOXORIBINE,9CAS0V66OI,Designated/Withdrawn,Public record,496,Loxoribine,2/24/1992,Treatment of common variable immunodeficiency.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute,"Route 202, P.O. Box 300",,Raritan,New Jersey,8869,United States,54390
MELPHALAN,Q41OR9510P,Designated/Approved,Public record,497,Melphalan,2/24/1992,Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.,Designated/Approved,,For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.,11/18/1992,11/18/1999,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,27709,United States,60991
THYROTROPIN,02KSI6Z9AK,Designated/Approved,Public record,498,Thyrotropin alpha,2/24/1992,As an adjunct in the diagnosis of thyroid cancer.,Designated/Approved,,As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.,11/30/1998,11/30/2005,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,63191
DIAZEPAM,Q3JTX2Q7TU,Designated/Approved,Public record,499,Diazepam viscous solution for rectal administration,2/25/1992,"For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.",Designated/Approved,,,7/29/1997,7/29/2004,,Valeant Pharmaceuticals,3300 Hyland Avenue,,Costa Mesa,California,92626,United States,61591
PILOCARPINE HYDROCHLORIDE,0WW6D218XJ,Designated/Approved,Public record,500,Pilocarpine HCl,2/28/1992,Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.,Designated/Approved,,Treatment of dry mouth in patients with Sjogren's syndrome.,2/11/1998,2/11/2005,,"MGI Pharma, Inc.",5775 West Old Shakoppe Rd.,Suite 100,Bloomington,Minnesota,55437,United States,62091
MELPHALAN,Q41OR9510P,Designated/Withdrawn,Public record,501,Melphalan,3/3/1992,For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Research and Development,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,27709,United States,64291
BUTYRYLCHOLINESTERASE,1M8W6DVG0L,Designated,Public record,503,Butyrylcholinesterase,3/25/1992,For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.,1550 East Gude Drive,,Rockville,Maryland,20850,United States,63591
"""HUMAN CILIARY NEUROTROPHIC FACTOR, RECOMBINANT (E. COLI)""",0YMN57H314,Designated/Withdrawn,Public record,506,"Ciliary neurotrophic factor, recombinant human",4/2/1992,Treatment of spinal muscular atrophies.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Syntex-Synergen Neuroscience,3200 Walnut Street,,Boulder,Colorado,80301,United States,66392
ARGININE BUTYRATE,IK8S1P79MU,Designated,Public record,507,Arginine butyrate,4/7/1992,Treatment of beta-hemoglobinopathies and beta-thalassemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Perrine, Susan P., M.D.",Boston University,Cancer Research Center,Boston,Massachusetts,2118,United States,66292
ALITRETINOIN,1UA8E65KDZ,Designated,Public record,509,Alitretinoin,4/10/1992,Treatment of acute promyelocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Ligand Pharmaceuticals, Inc.",10275 Science Center Dr.,,San Diego,California,92121,United States,66592
ANARITIDE ACETATE,EGV6V52K6N,Designated/Withdrawn,Public record,510,Anaritide acetate,4/10/1992,Improvement of early renal allograft function following renal transplantation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Scios, Inc.",2450 Bayshore Parkway,,Mountain View,California,94043,United States,62291
"""HUMAN CILIARY NEUROTROPHIC FACTOR, RECOMBINANT (E. COLI)""",0YMN57H314,Designated/Withdrawn,Public record,512,"Ciliary neurotrophic factor, recombinant human",5/8/1992,"Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis).",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Syntex-Synergen Neuroscience,3200 Walnut Street,,Boulder,Colorado,80301,United States,66492
"""5,6-DIHYDRO-5-AZACYTIDINE""",0627D8VG1C,Designated,Public record,513,"5,6-dihydro-5-azacytidine",5/11/1992,Treatment of malignant mesothelioma.,Designated,Not FDA Approved for Orphan Indication,,,,,"ILEX Oncology, Inc.",4545 Horizon Hill Blvd.,,San Antonio,Texas,78229,United States,67292
MINOCYCLINE HYDROCHLORIDE,0020414E5U,Designated/Withdrawn,Public record,516,Minocycline HCl,6/19/1992,Treatment of chronic malignant pleural effusion.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Lederle Laboratories Division,Division of American Cyanamid Company,401 N. Middletown Road,Pearl River,New York,10965,United States,67092
PROTEIN C,3Z6S89TXPW,Designated,Public record,517,Protein C concentrate,6/19/1992,For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.,Designated,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,"750 Lexington Avenue, 19th Floor",,New York,New York,10022,United States,65192
PROTEIN C,3Z6S89TXPW,Designated/Approved,Public record,518,Protein C concentrate,6/23/1992,"For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.",Designated/Approved,,Prevention and treatment of venous thrombosis and purpura fulminans,3/30/2007,3/30/2014,,"Baxalta US, Inc.",One Baxter Way,,West Lake Village,California,91362,United States,65392
SECRETORY LEUKOCYTE PROTEASE INHIBITOR,909E17P4ZW,Designated,Public record,520,Secretory leukocyte protease inhibitor,6/30/1992,Treatment of bronchopulmonary dysplasia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Synergen, Inc.",1885 33rd Street,,Boulder,Colorado,80301,United States,68292
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,521,sodium phenylbutyrate,7/2/1992,"Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy, and S-thalassemia hemoglobinopathy.",Designated,Not FDA Approved for Orphan Indication,,,,,Medicis Pharmaceutical Corp.,8125 N. Hayden Road,,Scottsdale,Alaska,85258,United States,68192
FIALURIDINE,53T7IN77LC,Designated,Public record,522,fialuridine,7/24/1992,Adjunctive treatment of chronic active hepatitis B.,Designated,Not FDA Approved for Orphan Indication,,,,,"Oclassen Pharmaceuticals, Inc.",100 Pelican Way,,San Rafael,California,94901,United States,67892
INTERFERON BETA-1A,XRO4566Q4R,Designated,Public record,523,Interferon beta-1a (recombinant human),7/24/1992,"Treatment of acute non-A, non-B hepatitis.",Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,62891
THREONINE,2ZD004190S,Designated/Withdrawn,Public record,524,L-threonine,7/24/1992,Treatment of spasticity associated with familial spastic paraparesis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Interneuron Pharmaceuticals, Inc.","99 Hayden Ave., Suite 200",,Lexington,Massachusetts,2421,United States,62191
ANARITIDE ACETATE,EGV6V52K6N,Designated/Withdrawn,Public record,525,Anaritide acetate,8/27/1992,Treatment of patients with acute renal failure.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Scios, Inc.",2450 Bayshore Parkway,,Mountain View,California,94043,United States,62391
BOTULINUM TOXIN TYPE A,E211KPY694,Designated,Public record,526,Botulinum toxin type A,9/15/1992,Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.,Designated,Not FDA Approved for Orphan Indication,,,,,"Botulinum Toxin Research Associates, Inc.",1261 Furnace Brook Parkway,,Quincy,Massachusetts,2169,United States,64591
BUTYRYLCHOLINESTERASE,1M8W6DVG0L,Designated,Public record,527,Butyrylcholinesterase,9/30/1992,Treatment of post-surgical apnea.,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.,1550 East Gude Drive,,Rockville,Maryland,20850,United States,69192
OXALIPLATIN,04ZR38536J,Designated,Public record,528,Oxaliplatin,10/6/1992,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Debiopharm S.A.,17 Rue des Terreaux,,Lausanne,,,Switzerland,69492
IMMUNE GLOBULIN INTRAVENOUS (HUMAN),,Designated/Withdrawn,Public record,530,Immune globulin intravenous (human),10/13/1992,Treatment of polymyositis/dermatomyositis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,155 East 56th Street,,New York,New York,10022,United States,68992
ALLOPURINOL SODIUM,428673RC2Z,Designated/Approved,Public record,531,Allopurinol sodium,10/16/1992,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",Designated/Approved,,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",5/17/1996,5/17/2003,,"Catalytica Pharmaceuticals, Inc",PO Box 1887,,Greenville,North Carolina,27835,United States,68392
"""ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN), DRIED, PASTEURIZED""",,Designated/Approved,Public record,532,"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized",10/16/1992,Treatment of patients with von Willebrand's disease,Designated/Approved,,"(1) In adult patients for treatment and prevention of bleeding in hemophilia A (classic hemophilia) and (2) in adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and",4/1/1999,4/1/2006,,CSL Behring,1020 First Avenue,PO Box 61501,King Of Prussia,Pennsylvania,19406,United States,67992
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Approved,Public record,533,C1 esterase inhibitor (human),10/16/1992,Prevention and/or treatment of acute attacks of hereditary angioedema.,Designated/Approved,,Treatment of acute attacks of hereditary angioedema.,10/8/2009,10/8/2016,,CSL Behring LLC,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,67592
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Approved,Public record,534,C1 esterase inhibitor subcutaneous (human),10/16/1992,Prevention and/or treatment of acute attacks of hereditary angioedema.,Designated/Approved,,HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older,9/24/2020,,,CSL Behring LLC,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,67592
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Approved,Public record,535,C1 esterase inhibitor subcutaneous (human),10/16/1992,Prevention and/or treatment of acute attacks of hereditary angioedema.,Designated/Approved,,For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.,6/22/2017,6/22/2024,For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.,CSL Behring LLC,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,67592
ANAKINRA,9013DUQ28K,Designated,Public record,537,"Interleukin-1 receptor antagonist, human recombinant",10/16/1992,Prevention and treatment of graft versus host disease in transplant recipients.,Designated,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ) (SOBI),SE-112 76,,Stockholm,,,Sweden,65892
TOPIRAMATE,0H73WJJ391,Designated/Approved,Public record,538,Topiramate,11/25/1992,Treatment of Lennox-Gastaut syndrome.,Designated/Approved,,As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.,8/28/2001,8/28/2008,,"Johnson & Johnson Pharmaceutical R & D, LLC","Route 202, P.O. Box 300",,Raritan,New Jersey,8869,United States,70792
IDARUBICIN,ZRP63D75JW,Designated/Withdrawn,Public record,539,Idarubicin,12/1/1992,Treatment of myelodysplastic syndromes.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,Unit 0633-298-113,Kalamazoo,Michigan,49001,United States,70892
IDARUBICIN,ZRP63D75JW,Designated/Withdrawn,Public record,540,Idarubicin,12/2/1992,Treatment of chronic myelogenous leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,Unit 0633-298-113,Kalamazoo,Michigan,49001,United States,70992
INTERFERON BETA-1A,XRO4566Q4R,Designated/Withdrawn,Public record,541,Interferon beta-1a (recombinant),12/2/1992,Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,63391
IMMUNE GLOBULIN INTRAVENOUS (HUMAN),,Designated/Withdrawn,Public record,543,Immune globulin intravenous (human),12/16/1992,Treatment of juvenile rheumatoid arthritis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,"750 Lexington Avenue, 19th Floor",,New York,New York,10022,United States,68892
ISOBUTYRAMIDE,82UOE7B38Z,Designated,Public record,544,Isobutyramide,12/18/1992,Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.,Designated,Not FDA Approved for Orphan Indication,,,,,"Perrine, Susan P., M.D.",Boston University,Cancer Research Center,Boston,Massachusetts,2118,United States,71792
CETERMIN,693Y43MXY4,Designated,Public record,545,Transforming growth factor-beta 2,12/18/1992,Treatment of full thickness macular holes.,Designated,Not FDA Approved for Orphan Indication,,,,,"Celtrix Pharmaceuticals, Inc.",3055 Patrick Henry Drive,,Santa Clara,California,95054,United States,71092
TYLOXAPOL,Y27PUL9H56,Designated/Withdrawn,Public record,550,"Colfosceril palmitate, cetyl alcohol, tyloxapol",1/11/1993,Treatment of adult respiratory distress syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,5 Moore Drive,P.O. Box 13398,Research Triangle Park,North Carolina,27709,United States,68492
COLFOSCERIL PALMITATE,319X2NFW0A,Designated/Withdrawn,Public record,550,"Colfosceril palmitate, cetyl alcohol, tyloxapol",1/11/1993,Treatment of adult respiratory distress syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,5 Moore Drive,P.O. Box 13398,Research Triangle Park,North Carolina,27709,United States,68492
CETYL ALCOHOL,936JST6JCN,Designated/Withdrawn,Public record,550,"Colfosceril palmitate, cetyl alcohol, tyloxapol",1/11/1993,Treatment of adult respiratory distress syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,5 Moore Drive,P.O. Box 13398,Research Triangle Park,North Carolina,27709,United States,68492
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,551,Thalidomide,1/12/1993,Treatment of the clinical manifestations of mycobacterial infection caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria.,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,7059,United States,72092
INTERFERON BETA-1A,XRO4566Q4R,Designated/Withdrawn,Public record,552,Interferon beta (recombinant human),1/13/1993,Treatment of primary brain tumors.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen Idec, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,69392
TRETINOIN,5688UTC01R,Designated,Public record,553,Tretinoin,1/14/1993,Treatment of acute and chronic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Antigenics, Inc.",3 Forbes Road,,Lexington,Massachusetts,2421,United States,71692
SOMATROPIN,NQX9KB6PCL,Designated/Withdrawn,Public record,554,Somatropin,2/12/1993,Treatment of cachexia associated with AIDS.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,8830,United States,71592
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated/Approved,Public record,555,"Immune globulin intravenous, human",2/18/1993,Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.,Designated/Approved,,"For prophylaxis of children with clinical or immunologic evidence of human immunodeficiency virus to decrease the frequency of serious and minor bacterial infections and the frequency of hospitalization, and to increase the time free of serious bacterial",12/27/1993,12/27/2000,,Bayer Corporation,"Pharmaceutical Division, Biological Products",400 Morgan Lane,New Haven,Connecticut,6516,United States,70592
DACLIZUMAB,CUJ2MVI71Y,Designated/Approved,Public record,556,Daclizumab,3/5/1993,Prevention of acute renal allograft rejection.,Designated/Approved,,"Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.",12/10/1997,12/10/2004,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,67692
DACLIZUMAB,CUJ2MVI71Y,Designated,Public record,557,Humanized anti-tac,3/5/1993,Prevention of acute graft-vs-host disease following bone marrow transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,67792
MODAFINIL,R3UK8X3U3D,Designated/Approved,Public record,558,Modafinil,3/15/1993,Treatment of excessive daytime sleepiness in narcolepsy.,Designated/Approved,,Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.,12/24/1998,12/24/2005,,"Cephalon, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,73793
ATOVAQUONE,Y883P1Z2LT,Designated/Withdrawn,Public record,559,Atovaquone,3/16/1993,Treatment and suppression of Toxoplasma gondii encephalitis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline, Inc.",5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,27709,United States,66692
ATOVAQUONE,Y883P1Z2LT,Designated/Withdrawn,Public record,560,Atovaquone,3/16/1993,Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline, Inc.",5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,27709,United States,66792
RILUZOLE,7LJ087RS6F,Designated/Approved,Public record,561,Riluzole,3/16/1993,Treatment of amyotrophic lateral sclerosis.,Designated/Approved,,Treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.,12/12/1995,12/12/2002,,"Rhone-Poulenc Rorer Pharmaceuticals, Inc.","500 Arcola Road, P.O. Box 1200",,Collegeville,Pennsylvania,19426,United States,72792
AMINOSALICYLATE SODIUM,S38B9W6AXW,Designated/Withdrawn,Public record,562,Aminosalicylate sodium,4/6/1993,Treatment of Crohn's disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Syncom Pharmaceuticals, Inc.",66 Hanover Road,,Florham Park,New Jersey,7932,United States,68592
CLADRIBINE,47M74X9YT5,Designated/Withdrawn,Public record,563,Cladribine,4/19/1993,Treatment of non-Hodgkin's lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,68092
APOMORPHINE HYDROCHLORIDE,F39049Y068,Designated/Approved,Public record,564,Apomorphine HCl,4/22/1993,Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.,Designated/Approved,,"For the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose-wearing-off"" and unpredictable :on/off"" episodes) associated with advanced Parkinson's disease",4/20/2004,4/20/2011,,"MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc.",9715 Key West Avenue,,Rockville,Maryland,20850,United States,57591
CATRIDECACOG,NU23Q531G1,Designated/Withdrawn,Public record,565,"Factor XIII, recombinant",4/22/1993,Treatment of congenital factor XIII deficiency.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Zymogenetics, Inc.",4225 Roosevelt Way,,Seattle,Washington,98105,United States,73993
PROTEIN C,3Z6S89TXPW,Designated/Withdrawn,Public record,566,Protein C concentrate,4/22/1993,For use in the prevention and treatment of purpura fulminans in meningococcemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,"750 Lexington Avenue, 19th Floor",,New York,New York,10022,United States,65292
GLYCERYL LAURATE,Y98611C087,Designated,Public record,567,Monolaurin,4/29/1993,Treatment of congenital primary ichthyosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Inc.,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,27709,United States,71892
FENRETINIDE,187EJ7QEXL,Designated,Public record,568,RII retinamide,5/6/1993,Treatment of myelodysplastic syndromes.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sparta Pharmaceuticals, Inc.",111 Rock Road,,Horsham,Pennsylvania,19044,United States,74193
PAROMOMYCIN SULFATE,845NU6GJPS,Designated,Public record,569,Aminosidine,5/14/1993,Treatment of tuberculosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Kanyok, Thomas P. Pharm.D.",University Of Illinois At Chicago College of Pharm,833 South Wood Street (m/c886) Rm. 176,Chicago,Illinois,60612,United States,74693
DAUNORUBICIN CITRATE,5L84T2Z6NP,Designated/Approved,Public record,570,Daunorubicin citrate liposome injection,5/14/1993,Treatment of patients with advanced HIV-associated Kaposi's sarcoma.,Designated/Approved,,"First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma.",4/8/1996,4/8/2003,,"NeXstar Pharmaceuticals, Inc.",650 Cliffside Drive,,San Dimas,California,91773,United States,73693
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,D7RD81HE4W,Designated,Public record,571,Anti-thymocyte serum,6/2/1993,"Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.",Designated,Not FDA Approved for Orphan Indication,,,,,Applied Medical Research,1600 Hayes Street,,Nashville,Tennessee,37203,United States,64491
CYTARABINE,04079A1RDZ,Designated/Approved,Public record,572,Cytarabine liposomal,6/2/1993,Treatment of neoplastic meningitis.,Designated/Approved,,Intrathecal treatment of lymphomatous meningitis.,4/1/1999,4/1/2006,,"Pacira Pharmaceuticals, Inc.",10450 Science Center Drive,,San Diego,California,92121,United States,73393
CLODRONATE DISODIUM,N030400H8J,Designated,Public record,573,Disodium clodronate,6/16/1993,Treatment of hypercalcemia of malignancy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Discovery Experimental & Development, Inc.",29949 S.R. 54 West,,Wesley Chapel,Florida,33543,United States,72292
METHOXSALEN,U4VJ29L7BQ,Designated,Public record,574,8-methoxsalen,6/22/1993,For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Hospital Products IP Limited,440 Route 22 East,,Bridgewater,New Jersey,8807,United States,74293
NITRIC OXIDE,31C4KY9ESH,Designated/Approved,Public record,575,Nitric oxide,6/22/1993,Treatment of persistent pulmonary hypertension in the newborn.,Designated/Approved,,"In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it i",12/23/1999,12/23/2006,,Mallinckrodt Hospital Products,1425 U.S. 206,,Bedminster Township,New Jersey,7921,United States,74493
VASOACTIVE INTESTINAL PEPTIDE,6J2WVD66KR,Designated,Public record,576,Vasoactive intestinal polypeptide,6/23/1993,Treatment of acute esophageal food impaction.,Designated,Not FDA Approved for Orphan Indication,,,,,Research Triangle Pharmaceuticals,200 Westpark Corporate Center,4364 South Alston Avenue,Durham,North Carolina,27713,United States,72192
ROQUINIMEX,372T2944C0,Designated/Withdrawn,Public record,577,Roquinimex,7/1/1993,To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,49001,United States,72893
SUCRALFATE,XX73205DH5,Designated/Withdrawn,Public record,578,Sucralfate,7/15/1993,Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Fuisz Technologies, Ltd.",14555 Avion at Lakeside,,Chantilly,Virginia,20151,United States,73893
PRIMAQUINE PHOSPHATE,H0982HF78B,Designated,Public record,579,Primaquine phosphate,7/23/1993,For use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sanofi Winthrop, Inc.",90 Park Avenue,,New York,New York,10016,United States,74793
SECALCIFEROL,460029IUDA,Designated,Public record,580,Secalciferol,7/26/1993,Treatment of familial hypophosphatemic rickets.,Designated,Not FDA Approved for Orphan Indication,,,,,Teva Pharmaceuticals USA,650 Cathill Rd.,,Sellersville,Pennsylvania,18960,United States,75193
PORACTANT ALFA,KE3U2023NP,Designated/Approved,Public record,581,"Pulmonary surfactant replacement, porcine",8/2/1993,For the treatment and prevention of respiratory distress syndrome in premature infants.,Designated/Approved,,Treatment (rescue) of respiratory distress syndrome in premature infants.,11/18/1999,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,71192
AMIODARONE,N3RQ532IUT,Designated,Public record,582,Amiodarone,8/17/1993,Treatment of incessant ventricular tachycardia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Academic Pharmaceuticals, Inc.",21 N. Skokie Valley Highway,Suite G3,Lake Bluff,Illinois,60044,United States,70292
TOREMIFENE,7NFE54O27T,Designated,Public record,583,Toremifene,8/17/1993,Treatment of desmoid tumors.,Designated,Not FDA Approved for Orphan Indication,,,,,Orion Corporation,Orionintie 1,,Espoo,,,Finland,75393
MITOMYCIN,50SG953SK6,Designated,Public record,584,Mitomycin-C,8/20/1993,Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.,Designated,Not FDA Approved for Orphan Indication,,,,,IOP Inc.,"3100 Airway Avenue, Suite 106",,Costa Mesa,California,92626,United States,73493
METHOTREXATE,YL5FZ2Y5U1,Designated/Withdrawn,Public record,585,methotrexate,8/23/1993,Treatment of juvenile rheumatoid arthritis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Wyeth-Ayerst Laboratories,P.O. Box 8299,,Philadelphia,Pennsylvania,19101,United States,76693
PROTIRELIN,5Y5F15120W,Designated/Withdrawn,Public record,586,Protirelin,8/24/1993,Prevention of infant respiratory distress syndrome associated with prematurity.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"UCB Pharma, Inc.",1950 Lake Park Drive,,Smyrna,Georgia,30080,United States,75093
BLEOMYCIN SULFATE,7DP3NTV15T,Designated/Approved,Public record,588,Bleomycin sulfate,9/17/1993,Treatment of malignant pleural effusion.,Designated/Approved,,Treatment of malignant pleural effusion.,2/20/1996,2/20/2003,,Bristol-Myers Squibb Pharmaceutical Research Institute,P.O. Box 4000,,Princeton,New Jersey,8543,United States,76193
WHEY PROTEIN,,Designated,Public record,589,Bovine whey protein concentrate,9/30/1993,Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biomune Systems, Inc.","540 Arapeen Drive, Suite 202",,Salt Lake City,Utah,84108,United States,76593
MUPLESTIM,A802907MI4,Designated/Withdrawn,Public record,590,"Interleukin-3, human, recombinant",9/30/1993,For sequential administration with sargramostim to accelerate neutrophil and platelet recovery in patients undergoing autologous bone marrow transplantation for the treatment of Hodgkin's disease or non-Hodgkin's lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sandoz Pharmaceuticals Corp.,59 Route 10,,East Hanover,New Jersey,7936,United States,74093
PELDESINE,7B646RJ70F,Designated,Public record,592,Peldesine,10/5/1993,Treatment of cutaneous T-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"BioCryst Pharmaceuticals, Inc.",2190 Parkway Lake Drive,,Birmingham,Alabama,35244,United States,76293
ALPROSTADIL,F5TD010360,Designated/Withdrawn,Public record,593,Alprostadil,10/20/1993,"Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Schwarz Pharma, Inc.",P.O. Box 2038,,Milwaukee,Wisconsin,53201,United States,70092
HUMAN RHO(D) IMMUNE GLOBULIN,48W7181FLP,Designated/Approved,Public record,594,Rho (D) immune globulin intravenous (human),11/9/1993,Treatment of immune thrombocytopenic purpura.,Designated/Approved,,Treatment of adults and children with chronic and acute immune thrombocytopenic purpura.,3/24/1995,3/24/2002,,"Rh Pharmaceuticals, Inc.",104 Chancellor Matheson Road,U of Manitoba,Winnipeg,,,Canada,74993
PAROMOMYCIN SULFATE,845NU6GJPS,Designated,Public record,595,Aminosidine,11/15/1993,Treatment of Mycobacterium avium complex.,Designated,Not FDA Approved for Orphan Indication,,,,,"Kanyok, Thomas P. Pharm.D.",University Of Illinois At Chicago College of Pharm,833 South Wood Street (m/c886) Rm. 176,Chicago,Illinois,60612,United States,77193
MELATONIN,JL5DK93RCL,Designated,Public record,596,Melatonin,11/15/1993,Treatment of circadian rhythm sleep disorders in blind people with no light perception.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sack, Robert, M.D.",Oregon Health Sciences University,3181 S.W. Sam Jackson Park Road,Portland,Oregon,97201,United States,77593
APROTININ,04XPW8C0FL,Designated/Approved,Public record,598,Aprotinin,11/17/1993,"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",Designated/Approved,,,12/29/1993,12/29/2000,,Bayer Corporation,Pharmaceutical Division,400 Morgan Lane,West Haven,Connecticut,6516,United States,66992
Benzoic acid,8SKN0B0MIM,Designated/Approved,Public record,599,benzoate/phenylacetate,11/22/1993,Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.,Designated/Approved,,Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.,2/17/2005,2/17/2012,,Medicis Pharmaceutical Corp.,8125 N. Hayden Road,,Scottsdale,Alaska,85258,United States,77993
PHENYL ACETATE,355G9R500Y,Designated/Approved,Public record,599,benzoate/phenylacetate,11/22/1993,Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.,Designated/Approved,,Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.,2/17/2005,2/17/2012,,Medicis Pharmaceutical Corp.,8125 N. Hayden Road,,Scottsdale,Alaska,85258,United States,77993
IMMUNE GLOBULIN INTRAVENOUS (HUMAN),,Designated/Withdrawn,Public record,600,Immune globulin intravenous (human),11/22/1993,Treatment of patients with acute myocarditis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,"750 Lexington Avenue, 19th Floor",,New York,New York,10022,United States,75893
LEVOCARNITINE,0G389FZZ9M,Designated,Public record,601,Levocarnitine,11/22/1993,Treatment of pediatric cardiomyopathy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,20878,United States,76393
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated/Approved,Public record,602,sodium phenylbutyrate,11/22/1993,"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.",Designated/Approved,,"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase.",4/30/1996,4/30/2003,,Medicis Pharmaceutical Corp.,8125 N. Hayden Road,,Scottsdale,Alaska,85258,United States,77893
RINTATOLIMOD,94325AJ25N,Designated,Public record,603,Poly I: poly C12U,12/9/1993,"Treatment of invasive metastatic melanoma (stage IIb, III, IV).",Designated,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,783 Jersey Avenue,,New Brunswick,New Jersey,8901,United States,76893
RINTATOLIMOD,94325AJ25N,Designated,Public record,604,Poly I: poly C12U,12/9/1993,Treatment of chronic fatigue syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,783 Jersey Avenue,,New Brunswick,New Jersey,8901,United States,75993
SACROSIDASE,8A7F670F2Y,Designated/Approved,Public record,605,Sacrosidase,12/10/1993,Treatment of congenital sucrase-isomaltase deficiency,Designated/Approved,,"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.",4/9/1998,4/9/2005,,"QOL Medical, LLC","4445 North Highway A1A, 241",,Vero Beach,Florida,32963,United States,78693
IBALIZUMAB,LT369U66CE,Designated/Withdrawn,Public record,606,"5a8, monoclonal antibody to CD4",12/20/1993,For use in post-exposure prophylaxis for occupational exposure to human immunodeficiency virus.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,70692
Beractant,S866O45PIG,Designated,Public record,607,Beractant,12/20/1993,"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.",Designated,Not FDA Approved for Orphan Indication,,,,,Ross Laboratories,625 Cleveland Avenue,,Columbus,Ohio,43215,United States,76793
EPOETIN ALFA,,Designated,Public record,608,Epoetin alfa,12/20/1993,Treatment of myelodysplastic syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Johnson & Johnson Pharmaceutical Research & Dev.,",920 U.S. Highway,"Route 202, P.O. Box 300",Raritan,New Jersey,8869,United States,78793
HEMIN,743LRP9S7N,Designated,Public record,609,Hemin and zinc mesoporphyrin,12/20/1993,Treatment of acute porphyric syndromes.,Designated,Not FDA Approved for Orphan Indication,,,,,"Bonkovsky, Herbert L. M.D.",University Of Massachusetts Medical Center,55 Lake Avenue North,Worcester,Massachusetts,1655,United States,77393
ZINC MESOPORPHYRIN,99LY10G7K9,Designated,Public record,609,Hemin and zinc mesoporphyrin,12/20/1993,Treatment of acute porphyric syndromes.,Designated,Not FDA Approved for Orphan Indication,,,,,"Bonkovsky, Herbert L. M.D.",University Of Massachusetts Medical Center,55 Lake Avenue North,Worcester,Massachusetts,1655,United States,77393
CYLEXIN,WLZ3BA9R26,Designated,Public record,610,Neutrophil-endothelial interaction inhibitor,12/22/1993,Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.,Designated,Not FDA Approved for Orphan Indication,,,,,Cytel Corporation,3525 John Hopkins Court,,San Diego,California,92121,United States,77693
CROTALUS ATROX IMMUNE FAB ANTIVENIN (OVINE),RBR61YAJ4V,Designated/Approved,Public record,611,"Antivenin, crotalidae polyvalent immune Fab (ovine)",1/12/1994,Treatment of envenomations inflicted by North American crotalid snakes.,Designated/Approved,,Treatment of minimal and moderate North American Crotalidae envenomation,10/2/2000,10/2/2007,,"Protherics, Inc.","1207 17th Ave. S., Suite 103",,Nashville,Tennessee,37212,United States,78993
AGKISTRODON PISCIVORUS IMMUNE FAB ANTIVENIN (OVINE),IA6O0K772M,Designated/Approved,Public record,611,"Antivenin, crotalidae polyvalent immune Fab (ovine)",1/12/1994,Treatment of envenomations inflicted by North American crotalid snakes.,Designated/Approved,,Treatment of minimal and moderate North American Crotalidae envenomation,10/2/2000,10/2/2007,,"Protherics, Inc.","1207 17th Ave. S., Suite 103",,Nashville,Tennessee,37212,United States,78993
CROTALUS ADAMANTEUS IMMUNE FAB ANTIVENIN (OVINE),A4229A7019,Designated/Approved,Public record,611,"Antivenin, crotalidae polyvalent immune Fab (ovine)",1/12/1994,Treatment of envenomations inflicted by North American crotalid snakes.,Designated/Approved,,Treatment of minimal and moderate North American Crotalidae envenomation,10/2/2000,10/2/2007,,"Protherics, Inc.","1207 17th Ave. S., Suite 103",,Nashville,Tennessee,37212,United States,78993
CROTALUS SCUTULATUS IMMUNE FAB ANTIVENIN (OVINE),7WZ1744G86,Designated/Approved,Public record,611,"Antivenin, crotalidae polyvalent immune Fab (ovine)",1/12/1994,Treatment of envenomations inflicted by North American crotalid snakes.,Designated/Approved,,Treatment of minimal and moderate North American Crotalidae envenomation,10/2/2000,10/2/2007,,"Protherics, Inc.","1207 17th Ave. S., Suite 103",,Nashville,Tennessee,37212,United States,78993
GELSOLIN,JBT6SFF5BV,Designated,Public record,612,Recombinant human gelsolin,1/12/1994,Treatment of the respiratory symptoms of cystic fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"BioAegis Therapeutics, Inc.",6 East Cove Lane,,Morristown,New Jersey,7960,United States,78393
TIOMOLIBDATE DIAMMONIUM,4V6I63LW1E,Designated,Public record,613,Ammonium tetrathiomolybdate,1/31/1994,Treatment of Wilson's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Pipex Pharmaceuticals, Inc.",3930 Varsity Drive,,Ann Arbor,Michigan,48108,United States,79993
TIZANIDINE HYDROCHLORIDE,B53E3NMY5C,Designated,Public record,614,Tizanidine HCl,1/31/1994,Treatment of spasticity associated with multiple sclerosis and spinal cord injury.,Designated,Not FDA Approved for Orphan Indication,,,,,"Athena Neurosciences, Inc.",800 Gateway Boulevard,,South San Francisco,California,94080,United States,79193
CHOLINE CHLORIDE,45I14D8O27,Designated,Public record,615,Choline chloride,2/10/1994,"Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.",Designated,Not FDA Approved for Orphan Indication,,,,,"Protara Therapeutics, Inc.","345 Park Avenue South, 3rd Floor",,New York,New York,10010,United States,76993
EXISULIND,K619IIG2R9,Designated,Public record,616,Exisulind,2/14/1994,For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.,Designated,Not FDA Approved for Orphan Indication,,,,,"OSI Pharmaceuticals, Inc.",41 Pinelawn Road,,Melville,New York,11747,United States,79293
GLUTATHIONE,GAN16C9B8O,Designated,Public record,617,Reduced L-glutathione,2/14/1994,Treatment of AIDS-associated cachexia.,Designated,Not FDA Approved for Orphan Indication,,,,,Telluride Pharmaceutical Corporation,146 Flanders Drive,,Hillsborough,New Jersey,8876,United States,77493
HEME ARGINATE,R1B526117P,Designated,Public record,619,Heme arginate,3/1/1994,Treatment of myelodysplastic syndromes.,Designated,Not FDA Approved for Orphan Indication,,,,,Orphan Europe SARL,Immeuble Le Wilson,"70 avenue du General de Gaulle,",Puteaux,,,France,79893
SULFADIAZINE,0N7609K889,Designated/Approved,Public record,620,Sulfadiazine,3/14/1994,For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.,Designated/Approved,,"Toxoplasmosis, as adjunctive with pyrimethamine",7/29/1994,7/29/2001,,"Eon Labs Manufacturing, Inc.",227-15 North Conduit Avenue,,Laurelton,New York,11413,United States,78093
AMIODARONE HYDROCHLORIDE,976728SY6Z,Designated/Approved,Public record,621,Amiodarone HCl,3/16/1994,For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.,Designated/Approved,,For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.,8/3/1995,8/3/2002,,Wyeth-Ayerst Laboratories,P.O. Box 8299,,Philadelphia,Pennsylvania,19101,United States,77293
CY-1899,HM7AT2E2B6,Designated,Public record,622,Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val,3/16/1994,Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Cytel Corporation,3525 John Hopkins Court,,San Diego,California,92121,United States,74893
MITOGUAZONE,OD5Q0L447W,Designated,Public record,623,Mitoguazone,3/18/1994,"Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.",Designated,Not FDA Approved for Orphan Indication,,,,,"ILEX Oncology, Inc.",4545 Horizon Hill Blvd.,,San Antonio,Texas,78229,United States,80094
OXANDROLONE,7H6TM3CT4L,Designated/Withdrawn,Public record,624,Oxandrolone,3/18/1994,Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"One Tower Center Boulevard, 12 th floor",,East Brunswick,New Jersey,8816,United States,75793
CLADRIBINE,47M74X9YT5,Designated,Public record,625,Cladribine,4/19/1994,Treatment of the chronic progressive form of multiple sclerosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Johnson & Johnson Pharmaceutical R & D, LLC",920 Route 202,PO Box 300,Raritan,New Jersey,8869,United States,77793
BUSULFAN,G1LN9045DK,Designated,Public record,626,Busulfan,4/21/1994,For use as preparative therapy for malignancies treated with bone marrow transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sparta Pharmaceuticals, Inc.",111 Rock Road,,Horsham,Pennsylvania,19044,United States,81694
METHOXSALEN,U4VJ29L7BQ,Designated,Public record,627,methoxsalen,5/12/1994,For the prevention of acute rejection of cardiac allografts,Designated,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Hospital Products IP Limited,440 Route 22 East,,Bridgewater,New Jersey,8807,United States,80594
BETAINE,3SCV180C9W,Designated/Approved,Public record,628,Betaine,5/16/1994,Treatment of homocystinuria.,Designated/Approved,,Treatment of homocystinuria to decrease elevated homocysteine blood levels.,10/25/1996,10/25/2003,,Orphan Europe SARL,70 Avenue du Général de Gaulle,,Puteaux,Île-de-France,,France,81794
CYSTEINE,K848JZ4886,Designated,Public record,629,L-cysteine,5/16/1994,For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.,Designated,Not FDA Approved for Orphan Indication,,,,,Brigham and Women's Hospital,Channing Laboratory,181 Longwood Ave.,Boston,Massachusetts,2115,United States,79693
TOSITUMOMAB,0343IGH41U,Designated/Approved,Public record,630,Tositumomab and iodine I 131 tositumomab,5/16/1994,Treatment of non-Hodgkin's B-cell lymphoma.,Designated/Approved,,"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy",6/27/2003,6/27/2010,,GlaxoSmithKline LLC,Corporation Service Company,"2711 Centerville Road, Suite 400",Wilmington,Delaware,19808,United States,79493
TOSITUMOMAB I-131,K1KT5M40JC,Designated/Approved,Public record,630,Tositumomab and iodine I 131 tositumomab,5/16/1994,Treatment of non-Hodgkin's B-cell lymphoma.,Designated/Approved,,"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy",6/27/2003,6/27/2010,,GlaxoSmithKline LLC,Corporation Service Company,"2711 Centerville Road, Suite 400",Wilmington,Delaware,19808,United States,79493
TREOSULFAN,CO61ER3EPI,Designated,Public record,631,Treosulfan,5/16/1994,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Medac GmbH,Fehlandtstrasse 3,,Hamburg,,,Germany,81294
VALRUBICIN,2C6NUM6878,Designated/Approved,Public record,632,Valrubicin,5/23/1994,Treatment of carcinoma in situ of the urinary bladder.,Designated/Approved,,For intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.,9/25/1998,9/25/2005,,"Anthra Pharmaceuticals, Inc.","103 Carnegie Center, Suite 102",,Princeton,New Jersey,8540,United States,82194
ARGININE BUTYRATE,IK8S1P79MU,Designated/Withdrawn,Public record,633,Arginine butyrate,5/25/1994,Treatment of sickle cell disease and beta thalassemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,130 Waverly Street,,Cambridge,Massachusetts,2139,United States,82094
GANAXOLONE,98WI44OHIQ,Designated,Public record,634,Ganaxolone,5/25/1994,Treatment of infantile spasms.,Designated,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",21 Business Park Drive,,Branford,Connecticut,6405,United States,81894
ISOBUTYRAMIDE,82UOE7B38Z,Designated,Public record,635,Isobutyramide,5/25/1994,Treatment of sickle cell disease and beta thalassemia.,Designated,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,90032,United States,82494
RITUXIMAB,4F4X42SYQ6,Designated/Approved,Public record,636,rituximab,6/13/1994,Treatment of non-Hodgkin's B-cell lymphoma,Designated/Approved,,"treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combinatio",12/2/2021,12/2/2028,"treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)","Genentech, Inc.","1 DNA Way, MS 242",,South San Francisco,California,94080,United States,79793
RITUXIMAB,4F4X42SYQ6,Designated/Approved,Public record,637,rituximab,6/13/1994,Treatment of non-Hodgkin's B-cell lymphoma,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma",11/26/1997,11/26/2004,,"Genentech, Inc.","1 DNA Way, MS 242",,South San Francisco,California,94080,United States,79793
OXOTHIAZOLIDINECARBOXYLIC ACID,X7063P804E,Designated,Public record,638,L-2-oxothiazolidine-4-carboxylic acid,6/14/1994,Treatment of adult respiratory distress syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Transcend Therapeutics, Inc.","640 Memorial Drive, 3rd Floor West",,Cambridge,Massachusetts,2139,United States,81994
BUPRENORPHINE HYDROCHLORIDE,56W8MW3EN1,Designated/Approved,Public record,639,Buprenorphine hydrochloride,6/15/1994,Treatment of opiate addiction in opiate users.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Indivior, Inc.",10710 Midlothian Turnpike,Suite 125,North Chesterfield,Virginia,23235,United States,75293
BUPRENORPHINE HYDROCHLORIDE,56W8MW3EN1,Designated/Approved,Public record,640,Buprenorphine hydrochloride,6/15/1994,Treatment of opiate addiction in opiate users.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Indivior, Inc.",10710 Midlothian Turnpike,Suite 125,North Chesterfield,Virginia,23235,United States,75293
PRASTERONE,459AG36T1B,Designated/Withdrawn,Public record,643,Dehydroepiandrosterone,7/13/1994,Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,P. O. Box 13398,Five Moore Drive,Research Triangle Park,North Carolina,27709,United States,83794
GAMOLENIC ACID,78YC2MAX4O,Designated,Public record,644,Gammalinolenic acid,7/27/1994,Treatment of juvenile rheumatoid arthritis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Zurier, Robert B. M.D.",University of Massachusetts Medical Center,55 Lake Avenue,Worcester,Massachusetts,1655,United States,82994
BUSULFAN,G1LN9045DK,Designated/Approved,Public record,645,Busulfan,7/28/1994,As preparative therapy in the treatment of malignancies with bone marrow transplantation.,Designated/Approved,,For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.,2/4/1999,2/4/2006,,"Otsuka Pharmaceutical Company, Ltd","2-9, Kanda-Tsukasamachi",,Tokyo,,,Japan,83094
CLONAZEPAM,5PE9FDE8GB,Designated,Public record,646,Clonazepam,8/4/1994,Treatment of hyperekplexia (startle disease).,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,82794
IBRITUMOMAB TIUXETAN,4Q52C550XK,Designated/Approved,Public record,649,ibritumomab tiuxetan,9/6/1994,Treatment of B-cell non-Hodgkin's lymphoma.,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma",2/19/2002,2/19/2009,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,84894
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,651,Somatropin,9/6/1994,Treatment of adults with growth hormone deficiency.,Designated/Approved,,,10/31/1997,10/31/2004,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,49001,United States,83594
PAROMOMYCIN SULFATE,845NU6GJPS,Designated,Public record,652,Aminosidine,9/9/1994,Treatment of visceral leishmaniasis (kala-azar).,Designated,Not FDA Approved for Orphan Indication,,,,,"Kanyok, Thomas P. Pharm.D.",University of Illinois at Chicago College of Pharm,833 South Wood Street (m/c886) Rm. 176,Chicago,Illinois,60612,United States,83194
BACLOFEN,H789N3FKE8,Designated,Public record,655,Baclofen,9/26/1994,Treatment of spasticity associated with cerebral palsy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Medtronic, Inc.",800 53rd Avenue N.E.,P.O. 1250,Minneapolis,Minnesota,55440,United States,80494
COAGULATION FACTOR IX RECOMBINANT HUMAN,382L14738L,Designated/Approved,Public record,656,Coagulation Factor IX (recombinant),10/3/1994,Treatment of hemophilia B,Designated/Approved,,Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease),10/5/2021,,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",235 E. 42nd St 219/9/1,,New York,New York,10017,United States,82294
COAGULATION FACTOR IX RECOMBINANT HUMAN,382L14738L,Designated/Approved,Public record,657,Coagulation Factor IX (recombinant),10/3/1994,Treatment of hemophilia B,Designated/Approved,,"For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings.",2/11/1997,2/11/2004,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",235 E. 42nd St 219/9/1,,New York,New York,10017,United States,82294
COAGULATION FACTOR IX RECOMBINANT HUMAN,382L14738L,Designated/Approved,Public record,658,Coagulation Factor IX (recombinant),10/3/1994,Treatment of hemophilia B,Designated/Approved,,Routine prophylaxis to reduce the frequency of bleeding episodes in patients 16 years of age and older with hemophilia B (congenital factor IX deficiency or Christmas disease).,6/26/2020,,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",235 E. 42nd St 219/9/1,,New York,New York,10017,United States,82294
LUTROPIN ALFA,3JGY52XJNA,Designated/Approved,Public record,659,Recombinant human luteinizing hormone,10/7/1994,For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.,Designated/Approved,,"Luveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH (less t",10/8/2004,10/8/2011,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,80292
TOBRAMYCIN,VZ8RRZ51VK,Designated/Approved,Public record,661,Tobramycin for inhalation,10/13/1994,Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.,Designated/Approved,,Management of cystic fibrosis patients with P.aeruginosa.,12/22/1997,12/22/2004,,Mylan Specialty LP,781 Chestnut Ridge Road,Regulatory Affairs-Greenbag Road,Morgantown,West Virginia,26505,United States,84494
NALOXONE,36B82AMQ7N,Designated/Approved,Public record,662,buprenorphine in combination with naloxone,10/27/1994,Treatment of opiate addiction in opiate users,Designated/Approved,,Treatment of opioid dependence in patients 16 years of age or older,10/8/2002,10/8/2009,,"Indivior, Inc.",10710 Midlothian Turnpike,Suite 430,Richmond,Virginia,23235,United States,79093
BUPRENORPHINE,40D3SCR4GZ,Designated/Approved,Public record,662,buprenorphine in combination with naloxone,10/27/1994,Treatment of opiate addiction in opiate users,Designated/Approved,,Treatment of opioid dependence in patients 16 years of age or older,10/8/2002,10/8/2009,,"Indivior, Inc.",10710 Midlothian Turnpike,Suite 430,Richmond,Virginia,23235,United States,79093
OXYBATE,30IW36W5B2,Designated/Approved,Public record,663,"calcium, magnesium, potassium, and sodium oxybates",11/7/1994,Treatment of narcolepsy.,Designated/Approved,,XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.,7/21/2020,7/21/2027,XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin 4,,,Ireland,85894
THYMALFASIN,W0B22ISQ1C,Designated,Public record,664,Thymalfasin,1/8/1998,Treatment of DiGeorge anomaly with immune defects.,Designated,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",901 Mariner's Island Blvd.,,San Mateo,California,94404,United States,109597
CARGLUMIC ACID,5L0HB4V1EW,Designated/Approved,Public record,665,carglumic acid,1/20/1998,Treatment of N-acetylglutamate synthetase deficiency.,Designated/Approved,,As an adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) and as manitenance therapy for chronic hyperammonemia due to NAGS deficiency,3/18/2010,3/18/2017,,Orphan Europe SARL,Immeuble Le Wilson,70 avenue du General de Gaulle,Puteaux,,,France,109997
BINDARIT,JQ11LH711M,Designated,Public record,666,Bindarit,2/3/1998,Treatment of lupus nephritis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Angelini Pharmaceuticals, Inc.",70 Grand Avenue,Suite 109,River Edge,New Jersey,7661,United States,110097
RUPLIZUMAB,562JQF15GN,Designated,Public record,667,Recombinant humanized monclonal antibody 5c8,2/3/1998,Treatment of immune thrombocytopenic purpura.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,109897
RIFAXIMIN,L36O5T016N,Designated/Approved,Public record,668,rifaximin,2/10/1998,Treatment of hepatic encephalopathy,Designated/Approved,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age,3/24/2010,3/24/2017,,"Salix Pharmaceuticals, Inc.",400 Somerset Corporate Blvd,,Somerset,New Jersey,8807,United States,109497
RUPLIZUMAB,562JQF15GN,Designated,Public record,669,Recombinant humanized monoclonal antibody 5c8,2/18/1998,Treatment of systemic lupus erythematosus.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,111298
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,670,Thalidomide,2/27/1998,Treatment of primary brain malignancies.,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,7059,United States,110197
ARSENIC TRIOXIDE,S7V92P67HO,Designated/Approved,Public record,671,Arsenic trioxide,3/3/1998,Treatment of acute promyelocytic leukemia.,Designated/Approved,,In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,1/12/2018,1/12/2025,In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,"Teva Branded Pharmaceutical Products R&D, Inc.",41 Moores Road,,Frazer,Pennsylvania,19355,United States,109697
ARSENIC TRIOXIDE,S7V92P67HO,Designated/Approved,Public record,672,Arsenic trioxide,3/3/1998,Treatment of acute promyelocytic leukemia.,Designated/Approved,,"For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) transloc",9/25/2000,9/25/2007,,"Teva Branded Pharmaceutical Products R&D, Inc.",41 Moores Road,,Frazer,Pennsylvania,19355,United States,109697
PHENYL ACETATE,355G9R500Y,Designated,Public record,673,Phenylacetate,3/6/1998,"For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.",Designated,Not FDA Approved for Orphan Indication,,,,,"Elan Drug Delivery, Inc.",1300 Gould Dr.,,Gainesville,Georgia,30504,United States,110698
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,674,recombinant human alpha-1 antitrypsin,3/6/1998,Treatment of cystic fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,PPL Therapeutics (Scotland) Limited,Roslin,,Edinburgh,Scotland,,United Kingdom,111098
ALITRETINOIN,1UA8E65KDZ,Designated/Approved,Public record,675,Alitretinoin,3/24/1998,Treatment of AIDS-related Kaposi's sarcoma.,Designated/Approved,,Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.,2/2/1999,2/2/2006,,Concordia Pharmaceuticals Inc.,Canewood Business Centre,5 Canewood Industrial Park,St Michael,,,Barbados,110998
BECLOMETHASONE DIPROPIONATE,5B307S63B2,Designated,Public record,676,beclomethasone dipropionate,3/27/1998,For oral administration in the treatment of intestinal graft-versus-host disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,8540,United States,111198
PENTOSTATIN,395575MZO7,Designated,Public record,677,Pentostatin,3/27/1998,Treatment of cutaneous T-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,111998
CORTICORELIN,305OE8862Y,Designated,Public record,678,"Corticotropin-releasing factor, human",4/6/1998,Treatment of peritumoral brain edema.,Designated,Not FDA Approved for Orphan Indication,,,,,"Neurobiological Technologies, Inc.",1387 Marina Way South,,Richmond,California,94804,United States,108097
Dimethyl sulfoxide,YOW8V9698H,Designated,Public record,679,Dimethylsulfoxide,4/6/1998,Treatment of palmar-plantar erythrodysethesia syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cancer Technologies, Inc.",7301 East 22nd Street,Suite 10E,Tucson,Alaska,85710,United States,108697
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,680,Tacrolimus,4/6/1998,Prophylaxis of graft-versus-host-disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,60015,United States,111398
TIAPRIDE,LAH70H9JPH,Designated/Withdrawn,Public record,681,Tiapride,4/21/1998,Treatment of Tourette's syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sanofi-Synthelabo, Inc.",9 Great Valley Parkway,PO Box 3026,Malvern,Pennsylvania,19355,United States,111798
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,682,Sodium phenylbutyrate,4/24/1998,"For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.",Designated,Not FDA Approved for Orphan Indication,,,,,"Elan Drug Delivery, Inc.",1300 Gould Dr.,,Gainesville,Georgia,30504,United States,110598
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,683,Liposomal cyclosporin A,4/30/1998,Prevention of fetal and neonatal alloimmune thrombocytopenia,Designated,Not FDA Approved for Orphan Indication,,,,,"Vernon Knight, M.D.","Baylor College of Medicine, Dept. of Molecular Phy",One Baylor Plaza,Houston,Texas,77030,United States,112798
ADEMETIONINE,7LP2MPO46S,Designated,Public record,684,S-adenosylmethionine,4/30/1998,Treatment of AIDS-myelopathy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Genopia USA, Inc.","90 Gold Street, 6N",,New York,New York,10038,United States,111498
MIGLUSTAT,ADN3S497AZ,Designated,Public record,685,"1,5-(Butylimino)-1,5 dideoxy,D-glucitol",5/12/1998,Treatment of Fabry's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Oxford GlycoSciences,"10, The Quadrant",Abington Science Park,Abington,Oxfordshire,,United Kingdom,112198
AMIFOSTINE,M487QF2F4V,Designated/Approved,Public record,686,Amifostine,5/12/1998,Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.,Designated/Approved,,"Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.",6/24/1999,6/24/2006,,"Medimmune Oncology, Inc.",One Tower Bridge,"100 Front Street, Suite 400",West Conshohocken,Pennsylvania,19428,United States,111698
TETRABENAZINE,Z9O08YRN8O,Designated,Public record,687,Tetrabenazine,5/12/1998,Treatment of moderate/severe tardive dyskinesia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Prestwick Pharmaceuticals, Inc.","1825 K Street, NW",Suite 1475,Washington,District of Columbia,20006,United States,109797
TAK-603,W6RZK26FCB,Designated/Withdrawn,Public record,688,"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate",5/13/1998,Treatment of Crohn's disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Tap Holdings Inc.,2355 Waukegan Road,,Deerfield,Illinois,60015,United States,112698
BENZYDAMINE HYDROCHLORIDE,K2GI407R4Q,Designated,Public record,689,Benzydamine hydrochloride,5/18/1998,Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Angelini Pharmaceuticals, Inc.",70 Grand Avenue,,River Edge,New Jersey,7661,United States,111898
DAPSONE,8W5C518302,Designated,Public record,690,Dapsone,11/7/1994,Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.,Designated,Not FDA Approved for Orphan Indication,,,,,"Jacobus Pharmaceutical Company, Inc.",37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,8540,United States,85694
OXYBATE,30IW36W5B2,Designated/Approved,Public record,691,sodium oxybate,11/7/1994,Treatment of narcolepsy.,Designated/Approved,,Treatment of excessive daytime sleepiness in patients with narcolepsy,11/18/2005,11/18/2012,,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin 4,,,Ireland,85894
OXYBATE,30IW36W5B2,Designated/Approved,Public record,692,sodium oxybate,11/7/1994,Treatment of narcolepsy.,Designated/Approved,,Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.,10/26/2018,10/26/2025,Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in pediatric patients 7 years of age and older with narcolepsy.,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin 4,,,Ireland,85894
OXYBATE,30IW36W5B2,Designated/Approved,Public record,693,sodium oxybate,11/7/1994,Treatment of narcolepsy.,Designated/Approved,,Treatment of cataplexy associated with narcolepsy,7/17/2002,7/17/2009,,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin 4,,,Ireland,85894
Sodium dichloroacetate,42932X67B5,Designated,Public record,694,Sodium dichloroacetate,11/10/1994,Treatment of lactic acidosis in patients with severe malaria.,Designated,Not FDA Approved for Orphan Indication,,,,,"Stacpoole, Peter W. M.D., Ph.D.",University of Florida,P.O. Box 100277,Gainesville,Florida,32610,United States,83694
CDX-1135,2RF4H67MOG,Designated,Public record,695,Soluble recombinant human complement receptor type 1,11/21/1994,Prevention or reduction of adult respiratory distress syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"T Cell Sciences, Inc.",119 Fourth Avenue,,Needham Heights,Massachusetts,2194,United States,82894
Dimethyl sulfoxide,YOW8V9698H,Designated,Public record,696,Dimethyl sulfoxide,11/22/1994,"Treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.",Designated,Not FDA Approved for Orphan Indication,,,,,"Abela Pharmaceuticals, Inc.",21581 Midcrest Drive,,Lake Forest,California,92630,United States,81394
RECOMBINANT METHIONYL HUMAN BRAIN-DERIVED NEUROTROPHIC FACTOR,7171WSG8A2,Designated,Public record,697,Recombinant methionyl brain-derived neurotrophic factor,11/28/1994,Treatment of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Dr.,M/S: 17-2-B,Thousand Oaks,California,91320,United States,86394
COUMARIN,A4VZ22K1WT,Designated,Public record,698,Coumarin,12/22/1994,Treatment of renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Drossapharm LTD,Ariesheim,,Basel,,,Switzerland,84294
Orgotein,PKE82W49V1,Designated/Withdrawn,Public record,699,Orgotein for injection,12/22/1994,"Treatment of familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Oxis International, Inc.","6040 N. Cutter Circle, Suite 317",,Portland,Oregon,97217,United States,87294
Progesterone,4G7DS2Q64Y,Designated,Public record,700,progesterone,12/22/1994,Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.,Designated,Not FDA Approved for Orphan Indication,,,,,"Watson Laboratories, Inc.",311 Bonnie Circle,,Corona,California,91720,United States,82694
SOMATOSTATIN,6E20216Q0L,Designated,Public record,701,Somatostatin,12/22/1994,Treatment of bleeding esophageal varices.,Designated,Not FDA Approved for Orphan Indication,,,,,Eumedica Pharmaceuticals A.G. (Schweiz),Arnold Bocklin-Strasse 1,CH-4051,BASEL,,,Switzerland,86094
AMINOCAPROIC ACID,U6F3787206,Designated,Public record,703,Aminocaproic acid,1/6/1995,For the topical treatment of traumatic hyphema of the eye.,Designated,Not FDA Approved for Orphan Indication,,,,,Eastern Virginia Medical School,Department of Ophthalomology,"880 Kempsville Road, Suite 2500",Norfolk,Virginia,23502,United States,83294
ELOSULFASE ALFA,ODJ69JZG85,Designated/Withdrawn,Public record,704,Chondroitinase,2/9/1995,Treatment of patients undergoing vitrectomy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bausch & Lomb Pharmaceuticals, Inc.",8500 Hidden River Pkwy.,,Tampa,Florida,33637,United States,87794
GLYCERYL TRIOLEATE,O05EC62663,Designated,Public record,706,Glyceryl trioleate and glyceryl trierucate,2/14/1995,Treatment of adrenoleukodystrophy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Moser, Hugo W. M.D.",Johns Hopkins University,"Kennedy Krieger Institute, 707 North Broadway",Baltimore,Maryland,21205,United States,87594
GLYCERYL TRIERUCATE,I0IDQ0M20R,Designated,Public record,706,Glyceryl trioleate and glyceryl trierucate,2/14/1995,Treatment of adrenoleukodystrophy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Moser, Hugo W. M.D.",Johns Hopkins University,"Kennedy Krieger Institute, 707 North Broadway",Baltimore,Maryland,21205,United States,87594
GLUTAMINE,0RH81L854J,Designated/Approved,Public record,708,Glutamine,3/6/1995,For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).,Designated/Approved,,Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication.,6/10/2004,6/10/2011,,"Emmaus Medical, Inc.",20725 S. Western Avenue,Suite 136,Torrence,California,90501,United States,85794
GELSOLIN,JBT6SFF5BV,Designated,Public record,709,Recombinant human gelsolin,3/6/1995,Treatment of acute and chronic respiratory symptoms of bronchiectasis.,Designated,Not FDA Approved for Orphan Indication,,,,,"BioAgeis, Therapeutics, Inc.",6 East Cove Lane,,Morristown,New Jersey,7960,United States,85394
SARGRAMOSTIM,5TAA004E22,Designated/Approved,Public record,710,Sargramostim,3/6/1995,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.,9/15/1995,9/15/2002,,Immunex Corporation,51 University Street,,Seattle,Washington,98101,United States,81494
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,711,Somatropin (r-DNA),3/6/1995,For use alone or in combination with glutamine in the treatment of short bowel syndrome.,Designated/Approved,,Treatment of short bowel syndrome in patients receiving specialized nutritional support,12/1/2003,12/1/2010,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,80394
HEPATITIS B IMMUNE GLOBULIN INTRAVENOUS (HUMAN),,Designated,Public record,713,Hepatitis B immune globulin intravenous (human),3/8/1995,Prophylaxis against hepatitis B virus reinfection in liver transplant patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Biotest Pharmaceuticals Corporation,"5800 Park of Commerce Blvd., NW",,Boca Raton,Florida,33487,United States,76093
PEGVALIASE,N6UAH27EUV,Designated/Approved,Public record,714,pegvaliase-pqpz,3/8/1995,Treatment of hyperphenylalaninemia,Designated/Approved,,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management,5/24/2018,5/24/2025,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,94949,United States,88195
TYLOXAPOL,Y27PUL9H56,Designated,Public record,715,Tyloxapol,3/8/1995,Treatment of cystic fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Kennedy & Hoidal, M.D.'s",University of Utah Health Sciences Center,"50 North Medical Drive, Room 4R240",Salt Lake City,Utah,84132,United States,87994
CLOTRIMAZOLE,G07GZ97H65,Designated,Public record,717,Clotrimazole,4/24/1995,Treatment of sickle cell disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Brugnara, Carlo M.D.",The Children's Hospital,"300 Longwood Avenue, Bader 760",Boston,Massachusetts,2115,United States,88094
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,718,Thalidomide,5/1/1995,"Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.",Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,7059,United States,80194
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,719,Thalidomide,5/15/1995,"Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.",Designated,Not FDA Approved for Orphan Indication,,,,,Andrulis Research Corporation,"11800 Baltimore Avenue, Suite 113",,Beltsville,Maryland,20705,United States,82594
NITISINONE,K5BN214699,Designated/Approved,Public record,720,Nitisinone; Nitisinone,5/16/1995,Treatment of tyrosinemia type 1.,Designated/Approved,,Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1,1/18/2002,1/18/2009,,Swedish Orphan Biovitrum AB (publ),Tomtebodavägen 23A,,Stockholm,,,Sweden,89095
NITISINONE,K5BN214699,Designated/Approved,Public record,721,Nitisinone; Nitisinone,5/16/1995,Treatment of tyrosinemia type 1.,Designated/Approved,,Treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.,4/22/2016,,,Swedish Orphan Biovitrum AB (publ),Tomtebodavägen 23A,,Stockholm,,,Sweden,89095
LEFLUNOMIDE,G162GK9U4W,Designated,Public record,722,N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide,5/25/1995,Treatment of malignant glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sugen, Inc.",230 East Grand Ave.,,South San Francisco,California,94080,United States,89895
GANCICLOVIR,P9G3CKZ4P5,Designated/Approved,Public record,723,Ganciclovir intravitreal implant,6/7/1995,Treatment of cytomegalovirus retinitis.,Designated/Approved,,Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.,3/4/1996,3/4/2003,,"Bausch & Lomb Surgical, Chiron Vision Products",9342 Jeronimo Road,,Irvine,California,92718,United States,86494
MECASERMIN,7GR9I2683O,Designated/Withdrawn,Public record,724,Recombinant human insulin-like growth factor 1,6/7/1995,Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,49001,United States,90895
MECASERMIN,7GR9I2683O,Designated/Withdrawn,Public record,725,Recombinant human insulin-like growth factor 1,6/7/1995,Treatment of growth hormone receptor deficiency.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,49001,United States,89795
RIFAPENTINE,XJM390A33U,Designated/Approved,Public record,726,Rifapentine,6/9/1995,Treatment of pulmonary tuberculosis.,Designated/Approved,,,6/22/1998,6/22/2005,,Hoechst Marion Roussel,P.O. Box 9627,Mail Station: H3-M2516,Kansas City,Missouri,64134,United States,89495
RIFAPENTINE,XJM390A33U,Designated,Public record,727,Rifapentine,6/9/1995,Treatment of Mycobacterium avium complex in patients with AIDS.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoechst Marion Roussel , Inc.",P.O. Box 9627,Mail Station: H3-M2516,Kansas City,Missouri,64134,United States,89595
"""SODIUM CITRATE, UNSPECIFIED FORM""",1Q73Q2JULR,Designated,Public record,728,Trisodium citrate concentration,6/15/1995,For use in leukapheresis procedures.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hemotec Medical Products, Inc.",Box 19255,,Johnston,Rhode Island,2919,United States,87094
ANCESTIM,PYB4Q6JG41,Designated/Withdrawn,Public record,729,Ancestim,7/5/1995,For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91320,United States,86594
GABAPENTIN,6CW7F3G59X,Designated,Public record,731,gabapentin,7/5/1995,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,Parke-Davis Pharmaceutical Research Division,2800 Plymouth Road,Ann Arbor,Michigan,48105,United States,88695
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,732,Nitric oxide,7/10/1995,Treatment of acute respiratory distress syndrome in adults.,Designated,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Hopspital Products,1425 U.S. 206,,Bedminster Township,New Jersey,7921,United States,90595
MITOLACTOL,LJ2P1SIK8Y,Designated,Public record,733,Mitolactol,7/12/1995,As adjuvant therapy in the treatment of primary brain tumors.,Designated,Not FDA Approved for Orphan Indication,,,,,"Targent, Inc.",155 Lambert Drive,,Princeton,New Jersey,8540,United States,90295
APOMORPHINE,N21FAR7B4S,Designated,Public record,734,Apomorphine,7/17/1995,Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Pentech Pharmaceuticals, Inc.",1110 Lake Cook Rd.,Suite 257,Buffalo Grove,Illinois,60089,United States,89295
FILGRASTIM,PVI5M0M1GW,Designated/Approved,Public record,735,Filgrastim,7/17/1995,For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.,Designated/Approved,,For use in the mobilization of hematopoietic progenitor cells into the peripheral blood collection by leukapheresis.,12/28/1995,12/28/2002,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,91320,United States,89395
LUCINACTANT,5BSH2G9BH8,Designated,Public record,736,Lucinactant,7/17/1995,Treatment of acute respiratory distress syndrome in adults.,Designated,Not FDA Approved for Orphan Indication,,,,,"Windtree Therapeutics, Inc.",2600 Kelly Road,Suite 100,Warrington,Pennsylvania,18976,United States,89995
ALGLUCERASE,27T56C7KK0,Designated,Public record,738,Alglucerase injection,7/21/1995,Replacement therapy in patients with Type II and III Gaucher's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,91095
THALIDOMIDE,4Z8R6ORS6L,Designated/Approved,Public record,739,Thalidomide,7/26/1995,Treatment of erythema nodosum leprosum.,Designated/Approved,,Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.,7/16/1998,7/16/2005,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,90795
FIBRINOGEN HUMAN,N94833051K,Designated,Public record,740,Fibrinogen (human),8/23/1995,For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.,Designated,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,90032,United States,88595
LAMOTRIGINE,U3H27498KS,Designated/Approved,Public record,741,Lamotrigine,8/23/1995,Treatment of Lennox-Gastaut syndrome.,Designated/Approved,,Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.,8/24/1998,8/24/2005,,Glaxo Wellcome Research and Development,5 Moore Drive,P.O. Box 13398,Research Triangle Park,North Carolina,27709,United States,91695
BROXURIDINE,G34N38R2N1,Designated,Public record,743,Broxuridine,9/18/1995,Radiation sensitizer in the treatment of primary brain tumors.,Designated,Not FDA Approved for Orphan Indication,,,,,"NeoPharm, Inc.","225 East Deerpath, Suite 250",,Lake Forest,Illinois,60045,United States,91295
TALC,7SEV7J4R1U,Designated/Approved,Public record,744,Sterile talc powder,9/18/1995,Treatment of malignant pleural effusion.,Designated/Approved,,Prevention of recurrence of malignant pleural effusions in symptomatic patients.,12/24/1997,12/24/2004,,"Sciarra Laboratories, Inc.",485-09 South Broadway,,Hicksville,New York,11801,United States,91595
PORFIROMYCIN,H1WK901OA6,Designated,Public record,745,Porfiromycin,9/19/1995,Treatment of head and neck cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,91495
ELCATONIN,W0CMS474JK,Designated,Public record,746,Elcatonin,9/25/1995,Intrathecal treatment of intractable pain.,Designated,Not FDA Approved for Orphan Indication,,,,,"Innapharma, Inc.",10 Mountainview Road,,Upper Saddle River,New Jersey,7458,United States,81594
MECASERMIN,7GR9I2683O,Designated/Withdrawn,Public record,748,Recombinant human insulin-like growth factor-I,10/13/1995,Treatment of post-poliomyelitis syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Product R&D, Inc.",41 Moores Road,,Frazer,Pennsylvania,19355,United States,91995
LUCINACTANT,5BSH2G9BH8,Designated,Public record,749,Lucinactant,10/18/1995,Treatment of respiratory distress syndrome in premature infants.,Designated,Not FDA Approved for Orphan Indication,,,,,"Windtree Therapeutics, Inc.",2600 Kelly Road,Suite 100,Warrington,Pennsylvania,18976,United States,91395
LIDOCAINE,98PI200987,Designated/Approved,Public record,750,Lidocaine patch 5%,10/24/1995,"For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.",Designated/Approved,,,3/19/1999,3/19/2006,,"Teikoku Pharma USA, Inc.",745-D Camden Ave.,,Campbell,California,95008,United States,92395
ETIOCHOLANEDIONE,213MVW2TZD,Designated,Public record,751,Etiocholanedione,11/3/1995,Treatment of aplastic anemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,92695
SERELAXIN,W0122B976Y,Designated/Withdrawn,Public record,752,Recombinant human relaxin,11/3/1995,Treatment of progressive systemic sclerosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Connetics Corporation,3400 West Bayshore Road,,Palo Alto,California,94303,United States,92995
SORIVUDINE,C7VOZ162LV,Designated/Withdrawn,Public record,753,Sorivudine,11/9/1995,Treatment of herpes zoster (shingles) in immunocompromised patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,6492,United States,92295
INFLIXIMAB,B72HH48FLU,Designated/Approved,Public record,754,infliximab,11/14/1995,Treatment of Crohn's disease,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in",8/24/1998,8/24/2005,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,92495
ANCESTIM,PYB4Q6JG41,Designated/Withdrawn,Public record,756,Recombinant methionyl human stem cell factor,11/22/1995,Treatment of primary bone marrow failure.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91320,United States,88395
INTERFERON GAMMA-1B,21K6M2I7AG,Designated,Public record,757,Interferon gamma-1b,12/4/1995,Treatment of renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Horizon Therapeutic Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin 4,,,Ireland,93595
URIDINE 5'-TRIPHOSPHATE,UT0S826Z60,Designated/Withdrawn,Public record,758,Uridine 5'-triphosphate,12/4/1995,Treatment of cystic fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Inspire Pharmaceuticals, Inc.","4222 Emperor Boulevard, Suite 470",,Durham,North Carolina,27703,United States,93495
MECASERMIN,7GR9I2683O,Designated/Approved,Public record,759,Mecasermin,12/12/1995,Treatment of growth hormone insensitivity syndrome.,Designated/Approved,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.,8/30/2005,8/30/2012,,"Ipsen Biopharmaceuticals, Inc.",106 Allen Road,,Basking Ridge,New Jersey,7920,United States,93695
ANTIHEMOPHILIC FACTOR (HUMAN),,Designated/Approved,Public record,760,Antihemophilic factor (human),1/5/1996,Treatment of von Willebrand's disease,Designated/Approved,,For surgical and/or invasive procedures in patients with von Willebrand Disease (VWD) in whom desmopressin is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery,1/31/2007,1/31/2014,,Grifols Biologicals Inc.,5555 Valley Boulevard,,Los Angeles,California,90032,United States,93895
LEUCINE,GMW67QNF9C,Designated,Public record,761,"Valine, isoleucine and leucine",1/5/1996,Treatment of hyperphenylalaninemia,Designated,Not FDA Approved for Orphan Indication,,,,,Leas Research Products,78 Fallon Drive,,North Haven,Connecticut,6473,United States,93095
VALINE,HG18B9YRS7,Designated,Public record,761,"Valine, isoleucine and leucine",1/5/1996,Treatment of hyperphenylalaninemia,Designated,Not FDA Approved for Orphan Indication,,,,,Leas Research Products,78 Fallon Drive,,North Haven,Connecticut,6473,United States,93095
ISOLEUCINE,04Y7590D77,Designated,Public record,761,"Valine, isoleucine and leucine",1/5/1996,Treatment of hyperphenylalaninemia,Designated,Not FDA Approved for Orphan Indication,,,,,Leas Research Products,78 Fallon Drive,,North Haven,Connecticut,6473,United States,93095
ALBENDAZOLE,F4216019LN,Designated/Approved,Public record,762,Albendazole,1/17/1996,Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).,Designated/Approved,,"Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.",6/11/1996,6/11/2003,,"Impax Laboratories, LLC",400 Crossing Boulevard,Third Floor,Bridgewater,New Jersey,8807,United States,94195
ALBENDAZOLE,F4216019LN,Designated/Approved,Public record,763,Albendazole,1/18/1996,"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocys",Designated/Approved,,"Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.",6/11/1996,6/11/2003,,"Impax Laboratories, LLC",400 Crossing Boulevard,Third Floor,Bridgewater,New Jersey,8807,United States,94295
ANDROSTANOLONE,08J2K08A3Y,Designated,Public record,764,Dihydrotestosterone,2/5/1996,Treatment of weight loss in AIDS patients with HIV-associated wasting.,Designated,Not FDA Approved for Orphan Indication,,,,,"Besins Internaitonal, US Inc.",610 Herndon Parkway,Suite 750,Herndon,Virginia,20170,United States,93995
TESTOSTERONE,3XMK78S47O,Designated/Withdrawn,Public record,765,Testosterone,2/5/1996,Treatment of weight loss in AIDS patients with HIV-associated wasting.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Unimed Pharmaceuticals, Inc.",901 Sawyer Rd.,,Marietta,Georgia,30062,United States,94595
"""ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT""",P89DR4NY54,Designated/Approved,Public record,766,Antihemophilic factor (recombinant),2/8/1996,For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).,Designated/Approved,,,3/6/2000,,,"Wyeth Pharmaceuticals, Inc.",P. O. Box 8299,,Philadelphia,Pennsylvania,19101,United States,94495
INTERFERON BETA-1A,XRO4566Q4R,Designated/Withdrawn,Public record,767,Interferon beta-1a,3/11/1996,Treatment of patients with secondary progressive multiple sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,95195
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,768,Thalidomide,3/11/1996,Treatment of HIV-associated wasting syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,7059,United States,94995
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,9X7O8V25IT,Designated/Approved,Public record,769,collagenase clostridium histolyticum,3/12/1996,Treatment of Peyronie's disease.,Designated/Approved,,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,12/6/2013,12/6/2020,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,"Auxilium Pharmaceuticals, Inc.",640 Lee Road,,Chesterbrook,Pennsylvania,19087,United States,95496
LEFLUNOMIDE,G162GK9U4W,Designated,Public record,770,N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide,3/12/1996,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sugen, Inc.",230 East Grand Ave.,,South San Francisco,California,94080,United States,95095
RIFAPENTINE,XJM390A33U,Designated,Public record,771,Rifapentine,3/12/1996,Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoechst Marion Roussel, Inc.",P.O. Box 9627,Mail Station: H3-M2516,Kansas City,Missouri,64134,United States,89695
SOMATROPIN,NQX9KB6PCL,Designated,Public record,772,Somatropin (r-DNA) for injection,3/26/1996,Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,94695
IDOXURIDINE,LGP81V5245,Designated,Public record,773,Idoxuridine,4/8/1996,Treatment of nonparenchymatous sarcomas.,Designated,Not FDA Approved for Orphan Indication,,,,,"NeoPharm, Inc.","225 East Deerpath, Suite 250",,Lake Forest,Illinois,60045,United States,95696
ALPROSTADIL,F5TD010360,Designated/Withdrawn,Public record,775,Liposomal prostaglandin E1 injection,4/25/1996,Treatment of acute respiratory distress syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,8540,United States,95596
Amphotericin B,7XU7A7DROE,Designated/Withdrawn,Public record,776,Amphotericin B lipid complex,5/6/1996,Treatment of invasive zygomycosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,8540,United States,97096
Amphotericin B,7XU7A7DROE,Designated/Withdrawn,Public record,777,Amphotericin B lipid complex,5/6/1996,Treatment of invasive coccidioidomycosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,8540,United States,97396
ETIOCHOLANEDIONE,213MVW2TZD,Designated,Public record,778,Etiocholanedione,5/7/1996,Treatment of Prader-Willi syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,95896
ARCITUMOMAB,79T6JRG308,Designated/Withdrawn,Public record,779,Arcitumomab,5/10/1996,"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,96596
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,9X7O8V25IT,Designated/Approved,Public record,780,collagenase clostridium histolyticum,5/23/1996,Treatment of advanced (involutional or residual stage) Dupuytren's disease,Designated/Approved,,Treatment of adult patients with Dupuytren's contracture with a palpable cord,2/2/2010,2/2/2017,,"Auxilium Pharmaceuticals, Inc.",40 Valley Stream Parkway,,Malvern,Pennsylvania,19335,United States,92595
DMP-777,3Q0469283P,Designated,Public record,781,Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase,6/4/1996,Therapeutic management of patients with lung disease attributable to cystic fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,DuPont Pharmaceuticals Company,"Chestnut Run, Maple Run",Centre Rd.,Wilmington,Delaware,19805,United States,96496
METHYLNALTREXONE,0RK7M7IABE,Designated/Withdrawn by OPD,Public record,782,Methylnaltrexone,6/17/1996,Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Progenics Pharmaceuticals, Inc.",765 Old Saw Mill River Rd.,,Tarrytown,New York,10591,United States,92195
URIDINE 5'-TRIPHOSPHATE,UT0S826Z60,Designated/Withdrawn,Public record,783,Uridine 5'-triphosphate,6/26/1996,To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Inspire Pharmaceuticals, Inc.","4222 Emperor Boulevard, Suite 470",,Durham,North Carolina,27703,United States,99096
Amphotericin B,7XU7A7DROE,Designated/Withdrawn,Public record,784,Amphotericin B lipid complex,6/27/1996,Treatment of invasive candidiasis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,8540,United States,96996
GUSPERIMUS,UJ0ZJ76DO9,Designated/Withdrawn,Public record,785,Gusperimus,6/27/1996,Treatment of acute renal graft rejection episodes.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Pharmaceutical Research Institute,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,6492,United States,96896
OXOTHIAZOLIDINECARBOXYLIC ACID,X7063P804E,Designated,Public record,786,L-2-oxothiazolidine-4-carboxylic acid,7/30/1996,Treatment of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Transcend Therapeutics, Inc.","640 Memorial Drive, 3rd Floor West",,Cambridge,Massachusetts,2139,United States,99296
LUCINACTANT,5BSH2G9BH8,Designated/Withdrawn,Public record,787,Lucinactant,7/30/1996,Treatment of meconium aspiration syndrome in newborn infants,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Windtree Therapeutics, Inc.",2600 Kelly Road,Suite 100,Warrington,Pennsylvania,18976,United States,99796
Amphotericin B,7XU7A7DROE,Designated/Withdrawn,Public record,788,Amphotericin B lipid complex,8/21/1996,Treatment of invasive protothecosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,8540,United States,97796
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated,Public record,789,C1 esterase inhibitor (human),8/21/1996,Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,90032,United States,95296
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated,Public record,789,C1 esterase inhibitor (human),8/21/1996,Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,90032,United States,95296
DENILEUKIN DIFTITOX,25E79B5CTM,Designated/Approved,Public record,790,denileukin diftitox,8/21/1996,Treatment of patients with cutaneous T-cell lymphoma,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.,2/5/1999,2/5/2006,,"Eisai, Inc.",300 Tice Boulevard,,Woodcliff Lake,New Jersey,7677,United States,99396
METHIONINE,AE28F7PNPL,Designated,Public record,791,Methionine/L-methionine,8/21/1996,Treatment of AIDS myelopathy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Genopia USA, Inc.","90 Gold Street, 6N",,New York,New York,10038,United States,91795
MITOXANTRONE,BZ114NVM5P,Designated/Approved,Public record,792,Mitoxantrone,8/21/1996,Treatment of hormone refractory prostate cancer.,Designated/Approved,,In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.,11/13/1996,11/13/2003,,Serono,One Technology Place,,Rockland,Massachusetts,2370,United States,96696
Doxecitine,0W860991D6,Designated,Public record,793,2'-deoxycytidine,9/9/1996,As a host-protective agent in the treatment of acute myelogenous leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Grant, Steven M.D.","Massey Cancer Center, VCU",P.O. Box 980230,Richmond,Virginia,23298,United States,99996
ALDESLEUKIN,M89N0Q7EQR,Designated/Approved,Public record,794,Aldesleukin,9/10/1996,Treatment of metastatic melanoma.,Designated/Approved,,Treatment of adults with metastatic melanoma.,1/9/1998,1/9/2005,,Chiron Corporation,4560 Horton Street,,Emeryville,California,94608,United States,100696
ALGLUCOSIDASE ALFA,DTI67O9503,Designated/Withdrawn,Public record,795,"Human acid precursor alpha-glucosidase, recombinant",9/10/1996,Treatment of glycogen storage disease type II.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pharming/Genzyme LLC,1 Mountain Rd.,PO Box 9322,Framingham,Massachusetts,1701,United States,100496
ALPROSTADIL,F5TD010360,Designated/Withdrawn,Public record,796,Prostaglandin E1 in lipid emulsion,9/10/1996,Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,90032,United States,88795
RUBITECAN,H19C446XXB,Designated,Public record,797,9-nitro-20-(S)-camptothecin,9/16/1996,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,100196
Amphotericin B,7XU7A7DROE,Designated/Withdrawn,Public record,798,Amphotericin B lipid complex,9/23/1996,Treatment of invasive sporotrichosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,8540,United States,97696
INTERFERON GAMMA-1B,21K6M2I7AG,Designated/Approved,Public record,799,Interferon gamma-1b,9/30/1996,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.",Designated/Approved,,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.",2/10/2000,2/10/2007,,Horizon Therapeutic Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin 4,,,Ireland,98796
RILUZOLE,7LJ087RS6F,Designated,Public record,800,Riluzole,10/15/1996,Treatment of Huntington's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Rhone-Poulenc Rorer Pharmaceuticals, Inc.",500 Arcola Road,PO Box 5096,Collegeville,Pennsylvania,19426,United States,100796
LEFLUNOMIDE,G162GK9U4W,Designated,Public record,801,Leflunomide,10/18/1996,Prevention of acute and chronic rejection in patients who have received solid organ transplants.,Designated,Not FDA Approved for Orphan Indication,,,,,"Williams, MD, James W.","Rush-Presbyterian-St. Luke's Medical Ctr., Dept. o",1653 West Congress Parkway,Chicago,Illinois,60612,United States,100296
IBUPROFEN,WK2XYI10QM,Designated,Public record,802,Ibuprofen i.v. solution,10/29/1996,Prevention of patent ductus arteriosus.,Designated,Not FDA Approved for Orphan Indication,,,,,"Farmacon-IL, LLC",1720 Post Road East,Suite 213,Westport,Connecticut,6880,United States,100896
IBUPROFEN LYSINE,N01ORX9D6S,Designated/Approved,Public record,803,Ibuprofen lysine,10/29/1996,Treatment of patent ductus arteriosus,Designated/Approved,,"For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, et",4/13/2006,4/13/2013,,"Lundbeck, Inc.",Four Parkway North,,Deerfield,Illinois,60015,United States,101496
FILGRASTIM,PVI5M0M1GW,Designated/Approved,Public record,804,Filgrastim,11/7/1996,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.",Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.",4/2/1998,4/2/2005,,"Amgen, Inc.",One Amgen Center Dr.,,Thousand Oaks,California,91320,United States,101096
IMEXON,8F63U28T2V,Designated,Public record,805,Imexon,11/8/1996,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,AmpliMed Corporation,2321 Camino La Zorrela,,Tucson,Alaska,85718,United States,100996
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,806,Somatropin for injection,11/18/1996,As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.,Designated/Approved,,,12/15/1997,12/15/2004,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,94080,United States,100396
OREGOVOMAB,HX101E7L6S,Designated,Public record,807,Monoclonal antibody-B43.13,11/25/1996,Treatment of epithelial ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,CanariaBio Inc.,29 Jungang-ro,,Pyeongtaek-si,Gyeonggi-do,,South Korea,101396
Amphotericin B,7XU7A7DROE,Designated/Approved,Public record,808,Liposomal amphotericin B,12/6/1996,Treatment of visceral leishmaniasis.,Designated/Approved,,Treatment of visceral leishmaniasis.,8/11/1997,8/11/2004,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,60015,United States,99596
Amphotericin B,7XU7A7DROE,Designated,Public record,809,Liposomal amphotericin B,12/10/1996,Treatment of histoplasmosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,60015,United States,99696
Amphotericin B,7XU7A7DROE,Designated/Approved,Public record,810,Liposomal amphotericin B,12/10/1996,Treatment of cryptococcal meningitis.,Designated/Approved,,Treatment of disseminated cryptococcosis including meningitis.,8/11/1997,8/11/2004,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,60015,United States,99496
ACECAINIDE,910Q707V6F,Designated,Public record,811,N-acetyl-procainamide,12/10/1996,Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.,Designated,Not FDA Approved for Orphan Indication,,,,,NAPA of the Bahamas,"3560 Pennsylvania Avenue, Suite 7",,Dubuque,Iowa,52002,United States,99196
NITAZOXANIDE,SOA12P041N,Designated/Approved,Public record,814,Nitazoxanide,12/12/1996,Treatment of cryptosporidiosis.,Designated/Approved,,Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia,11/22/2002,11/22/2009,,"Romark Laboratories, L.C.",6200 Courtney Campbell Causeway,Suite 880,Tampa,Florida,33607,United States,91895
OPRELVEKIN,HM5641GA6F,Designated/Approved,Public record,815,Oprelvekin,12/17/1996,Prevention of severe chemotherapy-induced thrombocytopenia.,Designated/Approved,,,11/25/1997,11/25/2004,,"Genetics Institute, Inc.",87 Cambridge Park Drive,,Cambridge,Massachusetts,2140,United States,96796
ALITRETINOIN,1UA8E65KDZ,Designated/Withdrawn,Public record,818,9-cis-retinoic acid,1/2/1997,Prevention of retinal detachment due to proliferative vitreoretinopathy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,92623,United States,101296
PRASTERONE SODIUM SULFATE ANHYDROUS,B9840IHU4T,Designated,Public record,819,Dehydroepiandrosterone sulfate sodium,1/28/1997,To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharmadigm, Inc.",2401 Foothill Drive,,Salt Lake City,Utah,84109,United States,101996
ENADOLINE HYDROCHLORIDE,086I9HO04E,Designated,Public record,820,Enadoline hydrochloride,1/28/1997,Treatment of severe head injury.,Designated,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,Parke-Davis Pharmaceutical Research Division,2800 Plymouth Road,Ann Arbor,Michigan,48105,United States,102496
PRASTERONE SODIUM SULFATE ANHYDROUS,B9840IHU4T,Designated,Public record,821,Dehydroepiandrosterone sulfate sodium,1/29/1997,Treatment of serious burns requiring hospitalization.,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharmadigm, Inc.",2401 Foothill Drive,,Salt Lake City,Utah,84109,United States,102196
LEPIRUDIN,Y43GF64R34,Designated/Approved,Public record,822,Lepirudin,2/13/1997,Treatment of heparin-associated thrombocytopenia type II.,Designated/Approved,,For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.,3/6/1998,3/6/2005,,Hoechst Marion Roussel,Frankfurt am Main,P.O. Box 1140,Marburg,,,Germany,102796
Hydrochloric acid,QTT17582CB,Designated,Public record,823,chlorobutanol/propylene glycol/hydrochloric acid,2/18/1997,Treatment of patulous eustachian tube,Designated,Not FDA Approved for Orphan Indication,,,,,Ear Foundation,"2420 Castillo Street, Suite 100",,Santa Barbara,California,93105,United States,98896
CHLOROBUTANOL,HM4YQM8WRC,Designated,Public record,823,chlorobutanol/propylene glycol/hydrochloric acid,2/18/1997,Treatment of patulous eustachian tube,Designated,Not FDA Approved for Orphan Indication,,,,,Ear Foundation,"2420 Castillo Street, Suite 100",,Santa Barbara,California,93105,United States,98896
PROPYLENE GLYCOL,6DC9Q167V3,Designated,Public record,823,chlorobutanol/propylene glycol/hydrochloric acid,2/18/1997,Treatment of patulous eustachian tube,Designated,Not FDA Approved for Orphan Indication,,,,,Ear Foundation,"2420 Castillo Street, Suite 100",,Santa Barbara,California,93105,United States,98896
PORFIROMYCIN,H1WK901OA6,Designated,Public record,824,Porfiromycin,3/13/1997,Treatment of cervical cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,103597
HILTONOL,7KYP9TKT70,Designated,Public record,825,Poly-ICLC,3/17/1997,Treatment of primary brain tumors.,Designated,Not FDA Approved for Orphan Indication,,,,,Oncovir,3202 Cleveland Avenue N.W.,,Washington,District of Columbia,20008,United States,103197
"""8-CYCLOPENTYL-1,3-DIPROPYLXANTHINE""",9PTP4FOI9E,Designated/Withdrawn,Public record,826,"8 Cyclopentyl 1,3-dipropylxanthine",3/24/1997,Treatment of cystic fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",901 Mariner's Island Boulevard,,San Mateo,California,94404,United States,103997
ALETHINE,LY583605Y8,Designated,Public record,827,Beta alethine,3/24/1997,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Dovetail Technologies, Inc.","Bldg. 337, Paint Branch Drive",,College Park,Maryland,20742,United States,103297
ALETHINE,LY583605Y8,Designated,Public record,828,Beta alethine,3/24/1997,Treatment of metastatic melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Dovetail Technologies, Inc.","Bldg. 337, Paint Branch Drive",,College Park,Maryland,20742,United States,103397
PACLITAXEL,P88XT4IS4D,Designated/Approved,Public record,830,Paclitaxel,3/25/1997,Treatment of AIDS-related Kaposi's sarcoma.,Designated/Approved,,For the second line treatment of AIDS-related Kaposi's sarcoma.,8/4/1997,8/4/2004,,Bristol-Myers Squibb Pharmaceutical Research Institute,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,6492,United States,103497
LEVOCARNITINE,0G389FZZ9M,Designated,Public record,832,Levocarnitine,4/7/1997,Treatment of zidovudine-induced mitochondrial myopathy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Boulevard,Suite 500,Gaithersburg,Maryland,20878,United States,103897
Dimethyl sulfoxide,YOW8V9698H,Designated,Public record,833,Dimethylsulfoxide,4/15/1997,Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cancer Technologies, Inc.",7301 East 22nd Street,Suite 10E,Tucson,Alaska,85710,United States,104097
PACLITAXEL,P88XT4IS4D,Designated,Public record,834,Paclitaxel,4/15/1997,Treatment of AIDS-related Kaposi's sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Baker Norton Pharmaceuticals, Inc.",4400 Biscayne Boulevard,,Miami,Florida,33137,United States,104797
OXANDROLONE,7H6TM3CT4L,Designated,Public record,835,Oxandrolone,4/22/1997,Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Savient Pharmaceuticals, Inc.","One Tower Center Boulevard, 12th floor",,East Brunswick,New Jersey,8816,United States,103797
SURAMIN,6032D45BEM,Designated,Public record,837,Suramin,5/6/1997,Treatment of hormone-refractory prostate cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,Parke-Davis Pharmaceutical Research Division,2800 Plymouth Road,Ann Arbor,Michigan,48105,United States,104897
DALFAMPRIDINE,BH3B64OKL9,Designated,Public record,838,Fampridine,6/2/1997,"Treatment of chronic, incomplete spinal cord injury.",Designated,Not FDA Approved for Orphan Indication,,,,,"Acorda Therapeutics, Inc.",15 Skyline Dr.,,Hawthorne,New York,10532,United States,104497
TREPROSTINIL,RUM6K67ESG,Designated/Approved,Public record,839,treprostinil,6/4/1997,Treatment of pulmonary arterial hypertension.,Designated/Approved,,Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.,12/20/2013,12/20/2020,For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.,United Therapeutics Corp.,55 T.W. Alexander Dr.,,Research Triangle Park,North Carolina,27709,United States,105197
TREPROSTINIL,RUM6K67ESG,Designated/Approved,Public record,840,treprostinil,6/4/1997,Treatment of pulmonary arterial hypertension.,Designated/Approved,,Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.,10/18/2019,10/18/2026,Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression.,United Therapeutics Corp.,55 T.W. Alexander Dr.,,Research Triangle Park,North Carolina,27709,United States,105197
TREPROSTINIL,RUM6K67ESG,Designated/Approved,Public record,841,treprostinil,6/4/1997,Treatment of pulmonary arterial hypertension.,Designated/Approved,,Treatment of pulmonary arterial hypertension.,5/21/2002,5/21/2009,,United Therapeutics Corp.,55 T.W. Alexander Dr.,,Research Triangle Park,North Carolina,27709,United States,105197
PEGVISOMANT,N824AOU5XV,Designated/Approved,Public record,843,Pegvisomant,6/24/1997,Treatment of acromegaly.,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate",3/25/2003,3/25/2010,,Sensus Corporation,"Suite 430,",98 San Jacinto Boulevard,Austin,Texas,78701,United States,105097
BUSULFAN,G1LN9045DK,Designated,Public record,845,Busulfan,7/7/1997,Treatment of primary brain malignancies.,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,105897
ICODEXTRIN,2NX48Z0A9G,Designated/Approved,Public record,847,Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution,7/18/1997,Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.,Designated/Approved,,For use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.,12/20/2002,12/20/2009,,Baxter Healthcare Corporation,Renal Division,1620 Waukegan Road,McGaw Park,Illinois,60085,United States,105697
CYLEXIN,WLZ3BA9R26,Designated,Public record,848,"Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit",7/18/1997,Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.,Designated,Not FDA Approved for Orphan Indication,,,,,Cytel Corporation,3525 John Hopkins Court,,San Diego,California,92121,United States,106297
POLOXAMER 188,LQA7B6G8JG,Designated,Public record,849,Poloxamer 188,8/5/1997,Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,154 Technology Parkway,,Norcross,Georgia,30092,United States,102696
INTERMEDINE,OVF025LA77,Designated,Public record,850,Alpha-melanocyte stimulating hormone,8/19/1997,Prevention and treatment of intrinsic acute renal failure due to ischemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"National Institute of Diabetes, and Digestive and Kidney Diseases","National Institutes of Health, 31 Center Drive MSC","Building 31, Room 9N-222",Bethesda,Maryland,20892,United States,106497
CYSTEAMINE HYDROCHLORIDE,IF1B771SVB,Designated/Approved,Public record,851,Cysteamine hydrochloride,8/19/1997,Treatment of corneal cystine crystal accumulation in cystinosis patients.,Designated/Approved,,Treatment of corneal cystine crystal accumulation in patients with cystinosis,10/2/2012,10/2/2019,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,20878,United States,105997
ALGLUCOSIDASE ALFA,DTI67O9503,Designated/Approved,Public record,852,Recombinant human acid alpha-glucosidase; alglucosidase alfa,8/19/1997,Treatment of glycogen storage disease type II.,Designated/Approved,,"Myozyme for use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in patients with infantile onset Pompe disease as compared to an untreated historical control, whereas use of Alphagluco",4/28/2006,4/28/2013,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,106597
ALGLUCOSIDASE ALFA,DTI67O9503,Designated/Approved,Public record,853,Recombinant human acid alpha-glucosidase; alglucosidase alfa,8/19/1997,Treatment of glycogen storage disease type II.,Designated/Approved,,Lumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of Lumizyme (alglucosidase alfa) have not been evaluated in controlled clinical,5/24/2010,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,106597
ALGLUCOSIDASE ALFA,DTI67O9503,Designated/Approved,Public record,854,Recombinant human acid alpha-glucosidase; alglucosidase alfa,8/19/1997,Treatment of glycogen storage disease type II.,Designated/Approved,,(Lumizyme) Patients with Pompe disease (acid alpha-glucosidase (GAA deficiency)).,8/1/2014,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,106597
TESTOSTERONE,3XMK78S47O,Designated,Public record,857,Testosterone,9/22/1997,For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.,Designated,Not FDA Approved for Orphan Indication,,,,,Watson Laboratories,Research Park,417 Wakara Way,Salt Lake City,Utah,84108,United States,104197
LARONIDASE,WP58SVM6R4,Designated/Approved,Public record,858,laronidase,9/24/1997,Treatment of patients with mucopolysaccharidosis-I.,Designated/Approved,,Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms,4/30/2003,4/30/2010,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,94949,United States,106097
ALEMTUZUMAB,3A189DH42V,Designated/Approved,Public record,860,alemtuzumab,10/20/1997,Treatment of chronic lymphocytic leukemia.,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.,5/7/2001,5/7/2008,,Genzyme Corporation,4545 Horizon Hill Blvd.,,San Antonio,Texas,78229,United States,107197
APOMORPHINE,N21FAR7B4S,Designated/Withdrawn,Public record,861,Apomorphine,10/20/1997,For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Scherer DDS,Frankland Road,Swindon SN5 8RU,Wiltshire,,,United Kingdom,107997
INTERLEUKIN-12 HUMAN RECOMBINANT,02FXP10O2U,Designated,Public record,863,Recombinant human interleukin-12,10/20/1997,Treatment of renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Genetics Institute, Inc.",87 Cambridge Park Drive,,Cambridge,Massachusetts,2140,United States,107597
CALCIUM GLUCONATE,SQE6VB453K,Designated,Public record,864,Calcium gluconate,11/20/1997,For use as a wash for hydrofluoric acid spills on human skin.,Designated,Not FDA Approved for Orphan Indication,,,,,Calgonate Corp.,3310 South Ocean Blvd,Unit 132,Highland Beach,Florida,33487,United States,108997
PERGOLIDE,24MJ822NZ9,Designated/Withdrawn,Public record,865,Pergolide,11/20/1997,Treatment of Tourette's syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sallee, Floyd R. M.D., Ph.D.",Cincinnati Children's Hospital Medical Center,3333 Burnet Ave.,Cincinnati,Ohio,45229,United States,108197
Urofollitropin,W9BB98U6HP,Designated/Withdrawn,Public record,867,Urofollitropin,12/5/1997,"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,107397
TALC,7SEV7J4R1U,Designated/Approved,Public record,868,Sterile talc,12/8/1997,Treatment of pneumothorax,Designated/Approved,,Steritalc is indicated in adults to decrease the recurrence of pneumothorax.,5/1/2017,5/1/2024,To decrease the recurrence of pneumothorax in adults.,Novatech SA,Z.I. Athelia III,,La Ciotat,CEDEX,,France,109297
TALC,7SEV7J4R1U,Designated/Approved,Public record,869,Sterile talc,12/8/1997,Treatment of malignant pleural effusion,Designated/Approved,,To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion.,5/1/2017,5/1/2024,To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion.,Novatech SA,Z.I. Athelia III,,La Ciotat,CEDEX,,France,106797
LANCOVUTIDE,BPR0F3X56H,Designated,Public record,870,Duramycin,12/11/1997,Treatment of cystic fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.",100 Europa Drive,Suite 421,Chapel Hill,North Carolina,27517,United States,107897
SENLIZUMAB,1V3N66A87N,Designated,Public record,871,Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha,12/11/1997,Treatment of Crohn's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Celltech Chiroscience Limited,216 Bath Road,,Slough,Berkshire,,United Kingdom,108497
TETRABENAZINE,Z9O08YRN8O,Designated/Approved,Public record,872,Tetrabenazine,12/11/1997,Treatment of Huntington's disease,Designated/Approved,,Treatment of chorea associated with Huntington's disease,8/15/2008,8/15/2015,,"Prestwick Pharmaceuticals, Inc",1825 K Street NW,Suite 1475,Washington,District of Columbia,20006,United States,108897
BASILIXIMAB,9927MT646M,Designated/Approved,Public record,873,Basiliximab,12/12/1997,Prophylaxis of solid organ rejection.,Designated/Approved,,Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.,5/12/1998,5/12/2005,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,109197
Sodium dichloroacetate,42932X67B5,Designated/Withdrawn,Public record,874,Sodium dichloroacetate,12/31/1997,Treatment of congenital lactic acidosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Questcor Pharmaceuticals, Inc.",3260 Whipple Rd.,,Union City,California,94587,United States,108797
"""BACLOFEN, (S)-""",3OHN4989XM,Designated,Public record,875,L-baclofen,1/6/1998,Treatment of trigeminal neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,Osmotica Pharmaceutical Corp.,1205 Culbreth Dr.,Suite 200,Wilmington,North Carolina,28405,United States,109397
FOSFRUCTOSE,M7522JYX1H,Designated/Withdrawn,Public record,876,"Fructose-1,6-diphosphate",5/29/1998,Treatment of painful vaso-occlusive episodes associated with sickle cell disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Questcor Pharmaceuticals, Inc.",3260 Whipple Road,,Union City,California,94587,United States,112398
MIGLUSTAT,ADN3S497AZ,Designated/Approved,Public record,877,miglustat,5/29/1998,Treatment of Gaucher disease.,Designated/Approved,,"Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access).",7/31/2003,7/31/2010,,IC-MedTech Corporation,9902 Indian Creek Lane,,San Diego,California,92021,United States,112598
DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL,6PHSP9EORV,Designated,Public record,878,Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl,6/10/1998,Treatment of Ewing's sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Endorex Corp.,900 North Shore Drive,,Lake Bluff,Illinois,60044,United States,114898
DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL,6PHSP9EORV,Designated,Public record,879,Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl,6/10/1998,Treatment of osteosarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Endorex Corp.,900 North Shore Drive,,Lake Bluff,Illinois,60044,United States,114098
ECRAPROST,Q2XM6VR8DO,Designated,Public record,880,Prostaglandin E1 enol ester (AS-013),6/12/1998,Treatment of Fontaine Stage IV chronic critical limb ischemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"LTT Baio-Pharma Co., Ltd",Research & Development Division,2-5-1 Atago,Minato-ku,Tokyo,,Japan,112898
AGALSIDASE ALFA,2HLC17MX9G,Designated,Public record,881,Alpha-galactosidase A,6/22/1998,Long-term enzyme replacement therapy for the treatment of Fabry disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc.",700 Main Street,,Cambridge,Massachusetts,2139,United States,112998
OPEBACAN,4X9EPQ6FMA,Designated/Withdrawn,Public record,882,Recombinant bactericidal/permeability-increasing protein,6/22/1998,Treatment of severe meningococcal disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Xoma (US) LLC,2910 Seventh Street,,Berkeley,California,94710,United States,112298
EPRATUZUMAB,3062P60MH9,Designated,Public record,883,epratuzumab,7/13/1998,Treatment of non-Hodgkin's lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,113298
PEGINTERFERON ALFA-2A,Q46947FE7K,Designated,Public record,884,Peginterferon alfa-2a,7/13/1998,Treatment of renal cell carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.,340 Kingsland St.,,Nutley,New Jersey,7110,United States,113898
RHCC10,MRS7SR55LQ,Designated,Public record,885,Recombinant human Clara Cell 10kDa protein,7/13/1998,Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Trove Therapeutics, Inc.",9430 Key West Avenue,,Rockville,Maryland,20850,United States,113998
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,886,Thalidomide,7/29/1998,Treatment of Kaposi's sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,7059,United States,114998
ALDESLEUKIN,M89N0Q7EQR,Designated/Withdrawn,Public record,887,Aldesleukin,7/31/1998,Treatment of acute myelogenous leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation,4560 Horton Street,,Emeryville,California,94608,United States,113098
BOTULINUM TOXIN TYPE A,E211KPY694,Designated,Public record,888,Botulinum toxin type A,8/12/1998,Treatment of spasmodic torticollis (cervical dystonia).,Designated,Not FDA Approved for Orphan Indication,,,,,Ipsen Biopharm Limited,1 Bath Road,Maidenhead,"Berkshire, SL6 4UH",,,United Kingdom,114198
OCTREOTIDE,RWM8CCW8GP,Designated/Approved,Public record,889,Octreotide,8/24/1998,Treatment of acromegaly.,Designated/Approved,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.,11/25/1998,11/25/2005,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,114598
OCTREOTIDE,RWM8CCW8GP,Designated/Approved,Public record,890,Octreotide,8/24/1998,Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,Designated/Approved,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.,11/25/1998,11/25/2005,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,114698
OCTREOTIDE,RWM8CCW8GP,Designated/Approved,Public record,891,Octreotide,8/24/1998,Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).,Designated/Approved,,Treatment of profuse watery diarrhea associated with VIPoma.,11/25/1998,11/25/2005,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,116898
SEMAXANIB,71IA9S35AJ,Designated,Public record,892,"3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one",9/11/1998,Treatment of Kaposi's sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sugen, Inc.",230 East Grand Ave.,,South San Francisco,California,94080,United States,116398
DEXAMETHASONE,7S5I7G3JQL,Designated/Approved,Public record,893,dexamethasone intravitreal implant,9/11/1998,"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis",Designated/Approved,,For treatment of non-infectious uveitis affecting the posterior segment of the eye,9/24/2010,9/24/2017,,Allergan,2525 Dupont Drive,,Irvine,California,92623,United States,115298
SIPLIZUMAB,KUW1QG1ZM3,Designated/Withdrawn,Public record,894,Humanized anti-human CD2 MAb,9/17/1998,"For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biotransplant, Inc.","Building 75, 3rd. Ave.",Charlestown Navy Yard,Charlestown,Massachusetts,2129,United States,107797
LABETUZUMAB,EFE6X5M3UY,Designated,Public record,895,MN14 monoclonal antibody to carcinoembryonic antigen,9/18/1998,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,113498
TEMOZOLOMIDE,YF1K15M17Y,Designated/Approved,Public record,896,temozolomide,10/5/1998,Treatment of recurrent malignant glioma.,Designated/Approved,,Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment,3/15/2005,3/15/2012,,Schering-Plough Research Institute,2000 Galloping Hill Rd.,,Kenilworth,New Jersey,7033,United States,116798
TEMOZOLOMIDE,YF1K15M17Y,Designated/Approved,Public record,897,temozolomide,10/5/1998,Treatment of recurrent malignant glioma.,Designated/Approved,,"Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine",8/11/1999,8/11/2006,,Schering-Plough Research Institute,2000 Galloping Hill Rd.,,Kenilworth,New Jersey,7033,United States,116798
INTERFERON BETA-1A,XRO4566Q4R,Designated/Withdrawn,Public record,898,interferon Beta-1a,10/14/1998,Treatment of juvenile rheumatoid arthritis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,115498
MECAMYLAMINE,6EE945D3OK,Designated,Public record,899,Mecamylamine,10/14/1998,Treatment of Tourette's syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Targacept, Inc.",200 East First St.,Suite 300,Winston-Salem,North Carolina,27101,United States,117598
METHOXSALEN,U4VJ29L7BQ,Designated,Public record,900,Methoxsalen,10/14/1998,For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Hospital Products IP Limited,440 Route 22 East,,Bridgewater,New Jersey,8807,United States,117298
RUPLIZUMAB,562JQF15GN,Designated,Public record,901,Recombinant humanized MAb 5c8,10/14/1998,Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,113798
TEMOZOLOMIDE,YF1K15M17Y,Designated/Withdrawn,Public record,902,Temozolomide,10/14/1998,Treatment of advanced metastatic melanoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Merck & Company,2000 Galloping Hill Rd.,,Kenilworth,New Jersey,7033,United States,117198
THALIDOMIDE,4Z8R6ORS6L,Designated/Approved,Public record,903,Thalidomide,10/14/1998,Treatment of multiple myeloma,Designated/Approved,,Treatment of patients with newly diagnosed multiple myeloma,5/25/2006,5/25/2013,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,7059,United States,115598
ETANERCEPT,OP401G7OJC,Designated/Approved,Public record,904,etanercept,10/27/1998,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older,5/27/1999,5/27/2006,,Immunex Corporation,One Amgen Center Drive,,Thousand Oaks,California,91320,United States,116198
DIQUAFOSOL TETRASODIUM,X8T9SBH9LL,Designated/Withdrawn,Public record,905,"P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt",10/27/1998,Treatment of cystic fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Inspire Pharmaceuticals, Inc.","4222 Emperor Blvd., Suite 470",,Durham,North Carolina,27703,United States,116998
DOXORUBICIN,80168379AG,Designated/Approved,Public record,906,Doxorubicin liposome,11/4/1998,Treatment of ovarian cancer.,Designated/Approved,,"Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months o",6/28/1999,6/28/2006,,Alza Corporation,1550 Plymouth St.,PO Box 7210,Mountain View,California,94039,United States,117398
OXYPURINOL,G97OZE5068,Designated,Public record,907,Oxypurinol,11/9/1998,Treatment of hyperuricemia in patients intolerant to allopurinol.,Designated,Not FDA Approved for Orphan Indication,,,,,Cardiome Pharma Corp.,3650 Westbrook Mall,,Vancouver,,,Canada,115798
SIPLIZUMAB,KUW1QG1ZM3,Designated/Withdrawn,Public record,908,Humanized anti-CD2 monoclonal antibody,11/13/1998,Treatment of graft-versus-host disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, Inc.",35 West Watkins Mill Rd.,,Gaithersburg,Maryland,20878,United States,116498
ALDESLEUKIN,M89N0Q7EQR,Designated,Public record,909,Aldesleukin,11/24/1998,For the treatment non-Hodgkin's lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Melanie-Rose Brown,45 Great Valley Parkway,Malvern,Pennsylvania,19355,United States,116598
AMIFOSTINE,M487QF2F4V,Designated,Public record,910,Amifostine,11/24/1998,For the reduction of the incidence and severity of toxicities associated with cisplatin administration.,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Merav Edan,45 Great Valley Parkway,Malvern,Pennsylvania,19355,United States,116298
LABETUZUMAB,EFE6X5M3UY,Designated/Withdrawn,Public record,911,MN14 monoclonal antibody to carcinoembryonic antigen,11/24/1998,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,117998
FOLLITROPIN ALFA,VV3HN9ZPB5,Designated/Approved,Public record,915,"Follitropin alfa, recombinant",12/21/1998,"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with pr",Designated/Approved,,For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.,5/24/2000,5/24/2007,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,119398
"""TRYPSIN, UNSPECIFIED FORM""",GV54A213NN,Designated,Public record,916,"Papain, trypsin, and chymotrypsin",12/21/1998,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Marlyn Nutraceuticals, Inc.",14851 N. Scottsdale Rd.,,Scottsdale,Alaska,85254,United States,117498
Chymotrypsin,BVS505O332,Designated,Public record,916,"Papain, trypsin, and chymotrypsin",12/21/1998,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Marlyn Nutraceuticals, Inc.",14851 N. Scottsdale Rd.,,Scottsdale,Alaska,85254,United States,117498
Papain,A236A06Y32,Designated,Public record,916,"Papain, trypsin, and chymotrypsin",12/21/1998,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Marlyn Nutraceuticals, Inc.",14851 N. Scottsdale Rd.,,Scottsdale,Alaska,85254,United States,117498
PEGADRICASE,50XB37EKN8,Designated,Public record,917,Polyethylene glycol-modified uricase,12/21/1998,Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Selecta Biosciences, Inc.",480 Arsenal Way,,Watertown,Massachusetts,2472,United States,117798
INTERFERON BETA-1A,XRO4566Q4R,Designated/Withdrawn,Public record,918,Interferon beta-1a (recombinant human),1/7/1999,Treatment of pulmonary fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen Idec, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,111598
OXITRIPTAN,C1LJO185Q9,Designated,Public record,919,L-5-hydroxytryptophan,1/20/1999,Treatment of tetrahydrobiopterin deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,"Watson Laboratories, Inc.",311 Bonnie Circle,P.O. Box 1900,Corona,California,91718,United States,118298
BLEOMYCIN,40S1VHN69B,Designated,Public record,920,Bleomycin,2/9/1999,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Genetronics, Inc.",11199 Sorrento Valley Rd.,,San Diego,California,92121,United States,118498
TORALIZUMAB,KX44A9HM0B,Designated/Withdrawn,Public record,921,Humanized MAb (IDEC-131) to CD40L,2/9/1999,Treatment of systemic lupus erythematosus.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Biogen IdecInc.,3030 Callan Rd.,,San Diego,California,92121,United States,119298
DOTMP HO-166,9F972459OC,Designated,Public record,922,Chelating agent delivering Holmium-166,2/10/1999,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,NeoRx Corporation,410 W. Harrison Street,,Seattle,Washington,98119,United States,119998
IODINE I-131 DERLOTUXIMAB BIOTIN,1724UJB90B,Designated,Public record,923,Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B),2/12/1999,Treatment of glioblastoma multiforme and anaplastic astrocytoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Peregrine Pharmaceuticals, Inc.",14282 Franklin Ave.,,Tustin,California,92780,United States,119098
GALSULFASE,59UA429E5G,Designated/Approved,Public record,924,"N-acetylgalactosamine-4-sulfatase, recombinant human",2/17/1999,Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).,Designated/Approved,,For patients with mucopolysaccharidosis VI. Galsulfase has been shown to improve walking and stair-climbing capacity.,5/31/2005,5/31/2012,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,94949,United States,119898
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Approved,Public record,926,C1-esterase inhibitor (recombinant),2/23/1999,Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.,Designated/Approved,,Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.,7/16/2014,7/16/2021,Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.,Pharming Group N.V.,P. O. Box 451 Darwinweg 24,,Leiden,,,Netherlands,123599
"""HUMAN C1-ESTERASE INHIBITOR, RECOMBINANT""",RB0RV8I60K,Designated,Public record,927,Recombinant human C1-esterase inhibitor,2/23/1999,Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,Pharming Group N.V.,P. O. Box 451 Darwinweg 24,,Leiden,,,Netherlands,122498
DECITABINE,776B62CQ27,Designated/Approved,Public record,928,decitabine,3/8/1999,Treatment of myelodysplastic syndromes.,Designated/Approved,,"for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia",5/2/2006,5/2/2013,,Otsuka Pharmaceutical Development,"and Commercialization, Inc.",508 Carnegie Center Drive,Princeton,New Jersey,8540,United States,122298
DECITABINE,776B62CQ27,Designated/Withdrawn,Public record,929,decitabine,3/8/1999,Treatment of chronic myelogenous leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Otsuka Pharmaceutical Development &,"Commercialization, Inc.",508 Carnegie Center Drive,Princeton,New Jersey,8540,United States,123399
EPOPROSTENOL,DCR9Z582X0,Designated/Approved,Public record,930,epoprostenol,3/22/1999,Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.,Designated/Approved,,treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH ass,4/14/2000,4/14/2007,,GlaxoSmithKline,2301 Renaissance Blvd,P. O. Box 61540,King of Prussia,Pennsylvania,19406,United States,121698
RUPLIZUMAB,562JQF15GN,Designated,Public record,932,Recombinant humanized MAb 5c8,3/22/1999,Prevention of rejection of solid organ transplants.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,120098
RUPLIZUMAB,562JQF15GN,Designated,Public record,933,Recombinant humanized MAb 5c8,3/22/1999,Prevention of rejection of pancreatic islet cell transplants.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,123499
PEGARGIMINASE,0B7PYQ9YRT,Designated,Public record,934,pegylated arginine deiminase,3/26/1999,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.",A Polaris Group Company,6370 Nancy Ridge Drive,San Diego,California,92121,United States,118398
IROFULVEN,6B799IH05A,Designated/Withdrawn,Public record,935,6-hydroxymethylacylfulvene,4/6/1999,Treatment of histologically confirmed advanced or metastatic pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,7677,United States,122198
EPRODISATE,6QFP76V7S7,Designated,Public record,936,eprodisate,4/6/1999,Treatment of secondary amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"C. T. Development America, Inc.",663 Fifth Avenue,7th Floor,New York,New York,10022,United States,118998
ETANERCEPT,OP401G7OJC,Designated/Withdrawn,Public record,937,Etanercept,4/6/1999,Treatment of Wegener's granulomatosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation,51 University Street,,Seattle,Washington,98101,United States,122999
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,938,Thalidomide,4/6/1999,Treatment of Crohn's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,7059,United States,121898
PEGARGIMINASE,0B7PYQ9YRT,Designated,Public record,939,Pegylated arginine deiminase,4/12/1999,Treatment of invasive malignant melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.",A Polaris Group Company,Suite 106,San Diego,California,92121,United States,120898
RIFALAZIL,S1976TE8QK,Designated,Public record,941,Rifalazil,4/13/1999,Treatment of pulmonary tuberculosis.,Designated,Not FDA Approved for Orphan Indication,,,,,PathoGenesis Corporation,201 Elliott Avenue West,Suite 150,Seattle,Washington,98119,United States,122699
CT-2584 MESYLATE,6YX1G1VY8K,Designated/Withdrawn,Public record,942,CT-2584 Mesylate,4/16/1999,Treatment of adult soft tissue sarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cell Therapeutics, Inc.",501 Elliott Ave. West,Suite 400,Seattle,Washington,98119,United States,121798
CT-2584 MESYLATE,6YX1G1VY8K,Designated/Withdrawn,Public record,943,CT-2584 mesylate,4/16/1999,Treatment of malignant mesothelioma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cell Therapeutics, Inc.",501 Elliott Ave. West,Suite 400,Seattle,Washington,98119,United States,124899
BERAPROST,35E3NJJ4O6,Designated,Public record,945,Beraprost,4/29/1999,"Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LungRx, Inc.",1040 Spring Street,,Silver Spring,Maryland,20910,United States,123099
FLUOXETINE,01K63SUP8D,Designated,Public record,946,Fluoxetine,4/30/1999,Treatment of autism.,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuropharm, Ltd.",Felcham Park House,,Surrey,,,United Kingdom,123199
CANNABIS SATIVA SUBSP. INDICA TOP,FTS5RM302N,Designated,Public record,950,Marijuana,5/25/1999,Treatment of HIV-associated wasting syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Multidisciplinary Association for Psychedelic Studies, Inc.",3 Francis St.,,Belmont,Massachusetts,2478,United States,105397
INDIUM IN-111 PENTETREOTIDE KIT,,Designated,Public record,951,111Indium pentetreotide,6/10/1999,Treatment of somatostatin receptor positive neuroendocrine tumors.,Designated,Not FDA Approved for Orphan Indication,,,,,Louisiana State University Medical Center Foundation,1600 Canal St.,10th Floor,New Orleans,Louisiana,70112,United States,121198
"""LISOFYLLINE, (?)-""",R99EE080JS,Designated,Public record,952,Lisofylline,6/10/1999,Treatment of patients undergoing induction therapy for acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cell Therapeutics, Inc.",501 Elliott Avenue West,Suite 400,Seattle,Washington,98119,United States,124099
Sodium dichloroacetate,42932X67B5,Designated/Withdrawn,Public record,953,Sodium dichloroacetate,6/14/1999,Treatment of severe head injury.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Questcor Pharmaceuticals, Inc.",3260 Whipple Rd.,,Union City,California,94587,United States,114798
MECASERMIN RINFABATE,NZ8M50KKRG,Designated,Public record,954,Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3,6/15/1999,Treatment of major burns that require hospitalization.,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",10 Finderne Ave,Building 10,Bridgewater,New Jersey,8807,United States,114298
SECRETIN HUMAN,A0426J905J,Designated/Approved,Public record,955,Synthetic human secretin,6/16/1999,For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.,Designated/Approved,,"Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the ide",4/9/2004,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,20905,United States,120798
SECRETIN HUMAN,A0426J905J,Designated,Public record,956,Synthetic human secretin,6/16/1999,For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,20905,United States,120698
SECRETIN HUMAN,A0426J905J,Designated,Public record,957,Synthetic human secretin,6/16/1999,For use in the evaluation of exocrine pancreas function.,Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,20905,United States,120598
BEXAROTENE,A61RXM4375,Designated/Approved,Public record,958,Bexarotene,6/18/1999,Treatment of cutaneous T-cell lymphoma.,Designated/Approved,,Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.,12/29/1999,12/29/2006,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,7677,United States,124699
SECRETIN PORCINE,D0L9J6I13I,Designated/Approved,Public record,959,Synthetic porcine secretin,6/18/1999,For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.,Designated/Approved,,Use in secretin stimulation testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma,4/4/2002,4/4/2009,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,20905,United States,120498
SECRETIN PORCINE,D0L9J6I13I,Designated/Approved,Public record,960,Synthetic porcine secretin,6/18/1999,For use in the evaluation of exocrine pancreas function.,Designated/Approved,,For use in secretin stimulation testing for: Stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangio-pancreatography (ERCP),11/1/2002,11/1/2009,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,20905,United States,120298
SECRETIN PORCINE,D0L9J6I13I,Designated,Public record,961,Synthetic porcine secretin,6/18/1999,For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,20905,United States,120398
TOBRAMYCIN,VZ8RRZ51VK,Designated,Public record,962,Tobramycin,6/18/1999,Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,Office 315,East Hanover,New Jersey,7936,United States,121098
"""LACTIC ACID, UNSPECIFIED FORM""",33X04XA5AT,Designated,Public record,963,Lactic acid,6/29/1999,"Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.",Designated,Not FDA Approved for Orphan Indication,,,,,"Frontier Pharmaceutical, Inc.",SUNY Farmingdale,Conklin Hall,Farmingdale,New York,11735,United States,122098
IROFULVEN,6B799IH05A,Designated/Withdrawn,Public record,964,irofulven,7/6/1999,Treatment of ovarian cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,7677,United States,124399
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,965,Somatropin [rDNA],7/6/1999,Treatment of short stature in patients with Prader-Willi syndrome.,Designated/Approved,,Long-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS).,6/20/2000,6/20/2007,,Pharmacia & Upjohn,7000 Portage Rd.,0633-298-113,Kalamazoo,Michigan,49001,United States,124799
ARTESUNATE,60W3249T9M,Designated,Public record,966,Artesunate,7/19/1999,Treatment of malaria.,Designated,Not FDA Approved for Orphan Indication,,,,,World Health Organization,Special Programme for Research and Training in Tro,"Via Appia ,",Geneva 27,,,Switzerland,125599
IROFULVEN,6B799IH05A,Designated/Withdrawn,Public record,967,irofulven,7/27/1999,Treatment of renal cell carcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,7677,United States,125399
GUANFACINE,30OMY4G3MK,Designated,Public record,969,guanfacine,8/5/1999,Treatment of fragile X syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Watson Laboratories, Inc.",311 Bonnie Circle,P.O. Box 1900,Corona,California,91718,United States,124199
MITOXANTRONE,BZ114NVM5P,Designated/Approved,Public record,970,Mitoxantrone,8/13/1999,Treatment of secondary-progressive multiple sclerosis.,Designated/Approved,,"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly",10/13/2000,10/13/2007,,"Serono, Inc.",One Technoloogy Place,,Rockland,Massachusetts,2370,United States,125199
MITOXANTRONE,BZ114NVM5P,Designated/Approved,Public record,971,Mitoxantrone,8/13/1999,Treatment of progressive-relapsing multiple sclerosis.,Designated/Approved,,"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly",10/13/2000,10/13/2007,,"Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,128499
AROPLATIN,J7M4Z2D183,Designated/Withdrawn,Public record,972,"Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)",9/1/1999,Treatment of malignant mesothelioma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Antigenics Incorporated,3 Forbes Road,,Lexington,Massachusetts,2421,United States,126599
NELARABINE,60158CV180,Designated,Public record,973,nelarabine,9/2/1999,Treatment of chronic lymphocytic leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,125999
AZATHIOPRINE,MRK240IY2L,Designated,Public record,974,Azathioprine,9/14/1999,Treatment of oral manifestations of graft-versus-host disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Oral Solutions, Inc.","787 Seventh Ave., 48th Floor",,New York,New York,10019,United States,128099
EPIRUBICIN,3Z8479ZZ5X,Designated/Approved,Public record,975,Epirubicin,9/14/1999,Treatment of breast cancer.,Designated/Approved,,Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.,9/15/1999,9/15/2006,,Pharmacia & Upjohn Company,0634-298-113,7000 Portage Rd.,Kalamazoo,Michigan,49001,United States,121498
PEGADRICASE,50XB37EKN8,Designated,Public record,976,Polyethylene glycol-modified uricase,9/14/1999,Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Selecta Biosciences, Inc.",480 Arsenal Way,,Watertown,Massachusetts,2472,United States,118598
PEGINTERFERON ALFA-2A,Q46947FE7K,Designated,Public record,978,Peginterferon alfa-2a,9/30/1999,Treatment of chronic myelogenous leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.,340 Kingsland St.,,Nutley,New Jersey,7110,United States,125299
AMIFOSTINE,M487QF2F4V,Designated,Public record,979,Amifostine,10/4/1999,Treatment of myelodysplastic syndromes.,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Merav Edan,45 Great Valley Parkway,Malvern,Pennsylvania,19355,United States,128399
BOTULINUM TOXIN TYPE A,E211KPY694,Designated/Approved,Public record,980,Botulinum toxin type A,10/20/1999,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,Designated/Approved,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older,7/29/2016,7/29/2023,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.",650 East Kendall Street,,Cambridge,Massachusetts,2142,United States,128299
OGLUFANIDE,4RHY598T5U,Designated,Public record,981,L-glutamyl-L-tryptophan,10/20/1999,Treatment of AIDS-related Kaposi's sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Implicit Bioscience Pty Ltd,P. O. Box 2072.,Toowong Business Center,,,,Australia,126799
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,982,Somatropin (rDNA origin),10/28/1999,Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,Designated/Approved,,Long-term treatment of growth failure due to a lack of adequate endogenous growth hormone secetion for once- or twice-a-month administration.,12/22/1999,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,115098
TEMOPORFIN,FU21S769PF,Designated,Public record,983,Temoporfin,10/28/1999,"Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.",Designated,Not FDA Approved for Orphan Indication,,,,,Biolitec Pharma Ireland Ltd.,United Drug House,,Dublin,,,Ireland,128899
TERIPARATIDE,10T9CSU89I,Designated,Public record,984,Teriparatide,10/28/1999,Treatment of idiopathic osteoporosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biomeasure, Inc.",27 Maple St.,,Milford,Massachusetts,1757,United States,127099
CERIC AMMONIUM NITRATE,U99S55ED6B,Designated,Public record,986,Silver sulfadiazine and cerium nitrate,11/17/1999,Treatment of patients with severe dermal burns,Designated,Not FDA Approved for Orphan Indication,,,,,Alliance Pharmaceuticals Ltd,Avonbridge House,"Bath Road, Chippenham",Wiltshire,,,United Kingdom,110798
SILVER SULFADIAZINE,W46JY43EJR,Designated,Public record,986,Silver sulfadiazine and cerium nitrate,11/17/1999,Treatment of patients with severe dermal burns,Designated,Not FDA Approved for Orphan Indication,,,,,Alliance Pharmaceuticals Ltd,Avonbridge House,"Bath Road, Chippenham",Wiltshire,,,United Kingdom,110798
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated/Withdrawn,Public record,987,Alpha1-proteinase inhibitor (human),11/24/1999,For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,CSL Behring L.L.C.,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,124299
RIMIDUCID,H564L1W5J2,Designated,Public record,988,Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP),11/24/1999,Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"Bellicum Pharmaceuticals, Inc.",6400 Fannin Street,Suite 2300,Houston,Texas,77030,United States,126299
GEMTUZUMAB OZOGAMICIN,8GZG754X6M,Designated/Approved,Public record,989,Gemtuzumab ozogamicin,11/24/1999,Treatment of acute myeloid leukemia,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,9/1/2017,9/1/2024,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company",10646 Science Center Drive,,San Diego,California,92121,United States,127899
GEMTUZUMAB OZOGAMICIN,8GZG754X6M,Designated/Approved,Public record,990,Gemtuzumab ozogamicin,11/24/1999,Treatment of acute myeloid leukemia,Designated/Approved,,Mylotarg¿ is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric pat,6/16/2020,6/16/2027,For the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in pediatric patients 1 month and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company",10646 Science Center Drive,,San Diego,California,92121,United States,127899
GEMTUZUMAB OZOGAMICIN,8GZG754X6M,Designated/Approved,Public record,991,Gemtuzumab ozogamicin,11/24/1999,Treatment of acute myeloid leukemia,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy,5/17/2000,5/17/2007,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company",10646 Science Center Drive,,San Diego,California,92121,United States,127899
PENTOSTATIN,395575MZO7,Designated,Public record,992,Pentostatin,11/24/1999,Treatment of peripheral T-cell lymphomas.,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,123899
TRASTUZUMAB,P188ANX8CK,Designated,Public record,993,trastuzumab,12/14/1999,Treatment of patients with pancreatic cancer that overexpress p185HER2.,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,129399
UBIDECARENONE,EJ27X76M46,Designated,Public record,994,Ubiquinone,12/14/1999,Treatment of mitochondrial cytopathies.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gel-Tec, Division of Tishcon Corp.",30 New York Avenue,P. O. Box 331,Westbury,New York,11590,United States,125099
HISTAMINE,820484N8I3,Designated,Public record,996,Histamine,12/15/1999,Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,EpiCept Corporation,777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,127399
PALIFERMIN,QMS40680K6,Designated,Public record,997,Recombinant human keratinocyte growth factor,12/20/1999,Reducing the incidence and severity of radiation-induced xerostomia.,Designated,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ) (SOBI),SE-112 76,,Stockholm,,,Sweden,130699
VAPREOTIDE,2PK59M9GFF,Designated,Public record,998,vapreotide,1/10/2000,Treatment of gastrointestinal and pancreatic fistulas.,Designated,Not FDA Approved for Orphan Indication,,,,,Debiopharm S.A.,17 rue des Terreaux,,Lausanne,,,Switzerland,129599
VAPREOTIDE,2PK59M9GFF,Designated,Public record,999,vapreotide,1/10/2000,Treatment of esophageal variceal hemorrhage patients with portal hypertension.,Designated,Not FDA Approved for Orphan Indication,,,,,"Debiovision, Inc.",666 Sherbrooke Street West,Suite 1400,Montreal,,,Canada,129899
CT-2584 MESYLATE,6YX1G1VY8K,Designated/Withdrawn,Public record,1000,"1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate",1/18/2000,Treatment of hormone refractory prostate carcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cell Therapeutics, Inc.",201 Elliott Avenue West,Suite 400,Seattle,Washington,98119,United States,125899
CARBIDOPA,MNX7R8C5VO,Designated/Approved,Public record,1001,levodopa and carbidopa,1/18/2000,Treatment of late stage Parkinson's disease,Designated/Approved,,Treatment of motor flucuations in patients with advanced Parkinson's disease,1/9/2015,1/9/2022,Treatment of motor flucuations in patients with advanced Parkinson's disease,"AbbVie, Inc.",1 N. Waukegan Road,Building AP30-1,North Chicago,Illinois,60064,United States,129499
LEVODOPA,46627O600J,Designated/Approved,Public record,1001,levodopa and carbidopa,1/18/2000,Treatment of late stage Parkinson's disease,Designated/Approved,,Treatment of motor flucuations in patients with advanced Parkinson's disease,1/9/2015,1/9/2022,Treatment of motor flucuations in patients with advanced Parkinson's disease,"AbbVie, Inc.",1 N. Waukegan Road,Building AP30-1,North Chicago,Illinois,60064,United States,129499
PHENYLBUTYRIC ACID,7WY7YBI87E,Designated,Public record,1003,Phenylbutyrate,1/19/2000,Treatment of acute promyelocytic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Elan Drug Delivery, Inc.",1300 Gould Dr.,,Gainesville,Georgia,30504,United States,126199
HISTAMINE,820484N8I3,Designated,Public record,1004,Histamine,2/1/2000,For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,EpiCept Corporation,777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,127199
BRIMONIDINE,E6GNX3HHTE,Designated,Public record,1005,Brimonidine,2/7/2000,Treatment of anterior ischemic optic neuropathy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Dr.,,Irvine,California,92612,United States,125699
HALOFUGINONE,L31MM1385E,Designated,Public record,1006,Halofuginone,2/7/2000,Treatment of systemic sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Collgard Biopharmaceuticals Ltd.,"Textile House, 2 Koifman St.",,Tel-Aviv,,,Israel,131699
Hypericin,7V2F1075HD,Designated,Public record,1007,hypericin,2/7/2000,Treatment of cutaneous T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,8540,United States,131099
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,1008,Angiotensin 1-7,2/16/2000,Treatment of neutropenia associated with autologous bone marrow transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,Tarix Pharmaceuticals Ltd,12 Bow Street,,Cambridge,Massachusetts,2138,United States,129999
ETARFOLATIDE,40UB1H6Q6T,Designated,Public record,1009,etarfolatide,2/16/2000,For the identification of ovarian carcinomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Endocyte, Inc.",3000 Kent Ave.,Suite A1-100,West Lafayette,Indiana,47906,United States,131399
MECASERMIN,7GR9I2683O,Designated,Public record,1010,Recombinant human insulin-like growth factor-I,2/16/2000,Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.,Designated,Not FDA Approved for Orphan Indication,,,,,GroPep Pty Ltd.,"Gate 11, Victoria Dr.",Adelaide SA 5000,,,,Australia,128999
SENICAPOC,TS6G201A6Q,Designated,Public record,1012,Bis(4-fluorophenyl)phenylacetamide,3/2/2000,Treatment of sickle cell disease.,Designated,Not FDA Approved for Orphan Indication,,,,,ICAgen Inc.,Ion Channel Advances,PO Box 14487,Durham,North Carolina,27709,United States,131999
REMACEMIDE,EH6763C1IC,Designated/Withdrawn,Public record,1013,Remacemide,3/6/2000,Treatment of Huntington's disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AstraZeneca LP,725 Chesterbrook Blvd.,,Wayne,Pennsylvania,19087,United States,130599
CDX-1135,2RF4H67MOG,Designated,Public record,1014,Soluble complement receptor type 1,3/6/2000,Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.,Designated,Not FDA Approved for Orphan Indication,,,,,"Avant Immunotherapeutics, Inc.",119 Fourth Ave.,,Needham,Massachusetts,2494,United States,131899
THYMALFASIN,W0B22ISQ1C,Designated,Public record,1015,Thymalfasin,3/6/2000,Treatment of hepatocellular carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",950 Tower Lane,Suite 900,Foster city,California,94404,United States,132600
VAPREOTIDE,2PK59M9GFF,Designated,Public record,1016,vapreotide,3/6/2000,Prevention of early postoperative complications following pancreatic resection.,Designated,Not FDA Approved for Orphan Indication,,,,,Debiopharm S.A.,17 rue des Terreaux,,Lausanne,,,Switzerland,129699
SECRETIN HUMAN,A0426J905J,Designated,Public record,1017,Synthetic human secretin,3/7/2000,"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.",Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,20905,United States,130199
SECRETIN PORCINE,D0L9J6I13I,Designated/Approved,Public record,1018,Synthetic porcine secretin,3/7/2000,"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion.",Designated/Approved,,"Use in secretin stimulation testing for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction",4/4/2002,4/4/2009,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,20905,United States,130299
SEMAXANIB,71IA9S35AJ,Designated,Public record,1019,"3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one",3/23/2000,Treatment of von Hippel-Lindau disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sugen, Inc.",230 East Grand Ave.,,South San Francisco,California,94080,United States,127699
EPINEPHRINE,YKH834O4BH,Designated,Public record,1020,Cisplatin/epinephrine,4/3/2000,Treatment of squamous cell carcinoma of the head and neck.,Designated,Not FDA Approved for Orphan Indication,,,,,"Matrix Pharmaceutical, Inc.",34700 Campus Drive,,Fremont,California,94555,United States,133200
CISPLATIN,Q20Q21Q62J,Designated,Public record,1020,Cisplatin/epinephrine,4/3/2000,Treatment of squamous cell carcinoma of the head and neck.,Designated,Not FDA Approved for Orphan Indication,,,,,"Matrix Pharmaceutical, Inc.",34700 Campus Drive,,Fremont,California,94555,United States,133200
ICOSAPENT ETHYL,6GC8A4PAYH,Designated,Public record,1022,Ethyl eicosapentaenoate,4/6/2000,Treatment of Huntington's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Laxdale Ltd.,"Kings Park House, Laurelhill Business Park",Polmaise Road,Stirling,,,United Kingdom,134300
Bizaxofusp,FRY3MOL2QU,Designated,Public record,1023,IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL),4/6/2000,Treatment of astrocytic glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Medicenna Therapeutics, Inc.",220-1075 West George Street,,Vancouver,,,Canada,132199
ANTITHROMBIN ALFA,AWV6I5L6H2,Designated,Public record,1024,Recombinant human antithrombin III,4/6/2000,Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.,Designated,Not FDA Approved for Orphan Indication,,,,,AT III LLC,c/o Genzyme Corporation,"15 Pleasant St. Connector, P.O. Box 9322",Framingham,Massachusetts,1701,United States,118798
MEROPENEM,FV9J3JU8B1,Designated/Withdrawn,Public record,1025,Meropenem,4/27/2000,"Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals,1800 Concord Pike,PO Box 15437,Wilmington,Delaware,19850,United States,130799
ARSENIC TRIOXIDE,S7V92P67HO,Designated,Public record,1026,Arsenic trioxide,4/28/2000,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,"TEVA Branded Pharmaceutical Products R & D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,134700
"""3,3',5,5'-TETRAIODOTHYROACETIC ACID""",PA7UX1FFYQ,Designated,Public record,1028,Tetraiodothyroacetic acid,5/1/2000,Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.,Designated,Not FDA Approved for Orphan Indication,,,,,"Danforth, Jr., MD, Elliot",University of Vermont,84 Beartown Rd.,Underhill,Vermont,5489,United States,133100
OMEGA-3-ACID ETHYL ESTERS,D87YGH4Z0Q,Designated,Public record,1029,Omega-3 (n-3) polyunsaturated fatty acids,5/4/2000,Treatment of IgA nephropathy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Pronova Biocare, AS",PO Box 420,,Lysaker,,,Norway,128799
SCORPION (CENTRUROIDES) IMMUNE FAB2 ANTIVENIN (EQUINE),DDA050FCEA,Designated/Approved,Public record,1030,Centruroides immune F(ab)2,6/12/2000,Treatment of scorpion envenomations requiring medical attention.,Designated/Approved,,Treatment of clinical signs of scorpion envenomation,8/4/2011,8/4/2018,,"Rare Disease Therapeutics, Inc.",12975 Brookprinter Drive,Suite 170,Poway,California,92064,United States,135900
VIGABATRIN,GR120KRT6K,Designated/Approved,Public record,1031,vigabatrin,6/12/2000,Treatment of infantile spasms.,Designated/Approved,,For infantile spasms (IS) - 1 month to 2 years of age.,8/21/2009,8/21/2016,,H. Lundbeck A/S,Four Parkway North,,Deerfield,Illinois,60015,United States,135100
NYSTATIN,BDF1O1C72E,Designated,Public record,1032,Liposomal nystatin,6/13/2000,Treatment of invasive fungal infections.,Designated,Not FDA Approved for Orphan Indication,,,,,The University of Texas,M.D. Anderson Cancer Center,Unit 038,Houston,Texas,77030,United States,133800
FLUOROURACIL,U3P01618RT,Designated,Public record,1033,Fluorouracil,6/29/2000,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,Ethypharm SA,194 Bureaux de la Colline - Batiment D,,92213 Saint-Cloud Cedex,,,France,131799
TEDUGLUTIDE,7M19191IKG,Designated/Approved,Public record,1034,teduglutide [rDNA origin]; teduglutide [rDNA origin],6/29/2000,Treatment of short bowel syndrome.,Designated/Approved,,GATTEX® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.,5/16/2019,5/16/2026,Treatment of pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,126999
TEDUGLUTIDE,7M19191IKG,Designated/Approved,Public record,1035,teduglutide [rDNA origin]; teduglutide [rDNA origin],6/29/2000,Treatment of short bowel syndrome.,Designated/Approved,,Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support,12/21/2012,12/21/2019,,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,126999
CARMUSTINE,U68WG3173Y,Designated,Public record,1036,Carmustine,7/3/2000,Treatment of intracranial malignancies.,Designated,Not FDA Approved for Orphan Indication,,,,,"Direct Therapeutics, Inc.",460 Seaport Court,Suite 220,Redwood,California,94063,United States,134500
CETUXIMAB,PQX0D8J21J,Designated/Approved,Public record,1037,cetuximab,7/3/2000,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom",3/1/2006,3/1/2013,,ImClone Systems Incorporated,33 ImClone Drive,,Branchburg,New Jersey,8876,United States,132700
ARSENIC TRIOXIDE,S7V92P67HO,Designated,Public record,1038,arsenic trioxide,7/17/2000,Treatment of myelodysplastic syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,135200
GIRENTUXIMAB,539B57DFJF,Designated/Withdrawn,Public record,1039,Chimeric (human-murine) G250 IgG monoclonal antibody,7/24/2000,Treatment of renal cell carcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Wilex Biotechnology GmbH,Grillparzerstrasse 10B,,81675 Munich,,,Germany,133300
ABETIMUS,P3UVQ22SHK,Designated,Public record,1040,Abetimus,7/28/2000,Treatment of lupus nephritis.,Designated,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceutical Co.,6455 Nancy Ridge Dr.,,San Diego,California,92121,United States,133600
FLUOCINOLONE,CT1IX58L9S,Designated/Approved,Public record,1041,Fluocinolone,7/31/2000,Treatment uveitis involving the posterior segment of the eye.,Designated/Approved,,Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye,4/8/2005,4/8/2012,,"Bausch & Lomb Pharmaceuticals, Inc.",8500 Hidden River Parkway,,Tampa,Florida,33637,United States,132800
OBLIMERSEN,85J5ZP6YSL,Designated,Public record,1042,oblimersen,7/31/2000,"Treatment of advanced malignant melanoma (Stages II,III, IV).",Designated,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkeley Heights,New Jersey,7922,United States,134600
PAGIBAXIMAB,23KB56UHN9,Designated,Public record,1043,"Chimeric, humanized monoclonal antibody to staphylococcus",8/3/2000,Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biosynexus, Inc.",9298 Gaither Road,,Rockville,Maryland,20877,United States,132099
Hypericin,7V2F1075HD,Designated,Public record,1044,Hypericin,8/3/2000,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive Suite B-10,,Princeton,New Jersey,8540,United States,131199
OLIPUDASE ALFA,6D5766Q4OP,Designated,Public record,1045,olipudase alfa-rpcp,8/3/2000,Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease),Designated/Approved,,Treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients,8/31/2022,8/31/2029,Treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients,Genzyme Corporation,55 Corporate Drive,,Bridgewater,New Jersey,8807,United States,132900
TRIMETREXATE,UPN4ITI8T4,Designated/Withdrawn,Public record,1047,Trimetrexate,8/10/2000,Treatment of metastatic osteogenic sarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Medimmune Oncology, Inc.",One MedImmune Way,,Gaithersburg,Maryland,20878,United States,132299
ZOLEDRONIC ACID ANHYDROUS,70HZ18PH24,Designated/Approved,Public record,1048,Zoledronate,8/18/2000,Treatment of tumor induced hypercalcemia.,Designated/Approved,,Treatment of hypercalcemia of malignancy.,8/20/2001,8/20/2008,,Novartis Pharmaceuticals Corp.,59 Route 10,,East Hanover,New Jersey,7936,United States,130899
CALFACTANT,Q4K217VGA9,Designated,Public record,1049,calfactant,9/5/2000,Treatment of acute respiratory distress syndrome (ARDS),Designated,Not FDA Approved for Orphan Indication,,,,,"ONY, Inc.",Baird Research Park,Suite 114,Amherst,New York,14228,United States,136400
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,D7RD81HE4W,Designated/Withdrawn,Public record,1050,anti-thymocyte Globulin (rabbit),9/6/2000,Treatment of myelodysplastic syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,A Sanofi Company,500 Kendall Street,Cambridge,Massachusetts,2142,United States,136800
CISPLATIN,Q20Q21Q62J,Designated,Public record,1051,Cisplatin/epinephrine,9/7/2000,Treatment of metastatic malignant melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Matrix Pharmaceutical, Inc.",34700 Campus Drive,,Fremont,California,94555,United States,134800
EPINEPHRINE,YKH834O4BH,Designated,Public record,1051,Cisplatin/epinephrine,9/7/2000,Treatment of metastatic malignant melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Matrix Pharmaceutical, Inc.",34700 Campus Drive,,Fremont,California,94555,United States,134800
LANREOTIDE,0G3DE8943Y,Designated/Approved,Public record,1052,Lanreotide,9/11/2000,Treatment for acromegly,Designated/Approved,,Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy,8/30/2007,8/30/2014,,"IPSEN, Inc.",27 Maple Street,,Milford,Massachusetts,1757,United States,136300
TIRATRICOL,29OQ9EU4R1,Designated,Public record,1053,"3,5,3'-triiodothyroacetate",9/20/2000,"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.",Designated,Not FDA Approved for Orphan Indication,,,,,"Elliot Danforth, Jr., M.D.",University of Vermont,84 Beartown Road,Underhill,Vermont,5489,United States,137200
ECULIZUMAB,A3ULP0F556,Designated,Public record,1056,Eculizumab,9/21/2000,Treatment of dermatomyositis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,136100
HYDROXOCOBALAMIN,Q40X8H422O,Designated,Public record,1057,Hydroxocobalamin,9/22/2000,Treatment of acute cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Rare Disease Therapeutics, Inc.",12975 Brookprinter Pl,Suite 170,Poway,California,92064,United States,137600
BOSENTAN,Q326023R30,Designated/Approved,Public record,1058,bosentan,10/6/2000,Treatment of pulmonary arterial hypertension,Designated/Approved,,Treatment of pulmonary arterial hypertension.,11/20/2001,11/20/2008,,Actelion Pharmaceuticals Ltd,1840 Gateway Drive,Suite 300,Cherry Hill,New Jersey,8002,United States,134200
BOSENTAN,Q326023R30,Designated/Approved,Public record,1059,bosentan,10/6/2000,Treatment of pulmonary arterial hypertension,Designated/Approved,,"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise abili",9/5/2017,9/5/2024,"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise abili",Actelion Pharmaceuticals Ltd,1840 Gateway Drive,Suite 300,Cherry Hill,New Jersey,8002,United States,134200
RASBURICASE,08GY9K1EUO,Designated/Approved,Public record,1060,rasburicase,10/11/2000,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.",7/12/2002,7/12/2009,,Sanofi-Synthelabo Research,9 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,131499
RASBURICASE,08GY9K1EUO,Designated,Public record,1061,Recombinant urate oxidase,10/11/2000,Prophylaxis of chemotherapy-induced hyperuricemia.,Designated,Not FDA Approved for Orphan Indication,,,,,Sanofi-Synthelabo Research,9 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,131599
GAVILIMOMAB,TCR92293RC,Designated/Withdrawn,Public record,1064,Gavilimomab,11/20/2000,Acute graft-versus-host disease (aGVHD),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Amgen,One Amgen Center Drive,Mail Stop 17-2-A,Thousand Oaks,California,91320,United States,136900
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,1065,Cyclosporine in combination with omega-3 polyunsaturated fatty acids,12/6/2000,Prevention of solid organ graft rejection.,Designated,Not FDA Approved for Orphan Indication,,,,,RTP Pharma Corporation,200 Westpark Corporate Center,4364 South Alston Avenue,Durham,North Carolina,27713,United States,138500
CANTUZUMAB MERTANSINE,7Z7EUX7R6M,Designated,Public record,1066,N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody,12/7/2000,For pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,SmithKline Beecham Pharmaceuticals,1250 S. Collegeville Road,,Collegeville,Pennsylvania,19426,United States,138400
NACYSTELYN,8G1KV0RT1P,Designated,Public record,1067,N-acetylcysteinate Lysine,12/27/2000,For the management of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Galephar Pharmaceutical Research, Inc.","Road 198, No. 100 km. 14.7",Juncos Industrial Park,Juncos,,,United States,139200
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,1068,somatropin [rDNA],12/27/2000,Treatment of growth failure in children who were born small for gestational age.,Designated/Approved,,For long-term treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by two years of age.,7/25/2001,7/25/2008,,Pharmacia and Upjohn Company,7000 Portage Road,,Kalamazoo,Michigan,49001,United States,135400
TIAZOFURIN,ULJ82834RE,Designated,Public record,1069,Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide),12/27/2000,Chronic myelogenous leukemia (CML),Designated,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America,3300 Hyland Avenue,,Costa Mesa,California,92626,United States,139500
DOXORUBICIN,80168379AG,Designated,Public record,1070,MTC-DOX for Injection,1/3/2001,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,FeRx Incorporated,4330 La Jolla Village Drive,Suite #250,San Diego,California,92122,United States,139800
ALFIMEPRASE,GPN9HBH1HS,Designated/Withdrawn,Public record,1071,Novel Acting Thrombolytic (NAT),1/26/2001,Treatment of peripheral arterial occlusion (PAO),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Nuvelo, Inc. Inc.",201 Industrial Road,Suite 310,San Carlos,California,94070,United States,137700
TERIPARATIDE,10T9CSU89I,Designated/Withdrawn,Public record,1072,Synthetic Human Parathyroid Hormone 1-34,1/26/2001,Treatment of hypoparathyroidism,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Rare Disease Therapeutics, Inc.",2550 Meridian Blvd,,Nashville,Tennessee,37217,United States,138100
IMATINIB,BKJ8M8G5HI,Designated/Approved,Public record,1073,Imatinib,1/31/2001,Treatment of chronic myelogenous leukemia,Designated/Approved,,"Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",5/10/2001,5/10/2008,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,7936,United States,140100
BOS TAURUS BILE IMMUNOMODULATOR,E5SF1Z7U1S,Designated,Public record,1074,Virulizin,2/1/2001,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"ZOR Pharmaceuticals, LLC",100-A Eastwood Center Drive,Suite 118,Wilmington,North Carolina,28403,United States,139600
ALENDRONATE DISODIUM,I2U0WCC042,Designated,Public record,1075,Alendronate disodium,2/13/2001,Treatment of the bone manifestations of Gaucher disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Richard J. Wenstrup, M.D.",Division of Human Genetics,Children's Hospital Research Foundation,Cincinnati,Ohio,45229,United States,140000
"""TUMOR NECROSIS FACTOR (LIGAND) SUPERFAMILY, MEMBER 13B, SOLUBLE FORM""",2IL2N4764F,Designated/Withdrawn,Public record,1076,B Lymphocyte Stimulator,2/21/2001,Treatment of common variable immunodeficiency (CVID),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Human Genome Sciences, Inc.",9410 Key West Avenue,,Rockville,Maryland,20850,United States,140600
NITROPRUSSIDE,169D1260KM,Designated,Public record,1077,Nitroprusside,2/21/2001,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan",Thomas Jefferson University and Wills Neurosensory,"834 Walnut Street, Suite 650",Philadelphia,Pennsylvania,19107,United States,112498
PEGLOTICASE,R581OT55EA,Designated/Approved,Public record,1078,pegloticase,2/21/2001,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.,Designated/Approved,,Treatment of chronic gout in adult patients refractory to conventional therapy,7/7/2022,,,Horizon Therapeutics Ireland DAC,70 St. Stephen’s Green,,Dublin,,,Ireland,135600
PEGLOTICASE,R581OT55EA,Designated/Approved,Public record,1079,pegloticase,2/21/2001,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective,Designated/Approved,,Treatment of chronic gout in adult patients refractory to conventional treatment,9/14/2010,9/14/2017,,Horizon Therapeutics Ireland DAC,70 St. Stephen’s Green,,Dublin,,,Ireland,135600
PYRUVIC ACID,8558G7RUTR,Designated,Public record,1080,Pyruvate,2/21/2001,Treatment of interstitial lung disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cellular Sciences, Inc",84 park Avenue,P.O. Box 968,Flemington,New Jersey,8822,United States,140900
MEDROXYPROGESTERONE ACETATE,C2QI4IOI2G,Designated,Public record,1081,Medroxyprogesterone acetate,2/22/2001,Treatment of immune thrombocytopenic purpura.,Designated,Not FDA Approved for Orphan Indication,,,,,"ZaBeCor Pharmaceutical Company, LLC",821 Westview Street,,Philadelphia,Pennsylvania,19119,United States,141901
BUSULFAN,G1LN9045DK,Designated/Withdrawn,Public record,1083,Busulfan,3/5/2001,Intrathecal therapy for neoplastic meningitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Boulevard,,Dublin,California,94568,United States,140700
UBIDECARENONE,EJ27X76M46,Designated,Public record,1084,Coenzyme Q10,3/5/2001,Treatment of Huntington's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Integrative Therapeutics, Inc.",825 Challenger Drive,,Green Bay,Wisconsin,54311,United States,138700
PACLITAXEL,P88XT4IS4D,Designated/Withdrawn,Public record,1085,docosahexanoic acid-paclitaxel,3/5/2001,Treatment of hormone-refractory prostate cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,,Shirley,New York,11976,United States,141701
DOCONEXENT,ZAD9OKH9JC,Designated/Withdrawn,Public record,1085,docosahexanoic acid-paclitaxel,3/5/2001,Treatment of hormone-refractory prostate cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,,Shirley,New York,11976,United States,141701
ECULIZUMAB,A3ULP0F556,Designated,Public record,1086,eculizumab,3/5/2001,Treatment of idiopathic membranous glomerular nephropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,138800
DENUFOSOL TETRASODIUM,82M942WZ4A,Designated/Withdrawn,Public record,1087,"p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt",3/7/2001,For the treatment of cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Inspire Pharmaceuticals, Inc.",4222 Emperor Blvd.,Suite 200,Durham,North Carolina,27703,United States,139400
VASOACTIVE INTESTINAL PEPTIDE,6J2WVD66KR,Designated,Public record,1088,Vasoactive intestinal peptide,3/9/2001,Treatment of Acute Respiratory Distress Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,mondoBIOTECH,Europark,FL - 9490 Vaduz,Liechtenstein,,,Switzerland,142001
GIRENTUXIMAB,539B57DFJF,Designated,Public record,1090,Girentuximab,3/22/2001,Treatment of renal cell carcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Heidelberg Pharma AG,101 Schriesheimer Straße,,Ladenburg,Baden-Württemberg,,Germany,139000
INTERFERON ALFA-1B,G7407IV2FS,Designated,Public record,1092,Interferon-alfa-1b,4/17/2001,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Ernest C.Borden,Center for Cancer Drud Discovery and Development,9500 Euclid Avenue,Clevland,Ohio,44195,United States,142601
PERFLUBRON,Q1D0Q7R4D9,Designated,Public record,1093,Perflubron,4/26/2001,Treatment of acute respiratory distress disease (ARDS) in adults,Designated,Not FDA Approved for Orphan Indication,,,,,PFC Development/New Alliance Pharmaceutical,15021 Venture Blvd,,Sherman Oaks,California,91403,United States,141100
SQUALAMINE LACTATE,4WE915J1KX,Designated,Public record,1094,squalamine lactate,5/11/2001,Treatment of ovarian cancer refractory or resistant to standard chemotherapy,Designated,Not FDA Approved for Orphan Indication,,,,,Genaera Corporation,5110 Campus Drive,,Plymouth Meeting,Pennsylvania,19462,United States,143101
RUBITECAN,H19C446XXB,Designated,Public record,1095,9-nitro-20-(S)-camptothecin,5/15/2001,Treatment of pediatric HIV infection/AIDS,Designated,Not FDA Approved for Orphan Indication,,,,,"NovoMed Pharmaceuticals, Inc.",P.O. Box 900,,Germantown,Maryland,20875,United States,142201
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated,Public record,1096,human gammaglobulin,5/25/2001,Treatment for juvenile rheumatoid arthritis,Designated,Not FDA Approved for Orphan Indication,,,,,"Latona Life Sciences, Inc.",10 Village St.,,Mills,Massachusetts,2054,United States,142901
GLATIRAMER ACETATE,5M691HL4BO,Designated,Public record,1097,Glatiramer acetate for injection,6/5/2001,Treatment of primary-progressive multiple sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Teva Pharmaceuticals USA,650 Cathill Rd.,,Sellersville,Pennsylvania,18960,United States,140500
MIFAMURTIDE,1LM890Q4FY,Designated,Public record,1098,mifamuritide,6/5/2001,Treatment of osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,143401
INH-A21,9LKK68BOP0,Designated/Withdrawn,Public record,1101,Staphylococcal immunoglobulin (human),6/13/2001,Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Inhibitex, Inc.",8995 Westside Parkway,Suite 150,Alpharetta,Georgia,30004,United States,144501
BLACK WIDOW SPIDER (LATRODECTUS MACTANS) IMMUNE FAB2 ANTIVENIN (EQUINE),APK07X226X,Designated,Public record,1102,Latrodectus immune F(ab)2,6/18/2001,Treatment of black widow spider envenomations,Designated,Not FDA Approved for Orphan Indication,,,,,"Instituto Bioclon, S.A. de C.V.","Tlalpan,",No. 4687 Colonia Toriello Guerra,Tlalpan,,,Mexico,144001
REVIPARIN SODIUM,5XQ9UBJ16W,Designated,Public record,1103,Reviparin sodium,6/18/2001,Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients,Designated,Not FDA Approved for Orphan Indication,,,,,Abbott,"Abbott Laboratories, Dept. 389, Bldg. J-45",200 Abbott Park Rd.,Abbott Park,Illinois,60064,United States,143501
REVIPARIN SODIUM,5XQ9UBJ16W,Designated,Public record,1104,Reviparin sodium,6/18/2001,Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,Abbott,"Abbott Laboratories, Dept. 389, Bldg. J-45",200 Abbott Park Rd.,Abbott Park,Illinois,60064,United States,143601
2-METHOXYESTRADIOL,6I2QW73SR5,Designated/Withdrawn,Public record,1105,2-methoxyestradiol,7/10/2001,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",Research Triangle Park Center,Suite 400,Durham,North Carolina,27703,United States,143801
FLUORIDE ION,Q80VPU408O,Designated,Public record,1106,Intraoral fluoride releasing system,7/31/2001,Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Digestive Care, Inc.",1120 Win Drive,,Bethlehem,Pennsylvania,18017,United States,143901
SITIMAGENE CERADENOVEC,,Designated,Public record,1107,sitimagene ceradenovec,7/31/2001,Use with gancyclovir in the treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Gliotherapy, Ltd.",Sanderum House,Oakley Road,London,,,United Kingdom,145801
GLUTAMINE,0RH81L854J,Designated/Approved,Public record,1108,L-glutamine,8/1/2001,Treatment of sickle cell disease,Designated/Approved,,To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.,7/7/2017,7/7/2024,To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.,"Emmaus Medical, Inc.","21250 Hawthorne Blvd., Suite 800",,Torrance,California,90503,United States,145901
2-CHLOROETHYL-3-SARCOSINAMIDE-1-NITROSOUREA,BHB013S3MO,Designated,Public record,1109,2-chloroethyl-3-sarcosinamide-1-nitrosourea,8/3/2001,Treatment for malignant gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Lawrence Panasci, MD","Professor of Medicine, McGill University",3755 Cote Ste Catherine,"Montreal, Quebec H3T 1E2",,,Canada,146101
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,1110,Angiotensin 1-7,8/3/2001,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Tarix Pharmaceuticals, Ltd",12 Bow Street,,Cambridge,Massachusetts,2138,United States,144601
IMEXON,8F63U28T2V,Designated/Withdrawn,Public record,1111,Imexon,8/3/2001,Treatment of metastatic malignant melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AmpliMed Corporation,2321 Camino La Zorrela,,Tucson,Alaska,85718,United States,142501
THYROTROPIN ALFA,AVX3D5A4LM,Designated/Approved,Public record,1112,Thyrotropin alfa,8/3/2001,"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid",Designated/Approved,,For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer,12/14/2007,12/14/2014,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,142301
TITANIUM DIOXIDE,15FIX9V2JP,Designated,Public record,1113,"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide",8/13/2001,For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy,Designated,Not FDA Approved for Orphan Indication,,,,,Fallien Cosmeceuticals Ltd.,677 W. Dekalb Pike,,King of Prussia,Pennsylvania,19406,United States,142401
Zinc oxide,SOI2LOH54Z,Designated,Public record,1113,"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide",8/13/2001,For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy,Designated,Not FDA Approved for Orphan Indication,,,,,Fallien Cosmeceuticals Ltd.,677 W. Dekalb Pike,,King of Prussia,Pennsylvania,19406,United States,142401
OCTINOXATE,4Y5P7MUD51,Designated,Public record,1113,"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide",8/13/2001,For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy,Designated,Not FDA Approved for Orphan Indication,,,,,Fallien Cosmeceuticals Ltd.,677 W. Dekalb Pike,,King of Prussia,Pennsylvania,19406,United States,142401
OXYBENZONE,95OOS7VE0Y,Designated,Public record,1113,"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide",8/13/2001,For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy,Designated,Not FDA Approved for Orphan Indication,,,,,Fallien Cosmeceuticals Ltd.,677 W. Dekalb Pike,,King of Prussia,Pennsylvania,19406,United States,142401
AVOBENZONE,G63QQF2NOX,Designated,Public record,1113,"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide",8/13/2001,For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy,Designated,Not FDA Approved for Orphan Indication,,,,,Fallien Cosmeceuticals Ltd.,677 W. Dekalb Pike,,King of Prussia,Pennsylvania,19406,United States,142401
"""ENDOSTATIN, N-TERMINAL-MGGSHHHHH""",GVG18ZDN65,Designated,Public record,1114,Recombinant human endostatin protein,8/13/2001,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,20850,United States,146301
METRELEPTIN,TL60C27RLH,Designated/Approved,Public record,1115,metreleptin,8/22/2001,Treatment of metabolic disorders secondary to lipodystrophy,Designated/Approved,,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,2/24/2014,2/24/2021,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,Amryt Pharmaceutical DAC,45 Mespil Road,,Dublin,,4,Ireland,146701
METRELEPTIN,TL60C27RLH,Designated,Public record,1116,metreleptin,8/22/2001,Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Amryt Pharmaceutical DAC,45 Mespil Road,,Dublin,,4,Ireland,144301
BECLOMETHASONE DIPROPIONATE,5B307S63B2,Designated,Public record,1117,"beclomethasone 17,21-dipropionate",8/28/2001,Prevention of gastrointestinal graft-versus-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,8540,United States,146501
OBLIMERSEN,85J5ZP6YSL,Designated,Public record,1118,oblimersen,8/28/2001,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkeley Heights,New Jersey,7922,United States,145601
OBLIMERSEN,85J5ZP6YSL,Designated,Public record,1119,oblimersen,8/28/2001,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkeley Heights,New Jersey,7922,United States,145501
OBLIMERSEN,85J5ZP6YSL,Designated,Public record,1120,oblimersen,8/28/2001,Treatment of acute myelocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkeley Heights,New Jersey,7922,United States,144901
PEMETREXED DISODIUM,2PKU919BA9,Designated/Approved,Public record,1121,pemetrexed disodium,8/28/2001,Treatment of malignant pleural mesothelioma,Designated/Approved,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery,2/4/2004,2/4/2011,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,145101
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,1122,recombinant human alpha-1 antitrypsin (rAAT),8/28/2001,To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis,Designated,Not FDA Approved for Orphan Indication,,,,,AiroMedica LLC,6114 LaSalle Avenue,Suite 141,Oakland,California,94611,United States,147601
URTOXAZUMAB,232D35B3NT,Designated/Withdrawn,Public record,1123,humanized monoclonal antibody against Shiga-like toxin II,9/12/2001,To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teijin America, Inc.",600 Alexander Park,Suite 304,Princeton,New Jersey,8540,United States,148101
LENALIDOMIDE,F0P408N6V4,Designated/Approved,Public record,1124,lenalidomide,9/20/2001,Treatment of multiple myeloma,Designated/Approved,,REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).,2/17/2015,2/17/2022,For use in combination with dexamethasone for the treatment of patients with multiple myeloma who have not received at least one prior therapy (first-line therapy).,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,147701
LENALIDOMIDE,F0P408N6V4,Designated/Approved,Public record,1125,lenalidomide,9/20/2001,Treatment of multiple myeloma,Designated/Approved,,For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy,6/29/2006,6/29/2013,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,147701
LENALIDOMIDE,F0P408N6V4,Designated/Approved,Public record,1126,lenalidomide,9/20/2001,Treatment of multiple myeloma,Designated/Approved,,"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)",2/22/2017,2/22/2024,"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)",Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,147701
OGLUFANIDE SODIUM,Q60AU1LLNU,Designated,Public record,1127,oglufanide disodium,9/24/2001,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Implicit Bioscience Pty Ltd,P. O. Box 2072,Toowong Business Center,Brisbane,Queensland,,Australia,147901
PACLITAXEL DOCOSAHEXAENOIC ACID,OJE5810C4F,Designated/Withdrawn,Public record,1128,DHA-paclitaxel,9/25/2001,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,,Shirley,New York,11976,United States,147801
TIK-301,3ZX95B1ZWK,Designated,Public record,1129,(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide,10/3/2001,Treatment of circadian rhythm sleep disorders in blind people with no light perception,Designated,Not FDA Approved for Orphan Indication,,,,,"Phase 2 Discovery, Inc.","3130 Highland Avenue, Third Floor",,Cincinnati,Ohio,45219,United States,147501
ARSENIC TRIOXIDE,S7V92P67HO,Designated,Public record,1130,arsenic trioxide,10/18/2001,Treatment of chronic myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,145701
Digitoxin,E90NZP2L9U,Designated,Public record,1131,digitoxin,10/18/2001,Treatment of soft tissue sarcomas,Designated,Not FDA Approved for Orphan Indication,,,,,SimRx Advisors LLC,247 West 87th Street,Suite 7G,New York,New York,10024,United States,149701
NOLATREXED,K75ZUN743Q,Designated/Withdrawn,Public record,1132,nolatrexed,10/18/2001,Treatment of hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,EXIMIAS Pharmaceutical Corporation,1055 Westlakes Drive,Suite 200,Berwyn,Pennsylvania,19312,United States,148801
ACETYLCYSTEINE,WYQ7N0BPYC,Designated/Approved,Public record,1133,acetylcysteine,10/19/2001,For the intravenous treatment of moderate to severe acetaminophen overdose,Designated/Approved,,"For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur",1/23/2004,1/23/2011,,"Cumberland Pharmaceuticals, Inc.",209 10th Street South,Suite 332,Nashville,Tennessee,37203,United States,148401
NITISINONE,K5BN214699,Designated,Public record,1134,nitisinone,10/19/2001,Treatment of alkaptonuria,Designated,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ),Tomtebodavägen 23A,,Stockholm,,,Sweden,148701
PORFIMER,M15H03K69B,Designated/Approved,Public record,1135,porfimer,10/19/2001,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy,8/1/2003,8/1/2010,,Axcan Scandipharm Inc.,22 Inverness Parkway,Suite 310,Birmingham,Alabama,35242,United States,146601
NITAZOXANIDE,SOA12P041N,Designated,Public record,1136,nitazoxanide,10/23/2001,Treatment for intestinal amebiasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Romark Laboratories, L.C.",6200 Courtney Campbell Causeway,Suite 880,Tampa,Florida,33607,United States,150501
IMATINIB MESYLATE,8A1O1M485B,Designated/Approved,Public record,1137,imatinib mesylate,11/1/2001,Treatment of gastrointestinal stromal tumors,Designated/Approved,,Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST).,12/19/2008,12/19/2015,,Novartis Pharmaceuticals Corp.,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,7936,United States,149201
IMATINIB MESYLATE,8A1O1M485B,Designated/Approved,Public record,1138,imatinib mesylate,11/1/2001,Treatment of gastrointestinal stromal tumors,Designated/Approved,,Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST),2/1/2002,2/1/2009,,Novartis Pharmaceuticals Corp.,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,7936,United States,149201
ARSENIC,N712M78A8G,Designated,Public record,1140,arsenic,11/2/2001,"Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7",Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,146001
CINTREDEKIN BESUDOTOX,ZL04JX89M7,Designated/Withdrawn,Public record,1141,cintredekin besudotox,11/2/2001,Treatment of malignant glioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.","1333 South Sprectum Blvd, Suite 100",,Chandler,Alaska,85286,United States,149801
Digitoxin,E90NZP2L9U,Designated,Public record,1142,digitoxin,11/2/2001,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,SimRx Advisors LLC,247 West 87th Street,Suite 7G,New York,New York,10024,United States,149601
2-CHLOROETHYL-3-SARCOSINAMIDE-1-NITROSOUREA,BHB013S3MO,Designated,Public record,1143,2-chloroethyl-3-sarcosinamide-1-nitrosourea,11/15/2001,Treatment for malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Pangene Corporation,5500 Stewart Avenue,,Fremont,California,94538,United States,150601
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,1144,recombinant human alpha 1-antitrypsin (rAAT),11/20/2001,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,AiroMedica LLC,6114 LaSalle Avenue,Suite 141,Oakland,California,94611,United States,149301
APOLIZUMAB,G88KCP51RE,Designated,Public record,1146,"Hu1D10, humanized monoclonal antibody",11/28/2001,For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"PDL BioPharma, Inc.",34801 Campus Drive,,Fremont,California,94555,United States,144701
IDURSULFASE,5W8JGG2651,Designated/Approved,Public record,1147,idursulfase,11/28/2001,Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome),Designated/Approved,,"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients",7/24/2006,7/24/2013,,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,147301
AZACITIDINE,M801H13NRU,Designated/Approved,Public record,1148,azacitidine,12/3/2001,Treatament of myelodysplastic syndromes,Designated/Approved,,"Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blast",5/19/2004,5/19/2011,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,150101
BRYOSTATIN 1,37O2X55Y9E,Designated,Public record,1149,bryostatin-1,12/3/2001,For use in combination with paclitaxel in the treatment of esophageal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"GPC Biotech, Inc.",610 Lincoln Street,,Waltham,Massachusetts,2451,United States,148201
DEFERIPRONE,2BTY8KH53L,Designated/Approved,Public record,1151,deferiprone,12/12/2001,Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,Designated/Approved,,Ferriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.,5/19/2020,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,150701
DEFERIPRONE,2BTY8KH53L,Designated/Approved,Public record,1152,deferiprone,12/12/2001,Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,Designated/Approved,,treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with sickle cell disease or,4/30/2021,4/30/2028,"treatment of transfusional iron overload in adult patients with thalassemia syndromes excluding adult patients covered by the indication for thalassemia syndromes approved on October 14, 2011; treatment of transfusional iron overload in pediatric patients","Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,150701
DEFERIPRONE,2BTY8KH53L,Designated/Approved,Public record,1153,deferiprone,12/12/2001,Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,Designated/Approved,,treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with sickle cell disease or,4/30/2021,4/30/2028,"treatment of transfusional iron overload in adult patients with thalassemia syndromes excluding adult patients covered by the indication for thalassemia syndromes approved on October 14, 2011; treatment of transfusional iron overload in pediatric patients","Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,150701
DEFERIPRONE,2BTY8KH53L,Designated/Approved,Public record,1154,deferiprone,12/12/2001,Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,Designated/Approved,,Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate,10/14/2011,10/14/2018,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,150701
FRESOLIMUMAB,375142VBIA,Designated/Withdrawn,Public record,1155,human anti-transforming growth factor beta 1 monoclonal antibody,1/11/2002,Treatment of systemic sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,2139,United States,151101
AMELUBANT,E0018IF0K4,Designated/Withdrawn,Public record,1156,"carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester",1/15/2002,Management of cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc",900 Ridgebury Road,P.O. Box 368,Ridgefield,Connecticut,6877,United States,148601
BIFIDOBACTERIUM SPP.,IO1WP3918D,Designated,Public record,1157,"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)",1/15/2002,Treatment of active chronic pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"VSL Pharmaceuticals, Inc.",800 S. Frederick Ave.,,Gaithersburg,Maryland,20877,United States,145201
LIPROTAMASE PROTEASE,6435YY37C0,Designated/Withdrawn by OPD,Public record,1159,"lipase, amylase, and protease",1/23/2002,Treatment of pancreatic insufficiency,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Altus Biologics Inc.,625 Putnam Avenue,,Cambridge,Massachusetts,2139,United States,148501
LIPROTAMASE AMYLASE,I909J9CFAT,Designated/Withdrawn by OPD,Public record,1159,"lipase, amylase, and protease",1/23/2002,Treatment of pancreatic insufficiency,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Altus Biologics Inc.,625 Putnam Avenue,,Cambridge,Massachusetts,2139,United States,148501
LIPROTAMASE LIPASE,9VP88M3N3O,Designated/Withdrawn by OPD,Public record,1159,"lipase, amylase, and protease",1/23/2002,Treatment of pancreatic insufficiency,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Altus Biologics Inc.,625 Putnam Avenue,,Cambridge,Massachusetts,2139,United States,148501
CLOFARABINE,762RDY0Y2H,Designated/Approved,Public record,1160,clofarabine,2/7/2002,Treatment of acute lymphoblastic leukemia,Designated/Approved,,Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,12/28/2004,12/28/2011,,Genzyme Corporation,4545 Horizon Hill Blvd.,,San Antonio,Texas,78229,United States,153201
OMACETAXINE MEPESUCCINATE,6FG8041S5B,Designated,Public record,1161,homoharringtonine,2/8/2002,Treatment for chronic myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"American BioScience, Inc.",2730 Wilshire Blvd. #110,,Santa Monica,California,90403,United States,152901
CREATINE,MU72812GK0,Designated,Public record,1165,creatine,2/12/2002,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Avicena Group, Inc.",580 California St.,Suite 1600,San Francisco,California,94104,United States,152701
CHLOROTOXIN I-131,544WOQ7W6W,Designated,Public record,1166,I(131)-TM-601 (chlorotoxin),2/14/2002,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,,United States,152201
NITAZOXANIDE,SOA12P041N,Designated/Approved,Public record,1167,nitazoxanide,2/14/2002,Treatment of intestinal giardiasis,Designated/Approved,,Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia,11/22/2002,11/22/2009,,"Romark Laboratories, L.C.",6200 Courtney Campbell Causeway,Suite 880,Tampa,Florida,33607,United States,150401
PHENYLEPHRINE,1WS297W6MV,Designated,Public record,1168,phenylephrine,2/14/2002,Treatment of ileal pouch anal anastomosis related fecal incontinence,Designated,Not FDA Approved for Orphan Indication,,,,,S.L.A. Pharma,"Unit 3, Hill Farm Industrial Estate",,"Leavesden, Watford",,,United Kingdom,147201
"""ENDOSTATIN, N-TERMINAL-MGGSHHHHH""",GVG18ZDN65,Designated,Public record,1169,recombinant human endostatin protein,2/21/2002,Treatment of metastatic melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,20850,United States,153101
ALBUTEROL,QF8SVZ843E,Designated,Public record,1170,Albuterol,3/12/2002,Prevention of paralysis due to spinal cord injury,Designated,Not FDA Approved for Orphan Indication,,,,,"MotoGen, Inc.",3 Pine View Road,,Mount Kisco,New York,10549,United States,152501
AZTREONAM,G2B4VE5GH8,Designated/Approved,Public record,1171,aztreonam,3/12/2002,Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,Designated/Approved,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa,2/22/2010,2/22/2017,,"Gilead Sciences, Inc.",199 East Blaine St,,Seattle,Washington,98102,United States,155002
RITUXIMAB,4F4X42SYQ6,Designated,Public record,1172,rituximab,3/12/2002,Treatment of immune thrombocytopenic purpura,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,155102
CLOFARABINE,762RDY0Y2H,Designated,Public record,1173,clofarabine,3/14/2002,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Genzyme Corp (Ilex Products, Inc.)",4545 Horizon Hill Blvd.,,San Antonio,Texas,78229,United States,154802
"""THALIDOMIDE, (S)-""",TG87FSR590,Designated,Public record,1174,S(-)-3-[3-amino-phthalimido]-glutaramide,3/14/2002,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,EntreMed Incorporated,9640 Medical Center Dr.,,Rockville,Maryland,20850,United States,151701
TORALIZUMAB,KX44A9HM0B,Designated/Withdrawn,Public record,1175,toralizumab,3/14/2002,Treatment of immune thrombocytopenic purpura,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Biogen IDEC Inc.,3030 Callan Road,,San Diego,California,92121,United States,154302
HYALURONIC ACID (NON-ANIMAL STABILIZED),B7SG5YV2SI,Designated,Public record,1176,hyaluronic acid,3/19/2002,Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,CoTherix,5000 Shoreline Court,Suite 101,South San Francisco,California,94080,United States,153501
HYALURONIC ACID,S270N0TRQY,Designated,Public record,1176,hyaluronic acid,3/19/2002,Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,CoTherix,5000 Shoreline Court,Suite 101,South San Francisco,California,94080,United States,153501
TINIDAZOLE,033KF7V46H,Designated/Approved,Public record,1178,tinidazole,4/18/2002,Treatment of giardiasis,Designated/Approved,,Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age,5/17/2004,5/17/2011,,"Presutti Laboratories, Inc.",1607 N. Douglas Ave.,,Arlington Heights,Illinois,60004,United States,155402
NS-3728,943YH53W21,Designated/Withdrawn,Public record,1182,"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea",5/13/2002,Treatment of sickle cell disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,NeuroSearch A/S,93 Pederstrupvej,,DK-2750 Ballerup,,,Denmark,153901
MECASERMIN RINFABATE,NZ8M50KKRG,Designated/Approved,Public record,1184,mecasermin rinfabate,5/17/2002,Treatment of growth hormone insensitivity syndrome (GHIS),Designated/Approved,,Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,12/12/2005,12/12/2012,,"Insmed, Inc.",10 Finderne Ave,Building 10,Bridgewater,New Jersey,8807,United States,156302
TRABEDERSEN,98OYR854NY,Designated,Public record,1185,trabedersen,6/5/2002,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Oncotelic Inc.,29397 Agoura Road,Suite 107,Agoura Hills,California,91301,United States,155602
G17DT IMMUNOGEN,J9W34L3K8B,Designated,Public record,1187,G17DT Immunogen,7/10/2002,Treatment of adenocarcinoma of the pancreas,Designated,Not FDA Approved for Orphan Indication,,,,,"Cancer Advances, Inc.",Westpark Corporate Center,Suite 210,Durham,North Carolina,27713,United States,156902
RUBITECAN,H19C446XXB,Designated,Public record,1190,rubitecan,7/17/2002,Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,156602
G17DT IMMUNOGEN,J9W34L3K8B,Designated,Public record,1191,G17DT Immunogen,7/18/2002,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Cancer Advances, Inc.",Westpark Corporate Center,Suite 210,Durham,North Carolina,27713,United States,157002
HILTONOL,7KYP9TKT70,Designated,Public record,1192,polyinosinic-polycytidilic acid,8/2/2002,As an adjuvant to smallpox vaccination,Designated,Not FDA Approved for Orphan Indication,,,,,Oncovir,"3203 Cleveland Ave., NW",,Washington,District of Columbia,20008,United States,157802
DECITABINE,776B62CQ27,Designated/Withdrawn,Public record,1193,decitabine,9/9/2002,Treatment of sickle cell anemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Otsuka Pharmaceutical Development &,"Commercialization, Inc.",508 Carnegie Center Drive,Princeton,New Jersey,8540,United States,159702
LINTUZUMAB,V00Y10W60W,Designated/Withdrawn,Public record,1194,lintuzumab,9/9/2002,Treatment of acute myelogenous leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.",34801 Campus Drive,,Fremont,California,94555,United States,158502
ACETYLCYSTEINE,WYQ7N0BPYC,Designated,Public record,1195,N-acetylcysteine,9/9/2002,Treatment of acute liver failure,Designated,Not FDA Approved for Orphan Indication,,,,,"Cumberland Pharmaceuticals, Inc.",2525 West End Ave.,Suite 950,Nashville,Tennessee,37203,United States,158102
"""PORPHOBILINOGEN DEAMINASE, RECOMBINANT HUMAN ERYTHROID ISOFORM""",5AE6296X3G,Designated,Public record,1196,recombinant human porphobilinogen deaminase,9/9/2002,Treatment of acute intermittent porphyria attacks,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,157202
INTERFERON GAMMA-1B,21K6M2I7AG,Designated/Withdrawn,Public record,1197,interferon gamma-1b,9/12/2002,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"InterMune, Inc.",3280 Bayshore Boulevard,,Brisbane,California,94005,United States,152301
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated,Public record,1198,human gammaglobulin,9/16/2002,"Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.",Designated,Not FDA Approved for Orphan Indication,,,,,"Latona Life Sciences, Inc.",10 Village St.,,Mills,Massachusetts,2054,United States,152101
EFUNGUMAB,BM86P708HW,Designated,Public record,1199,recombinant human monoclonal antibody to hsp90,9/16/2002,Treatment of invasive candidiasis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,,United Kingdom,158402
PACLITAXEL DOCOSAHEXAENOIC ACID,OJE5810C4F,Designated/Withdrawn,Public record,1200,DHA-paclitaxel,10/10/2002,Treatment of metastatic malignant melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",1000 Madison Ave,,Norristown,Pennsylvania,19403,United States,153001
SHARK CARTILAGE EXTRACT,,Designated,Public record,1201,antiangiogenic components extracted from marine cartilage,10/16/2002,Treatment of renal cell carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"AEterna Zentaris, Inc.",Dr. Claude Hariton,"Chief Medical Officer, VP, Cli",Quebec,,,Canada,159202
CAPSAICIN,S07O44R1ZM,Designated,Public record,1202,capsaicin,10/23/2002,Treatment of erythromelalgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Averitas Pharma, Inc.",360 Mount Kemble Avenue,,Morristown,New Jersey,7960,United States,158202
P-113D,513P3772TA,Designated,Public record,1203,D-peptide of the sequence AKRHHGYKRKFH - NH2,10/23/2002,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Demegen, Inc.",100 Technology Drive,Suite 440 B,Pittsburgh,Pennsylvania,15219,United States,156502
INFLIXIMAB,B72HH48FLU,Designated,Public record,1204,infliximab,10/23/2002,Treatment of juvenile rheumatoid arthritis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",,200 Great Valley Parkway,Malvern,Pennsylvania,19355,United States,160202
INOLIMOMAB,GO90DFK14U,Designated,Public record,1205,inolimomab,10/23/2002,Treatment of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,ElsaLys Biotech SAS,317 Avenue Jean Jaures,Batiment Accinov,Lyon,,,France,158602
TIRAPAZAMINE,1UD32YR59G,Designated,Public record,1206,tirapazamine,10/23/2002,Treatment of head and neck cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Sanofi-Aventis US, Inc.",11 Great Valley Parkway,P. O. Box 3026,Malvern,Pennsylvania,19355,United States,155502
COBIPROSTONE,IL870Q3Z8I,Designated/Withdrawn,Public record,1207,cobiprostone,11/14/2002,Treatment of cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sucampo Pharma Americas, LLC.",4520 East-West Highway,Suite 300,Bethesda,Maryland,20814,United States,158302
HEPATITIS C IMMUNE GLOBULIN (HUMAN),U5V5MUD1KD,Designated/Withdrawn,Public record,1208,Hepatitis C virus immune globulin (human),11/14/2002,Prophylaxis of hepatitis C infection in liver transplant recipients.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ADMA Biologics, Inc.",465 Route 17 South,,Ramsey,New Jersey,7446,United States,73193
HILTONOL,7KYP9TKT70,Designated,Public record,1210,polyinosinic-polycytidilic acid (Poly-ICLC),11/19/2002,Treatment for orthopox virus infections,Designated,Not FDA Approved for Orphan Indication,,,,,Oncovir,"3203 Cleveland Ave., NW",,Washington,District of Columbia,20008,United States,157702
Allantoin,344S277G0Z,Designated,Public record,1211,allantoin,11/21/2002,Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Scioderm, Inc.",1007 Slater Road,Suite 170,Durham,North Carolina,27703,United States,151001
DEFERASIROX,V8G4MOF2V9,Designated/Approved,Public record,1212,Deferasirox,11/21/2002,Treatment of chronic iron overload in patients with transfusion-dependent anemias,Designated/Approved,,treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older,5/18/2017,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Hampshire,7936,United States,161002
DEFERASIROX,V8G4MOF2V9,Designated/Approved,Public record,1213,Deferasirox,11/21/2002,Treatment of chronic iron overload in patients with transfusion-dependent anemias,Designated/Approved,,Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older,11/2/2005,11/2/2012,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Hampshire,7936,United States,161002
MELOXICAM,VG2QF83CGL,Designated/Approved,Public record,1215,meloxicam,11/22/2002,Treatment of juvenile rheumatoid arthritis,Designated/Approved,,For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older,8/11/2005,8/11/2012,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,160602
BUSULFAN,G1LN9045DK,Designated,Public record,1216,busulfan,11/25/2002,Preparative therapy for pediatric patients undergoing bone marrow transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,94568,United States,160402
BUSULFAN,G1LN9045DK,Designated/Withdrawn,Public record,1217,"(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3?,4?:6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime",11/29/2002,Treatment malignant glioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sigma-Tau Research, Inc.",9841 Washingtonian Blvd,Suite 502,Gaithersburg,Maryland,20878,United States,161602
ZUCAPSAICIN,15OX67P384,Designated,Public record,1219,civamide,12/9/2002,Treatment of postherpetic neuralgia of the trigeminal nerve,Designated,Not FDA Approved for Orphan Indication,,,,,"Winston Laboratories, Inc.","100 Fairway Drive, Suite 134",,Vernon Hills,Illinois,60061,United States,159102
"""ETODOLAC, (R)-""",Y1RAH31T6K,Designated/Withdrawn,Public record,1220,R-etodolac,12/9/2002,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cephalon, Inc.",41 Moores Road,,Frazer,Pennsylvania,19355,United States,162702
URIDINE TRIACETATE,2WP61F175M,Designated/Withdrawn,Public record,1221,"2',3',5'-tri-o-acetyluridine",1/13/2003,Treatment of mitochondrial disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Repligen Corporation,41 Seyon Street,"Building 1, Suite 100",Waltham,Massachusetts,2453,United States,163202
BORTEZOMIB,69G8BD63PP,Designated/Approved,Public record,1222,bortezomib,1/15/2003,Treatment of multiple myeloma,Designated/Approved,,First-line therapy of multiple myeloma.,6/20/2008,6/20/2015,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,163002
BORTEZOMIB,69G8BD63PP,Designated/Approved,Public record,1223,bortezomib,1/15/2003,Treatment of multiple myeloma,Designated/Approved,,Treatment of multiple myeloma patients who have received at least one prior therapy,3/25/2005,3/25/2012,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,163002
BORTEZOMIB,69G8BD63PP,Designated/Approved,Public record,1224,bortezomib,1/15/2003,Treatment of multiple myeloma,Designated/Approved,,Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,5/13/2003,5/13/2010,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,163002
POMALIDOMIDE,D2UX06XLB5,Designated/Approved,Public record,1225,pomalidomide,1/15/2003,Treatment of multiple myeloma,Designated/Approved,,Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.,2/8/2013,2/8/2020,Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,161402
BIFIDOBACTERIUM LONGUM INFANTIS 35624,0Z1FKO93PO,Designated,Public record,1226,bifidobacterium longum infantis 35624,1/16/2003,Treatment of pediatric Crohn's disease,Designated,Not FDA Approved for Orphan Indication,,,,,Alimentary Health Limited,"Guardwell, Kinsale",,Cork,,,Ireland,161902
GOLIMUMAB,91X1KLU43E,Designated/Withdrawn,Public record,1227,Human Anti-tumor Necrosis factor alpha monoclonal antibody,1/16/2003,"Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,159402
Pegunigalsidase Alfa,8M7V7Q6537,Designated,Public record,1228,a-Galactosidase A,1/21/2003,Treatment of Fabry's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"iBio, Inc.",9 Innovation Way,Suite 100,Newark,Delaware,19711,United States,162302
MAFOSFAMIDE,5970HH9923,Designated,Public record,1229,Mafosfamide,1/21/2003,Treatment of neoplastic meningitis,Designated,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corporation,Route 120 & Wilson Road,,Round Lake,Illinois,60073,United States,162202
ALTEPLASE,1RXS4UE564,Designated,Public record,1230,alteplase,1/27/2003,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD",Johns Hopkins University,"600 N. Wolfe St., Jefferson 1-109",Baltimore,Maryland,21287,United States,163502
MOTEXAFIN GADOLINIUM,6433A42F4F,Designated,Public record,1231,motexafin gadolinium,1/27/2003,For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,152401
REPARIXIN LYSINE,4RZ9P05120,Designated,Public record,1233,reparixin,1/27/2003,Prevention of delayed graft function in solid organ transplant,Designated,Not FDA Approved for Orphan Indication,,,,,Dompe S.p.A.,Via Campo di Pile,,L'Aquila,,,Italy,162802
REPARIXIN,U604E1NB3K,Designated,Public record,1233,reparixin,1/27/2003,Prevention of delayed graft function in solid organ transplant,Designated,Not FDA Approved for Orphan Indication,,,,,Dompe S.p.A.,Via Campo di Pile,,L'Aquila,,,Italy,162802
TEZACITABINE,UCC4EQS7WL,Designated,Public record,1235,Tezacitabine,1/27/2003,Treatment of adenocarcinoma of the esophagus and stomach,Designated,Not FDA Approved for Orphan Indication,,,,,"Sanofi-Aventis US, Inc.",9 Great valley Parkway,,Malvern,Pennsylvania,19355,United States,164002
ECALLANTIDE,5Q6TZN2HNM,Designated/Approved,Public record,1236,ecallantide,2/4/2003,Treatment of angioedema,Designated/Approved,,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older,3/28/2014,3/28/2021,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,160802
ECALLANTIDE,5Q6TZN2HNM,Designated/Approved,Public record,1237,ecallantide,2/4/2003,Treatment of angioedema,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older,12/1/2009,12/1/2016,,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,160802
GOMILIXIMAB,8Z13S29R5A,Designated/Withdrawn,Public record,1238,"anti-CD23 IgG1, kappa monoclonal antibody",2/12/2003,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen IDEC, Inc.",,5200 Research Place,San Diego,California,92122,United States,160502
HILTONOL,7KYP9TKT70,Designated,Public record,1240,polyinosinic-polycytidilic acid,3/3/2003,"Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses",Designated,Not FDA Approved for Orphan Indication,,,,,Oncovir,"3203 Cleveland Ave., NW",,Washington,District of Columbia,20008,United States,163302
GTI-2040,5WY0FWR2CF,Designated,Public record,1241,antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA],3/12/2003,Treatment for renal cell carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Lorus Therapeutics, Inc",2 Meridan Road,,Toronto,,,Canada,165202
DEXTRAN 1,I8LHQ0D645,Designated,Public record,1242,dextran 1,3/21/2003,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,BCY LifeSciences Inc.,160 Eglinton Ave. East,Suite 600,Toronto,,,Canada,157602
ROMIPLOSTIM,GN5XU2DXKV,Designated/Approved,Public record,1243,romiplostim,3/27/2003,Treatment of immune thrombocytopenic purpura,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",10/17/2019,10/17/2026,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.",One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,91320,United States,165402
ROMIPLOSTIM,GN5XU2DXKV,Designated/Approved,Public record,1244,romiplostim,3/27/2003,Treatment of immune thrombocytopenic purpura,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",8/22/2008,8/22/2015,,"Amgen, Inc.",One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,91320,United States,165402
ROMIPLOSTIM,GN5XU2DXKV,Designated/Approved,Public record,1245,romiplostim,3/27/2003,Treatment of immune thrombocytopenic purpura,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.",12/14/2018,12/14/2025,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.",One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,91320,United States,165402
SC-41930,EVH7O0422T,Designated/Withdrawn,Public record,1246,"(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid",3/31/2003,Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Intarcia Therapeutics, Inc.",24650 Industrial Blvd,,Hayward,California,94545,United States,164102
ALENDRONIC ACID,X1J18R4W8P,Designated/Withdrawn,Public record,1247,alendronate,3/31/2003,Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharpe & Dohme Corp.",126 East Lincoln Ave.,RY 33-212,Rahway,New Jersey,7065,United States,166603
SODIUM PYRUVATE,POD38AIF08,Designated,Public record,1248,Sodium pyruvate,3/31/2003,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Cellular Sciences, Inc",84 park Avenue,P.O. Box 968,Flemington,New Jersey,8822,United States,165602
RIBAVIRIN,49717AWG6K,Designated/Approved,Public record,1249,ribavirin,4/4/2003,Treatment of chronic hepatitis C in pediatric patients,Designated/Approved,,Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.,7/29/2003,7/29/2010,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,162402
TH-9402,RVY229824B,Designated/Withdrawn,Public record,1250,"4,5-dibromorhodamine 123",4/10/2003,Treatment of chronic myelogenous leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Kiadis Pharma Canada, Inc.",2525 Marie-Curie,,Saint-Laurent (Quebec),,,Canada,166203
TRETINOIN,5688UTC01R,Designated,Public record,1251,Tretinoin,4/11/2003,Treatment of T-cell non-Hodgkin's lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Antigenics, Inc.",3 Forbes Road,,Lexington,Massachusetts,2421,United States,165802
PACLITAXEL DOCOSAHEXAENOIC ACID,OJE5810C4F,Designated/Withdrawn,Public record,1252,DHA-paclitaxel,5/1/2003,Treatment of adenocarcinoma of the stomach or lower esophagus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",1000 Madison Ave,,Norristown,Pennsylvania,19403,United States,153301
FERRIC FERROCYANIDE,TLE294X33A,Designated/Approved,Public record,1253,iron(III)-hexacyanoferrate(II),5/1/2003,Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium,Designated/Approved,,Treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination,10/2/2003,10/2/2010,,"Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG",Goerzallee 253,D-14167,Berlin,,,Germany,169203
CAPSAICIN,S07O44R1ZM,Designated,Public record,1254,capsaicin,5/2/2003,Treatment of painful HIV-associated neuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Averitas Pharma, Inc.",360 Mount Kemble Avenue,,Morristown,New Jersey,7960,United States,165502
RTL-1000,8D7IFF667N,Designated,Public record,1255,Recombinant T-cell receptor ligand,5/2/2003,Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55,Designated,Not FDA Approved for Orphan Indication,,,,,"Artielle ImmunoTherapeutics, Inc.",9020 SW Washington Square Road,Suite 450,"Tigard,",Oregon,97223,United States,163102
INFLIXIMAB,B72HH48FLU,Designated/Withdrawn,Public record,1256,infliximab,5/6/2003,Treatment of giant cell arteritis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,166303
CINACALCET,UAZ6V7728S,Designated/Approved,Public record,1257,cinacalcet,5/12/2003,Treatment of hypercalcemia in patients with parathyroid carcinoma,Designated/Approved,,Treatment of hypercalcemia in patients with parathyroid carcinoma,3/8/2004,3/8/2011,,"Amgen, Inc.",,One Amgen Center Drive,Thousand Oaks,California,91320,United States,163402
ARSENIC TRIOXIDE,S7V92P67HO,Designated,Public record,1258,Arsenic trioxide,5/13/2003,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,167203
RESINIFERATOXIN,A5O6P1UL4I,Designated,Public record,1259,resiniferatoxin,5/13/2003,Treatment of intractable pain at end-stage disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Sorrento Theraeputics, Inc.",9380 Judicial Drive,,San Diego,California,92121,United States,164802
DEFIBROTIDE SODIUM,L7CHH2B2J0,Designated/Approved,Public record,1261,defibrotide,5/21/2003,For the treatment of hepatic veno-occlusive disease,Designated/Approved,,"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).",3/30/2016,3/30/2023,"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).","Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,94304,United States,168803
CATRIDECACOG,NU23Q531G1,Designated,Public record,1262,"Factor XIII [A2] homodimer, recombinant DNA origin",5/21/2003,Treatment of congenital FXIII deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk Pharmaceuticals, INc.",100 College Road West,,Princeton,New Jersey,8540,United States,168603
INFLIXIMAB,B72HH48FLU,Designated,Public record,1263,Infliximab,5/21/2003,Treatment of chronic sarcoidosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,168303
PACLITAXEL CERIBATE,B3C86E80A0,Designated,Public record,1265,Protaxel,5/21/2003,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Biophysica, Inc.",2159 Avenida de la Playa,Suite B,La Jolla,California,92037,United States,168203
Corticotropin,K0U68Q2TXA,Designated/Approved,Public record,1266,repository corticotropin or adrenocorticotropic hormone,5/21/2003,Treatment of infantile spasms,Designated/Approved,,To treat infantile spasms,10/15/2010,10/15/2017,,"Questcor Pharmaceuticals, Inc.",26118 Research Road,,Hayward,California,94545,United States,168103
VORINOSTAT,58IFB293JI,Designated/Withdrawn,Public record,1267,vorinostat,6/12/2003,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Merck Research Laboratories,"Merck & Co., Inc.","P. O. Box 2000, RY 33-212",Rahway,New Jersey,7065,United States,169503
ARSENIC TRIOXIDE,S7V92P67HO,Designated,Public record,1268,arsenic trioxide,6/13/2003,Treatment of liver cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,167303
CURCUMIN,IT942ZTH98,Designated/Withdrawn,Public record,1269,diferuloylmethane,6/13/2003,Treatment of cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Allertein Therapeutics, LLC",640 Sasco Hill Road,,Fairfield,Connecticut,6824,United States,167603
DIPHENCYPRONE,I7G14NW5EC,Designated,Public record,1270,diphenylcyclopenone,6/13/2003,Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU]),Designated,Not FDA Approved for Orphan Indication,,,,,"Lloyd E. King, Jr.",1900 Patterson Street,Suite 104,Nashville,Tennessee,37203,United States,164502
FERRIC FERROCYANIDE,TLE294X33A,Designated,Public record,1271,"ferric hexacyanoferrate (II) ""Prussian Blue""",6/26/2003,Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium,Designated,Not FDA Approved for Orphan Indication,,,,,Degussa AG,Weissfrauenstr 9,,Frankfurt,,,Germany,173403
TIK-301,3ZX95B1ZWK,Designated,Public record,1272,(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide,7/3/2003,Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Phase 2 Discovery, Inc.",3130 Highland Ave.,Third Floor,Cincinnati,Ohio,45219,United States,157102
Sodium dichloroacetate,42932X67B5,Designated,Public record,1273,sodium dichloroacetate,7/3/2003,Use as an antidote in the management of systemic monochloroacetic acid poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,EBD Group,2032 Corte del Nogal,Suite 120,Carlsbad,California,92011,United States,169803
PLERIXAFOR,S915P5499N,Designated/Approved,Public record,1274,plerixafor,7/10/2003,For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy,Designated/Approved,,To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma,12/15/2008,12/15/2015,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,167903
LIBIVIRUMAB,J1R33H8X7A,Designated/Withdrawn,Public record,1275,"Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab",7/15/2003,For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Cubist Pharmaceuticals,65 Hayden Avenue,,Lexington,Massachusetts,2421,United States,171103
EXBIVIRUMAB,5Q374M1S1P,Designated/Withdrawn,Public record,1275,"Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab",7/15/2003,For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Cubist Pharmaceuticals,65 Hayden Avenue,,Lexington,Massachusetts,2421,United States,171103
SIPLIZUMAB,KUW1QG1ZM3,Designated/Withdrawn,Public record,1276,siplizumab,7/15/2003,Treatment of T-cell lymphomas,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC",One MedImmune Way,,Gaithersburg,Maryland,20878,United States,170603
BRENTUXIMAB,C67ORA155P,Designated/Withdrawn,Public record,1277,Chimeric monoclonal antibody to CD30 (anti-CD30 antibody),7/18/2003,Treatment of Hodgkin's disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc","21823 30th Drive, Southeast",,Bothell,Washington,98021,United States,171303
CHOLIC ACID,G1JO7801AE,Designated/Approved,Public record,1278,cholic acid,7/18/2003,Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism,Designated/Approved,,Treatment of bile acid synthesis disorders due to single enzyme defects,3/17/2015,3/17/2022,Treatment of bile acid synthesis disorders due to single enzyme defects,"Retrophin, Inc.",777 Third Avenue,22nd Floor,New York,New York,10017,United States,170503
ERLOTINIB HYDROCHLORIDE,DA87705X9K,Designated,Public record,1280,Erlotinib Hydrochloride,7/18/2003,Treatment of malignant gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc",1 DNA Way,,South San Francisco,California,94080,United States,172003
FOSBRETABULIN,I5590ES2QZ,Designated,Public record,1281,Combretastatin A4 Phosphate,7/23/2003,"Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer",Designated,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Boulevard,Suite 210,South San Francisco,California,94080,United States,167503
INO-4995,3LM5SX2N4X,Designated,Public record,1282,"2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate",8/15/2003,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Inologic, Inc.","101 Elliott Ave., West",,Seattle,Washington,98119,United States,169003
EMRICASAN,P0GMS9N47Q,Designated,Public record,1286,"(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid",8/19/2003,Treatment of patients undergoing solid organ transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,Pfizer Global Research and Development,50 Pequot Avenue,,New London,Connecticut,6320,United States,169603
PRASTERONE,459AG36T1B,Designated,Public record,1287,Dehydroepiandrosterone (DHEA),8/19/2003,Replacement therapy in individuals with adrenal insufficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Paladin Labs, Inc.","6111 Royalmount Avenue, Suite 102",,Montreal,,,Canada,172303
GLUCARPIDASE,2GFP9BJD79,Designated/Approved,Public record,1288,glucarpidase,8/19/2003,Treatment of patients at risk of methotrexate toxicity,Designated/Approved,,Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.,1/17/2012,1/17/2019,,BTG International Inc.,5214 Maryland Way,Suite 405,Brentwood,Tennessee,37027,United States,163702
UKRAIN,6251Q9UK1S,Designated,Public record,1289,"5,5',5""-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride",8/20/2003,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Now Pharm AG,"241, route d'Arlon",,Luxembourg,,,Luxembourg,169303
STEM BROMELAIN,ZLM4P8929R,Designated,Public record,1290,anacaulase-bcdb,8/20/2003,"Debridement of acute, deep dermal burns in hospitalized patients",Designated/Approved,,eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns,12/28/2022,12/28/2029,eschar removal in hospitalized adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns,"MediWound, Ltd.",42 Hayarkon Street,,Yavne,,,Israel,156102
ECULIZUMAB,A3ULP0F556,Designated/Approved,Public record,1291,eculizumab,8/20/2003,Treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,3/16/2007,3/16/2014,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,173203
TALACTOFERRIN ALFA,7A055A9QRR,Designated,Public record,1292,talactoferrin alfa,8/20/2003,For the prevention of graft-versus-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.",8 Greenway Plaza,Suite 910,Houston,Texas,77046,United States,162102
TALACTOFERRIN ALFA,7A055A9QRR,Designated,Public record,1293,talactoferrin alfa,8/20/2003,For the treatment of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.",8 Greenway Plaza,Suite 910,Houston,Texas,77046,United States,165703
TINIDAZOLE,033KF7V46H,Designated/Approved,Public record,1294,Tinidazole,8/20/2003,Treatment of amebiasis,Designated/Approved,,Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage.,5/17/2004,5/17/2011,,"Presutti Laboratories, Inc.",1607 N. Douglas Ave.,,Arlington Heights,Illinois,60004,United States,173603
ATOMOXETINE HYDROCHLORIDE,57WVB6I2W0,Designated/Withdrawn,Public record,1295,Atomoxetine hydrochloride,8/26/2003,Treatment of Tourette's Syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly & Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,173003
IMEXON,8F63U28T2V,Designated/Withdrawn,Public record,1296,Imexon,11/1/2003,Treatment of pancreatic adenocarcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AmpliMed Corporation,4380 North Campbell Avenue,Suite 205,Tucson,Alaska,85718,United States,165903
ROSTAPORFIN,466G63QE7G,Designated,Public record,1297,tin ethyl etiopurpurin,11/4/2003,Prevention of access graft disease in hemodialysis patients,Designated,Not FDA Approved for Orphan Indication,,,,,Miravant Medical Technologies,336 Bollay Drive,,Goleta,California,93117,United States,168703
VAPREOTIDE,2PK59M9GFF,Designated,Public record,1298,vapreotide,11/4/2003,Treatment of acromegaly,Designated,Not FDA Approved for Orphan Indication,,,,,"H3 Pharma, Inc.","666 Sherbrooke Street West,",Suite 1400,Montreal,,,Canada,175203
AEOL-10150,KPKO7W46E8,Designated,Public record,1299,"[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride",11/4/2003,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Aeolus Pharmaceuticals, Inc.",PO Box 14287; 79 T.W. Alexander Dr.,Suite 200,Research Triangle Park,North Carolina,27709,United States,176703
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,1300,bevacizumab,11/6/2003,Treatment of renal cell carcinoma,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa,7/31/2009,7/31/2016,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,172903
CATRIDECACOG,NU23Q531G1,Designated/Approved,Public record,1301,coagulation factor XIII A-subunit (recombinant),11/6/2003,Prophylaxis of bleeding associated with congential factor XIII deficiency,Designated/Approved,,Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.,12/23/2013,12/23/2020,Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.,"Novo Nordisk, Inc.",800 Scudders Mill Rd.,,Plainsboro,New Jersey,8536,United States,174803
INFLIXIMAB,B72HH48FLU,Designated/Approved,Public record,1302,Infliximab,11/12/2003,Treatment of pediatric (0 to 16 years of age) Crohn's Disease,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy,5/19/2006,5/19/2013,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,175803
INFLIXIMAB,B72HH48FLU,Designated/Approved,Public record,1303,infliximab,11/12/2003,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy,9/23/2011,9/23/2018,,"Janssen Biotech, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,175903
RAXIBACUMAB,794PGL549S,Designated/Approved,Public record,1304,raxibacumab,11/12/2003,Treatment of anthrax,Designated/Approved,,"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,",12/14/2012,12/14/2019,,"Human Genome Sciences, Inc.",14200 Shady Grove Road,,Rockville,Maryland,20850,United States,175503
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated,Public record,1306,human gammaglobulin,11/14/2003,Treatment of idiopathic inflammatory myopathies,Designated,Not FDA Approved for Orphan Indication,,,,,"Latona Life Sciences, Inc.",10 Village St.,,Mills,Massachusetts,2054,United States,176003
MONARSEN,4TT3V55XYT,Designated/Withdrawn,Public record,1307,monarsen,11/14/2003,Treatment of myasthenia gravis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bioline Rx, Ltd.",19 Hartum Street,P. O. Box 45158,Jerusalem,,,Israel,173903
ABAGOVOMAB,3YK0326U7X,Designated/Withdrawn,Public record,1309,abagovomab,11/25/2003,Treatment of epithelial ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Menarini Ricerche S.p.A.,Via Tito Speri 10,Pomezia,Roma,,,Italy,171803
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,1310,Cyclosporine,11/25/2003,Prophylaxis of organ rejection in patients receiving allogeneic lung transplant,Designated,Not FDA Approved for Orphan Indication,,,,,"APT Pharmaceuticals, Inc.",700 Airport Blvd.,Suite 350,Burlingame,California,94010,United States,180103
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,1311,Cyclosporine,11/25/2003,Treatment of acute rejection in patients requiring allogenic lung transplants,Designated,Not FDA Approved for Orphan Indication,,,,,"APT Pharmaceuticals, Inc.",700 Airport Blvd.,Suite 350,Burlingame,California,94010,United States,176303
HYDROXOCOBALAMIN,Q40X8H422O,Designated/Approved,Public record,1312,Hydroxocobalamin,11/25/2003,Treatment of acute cyanide poisoning,Designated/Approved,,Treatment on known or suspected cyanide poisoning,12/15/2006,12/15/2013,,"SERB, S.A.",480 Avenue Louise,,Brussels,Brussels,,Belgium,177403
ICATIBANT,7PG89G35Q7,Designated/Approved,Public record,1313,icatibant,11/25/2003,Treatment of angioedema,Designated/Approved,,Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older,8/25/2011,8/25/2018,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,176203
ATIPRIMOD,MG7D3QD743,Designated,Public record,1314,"2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate",12/2/2003,Treatment of mulitple myeloma and associated bone resorption,Designated,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.",2 Executive Drive,Suite 450,Somerset,New Jersey,8873,United States,167103
BACLOFEN,H789N3FKE8,Designated,Public record,1315,baclofen,12/2/2003,Treatment of dystonia,Designated,Not FDA Approved for Orphan Indication,,,,,Medtronic Neurological,710 Medtronic Parkway NE,,Minneapolis,Minnesota,55432,United States,174703
TRANILAST,HVF50SMY6E,Designated,Public record,1316,Tranilast,12/2/2003,For the treatment of maligant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Angiogen Pharmaceuticals, Pty. Ltd.","Level 31, ABN AMRO Tower",88 Phillip Street,Sydney,,,Australia,176803
ABT-510 ACETATE,X1616TFEWT,Designated/Withdrawn,Public record,1318,N-acetyl-sarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl_L-prolylethylaminde acetate,12/9/2003,Treatment of soft tissue sarcoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,177803
DEPELESTAT,2M3V3B8OEA,Designated,Public record,1319,recombinant human neutrophil inhibitor (hNE),12/9/2003,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Dyax Corporation,300 Technology Square,,Cambridge,Massachusetts,2139,United States,173503
MECASERMIN RINFABATE,NZ8M50KKRG,Designated,Public record,1320,rhIGF-I/rhIGFBP-3,12/9/2003,"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)",Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",10 Finderne Ave,Building 10,Bridgewater,New Jersey,8807,United States,168903
FORODESINE HYDROCHLORIDE,6SN82Y9U73,Designated,Public record,1321,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride",1/29/2004,Treatment of T-cell non-Hodgkin's lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Mundipharma Research Limited,Cambridge Science Park,Cambridge CB4 0GW,England,,,United Kingdom,172403
YTTRIUM Y-90 CLIVATUZUMAB TETRAXETAN,2L271110ED,Designated/Withdrawn,Public record,1322,90Y-hPAMA4,1/29/2004,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,178503
CHENODIOL,0GEI24LG0J,Designated,Public record,1323,Chenodeoxycholic acid,1/29/2004,Treatment of cerebrotendinous xanthomatosis,Designated,Not FDA Approved for Orphan Indication,,,,,Dr. Falk Pharma GmbH,Leinenweberstrasse 5,,Freiburg,,,Germany,175303
PIT VIPER (CROTALINAE) IMMUNE GLOBULIN ANTIVENIN (EQUINE),92VV7G83ED,Designated/Approved,Public record,1324,crotalidae immune F(ab')2 (equine),1/29/2004,Treatment of envenomation by Crotaline snakes,Designated/Approved,,For the management of adult and pediatric patients with North American Pit Viper envenomation,4/1/2021,,,"Rare Disease Therapeutics, Inc.",12975 Brookprinter Place,Suite 170,Poway,California,92064,United States,177503
PIT VIPER (CROTALINAE) IMMUNE GLOBULIN ANTIVENIN (EQUINE),92VV7G83ED,Designated/Approved,Public record,1325,crotalidae immune F(ab')2 (equine),1/29/2004,Treatment of envenomation by Crotaline snakes,Designated/Approved,,Management of adult and pediatric patients with North American rattlesnake envenomation,5/6/2015,5/6/2022,Management of adult and pediatric patients with North American rattlesnake envenomation,"Rare Disease Therapeutics, Inc.",12975 Brookprinter Place,Suite 170,Poway,California,92064,United States,177503
LENALIDOMIDE,F0P408N6V4,Designated/Approved,Public record,1326,lenalidomide,1/29/2004,Treatment of myelodysplastic syndromes,Designated/Approved,,Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities,12/27/2005,12/27/2012,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,180303
HEPARIN,T2410KM04A,Designated,Public record,1327,oral unfractionated heparin,1/29/2004,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Technologies, Inc.","863 Mitten Road, Suite 101",,Burlingame,California,94010,United States,178103
VELAFERMIN,6Z25C35927,Designated/Withdrawn,Public record,1328,recombinant human fibroblast growth factor-20,1/29/2004,Treatment of radiation induced oral mucositis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,CuraGen Corporation,322 East Main Street,,Branford,Connecticut,6405,United States,179203
RITUXIMAB,4F4X42SYQ6,Designated/Approved,Public record,1329,rituximab,1/29/2004,Treatment of chronic lymphocytic leukemia,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide,2/18/2010,2/18/2017,,"Genentech, Inc.",1DNA Way,MS 241A,South San Francisco,California,94080,United States,177603
SAPROPTERIN,EGX657432I,Designated/Approved,Public record,1330,sapropterin,1/29/2004,Treatment of hyperphenylalaninemia,Designated/Approved,,Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.,12/13/2007,12/13/2014,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,94949,United States,181503
HUMAN STAPHYLOCOCCUS AUREUS IMMUNE GLOBULIN,SX5Y4A7UBI,Designated,Public record,1331,Staphylococcus aureus Immune Globulin (Human),1/29/2004,Prophylaxis against Staphylococcus aureus infections in low birth weight neonates,Designated,Not FDA Approved for Orphan Indication,,,,,Biotest Pharmaceuticals Corporation,"5800 Park of Commerce Blvd, NW",,Boca Raton,Florida,33487,United States,178703
BRENTUXIMAB,C67ORA155P,Designated/Withdrawn,Public record,1332,Chimeric monoclonal antibody to CD30 (anti-CD30 antibody),2/18/2004,Treatment of CD30 positive T-cell lymphomas,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,178203
MIGALASTAT HYDROCHLORIDE,CLY7M0XD20,Designated,Public record,1333,migalastat hydrochloride,2/25/2004,Treatment of Fabry Disease,Designated/Approved,,GALAFOLD¿ is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data,8/10/2018,8/10/2025,GALAFOLD¿ is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data,"Amicus Therapeutics, Inc.",1 Cedarbrook Drive,,Cranbury,New Jersey,8512,United States,180003
PENTETATE ZINC TRISODIUM,NXU65IC8PG,Designated,Public record,1334,Trisodium zinc Diethylenetriaminepentaacetate,2/27/2004,"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.",Designated,Not FDA Approved for Orphan Indication,,,,,CustomCare Pharmacy,5710 Hoover Blvd,,Tampa,Florida,33634,United States,181003
BECATECARIN,A60X6MBU6G,Designated,Public record,1335,DEAE-rebeccamycin,3/1/2004,Treatment of bile duct tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Helsinn Healthcare SA,"Via Pian Scairolo, 6912 Pazzallo",,Lugano,,,Switzerland,179903
ALPHA-1-ACID GLYCOPROTEIN,31V857ZRPY,Designated/Withdrawn,Public record,1336,Alpha-1-acid glycoprotein,3/5/2004,Treatment of cocaine overdose,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bio Products Laboratory,Dagger Lane,,Borehamwood,,,United Kingdom,173103
PIRFENIDONE,D7NLD2JX7U,Designated/Approved,Public record,1337,pirfenidone,3/5/2004,Treatment of idiopathic pulmonary fibrosis,Designated/Approved,,Treatment of idiopathic pulmonary fibrosis,10/15/2014,10/15/2021,Treatment of idiopathic pulmonary fibrosis,Genentech,1 DNA Way,,South San Francisco,California,94080,United States,177903
SUSOCTOCOG ALFA,6892UQT2GK,Designated/Approved,Public record,1339,"antihemophilic factor (recombinant), porcine sequence",3/16/2004,Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII,Designated/Approved,,Treatment of bleeding episodes in adults with acquired hemophilia A.,10/23/2014,10/23/2021,Treatment of bleeding episodes in adults with acquired hemophilia A.,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,181403
OCRIPLASMIN,7V6HE3DM5A,Designated,Public record,1340,"rh-microplasmin, ocriplasmin",3/16/2004,Adjunct to surgery in cases of pediatric vitrectomy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ThromboGenics Inc.,Unit 14,Walkinstown Avenue,Dublin 12,,,Ireland,180703
ROFECOXIB,0QTW8Z7MCR,Designated,Public record,1341,rofecoxib,3/16/2004,Treatment of juvenile rheumatoid arthritis,Designated,Not FDA Approved for Orphan Indication,,,,,"MERCK & Co., Inc.",126 East Lincoln Ave.,,Rahway,New Jersey,7065,United States,181703
SOMATROPIN,NQX9KB6PCL,Designated,Public record,1342,Somatropin,3/16/2004,Treatment of patients with HIV-associated adipose redistribution syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,169403
VORINOSTAT,58IFB293JI,Designated/Approved,Public record,1343,vorinostat,3/16/2004,Treatment of T-cell non-Hodgkin's lymphoma,Designated/Approved,,"Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies.",10/6/2006,10/6/2013,,"Merck & Co., Inc.","P. O. Box 2000, RY 32-605",,Rahway,New Jersey,7065,United States,174203
ALPHA-1-ACID GLYCOPROTEIN,31V857ZRPY,Designated/Withdrawn,Public record,1344,Alpha-1-acid glycoprotein,3/17/2004,Treatment of tricyclic antidepressant poisoning,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bio Products Laboratory,Dagger Lane,,Borehamwood,,,United Kingdom,172803
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,1346,sodium thiosulfate,3/17/2004,Prevention of platinum-induced ototoxicity in pediatric patients,Designated/Approved,,"To reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors",9/20/2022,9/20/2029,"To reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors","Fennec Pharmaceuticals, Inc.",PO Box 13628,68 T.W. Alexander Drive,Research Triangle Park,North Carolina,27709,United States,177303
VORINOSTAT,58IFB293JI,Designated/Withdrawn,Public record,1347,vorinostat,3/17/2004,Treatment of mesothelioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","P. O. Box 2000, RY 32-605",,Rahway,New Jersey,7065,United States,177203
DEXRAZOXANE,048L81261F,Designated/Approved,Public record,1348,dexrazoxane,3/25/2004,Treatment of anthracycline extravasation during chemotherapy,Designated/Approved,,Treatment of extravasation resulting from IV anthracycline chemotherapy,9/6/2007,9/6/2014,,"Clinigen, Inc.",790 Township Line Road,Suite 120,Yardley,Pennsylvania,19067,United States,181103
IDEBENONE,HB6PN45W4J,Designated,Public record,1349,idebenone,3/25/2004,Treatment of Friedreich's ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,Santhera Pharmaceuticals (Switzerland) Limited,Hammerstrass 49,CH-4410 Liestal,Liestal,,,Switzerland,178303
VAPREOTIDE,2PK59M9GFF,Designated,Public record,1350,Vapreotide,4/6/2004,Treatment of symptomatic carcinoid tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"H3 Pharma, Inc.",666 Sherbrooke Street West,Suite 1400,Montreal,,,Canada,175403
HYDRALAZINE,26NAK24LS8,Designated,Public record,1351,Hydralazine,4/9/2004,Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy,Designated,Not FDA Approved for Orphan Indication,,,,,Bioniche Pharma USA LLC,272 E. Deerpath Road,Suite 304,Lake Forest,Illinois,60045,United States,166703
PENTETATE TRISODIUM,79FZD535SC,Designated,Public record,1352,pentetate trisodium,4/12/2004,"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.",Designated,Not FDA Approved for Orphan Indication,,,,,Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG,Goerzallee 253,,Berlin,,,Germany,183004
UBIQUINOL,M9NL0C577Y,Designated,Public record,1353,ubiquinol,4/12/2004,Treatment of Huntington's Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Gel-Tec, Division of Tishcon Corp.",30 New York Avenue,P. O. Box 331,Westbury,New York,11590,United States,179403
UBIDECARENONE,EJ27X76M46,Designated,Public record,1354,"Ubiquinol, coenzyme Q10, ubiquinone",4/12/2004,Treatment of pediatric congestive heart failure,Designated,Not FDA Approved for Orphan Indication,,,,,"Gel-Tec, Division of Tishcon Corporation",30 New York Avenue,P. O. Box 331,Westbury,New York,11590,United States,174603
DEFERITRIN,T69Y9LDN44,Designated/Withdrawn,Public record,1355,Deferitrin,4/14/2004,Treatment of iron overload,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,153 Second Avenue,,Waltham,Massachusetts,2451,United States,178603
PENTETIC ACID,7A314HQM0I,Designated,Public record,1356,diethylenetriaminepentaacetate (DPTA),4/14/2004,"For treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.",Designated,Not FDA Approved for Orphan Indication,,,,,CIS-US,10 DeAngelo Drive,,Bedford,Massachusetts,1730,United States,180203
ETARACIZUMAB,41W9MFI160,Designated/Withdrawn,Public record,1357,etaracizumab,4/14/2004,"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC",One MedImmune Way,,Gaithersburg,Maryland,20878,United States,178403
FLUOXETINE,01K63SUP8D,Designated,Public record,1358,Fluoxetine,4/14/2004,Treatment of body dysmorphic disorder in children and adolescents,Designated,Not FDA Approved for Orphan Indication,,,,,"Hollander, Eric MD",The Mount Sinai School of Medicine,One Gustave L. Levy Place,New York,New York,10029,United States,183504
TEMOCILLIN SODIUM,96IIP39ODH,Designated,Public record,1359,temocillin sodium,4/21/2004,Treatment of pulmonary infections caused by Burkholderia cepacia,Designated,Not FDA Approved for Orphan Indication,,,,,Belpharma S.A.,"5, Rue de Bonnevoie",L-2160,Luxembourg,,,Germany,182903
MUPARFOSTAT,P2BKS6T40H,Designated,Public record,1360,mannopentaose phosphate sulfate,4/27/2004,"Treatment of high-risk Stage II, Stage III, and Stage IV melanoma",Designated,Not FDA Approved for Orphan Indication,,,,,Medigen Biotechnology Corp.,"14F, No. 3, Yuancyu St.",Nangang District,Taipei City 11503,,,Taiwan,179603
PENTETIC ACID,7A314HQM0I,Designated/Approved,Public record,1361,Diethylenetriaminepentaacetic acid (DTPA),4/28/2004,"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.",Designated/Approved,,"Treatment of internal contamination with plutonium, americium or curium",8/11/2004,8/11/2011,,Hameln Pharmaceuticals gmbh,Langes Feld 13,,Hameln,,,Germany,186804
IMMUNE GLOBULIN INTRAVENOUS (HUMAN),,Designated,Public record,1362,Immune Globulin Intravenous (human),5/4/2004,Treatment for Guillain Barre Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,ZLB Bioplasma AG,Wankdorfstrasse 10,,CH-3000 Bern 22,,,Switzerland,184704
ICATIBANT,7PG89G35Q7,Designated/Withdrawn,Public record,1363,icatibant,5/5/2004,Treatment of burn patients hospitalized with burn-induced edema,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Shire Human Genetic Therapies,700 Main Street,,Cambridge,Massachusetts,2139,United States,184804
DIETHYLNORSPERMINE,HLI827Z1ST,Designated/Withdrawn,Public record,1364,Diethylnorspermine (DENSPM),5/25/2004,Treatment for hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,153 Second Avenue,,Waltham,Massachusetts,2451,United States,182803
MEPOLIZUMAB,90Z2UF0E52,Designated,Public record,1365,mepolizumab,5/28/2004,For treatment of hypereosinophilic syndrome,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,9/25/2020,9/25/2027,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC,1250 S. Collegeville Road,,Collegeville,Pennsylvania,19426,United States,182103
THYMOSIN .BETA.-4,549LM7U24W,Designated,Public record,1366,Thymosin beta 4,5/28/2004,Treatment of epidermolysis bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,"HLB Therapeutics Co., Ltd","22nd FL, Parkview Tower","248 Jungjail-ro, Bundang-gu,",Seongnam-si,Gyeonggi-do,,South Korea,165302
IPILIMUMAB,6T8C155666,Designated/Approved,Public record,1367,ipilimumab,6/3/2004,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",10/28/2015,10/28/2022,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,8543,United States,177703
IPILIMUMAB,6T8C155666,Designated/Approved,Public record,1368,ipilimumab,6/3/2004,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",Designated/Approved,,Treatment of unresectable or metastatic melanoma,3/25/2011,3/25/2018,,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,8543,United States,177703
IPILIMUMAB,6T8C155666,Designated/Approved,Public record,1369,ipilimumab,6/3/2004,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older),7/21/2017,7/21/2024,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,8543,United States,177703
IPILIMUMAB,6T8C155666,Designated/Approved,Public record,1370,ipilimumab,6/3/2004,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",Designated/Approved,,"In combination with nivolumab, for the treatment of unresectable or metastatic melanoma in adult patients",5/25/2021,,,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,8543,United States,177703
QUININE SULFATE,KF7Z0E0Q2B,Designated/Approved,Public record,1371,quinine Sulfate,6/3/2004,Treatment of malaria,Designated/Approved,,Treatment of uncomplicated Plasmodium falciparum malaria,8/12/2005,8/12/2012,,"AR Holding Company, Inc.",1100 Orthodox Street,,Philadelphia,Pennsylvania,19124,United States,185004
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated/Approved,Public record,1372,Coagulation factor VIIa (recombinant),6/18/2004,"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors",Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX,8/12/2005,8/12/2012,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,186104
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated/Approved,Public record,1373,coagulation factor VIIa (recombinant),6/18/2004,Treatment of bleeding episodes in Glanzmann's thrombasthenia,Designated/Approved,,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.",7/2/2014,7/2/2021,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.",Novo Nordisk Inc.,800 Scudders Mill Rd.,,Plainsboro,New Jersey,8536,United States,186004
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated,Public record,1374,Coagulation factor VIIa (recombinant),6/18/2004,Prevention of bleeding episodes in Glanzmann's thrombasthenia,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",100 College Road West,,Princeton,New Jersey,8540,United States,190004
LIAROZOLE,K0Q29TGV9Y,Designated/Withdrawn,Public record,1375,liarozole,6/18/2004,Treatment of congenital ichthyosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Stiefel Laboratories, Inc.",20 T.W. Alexander Drive,P. O. Box 14910,Research Triangle Park,North Carolina,27709,United States,183904
PLITIDEPSIN,Y76ID234HW,Designated/Withdrawn,Public record,1376,Plitidepsin,6/18/2004,Treatment of acute lymphoblastic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"PharmaMar USA, Inc",University Park at M.I.T.,Sidney Street,Cambridge,Massachusetts,2139,United States,187404
SARSAGENIN,CFS802C28F,Designated/Withdrawn,Public record,1377,sarsasapogenin,6/18/2004,Treatment of amyotrophic lateral sclerosis (ALS),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Phytopharm plc,Corpus Christi House,,Godmanchester,Cambridgeshire,,United Kingdom,185704
TIPIFARNIB,MAT637500A,Designated,Public record,1380,Tipifarnib,7/6/2004,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical Research & Dev.,920 U.S. Highway 202,,Raritan,New Jersey,8869,United States,187104
FRESOLIMUMAB,375142VBIA,Designated/Withdrawn,Public record,1381,"human anti-transforming growth factor-B1,2,3",7/9/2004,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,187304
MELATONIN,JL5DK93RCL,Designated,Public record,1382,Melatonin,7/9/2004,Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception,Designated,Not FDA Approved for Orphan Indication,,,,,"Neurim Pharmaceuticals, Ltd.",8 Hanechoshet St.,,Tel-Aviv,,,Israel,181203
"""AMBRISENTAN, (?)-""",7B43003091,Designated/Approved,Public record,1383,ambrisentan,7/16/2004,Treatment of pulmonary arterial hypertension,Designated/Approved,,Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening,6/15/2007,6/15/2014,,Gilead Colorado,7575 West 103rd Avenue,Suite 102,Westminister,Colorado,80021,United States,183604
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Approved,Public record,1384,C1 esterase inhibitor (human),7/16/2004,Treatment of angioedema,Designated/Approved,,"CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).",6/20/2018,6/20/2025,CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE).,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,185804
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated/Approved,Public record,1385,C1 esterase inhibitor (human),7/16/2004,Treatment of angioedema,Designated/Approved,,Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE),10/10/2008,10/10/2015,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,185804
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated/Approved,Public record,1386,Coagulation Factor VIIa (Recombinant),7/16/2004,Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX,Designated/Approved,,Treatment of bleeding episodes in surgical interventions or invasive procedures in patients with acquired hemophilia,10/13/2006,10/13/2013,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,186204
DORIPENEM,BHV525JOBH,Designated,Public record,1387,Doripenem,7/16/2004,Treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with Pseudomonas aeruginosa or Burkholderia cepacia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Shionogi, Inc.",300 Campus Drive,Suite 300,Florham Park,New Jersey,7932,United States,188104
POSACONAZOLE,6TK1G07BHZ,Designated,Public record,1389,posaconazole,7/16/2004,Treatment of zygomycosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,187604
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated/Approved,Public record,1390,Coagulation factor VIIa (recombinant),7/21/2004,Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia,10/13/2006,10/13/2013,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,190104
IMMUNE GLOBULIN (HUMAN),,Designated/Approved,Public record,1391,Immune Globulin (Human),7/27/2004,Treatment of chronic inflammatory demyelinating polyneuropathy,Designated/Approved,,Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse,9/12/2008,9/12/2015,,"Grifols Therapeutics, Inc.",8368 US 70 Busines Hwy West,,Clayton,North Carolina,27520,United States,185604
IMMUNE GLOBULIN HUMAN,,Designated/Approved,Public record,1391,Immune Globulin (Human),7/27/2004,Treatment of chronic inflammatory demyelinating polyneuropathy,Designated/Approved,,Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse,9/12/2008,9/12/2015,,"Grifols Therapeutics, Inc.",8368 US 70 Busines Hwy West,,Clayton,North Carolina,27520,United States,185604
PASIREOTIDE,98H1T17066,Designated/Withdrawn,Public record,1392,Multi-ligand somatostatin analog,7/27/2004,"Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,188804
EFAPROXIRAL,J81E81G364,Designated,Public record,1393,efaproxiral,7/28/2004,Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Allos Therapeutics, Inc.",11080 CirclePoint Road,Suite 200,Westminster,Colorado,80020,United States,158802
FORODESINE HYDROCHLORIDE,6SN82Y9U73,Designated,Public record,1394,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride",8/10/2004,"Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia",Designated,Not FDA Approved for Orphan Indication,,,,,Mundipharma Research Ltd.,Cambridge Science Park,,Cambridge CB4 0GW,,,United Kingdom,190504
NELARABINE,60158CV180,Designated/Approved,Public record,1395,nelarabine,8/10/2004,Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma,Designated/Approved,,Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,10/28/2005,10/28/2012,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,184404
DEXANABINOL,R6VT8U5372,Designated,Public record,1396,dexanabinol,8/11/2004,For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury,Designated,Not FDA Approved for Orphan Indication,,,,,Pharmos Corporation,99 Wood Avenue,Suite 311,Iselin,New Jersey,8830,United States,179803
FORODESINE HYDROCHLORIDE,6SN82Y9U73,Designated,Public record,1397,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride",8/13/2004,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Mundipharma Research Limited,Cambridge Science Park,Cambridge CB4 0GW,England,,,United Kingdom,190404
ARFOLITIXORIN,Z8R4A37V9Q,Designated,Public record,1398,"(6R,S)5,10-methylene-tetrahydrofolic acid",8/13/2004,For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Adventrx Pharmaceuticals, Inc.",6725 Mesa Ridge Road,Suite 100,San Diego,California,92121,United States,189304
DACETUZUMAB,UT59FF4T5X,Designated,Public record,1399,dacetuzumab,8/13/2004,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,188004
ZANOLIMUMAB,HG3L8885M0,Designated,Public record,1400,human anti-CD4 monoclonal antibody,8/13/2004,Treatment of mycosis fungoides,Designated,Not FDA Approved for Orphan Indication,,,,,"Emergent Product Development Seattle, LLC",,2401 Fourth Avenue,Seattle,Washington,98121,United States,188504
IMPLITAPIDE,Q70OH404HR,Designated/Withdrawn,Public record,1401,Implitapide,8/13/2004,Treatment of homozygous familial hypercholesterolemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Medical Research Laboratories International,2 Tesseneer Drive,,Highland Heights,Kentucky,41076,United States,188904
CPG-52852,6PJC3KPK6S,Designated/Withdrawn,Public record,1402,"N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide",8/13/2004,Treatment of stages IIB-IV melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",50 Pequot,6025-A3106,New London,Connecticut,6320,United States,176603
ILOPROST,JED5K35YGL,Designated/Approved,Public record,1403,Iloprost inhalation solution,8/17/2004,Treatment of pulmonary arterial hypertension,Designated/Approved,,Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms,12/29/2004,12/29/2011,,"CoTherix, Inc.",5000 Shoreline Court,,South San Francisco,California,94080,United States,186904
MECHLORETHAMINE,50D9XSG0VR,Designated/Approved,Public record,1404,meclorethamine,8/17/2004,Treatment of mycosis fungoides,Designated/Approved,,Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.,8/23/2013,8/23/2020,Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.,Helsinn Birex Pharmaceuticals Ltd.,Damastown,,Mulhuddart,County Dublin,,Ireland,188404
IMPLITAPIDE,Q70OH404HR,Designated/Withdrawn,Public record,1406,Implitapide,8/19/2004,Treatment of patients with Fredrickson type I or V hyperlipoproteinemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Medical Research Laboratories International,2 Tesseneer Drive,,Highland Heights,Kentucky,41076,United States,188704
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,1408,Alpha1-Proteinase Inhibitor (Human),9/1/2004,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.,7 Sapir Street,,Ness Ziona,,,Israel,190704
ATALUREN,K16AME9I3V,Designated/Withdrawn,Public record,1409,ataluren,9/1/2004,For use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,192004
TANESPIMYCIN,4GY0AVT3L4,Designated,Public record,1410,17-allylamino-17-demethoxygeldanamycin (17-AGG),9/3/2004,Treatment of chronic myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,Research & Development,5 Research Parkway,Wallingford,Connecticut,6492,United States,191304
PHENYLACETYLGLUTAMINE,92358I79RG,Designated,Public record,1411,A10 & AS2-1 Antineoplaston,9/3/2004,Treatment for patients with brain stem glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Burzynski Research Institute, Inc.",9432 Old Katy Road,,Houston,Texas,77055,United States,189804
PHENYLACETIC ACID,ER5I1W795A,Designated,Public record,1411,A10 & AS2-1 Antineoplaston,9/3/2004,Treatment for patients with brain stem glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Burzynski Research Institute, Inc.",9432 Old Katy Road,,Houston,Texas,77055,United States,189804
ANTINEOPLASTON A10,16VY3TM7ZO,Designated,Public record,1411,A10 & AS2-1 Antineoplaston,9/3/2004,Treatment for patients with brain stem glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Burzynski Research Institute, Inc.",9432 Old Katy Road,,Houston,Texas,77055,United States,189804
URSODIOL,724L30Y2QR,Designated,Public record,1413,Buffered Ursodeoxycholic Acid,9/3/2004,Treatment of pruritus in patients with Alagille Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Digestive Care, Inc.",1120 Win Drive,,Bethlehem,Pennsylvania,18017,United States,191204
PR1 LEUKEMIA PEPTIDE VACCINE,54XUF2TZ7G,Designated,Public record,1415,Nine amino acid polypeptide derived from proteinase 3,9/3/2004,Treatment of chronic myelogenous leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,The Vaccine Company,P. O. Box 93921,,Carmel,California,93921,United States,187704
PR1 LEUKEMIA PEPTIDE VACCINE,54XUF2TZ7G,Designated,Public record,1416,Nine amino acid polypeptide derived from proteinase 3,9/3/2004,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,The Vaccine Company,P. O. Box 93921,,Carmel,California,93921,United States,187804
PR1 LEUKEMIA PEPTIDE VACCINE,54XUF2TZ7G,Designated,Public record,1417,Nine amino acid polypeptide derived from proteinase 3,9/3/2004,Treatment of myelodysplastic syndromes requiring therapy,Designated,Not FDA Approved for Orphan Indication,,,,,The Vaccine Company,P. O. Box 93921,,Carmel,California,93921,United States,187904
TANESPIMYCIN,4GY0AVT3L4,Designated,Public record,1418,Tanespimycin,9/9/2004,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,6492,United States,191504
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated/Approved,Public record,1419,Coagulation factor VIIa (recombinant),9/10/2004,Prevention of bleeding episodes in patients with congenital Factor VII deficiency,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency,7/11/2005,7/11/2012,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,189904
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated/Approved,Public record,1420,Coagulation factor VIIa (recombinant),9/10/2004,Treatment of bleeding episodes in patients with congenital factor VII deficiency,Designated/Approved,,Treatment of bleeding episodes in patients with Factor VII Deficiency,7/11/2005,7/11/2012,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,8540,United States,185904
TYROSERLEUTIDE,L9TIM50J8N,Designated,Public record,1421,L-tyrosine-L-serine-L-leucine,9/10/2004,Treatment of hepatocellular carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,CMS Peptides Patent Holding Company Limited,"Unit 2106, 21st Floor, Island Place Tower",510 King's Rd,North Point,,,,190604
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated/Withdrawn,Public record,1422,Immune Globulin Subcutaneous (Human),9/22/2004,Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,19406,United States,180503
IRATUMUMAB,AYH22O1B1U,Designated,Public record,1423,Human anti-CD30 monoclonal antibody,9/27/2004,Treatment of Hodgkin's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Bristol-Myers Squibb, Inc.",519 Route 173 West,,Bloomsbury,New Jersey,8804,United States,192904
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,1424,Nitric oxide,9/27/2004,To reduce the risk of chronic lung disease in premature neonates,Designated,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Pharmaceuticals Ireland Ltd.,College Business & Technology Park,Cruiserath Road,Blanchardstown,Dublin,,Ireland,192104
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,1425,thalidomide,9/27/2004,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,187204
ABT-751,WDT5V5OB9F,Designated/Withdrawn,Public record,1426,N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide,9/30/2004,Treatment of neuroblastoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,188604
PLITIDEPSIN,Y76ID234HW,Designated,Public record,1427,plitidepsin,9/30/2004,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"PharmaMar USA, Inc.",205 East 42nd St.,Suite 15003,New York,New York,10017,United States,191604
ROMIDEPSIN,CX3T89XQBK,Designated/Approved,Public record,1428,romidepsin,9/30/2004,Treatment of non-Hodgkin T-cell lymphomas,Designated/Approved,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy,11/5/2009,11/5/2016,,Celgene Corporation,One Broadway,14th Floor,Cambridge,Massachusetts,2142,United States,193404
ROMIDEPSIN,CX3T89XQBK,Designated/Approved,Public record,1429,romidepsin,9/30/2004,Treatment of non-Hodgkin T-cell lymphomas,Designated/Approved,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy,6/16/2011,6/16/2018,,Celgene Corporation,One Broadway,14th Floor,Cambridge,Massachusetts,2142,United States,193404
TRABECTEDIN,ID0YZQ2TCP,Designated/Approved,Public record,1430,trabectedin,9/30/2004,Treatment of soft tissue sarcoma,Designated/Approved,,For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen,10/23/2015,10/23/2022,For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,193604
OBATOCLAX MESYLATE,39200FJ43J,Designated/Withdrawn,Public record,1431,obatoclax mesylate,10/8/2004,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",41 Moores Road,P. O. Box 4011,Frazer,Pennsylvania,19355,United States,193804
RUFINAMIDE,WFW942PR79,Designated/Approved,Public record,1432,rufinamide,10/8/2004,Treatment of Lennox-Gastaut Syndrome.,Designated/Approved,,Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.,11/14/2008,11/14/2015,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,7677,United States,193504
SORAFENIB,9ZOQ3TZI87,Designated/Approved,Public record,1433,Sorafenib,10/8/2004,Treatment of renal cell carcinoma.,Designated/Approved,,Treatment of patients with advanced renal cell carcinoma,12/20/2005,12/20/2012,,Bayer Pharmaceutical Corporation,400 Morgan Lane,,West Haven,Connecticut,6516,United States,185204
TEMOZOLOMIDE,YF1K15M17Y,Designated/Withdrawn,Public record,1434,Temozolomide,10/18/2004,Treatment of newly diagnosed high grade glioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Merck & Company,2000 Galloping Hill Road,,Kenilworth,New Jersey,7033,United States,193904
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,1435,bevacizumab,10/20/2004,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.","1 DNA Way, MS #242",,South San Francisco,California,94080,United States,193704
LAROMUSTINE,14J2G0U3NQ,Designated,Public record,1436,laromustine,10/21/2004,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Vion Pharmaceuticals, Inc.",Four Science Park,,New Haven,Connecticut,6511,United States,194104
PI-0824,UG5KU6AQ0Z,Designated,Public record,1437,Desmoglein 3 synthetic peptide (PI-0824),10/26/2004,Treatment of pemphigus vulgaris,Designated,Not FDA Approved for Orphan Indication,,,,,"Peptimmune, Inc.",64 Sidney Street,,Cambridge,Massachusetts,2139,United States,190904
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,1438,Cyclosporin A,10/29/2004,Treatment of amyotrophic lateral sclerosis and its variants,Designated,Not FDA Approved for Orphan Indication,,,,,"Maas Biolab,LLC",Tecnology Ventures Corporation Technopolis,"1155 University Blvd., SE",Albuquerque,New Mexico,87106,United States,194704
TERLIPRESSIN,7Z5X49W53P,Designated,Public record,1439,terlipressin,10/29/2004,Treatment of Hepatorenal Syndrome,Designated/Approved,,To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function,9/14/2022,9/14/2029,To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function,Mallinckrodt Pharmaceuticals Ireland Ltd,College Business & Technology Park,Cruiserath Road,"Blanchardstown, Dublin, Ireland D15 TX2V",,,Ireland,191804
GOLIMUMAB,91X1KLU43E,Designated/Withdrawn,Public record,1440,golimumab,11/2/2004,Treatment of chronic sarcoidosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,194204
SITAXENTAN SODIUM,6V9JH46E20,Designated,Public record,1442,Sitaxsentan Sodium,11/2/2004,For the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.,Designated,Not FDA Approved for Orphan Indication,,,,,Pfizer Global Research and Development,50 Pequot Avenue 6025-B4137,,New London,Connecticut,6320,United States,180803
NIMOTUZUMAB,6NS400BXKH,Designated,Public record,1443,Nimotuzumab,11/17/2004,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,InnoKeys PTE Ltd.,26 Bukit Batok East Avenue 2,,#03-10,,,Singapore,192504
Potassium iodide,1C4QK22F9J,Designated/Approved,Public record,1444,Potassium Iodide Oral Solution,11/17/2004,For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine,Designated/Approved,,For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine,1/12/2005,,,"Fleming & Company, Pharmaceuticals",1733 Gilsinn Lane,,Fenton,Missouri,63026,United States,190304
PORFIMER SODIUM,Y3834SIK5F,Designated,Public record,1445,Porfimer sodium,11/18/2004,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Concordia Laboratories, Inc., Sarl",8-10 Avenue de la Gare - L-1610,,Luxembourg,Grand Duchy of Luxembourg,,Luxembourg,191904
ARCHEXIN,4TEW51C830,Designated,Public record,1446,20-mer oligonucleotide complementary to Akt mRNA,12/1/2004,Treatment of renal cell carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,20850,United States,195704
ARCHEXIN,4TEW51C830,Designated,Public record,1447,20-mer oligonucleotide complementary to Akt mRNA,12/1/2004,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,20850,United States,195504
INTETUMUMAB,GQE1BJE2NI,Designated/Withdrawn,Public record,1448,human anti-integrin receptor avb3/avb5 monoclonal antibody,12/1/2004,"Treatment of patients with high-risk stage II, stage III, and stage IV malignant melanoma",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,173803
INO-1001,55E08EN074,Designated,Public record,1449,"(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid",12/8/2004,Prevention of post-operative complications of aortic anuerysm surgical repair,Designated,Not FDA Approved for Orphan Indication,,,,,Inotek Pharmaceuticals Corporation,100 Cummings Center,,Beverly,Massachusetts,1915,United States,195404
ARCHEXIN,4TEW51C830,Designated,Public record,1450,20-mer oligonucleotide complementary to Akt mRNA,12/8/2004,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,20850,United States,196204
ARCHEXIN,4TEW51C830,Designated,Public record,1451,20-mer oligonucleotide complementary to Akt mRNA,12/8/2004,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,20850,United States,196004
ARCHEXIN,4TEW51C830,Designated,Public record,1452,20-mer complementary to Akt mRNA,12/10/2004,Treatment of stomach cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,20850,United States,196104
TEMSIROLIMUS,624KN6GM2T,Designated/Approved,Public record,1453,Temsirolimus,12/16/2004,Treatment of renal cell carcinoma,Designated/Approved,,Treatment of advanced renal cell carcinoma,5/30/2007,5/30/2014,,"Wyeth Pharmaceuticals, Inc.",P. O. Box 8299,,Phildelphia,Pennsylvania,19101,United States,196404
RILONACEPT,8K80YB5GMG,Designated/Approved,Public record,1454,Rilonacept,12/20/2004,Treatment of CIAS1-Associated Periodic Syndromes,Designated/Approved,,Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS),2/27/2008,2/27/2015,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,196904
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,1455,Alpha1-Proteinase Inhibitor (Human),12/22/2004,Inhalation therapy for the treatment of congential deficiency of alpha1-proteinase inhibitor.,Designated,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.,7 Sapir Street,,Ness Ziona,,,Israel,190804
FLOXURIDINE,039LU44I5M,Designated,Public record,1456,"Floxuridine, FUDR",12/22/2004,Intraperitoneal treatment of gastric cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Franco Muggia, M.D.",160 East 34th Street,,New York,New York,10016,United States,195104
PACLITAXEL,P88XT4IS4D,Designated/Withdrawn,Public record,1457,paclitaxel,12/22/2004,Treatment of non-superficial urothelial cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sonus Pharmaceuticals, Inc.",22026 20th Avenue SE,,Bothell,Washington,98021,United States,186404
DOXORUBICIN HYDROCHLORIDE,82F2G7BL4E,Designated/Approved,Public record,1458,doxorubicin HCL liposome injection,12/29/2004,Treatment of multiple myeloma,Designated/Approved,,For use in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have at least one prior therapy.,5/17/2007,5/17/2014,,Johnson & Johnson Pharmaceutical Research & Dev.,"920 US Highway 202, P. O. Box 300",,Raritan,,8869,United States,191704
MANITIMUS,4B135RK2KL,Designated,Public record,1459,(2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide,1/10/2005,"Prevention of acute rejection following kidney, heart, and liver transplantation",Designated,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma US, Inc.",Three Parkway North,,Deerfield,Illinois,60015,United States,187004
ATALUREN,K16AME9I3V,Designated,Public record,1460,ataluren,1/10/2005,Treatment of Muscular Dystrophy resulting from premature stop mutations in the dystrohin gene,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,197204
BEDAQUILINE,78846I289Y,Designated/Approved,Public record,1461,bedaquiline,1/10/2005,Treatment of active tuberculosis,Designated/Approved,,SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use,5/27/2020,5/27/2027,As part of combination therapy in the treatment of pediatric patients 5 years and older to less than 12 years of age and weighing at least 15 kg with pulmonary multi-drug resistant tuberculosis (MDR-TB),"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,199304
BEDAQUILINE,78846I289Y,Designated/Approved,Public record,1462,bedaquiline,1/10/2005,Treatment of active tuberculosis,Designated/Approved,,SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (M,8/9/2019,8/9/2026,As part of combination therapy in the treatment of pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB),"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,199304
BEDAQUILINE,78846I289Y,Designated/Approved,Public record,1463,bedaquiline,1/10/2005,Treatment of active tuberculosis,Designated/Approved,,Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).,12/28/2012,12/28/2019,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,199304
MISOPROSTOL,0E43V0BB57,Designated,Public record,1464,misoprostol,1/10/2005,Treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gynuity Health Projects, LLC",15 East 26th Street,,New York,New York,10010,United States,186604
MOTESANIB DIPHOSPHATE,T6Q3060U91,Designated/Withdrawn,Public record,1465,"N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, phosphate (1:2)",1/13/2005,Treatment of gastrointestinal stromal tumors,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91320,United States,197104
OPORTUZUMAB MONATOX,945CY7ZMI2,Designated,Public record,1468,recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin,1/28/2005,Treatment of Ep-CAM-positive squamous cell carcinoma of the head and neck,Designated,Not FDA Approved for Orphan Indication,,,,,"Sesen Bio, Inc. (Sesen Bio)",2929 Arch Street,17th Floor,Philadelphia,Pennsylvania,19104,United States,195304
TRAMADOL HYDROCHLORIDE,9N7R477WCK,Designated,Public record,1469,Tramadol hydrochloride,1/28/2005,Treatment of painful HIV-associated neuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"TheraQuest Biosciences, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,19422,United States,197004
MIFEPRISTONE,320T6RNW1F,Designated/Withdrawn,Public record,1470,Mifepristone,2/7/2005,Treatment of Cushing's syndrome secondary to ectopic ACTH secretion,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,HRA Pharma,"15 , rue Beranger",75003,Paris,,,France,196304
MANNITOL,3OWL53L36A,Designated,Public record,1471,MANNITOL,2/11/2005,For use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis,Designated/Approved,,as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only for adults who have passed the Bronchitol Tolerance Test.,10/30/2020,10/30/2027,as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis and who have passed the Bronchitol Tolerance Test,"Chiesi Farmaceutici S.p.A (Chiesi USA, Inc.)",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,198704
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,1473,Nitric oxide,2/16/2005,Diagnosis of sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,SensorMedics Corporation,22705 Savi Ranch Parkway,,Yorba Linda,California,92887,United States,193304
STAMULUMAB,V43X8G4797,Designated/Withdrawn,Public record,1474,Recombinant human anti-GDF-8 (growth and differentiation factor-8) antibody,2/16/2005,Treatment of Duchenne and Becker muscular dystrophies,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Wyeth Pharmaceuticals, Inc.",P. O. Box 8299,,Philadelphia,Pennsylvania,19101,United States,199104
AVIPTADIL,A67JUW790C,Designated,Public record,1475,aviptadil,2/22/2005,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Mondobiotech Laboratories AG,Herrengasse 21,,Furstentum Liechtenstein,,,Germany,180903
ARSENIC TRIOXIDE,S7V92P67HO,Designated,Public record,1477,Arsenic trioxide,3/4/2005,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,201305
SODIUM ALUMINOSILICATE,058TS43PSM,Designated,Public record,1478,Sodium aluminosilicate,3/4/2005,Treatment of chronic hepatic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Westhaven Therapeutics Corporation,1825 K Street Northwest,Suite 510,Washington,District of Columbia,20006,United States,192704
DOXORUBICIN,80168379AG,Designated,Public record,1480,doxorubicin nanoparticles,3/14/2005,Treatment of hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Onxeo SA,"49 Boulevard du general Martial Valin, 75015",,Paris,,,France,199904
ADALIMUMAB,FYS6T7F842,Designated/Approved,Public record,1481,adalimumab,3/21/2005,Treatment of juvenile rheumatoid arthritis,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.,2/21/2008,2/21/2015,,AbbVie Inc.,1 North Waukegan Road,Bldg. AP-30,North Chicago,Illinois,60064,United States,200905
ADALIMUMAB,FYS6T7F842,Designated/Approved,Public record,1482,adalimumab,3/21/2005,Treatment of juvenile rheumatoid arthritis,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.,9/30/2014,9/30/2021,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.,1 North Waukegan Road,Bldg. AP-30,North Chicago,Illinois,60064,United States,200905
GMA-161,I0TG4Z02RN,Designated/Withdrawn,Public record,1483,humanized anti-human CD16 monoclonal antibody,3/21/2005,Treatment of adult idiopathic thrombocytopenic purpura,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,199504
PAROMOMYCIN SULFATE,845NU6GJPS,Designated,Public record,1484,aminosidine,3/29/2005,Treatment of visceral leishmaniasis,Designated,Not FDA Approved for Orphan Indication,,,,,The Institute for One World Health,50 California Street,Suite 500,San Francisco,California,94111,United States,201705
ARIMOCLOMOL,EUT3557RT5,Designated,Public record,1485,arimoclomol,3/29/2005,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,KemPharm Denmark A/S,Ole Maaløes Vej 3,,Copenhagen,København,2200,Denmark,202705
TRABECTEDIN,ID0YZQ2TCP,Designated,Public record,1488,trabectedin,3/29/2005,Treatment of patients with ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,199004
2-METHOXYESTRADIOL,6I2QW73SR5,Designated/Withdrawn,Public record,1489,2-methoxyestradiol,4/4/2005,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",Research Triangle Park Center,"4819 Emperor Blvd., Suite 400",Durham,North Carolina,27703,United States,201405
RILONACEPT,8K80YB5GMG,Designated,Public record,1492,Interleukin-1 Trap,4/4/2005,Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,197604
TROXACITABINE,60KQZ0388Y,Designated/Withdrawn,Public record,1493,Troxacitabine,4/4/2005,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Structural GenomiX, Inc. (SGX)",10505 Roselle Street,,San Diego,California,92121,United States,202005
INOSITOL,4L6452S749,Designated,Public record,1494,myo-inositol,4/7/2005,Prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity,Designated,Not FDA Approved for Orphan Indication,,,,,Abbott Nutrition,Abbott Laboratories,625 Cleveland Ave.,Columbus,Ohio,43215,United States,202105
2-METHOXYESTRADIOL,6I2QW73SR5,Designated,Public record,1495,2-methoxyestradiol,4/11/2005,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"PR Pharmaceuticals, Inc.",1716 Heath Parkway,,Fort Collins,Colorado,80524,United States,202905
TILARGININE ACETATE,2FL3530AF2,Designated,Public record,1496,Tilarginine acetate,4/11/2005,Treatment of cardiogenic shock,Designated,Not FDA Approved for Orphan Indication,,,,,"Arginox Pharmceuticals, Inc.",120 Constitution Drive,,Menlo Park,California,94025,United States,198804
ANATIBANT,CLO4JRD21F,Designated,Public record,1497,Anatibant,4/15/2005,Treatment of patients having experienced a severe traumatic brain injury (Glasgow Coma Scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome,Designated,Not FDA Approved for Orphan Indication,,,,,"Xytis, Inc.",400 South El Camino Real,Suite 1200,San Mateo,California,94402,United States,153801
Hydroxyurea,X6Q56QN5QC,Designated,Public record,1499,hydroxyurea,4/15/2005,Treatment of pediatric patients with sickle cell anemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"UPM Pharmaceuticals, Inc.",6200 Seaforth Street,,Baltimore,Maryland,21224,United States,202605
MASITINIB,M59NC4E26P,Designated,Public record,1500,masitinib,4/20/2005,Treatment of malignant gastrointestinal stromal tumors,Designated,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue George V",,Paris,,,France,201005
RAPASTINEL,6A1X56B95E,Designated,Public record,1501,L-threonyl-L-prolyl-L-prolyl-L-threonine,4/26/2005,Treatment of neuropathic pain associated with spinal cord injury,Designated,Not FDA Approved for Orphan Indication,,,,,"Nyxis Neurotherapies, Inc.",1801 Maple Avenue,Suite 4300,Evanston,Illinois,60201,United States,199404
TRAMADOL HYDROCHLORIDE,9N7R477WCK,Designated,Public record,1502,Tramadol hydrochloride,4/26/2005,Management of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"TheraQuest Biosciences, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,19422,United States,192804
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,1503,Recombinant human alpha 1-antitrypsin,4/28/2005,Prevention of bronchopulmonary dysplasia,Designated,Not FDA Approved for Orphan Indication,,,,,"Arriva Pharmaceuticals, Inc.",1010 Atlantic Avenue,,Alameda,California,94501,United States,203705
INTETUMUMAB,GQE1BJE2NI,Designated/Withdrawn,Public record,1504,Human anti-integrin receptor av monoclonal antibody,5/5/2005,Treatment of patients with angiosarcoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,203605
GLYCEROL PHENYLBUTYRATE,ZH6F1VCV7B,Designated,Public record,1505,Glyceryl tri (4-phenylbutyrate),5/24/2005,Treatment of spinal muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Ucyclyd Pharma, Inc",Subsidiary of Medicis Pharmaceutical Corporation,7720 N. Dobson Road,Scottsdale,Alaska,85256,United States,204205
BISOCTRIZOLE,8NT850T0YS,Designated/Withdrawn,Public record,1506,Titanium dioxide and bisoctrizole,5/25/2005,"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prop",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Orfagen,CRDPF - LANGLADE,,Toulouse,Cedex,,France,199204
TITANIUM DIOXIDE,15FIX9V2JP,Designated/Withdrawn,Public record,1506,Titanium dioxide and bisoctrizole,5/25/2005,"For the secondary prevention (prevention of lesional induction) of disorders with UV-A and visible light-induced photosensitivity, specifically Actinic prurigo, Hydroa vacciniforme, Solar urticara (SU), Chronic Actinic Dermatitis (CAD), the cutaneous prop",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Orfagen,CRDPF - LANGLADE,,Toulouse,Cedex,,France,199204
CILENGITIDE,4EDF46E4GI,Designated/Withdrawn,Public record,1507,cilengitide,5/27/2005,Treatment of malignant glioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,205205
Digitoxin,E90NZP2L9U,Designated,Public record,1508,digitoxin,5/27/2005,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Silver Pharmaceuticals,350 Seven Locks Road,Suite 211,Rockville,Maryland,20854,United States,205005
IBOCTADEKIN,X08H9UZ7TO,Designated/Withdrawn,Public record,1510,Iboctadekin,6/3/2005,Treatment of renal cell carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline LLC,Corporation service Company,Suite 400,Wilmington,Delaware,19808,United States,193004
Sodium benzoate,OJ245FE5EU,Designated,Public record,1511,Sodium phenylacetate/sodium benzoate 10%/10% Injection,6/3/2005,Treatment of grade III and IV hepatic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Ucyclyd Pharma, Inc.",7720 N. Dobson Road,,Scottsdale,Alaska,85256,United States,197804
Sodium phenylacetate,48N6U1781G,Designated,Public record,1511,Sodium phenylacetate/sodium benzoate 10%/10% Injection,6/3/2005,Treatment of grade III and IV hepatic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Ucyclyd Pharma, Inc.",7720 N. Dobson Road,,Scottsdale,Alaska,85256,United States,197804
GENETICIN,A08F5XTI6G,Designated,Public record,1512,Geneticin,6/6/2005,Treatment of amoebiasis.,Designated,Not FDA Approved for Orphan Indication,,,,,"ProcesScience, Inc. (PSI)",117 Woodberry Lane,,Fayetteville,New York,13066,United States,204605
PEGADRICASE,50XB37EKN8,Designated,Public record,1513,Polyethylene glycol-modified uricase,6/6/2005,Treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated,Designated,Not FDA Approved for Orphan Indication,,,,,"Selecta Biosciences, Inc.",480 Arsenal Way,,Watertown,Massachusetts,2472,United States,118698
TACROLIMUS,WM0HAQ4WNM,Designated/Approved,Public record,1514,Tacrolimus,6/6/2005,Prophylaxis of organ rejection in patients receiving heart transplants.,Designated/Approved,,Prophylaxis of organ rejection in patients receiving allogenic heart transplants.,3/29/2006,3/29/2013,,"Astellas Pharma US, Inc.",Three Parkway North,,Deerfield,Illinois,60015,United States,203305
CLOTRIMAZOLE,G07GZ97H65,Designated,Public record,1515,Clotrimazole,6/14/2005,Topical treatment of children and adults with pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"AesRx, LLC",275 Grove Street,Suite 2-400,Newton,Massachusetts,2466,United States,204005
ANNAMYCIN,SNU299M83Q,Designated,Public record,1517,Liposomal annamycin,6/17/2005,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.",420 Lexington Avenue,,New York,New York,10170,United States,206205
ANNAMYCIN,SNU299M83Q,Designated,Public record,1518,Liposomal annamycin,6/17/2005,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.",420 Lexington Avenue,,New York,New York,10170,United States,206305
ULINASTATIN,OR3S9IF86U,Designated,Public record,1519,Recombinant truncated SPINT2 protease inhibitor,6/24/2005,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Aerovance, Inc.",2929 Seventh Street,,Berkeley,California,94710,United States,205905
VALPROATE SODIUM,5VOM6GYJ0D,Designated/Withdrawn,Public record,1520,"Valproic acid, sodium",6/24/2005,Treatment of familial adenomatous polyposis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Topotarget A/S,Fruebjergvej 3,DK-2100,Copenhagen,,,Denmark,200705
CONTULAKIN-G,G040R0738T,Designated,Public record,1521,Contulakin-G,7/7/2005,Intrathecal treatment of neuropathic pain associated with spinal cord injury,Designated,Not FDA Approved for Orphan Indication,,,,,"Cognetix, Inc.",421 Wakara Way,,Salt Lake City,Utah,84108,United States,205505
CTCE-9908,NF0BX95A31,Designated,Public record,1523,SDF-1 (108) Lysine Dlmer,7/7/2005,Treatment of osteogenic sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Chemokine Therapeutics Corporation,190 Agronomy Road (UBC),Suite 405,Vancouver,,,Canada,182403
ALFENTANIL,1N74HM2BS7,Designated,Public record,1524,Alfentanil,7/8/2005,Management of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Cinergen, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,19422,United States,206505
RALOXIFENE,YX9162EO3I,Designated/Approved,Public record,1526,raloxifene,7/14/2005,Reduction of the risk of breast cancer in postmenopausal women,Designated/Approved,,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer,9/13/2007,9/13/2014,,Eli Lilly and Company,Lilly Corporate Center,Drop Code 1853,Indianapolis,Indiana,46285,United States,197504
SEBELIPASE ALFA,K4YTU42T8G,Designated,Public record,1527,Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase,7/14/2005,"Treatment of lipase deficiencies, including Wolman Disease and cholesteryl ester storage disease",Designated,Not FDA Approved for Orphan Indication,,,,,"Lysosomal Acid Lipase, LLC","Subsidiary of Kentucky BioProcessing, LLC",3700 Airpark Drive,Owensboro,Kentucky,42301,United States,205805
EDOTREOTIDE,U194AS08HZ,Designated,Public record,1528,Edotreotide,7/28/2005,Treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,160902
CAPSAICIN,S07O44R1ZM,Designated,Public record,1530,Capsaicin,8/3/2005,Treatment of postherpetic neuralgia.,Designated,Not FDA Approved for Orphan Indication,,,,,"TheraQuest Biosciences, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,19422,United States,205705
ALFENTANIL,1N74HM2BS7,Designated,Public record,1531,Alfentanil,8/9/2005,Treatment of painful HIV-associated neuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Cinergen, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,19422,United States,206405
BICARBONATE ION,HN1ZRA3Q20,Designated/Approved,Public record,1532,bicarbonate infusate,8/9/2005,Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration,Designated/Approved,,Use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace water and to correct electrolytes and acid-base imbalances in adults and children,7/26/2006,7/26/2013,,"Dialysis Solutions, Inc.",14 Emmett Place,,Whitby,,,Canada,198904
RIDAFOROLIMUS,48Z35KB15K,Designated/Withdrawn,Public record,1533,Rapamycin (mTOR) inhibitor,8/9/2005,Treatment of bone sarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme Corp.,"S Merck & Co., Inc. Subsidiary","P. O. Box 1000, UG-2C50",North Wales,Pennsylvania,19454,United States,207705
BALSALAZIDE DISODIUM,1XL6BJI034,Designated/Approved,Public record,1534,Balsalazide disodium,8/12/2005,Treatment of pediatric patients with ulcerative colitis,Designated/Approved,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.,12/20/2006,12/20/2013,,"Salix Pharmaceuticals, Inc.",400 Somerset Corporate Blvd,,Bridgewater,New Jersey,8807,United States,208205
IMEXON,8F63U28T2V,Designated,Public record,1535,imexon,8/12/2005,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,AmpliMed Corporation,4380 N. Campbell Ave.,,Tucson,Alaska,85718,United States,207205
LUCATUMUMAB,P0EP9VFC4R,Designated/Withdrawn,Public record,1536,Recombinant anti-CD40 monoclonal antibody,8/12/2005,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,Oncology Business Unit,"One Health Plaza, Bldg 104",East Hanover,New Jersey,7936,United States,207605
RIDAFOROLIMUS,48Z35KB15K,Designated/Withdrawn,Public record,1537,ridaforolimus,8/12/2005,Treatment of soft tissue sarcoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme Corp.,"Merck & Co., Inc. Subsidiary","P. Box 1000, UG-2C50",North Wales,Oregon,19454,United States,207805
IMATINIB MESYLATE,8A1O1M485B,Designated/Approved,Public record,1539,Imatinib mesylate,8/25/2005,Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia,Designated/Approved,,Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRÿ}ÿ± fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CE,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,7936,United States,209005
IMATINIB MESYLATE,8A1O1M485B,Designated/Approved,Public record,1540,Imatinib mesylate,9/9/2005,Treatment of systemic mastocytosis without the D816V c-kit mutation,Designated/Approved,,Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,7936,United States,209205
MASITINIB,M59NC4E26P,Designated,Public record,1541,masitinib,9/14/2005,Treatment of mastocytosis,Designated,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue GeorgeV",75008,Paris,,,France,201505
ENZASTAURIN,UC96G28EQF,Designated,Public record,1542,Enzastaurin,9/19/2005,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,Denovo Biopharma LLC,6331 Nancy Ridge Drive,,San Diego,California,92121,United States,208505
IODINE I-131 MONOCLONAL ANTIBODY 81C6,D4E1UP3RMV,Designated,Public record,1543,Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131,10/4/2005,Treatment of primary malignant brain tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Bradmer Pharmaceuticals, Inc.",9900 Corporate Campus Drive,Suite 3000,Louisville,Kentucky,40223,United States,209405
PATUPILONE,UEC0H0URSE,Designated/Withdrawn,Public record,1545,Patupilone,10/4/2005,Treatment of ovarian cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,210205
DENENICOKIN,A4LY1V9F0H,Designated,Public record,1546,Recombinant Human Interleukin-21 (rIL-21),10/4/2005,"Treatment of stage II (T4), III or IV malignant melanoma.",Designated,Not FDA Approved for Orphan Indication,,,,,"Zymo Genetics, Inc",1201 Eastlake Avenue East,,Seattle,Washington,98102,United States,208005
BRIVARACETAM,U863JGG2IA,Designated,Public record,1547,brivaracetam,10/5/2005,Treatment of symptomatic myoclonus,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB Pharma, Inc.",1950 Lake Park Drive,,Smyra,Georgia,30080,United States,207305
BUTHIONINE SULFOXIMINE,LW4108Q0BV,Designated,Public record,1548,Buthionine sulfoxamine,10/5/2005,Use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors,Designated,Not FDA Approved for Orphan Indication,,,,,USC-CHLA Institute for Pediatric Clinical Research,Children's Hospital Los Angeles,MS 55,Los Angeles,California,90027,United States,213205
BUTHIONINE SULFOXIMINE,LW4108Q0BV,Designated,Public record,1549,Buthionine sulfoxamine,10/5/2005,For use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,USC-CHLA Institute for Pediatric Clinical Research,Children's Hospital Los Angeles,MS 55,Los Angeles,California,90027,United States,209705
FENRETINIDE,187EJ7QEXL,Designated,Public record,1550,Fenretinide,10/5/2005,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,USC-CHLA Institute for Pediatric Clinical Research,Children's Hospital Los Angeles,MS 55,Los Angeles,California,90027,United States,209805
IMATINIB MESYLATE,8A1O1M485B,Designated/Approved,Public record,1551,Imatinib mesylate,10/5/2005,Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements,Designated/Approved,,Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,7936,United States,209105
DACETUZUMAB,UT59FF4T5X,Designated,Public record,1552,dacetuzumab,10/6/2005,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,209305
DOXORUBICIN HYDROCHLORIDE,82F2G7BL4E,Designated,Public record,1553,Doxorubicin HCl with pluronic L-61 and pluronic F-127,10/7/2005,Treatment of esophageal carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Supratek Pharma Inc.,6100 Royalmount Avenue,,Montreal,,,Canada,210705
CREATINE,MU72812GK0,Designated/Withdrawn,Public record,1554,Creatine,10/11/2005,Treatment of Huntington's disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Marathon Pharmaceuticals, LLC",1033 Skokie Blvd,Suite 600,Northbrook,Illinois,60062,United States,210005
IMATINIB,BKJ8M8G5HI,Designated/Approved,Public record,1555,imatinib,10/11/2005,Treatment of Philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,1/25/2013,1/25/2020,Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,7936,United States,208905
IMATINIB,BKJ8M8G5HI,Designated/Approved,Public record,1556,imatinib,10/11/2005,Treatment of Philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL),10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,7936,United States,208905
SILTUXIMAB,T4H8FMA7IM,Designated/Withdrawn,Public record,1557,siltuximab,10/11/2005,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,200505
IOBENGUANE SULFATE I-123,23X1185WBO,Designated,Public record,1558,Iobenguane Sulfate I-123,10/17/2005,"For scintigraphic detection, localization and staging of neuroblastoma.",Designated,Not FDA Approved for Orphan Indication,,,,,"Brogan Pharmaceuticals, LLC",312 Lacebark Street,,Schererville,Indiana,46375,United States,208405
MASITINIB,M59NC4E26P,Designated,Public record,1559,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate,10/17/2005,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue GeorgeV",75008,Paris,,,France,210505
IOBENGUANE SULFATE I-123,23X1185WBO,Designated,Public record,1560,iobenguane sulfate I-123,10/21/2005,"For the detection, localization, and staging of pheochromocytomas.",Designated,Not FDA Approved for Orphan Indication,,,,,"Brogan Pharmaceuticals, Inc.",9800 Connecticut Drive,c/o Purdue Technology Center,Crown Point,Indiana,46307,United States,208305
LUCINACTANT,5BSH2G9BH8,Designated,Public record,1561,Lucinactant,10/21/2005,Treatment of bronchopulmonary dysplasia in premature infants.,Designated,Not FDA Approved for Orphan Indication,,,,,"Windtree Therapeutics, Inc.",2600 Kelly Road,Suite 100,Warrington,Pennsylvania,18976,United States,208705
VANDETANIB,YO460OQ37K,Designated/Approved,Public record,1562,vandetanib,10/21/2005,"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma",Designated/Approved,,Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease,4/6/2011,4/6/2018,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,211005
BIVALIRUDIN,TN9BEX005G,Designated,Public record,1563,bivalirudin,11/2/2005,For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,The Medicines Company,8 Sylvan Way,,Parsippany,New Jersey,7054,United States,200204
PICOPLATIN,B5TAN0L720,Designated,Public record,1564,Picoplatin,11/2/2005,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Poniard Pharmaceuticals,300 Elliott Avenue West,,Seattle,Washington,98119,United States,212305
SOLASONINE,TR60638HXL,Designated,Public record,1565,Solasonine and solamargine,11/2/2005,Treatment of renal cell carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Solbec Pharmaceuticals Limited,P. O. Box 2142,,WA 6018,,,Australia,211805
SOLAMARGINE,8KG991E7BN,Designated,Public record,1565,Solasonine and solamargine,11/2/2005,Treatment of renal cell carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Solbec Pharmaceuticals Limited,P. O. Box 2142,,WA 6018,,,Australia,211805
HEPARIN,T2410KM04A,Designated/Withdrawn,Public record,1566,Heparin,11/3/2005,Treatment of cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Vectura Group, Inc.",1 Prospect West,,Wiltshire,,,United Kingdom,211305
DASATINIB,RBZ1571X5H,Designated/Approved,Public record,1567,Dasatinib,11/18/2005,Treatment of Philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.,12/21/2018,12/21/2025,SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.,Bristol-Myers Squibb Company,P. O Box 5326,Mailstop C 4065,Princeton,New Jersey,8542,United States,214605
DASATINIB,RBZ1571X5H,Designated/Approved,Public record,1568,Dasatinib,11/18/2005,Treatment of Philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy,6/28/2006,6/28/2013,,Bristol-Myers Squibb Company,P. O Box 5326,Mailstop C 4065,Princeton,New Jersey,8542,United States,214605
HISTRELIN,H50H3S3W74,Designated/Approved,Public record,1570,Histrelin,11/18/2005,Treatment of central precocious puberty,Designated/Approved,,Treatment of central precocious puberty,5/3/2007,5/3/2014,,"Endo Pharmaceuticals Solutions, Inc.",100 Endo Blvd,,Chadds Ford,Pennsylvania,19317,United States,212605
PRACONASE,B36V5S1RFJ,Designated,Public record,1571,recombinant deriative of C3 transferase,11/18/2005,Treatment of acute spinal cord injury,Designated,Not FDA Approved for Orphan Indication,,,,,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,213505
DASATINIB,RBZ1571X5H,Designated/Approved,Public record,1572,dasatinib,11/28/2005,Treatment of chronic myelogenous leukemia,Designated/Approved,,Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase,11/9/2017,11/9/2024,Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase,Bristol-Myers Squibb Company,"3401 Princeton Pike, B-3043C",,Lawrence Township,New Jersey,8648,United States,212405
DASATINIB,RBZ1571X5H,Designated/Approved,Public record,1573,dasatinib,11/28/2005,Treatment of chronic myelogenous leukemia,Designated/Approved,,Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib,6/28/2006,6/28/2013,,Bristol-Myers Squibb Company,"3401 Princeton Pike, B-3043C",,Lawrence Township,New Jersey,8648,United States,212405
OLESOXIME,A6778U5IFY,Designated/Withdrawn,Public record,1574,"4-cholest-en-3-one, oxime",12/1/2005,Treatment of amyotrophic lateral sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Trophos SA,"Parc scientifique de Lumigny, Case 931",,1322 Marseille cedex,,,France,214305
PRIDOPIDINE HYDROCHLORIDE,QH6KD74EGF,Designated,Public record,1575,4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl,12/12/2005,Treatment of Huntington's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Prilenia Therapeutics,"10 Hamenofin St., 3rd Floor",,Herzliya,,,Israel,213905
DALFAMPRIDINE,BH3B64OKL9,Designated,Public record,1577,4-Aminopyridine,12/14/2005,Treatment chronic functional motor and sensory deficits from Guillain-Barre syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Acorda Therapeutics, Inc.",420 Saw Mill River Road,,Ardsley,New York,10502,United States,214205
UREA,8W8T17847W,Designated,Public record,1579,Urea for intravitreal injection,12/14/2005,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitreo Retinal Techologies, Inc",2 Venture Plaza,,Irvine,California,92618,United States,192204
Amphotericin B,7XU7A7DROE,Designated,Public record,1580,Amphotericin B inhalation powder,12/15/2005,"Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,150 Industrial Road,,San Carlos,California,94070,United States,210805
GEBASAXTUREV,4B57CWT710,Designated,Public record,1581,Coxsackievirus A21,12/15/2005,"Treatment of stage II (T4), stage III, and stage IV melanoma",Designated,Not FDA Approved for Orphan Indication,,,,,"Viralytics Limited, a wholly owned subsidiary of Merck Sharp & Dohme, LLC",P. O. Box 1045,"Unit 8/33 Ryde Road,","Pymble,",NSW,,Australia,212105
ENILURACIL,2E2W0W5XIU,Designated,Public record,1582,eniluracil,12/15/2005,Treatment of hepatocellular carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Adherex Technologies, Inc.",501 Eastowne Drive,Suite 140,Chapel Hill,North Carolina,27514,United States,211505
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,1583,Somatropin,12/15/2005,Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency,Designated/Approved,,Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed,11/1/2006,11/1/2013,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,211205
ZOSUQUIDAR TRIHYDROCHLORIDE,813AGY3126,Designated,Public record,1584,Zosuquidar trihydrochloride,12/15/2005,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Kanisa Pharmaceuticals, Inc.",12264 El Camino Real,,San Diego,California,2130,United States,212805
IMATINIB MESYLATE,8A1O1M485B,Designated/Approved,Public record,1585,imatinib mesylate,12/19/2005,Treatment of dermatofibrosarcoma protuberans,Designated/Approved,,"Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)",10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,7936,United States,208805
MYCOPHENOLATE MOFETIL,9242ECW6R0,Designated/Withdrawn,Public record,1586,Mycophenolate mofetil,12/19/2005,Treatment of myasthenia gravis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Hoffman-LaRoche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,215405
IRATUMUMAB,AYH22O1B1U,Designated,Public record,1587,Human immunoglobin anti-CD30 monoclonal antibody,1/10/2006,Treatment of CD30+ T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,519 Route 173 West,,Bloombury,New Jersey,8804,United States,215905
INALIMAREV,,Designated,Public record,1588,Inalimarev and falimarev,1/10/2006,Treatment of adenocarcinoma of the pancreas,Designated,Not FDA Approved for Orphan Indication,,,,,Therion Biologics Corporation,76 Rogers Street,,Cambridge,Massachusetts,2142,United States,215705
AFEGOSTAT TARTRATE,285ZJJ9773,Designated,Public record,1589,isofagomine tartrate,1/10/2006,Treatment of Gaucher disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amicus Therapeutics, Inc.",1 Cedarbrook Drive,,Cranbury,New Jersey,8512,United States,215605
EDI-200,AF6GZK1UMB,Designated,Public record,1590,Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1,1/11/2006,Treatment of X-linked hypohidrotic ectodermal dysplasia,Designated,Not FDA Approved for Orphan Indication,,,,,Espoir XLHED Sarl,EPFL Innovation Park,15 avenue Secheron,Geneva,Geneva,,Switzerland,216005
IOBENGUANE I-131,Q461L7AK4R,Designated,Public record,1592,Iobenguane I 131,1/18/2006,Treatment of neuroendocrine tumors,Designated/Approved,,"AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.",7/30/2018,7/30/2025,"AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.","Progenics Pharmaceuticals, Inc.",One World Trade Center.,"47th Floor, Suite J",New York,New York,10007,United States,216205
C-101,BK727F83NO,Designated,Public record,1593,L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal,1/18/2006,Treatment of Duchenne and Becker muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,CepTor Corporation,200 International Circle,,Hunt Valley,Maryland,21030,United States,214405
OCRIPLASMIN,7V6HE3DM5A,Designated,Public record,1594,Recombinant human microplasmin,1/23/2006,Treatment of peripheral arterial occlusion,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ThromboGenics Ltd,"Unit 14, Bridgecourt Office Park",,Dublin,,,Ireland,215805
ARIPIPRAZOLE,82VFR53I78,Designated/Approved,Public record,1595,aripiprazole,1/25/2006,Treatment of Tourette's syndrome,Designated/Approved,,Treatment of pediatric patients with Tourette's,12/12/2014,12/12/2021,Treatment of pediatric patients with Tourette's,Otsuka Pharmaceutical Development,and Commercialization,1st Floor,Princeton,New Jersey,8540,United States,207905
LUCATUMUMAB,P0EP9VFC4R,Designated/Withdrawn,Public record,1596,Recombinant anti-CD-40 monoclonal antibody,1/25/2006,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,Oncology Business Unit,"One Health Plaza, Bldg 104",East Hanover,New Jersey,7936,United States,214505
Velmanase Alfa,M91TG242P2,Designated,Public record,1597,velmanase alfa-tycv,2/2/2006,Treatment of alpha-mannosidosis,Designated/Approved,,treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients,2/16/2023,2/16/2030,treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,212005
DEVIMISTAT,E76113IR49,Designated,Public record,1598,"6,8-bis-benzylsulfanyl-octanoic acid",2/6/2006,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,8512,United States,216505
BLINATUMOMAB,4FR53SIF3A,Designated,Public record,1599,blinatumomab,2/6/2006,"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement",Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91230,United States,203405
N-ACETYL-GLUCOSAMINE THIAZOLINE,ML5FHL557A,Designated,Public record,1600,N-acetyl-glucosamine thiazoline,2/6/2006,Treatment of adult Tay-Sachs disease,Designated,Not FDA Approved for Orphan Indication,,,,,ExSAR Corporation,11 Deer Park Drive,,Monmouth Junction,New Jersey,8852,United States,216805
OTELIXIZUMAB,I5HF2X04PB,Designated,Public record,1601,otelixizumab,2/6/2006,Treatment of new-onset type I diabetes mellitus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,2301 Renaissance Blvd (RN0420),P. O. Box 61540,King of Prussia,Pennsylvania,19406,United States,216605
SOLASONINE,TR60638HXL,Designated,Public record,1602,Solasonine and solamargine,2/6/2006,"Treaatment of high risk stage II, stage III and stage IV melanoma",Designated,Not FDA Approved for Orphan Indication,,,,,Solbec Pharmaceuticals Limited,P. O. Box 2142,"Osbourne Park, Western Australia 6017",,,,Australia,211705
SOLAMARGINE,8KG991E7BN,Designated,Public record,1602,Solasonine and solamargine,2/6/2006,"Treaatment of high risk stage II, stage III and stage IV melanoma",Designated,Not FDA Approved for Orphan Indication,,,,,Solbec Pharmaceuticals Limited,P. O. Box 2142,"Osbourne Park, Western Australia 6017",,,,Australia,211705
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,1603,bevacizumab,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,216405
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,1604,bevacizumab,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regi",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,216405
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,1605,bevacizumab,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical rese",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,216405
NIKKOMYCIN Z,9Z22C3QQCJ,Designated,Public record,1606,Nikkomycin Z,2/14/2006,Treatment of coccidioidomycosis,Designated,Not FDA Approved for Orphan Indication,,,,,Valley Fever Center for Excellence (1-111 INF),University of Arizona,,Tucson,Alaska,85723,United States,217505
RITUXIMAB,4F4X42SYQ6,Designated/Approved,Public record,1607,rituximab,2/14/2006,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener?s Granulomatosis) and Microscopic Polyangiitis (MPA)",9/27/2019,9/27/2026,"indicated in combination with glucocorticoids, for the treatment of pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,216305
RITUXIMAB,4F4X42SYQ6,Designated/Approved,Public record,1608,rituximab,2/14/2006,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)",Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ),4/19/2011,4/19/2018,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,216305
CLAZOSENTAN,3DRR0X4728,Designated,Public record,1609,clazosentan,2/16/2006,Treatment of cerebral vasospasm following subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,Idorsia Pharmaceuticals US Inc.,1820 Chapel Avenue West,Suite 150,Cherry Hill,New Jersey,8002,United States,217105
MDX-1303,7D0R3114J3,Designated,Public record,1610,Recombinant fully human monoclonal antibody to anthrax protective antigen,2/16/2006,Treatment of anthrax infection,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Altimmune, Inc.","910 Clopper Road, Suite 201",,Gaithersburg,Maryland,20878,United States,218005
AMIKACIN,84319SGC3C,Designated,Public record,1611,liposomal amikacin,3/9/2006,Treatment of bronchopulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",Princeton Corporate Plaza,"9 Deer Park Drive, Suite C",Monmouth Junction,New Jersey,8852,United States,217305
OMACETAXINE MEPESUCCINATE,6FG8041S5B,Designated/Approved,Public record,1612,omacetaxine mepesuccinate,3/10/2006,Treatment of chronic myelogenous leukemia,Designated/Approved,,Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI),10/26/2012,10/26/2019,,IVAX International GmbH,Alpenstrasse 2,8640 Rapperswil,Frazer,,,Switzerland,218205
CLOTRIMAZOLE,G07GZ97H65,Designated,Public record,1613,Clotrimazole,3/13/2006,Treatment of Huntington's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"EnVivo Pharmaceuticals, Inc.",480 Arsenal Street,,Watertown,Massachusetts,2472,United States,216705
ALCOHOL,3K9958V90M,Designated/Withdrawn,Public record,1614,Ethanol gel,3/13/2006,Treatment of congenital lymphatic malformations,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Orfagen,CRDPF - LANGLADE,,Toulouse,Cedex,,France,212505
HUMAN UMBILICAL TISSUE-DERIVED CELLS,3T0UGR2M5Q,Designated/Withdrawn,Public record,1615,Human umbilical tissue-derived cells,3/13/2006,Treatment of retinitis pigmentosa,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,219006
THYMALFASIN,W0B22ISQ1C,Designated,Public record,1616,Thymalfasin,3/13/2006,Treatment of stage IIb through Stage IV malignant melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",950 Tower Lane,Suite 900,Foster City,California,94404,United States,218806
LESTAURTINIB,DO989GC5D1,Designated,Public record,1618,lestaurtinib,3/24/2006,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,219406
CPG-52852,6PJC3KPK6S,Designated/Withdrawn,Public record,1619,"N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide",3/24/2006,Treatment of cutaneous T-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",50 Pequot Avenue,6025-A3106,New London,Connecticut,6320,United States,218105
"""BRIMAPITIDE, C-TERMINAL ACID""",FU288768DP,Designated,Public record,1620,(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor),3/28/2006,Treatment of acute sensorineural hearing loss,Designated,Not FDA Approved for Orphan Indication,,,,,"Auris Medical, Inc.",444 North Michagan Ave.,Suite 1200,Chicago,Illinois,60611,United States,214905
.ALPHA.-TOCOPHEROL QUINONE,5W7XN0VOX8,Designated,Public record,1621,Alpha-tocopherol quinone,3/28/2006,Treatment of inherited mitochondrial respiratory chain diseases,Designated,Not FDA Approved for Orphan Indication,,,,,Penwest Pharmaceuticals Company,39 Old Ridgebury Road,Suite 11,Danbury,Connecticut,6810,United States,215205
ARTESUNATE,60W3249T9M,Designated,Public record,1622,artesunate,3/28/2006,Immediate treatment of malaria,Designated/Approved,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral an,5/26/2020,5/26/2027,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.,Amivas Inc.,"100 Tuscanney Drive, Suite B2",,Frederick,Maryland,21702,United States,221206
CEFTRIAXONE SODIUM,023Z5BR09K,Designated,Public record,1623,Ceftriaxone sodium,3/28/2006,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Mass General Hospital,"Merit E. Cudkowicz, MD, MSc","Building 149 13th Street, Room 2274",Charlestown,Massachusetts,2129,United States,218606
MINOCYCLINE HYDROCHLORIDE,0020414E5U,Designated,Public record,1624,Minocycline hydrochloride,3/28/2006,Treatment of sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,Autoimmunity Research Foundation,"Autoimmunity Research, Inc.",,Thousand Oaks,California,91360,United States,213305
ALCOHOL,3K9958V90M,Designated/Withdrawn,Public record,1625,Ethanol gel,3/29/2006,Treatment of congenital venous malformations,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Orfagen,CRDPF - LANGLADE,,Toulouse,Cedex,,France,212205
Oxalobacter formigenes,330ZY4KI6F,Designated,Public record,1627,Oxalobacter formigenes,3/29/2006,Treatment of primary hyperoxaluria,Designated,Not FDA Approved for Orphan Indication,,,,,OxThera Inc.,Regeringsgatan 111,,Stockholm,,,Sweden,219206
TORAPSEL,SU09HUV8AJ,Designated,Public record,1628,Recombinant P-Selectin glycoprotein ligand,3/29/2006,Prevention of delayed graft function in renal transplant patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Y's Therapeutics, Inc.",1111 Bayhill Drive,Suite 405,San Bruno,California,94066,United States,215305
CIPROFLOXACIN,5E8K9I0O4U,Designated,Public record,1629,liposomal ciprofloxacin for inhalation,4/19/2006,Management of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"6836 Bee Cave Road, Building 3, Suite 200",,Austin,Texas,78746,United States,216905
SORAFENIB,9ZOQ3TZI87,Designated/Approved,Public record,1630,Sorafenib,4/20/2006,Treatment of hepatocellular carcinoma,Designated/Approved,,Treatment of unresectable hepatocellular carcinoma,11/16/2007,11/16/2014,,Bayer Pharmaceuticals Corporation,400 Morgan Lane,,West Haven,Connecticut,6516,United States,220206
AMINOSALICYLIC ACID,5B2658E0N2,Designated,Public record,1631,4-aminosalicylic acid,4/26/2006,Treatment of acute flares in pediatric patients with ileo-cecal Crohn's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Jacobus Pharmaceutical Co., Inc.",37 Cleveland Lane,,Princeton,New Jersey,8540,United States,220506
DISITERTIDE,3N988KP8HD,Designated,Public record,1632,Peptide 144 TGF beta-1-inhibitor,4/26/2006,Treatment of localized scleroderma,Designated,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,,Spain,221006
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated,Public record,1633,Recombinant coagulation factor VIIa,4/26/2006,Treatment of diffuse alveolar hemorrhage,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,900 S. Capital Texas Highway,Suite 150,Austin,Texas,78746,United States,213005
NILOTINIB,F41401512X,Designated/Approved,Public record,1635,nilotinib,4/27/2006,Treatment of chronic myelogenous leukemia,Designated/Approved,,TASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than,3/22/2018,3/22/2025,TASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,220806
NILOTINIB,F41401512X,Designated/Approved,Public record,1636,nilotinib,4/27/2006,Treatment of chronic myelogenous leukemia,Designated/Approved,,Treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) the,9/23/2021,9/23/2028,Treatment of pediatric patients greater than or equal to 1 year of age with accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,220806
NILOTINIB,F41401512X,Designated/Approved,Public record,1637,nilotinib,4/27/2006,Treatment of chronic myelogenous leukemia,Designated/Approved,,For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.,10/29/2007,10/29/2014,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,220806
DISITERTIDE,3N988KP8HD,Designated,Public record,1638,peptide 144 TGF beta-1 inhibitor,4/27/2006,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,,Spain,219506
CENERSEN,K6KJ8AZ05F,Designated,Public record,1639,cenersen,5/8/2006,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.",1001 Twelve Oaks Center Drive,Suite 1002,Wayzata,Minnesota,55391,United States,220906
COMBRESTATIN A4,16U6OP69RQ,Designated,Public record,1640,Combretastatin A4 phosphate,5/8/2006,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Blvd,Suite 210,South San Francisco,California,94080,United States,217805
MIDAZOLAM,R60L0SM5BC,Designated,Public record,1641,midazolam,5/8/2006,Treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc",1950 Lake Park rive,,Smyrna,Georgia,30080,United States,217405
TALOTREXIN,A8E516A20K,Designated/Withdrawn,Public record,1642,Talotrexin,5/8/2006,Treatment of acute lymphoblastic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Hana Biosciences, Inc.",7000 Shoreline Court,Suite 370,South San Francisco,California,94080,United States,221306
APOMORPHINE HYDROCHLORIDE,F39049Y068,Designated,Public record,1643,Apomorphine hydrochloride,5/23/2006,For the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous),Designated,Not FDA Approved for Orphan Indication,,,,,"NeuroHealing Pharmaceuticals, Inc.",50 Undine Road,,Newton,Massachusetts,2135,United States,204305
CISPLATIN,Q20Q21Q62J,Designated,Public record,1644,Liposomal cisplatin,5/23/2006,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Eleison Pharmaceuticals LLC,103 Carnegie Center,Suite 300,Princeton,New Jersey,8540,United States,221906
LUCINACTANT,5BSH2G9BH8,Designated,Public record,1645,Lucinactant,5/23/2006,Prevention of bronchopulmonary dysplasia in premature infants,Designated,Not FDA Approved for Orphan Indication,,,,,"Windtree Therapeutics, Inc.",2600 Kelly Road,Suite 100,Warrington,Pennsylvania,18976,United States,211405
MIPOMERSEN,9GJ8S4GU0M,Designated/Approved,Public record,1646,mipomersen,5/23/2006,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hyperchol",1/29/2013,1/29/2020,"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hyperchol","Kastle Therapeutics, LLC",181 West Madison Street,Suite 3745,Chicago,Illinois,60602,United States,221406
TAFAMIDIS,8FG9H9D31J,Designated,Public record,1647,tafamidis,5/23/2006,Treatment of familial amyloid polyneuropathy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",P. O. Box 8299,,Philadelphia,Pennsylvania,19101,United States,220606
AES-103,70ETD81LF0,Designated,Public record,1648,5-hydroxymethyl-2-furfuraldehyde,5/26/2006,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Baxalta US, Inc.",ONe Baxter Way,,Westlake Village,California,91362,United States,222406
ROPIDOXURIDINE,3HX21A3SQF,Designated,Public record,1649,5-iodo-2-pyrimidinone-2'-deoxyribose,5/26/2006,Treatment of malginant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Hana Biosciences, Inc.",7000 Shoreline Court,Suite 370,South San Francisco,California,94080,United States,222606
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,1650,bevacizumab,5/26/2006,Treatment of malignant glioma,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy,5/5/2009,5/5/2016,,"Genentech, Inc.","1 DNA Way, MS 241B",,South San Francisco,California,94080,United States,222906
MYCOPHENOLATE MOFETIL,9242ECW6R0,Designated/Withdrawn,Public record,1651,Mycophenolate mofetil,5/26/2006,Treatment of pemphigus vulgaris,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Hoffman-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,223106
SILTUXIMAB,T4H8FMA7IM,Designated/Approved,Public record,1652,siltuximab,5/26/2006,Treatment of Castleman's disease,Designated/Approved,,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,4/23/2014,4/23/2021,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,EUSA Pharma (UK) Ltd.,Breakspear Park,Breakspear Way,Hertfordshire,,,United Kingdom,200605
TRIHEPTANOIN,2P6O7CFW5K,Designated,Public record,1653,Triheptanoin,5/26/2006,Treatment of fatty acid disorders,Designated,Not FDA Approved for Orphan Indication,,,,,Baylor Research Institute,Institute of Metabolic Disease,3812 Elm Street,Dallas,Texas,75226,United States,220306
CATUMAXOMAB,M2HPV837HO,Designated,Public record,1654,Catumaxomab,6/9/2006,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.",920 Winter Street,,Waltham,Massachusetts,2451,United States,223406
GLYCOPYRROLATE,V92SO9WP2I,Designated/Approved,Public record,1655,glycopyrrolate,6/9/2006,Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients,Designated/Approved,,To reduce chronic drooling in patients aged 3 - 16 with neurologic conditions associated with problem drooling (e.g. cerebral palsy),7/28/2010,7/28/2017,,"Shionogi, Inc.",300 Campus Drive,,Florham,New Jersey,7932,United States,204105
OBILTOXAXIMAB,29Z5DNL48C,Designated/Approved,Public record,1656,obiltoxaximab,6/9/2006,Treatment of exposure to B. anthracis spores,Designated/Approved,,Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available,3/18/2016,3/18/2023,"1) Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and (2) for prophylaxis of inhalational anthrax when alternative therapies are not available or are not a","Elusys Therapeutics, Inc.",25 Riverside Drive,P.O. Box 102,Pine Brook,New Jersey,7058,United States,224306
CONESTAT ALFA,5QS67N4551,Designated,Public record,1658,Recombinant human C1 inhibitor,6/9/2006,Treatment of capillary leakage syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Pharming Group N.V.,P. O. Box 451 Darwinweg 24,,Leiden,,,Netherlands,218406
CONESTAT ALFA,5QS67N4551,Designated,Public record,1659,Recombinant human C1 inhibitor,6/9/2006,Prevention and/or treatment of delayed graft function after solid organ transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Pharming Group N.V.,P. O. Box 451 Darwinweg 24,,Leiden,,,Netherlands,218306
2-METHOXYESTRADIOL,6I2QW73SR5,Designated/Withdrawn,Public record,1661,2-methoxyestradiol,6/16/2006,Treatment of multiforme glioblastoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",Research Triangle Park Center,"4819 Emperor Blvd., Suite 400",Durham,North Carolina,27703,United States,224006
FARLETUZUMAB,2O09BG0OWA,Designated,Public record,1662,farletuzumab,6/16/2006,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,,United States,204905
INDIUM IN-111 PENTETREOTIDE,M312JJ6Z32,Designated,Public record,1663,Indium-111 pentetreotide,6/16/2006,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,RadioIsotope Therapy of America (RITA) Foundation,9701 Richmond Avenue,,Houston,Texas,77042,United States,224706
SODIUM STIBOGLUCONATE ANHYDROUS,V083S0159D,Designated,Public record,1664,Sodium stibogluconate,6/16/2006,Treatment of cutaneous leishmaniasis,Designated,Not FDA Approved for Orphan Indication,,,,,"VioQuest Pharmaceuticals, Inc.",180 Mt. Airy Road,Suite 102,Basking Ridge,New Jersey,7920,United States,225906
Sodium nitrite,M0KG633D4F,Designated,Public record,1665,"Sodium thiosulfate, sodium nitrite, amyl nitrite",6/16/2006,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Pharmaceuticals, Inc.",26072 Merit Circle,,Laguna Hills,California,92653,United States,225606
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,1665,"Sodium thiosulfate, sodium nitrite, amyl nitrite",6/16/2006,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Pharmaceuticals, Inc.",26072 Merit Circle,,Laguna Hills,California,92653,United States,225606
AMYL NITRITE,22T8Z09XAK,Designated,Public record,1665,"Sodium thiosulfate, sodium nitrite, amyl nitrite",6/16/2006,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Pharmaceuticals, Inc.",26072 Merit Circle,,Laguna Hills,California,92653,United States,225606
VIBRIOLYSIN,VPW19O1UT2,Designated,Public record,1666,vibriolysin,6/16/2006,"Debridement of severe, deep dermal burns in hospitalized patients",Designated,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,94949,United States,128599
HEPARIN SODIUM,ZZ45AB24CA,Designated,Public record,1667,Heparin sodium,6/29/2006,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Ockham Biotech Limited,Manor Farm,,Swanwick,Hampshire,,United Kingdom,222106
JNJ-28312141,9M5069B3F8,Designated,Public record,1668,4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride,7/20/2006,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Johnson & Johnson Pharmaceutical Research & Dev,",920 U S Highway 202,P.O. Box 300,Raritan,New Jersey,8869,United States,224206
CHOLINE CHLORIDE,45I14D8O27,Designated,Public record,1669,Choline chloride,7/20/2006,Prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition,Designated,Not FDA Approved for Orphan Indication,,,,,"Protara Therapeutics, Inc.",1 Little West 12th Street,Suite 254,New York,New York,10014,United States,225206
PRALATREXATE,A8Q8I19Q20,Designated/Approved,Public record,1672,pralatrexate,7/20/2006,Treatment of T-cell lymphoma,Designated/Approved,,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,9/24/2009,9/24/2016,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,225306
GIMERACIL,UA8SE1325T,Designated,Public record,1673,Tegafur/gimeracil/oteracil,7/20/2006,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Taiho Oncology, Inc.",101 Carnegie Center,Suite 101,Princeton,New Jersey,8540,United States,225006
TEGAFUR,1548R74NSZ,Designated,Public record,1673,Tegafur/gimeracil/oteracil,7/20/2006,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Taiho Oncology, Inc.",101 Carnegie Center,Suite 101,Princeton,New Jersey,8540,United States,225006
OTERACIL,5VT6420TIG,Designated,Public record,1673,Tegafur/gimeracil/oteracil,7/20/2006,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Taiho Oncology, Inc.",101 Carnegie Center,Suite 101,Princeton,New Jersey,8540,United States,225006
TRYPAN BLUE,I2ZWO3LS3M,Designated/Approved,Public record,1675,Trypan blue,8/2/2006,Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures,Designated/Approved,,"For use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue",2/20/2009,2/20/2016,,Dutch Ophthalmic Research Center International BV,P.O. Box 43,,Zuidland,,,Netherlands,207505
DECITABINE,776B62CQ27,Designated/Withdrawn,Public record,1676,decitabine,8/4/2006,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Otsuka Pharmaceutical Development &,"Commercialization, Inc.",508 Carnegie Center Drive,Princeton,New Jersey,8540,United States,227106
PROCARBAZINE HYDROCHLORIDE,XH0NPH5ZX8,Designated,Public record,1677,Procarbazine HCl,8/8/2006,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Boulevard,Suite 500,Gaithersburg,Maryland,20878,United States,217005
"""BACILLUS CALMETTE-GUERIN LIVE ANTIGEN, UNSPECIFIED SUBSTRAIN""",8VJE55B0VG,Designated,Public record,1678,Bacillus Calmette-Guerin vaccine,8/9/2006,Treatment of stage IIb through IV metastatic melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,OncoVac Corporation,P. O. Box 970,,Pacific Palisades,California,90272,United States,223806
CLINDAMYCIN HYDROCHLORIDE,T20OQ1YN1W,Designated,Public record,1679,Clindamycin hydrochloride,8/9/2006,Treatment of sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,Autoimmunity Research Foundation,"Autoimmunity Research, Inc.",,Thousand Oaks,California,91360,United States,213405
SOMATROPIN,NQX9KB6PCL,Designated/Approved,Public record,1680,Somatropin,8/9/2006,Treatment of short stature in patients with Noonan syndrome,Designated/Approved,,Treatment of short stature in patients with Noonan syndrome,5/31/2007,5/31/2014,,Novo Nordisk Inc.,100 College Road West,,Princeton,New Jersey,8540,United States,226606
ATIPRIMOD DIMALEATE,YNU265SSR3,Designated,Public record,1682,"2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate",9/18/2006,Treatment of carcinoid tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.",420 Lexington Avenue,,New York,New York,10170,United States,227706
GLUFOSFAMIDE,1W5N8SZD9A,Designated,Public record,1683,glufosfamide,9/18/2006,For treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Eleison Pharmaceuticals LLC,103 Carnegie Center,Suite 300,Princeton,New Jersey,8540,United States,221606
PANOBACUMAB,62B4OXU259,Designated,Public record,1685,Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa,9/18/2006,Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosa,Designated,Not FDA Approved for Orphan Indication,,,,,Kenta Biotech Limited,Rehhagstrsase 79,,Berne,,,Switzerland,223706
LUSUPULTIDE,6MCT347Y2B,Designated,Public record,1686,rSP-C surfactant,9/18/2006,"For use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment",Designated,Not FDA Approved for Orphan Indication,,,,,Altana Pharma,220 Park avenue,,Florham Park,New Jersey,7932,United States,224406
SECRETIN HUMAN,A0426J905J,Designated,Public record,1687,Synthetic human secretin,9/18/2006,For use in conjunction with diagnostic procedures (excluding ERCP) for pancreatic disorders to increase pancreatic fluid secretion,Designated,Not FDA Approved for Orphan Indication,,,,,"Innovate Biopharmaceuticals, Inc.",8601 Six Forks Road,Suite 400,Raleigh,North Carolina,27615,United States,219906
TREMELIMUMAB,QEN1X95CIX,Designated,Public record,1688,tremelimumab,9/18/2006,Treatment of stage IIb to stage IV metastatic melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,MedImmune,One Medimmune Way,,Gaithersburg,Maryland,20878,United States,227306
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,D7RD81HE4W,Designated,Public record,1691,Rabbit anti-human thymocyte globulin (rATG),9/26/2006,Induction treatment to prevent rejection and to minimize maintenance immunosupression in pediatric liver transplant recipients,Designated,Not FDA Approved for Orphan Indication,,,,,Children's Hospital of Pittsburgh,University of Pittsburgh,,Pittsburgh,Pennsylvania,15213,United States,226006
CAPSAICIN,S07O44R1ZM,Designated,Public record,1692,capsaicin,9/29/2006,Treatment of intermetatarsal neuroma (Morton's Neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis,Designated,Not FDA Approved for Orphan Indication,,,,,Centrexion Corporation,509 S. Exeter Street,Suite 202,Baltimore,Maryland,21202,United States,222506
EFLORNITHINE,ZQN1G5V6SR,Designated,Public record,1693,Eflornithine,9/29/2006,Treatment of anaplastic glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Orbus Therapeutics, Inc.",1043 Via Tornasol,,Aptos,California,95003,United States,229306
SORAFENIB,9ZOQ3TZI87,Designated/Withdrawn,Public record,1694,Sorafenib,9/29/2006,Treatment of stage IIB through stage IV melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bayer Pharmaceuticals Corp.,100 Bayer Blvd,P. O. Box 915,Whippany,New Jersey,7981,United States,229206
TALACTOFERRIN ALFA,7A055A9QRR,Designated/Withdrawn,Public record,1695,talactoferrin alfa,9/29/2006,Treatment of renal cell carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.",8 Greenway Plaza,Suite 910,Houston,Texas,77046,United States,182203
TEPLIZUMAB,S4M959U2IJ,Designated,Public record,1696,teplizumab,9/29/2006,Treatment of recent-onset Type I diabetes,Designated,Not FDA Approved for Orphan Indication,,,,,"Provention Bio, Inc.",Box 666,,Oldwick,New Jersey,8858,United States,229606
COAGULATION FACTOR VIIA RECOMBINANT HUMAN,AC71R787OV,Designated/Withdrawn,Public record,1697,Coagulation Factor VIIa (Recombinant),10/3/2006,Treatment of bleeding in patients experiencing intracranial hemorrhage.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",P. O. Box 846,,Plainsboro,New Jersey,8536,United States,192404
DOVITINIB,I35H55G906,Designated/Withdrawn,Public record,1698,Dovitinib,10/3/2006,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,210105
MILTEFOSINE,53EY29W7EC,Designated/Approved,Public record,1699,miltefosine,10/10/2006,Treatment of leishmaniasis.,Designated/Approved,,"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.",3/19/2014,3/19/2021,"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.",Knight Therapeutics (USA),Corporation Trust Center,1209 Orange Street,Wilmington,Delaware,19801,United States,229406
DDP-225 FREE BASE ANHYDROUS,CU79LWT2HF,Designated,Public record,1700,4-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl),10/11/2006,Treatment of Chronic Functional Vomiting to include functional vomiting and cyclic vomiting syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Dynogen Pharmaceuticals, Inc.",52 Second Avenue,,Waltham,Massachusetts,2451,United States,199704
BERUBICIN HYDROCHLORIDE,7BA3X03948,Designated/Withdrawn,Public record,1701,"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)",10/11/2006,Treatment of malignant gliomas,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",1950 N. Stemmons Freeway,,Dallas,Texas,75207,United States,227606
MEPIVACAINE,B6E06QE59J,Designated,Public record,1702,mepivacaine,10/18/2006,Treatment of painful HIV-associated neuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Relmada Therapeutics, Inc.",750 3rd Avenue,9th Floor,New York,New York,10017,United States,206705
ADALIMUMAB,FYS6T7F842,Designated/Approved,Public record,1703,adalimumab,10/19/2006,Treatment of pediatric Crohn's disease,Designated/Approved,,Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathiop,9/23/2014,9/23/2021,Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathio,"AbbVie, Inc.",1 N. Waukegan Road,"Bldg AP30, Dept. PA77",North Chicago,Illinois,60064,United States,230306
CARLUMAB,6TC1BB2EV9,Designated,Public record,1704,carlumab,10/24/2006,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley PArkway,,Malvern,Pennsylvania,19355,United States,231506
CYSTEAMINE,5UX2SD1KE2,Designated/Approved,Public record,1705,cysteamine enteric coated,10/24/2006,Treatment of cystinosis,Designated/Approved,,PROCYSBI is indicated for the treatment of nephropathic cystinosis in adult and pediatric patients 2 years of age and older.,8/14/2015,8/14/2022,Treatment of nephropathic cystinosis in pediatric patients 2 years of age to less than 6 years of age.,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,60045,United States,231006
CYSTEAMINE,5UX2SD1KE2,Designated/Approved,Public record,1706,cysteamine enteric coated,10/24/2006,Treatment of cystinosis,Designated/Approved,,PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.,12/22/2017,12/22/2024,Treatment of nephropathic cystinosis in pediatric patients 1 year of age to less than 2 years of age.,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,60045,United States,231006
CYSTEAMINE,5UX2SD1KE2,Designated/Approved,Public record,1707,cysteamine enteric coated,10/24/2006,Treatment of cystinosis,Designated/Approved,,PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.,2/14/2020,,,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,60045,United States,231006
CYSTEAMINE,5UX2SD1KE2,Designated/Approved,Public record,1708,cysteamine enteric coated,10/24/2006,Treatment of cystinosis,Designated/Approved,,PROCYSBI is indicated for the management of nephropathic cystinosis in adults and children ages 6 years and older.,4/30/2013,4/30/2020,Management of nephropathic cystinosis in adults and children ages 6 years and older.,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,60045,United States,231006
"""GOSSYPOL, (R)-""",8DY2X8LXW4,Designated,Public record,1709,R-(-)-gossypol,10/24/2006,Treatment of chronic lymphocytic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Ascenta Therapeutics, Inc.",101 Lindenwood Drive,Suite 405,Malvern,Pennsylvania,19355,United States,230206
AMATUXIMAB,6HP0354G04,Designated/Withdrawn,Public record,1710,Chimeric monoclonal antibody to mesothelin,10/31/2006,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Morphotek, Inc.",210 Welsh Pool Road,,Exton,Pennsylvania,19341,United States,231606
ESTRADIOL,4TI98Z838E,Designated,Public record,1711,estradiol Gel,10/31/2006,Estrogen replacement therapy in females with Turner syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Ascend Therapeutics US, LLC",15 Mount Kemble Avenue,,Morristown,New Jersey,7960,United States,231706
IDEBENONE,HB6PN45W4J,Designated,Public record,1712,idebenone,10/31/2006,Treatment of Leber's hereditary optic neuropathy.,Designated,Not FDA Approved for Orphan Indication,,,,,Santhera Pharmaceuticals (Switzerland) Limited,Hammerstrass 49,CH-4410 Liestal,Liestal,,,Switzerland,232006
OBATOCLAX MESYLATE,39200FJ43J,Designated/Withdrawn,Public record,1713,Obatoclax mesylate,11/6/2006,Treatment of myelodysplastic syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gemin X, Inc.",400 Chesterfield Parkway,Suite 100,Malvern,Pennsylvania,19355,United States,232106
HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN,33T61IWL27,Designated/Approved,Public record,1714,Varicella Zoster Immune Globulin (Human),11/7/2006,"Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella",Designated/Approved,,Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella,12/20/2012,12/20/2019,,"Cangene bioPharma, Inc.",155 Innovation Drive,,Winnipeg,,,Canada,228006
PAFURAMIDINE MALEATE,K27F04K3A9,Designated,Public record,1715,pafuramidine maleate,11/17/2006,Treatment of pneumocystis jiroveci pneumonia,Designated,Not FDA Approved for Orphan Indication,,,,,"Immtech Pharmaceuticals, Inc.",150 Fairway Drive,Suite 150,Vernon Hills,Illinois,60061,United States,220706
FENOBAM HYDROCHLORIDE,18X2C0C12Z,Designated,Public record,1716,Fenobam hydrochloride,11/20/2006,Treatment of fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuropharm, Ltd.",87 Church Street,,"Crowthorne, Berkshire",,,United Kingdom,232406
IOBENGUANE I-123,P2TH1XYZ84,Designated/Approved,Public record,1717,Iobenguane I 123,12/1/2006,For the diagnosis of pheochromocytomas,Designated/Approved,,To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests,9/19/2008,9/19/2015,,"GE Healthcare, Inc.",101 Carnegie Center,,Princeton,New Jersey,8540,United States,226506
IOBENGUANE I-123,P2TH1XYZ84,Designated/Approved,Public record,1718,Iobenguane I 123,12/1/2006,For the diagnosis of neuroblastomas,Designated/Approved,,To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests,9/19/2008,9/19/2015,,"GE Healthcare, Inc.",101 Carnegie Center,,Princeton,New Jersey,8540,United States,226406
OBATOCLAX MESYLATE,39200FJ43J,Designated/Withdrawn,Public record,1719,Obatoclax mesylate,12/1/2006,Treatment of myelofibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gemin X Pharmaceuticals US, Inc.",400 Chesterfield Pkwy.,Suite 100,Malvern,Pennsylvania,19355,United States,233006
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,1720,"Amyl nitrite, sodium nitrite, sodium thiosulfate",12/18/2006,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Akorn, Inc.",2500 Millbrook Drive,,Buffalo Grove,Illinois,60089,United States,232506
Sodium nitrite,M0KG633D4F,Designated,Public record,1720,"Amyl nitrite, sodium nitrite, sodium thiosulfate",12/18/2006,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Akorn, Inc.",2500 Millbrook Drive,,Buffalo Grove,Illinois,60089,United States,232506
AMYL NITRITE,22T8Z09XAK,Designated,Public record,1720,"Amyl nitrite, sodium nitrite, sodium thiosulfate",12/18/2006,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Akorn, Inc.",2500 Millbrook Drive,,Buffalo Grove,Illinois,60089,United States,232506
RISEDRONATE SODIUM,OFG5EXG60L,Designated/Withdrawn,Public record,1721,risedronate sodium,12/18/2006,Treatment of patients with osteogenesis imperfecta,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Warner Chilcott Pharmaceuticals,100 Enterprise Drive,,Roakaway,New Jersey,7866,United States,229106
SALIRASIB,MZH0OM550M,Designated/Withdrawn,Public record,1722,salirasib,12/18/2006,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Kadmon Corporation, LLC",450 East 29th Street,5th Floor,New York,New York,10016,United States,231306
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,1723,Sodium thiosulfate and sodium nitrite,12/18/2006,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Akorn, Inc.",2500 Millbrook Drive,,Buffalo Grove,Illinois,60089,United States,233306
Sodium nitrite,M0KG633D4F,Designated,Public record,1723,Sodium thiosulfate and sodium nitrite,12/18/2006,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Akorn, Inc.",2500 Millbrook Drive,,Buffalo Grove,Illinois,60089,United States,233306
TADALAFIL,742SXX0ICT,Designated/Approved,Public record,1724,tadalafil,12/18/2006,Treatment of pulmonary arterial hypertension,Designated/Approved,,Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability,5/22/2009,5/22/2016,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,228206
TECOVIRIMAT,F925RR824R,Designated,Public record,1725,tecovirimat,12/18/2006,post exposure prophylaxis against smallpox,Designated,Not FDA Approved for Orphan Indication,,,,,"SIGA Technologies, Inc.",4575 SW Research Way,Suite 230,Corvallis,Oregon,97333,United States,233506
BUDESONIDE,Q3OKS62Q6X,Designated,Public record,1726,budesonide,12/20/2006,Treatment of patients with eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,227406
AMONAFIDE L-MALATE,LI06Q37TEG,Designated/Withdrawn,Public record,1727,Amonafide L-malate,12/20/2006,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Xanthus Pharmaceuticals, Inc.",An Antisoma Group Company,300 Technology Square,Cambridge,Massachusetts,2139,United States,227506
VOCLOSPORIN,2PN063X6B1,Designated,Public record,1728,"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}",12/20/2006,"Treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis",Designated,Not FDA Approved for Orphan Indication,,,,,"Lux Biosciences, Inc.",Hoarborside Financial Center,"Plaza 10, 14th Floor",Jersey City,New Jersey,7302,United States,227806
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1730,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R ; and treatment of CF in patients age 2 years and older who",3/17/2015,3/17/2022,"Treatment of cystic fibrosis (CF) in patients ages 2 to less than 6 years who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, and R117H.","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1731,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,5/17/2017,5/17/2024,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1732,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R; and treatment of CF in patients age 6 years and older who h",12/29/2014,12/29/2021,Treatment of cystic fibrosis (CF) in patients age 6 years and older who have an R117H mutation in the CFTR gene.,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1733,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.",2/21/2014,2/21/2021,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1734,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.,1/31/2012,1/31/2019,,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1735,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,treatment of cystic fibrosis (CF) in patients age 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,5/3/2023,,,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1736,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,12/21/2020,12/21/2027,treatment of cystic fibrosis (CF) in patients age 4 months and older who have one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to ivacaftor potentiation based on,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1737,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,9/24/2020,9/24/2027,treatment of cystic fibrosis (CF) in patients age 4 months to less than 6 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1738,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation,4/29/2019,4/29/2026,For the treatment of cystic fibrosis (CF) in patients age 6 months to less than 12 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1739,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 12 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,8/15/2018,8/15/2025,For the treatment of cystic fibrosis (CF) in patients age 12 months to less than 2 years who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,1740,ivacaftor,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,7/31/2017,7/31/2024,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: 711+3A G, E831X, 2789+5G A, 3272-26A G, and 3849+10kbC T.","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,228306
ROSE BENGAL SODIUM,956575SN5L,Designated,Public record,1741,Rose Bengal Disodium,12/21/2006,Treatment of metastatic melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Provectus BioPharmaceuticals, Inc.",10025 Investment Drive,Suite 250,Knoxville,Tennessee,37932,United States,233706
CIPROFLOXACIN,5E8K9I0O4U,Designated,Public record,1743,Liposomal ciprofloxacin for inhalation,12/27/2006,Management of bronchiectasis,Designated,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"6836 Bee Cave Road, Building 3, Suite 200",,Austin,Texas,78746,United States,230806
DOXORUBICIN HYDROCHLORIDE,82F2G7BL4E,Designated,Public record,1744,Liposomal doxorubicin hydrochloride,12/27/2006,Treatment of soft tissue sarcomas,Designated,Not FDA Approved for Orphan Indication,,,,,GP-Pharm SA,"Pol. Ind. Els Vinyets els Fogars n 2,",Quinti de Mediona,Barcelona,,,Spain,229006
BAFETINIB,NVW4Z03I9B,Designated,Public record,1745,"N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide",12/27/2006,Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,11726 San Vicente Blvd.,,Los Angeles,California,90049,United States,233206
TECOVIRIMAT,F925RR824R,Designated/Approved,Public record,1746,tecovirimat,12/27/2006,Treatment of smallpox,Designated/Approved,,Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 3 kg,5/18/2022,,,"SIGA Technologies, Inc.",4575 SW Research Way,Suite 230,Corvallis,Oregon,97333,United States,229806
TECOVIRIMAT,F925RR824R,Designated/Approved,Public record,1747,tecovirimat,12/27/2006,Treatment of smallpox,Designated/Approved,,TPOXX® is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.,7/13/2018,7/13/2025,TPOXX® is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.,"SIGA Technologies, Inc.",4575 SW Research Way,Suite 230,Corvallis,Oregon,97333,United States,229806
CYCLOSPORINE,83HN0GTJ6D,Designated/Withdrawn,Public record,1748,Cyclosporine A implant,1/8/2007,For the prevention of acute rejection in cornea transplant patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Lux Biosciences, Inc.",Harborside Financial Center,"Plaza 10, 14th Floor",Jersey City,New Jersey,7302,United States,224106
DEFIBROTIDE SODIUM,L7CHH2B2J0,Designated,Public record,1749,defibrotide,1/8/2007,For the prevention of hepatic veno-occlusive disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,94304,United States,228406
PIPERAQUINE,A0HV2Q956Y,Designated,Public record,1750,dihydroartemisinin and piperaquine,1/8/2007,"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale.""",Designated,Not FDA Approved for Orphan Indication,,,,,Alfasigma S.p.A,223 Viale Sarca,,Milano,Lombardia,,Italy,234006
ARTENIMOL,6A9O50735X,Designated,Public record,1750,dihydroartemisinin and piperaquine,1/8/2007,"Treatment of uncomplicated malaria caused by ""Plasmodium falciparum,"" Plasmodium vivax,"" Plasmodium malariae,"" or ""Plasmodium ovale.""",Designated,Not FDA Approved for Orphan Indication,,,,,Alfasigma S.p.A,223 Viale Sarca,,Milano,Lombardia,,Italy,234006
MEPIVACAINE,B6E06QE59J,Designated,Public record,1751,mepivacaine,1/8/2007,Treatment of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Relmada Therapeutics, Inc.",546 Fifth Avenue,14 Floor,New York,New York,10036,United States,206805
VINCRISTINE SULFATE LIPOSOME,,Designated/Approved,Public record,1753,vinCRIStine sulfate LIPOSOME injection,1/8/2007,Treatment of acute lymphoblastic leukemia,Designated/Approved,,Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.,8/9/2012,8/9/2019,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,234406
DROXIDOPA,J7A92W69L7,Designated/Approved,Public record,1754,droxidopa,1/17/2007,"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.",Designated/Approved,,"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy,",2/18/2014,2/18/2021,"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy,",Lundbeck LLC,"3530 Toringdon Way, Suite 200",,Charlotte,North Carolina,28277,United States,229506
LENALIDOMIDE,F0P408N6V4,Designated,Public record,1755,lenalidomide,1/17/2007,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,230606
Sodium nitrite,M0KG633D4F,Designated,Public record,1756,sodium nitrite,1/17/2007,Prevention of vasospasm associated with subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,233906
HYDROXYPROGESTERONE CAPROATE,276F2O42F5,Designated/Approved,Public record,1757,hydroxyprogesterone caproate,1/25/2007,Prevention of preterm birth in singleton pregnancies,Designated/Approved,,Makena auto-injector for subcutaneous injection is indicated to reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth.,2/14/2018,,,"AMAG Pharma USA, Inc.",1100 Winter Street,,Waltham,Massachusetts,2154,United States,218706
HYDROXYPROGESTERONE CAPROATE,276F2O42F5,Designated/Approved,Public record,1758,hydroxyprogesterone caproate,1/25/2007,Prevention of preterm birth in singleton pregnancies,Designated/Approved,,To reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth,2/3/2011,2/3/2018,,"AMAG Pharma USA, Inc.",1100 Winter Street,,Waltham,Massachusetts,2154,United States,218706
RANPIRNASE,ZE15FIT23E,Designated,Public record,1761,ranprinase,1/25/2007,Treatment of malignant mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,Alfacell Corporation,225 Belleville Ave.,,Bloomfield,New Jersey,7003,United States,236206
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,1763,Sodium phenylbutyrate,1/25/2007,Treatment of spinal muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"OrphaMed, Inc.",7720 N. Dobson Road,subsidiary of Medicis Pharmaceutical Corp.,Scottsdale,Alaska,85256,United States,235806
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated/Approved,Public record,1764,brentuximab vedotin,1/30/2007,Treatment of Hodgkin's lymphoma,Designated/Approved,,The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates,8/19/2011,8/19/2018,,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,235606
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated/Approved,Public record,1765,brentuximab vedotin,1/30/2007,Treatment of Hodgkin's lymphoma,Designated/Approved,,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,8/17/2015,8/17/2022,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,235606
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated/Approved,Public record,1766,brentuximab vedotin,1/30/2007,Treatment of Hodgkin's lymphoma,Designated/Approved,,"ADCETRIS® is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",3/20/2018,3/20/2025,"ADCETRIS® is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,235606
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated/Approved,Public record,1767,brentuximab vedotin,1/30/2007,Treatment of Hodgkin's lymphoma,Designated/Approved,,"treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide",11/10/2022,11/10/2029,treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL),Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,235606
CYTARABINE,04079A1RDZ,Designated,Public record,1768,cytarabine liposome,1/30/2007,Treatment of gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Bruce Frankel, MD",Medical University of South Carolina,"96 Jonathan Lucas Street, Suite 428 CSB",Charleston,South Carolina,29425,United States,234806
LINTUZUMAB,V00Y10W60W,Designated/Withdrawn,Public record,1769,lintuzumab,1/30/2007,Treatment of acute myeloid leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,235106
FENRETINIDE,187EJ7QEXL,Designated,Public record,1770,fenretinide,2/1/2007,Treatment of Ewing's sarcoma family of tumors.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Cancer Research UK,61 Lincoln's Inn Fields,WC2A 3PX,London,,,United Kingdom,236106
MARIBAVIR,PTB4X93HE1,Designated,Public record,1772,maribavir,2/1/2007,Prevention of cytomegalovirus viremia and disease in the populations at risk.,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Phrmaceuticals USA, Inc.",650 East Kendall Street,,Cambridge,Massachusetts,2142,United States,229906
BECAPLERMIN,1B56C968OA,Designated,Public record,1773,Recombinant human platelet derived growth factor BB,2/1/2007,Treatment of osteonecrosis of the jaws,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",800 Adams Avenue,Suite 100,Norristown,Pennsylvania,19403,United States,233106
CHENODIOL,0GEI24LG0J,Designated,Public record,1774,chenodeoxycholic acid,2/12/2007,Treatment of cerebrotendinous xanthomatosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Boulevard,Suite 500,Gaithersburg,Maryland,20878,United States,235406
IDEBENONE,HB6PN45W4J,Designated,Public record,1775,idebenone,2/16/2007,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Santhera Pharmaceuticals (Switzerland) Limited,Hammerstrass 49,CH-4410 Liestal,Liestal,,,Switzerland,231906
CETHROMYCIN,J0086219X6,Designated,Public record,1776,cethromycin,2/28/2007,Prophylactic treatment of patients exposed to inhalation anthrax.,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced LIfe Sciences, Inc.",1440 Davey Road,,Woodridge,Illinois,60517,United States,235906
AMINOLEVULINIC ACID HYDROCHLORIDE,V35KBM8JGR,Designated,Public record,1778,aminolevulinic acid hydrochloride,3/20/2007,Treatment of esophageal dysplasia,Designated,Not FDA Approved for Orphan Indication,,,,,"DUSA Pharmaceuticals, Inc.",25 Upton Place,,Wilmington,Massachusetts,1887,United States,236807
CISPLATIN,Q20Q21Q62J,Designated,Public record,1779,Cisplatin in liposomal formulation,3/20/2007,Treatment of osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Eleison Pharmaceuticals LLC,103 Carnegie Center,Suite 300,Princeton,New Jersey,8540,United States,238607
LINTUZUMAB,V00Y10W60W,Designated/Withdrawn,Public record,1780,lintuzumab,3/20/2007,Treatment of myelodysplastic syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,238007
NILOTINIB,F41401512X,Designated/Withdrawn,Public record,1781,nilotinib,3/20/2007,Treatment of gastrointestinal stromal tumors.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaeuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,237307
SIROLIMUS,W36ZG6FT64,Designated,Public record,1782,rapamycin,3/20/2007,Treatment of tuberous sclerosis complex,Designated,Not FDA Approved for Orphan Indication,,,,,"OncoImmune, Inc.",333 Parkland Plaza,Suite 1000,Ann Arbor,Michigan,48103,United States,237007
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,1783,Sodium phenylbutyrate,3/20/2007,Treatment of spinal muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Tikvah Therapeutics, Inc.","75 5th Street, NW.",,Atlanta,Georgia,30308,United States,236907
GANCICLOVIR,P9G3CKZ4P5,Designated/Approved,Public record,1784,ganciclovir,3/22/2007,Treatment of acute herpetic keratitis (dendritic and geographic ulcers),Designated/Approved,,Treatment of acute herpetic keratitis (dendritic ulcers),9/15/2009,9/15/2016,,"Sirion Therapeutics, Inc.",9314 East Broadway Avenue,,Tampa,Florida,33619,United States,237607
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,1785,Sodium nitrite/sodium thiosulfate,3/23/2007,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Pharmaceuticals, Inc.",26072 Merit Circle,,Laguna Hills,California,92653,United States,239207
Sodium nitrite,M0KG633D4F,Designated,Public record,1785,Sodium nitrite/sodium thiosulfate,3/23/2007,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Pharmaceuticals, Inc.",26072 Merit Circle,,Laguna Hills,California,92653,United States,239207
Sodium nitrite,M0KG633D4F,Designated,Public record,1786,sodium nitrite,4/2/2007,Treatment of vaso-occlusive crisis associated with sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,238707
THIOTEPA,905Z5W3GKH,Designated/Approved,Public record,1787,Thiotepa,4/2/2007,Conditioning treatment prior to hematopoietic stem cell transplantation,Designated/Approved,,Indicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogenic hematopoietic progenitor (stem) cell transplantation for pediatric patients with class 3 beta-t,1/26/2017,1/26/2024,Indicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogenic hematopoietic progenitor (stem) cell transplantation for pediatric patients with class 3 beta-t,ADIENNE S.A.,"Via Zurigo, 46",,Lugano,,,Switzerland,237807
ALVOCIDIB,45AD6X575G,Designated,Public record,1788,Alvocidib,4/13/2007,Teatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Dainippon Pharma Oncology, Inc.",640 Memorial Drive,,Cambridge,Massachusetts,2139,United States,239607
VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN),,Designated/Approved,Public record,1789,Human plasma coagulation Factor VIII and human plasma von Willebrand Factor,4/18/2007,Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated,Designated/Approved,,Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated,12/4/2009,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,7030,United States,234106
Sodium nitrite,M0KG633D4F,Designated,Public record,1790,sodium nitrite,4/18/2007,Treatment of cyanide poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd Street,Suite 125,Scottsdale,Alaska,85260,United States,233806
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,1792,cyclosporine,5/4/2007,Treatment of vernal keratoconjunctivitis,Designated/Approved,,Treatment of vernal keratoconjunctivitis (VKC) in children and adults,6/23/2021,6/23/2028,Treatment of vernal keratoconjunctivitis (VKC) in children and adults,Santen SAS,Batiment Genavenir IV,,F-91058-Evry cedex,,,France,239907
AXITINIB,C9LVQ0YUXG,Designated/Withdrawn,Public record,1794,N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide,5/4/2007,"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",10646 Science Center Drive,,San Diego,California,92121,United States,230706
MACIMORELIN ACETATE,AQZ1003RMG,Designated/Approved,Public record,1795,macimorelin acetate,5/14/2007,Diagnosis of growth hormone deficiency,Designated/Approved,,For the diagnosis of adult growth hormone deficiency,12/20/2017,12/20/2024,For the diagnosis of adult growth hormone deficiency.,Aeterna Zentaris GmbH,WeismilllerstraBe 50,,Frankfurt am Main,,60314,Germany,225506
PAFURAMIDINE MALEATE,K27F04K3A9,Designated,Public record,1796,Pafuramidine maleate,5/14/2007,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Immtech Pharmaceuticsl, Inc.",150 Fairway Drive,,Vernon Hills,Illinois,60061,United States,241207
"""PLEVITREXED, (?)-""",N094EYQ29D,Designated/Withdrawn,Public record,1797,Plevitrexed,5/14/2007,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,BTG International Ltd,10 Fleet Place,EC4M 7SB,London,,,United Kingdom,240307
VALINE-VALINE-GANCICLOVIR,ZW811N4EW6,Designated,Public record,1800,valine-valine-ganciclovir,5/21/2007,Treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HSV1 and HSV2.,Designated,Not FDA Approved for Orphan Indication,,,,,"Verenta Pharmaceuticals, Inc.",10901 Granada Lane,Suite 101,Leawood,Kansas,66211,United States,239007
LINIFANIB,CO93X137CW,Designated/Withdrawn,Public record,1801,N-[4-(3-amino1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl)urea,5/23/2007,Treatment of hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,240807
"""PLEVITREXED, (?)-""",N094EYQ29D,Designated/Withdrawn,Public record,1802,Plevitrexed,5/29/2007,Treatment of gastric (stomach cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,BTG International Ltd,10 Fleet Place,EC4M 7SB,London,,,United Kingdom,240207
AXITINIB,C9LVQ0YUXG,Designated/Withdrawn,Public record,1803,axitinib,5/31/2007,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",10646 Science Center Drive,,San Diego,California,92121,United States,240607
"""2'-HYDROXYETHOXYCAMPTOTHECIN, (5S,20S)-""",JY0ZTV10W1,Designated,Public record,1805,5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin,6/15/2007,Treatment of osteosarcoma (bone cancer),Designated,Not FDA Approved for Orphan Indication,,,,,"Dr. Reddy's Laboratories, Inc.",200 Somerset Corporate Blvd,"Building II, 7th Floor",Bridgewater,New Jersey,8807,United States,242107
CETUXIMAB,PQX0D8J21J,Designated/Withdrawn,Public record,1806,cetuximab,6/15/2007,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated,33 ImClone Drive,,Branchburg,New Jersey,8876,United States,237907
MIBEFRADIL,27B90X776A,Designated,Public record,1807,mibefradil,6/15/2007,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Cavion, LLC",600 E. Water Street,Suite E,Charlottesville,Virginia,22902,United States,224806
GENISTEIN,DH2M523P0H,Designated,Public record,1808,"5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one",6/18/2007,Prevention of acute radiation syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Humanetics Corporation,1550 Utica Avenue South,Suite 770,Eden Prairie,Minnesota,55416,United States,241107
DUVOGLUSTAT HYDROCHLORIDE,0RN23C42QR,Designated,Public record,1809,duvoglustat hydrochloride,6/18/2007,Treatment of Pompe disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amicus Therapeutics, Inc",1 Cedarbrook Drive,,Cranbury,New Jersey,8512,United States,238507
CORDYCEPIN,GZ8VF4M2J8,Designated,Public record,1810,Cordycepin,7/5/2007,Treatment of TdT-positive acute lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"OncoVista, Inc.",14785 Omicron Drive,,San Antonio,Texas,78245,United States,242507
IOBENGUANE I-131,Q461L7AK4R,Designated,Public record,1811,iobenguane I 131,7/5/2007,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Jubilant DraxImage, Inc.","Div. of Draxis Specialty Pharmaceuticals, Inc.",,Kirkland,,,Canada,241907
MIFEPRISTONE,320T6RNW1F,Designated/Approved,Public record,1812,mifepristone,7/5/2007,Treatment of the clinical manifestations of endogenous Cushing's syndrone,Designated/Approved,,for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.,2/17/2012,2/17/2019,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,94025,United States,239507
PRETOMANID,2XOI31YC4N,Designated,Public record,1813,Pretomanid,7/5/2007,Treatment of tuberculosis,Designated/Approved,,"Pretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB",8/14/2019,8/14/2026,As part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).,Global Alliance for TB Drug Development,40 Wall Street,24th Floor,New York,New York,10005,United States,243107
DELAMANID,8OOT6M1PC7,Designated,Public record,1814,"(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole",7/12/2007,Treatment of pulmonary tuberculosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Otsuka Pharmaceutical Company, Ltd","2-9, Kanda-Tsukasamachi",,Tokyo,,,Japan,244007
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated,Public record,1815,Intravenous immune globulin,7/26/2007,Treatment of Stage IIB to IV malignant melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,GammaCan Ltd.,39 Jerusalem Street,,,,,Israel,243307
SODIUM ASCORBATE,S033EH8359,Designated,Public record,1817,Sodium ascorbate and menadione sodium bisulfite,7/31/2007,Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer),Designated,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,San Diego,California,92021,United States,236606
MENADIONE SODIUM BISULFITE,6XF3C2HK77,Designated,Public record,1817,Sodium ascorbate and menadione sodium bisulfite,7/31/2007,Treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage III and IV bladder cancer),Designated,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,San Diego,California,92021,United States,236606
MOCETINOSTAT DIHYDROBROMIDE,4V9P667Y2G,Designated,Public record,1818,N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide,8/8/2007,Treatment of Hodgkin's lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",9363 Towne Center Drive,Suite 200,San Diego,California,92121,United States,244307
TALACTOFERRIN ALFA,7A055A9QRR,Designated/Withdrawn,Public record,1819,Talactoferrin alfa,8/8/2007,Treatment of stage III/IV non-small cell lung cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.",8 Greenway Plaza,Suite 910,Houston,Texas,77046,United States,236707
BETULINIC ACID,4G6A18707N,Designated,Public record,1820,Betulinic acid,8/9/2007,Topical treatment of metastatic melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Life Sciences, Inc. (ALS)",1440 Davey Road,,Woodridge,Illinois,60517,United States,244107
BENDAMUSTINE HYDROCHLORIDE,981Y8SX18M,Designated/Approved,Public record,1821,Bendamustine hydrochloride,8/17/2007,Treatment of chronic lymphocytic leukemia,Designated/Approved,,Treatment of patients with chronic lymphocytic leukemia,3/20/2008,3/20/2015,,"Cephalon, Inc.",41 Moores Road,,Frazer,Pennsylvania,19355,United States,244807
MB-07133,BNL5ERR07R,Designated,Public record,1822,"4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone",8/22/2007,Treatment of hepatocellular carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Ligand Pharmaceuticals, Inc.",11085 N. Torrey Pines Road,Suite 300,LaJolla,California,92037,United States,228106
ARTEMETHER,C7D6T3H22J,Designated/Approved,Public record,1823,artemether/lumefantrine,8/31/2007,For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.,Designated/Approved,,"Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum",4/7/2009,4/7/2016,,Novartis Pharmaceuticals,Bldg 405/4051,One Health Plaza,East Hanover,New Jersey,7936,United States,245507
LUMEFANTRINE,F38R0JR742,Designated/Approved,Public record,1823,artemether/lumefantrine,8/31/2007,For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.,Designated/Approved,,"Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum",4/7/2009,4/7/2016,,Novartis Pharmaceuticals,Bldg 405/4051,One Health Plaza,East Hanover,New Jersey,7936,United States,245507
ASCORBIC ACID,PQ6CK8PD0R,Designated/Approved,Public record,1824,ascorbic acid,8/31/2007,Treatment of scurvy,Designated/Approved,,"for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated",10/2/2017,10/2/2024,"for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated",McGuff Pharmaceuticals Inc.,2921 W. MacArthur Blvd.,Suite 141,Santa Ana,California,92704,United States,243707
PAFURAMIDINE MALEATE,K27F04K3A9,Designated,Public record,1825,Pafuramidine maleate,8/31/2007,Treatment of human African trypanosomiasis (sleeping sickness),Designated,Not FDA Approved for Orphan Indication,,,,,"Immtech Pharmaceuticals, Inc.",150 Fairway Drive,Suite 150,Vernon Hills,Illinois,60061,United States,244507
PARATHYROID HORMONE,N19A0T0E5J,Designated/Approved,Public record,1826,parathyroid hormone,8/31/2007,Treatment of hypoparathyroidism,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,1/23/2015,1/23/2022,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,246707
RETASPIMYCIN,BZF2ZM0I5Z,Designated/Withdrawn,Public record,1827,retaspimycin,8/31/2007,Treatment for gastrointestinal stromal tumor,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Infinity Pharmaceuticals, Inc.",780 Memorial Drive,,Cambridge,Massachusetts,2139,United States,242907
Colchicine,SML2Y3J35T,Designated,Public record,1828,Colchicine,9/25/2007,Treatment of Behcet's Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"AR Scientific, Inc.",1100 Orthodox Street,,Philadelphia,Pennsylvania,19124,United States,245707
Colchicine,SML2Y3J35T,Designated/Approved,Public record,1829,colchicine,9/25/2007,Treatment of familial Mediterranean fever,Designated/Approved,,Treatment of familial Mediterranean fever,7/29/2009,7/29/2016,,"AR Holding Company, Inc.",1100 Orthodox Street,,Philadelphia,Pennsylvania,19124,United States,245807
PANOBINOSTAT,9647FM7Y3Z,Designated/Withdrawn,Public record,1830,Panobinostat,9/26/2007,Treatment of cutaneous T-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,"One Health Plaza, 105/3W038",,East Hanover,New Jersey,7936,United States,244407
DEXPRAMIPEXOLE,WI638GUS96,Designated,Public record,1832,dexpramipexole,10/11/2007,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Knopp Biosciences LLC,2100 Wharton Street,Suite 615,Pittsburgh,Pennsylvania,15203,United States,247107
INTERFERON GAMMA,P050J5FWC5,Designated,Public record,1833,Interferon gamma,10/11/2007,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,mondoBIOTECH Laboratories AG,"Herrengasse 21, 9490 Vaduz",,Liechtenstein,,,Germany,246107
TAMIBAROTENE,08V52GZ3H9,Designated,Public record,1835,Tamibarotene,10/11/2007,Treatment of acute promyelocytic leukemia (APL).,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,11726 San Vicente Blvd.,,Los Angeles,California,90049,United States,247007
SQ-109,9AU7XUV31A,Designated,Public record,1836,N-adamantanyl-N'-Geranyl-ethylenediamine,10/16/2007,Treatment of tuberculosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sequella, Inc.",9610 Medical Center Drive,,Rockville,Maryland,20850,United States,247307
TH-9402 FREE BASE,934QHK1OOK,Designated,Public record,1837,"4,5 dibromorhodamine methyl ester",10/23/2007,For immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Kiadis Pharma Netherlands B.V.,Entrada 231 - 234,,Amsterdam,,,Netherlands,246307
ETEPLIRSEN,AIW6036FAS,Designated/Approved,Public record,1838,eteplirsen,10/23/2007,Treatment of Duchenne Muscular Dystrophy.,Designated/Approved,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,9/19/2016,9/19/2023,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.",215 First Street,Suite 415,Cambridge,Massachusetts,2142,United States,248407
LOMITAPIDE,82KUB0583F,Designated/Approved,Public record,1839,lomitapide,10/23/2007,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,"Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (",12/21/2012,12/21/2019,,"Aegerion Pharmaceuticals, Inc.","101 Main St., Suite 1850",,Cambridge,Massachusetts,2142,United States,245907
LINIFANIB,CO93X137CW,Designated/Withdrawn,Public record,1840,N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea,10/23/2007,Treatment of acute myelogenous leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,248007
URSODIOL,724L30Y2QR,Designated,Public record,1841,ursodiol,10/23/2007,Treatment of cystic fibrosis liver disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Asklepion Pharmaceuticals, LLC",5200 Maryland Way,,Brentwood,Tennessee,37027,United States,242607
ROMIPLOSTIM,GN5XU2DXKV,Designated,Public record,1842,romiplostim,10/31/2007,Treatment of thrombocytopenia associated with myelodysplasia syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,,Thousand Oaks,California,91320,United States,234506
BETAHISTINE HYDROCHLORIDE,49K58SMZ7U,Designated,Public record,1843,Betahistine dihydrochloride,11/8/2007,Treatment of obesity associated with Prader Willi syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Auris Medical Inc.,500 North Michigan Avenue,Suite 600,Chicago,Illinois,60611,United States,247407
CARLUMAB,6TC1BB2EV9,Designated/Withdrawn,Public record,1844,carlumab,11/8/2007,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",200 Great Vallley Parkway,,Malvern,Pennsylvania,19355,United States,250007
COAGULATION FACTOR X HUMAN,0P94UQE6SY,Designated/Approved,Public record,1845,Coagulation factor X (human),11/8/2007,Treatment of hereditary factor X deficiency,Designated/Approved,,Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency,10/20/2015,10/20/2022,Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency,Bio Products Laboratory Limited,Dagger Lane,,Elstree,Hertfordshire,,United Kingdom,246907
COAGULATION FACTOR X HUMAN,0P94UQE6SY,Designated/Approved,Public record,1846,Coagulation factor X (human),11/8/2007,Treatment of hereditary factor X deficiency,Designated/Approved,,COAGADEX is indicated in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patien,9/21/2018,9/21/2025,Coagadex is indicated for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hereditary Factor X deficiency; on-demand treatment and control of bleeding episodes in children under the age of 12 years with heredita,Bio Products Laboratory Limited,Dagger Lane,,Elstree,Hertfordshire,,United Kingdom,246907
COAGULATION FACTOR X HUMAN,0P94UQE6SY,Designated/Approved,Public record,1847,Coagulation factor X (human),11/8/2007,Treatment of hereditary factor X deficiency,Designated/Approved,,"in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with mild, moderate",4/14/2023,4/14/2030,perioperative management of bleeding in adults and children with severe hereditary Factor X deficiency,Bio Products Laboratory Limited,Dagger Lane,,Elstree,Hertfordshire,,United Kingdom,246907
COAGULATION FACTOR XIA,Y42G5XID5M,Designated/Withdrawn,Public record,1848,human coagulation factor XI,11/8/2007,Treatment of severe congential Factor XI deficiency.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Laboratoire francais du Fractionnement et des Biot,3 Avenue des Tropiques,B.P. 305-Les Ulis,Courtaboeuf Cedex,,,France,229706
METRONIDAZOLE,140QMO216E,Designated,Public record,1849,Metronidazole 10% ointment,11/8/2007,Topical treatment of active perianal Crohn's disease,Designated,Not FDA Approved for Orphan Indication,,,,,SLA Pharma (UK) Ltd,Elite House,Hill Farm Industrial Estate,Watford WD25 7SA,,,United Kingdom,247907
GLATIRAMER ACETATE,5M691HL4BO,Designated,Public record,1851,glatiramer acetate,11/14/2007,Treatment of amyotrophic lateral sclerosis (ALS).,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Neurosciences, Inc.",P. O. Box 1005,,Horsham,Pennsylvania,19044,United States,247507
BRIVUDINE,2M3055079H,Designated/Withdrawn,Public record,1852,Brivudin,11/15/2007,Adjunct treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",901 Mariner's Island Blvd.,,San Mateo,California,94404,United States,247807
MOXETUMOMAB PASUDOTOX,2NDX4B6N8F,Designated,Public record,1853,moxetumomab pasudotox,11/15/2007,Treatment of CD22-positive chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike PO Box 8355,,Wilmington,Delaware,,United States,248807
MOXETUMOMAB PASUDOTOX,2NDX4B6N8F,Designated,Public record,1854,moxetumomab pasudotox-tdfk,11/15/2007,Treatment of hairy cell leukemia,Designated/Approved,,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",9/13/2018,9/13/2025,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",AstraZeneca Pharmaceuticals LP,1800 Concord Pike PO Box 8355,,Wilmington,Delaware,,United States,248707
RINDOPEPIMUT,K3L4X0501F,Designated,Public record,1855,rindopepimut,11/19/2007,Treatment of EGFRvIII-expressing glioblastoma multiforme,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Celldex Therapeutics, Inc.",119 Fourth Avenue,,Needham,Massachusetts,2494,United States,249207
VARESPLADIB SODIUM,F6M52CDT0W,Designated/Withdrawn,Public record,1856,varespladib sodium,11/19/2007,Prevention of acute chest syndrome in at-risk patients with sickle cell disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Anthera Pharmaceuticals, Inc.",25801 Industrial Blvd.,Suite B,Hayward,California,94545,United States,240107
MECASERMIN,7GR9I2683O,Designated,Public record,1857,mecasermin,12/3/2007,Treatment of myotonic dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",10 Finderne Avenue,Building 10,Bridgewater,New Jersey,8817,United States,249707
ANTITHROMBIN ALFA,AWV6I5L6H2,Designated/Approved,Public record,1858,recombinant human antithrombin,12/7/2007,"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures",Designated/Approved,,"Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.",2/6/2009,2/6/2016,,"GTC Biotherapeutics, Inc.",175 Crossing Blvd,,Framingham,Massachusetts,1702,United States,246807
VELIPARIB,01O4K0631N,Designated,Public record,1859,2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide,12/18/2007,Treatment of malignant melanoma stages IIb through IV.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,246607
BECLOMETHASONE DIPROPIONATE,5B307S63B2,Designated,Public record,1860,"beclomethasone 17,21-diproprionate",12/18/2007,Treatment of pediatric patients with Crohn disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,8540,United States,144201
CANAKINUMAB,37CQ2C7X93,Designated/Approved,Public record,1861,canakinumab,12/18/2007,Treatment of cryopyrin-associated periodic syndromes,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.",6/17/2009,6/17/2016,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,250507
CHLOROTOXIN,06UV5RFW57,Designated,Public record,1862,Chlorotoxin,12/18/2007,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,,United States,250407
CLOBAZAM,2MRO291B4U,Designated/Approved,Public record,1863,clobazam,12/18/2007,Treatment of Lennox-Gastaut Syndrome,Designated/Approved,,Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome inpatients 2 years of age or older,10/21/2011,10/21/2018,,"Lundbeck, Inc.",Four Parkway North,,Deerfield,Illinois,60015,United States,248307
ELESCLOMOL,6UK191M53P,Designated,Public record,1864,Elesclomol,12/18/2007,Treatment of metastatic melanoma in combination with paclitaxel,Designated,Not FDA Approved for Orphan Indication,,,,,Synta Pharmaceuticals Corporation,45 Hartwell Ave.,,Lexington,Massachusetts,2421,United States,243607
FLUDARABINE PHOSPHATE,1X9VK9O1SC,Designated/Approved,Public record,1865,Fludarabine phosphate oral tablets,12/18/2007,Treatment of B-cell chronic lymphocytic leukemia,Designated/Approved,,Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen,12/18/2008,12/18/2015,,"Sanofi-Aventis U.S., Inc.",55 Corproate Drive,P. O. Box 5925,Bridgewater,New Jersey,8807,United States,250607
NAVITOCLAX DIHYDROCHLORIDE,W8FZ00AY2S,Designated,Public record,1867,Bcl-2 Family Protein Inhibitor,12/19/2007,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,"Dept #PA72, Bldg. AP30-4",North Chicago,Illinois,60064,United States,251307
NAVITOCLAX DIHYDROCHLORIDE,W8FZ00AY2S,Designated/Withdrawn,Public record,1868,"(R)-4-(3-morpholin-4-yl-l-phenylsulfanylmenthyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enylmethyl]-piperazin-l-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride",12/19/2007,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,249107
ALEFACEPT,ELK3V90G6C,Designated/Withdrawn,Public record,1869,Alefacept,12/19/2007,For use as prophylaxis of rejection in patients receiving allogenic solid organ transplants.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,249307
CLONAZEPAM,5PE9FDE8GB,Designated,Public record,1870,Clonazepam Intranasal Spray,12/19/2007,Treatment of recurrent acute repetitive seizures,Designated,Not FDA Approved for Orphan Indication,,,,,"Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,94304,United States,243507
RESLIZUMAB,35A26E427H,Designated,Public record,1872,reslizumab,12/19/2007,Treatment of children with eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC",145 Brandywine Pkwy.,,West Chester,Pennsylvania,19380,United States,237507
MITOMYCIN,50SG953SK6,Designated/Approved,Public record,1875,mitomycin-C,1/8/2008,Treatment of refractory glaucoma as an adjunct to surgery,Designated/Approved,,An adjunct to ab externo glaucoma surgery.,2/7/2012,2/7/2019,,"Mobius Therapeutics, LLC",1141 South 7th Street,,St. Louis,Missouri,63104,United States,251407
TIOTROPIUM BROMIDE ANHYDROUS,XX112XZP0J,Designated,Public record,1876,Tiotropium bromide,1/8/2008,To improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",P. O. Box 368,900 Ridgebury Road,Ridgefield,Connecticut,6877,United States,241507
IDRONOXIL,995FT1W541,Designated/Withdrawn,Public record,1877,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",1/10/2008,Treatment of cholangiocarcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Marshall Edwards, Inc.",11975 El Camino Real,Suite 101,San Diego,California,92130,United States,254407
IDRONOXIL,995FT1W541,Designated/Withdrawn,Public record,1878,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",1/10/2008,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Marshall Edwards, Inc.",11975 El Camino Real,Suite 101,San Diego,California,92130,United States,251707
CARFILZOMIB,72X6E3J5AR,Designated/Approved,Public record,1880,carfilzomib,1/18/2008,Treatment of multiple myeloma,Designated/Approved,,Treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with isatuximab and dexamethasone,6/30/2022,,,"Onyx Therapeutics, Inc.",249 East Grand Avenue,,South San Francisco,California,94080,United States,252507
CARFILZOMIB,72X6E3J5AR,Designated/Approved,Public record,1881,carfilzomib,1/18/2008,Treatment of multiple myeloma,Designated/Approved,,treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and hyaluronidase-fihj and dexamethasone,11/30/2021,,,"Onyx Therapeutics, Inc.",249 East Grand Avenue,,South San Francisco,California,94080,United States,252507
CARFILZOMIB,72X6E3J5AR,Designated/Approved,Public record,1882,carfilzomib,1/18/2008,Treatment of multiple myeloma,Designated/Approved,,Treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone.,8/20/2020,,,"Onyx Therapeutics, Inc.",249 East Grand Avenue,,South San Francisco,California,94080,United States,252507
CARFILZOMIB,72X6E3J5AR,Designated/Approved,Public record,1883,carfilzomib,1/18/2008,Treatment of multiple myeloma,Designated/Approved,,Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.,7/20/2012,7/20/2019,,"Onyx Therapeutics, Inc.",249 East Grand Avenue,,South San Francisco,California,94080,United States,252507
GENTAMICIN SULFATE,8X7386QRLV,Designated,Public record,1884,paromomycin sulfate/gentamicin sulfate,1/18/2008,Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World),Designated,Not FDA Approved for Orphan Indication,,,,,Appili Therapeutics Inc.,21-1344 Summer Street,,Halifax,Nova Scotia,,Canada,231206
PAROMOMYCIN SULFATE,845NU6GJPS,Designated,Public record,1884,paromomycin sulfate/gentamicin sulfate,1/18/2008,Treatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World),Designated,Not FDA Approved for Orphan Indication,,,,,Appili Therapeutics Inc.,21-1344 Summer Street,,Halifax,Nova Scotia,,Canada,231206
PRAMIPEXOLE,83619PEU5T,Designated,Public record,1885,pramipexole,1/31/2008,Treatment of Tourette's syndrome in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Boehringer-Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,,Ridgefield,Connecticut,6877,United States,252007
IDRONOXIL,995FT1W541,Designated/Withdrawn,Public record,1886,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",2/1/2008,Treatment of Stage IIB through Stage IV malignant melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Marshall Edwards, Inc.",11975 El Camino Real,Suite 101,San Diego,California,92130,United States,252307
COAGULATION FACTOR VII HUMAN,4156XVB4QD,Designated,Public record,1888,Human prothrombin complex concentrate,2/1/2008,Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,7030,United States,225806
COAGULATION FACTOR X HUMAN,0P94UQE6SY,Designated,Public record,1888,Human prothrombin complex concentrate,2/1/2008,Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,7030,United States,225806
PROTHROMBIN,8FB1K07F16,Designated,Public record,1888,Human prothrombin complex concentrate,2/1/2008,Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,7030,United States,225806
COAGULATION FACTOR IX (HUMAN),,Designated,Public record,1888,Human prothrombin complex concentrate,2/1/2008,Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,7030,United States,225806
PROTEIN S HUMAN,90J3F6N5FN,Designated,Public record,1888,Human prothrombin complex concentrate,2/1/2008,Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,7030,United States,225806
PROTEIN C,3Z6S89TXPW,Designated,Public record,1888,Human prothrombin complex concentrate,2/1/2008,Reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,7030,United States,225806
MOCETINOSTAT DIHYDROBROMIDE,4V9P667Y2G,Designated,Public record,1889,N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide,2/1/2008,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",9363 Towne Center Drive,Suite 200,San Diego,California,92121,United States,253007
PACLITAXEL,P88XT4IS4D,Designated,Public record,1890,paclitaxel aqueous gel,2/1/2008,Treatment of esophageal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"BTG International, Inc.",5214 Maryland Way,Suite 405,Brentwood,Tennessee,37027,United States,252907
TRICIRIBINE,2421HMY9N6,Designated,Public record,1891,triciribine,2/1/2008,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"VioQuest Pharmaceuticals, Inc.",180 Mt. Airy Road,,Basking Ridge,New Jersey,7920,United States,249907
TRIHEPTANOIN,2P6O7CFW5K,Designated,Public record,1892,Triheptanoin,2/1/2008,Treatment of glycogen storage disorder II (Pompe disease),Designated,Not FDA Approved for Orphan Indication,,,,,Baylor Research Institute,3330 Live Oak Blvd,,Dallas,Texas,75204,United States,220406
ADH-1,B058ME29VU,Designated,Public record,1894,Cys-His-Ala-Val-Cys,2/14/2008,"For use in conjunction with melphalen for the treatment of malignant melanoma, AJCC stages IIB, IIC, III and IV",Designated,Not FDA Approved for Orphan Indication,,,,,"Adherex Technologies, Inc.",4620 Creekstone Drive,,Durham,North Carolina,27703,United States,252607
EVEROLIMUS,9HW64Q8G6G,Designated/Approved,Public record,1895,everolimus,2/14/2008,Treatment of neuroendocrine tumors,Designated/Approved,,"Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.",5/5/2011,5/5/2018,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,254107
EVEROLIMUS,9HW64Q8G6G,Designated/Approved,Public record,1896,everolimus,2/14/2008,Treatment of neuroendocrine tumors,Designated/Approved,,"Treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease; and treatment of adult patients with progressive, well-differentiated, non-functional, ne",2/26/2016,2/26/2023,"Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) (excluding pancreatic) or lung origin, with unresectable, locally advanced or metastatic disease.",Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,254107
BELATACEPT,E3B2GI648A,Designated/Approved,Public record,1897,belatacept,2/20/2008,Prophylaxis of organ rejection in renal allograft recipients,Designated/Approved,,Prophylaxis of organ rejection in adult patients receiving kidney transplants,6/15/2011,6/15/2018,,Bristol-Myers Squibb Company,P. O. Box 4000,,Princeton,New Jersey,8543,United States,253907
DOXORUBICIN,80168379AG,Designated,Public record,1898,doxorubicin with pluronics F-127 and L-61,2/20/2008,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Supratek Pharma, Inc.",6100 Royalmount Avenue,,Montreal,,,Canada,248107
Cebsulfase alfa,KK93B9NF24,Designated,Public record,1899,arylsulfatase A (rhASA),2/27/2008,Treatment of metachromatic leukodystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,254207
CENERSEN,K6KJ8AZ05F,Designated,Public record,1900,cenersen,2/27/2008,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.",1001 Twelve Oaks Center Drive,Suite 1002,Wayzata,Minnesota,55391,United States,252807
FISH OIL,XGF7L72M0F,Designated,Public record,1901,fish oil triglycerides,2/27/2008,Treatment of parenteral nutrition-associated liver disease,Designated/Approved,,Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC),7/27/2018,7/27/2025,Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC),"Fresenius Kabi USA, LLC",3 Corporate Drive,,Lake Zurich,Illinois,60047,United States,251507
LEVOFLOXACIN,6GNT3Y5LMF,Designated,Public record,1902,Levofloxacin,2/27/2008,Treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,60045,United States,253707
MESALAMINE,4Q81I59GXC,Designated,Public record,1904,mesalamine; 5-aminosalicylic acid,2/27/2008,Treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).,Designated/Approved,,Lialda (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.,6/26/2020,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,253607
INDATUXIMAB RAVTANSINE,XGL4M23834,Designated,Public record,1905,N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody,2/27/2008,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Biotest AG,5 Landsteinerstraße,,Dreieich,Hessen,,Germany,255407
AMRUBICIN,93N13LB4Z2,Designated/Withdrawn,Public record,1906,amrubicin,3/10/2008,Treatment of small cell lung cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,9225 Indian Creek Parkway,Suite 900,Overland Park,Kansas,66210,United States,255307
ATALUREN,K16AME9I3V,Designated,Public record,1907,ataluren,3/10/2008,Treatment of spinal muscular atrophy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,255907
MILATUZUMAB,2OP4E0GC6V,Designated,Public record,1908,milatuzumab,3/10/2008,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,255807
RESVERATROL,Q369O8926L,Designated,Public record,1909,"5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol",3/13/2008,Treatment of MELAS syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Sirtris Pharmaceuticals, Inc.",200 Technology Square,,Cambridge,Massachusetts,2139,United States,241707
FIBRINOGEN HUMAN,N94833051K,Designated/Approved,Public record,1910,"human fibrinogen concentrate, pasteurized",3/13/2008,Treatment of fibrinogen deficient patients.,Designated/Approved,,Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia),1/16/2009,1/16/2016,,"CSL Behring, LLC",1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,19406,United States,245107
PACRITINIB,G22N65IL3O,Designated,Public record,1911,pacritinib,3/13/2008,"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF",Designated/Approved,,Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 x 109/L,2/28/2022,2/28/2029,Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 x 109/L,CTI BioPharma Corporation,3101 Western Avenue,Suite 800,Seattle,Washington,98121,United States,245607
BIFIDOBACTERIUM LONGUM INFANTIS 35624,0Z1FKO93PO,Designated,Public record,1912,bifidobacterium infantis 35624,3/24/2008,Treatment of pediatric ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,Alimentary Health Limited,"Cork Airport Business Park, Building 2800",,Cork,,,Ireland,255107
TALAMPANEL,CVS43XG1L5,Designated/Withdrawn,Public record,1915,talampanel,3/24/2008,Treatment of amyotrophic lateral sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,TEVA Neuroscience,P. O. Box 1005,425 Privet Road,Horsham,Pennsylvania,19044,United States,256007
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,1916,Alpha1-antitrypsin(human),4/3/2008,Treatment of bronchiectasis,Designated,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.,7 Sapir Street,,Ness Ziona,,,Israel,256508
OBETICHOLIC ACID,0462Z4S4OZ,Designated,Public record,1918,6-alpha-ethylchenodeoxycholic acid,4/9/2008,Treatment of primary sclerosing cholangitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Intercept Pharmaceuticals, Inc.",18 Desbrosses Street,,New York,New York,10013,United States,259008
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,1920,cyclosporine A,4/9/2008,Treatment of herpes simplex virus stromal keratitis,Designated,Not FDA Approved for Orphan Indication,,,,,Santen SAS,1 rue Pierre Fontaine,,91058 Evry cedex,,,France,254807
OBETICHOLIC ACID,0462Z4S4OZ,Designated/Approved,Public record,1921,obeticholic acid,4/9/2008,Treatment of primary biliary cirrhosis,Designated/Approved,,"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA",5/27/2016,5/27/2023,"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA","Intercept Pharmaceuticals, Inc.",4760 Eastgate Mall,,San Diego,California,92122,United States,253207
PEGINTERFERON ALFA-2B,G8RGG88B68,Designated/Approved,Public record,1922,peginterferon alfa-2b,4/9/2008,Treatment of malignant melanoma stages IIb through IV.,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy,3/29/2011,,,"Merck, Sharpe & Dohme Corp.",1 Merck Drive,,Whitehouse Station,New Jersey,8889,United States,249507
SODIUM THIOSULFATE,HX1032V43M,Designated/Approved,Public record,1923,sodium nitrite and sodium thiosulfate,4/9/2008,Treatment of known or suspected cyanide poisoning,Designated/Approved,,For sequential use for the treatment of cyanide poisoning that is judged to be life-threatening,1/14/2011,1/14/2018,,Hope Pharmaceuticals,16416 North 92nd Street,Suite 125,Scottsdale,Arizona,85260,United States,244207
Sodium nitrite,M0KG633D4F,Designated/Approved,Public record,1923,sodium nitrite and sodium thiosulfate,4/9/2008,Treatment of known or suspected cyanide poisoning,Designated/Approved,,For sequential use for the treatment of cyanide poisoning that is judged to be life-threatening,1/14/2011,1/14/2018,,Hope Pharmaceuticals,16416 North 92nd Street,Suite 125,Scottsdale,Arizona,85260,United States,244207
Cebsulfase alfa,KK93B9NF24,Designated/Withdrawn,Public record,1924,recombinant human arylsulphatase A,4/11/2008,Treatment of metachromatic leukodystrophy (MLD).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Shire Human Genetic Therapies,300 Patriot Way,,Lexington,Massachusetts,2421,United States,170903
TERGURIDE,21OJT43Q88,Designated/Withdrawn,Public record,1925,terguride,5/2/2008,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ErgoNex Pharma GmbH,Ruetistr. 20,,CH-9050 Appenzell,,,Switzerland,255007
NAVITOCLAX DIHYDROCHLORIDE,W8FZ00AY2S,Designated/Withdrawn,Public record,1926,"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride",5/5/2008,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,257408
TIOMOLIBDATE DIAMMONIUM,4V6I63LW1E,Designated,Public record,1927,ammonium tetrathiomolybdate,5/5/2008,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Pipex Pharmaceuticals, Inc.",3930 Varsity Drive,,Ann Arbor,Michigan,48108,United States,254007
ELTROMBOPAG,S56D65XJ9G,Designated/Approved,Public record,1928,eltrombopag,5/5/2008,Treatment of idiopathic thrombocytopenia purpura,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",11/20/2008,11/20/2015,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,251907
NABUMETONE,LW0TIW155Z,Designated,Public record,1929,nabumetone,5/5/2008,Treatment of pediatric juvenile rheumatoid arthritis,Designated,Not FDA Approved for Orphan Indication,,,,,Cook Pharma,109 Graylyn Drive,,Chapel Hill,North Carolina,27516,United States,255207
PALIFOSFAMIDE,6A4U6NN813,Designated/Withdrawn,Public record,1930,Palifosfamide,5/5/2008,Treatment of soft tissue sarcomas,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ZIOPHARM Oncology, Inc.","One First Avenue, Parris Building #34",Navy Yard Plaza,Boston,Massachusetts,2129,United States,257508
VALPROIC ACID,614OI1Z5WI,Designated,Public record,1931,Valproate,5/5/2008,Treatment of fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuropharm Ltd,",Fetcham Park House,,Surrey,,,United Kingdom,256908
CYSTEAMINE,5UX2SD1KE2,Designated,Public record,1932,cysteamine,5/9/2008,Treatment of Huntington's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,60045,United States,258008
Dimethyl sulfoxide,YOW8V9698H,Designated,Public record,1933,dimethyl sulfoxide,5/9/2008,For use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Abela Pharmaceuticals, Inc.",21581 Midcrest Drive,,Lake Forest,California,92630,United States,254707
VELIPARIB,01O4K0631N,Designated,Public record,1934,veliparib,5/9/2008,Treatment of glioblastoma multiforme when used in combination with DNA-damaging agents,Designated,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,257108
BLINATUMOMAB,4FR53SIF3A,Designated,Public record,1935,Blinatumomab,5/16/2008,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91230,United States,261708
BLINATUMOMAB,4FR53SIF3A,Designated,Public record,1936,blinatumomab,5/16/2008,Treatment for hairy cell leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91230,United States,261808
BLINATUMOMAB,4FR53SIF3A,Designated,Public record,1937,blinatumomab,5/16/2008,Treatment of prolymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91230,United States,261908
BLINATUMOMAB,4FR53SIF3A,Designated/Approved,Public record,1938,blinatumomab,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,12/3/2014,12/3/2021,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,"Amgen, Inc.",One Amgen Center Dr.,Mail Stop 17-2-A,Thousand Oaks,California,91320,United States,255707
BLINATUMOMAB,4FR53SIF3A,Designated/Approved,Public record,1939,blinatumomab,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children,7/11/2017,7/11/2024,treatment of Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children,"Amgen, Inc.",One Amgen Center Dr.,Mail Stop 17-2-A,Thousand Oaks,California,91320,United States,255707
BLINATUMOMAB,4FR53SIF3A,Designated/Approved,Public record,1940,blinatumomab,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),8/30/2016,8/30/2023,treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients weighing less than 45 kg,"Amgen, Inc.",One Amgen Center Dr.,Mail Stop 17-2-A,Thousand Oaks,California,91320,United States,255707
BLINATUMOMAB,4FR53SIF3A,Designated/Approved,Public record,1941,blinatumomab,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,BLINCYTO® is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.,3/29/2018,3/29/2025,For the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children,"Amgen, Inc.",One Amgen Center Dr.,Mail Stop 17-2-A,Thousand Oaks,California,91320,United States,255707
N-SULFOGLUCOSAMINE SULFOHYDROLASE,X0MD128U01,Designated,Public record,1942,sulfamidase,5/22/2008,For treatment of Sanfilippo Syndrome (MPS IIIA),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc.",300 Shire Way,,Lexington,Massachusetts,2421,United States,258408
"""SODIUM 2,2-DIMETHYLBUTYRATE""",XKM99SPB5I,Designated,Public record,1943,2 dimethylbutyrate,6/18/2008,Treatment of beta thalassemia,Designated,Not FDA Approved for Orphan Indication,,,,,"HemaQuest Pharmaceuticals, Inc.",1001 Fourth Avenue,Suite 3317,Seattle,Washington,98154,United States,259608
CTS-1027,2QD3F58224,Designated/Withdrawn,Public record,1944,4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl] tetrahydro-N-hydroxy-2H-pyran-4-carboxamide,6/18/2008,Prophylaxis of organ rejection in patients receiving allogeneic liver transplants,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Conatus Pharmaceuticals, Inc.",4365 Executive Drive,,San Diego,California,92121,United States,258308
AZACITIDINE,M801H13NRU,Designated,Public record,1945,Azacitidine,6/18/2008,Treatment of acute myeloid leukemia,Designated/Approved,,ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not ab,9/1/2020,9/1/2027,ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not ab,Bristol-Myers Squibb,86 Morris Ave,,Summit,New Jersey,7901,United States,257008
BUPIVACAINE,Y8335394RO,Designated,Public record,1946,bupivacaine,6/18/2008,Relief of persistent pain associated with postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,DURECT Corporation,10260 Bubb Road,,Cupertino,California,95014,United States,237207
CENERSEN,K6KJ8AZ05F,Designated,Public record,1947,cenersen,6/18/2008,Treatment of stage IIB through IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.",1001 Twelve Oaks Center Drive,Suite 1002,Wayzata,Minnesota,55391,United States,224506
ELACYTARABINE,TA7WJG93AR,Designated,Public record,1948,elacytarabine,6/18/2008,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,Clavis Pharma ASA,Parkveien 53 B,,Oslo,,,Norway,259408
STX-100,JD43Y6YF3N,Designated,Public record,1949,humanized monocloncal antibody against human integrin alphaVbeta6,6/18/2008,Treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.,Designated,Not FDA Approved for Orphan Indication,,,,,"Stromedix, Inc.",14 Cambridge Center,BIO 7-2,Cambridge,Massachusetts,2142,United States,258908
HYDROCORTISONE,WI4X0X7BPJ,Designated,Public record,1950,hydrocortisone modified release tabs,6/18/2008,Treatment of adrenal insufficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Shire ViroPharma, Inc.",300 Shire Way,,Lexington,Massachusetts,2421,United States,234906
ALICAFORSEN,J8435V445B,Designated,Public record,1952,alicaforsen,6/24/2008,Treatment of pouchitis.,Designated,Not FDA Approved for Orphan Indication,,,,,Atlantic Clinica Ltd.,Atlantic House,10 Rose & Crown Walk,Saffron Walden,Essex,,United Kingdom,260808
CARBON MONOXIDE,7U1EE4V452,Designated/Withdrawn,Public record,1953,carbon monoxide,6/24/2008,For use in the reduction of the incidence and severity of delayed graft function in patients undergoing solid organ transplanation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,INO Therapeutics,Perryville III Corporate Park,P. O. Box 9001,Hampton,New Jersey,8827,United States,241807
CARDIOTROPHIN 1,AJ7U77BR8I,Designated,Public record,1954,cardiotrophin-1,6/24/2008,To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,,Spain,244907
CICLETANINE HYDROCHLORIDE,T0SY6373OQ,Designated/Withdrawn,Public record,1955,cicletanine hydrochloride,6/24/2008,Treatment for pulmonary arterial hypertension.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,261608
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,1956,liposomal cyclosporine for inhalation,6/24/2008,Prevention of bronchiolitis obliterans.,Designated,Not FDA Approved for Orphan Indication,,,,,Zambon S.p.A.,Via Lillo del Duca 10,,Bresso,MI,20091,Italy,252207
MILATUZUMAB,2OP4E0GC6V,Designated,Public record,1957,milatuzumab,6/24/2008,Treatment of chronic lymphocytic leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,256608
OMIGAPIL,5V14HD0N4Q,Designated,Public record,1960,omigapil,6/24/2008,Treatment of congenital muscular dystrophy.,Designated,Not FDA Approved for Orphan Indication,,,,,Santhera Pharmaceuticals (Switzerland) Limited,Hammerstrass 49,CH-4410 Liestal,Liestal,,,Switzerland,260508
RETASPIMYCIN HYDROCHLORIDE,928Q33Q049,Designated/Withdrawn,Public record,1962,retaspimycin hydrochloride,6/24/2008,Treatment of melanoma stages IIb through IV.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,19803,United States,260608
VINCRISTINE SULFATE,T5IRO3534A,Designated,Public record,1964,vincristine sulfate liposomes,6/24/2008,Treatment of metastatic uveal melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,259108
Sodium nitrite,M0KG633D4F,Designated,Public record,1965,sodium nitrite,7/8/2008,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Airess Pharmaceuticals, Inc.","(subsidiary of Mast Therapeutics, Inc)",3611 Valley Centre Drive,San Diego,California,92130,United States,252707
AFAMELANOTIDE,QW68W3J66U,Designated,Public record,1966,afamelanotide,7/17/2008,Treatment of erythropoietic porphyrias,Designated/Approved,,SCENESSE® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP),10/8/2019,10/8/2026,Indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).,Clinuvel Inc.,P. O. Box 94026,,Menlo Park,California,94026,United States,263208
SINECATECHINS,T432289GYZ,Designated/Withdrawn,Public record,1967,polyphenon E,7/17/2008,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mitsui Norin Co., Ltd",223-1 Miyabara,426-0133,Fujieda City,,,Japan,260208
CRIZANLIZUMAB,L7451S9126,Designated,Public record,1968,crizanlizumab,7/22/2008,Treatment of sickle cell disease,Designated/Approved,,ADAKVEO® is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,11/15/2019,11/15/2026,Indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Novartis Pharmaceuticals Corporation,One Health Plaza,Building 337 B11.3D,East Hanover,New Jersey,,United States,259708
METYROSINE,DOQ0J0TPF7,Designated,Public record,1969,metyrosine,7/25/2008,Treatment of velocardiofacial syndrome associated psychosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cerberus Princeton, LLC",c/o Cerberus Capital Management L.P.,875 Third Avenue,New York,New York,10022,United States,265008
"""SODIUM 2,2-DIMETHYLBUTYRATE""",XKM99SPB5I,Designated,Public record,1970,"sodium 2, 2 dimethylbutyrate",7/25/2008,Treatment of sickle cell disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"HemaQuest Pharmaceuticals, Inc.",1001 Fourth Avenue,Suite 3317,Seattle,Washington,98154,United States,265108
SOTALOL,A6D97U294I,Designated/Approved,Public record,1971,sotalol (IV),7/25/2008,"For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.",Designated/Approved,,"For use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation /flutter, and for treatment of",7/2/2009,7/2/2016,,AltaThera Pharmaceuticals LLC,311 South Wacker Drive,Suite 2275A,Chicago,Illinois,60606,United States,247707
STX-107 DIHYDROCHLORIDE,70QU352PWM,Designated,Public record,1972,3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride,7/28/2008,Treatment of behavioral abnormalities associated with fragile X syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Seaside Therapeutics,840 Memorial Drive,,Cambridge,Massachusetts,2139,United States,263608
BERSANLIMAB,MP3N1L4OR6,Designated,Public record,1974,human anti-cellular adhesion molecule-1 monoclonal antibody,7/29/2008,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,BioInvent International AB,Solvegatan 41,,Lund,,,Sweden,258708
APADAMTASE ALFA,U5SFU33XUX,Designated,Public record,1975,Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs,7/29/2008,"Treatment of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic, and secondary forms.",Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,262208
APADAMTASE ALFA,U5SFU33XUX,Designated,Public record,1976,Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifs,7/29/2008,"Prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms.",Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,265208
AMUVATINIB,SO9S6QZB4R,Designated,Public record,1977,"4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide",7/30/2008,"Treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.",Designated,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd,,Dublin,California,94568,United States,262608
DEFERIPRONE,2BTY8KH53L,Designated,Public record,1978,deferiprone,7/31/2008,Treatment of Friedreich's ataxia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,264308
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated,Public record,1979,Intravenous immune globulin (human) 10%,7/31/2008,Treatment of stiff-person syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,,Hoboken,New Jersey,7030,United States,264208
BARDOXOLONE,7HT68L8941,Designated,Public record,1980,Bardoxolone,8/6/2008,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Drive,,Irving,Texas,75063,United States,264108
CYSTEAMINE,5UX2SD1KE2,Designated,Public record,1981,cysteamine,8/6/2008,Treatment of neuronal ceroid lipofuscinoses (Batten disease),Designated,Not FDA Approved for Orphan Indication,,,,,"Raptor Pharmaceuticals, Inc.",9 Commercial Blvd.,Suite 200,Novato,California,94949,United States,262408
CYTARABINE,04079A1RDZ,Designated/Approved,Public record,1983,Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection,8/22/2008,Treatment of acute myeloid leukemia,Designated/Approved,,treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients ages 1 year and older,3/30/2021,3/30/2028,treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients ages 1 year and older,"Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)",3170 Porter Drive,,Palo Alto,California,94304,United States,265808
DAUNORUBICIN,ZS7284E0ZP,Designated/Approved,Public record,1983,Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection,8/22/2008,Treatment of acute myeloid leukemia,Designated/Approved,,treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients ages 1 year and older,3/30/2021,3/30/2028,treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients ages 1 year and older,"Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)",3170 Porter Drive,,Palo Alto,California,94304,United States,265808
CYTARABINE,04079A1RDZ,Designated/Approved,Public record,1984,Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection,8/22/2008,Treatment of acute myeloid leukemia,Designated/Approved,,Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC),8/3/2017,8/3/2024,Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC),"Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)",3170 Porter Drive,,Palo Alto,California,94304,United States,265808
DAUNORUBICIN,ZS7284E0ZP,Designated/Approved,Public record,1984,Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection,8/22/2008,Treatment of acute myeloid leukemia,Designated/Approved,,Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC),8/3/2017,8/3/2024,Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC),"Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)",3170 Porter Drive,,Palo Alto,California,94304,United States,265808
CANOCTAKIN,MU4128F2CO,Designated,Public record,1985,glycafilin,8/22/2008,Prevention of delayed graft function after solid organ transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,ProtAffin Biotechnologies AG,Impulszentrum Graz - West,Reininghaustrasse 13 A,Graz,,,Austria,264808
SENECAVIRUS A,TXE79Q22ES,Designated,Public record,1986,Seneca Valley virus,8/22/2008,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Seneca Therapeutics, Inc.",202 St. Andrews Court,,Blue Bell,Pennsylvania,19422,United States,266008
LANSOPRAZOLE,0K5C5T2QPG,Designated,Public record,1987,"2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole",8/27/2008,Treatment of hepatocellular carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"BioQuant, Inc.",6330 Nancy Ridge Drive,,San Diego,California,92121,United States,264508
MOLGRAMOSTIM,B321AL142J,Designated,Public record,1988,granulocyte macrophage colony stimuling factor,8/27/2008,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"6836 Bee Cave Road, Building 3, Suite 201",,Austin,Texas,78746,United States,264908
VELTUZUMAB,BPD4DGQ314,Designated,Public record,1989,veltuzumab,8/28/2008,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,261308
DAUNORUBICIN CITRATE,5L84T2Z6NP,Designated,Public record,1990,Daunorubicin liposomal,9/5/2008,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Diatos USA, LLC",15310 Amberly Drive,,Tampa,Florida,33647,United States,266508
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,1992,nitric oxide,9/5/2008,Use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises),Designated,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Pharmaceuticals Ireland Ltd.,College Business & Technology Park,Cruiserath Road,Blanchardstown,Dublin,,Ireland,265708
PROPRANOLOL,9Y8NXQ24VQ,Designated/Approved,Public record,1993,propranolol,9/5/2008,Treatment of proliferating infantile hemangiomas requiring systemic therapy,Designated/Approved,,Treatment of proliferating infantile hemangioma requiring systemic therapy.,3/14/2014,3/14/2021,Treatment of proliferating infantile hemangioma requiring systemic therapy.,Pierre Fabre Dermatologie,"8 Campus Drive, 2nd Floor",,Parsippany,New Jersey,7054,United States,266708
RUXOLITINIB PHOSPHATE,436LRU32H5,Designated/Approved,Public record,1994,ruxolitinib phosphate,9/5/2008,Treatment of myelofibrosis,Designated/Approved,,"Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis",11/16/2011,11/16/2018,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,265308
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,D7RD81HE4W,Designated,Public record,1996,"anti-T-lymphocyte immune globulin, rabbit",9/12/2008,Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Neovii Biotech GmbH,Am Haag 6 + 7,,Graefelfing,,82166,Germany,182503
AQ-13,PKT9732S5K,Designated,Public record,1997,AQ-13 (4-aminoquinoline analog),9/12/2008,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Immtech Pharmaceuticals, Inc.",150 Fairway Drive,Suite 150,Vernon Hills,Illinois,60061,United States,266808
ASFOTASE ALFA,Z633861EIM,Designated/Approved,Public record,1998,Asfotase alfa,9/12/2008,Treatment of hypophosphatasia,Designated/Approved,,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),10/23/2015,10/23/2022,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),"Alexion Pharmaceuticals, Inc.",100 College St.,,New Haven,Connecticut,6510,United States,266608
ELIGLUSTAT,DR40J4WA67,Designated/Approved,Public record,2000,eliglustat,9/17/2008,Treatment of Type I Gaucher disease,Designated/Approved,,"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.",8/19/2014,8/19/2021,"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.",Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,265408
METRONIDAZOLE,140QMO216E,Designated,Public record,2001,metronidazole,9/17/2008,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,Avivia Project BV,Leeuwenhoekweg 12,,Schijndel,,,Netherlands,267008
IOFLUBENZAMIDE I-131,65O1D58Z6V,Designated,Public record,2002,[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide,9/17/2008,"Treatment of metastatic melanoma, stages IIB, IIC, III and IV",Designated,Not FDA Approved for Orphan Indication,,,,,"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,268008
BOSENTAN,Q326023R30,Designated/Withdrawn,Public record,2006,bosentan,9/30/2008,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,,Switzerland,267608
CANAKINUMAB,37CQ2C7X93,Designated/Approved,Public record,2007,canakinumab,9/30/2008,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.,5/9/2013,5/9/2020,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation,One Health Plaza,Bldg 135-566G,East Hanover,New Jersey,7936,United States,260408
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,2008,cyclosporine A,9/30/2008,Prevention of corneal graft rejection,Designated,Not FDA Approved for Orphan Indication,,,,,Santen SAS,Batiment Genavenir IV,,F-91058-Evry cedex,,,France,254907
DIFLUPREDNATE,S8A06QG2QE,Designated/Approved,Public record,2009,difluprednate,9/30/2008,Treatment of endogenous and traumatic anterior uveitis and panuveitis.,Designated/Approved,,Treatment of endogenous anterior uveitis,6/13/2012,6/13/2019,,Alcon Pharmaceuticals. Ltd.,Route Des Arsenaux 41,(P.O. Box 61),Fribourg,,,Switzerland,265608
EPRATUZUMAB,3062P60MH9,Designated,Public record,2010,epratuzumab,9/30/2008,Treatment of acute lymphoblastic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,260908
MIBEFRADIL,27B90X776A,Designated,Public record,2011,mibefradil,10/16/2008,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cavion, LLC",600 E. Water Street,Suite E,Charlottesville,Virginia,22902,United States,268608
ANTI-GD2 MONOCLONAL ANTIBODY 3F8,3GFS72WN4M,Designated,Public record,2012,monoclonal antibody 3F8,10/16/2008,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,United Therapeutics Corporation,55 TW Alexander Drive,P. O. Box 14186,Research Triangle Park,North Carolina,27709,United States,268808
PRALATREXATE,A8Q8I19Q20,Designated,Public record,2014,pralatrexate,10/20/2008,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,269008
PRALATREXATE,A8Q8I19Q20,Designated,Public record,2015,pralatrexate,10/20/2008,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,268308
CRIDANIMOD SODIUM,54W868ROLR,Designated,Public record,2016,recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3,10/20/2008,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Xenetic Biosciences Plc,London Bioscience Innovation Centre,2 Royal College Street,London,,,United Kingdom,267508
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated/Approved,Public record,2017,brentuximab vedotin,10/23/2008,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod",Designated/Approved,,The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen,8/19/2011,8/19/2018,,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,268908
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated/Approved,Public record,2018,brentuximab vedotin,10/23/2008,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod",Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and",11/16/2018,11/16/2025,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and",Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,268908
TH-9402 FREE BASE,934QHK1OOK,Designated,Public record,2020,"4, 5 dibromorhodamine methyl ester",10/30/2008,Treatment of follicular lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Kiadis Pharma Netherlands B.V.,Paasheuvelweg 25A,,Amsterdam,,,Netherlands,269808
TH-9402 FREE BASE,934QHK1OOK,Designated,Public record,2021,"4, 5 dibromorhodamine methyl ester",10/30/2008,Treatment of diffuse large B-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Kiadis Pharma Canada, Inc.",2525 Marie Curie,,Saint-Laurent (Quebec),,,Canada,255507
EFTRENONACOG ALFA,02E00T2QDE,Designated/Approved,Public record,2022,"Coagulation factor IX (recombinant), Fc fusion protein",10/30/2008,Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease),Designated/Approved,,"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",3/28/2014,3/28/2021,"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","Bioverativ Therapeutics, Inc.",225 2nd Avenue,,Waltham,Massachusetts,2451,United States,261508
ITRACONAZOLE,304NUG5GF4,Designated,Public record,2023,Itraconazole suspension,10/30/2008,Topical treatment of fungal otitis externa (otomycosis),Designated,Not FDA Approved for Orphan Indication,,,,,"Fairfield Clinical Trials, LLC",200 Steep Hill Road,,Weston,Connecticut,6883,United States,257308
TOPOTECAN HYDROCHLORIDE,956S425ZCY,Designated,Public record,2024,liposomal topotecan hydrochloride,10/30/2008,Treatment of gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"MedGenesis Therapeutix, Inc.",730-730 View Street,,Victoria,,,Canada,268508
STIRIPENTOL,R02XOT8V8I,Designated,Public record,2025,stiripentol,10/30/2008,Treatment of Dravet syndrome,Designated/Approved,,Treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more,7/14/2022,7/14/2029,Treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months to less than 2 years of age and weighing 7 kg or more,Biocodex,"7, avenue Gallieni",94250,Gentilly,,,France,266108
STIRIPENTOL,R02XOT8V8I,Designated,Public record,2026,stiripentol,10/30/2008,Treatment of Dravet syndrome,Designated/Approved,,DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.,8/20/2018,8/20/2025,DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.,Biocodex,"7, avenue Gallieni",94250,Gentilly,,,France,266108
GADODIAMIDE,84F6U3J2R6,Designated,Public record,2027,liposomal gadodiamide,11/12/2008,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"MedGenesis Therapeutix, Inc.",730-730 View Street,,Victoria,,,Canada,268408
MELPHALAN HYDROCHLORIDE,1VXP4V453T,Designated,Public record,2028,melphalan hydrochloride,11/12/2008,Treatment of patients with ocular (uveal) melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,10019,United States,271708
MELPHALAN HYDROCHLORIDE,1VXP4V453T,Designated,Public record,2029,melphalan hydrochloride,11/12/2008,Treatment of patients with cutaneous melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,10019,United States,270508
MIGLUSTAT,ADN3S497AZ,Designated/Withdrawn,Public record,2030,miglustat,11/12/2008,"Treatment of the neurological manifestations of Niemann-Pick disease,type C.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Actelion Pharmaceuticals Ltd,Innovation Centre,,Allschwil,,,Switzerland,270708
PHENYLACETIC ACID,ER5I1W795A,Designated,Public record,2032,"antineoplaston A10, antineoplaston AS2-1",11/21/2008,Treatment of gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Burzynski Research Institute, Inc.",9432 Old Katy Road,,Houston,Texas,77055,United States,267408
PHENYLACETYLGLUTAMINE,92358I79RG,Designated,Public record,2032,"antineoplaston A10, antineoplaston AS2-1",11/21/2008,Treatment of gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Burzynski Research Institute, Inc.",9432 Old Katy Road,,Houston,Texas,77055,United States,267408
ANTINEOPLASTON A10,16VY3TM7ZO,Designated,Public record,2032,"antineoplaston A10, antineoplaston AS2-1",11/21/2008,Treatment of gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Burzynski Research Institute, Inc.",9432 Old Katy Road,,Houston,Texas,77055,United States,267408
PENTOSAN POLYSULFATE SODIUM,914032762Y,Designated,Public record,2033,pentosan polysulfate sodium,11/21/2008,Treatment of sickle cell disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.",863 Mitten Road,,Burlingame,California,94010,United States,251607
TESETAXEL,UG97LO5M8Y,Designated,Public record,2034,tesetaxel,11/21/2008,"Treatment of stages IIB, IIC, III, and stage IV melanoma",Designated,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkley Heights,New Jersey,7922,United States,269108
MELPHALAN,Q41OR9510P,Designated/Approved,Public record,2036,melphalan,11/24/2008,High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation,Designated/Approved,,for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma,3/10/2016,3/10/2023,for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,270008
FOSFOMYCIN,2N81MY12TE,Designated,Public record,2037,fosfomycin/tobramycin,11/28/2008,Treatment of pulmonary infections associated with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"CURx Pharmaceuticals, Inc.",3210 Merryfield Row,,San Diego,California,92121,United States,271908
TOBRAMYCIN,VZ8RRZ51VK,Designated,Public record,2037,fosfomycin/tobramycin,11/28/2008,Treatment of pulmonary infections associated with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"CURx Pharmaceuticals, Inc.",3210 Merryfield Row,,San Diego,California,92121,United States,271908
ARBACLOFEN,NYU6UTW25B,Designated,Public record,2038,R-4-amino-3-(4-chlorophenyl)butanoic acid,11/28/2008,Treatment of the behavorial abnormalities associated with fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinical Research Associates, LLC",160 Fifth Avenue,7th Floor,New York,New York,10010,United States,271808
XMAB-2513,33VWC847G8,Designated,Public record,2039,anti-CD30 Fc engineered humanized monoclonal antibody,12/2/2008,Treatment of Hodgkin lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Xencor, Inc.",111 W. Lemon Avenue,,Monrovia,California,91016,United States,271208
CHLOROTOXIN,06UV5RFW57,Designated,Public record,2040,chlorotoxin,12/2/2008,"Treatment of stage IIb, IIc, III & IV melanoma",Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,,United States,264008
DEXAMETHASONE PHOSPHATE,2BP70L44PR,Designated,Public record,2041,dexamethasone phosphate,12/2/2008,Treatment of corneal graft rejection.,Designated,Not FDA Approved for Orphan Indication,,,,,"EyeGate Pharmaceuticals, Inc.",100 Beaver Street,,Waltham,Massachusetts,2453,United States,270608
QUININE SULFATE,KF7Z0E0Q2B,Designated,Public record,2042,quinine sulfate,12/2/2008,Treatment of malaria excluding Plasmodium faliparum,Designated,Not FDA Approved for Orphan Indication,,,,,"Zydus Pharmaceuticals, Inc.",210 Carnegie Center,,Princeton,New Jersey,8540,United States,272008
TOSEDOSTAT,KZK563J2UW,Designated,Public record,2044,Tosedostat,12/10/2008,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,CTI BioPharma Corporation,3101 Western Avenue,Suite 600,Seattle,Washington,98121,United States,272408
ENMD-2076,KXQ762CQTH,Designated,Public record,2045,2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,12/22/2008,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,20850,United States,270408
TESETAXEL,UG97LO5M8Y,Designated,Public record,2046,tesetaxel,12/22/2008,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Genta Inc.,200 Connell Drive,,Berkeley Heights,New Jersey,7922,United States,272508
PACLITAXEL,P88XT4IS4D,Designated,Public record,2047,paclitaxel aqueous gel,12/23/2008,Treatment of brain cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,BTG International Inc.,5214 Maryland Way,Suite 405,Brentwood,Tennessee,37027,United States,270208
LUTETIUM OXODOTREOTIDE LU-177,AE221IM3BB,Designated/Approved,Public record,2050,lutetium Lu 177 dotatate,1/12/2009,Treatment of gastro-entero-pancreatic neuroendocrine tumors,Designated/Approved,,"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults",1/26/2018,1/26/2025,"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults",Advanced Accelerator Applications,57 East Willow Street,,Millburn,New Jersey,7041,United States,271008
OMACETAXINE MEPESUCCINATE,6FG8041S5B,Designated,Public record,2051,omacetaine mepesuccinate,1/12/2009,Treatment of myelodysplastic syndromes,Designated,Not FDA Approved for Orphan Indication,,,,,IVAX International GmbH,Alpenstrasse 2,8640 Rapperswil,Frazer,,,Switzerland,272608
SHP-602,9X1ZQD68K7,Designated,Public record,2052,"(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid",2/4/2009,Treatment of chronic iron overload in patients with transfusion-dependent anemias,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Shire Development LLC,300 Shire Way,,Lexington,Massachusetts,2421,United States,269408
MUBODINA,5JUR4M77U7,Designated/Withdrawn,Public record,2054,recombinant human minibody against complement component C5,2/4/2009,Treatment of primary membranoproliferative glomerulonephritis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A.,Via Zurigo 46,6900,Lugno,,,Switzerland,270908
Ergidina,2Y94876JAR,Designated/Withdrawn,Public record,2055,recombinant human minibody against complement component C5 fused with RGD-motif,2/4/2009,Prevention of ischemia/reperfusion injury associated with solid organ transplantation.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A.,Via Zurigo 46,6900,Lugno,,,Switzerland,270308
RIVIPANSEL,4B115V09LB,Designated,Public record,2056,"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-",2/17/2009,Treatment of vaso-occlusive crisis in patients with sickle cell disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"GlycoMimetics, Inc.",9708 Medical Center Drive,,Rockville,Maryland,20850,United States,274608
OLESOXIME,A6778U5IFY,Designated,Public record,2057,"cholest-4-en-3-one, oxime",2/17/2009,Treatment of spinal muscular atrophy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",A Roche Group Member,1 DNA Way,South San Francisco,California,94080,United States,273108
ZUCAPSAICIN,15OX67P384,Designated,Public record,2058,civamide,2/17/2009,Treatment of postherpetic neuralgia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Winston Laboratories, Inc.",100 Fairway Drive,,Vernon Hills,Illinois,60061,United States,272308
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,2059,cyclosporine,2/17/2009,Prophylaxis of graft-versus-host disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sigmoid Pharma Limited,Dublin City University,,Dublin,,,Ireland,273308
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,2060,cyclosporine,2/17/2009,Treatment of graft-versus-host disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sigmoid Pharma Limited,Dublin City University,,Dublin,,,Ireland,275108
TALAMPANEL,CVS43XG1L5,Designated/Withdrawn,Public record,2061,talampanel,2/17/2009,Treatment of glioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"TEVA Neuroscience, Inc.",425 Privet Road,,Horsham,Pennsylvania,19044,United States,274408
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,2062,alpha1-proteinase inhibitor (human),2/20/2009,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring LLC,1020 First Avenue,P. O. Box 61501,King of Prussia,Pennsylvania,19406,United States,272908
2-IMINOBIOTIN,HXH71NRQ5C,Designated,Public record,2064,2-iminobiotin,2/24/2009,Treatment of perinatal asphyxia.,Designated,Not FDA Approved for Orphan Indication,,,,,Neurophyxia B.V.,Onderwijsboulevard 219,,5223 DE 's-Hertogenbosch,,,Netherlands,275609
BOSUTINIB,5018V4AEZ0,Designated/Approved,Public record,2065,bosutinib,2/24/2009,Treatment of chronic myelogenous leukemia,Designated/Approved,,BOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML).,12/19/2017,12/19/2024,Treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).,PF PRISM C.V.,Rivium Westlaan 142,,Capelle aan den IJssel,,,Netherlands,274808
BOSUTINIB,5018V4AEZ0,Designated/Approved,Public record,2066,bosutinib,2/24/2009,Treatment of chronic myelogenous leukemia,Designated/Approved,,"Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy",9/4/2012,9/4/2019,,PF PRISM C.V.,Rivium Westlaan 142,,Capelle aan den IJssel,,,Netherlands,274808
BECLOMETHASONE,KGZ1SLC28Z,Designated,Public record,2067,beclomethasone,3/4/2009,Treatment of pediatriac patients with ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Aptalis Pharma US, Inc.",100 Somerset corporate Blvd,,Bridgewater,New Jersey,8807,United States,274908
ENZASTAURIN,UC96G28EQF,Designated,Public record,2068,enzastaurin,3/4/2009,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Denovo Biopharma LLC,6331 Nancy Ridge Drive,,San Diego,California,92121,United States,277209
OFATUMUMAB,M95KG522R0,Designated/Approved,Public record,2069,ofatumumab,3/10/2009,Treatment of chronic lymphocytic leukemia,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,1/19/2016,1/19/2023,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,275809
OFATUMUMAB,M95KG522R0,Designated/Approved,Public record,2070,ofatumumab,3/10/2009,Treatment of chronic lymphocytic leukemia,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",4/17/2014,4/17/2021,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,275809
OFATUMUMAB,M95KG522R0,Designated/Approved,Public record,2071,ofatumumab,3/10/2009,Treatment of chronic lymphocytic leukemia,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine,10/26/2009,10/26/2016,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,275809
OFATUMUMAB,M95KG522R0,Designated/Approved,Public record,2072,ofatumumab,3/10/2009,Treatment of chronic lymphocytic leukemia,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).,8/30/2016,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,275809
DOXORUBICIN,80168379AG,Designated,Public record,2073,lyso-thermosensitive lipsomal doxorubicin,3/17/2009,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Celsion Corporation,997 Lenox Drive,Suite 100,Lawrenceville,New Jersey,8648,United States,276009
TECHNETIUM TC-99M SULFUR COLLOID,556Q0P6PB1,Designated/Approved,Public record,2074,"Technetium Tc99m sulfur colloid injection, lyophilized",3/17/2009,For localization of sentinel lymph nodes in patients with melanoma,Designated/Approved,,Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter,8/13/2012,8/13/2019,,"Pharmalucence, Inc.",10 DeAngelo Drive,,Bedford,Massachusetts,1730,United States,271608
TENOFOVIR,99YXE507IL,Designated/Approved,Public record,2075,tenofovir,3/17/2009,Treatment of pediatric HIV infection.,Designated/Approved,,Treatment of HIV infection in combination with other antiretroviral agents in patients 12 to less than 18 years of age,3/24/2010,3/24/2017,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster city,California,94404,United States,276209
ENMD-2076,KXQ762CQTH,Designated,Public record,2076,2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt,3/18/2009,Treatment of ovarian carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,20850,United States,277409
MILTEFOSINE,53EY29W7EC,Designated,Public record,2077,miltefosine,3/18/2009,Topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of T-cell lymphoma and B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,ExperGen Drug Development GmbH,Hernalser,,Haupstrasse 24/16,,,Austria,275409
QUIZARTINIB DIHYDROCHLORIDE,WK7Q6ZIZ10,Designated,Public record,2078,quizartinib,3/18/2009,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,7920,United States,277109
DISULFIDE ION,KD33TF3UJR,Designated/Withdrawn,Public record,2079,D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate,3/19/2009,"Treatment of melanoma, stages IIb through IV",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Thallion Pharmaceuticals, Inc.",7150 Alexander-Fleming,,Quebec,,,Canada,277709
FIBRINOLYSIN (HUMAN),D60E3WIF5Y,Designated/Withdrawn,Public record,2080,plasmin (human),3/30/2009,Treatment of acute peripheral arterial occlusion,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",8368 US 70 Busines Hwy West,,Clayton,North Carolina,27520,United States,275308
TOL-101,28X0AGG6P8,Designated,Public record,2082,Anti-T cell receptor murine monoclonal antibody,4/3/2009,Prophylaxis of acute rejection of solid organ transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Tolera Therapeutics, Inc.",4717 Campus Drive #800,,Kalamazoo,Michigan,49008,United States,275709
PACLITAXEL,P88XT4IS4D,Designated,Public record,2084,"paclitaxel, micellar",4/3/2009,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevar Therapeutics, Inc.",2825 E Cottonwood Parkway,Suite 180,Salt Lake City,Utah,84121,United States,278309
ALISERTIB SODIUM ANHYDROUS,23KN826MQ4,Designated/Withdrawn,Public record,2085,"sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate",4/3/2009,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,276309
VONAPANITASE,3LWJ2H14I9,Designated,Public record,2086,vonapanitase,4/3/2009,Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis,Designated,Not FDA Approved for Orphan Indication,,,,,"Proteon Therapeutics, Inc.",200 West Street,,Waltham,Massachusetts,2451,United States,273908
CAPLACIZUMAB,2R27AB6766,Designated,Public record,2087,Caplacizumab,4/14/2009,Treatment of thrombotic thrombocytopenic purpura,Designated/Approved,,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",2/6/2019,2/6/2026,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.","Ablynx, a wholly owned subsidiary of Sanofi Group",55 Corporate Drive,,Bridgewater,New Jersey,8807,United States,277909
MACITENTAN,Z9K9Y9WMVL,Designated/Withdrawn,Public record,2088,macitentan,4/14/2009,Treatment of idiopathic pulmonary fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,,Switzerland,279309
VITESPEN,H3598Y1TLJ,Designated,Public record,2089,oncophage,4/14/2009,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Agenus, Inc.",3 Forbes Road,,Lexington,Massachusetts,2421,United States,274208
TOBRAMYCIN,VZ8RRZ51VK,Designated/Withdrawn,Public record,2090,tobramycin liposomal for inhalation,4/14/2009,Treatment of chronic pulmonary infection due to P. aeruginosa in cystic fibrosis patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Axentis Pharma AG,138 Limmatquai,,Zurich,,,Switzerland,278009
MANNITOL,3OWL53L36A,Designated,Public record,2091,D-mannitol and L-proline,4/20/2009,Treatment of Cockayne syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,DNage B.V.,Darwinweg 24,,Leiden,,,Netherlands,277009
PROLINE,9DLQ4CIU6V,Designated,Public record,2091,D-mannitol and L-proline,4/20/2009,Treatment of Cockayne syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,DNage B.V.,Darwinweg 24,,Leiden,,,Netherlands,277009
DIAZEPINOMICIN,YPH994Y0RF,Designated/Withdrawn,Public record,2092,"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one",4/27/2009,Treatment of malignant glioma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Thallion Pharmaceuticals, Inc.",7150 Alexander-Fleming,,Quebec,,,Canada,278709
GLYCEROL PHENYLBUTYRATE,ZH6F1VCV7B,Designated/Approved,Public record,2094,glycerol phenylbutyrate,4/27/2009,Maintenance treatment of patients with deficiencies in enzymes of the urea cycle,Designated/Approved,,For use as a nitrogen-binding agent for chronic management of patients 2 months of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.,4/28/2017,4/28/2024,For use as a nitrogen-binding agent for chronic management of pediatric patients > or =2 months and,"Horizon Pharma USA, INc.",150 South Saunders Road,Suite 400,Lake Forest,Illinois,60045,United States,203505
GLYCEROL PHENYLBUTYRATE,ZH6F1VCV7B,Designated/Approved,Public record,2095,glycerol phenylbutyrate,4/27/2009,Maintenance treatment of patients with deficiencies in enzymes of the urea cycle,Designated/Approved,,Use as a nitrogen-binding agent for chronic management of adult and pediatric patients > or =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used,2/1/2013,2/1/2020,Use as a nitrogen-binding adjunctive therapy for chronic management of adult and pediatric patients at least 2 years of age with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAV,"Horizon Pharma USA, INc.",150 South Saunders Road,Suite 400,Lake Forest,Illinois,60045,United States,203505
LENALIDOMIDE,F0P408N6V4,Designated/Approved,Public record,2096,lenalidomide,4/27/2009,Treatment of mantle cell lymphoma,Designated/Approved,,"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.",6/5/2013,6/5/2020,"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.",Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,278809
ATELOCOLLAGEN,8WBS95X4J5,Designated,Public record,2097,purified bovine type collagen,4/27/2009,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Magnolia Therapeutics LLC,"605 Crescent Blvd., Suite 200",,Ridgeland,Mississippi,39157,United States,280609
"""ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT""",P89DR4NY54,Designated/Withdrawn,Public record,2098,Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent,4/29/2009,Treatment of hemophilia A,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare LLC,555 Whiteplains Road,,Tarrytown,New York,10591,United States,280309
ECULIZUMAB,A3ULP0F556,Designated/Approved,Public record,2099,eculizumab,4/29/2009,Treatment of atypical hemolytic uremic syndrome,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS),9/23/2011,9/23/2018,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,279509
PACLITAXEL,P88XT4IS4D,Designated,Public record,2100,paclitaxel,5/1/2009,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"SynCore Biotechnology Co., Ltd.",No. 84 Chung Shan Rd,Tung-Shan Shine I-Lan 269,,,,Taiwan,280409
URIDINE TRIACETATE,2WP61F175M,Designated/Approved,Public record,2101,uridine triacetate,5/1/2009,An antidote in the treatment of 5-fluorouracil or capecitabine poisoning,Designated/Approved,,"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous",12/11/2015,12/11/2022,"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous",Wellstat Therapeutics Corp.,14200 Shady Grove Road,Suite 600,Rockville,Maryland,20850,United States,273808
ASCORBIC ACID,PQ6CK8PD0R,Designated,Public record,2102,ascorbic acid,5/11/2009,Treatment of Charcot-Marie-Tooth disease type 1A.,Designated,Not FDA Approved for Orphan Indication,,,,,Murigenetics SAS,Faculte de Medecine Timone,,13005 Marseille,,,France,280909
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,2103,liposomal cyclosporine,5/11/2009,Treatment of bronchiolitis obliterans,Designated,Not FDA Approved for Orphan Indication,,,,,Zambon S.p.A.,Via Lillo del Duca 10,,Bresso,Ml,20091,Italy,252107
TOBRAMYCIN,VZ8RRZ51VK,Designated/Withdrawn,Public record,2105,tobramycin liposomal,5/11/2009,Treatment of pulmonary infection due to Burkholderia cepacia complex pathogens in cystic fibrosis patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Axentis Pharma AG,138 Limmatquai,,Zurich,,,Switzerland,281709
LATREPIRDINE,OD9237K1Z6,Designated,Public record,2106,dimebon,5/12/2009,Treatment of Huntington's Disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Medivation, Inc.",201 Spear Street,,San Francisco,California,94105,United States,282309
S-NITROSOGLUTATHIONE,78RRI89ZTO,Designated,Public record,2107,S-nitrosoglutathione,5/12/2009,Management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function,Designated,Not FDA Approved for Orphan Indication,,,,,"N30 PHARMAceuticals, LLC",3122 Sterling Circle,,Boulder,Colorado,80301,United States,281609
AZTREONAM,G2B4VE5GH8,Designated/Withdrawn,Public record,2108,aztreonam,5/15/2009,Improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",2025 1st Avenue,,Seattle,Washington,98121,United States,266208
ELOSULFASE ALFA,ODJ69JZG85,Designated/Approved,Public record,2109,elosulfase alfa,5/15/2009,Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome),Designated/Approved,,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),2/14/2014,2/14/2021,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,94949,United States,280809
OK-432,2F42BH7X2L,Designated,Public record,2110,picibanil,5/15/2009,Treatment of patients with lymphatic malformations,Designated,Not FDA Approved for Orphan Indication,,,,,"Royds Pharmaceuticals, Inc.",4365 Route 1 South,,Princeton,New Jersey,8540,United States,282009
TENECTEPLASE,WGD229O42W,Designated/Withdrawn,Public record,2111,tenecteplase,5/15/2009,Restore function to hemodialysis catheters,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,276709
FEDRATINIB HYDROCHLORIDE,UH9J2HBQWJ,Designated,Public record,2112,Fedratinib,5/18/2009,Treatment of secondary and primary myelofibrosis,Designated/Approved,,INREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,8/16/2019,8/16/2026,For the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,"Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation",86 Morris Avenue,,Summit,New Jersey,7901,United States,279409
CAPSAICIN,S07O44R1ZM,Designated/Approved,Public record,2113,capsaicin,5/22/2009,Management of neuropathic pain in patients with postherpetic neuralgia,Designated/Approved,,Management of neuropathic pain associated with postherpetic neuralgia,11/16/2009,11/16/2016,,"Averitas Pharma, Inc.",360 Mount Kemble Avenue,,Morristown,New Jersey,7960,United States,269508
IDEBENONE,HB6PN45W4J,Designated,Public record,2114,idebenone,5/22/2009,"Treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (MELAS)",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Santhera Pharmaceuticals (Switzerland) Ltd.,25 Hammerstrasse,,Liestal,Basel-Landschaft,,Switzerland,281909
MELPHALAN HYDROCHLORIDE,1VXP4V453T,Designated,Public record,2115,melphalan hydrochloride,5/22/2009,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,10019,United States,281809
ASTUPROTIMUT-R,50I23C5UOR,Designated/Withdrawn,Public record,2116,astuprotimut-R,5/29/2009,Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.",Rue de l'Institut 89,,B-1330 Rixensart,,,Belgium,283809
ASTUPROTIMUT-R,50I23C5UOR,Designated,Public record,2117,astuprotimut-R,5/29/2009,Treatment of MAGE-A3 positive non-small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.",Rue de I'Institut 89,,B-1330 Rixensart,,,Belgium,283709
LAPATINIB,0VUA21238F,Designated/Withdrawn,Public record,2118,lapatinib,5/29/2009,Treatment of ErbB2 positive gastric cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,284209
LAPATINIB DITOSYLATE,G873GX646R,Designated/Withdrawn,Public record,2119,lapatinib ditosylate hydrochloride,5/29/2009,Treatment of ErbB2 positive esophageal cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Hampshire,7936,United States,284309
PENTAGASTRIN,EF0NX91490,Designated,Public record,2120,pentagastrin,5/29/2009,To aid in the diagnosis of medullary thyroid carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,AOP Orphan IP AG,Staedtle 28,P.O. Box 838,Vaduz,,,Liechtenstein,277509
BICARBONATE ION,HN1ZRA3Q20,Designated,Public record,2122,"Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemopdialysis Solution",5/29/2009,For use as a replacement solution in adults and children during Continous Renal Replacement Therapy,Designated,Not FDA Approved for Orphan Indication,,,,,"Nikkiso America, Inc.",5910 Pacific Center Blvd,Suite 110,San Diego,California,92121,United States,276609
EVEROLIMUS,9HW64Q8G6G,Designated/Approved,Public record,2123,everolimus,6/8/2009,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",Designated/Approved,,For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.,4/10/2018,4/10/2025,For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,283609
EVEROLIMUS,9HW64Q8G6G,Designated/Approved,Public record,2124,everolimus,6/8/2009,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",Designated/Approved,,Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection,10/29/2010,10/29/2017,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,283609
EVEROLIMUS,9HW64Q8G6G,Designated/Approved,Public record,2125,everolimus,6/8/2009,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",Designated/Approved,,Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.,4/26/2012,4/26/2019,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,283609
PERTUZUMAB,K16AIQ8CTM,Designated,Public record,2126,pertuzumab,6/8/2009,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS # 355C,South San Francisco,California,94080,United States,284409
VELAGLUCERASE ALFA,23HYE36B0I,Designated/Approved,Public record,2127,velaglucerase-alfa,6/8/2009,Treatment of Gaucher disease,Designated/Approved,,Treatment of Type I Gaucher Disease,2/26/2010,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,283509
CATUMAXOMAB,M2HPV837HO,Designated,Public record,2128,catumaxomab,7/1/2009,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.",920 Winter Street,,Waltham,Massachusetts,2451,United States,284509
TETRABENAZINE,Z9O08YRN8O,Designated,Public record,2129,tetrabenazine,7/1/2009,"Treatment of Tourette's Syndrome in school-age children, ages 5-16",Designated,Not FDA Approved for Orphan Indication,,,,,Valeant International (Barbados) SRL,Welches Christ Church,,Barbados,,,Barbados,278109
OZANEZUMAB,123I05210W,Designated/Withdrawn,Public record,2130,anti-nogo-A monoclonal antibody,7/7/2009,Treatment of amyotrophic lateral sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,Glaxo Wellcome House,,"Greenford, Middlesex, UK UB6 0NN",,,United Kingdom,285709
MIDOSTAURIN,ID912S5VON,Designated/Approved,Public record,2132,midostaurin,7/7/2009,Treatment of acute myeloid leukemia,Designated/Approved,,"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.",4/28/2017,4/28/2024,"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.",Novartis Pharmaceuticals Corporation,"One Health Plaza, 105/3W038",,East Hanover,New Jersey,7936,United States,285909
ECOPIPAM HYDROCHLORIDE,5X1J3190JI,Designated,Public record,2133,ecopipam hydrochloride,7/21/2009,Symptomatic treatment of self injurious behaviors in patients with Lesch-Nyhan disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Emalex Biosciences, Inc.","1033 Skokie Bulevard, Suite 600",,Northbrook,Illinois,60062,United States,284109
MASITINIB,M59NC4E26P,Designated,Public record,2134,masitinib,7/21/2009,Treatment of patients with pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue George V",,"Paris,",,,France,285309
TRABEDERSEN,98OYR854NY,Designated,Public record,2135,trabedersen,7/21/2009,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Oncotelic Inc.,29397 Agoura Road,Suite 107,Agoura Hills,California,91301,United States,286709
BECLOMETHASONE DIPROPIONATE,5B307S63B2,Designated,Public record,2136,"beclomethasone 17,21-dipropionate",7/24/2009,Treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,8540,United States,285609
PASIREOTIDE,98H1T17066,Designated/Approved,Public record,2137,pasireotide,7/24/2009,Treatment of Cushing's disease,Designated/Approved,,SIGNIFOR® LAR is indicated for the treatment of patients with Cushing¿s disease for whom pituitary surgery is not an option or has not been curative.,6/29/2018,6/29/2025,Indicated for treatment of patients with Cushing¿s disease for whom pituitary surgery is not an option or has not been curative.,Novartis Pharmaceuticals Corporation,One Health Plaza,"Bldg 104, 3K28",East Hanover,New Jersey,7936,United States,288709
PASIREOTIDE,98H1T17066,Designated/Approved,Public record,2138,pasireotide,7/24/2009,Treatment of Cushing's disease,Designated/Approved,,Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative,12/14/2012,12/14/2019,,Novartis Pharmaceuticals Corporation,One Health Plaza,"Bldg 104, 3K28",East Hanover,New Jersey,7936,United States,288709
MEDI-547,D21E6RU881,Designated/Withdrawn,Public record,2139,Anti-EphA1 monoclonal antibody conjugated to mcMMAF,7/27/2009,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC",One MedImmune Way,,Gaithersburg,Maryland,20878,United States,288009
METHOTREXATE,YL5FZ2Y5U1,Designated,Public record,2142,methotrexate,8/20/2009,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Orbona Pharma Ltd,Old Chambers,93-94 West Street,Farnham,Surrey,,United Kingdom,286409
Acimtamig,ND470TT8Y3,Designated,Public record,2143,Recombinant antibody construct against human CD30 and CD16A,8/20/2009,Treatment of Hodgkin lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Affimed GmbH,Technologiepark,Im Neuenheimer Feld 582,Heidelberg,,,Germany,288109
RG-3039 FREE BASE,KSV93L7URW,Designated,Public record,2144,"5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine",8/25/2009,Treatment of spinal muscular atrophy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,CureSMA,925 Busse Avenue,,Elk Grove Village,Illinois,60007,United States,289509
DOXORUBICIN,80168379AG,Designated,Public record,2145,doxorubicin,8/25/2009,Treatment of hepatocellular carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,10019,United States,286109
AMIKACIN,84319SGC3C,Designated,Public record,2147,liposomal amikacin,8/25/2009,Treatment of bronchiectasis in patients with Pseudomonas aeruginosa or other susceptible microbial pathogens,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",Princeton Corpoarate Plaza,Suite C,Monmouth Junction,New Jersey,8852,United States,282109
MIBEFRADIL,27B90X776A,Designated,Public record,2148,mibefradil,8/25/2009,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cavion, LLC",600 E. Water Street,Suite E,Charlottesville,Virginia,22902,United States,289209
PASIREOTIDE,98H1T17066,Designated/Approved,Public record,2149,pasireotide,8/25/2009,Treatment of acromegaly,Designated/Approved,,Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option,12/15/2014,12/15/2021,Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option,Novartis Pharmaceuticals Corporation,One Health Plaza,"Bldg 104, 3K28",East Hanover,New Jersey,7936,United States,288609
MK-2206,4HA45S22ZZ,Designated,Public record,2152,"8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride",9/3/2009,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,291309
BELINOSTAT,F4H96P17NZ,Designated/Approved,Public record,2154,Belinostat,9/3/2009,Treatment of peripheral T-cell lymphoma (PTCL).,Designated/Approved,,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,7/3/2014,7/3/2021,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,289309
GLYCEROL PHENYLBUTYRATE,ZH6F1VCV7B,Designated,Public record,2155,gylceryl tri (4-pheynlybutyrate),9/3/2009,For intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.,Designated,Not FDA Approved for Orphan Indication,,,,,Horizon Therapeutics,1 Horizon Way,,Deerfield,Illinois,60015,United States,269308
IDURSULFASE,5W8JGG2651,Designated,Public record,2156,idursulfase IT,9/3/2009,For treatment of neurocognitive symptoms associated with Hunter Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Ave,,Lexington,Massachusetts,2421,United States,289709
LESTAURTINIB,DO989GC5D1,Designated,Public record,2157,lestaurtinib,9/3/2009,Treatment of Philadelphia-negative classic myeloproliferative disorders,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,289109
MACITENTAN,Z9K9Y9WMVL,Designated/Approved,Public record,2158,macitentan,9/3/2009,Treatment of pulmonary arterial hypertension,Designated/Approved,,"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance,",10/18/2013,10/18/2020,"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance,",Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,,Switzerland,282209
PACLITAXEL,P88XT4IS4D,Designated/Approved,Public record,2159,paclitaxel protein-bound particles,9/3/2009,Treatment of pancreatic cancer.,Designated/Approved,,"Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.",9/6/2013,9/6/2020,"Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.","Abraxis BioScience, LLC","9225 Indian Creek Parkway, Suite 900",,Overland Park,Kansas,66210,United States,291009
PERIFOSINE,2GWV496552,Designated/Withdrawn,Public record,2161,perifosine,9/3/2009,Treatment of multiple myeloma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Aeterna Zentaris GmbH,Weismuellerstrasse 50,,Frankfurt,,,Germany,290909
Progesterone,4G7DS2Q64Y,Designated/Withdrawn,Public record,2162,progesterone,9/3/2009,For early intervention in the treatment of moderate to severe closed-head traumatic brain injury,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"BHR Pharma, LLC",607 Herndon Parkway,Suite 110,Herndon,Virginia,20170,United States,284809
REBASTINIB TOSYLATE,042A5NJE6B,Designated,Public record,2163,Rebastinib,9/3/2009,Treatment of Philadelphia chromosome positive chronic myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Deciphera Pharmaceuticals, LLC",643 Massachusetts,,Lawrence,Kansas,66044,United States,290509
RIGOSERTIB,67DOW7F9GL,Designated,Public record,2164,rigosertib,9/3/2009,Treatment of myelodysplastic syndromes,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc.",375 Pheasant Run,,Newtown,Pennsylvania,18940,United States,289409
Sodium nitrite,M0KG633D4F,Designated,Public record,2165,sodium nitrite,9/3/2009,Prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,288209
TALIGLUCERASE ALFA,0R4NLX88O4,Designated/Approved,Public record,2166,Taliglucerase alfa,9/3/2009,Treatment of Gaucher's disease,Designated/Approved,,Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease,5/1/2012,,,"Pfizer, Inc.",235 East 42nd Street,,New York,New York,10017,United States,191004
TASISULAM SODIUM,O3955SHR9J,Designated/Withdrawn,Public record,2167,tasisulam sodium,9/3/2009,Treatment of melanoma stages IIB through IV,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,289909
URIDINE TRIACETATE,2WP61F175M,Designated,Public record,2168,uridine triacetate,9/3/2009,Treatment of mitchondrial disease,Designated,Not FDA Approved for Orphan Indication,,,,,Wellstat Therapeutics Corporation,14200 Shady Grove Road,Suite 600,Rockville,Maryland,20850,United States,290009
VELIPARIB,01O4K0631N,Designated,Public record,2169,veliparib,9/3/2009,Treatment of epithelial ovarian cancer in combination with DNA-damaging agents,Designated,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,290209
CETHROMYCIN,J0086219X6,Designated,Public record,2170,cethromycin,9/9/2009,Prophylactic treatment of plague due to Yersinia pestis,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Life Sciences, Inc.",1440 Davey Road,,Woodridge,Illinois,60517,United States,289009
CETHROMYCIN,J0086219X6,Designated,Public record,2171,cethromycin,9/9/2009,Prophylactic treatment of tularemia due to Francisella tularensis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Life Sciences, Inc.",1440 Davey Road,,Woodridge,Illinois,60517,United States,288909
ACETYLCYSTEINE,WYQ7N0BPYC,Designated,Public record,2172,mesalamine and N-acetycysteine,9/10/2009,Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years),Designated,Not FDA Approved for Orphan Indication,,,,,"Altheus Therapeutics, Inc.",755 Research Parkway,Suite 435,Oklahoma City,Oklahoma,73104,United States,275909
MESALAMINE,4Q81I59GXC,Designated,Public record,2172,mesalamine and N-acetycysteine,9/10/2009,Treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years),Designated,Not FDA Approved for Orphan Indication,,,,,"Altheus Therapeutics, Inc.",755 Research Parkway,Suite 435,Oklahoma City,Oklahoma,73104,United States,275909
NETAZEPIDE,HOU4I0G29C,Designated,Public record,2173,netazepide,9/10/2009,Treatment of gastric carcinoids,Designated,Not FDA Approved for Orphan Indication,,,,,Trio Medicines Ltd.,Pavillion View,19 New Road,Brighton,,,United Kingdom,243207
CIBINETIDE,9W5677JKDA,Designated,Public record,2175,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,9/18/2009,Prevention of delayed graft function following renal transplant,Designated,Not FDA Approved for Orphan Indication,,,,,"Araim Pharmaceuticals, Inc.",712 Kitchawan Raod,,Ossining,New York,10562,United States,289609
PANOBINOSTAT,9647FM7Y3Z,Designated/Withdrawn,Public record,2176,panobinostat,9/18/2009,Treatment of Hodgkin's lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,"One Health Plaza, 105/3W038",,East Hanover,New Jersey,7936,United States,291509
PACLITAXEL,P88XT4IS4D,Designated/Withdrawn,Public record,2178,Paclitaxel protein-bound particles for injection suspension,10/1/2009,Treatment of stage IIb to IV melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,400 Connell Drive,Suite 7000,Berkeley Heights,New Jersey,7922,United States,290709
TIDEGLUSIB,Q747Y6TT42,Designated/Withdrawn,Public record,2179,"4-benzyl-2-(a-naphtyl)-1,2,4-thiadiazolidine-3,5-dione",10/13/2009,Treatment of progressive supranuclear palsy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"NOSCIRA, S.A.","Avda. de la Industria, 52",,Madrid,,,Spain,290109
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,2180,bevacizumab,10/13/2009,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,291709
TRASTUZUMAB,P188ANX8CK,Designated/Approved,Public record,2182,trastuzumab,10/13/2009,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction",Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease",10/20/2010,10/20/2017,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,292409
DEXTRAN SULFATE SODIUM (5000 MW),V5LWP0C2L5,Designated,Public record,2183,low molecular weight dextran sulfate,10/20/2009,Prevention of graft rejection during pancreatic islet transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,TikoMed AB,P.O. Box 81 (Karlsfaltsvagen 349),"SE-263 03, Viken",Viken,,,Sweden,292609
MIDAZOLAM,R60L0SM5BC,Designated,Public record,2184,midazolam,10/20/2009,"Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)",Designated/Approved,,"NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 12 year",5/17/2019,5/17/2026,"NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 12 year","UCB, Inc.",1950 Lake Park Drive,Building 2100,Smyrna,Georgia,30080,United States,277809
PAZOPANIB,7RN5DR86CK,Designated/Approved,Public record,2185,pazopanib,10/20/2009,Treatment of soft tissue sarcomas,Designated/Approved,,Advanced soft tissue sarcoma (STS) who have received prior chemotherapy,4/26/2012,4/26/2019,,Novartis Pharmaceuticals Corp,1 Health Plaza,,East Hanover,New Jersey,7936,United States,293809
MALP-2,DZX5IUA94D,Designated,Public record,2186,"S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinly-GNNDESNISFKEK",10/20/2009,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,MBiotec GmBH,Hohenweg 13,,Seefeld,,,Germany,292809
DASIPROTIMUT-T,,Designated,Public record,2188,dasiprotimut-T,10/28/2009,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Biovest International, Inc.",324 S. Hyde Park Avenue,Suite 350,Tampa,Florida,33606,United States,291909
DIANEXIN,S5HS95L6CN,Designated,Public record,2189,diannexin,10/28/2009,Prevention of ischemia-reperfusion injury in solid organ transplants,Designated,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",Three Parkway North,,Deerfield,Illinois,60015,United States,294109
SODIUM STIBOGLUCONATE ANHYDROUS,V083S0159D,Designated,Public record,2191,sodium stibogluconate,10/28/2009,Treatment of cutaneous leishmaniasis,Designated,Not FDA Approved for Orphan Indication,,,,,Surgeon General of the US Army,US Army Medical Research & Materiel Command,1430 Veterans Drive,Ft. Detrick,Maryland,21702,United States,293609
VOSAROXIN,K6A90IIZ19,Designated,Public record,2192,vosaroxin,10/28/2009,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Sunesis Pharmaceuticals, Inc.",395 Oyster Point Blvd,Suite 400,South San Francisco,California,94080,United States,294509
SALMETEROL XINAFOATE,6EW8Q962A5,Designated,Public record,2193,salmeterol xinafoate/fluticasone propionate,10/29/2009,Treatment of symptomatic exophthalmos associated with thyroid related eye disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Lithera, Inc.",9191 Towne Center Drive,,San Diego,California,92122,United States,273208
FLUTICASONE PROPIONATE,O2GMZ0LF5W,Designated,Public record,2193,salmeterol xinafoate/fluticasone propionate,10/29/2009,Treatment of symptomatic exophthalmos associated with thyroid related eye disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Lithera, Inc.",9191 Towne Center Drive,,San Diego,California,92122,United States,273208
FOSDENOPTERIN,4X7K2681Y7,Designated,Public record,2195,fosdenopterin,11/5/2009,Treatment of molybdenum cofactor deficiency type A (MoCD),Designated/Approved,,to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A,2/26/2021,2/26/2028,to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A,"Origin Biosciences, Inc.",75 Park Plaza,,Boston,Massachusetts,2116,United States,291209
ALX-009,2BP92KEU27,Designated,Public record,2196,Hypothiocyanite and lactoferrin,11/5/2009,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Alaxia Biotechnologies Sante,3-11 Rue de la Perlerie,,Vaulx-en-velin,,,France,294609
HYPOTHIOCYANITE ION,N84CZ7T0OY,Designated,Public record,2196,Hypothiocyanite and lactoferrin,11/5/2009,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Alaxia Biotechnologies Sante,3-11 Rue de la Perlerie,,Vaulx-en-velin,,,France,294609
VERUBULIN HYDROCHLORIDE,33380QZ0QW,Designated,Public record,2197,Varbulin,11/5/2009,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"Myrexis, Inc.",305 Chipeta Way,,Salt Lake City,Utah,84108,United States,290809
AT-9283,XAV9KYN9WL,Designated,Public record,2198,1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea,11/12/2009,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Astex Therapeutics Ltd,436 Cambridge Science Park,,Milton,Cambridge,,United Kingdom,291809
AMIFAMPRIDINE PHOSPHATE,8HF8FIN815,Designated,Public record,2199,amifampridine,11/12/2009,Treatment of Lambert-Eaton Myasthenic Syndrome,Designated/Approved,,Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older,9/29/2022,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 1250,Coral Gables,Florida,33134,United States,295309
AMIFAMPRIDINE PHOSPHATE,8HF8FIN815,Designated,Public record,2200,amifampridine,11/12/2009,Treatment of Lambert-Eaton Myasthenic Syndrome,Designated/Approved,,Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults,11/28/2018,11/28/2025,Treatment of Lambert-Eaton myasthenic syndrome (LEMS),"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 1250,Coral Gables,Florida,33134,United States,295309
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,2201,bevacizumab,11/20/2009,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,294409
PONATINIB,4340891KFS,Designated/Approved,Public record,2202,ponatinib,11/20/2009,Treatment of chronic myeloid leukemia,Designated/Approved,,"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.",12/14/2012,12/14/2019,,ARIAD Pharmaceuticals Inc.,26 Landsdowne Steet,,Cambridge,Massachusetts,2139,United States,294709
PONATINIB,4340891KFS,Designated/Approved,Public record,2203,ponatinib,11/20/2009,Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL),Designated/Approved,,Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.,12/14/2012,12/14/2019,,ARIAD Pharmaceuticals Inc.,26 Landsdowne Steet,,Cambridge,Massachusetts,2139,United States,294809
VELIPARIB,01O4K0631N,Designated,Public record,2204,veliparib,11/20/2009,Treatment of hepatocellular carcinoma in combination with DNA-damaging agents,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,295509
NEVIRAPINE,99DK7FVK1H,Designated,Public record,2206,nevirapine,11/25/2009,Prevention of HIV infection in pediatric patients under the age of 16 years,Designated,Not FDA Approved for Orphan Indication,,,,,Auritec Pharmaceuticals,1434 6th Street,,Santa Monica,California,90401,United States,293409
INEBILIZUMAB,74T7185BMM,Designated,Public record,2207,inebilizumab,12/3/2009,Treatment of scleroderma,Designated,Not FDA Approved for Orphan Indication,,,,,Viela Bio,One MedImmune Way,,Gaithersburg,Maryland,20878,United States,295209
PEGADRICASE,50XB37EKN8,Designated,Public record,2208,pegsitacase,12/3/2009,Treatment of Lesch-Nyhan syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Selecta Biosciences, Inc.",480 Arsenal Way,,Watertown,Massachusetts,2472,United States,296309
GEMCITABINE ELAIDATE,231C73W7LG,Designated/Withdrawn,Public record,2209,"5'-O-(trans-9""-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine",12/7/2009,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Clovis Oncology, Inc.",5500 Flatiron Parkway,Suite 100,Boulder,Colorado,80301,United States,295909
MERCAPTOPURINE ANHYDROUS,PKK6MUZ20G,Designated,Public record,2210,6-mercaptopurine oral liquid,12/7/2009,Treatment of acute lymphoblastic leukemia in the pediatric population,Designated,Not FDA Approved for Orphan Indication,,,,,Orbona Pharma Ltd,Old Chambers,,Farnham,Surrey,,United Kingdom,286309
Lusacomfar Alfa,AYN2H2T5GU,Designated/Withdrawn,Public record,2211,complement factor H,12/7/2009,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,LFB Biotechnologies S.A.,"3, avenue des Tropiques",,Courtaboeuf Cedex,,,France,260308
DAVUNETIDE,GF00K3IIWE,Designated,Public record,2212,davunetide,12/7/2009,Treatment of progressive supranuclear palsy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Allon Therapeutics, Inc.",506-1168 Hamilton Street,,Vancouver,,,Canada,293909
ANSELAMIMAB,TL94QQ5RTW,Designated,Public record,2213,monoclonal antibody 11-1F4,12/7/2009,For use as a radioimmaging agent in amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Caelum Biosciences, Inc.",2 Gansevoort Street,9th Floor,New York,New York,10014,United States,293709
OCTREOTIDE ACETATE,75R0U2568I,Designated,Public record,2214,octreotide acetate subcutaneous implant,12/7/2009,Treatment of acromegaly,Designated,Not FDA Approved for Orphan Indication,,,,,"Endo Pharmaceuticals Solutions, Inc.",100 Endo Blvd,,Chadds Ford,Pennsylvania,19317,United States,286509
SELISISTAT,L19ECD5014,Designated,Public record,2215,selisistat,12/7/2009,Treatment of Huntington's disease,Designated,Not FDA Approved for Orphan Indication,,,,,AOP Orphan Pharmaceuticals AG,91/llf Wilhelminenstraße,,Wien,Wien,,Austria,295709
AFAMELANOTIDE,QW68W3J66U,Designated,Public record,2216,afamelanotide,12/11/2009,Treatment of solar urticaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinuvel, Inc.",30 Broad Street,Suites 1407 and 1408,New York,New York,10004,United States,292009
ANSELAMIMAB,TL94QQ5RTW,Designated,Public record,2217,monoclonal antibody 11-1F4,12/11/2009,For use as a therapeutic agent for patients AL amyloidosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Caelum Biosciences, Inc.",2 Gansevoort Street,9th Floor,New York,New York,10014,United States,290309
BUROSUMAB,G9WJT6RD29,Designated/Approved,Public record,2218,burosumab-twza,12/14/2009,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.,9/27/2019,9/27/2026,For the treatment of X-linked hypophosphatemia (XLH) in pediatric patients 6 months of age to less than 1 year of age,"Kyowa Kirin, Inc.",135 US Highway 202/206,Suite 6,Bedminster,New Jersey,7921,United States,296109
BUROSUMAB,G9WJT6RD29,Designated/Approved,Public record,2219,burosumab-twza,12/14/2009,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,4/17/2018,4/17/2025,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,"Kyowa Kirin, Inc.",135 US Highway 202/206,Suite 6,Bedminster,New Jersey,7921,United States,296109
BRILLIANT BLUE G,M1ZRX790SI,Designated,Public record,2220,brilliant blue G,12/16/2009,For use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Fluoron GmbH,Biberkopfweg 1,,,,,Germany,257908
"""AMBRISENTAN, (?)-""",7B43003091,Designated/Withdrawn,Public record,2221,ambrisentan,12/23/2009,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine Street,,Seattle,Washington,98102,United States,266908
TEPRASIRAN,O03W5S19PJ,Designated,Public record,2222,Teprasiran,12/23/2009,Prophylaxis of delayed graft function in renal transplant patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Quark Pharmaceuticals, Inc.","7999 Gateway Boulevard, Suite 310",,Newark,California,94560,United States,296509
PANOBACUMAB,62B4OXU259,Designated,Public record,2223,human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa,1/6/2010,Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosa,Designated,Not FDA Approved for Orphan Indication,,,,,Kenta Biotech Limited,Rehhagstrasase 79,,Berne,,,Switzerland,297009
ASPARAGINASE,G4FQ3CKY5R,Designated,Public record,2224,L-asparaginase encapsulated in red blood cells,1/6/2010,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Erytech Pharma,Batiment Adenine,"60, Avenue Rockfeller",LYON,,,France,239807
CENISERTIB BENZOATE,S68QU67MAZ,Designated/Withdrawn,Public record,2225,"(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate",1/19/2010,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,299109
AMITRIPTYLINE,1806D8D52K,Designated,Public record,2227,amitriptyline and ketamine,1/19/2010,Treatment of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Immune Pharmaceuicals, Inc.",Alexandria Center for LIfe Sciences,430 E. 29th St.,New York,New York,10016,United States,288809
KETAMINE,690G0D6V8H,Designated,Public record,2227,amitriptyline and ketamine,1/19/2010,Treatment of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Immune Pharmaceuicals, Inc.",Alexandria Center for LIfe Sciences,430 E. 29th St.,New York,New York,10016,United States,288809
ARTEFENOMEL MESYLATE,PXW0Q9H3IJ,Designated,Public record,2228,"cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate",1/19/2010,"Treatment of malaria caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, or Plasmodium malariae",Designated,Not FDA Approved for Orphan Indication,,,,,Medicines for Malaria Venture (MMV),International Centre Cointrin,P. O. Box 1826,CH-1215 Geneva 15,,,Switzerland,297309
MESALAMINE,4Q81I59GXC,Designated,Public record,2229,mesalamine,1/19/2010,Treatment of pediatric ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Forest Laboratories, Inc.",Harborside Financial Center,"Plaza V, Suite 1900",Jersey City,New Jersey,7311,United States,298109
NALTREXONE,5S6W795CQM,Designated,Public record,2230,naltrexone,1/19/2010,Treatment of Crohn's disease in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Statera BioPharma, Inc.",2537 Research Boulevard,Suite 201,Ft. Collins,Colorado,80526,United States,296909
POLOXAMER 188,LQA7B6G8JG,Designated,Public record,2231,poloxamer-188 NF,1/19/2010,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Phrixus Pharmaceuticals, Inc.",300 N. Fifth Avenue,,Ann Arbor,Michigan,48104,United States,296409
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,2232,sodium phenylbutyrate,1/19/2010,Treatment of urea cycle disorder.,Designated,Not FDA Approved for Orphan Indication,,,,,Navinta LLC,1499 Lower Ferry Road,,Ewing,New Jersey,8618,United States,293309
TASIMELTEON,SHS4PU80D9,Designated/Approved,Public record,2233,tasimelteon,1/19/2010,Non-24-hour sleepwake disorder in blind individuals without light perception,Designated/Approved,,Treatment of non-24-hour sleep-wake disorder,1/31/2014,1/31/2021,Treatment of non-24-hour sleep-wake disorder,"Vanda Pharmaceuticals, Inc.","2200 Penn. Ave., NW",Suite 300 E,Washington,District of Columbia,20037,United States,297409
SOLNATIDE,17ZS80333G,Designated,Public record,2234,17 amino acid peptide,1/29/2010,Prevention of ischemia reperfusion injury in the lung during lung tranplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Apeptico Forschung und Entwicklung GmbH (APEPTICO),Mariahilferstrabe 136,Top 1150,Vienna,,,Austria,298009
ENMD-2076,KXQ762CQTH,Designated,Public record,2235,2-(2-phenylvinyl)-4-[-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,1/29/2010,Treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,20850,United States,298609
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,2236,alpha1 proteinase inhibitor (human),1/29/2010,Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",79 TW Alexander Drive,,Research Triangle Park,North Carolina,27709,United States,294309
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,2237,angiotensin 1-7,1/29/2010,Treatment of sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"W. Jeffrey Petty, MD",Wake Forest University Health Sciences,,Winston-Salem,North Carolina,27157,United States,295809
ARC-19499,0493WH50VT,Designated,Public record,2238,Inhibitor of Tissue Factor Pathway Inhibitor (TFPI),1/29/2010,Treatment of hemophilia A and hemophilia B.,Designated,Not FDA Approved for Orphan Indication,,,,,"Baxter Healthcare Corporation, Baxter BioScience",One Baxter Way,,Westlake Village,California,91362,United States,298409
PIMASERTIB HYDROCHLORIDE,6GS1ULF5HV,Designated,Public record,2239,pimasertib,1/29/2010,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,297909
PEGCRISANTASPASE,Y8KTZ6Y35U,Designated,Public record,2242,mPEG-r-crisantaspase,2/1/2010,Treatment of acute lymphoblastic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,94304,United States,299609
CIPROFLOXACIN,5E8K9I0O4U,Designated,Public record,2244,ciprofloxacin DPI,2/2/2010,Management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",P. O. Box 1000,,Montville,New Jersey,7045,United States,297209
PATUPILONE,UEC0H0URSE,Designated/Withdrawn,Public record,2246,patupilone,2/2/2010,Treatment of primary fallopian tube cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,298809
PATUPILONE,UEC0H0URSE,Designated/Withdrawn,Public record,2247,patupilone,2/2/2010,Treatment of primary pertitoneal cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,298909
LUMACAFTOR,EGP8L81APK,Designated/Withdrawn,Public record,2249,"3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid",3/2/2010,Treatment of cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,130 Waverly Street,,Cambridge,Massachusetts,2139,United States,301610
IMMUNE GLOBULIN HUMAN,,Designated,Public record,2250,immune globulin (human),3/2/2010,Treatment of Guillain-Barre syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,Suite 1201,Hoboken,New Jersey,7030,United States,301110
IMMUNE GLOBULIN (HUMAN),,Designated,Public record,2250,immune globulin (human),3/2/2010,Treatment of Guillain-Barre syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,Suite 1201,Hoboken,New Jersey,7030,United States,301110
LORVOTUZUMAB MERTANSINE,0IVD6ASY0W,Designated/Withdrawn,Public record,2251,maytansinoid DM1-conjugated humanized monoclonal antibody N901,3/2/2010,Treatment of Merkel cell carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,2451,United States,300309
TIRASEMTIV,G8WSM7R635,Designated,Public record,2253,tirasemtiv,3/2/2010,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,Cytokinetics Inc.,280 East Grand Avenue,,South San Francisco,California,94080,United States,301710
CHENODIOL,0GEI24LG0J,Designated,Public record,2254,chenodiol,3/22/2010,Treatment of cerebrotendinous xanthomatosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Travere Therapeutics, Inc.","3611 Valley Centre Drive, Suite 300",,San Diego,California,92130,United States,300510
GLUTAMATE DECARBOXYLASE 2,I7YY5T4995,Designated,Public record,2255,Recombinant human glutamic acid decarboxylase 65KDa isoform,3/22/2010,Treatment of Type I diabetes with residual beta cell function,Designated,Not FDA Approved for Orphan Indication,,,,,Diamyd Therapeutics AB,Linnegatan 89B,,Stockholm,,,Sweden,274508
VALZIFLOCEPT,EA2075XV4Y,Designated,Public record,2256,Recombinant Human soluble Fc-gamma Receptor IIb,3/22/2010,Treatment of idiopathic thrombocytopenic purpura,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Baxalta US Inc., now part of Shire Plc",650 Kendall Street,,Cambridge,Massachusetts,2142,United States,287709
RUXOLITINIB PHOSPHATE,436LRU32H5,Designated,Public record,2257,ruxolitinib phosphate,3/22/2010,Treatment of essential thrombocythemia,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,302510
TAURINE,1EQV5MLY3D,Designated,Public record,2258,taurine,3/22/2010,Treatment of cystathionine beta-synthase deficient homocystinuria,Designated,Not FDA Approved for Orphan Indication,,,,,"Johan L. Van Hove, MD, PhD",Department of Pediatrics/University of Colorado De,"13121 E. 17th Ave., P. O. Box 6508",Aurora,Colorado,80045,United States,298709
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,D7RD81HE4W,Designated,Public record,2259,"anti-T-lymphocyte immune globulin, rabbit",3/26/2010,Prevention of graft versus host disease (GVHD),Designated,Not FDA Approved for Orphan Indication,,,,,Neovii Biotech GmbH,Am Haag 6 + 7,,Graefelfing,,82166,Germany,301810
EMAPALUMAB,3S252O2Z4X,Designated,Public record,2260,Emapalumab-lzsg,3/26/2010,Treatment of hemophagocytic lymphohistiocytosis,Designated/Approved,,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",11/20/2018,11/20/2025,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",Swedish Orphan Biovitrum AB,SE-112,75 Stockholm,Stockholm,,,Sweden,302910
DM-1157,6X58GJ0RMS,Designated,Public record,2262,reversal agent linked to chloroquine-like moiety,3/26/2010,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,DesignMedix,2828 SW Corbett Avenue,,Portland,Oregon,97201,United States,303710
RUXOLITINIB,82S8X8XX8H,Designated/Approved,Public record,2263,ruxolitinib,3/26/2010,Treatment of polycythemia vera,Designated/Approved,,Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.,12/4/2014,12/4/2021,Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,302310
SECUKINUMAB,DLG4EML025,Designated/Withdrawn,Public record,2264,secukinumab,3/26/2010,Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,One Health Plaza,Bldg 404/470,East Hanover,New Jersey,7936,United States,281309
VITAMIN A PALMITATE,1D1K0N0VVC,Designated,Public record,2265,Water-miscible vitamin A palmitate,3/26/2010,Prevention of bronchopulmonary dysplasia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Fox Pharma, Inc.",6097 Hidden Valley Drive,,Doylestown,Pennsylvania,18902,United States,295109
N-ACETYLMANNOSAMINE,X80PR7P73R,Designated,Public record,2266,N-Acetylmannosamine (ManNAc),4/5/2010,Treatment of GNE Myopathy (Hereditary Inclusion Body Myopathy Type 2),Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.","9841 Washingtonian Blvd, Suite 500",,Gaithersburg,Maryland,20878,United States,303510
FENRETINIDE,187EJ7QEXL,Designated,Public record,2267,Fenretinide,4/7/2010,Treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients,Designated,Not FDA Approved for Orphan Indication,,,,,McGill University,McGill University,,Montreal,,,Canada,303210
IMATINIB,BKJ8M8G5HI,Designated/Withdrawn,Public record,2268,imatinib,4/7/2010,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis,One Health Plaza,,East Hanover,New Jersey,7936,United States,303810
ORNITHINE PHENYLACETATE,9D6YZ105SN,Designated,Public record,2269,L-ornithine phenylacetate,4/7/2010,Treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disase,Designated,Not FDA Approved for Orphan Indication,,,,,"Ocera Therapeutics Inc, a Mallinckrodt Pharmaceuticals Company",440 Route 22 East,,Bridgewater,New Jersey,8807,United States,287309
AMIFAMPRIDINE,RU4S6E2G0J,Designated,Public record,2270,"3,4 diaminopyridine and choline bitartrate",4/30/2010,Treatment of Lambert-Eaton myasthenic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,MS Therapeutics Limited,Beechy House,,Berkshire,,,United Kingdom,299909
CHOLINE BITARTRATE,6K2W7T9V6Y,Designated,Public record,2270,"3,4 diaminopyridine and choline bitartrate",4/30/2010,Treatment of Lambert-Eaton myasthenic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,MS Therapeutics Limited,Beechy House,,Berkshire,,,United Kingdom,299909
ZOPTARELIN DOXORUBICIN ACETATE,4IA03SIO30,Designated/Withdrawn,Public record,2271,AEZS-108 (LHRH-agonist linked to doxorubicin),4/30/2010,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Aeterna Zentaris,"100 Marketplace, Suite 203",25 Mountainview Blvd,Basking Ridge,New Jersey,7920,United States,304410
AURANOFIN,3H04W2810V,Designated,Public record,2272,auranofin,4/30/2010,Treatment of amebiasis,Designated,Not FDA Approved for Orphan Indication,,,,,Ctr for Discovery & Innovation in Parasitic Diseas,"U. of CA, San Francisco","QB3, Byers Hall 508B",San Francisco,California,94158,United States,305210
CINACALCET,UAZ6V7728S,Designated/Approved,Public record,2274,cinacalcet,4/30/2010,"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",Designated/Approved,,Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy,2/25/2011,2/25/2018,,"Amgen, Inc.",One Amgen Center Drive,"Bldg 17, 1A-4-4, Mail Stop 17-1-B",Thousand Oaks,California,91320,United States,165102
CINACALCET,UAZ6V7728S,Designated/Approved,Public record,2275,cinacalcet,4/30/2010,"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",Designated/Approved,,"Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.",11/21/2014,11/21/2021,"Treatment of less severe hypercalcemia (serum calcium >11.2 mg/dl and <= 12.5 mg/dl) in adult patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo","Amgen, Inc.",One Amgen Center Drive,"Bldg 17, 1A-4-4, Mail Stop 17-1-B",Thousand Oaks,California,91320,United States,165102
CINTREDEKIN BESUDOTOX,ZL04JX89M7,Designated,Public record,2276,Cintredekin Besudotox,4/30/2010,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.","1333 South Sprectum Blvd, Suite 100",,Chandler,Alaska,85286,United States,305110
DENILEUKIN DIFTITOX,25E79B5CTM,Designated,Public record,2277,denileukin diftitox,4/30/2010,Treatment of peripheral T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",300 Tice Boulevard,,Woodcliff Lake,New Jersey,7677,United States,302010
FINGOLIMOD,3QN8BYN5QF,Designated,Public record,2279,fingolimod,4/30/2010,Treatment of chronic inflammatory demyelinating polyneuropathy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,305910
CARLUMAB,6TC1BB2EV9,Designated,Public record,2281,Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888),4/30/2010,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Ortho Biotech,200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,306810
LEVETIRACETAM,44YRR34555,Designated,Public record,2283,levetiracetam,4/30/2010,Treatment of neonatal seizures,Designated,Not FDA Approved for Orphan Indication,,,,,University of California,UCSD Medical Center 0935,,La Jolla,California,92093,United States,303310
GLUTATHIONE,GAN16C9B8O,Designated,Public record,2284,Liposomal Glutathione,4/30/2010,Support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (IEMG),Designated,Not FDA Approved for Orphan Indication,,,,,"Your Energy Systems, LLC",555 Bryant Street #305,,Palo Alto,California,94301,United States,303410
MIDOSTAURIN,ID912S5VON,Designated/Approved,Public record,2285,midostaurin,4/30/2010,Treatment of mastocytosis,Designated/Approved,,"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)",4/28/2017,4/28/2024,"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)",Novartis Pharmaceuticals Corporation,"One Health Plaza, 105/3W038",,East Hanover,New Jersey,7936,United States,306410
NIRAPARIB,HMC2H89N35,Designated/Approved,Public record,2286,niraparib,4/30/2010,Treatment of ovarian cancer,Designated/Approved,,"ZEJULA® is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination",10/23/2019,10/23/2026,Indicated for the treatment of adult patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either,"GlaxoSmithKline, LLC.",1000 Winter St.,Suite 3300,Waltham,Massachusetts,2451,United States,306510
NIRAPARIB,HMC2H89N35,Designated/Approved,Public record,2287,niraparib,4/30/2010,Treatment of ovarian cancer,Designated/Approved,,"ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy",4/29/2020,4/29/2027,Indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer who are in a complete or partial response to first-line platinum-based chemotherapy.,"GlaxoSmithKline, LLC.",1000 Winter St.,Suite 3300,Waltham,Massachusetts,2451,United States,306510
NIRAPARIB,HMC2H89N35,Designated/Approved,Public record,2288,niraparib,4/30/2010,Treatment of ovarian cancer,Designated/Approved,,"Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy",3/27/2017,3/27/2024,Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in a complete or partial response to platinum-based chemotherapy,"GlaxoSmithKline, LLC.",1000 Winter St.,Suite 3300,Waltham,Massachusetts,2451,United States,306510
SELEXIPAG,5EXC0E384L,Designated/Approved,Public record,2290,selexipag,4/30/2010,Treatment of pulmonary arterial hypertension,Designated/Approved,,"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",12/21/2015,12/21/2022,"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,,Switzerland,304810
SELEXIPAG,5EXC0E384L,Designated/Approved,Public record,2291,selexipag,4/30/2010,Treatment of pulmonary arterial hypertension,Designated/Approved,,"Treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",7/29/2021,,,Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,,Switzerland,304810
GLIADIN,GR9478B3Q3,Designated,Public record,2292,"superoxide dismutase, gliadin",4/30/2010,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Verius Limited,Chartwell House,,Cambridge,,,United Kingdom,302110
TASIMELTEON,SHS4PU80D9,Designated,Public record,2293,tasimelteon,4/30/2010,Treatment of the sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion.,Designated/Approved,,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older,12/1/2020,12/1/2027,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.,"Vanda Pharmaceuticals, Inc.",9605 Medical Center Drive,,Rockville,Maryland,20850,United States,301410
TASIMELTEON,SHS4PU80D9,Designated,Public record,2294,tasimelteon,4/30/2010,Treatment of the sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion.,Designated/Approved,,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age,12/1/2020,12/1/2027,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age,"Vanda Pharmaceuticals, Inc.",9605 Medical Center Drive,,Rockville,Maryland,20850,United States,301410
PRALATREXATE,A8Q8I19Q20,Designated,Public record,2295,pralatrexate,5/3/2010,Treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder,Designated,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,8520,United States,260708
BUDESONIDE,Q3OKS62Q6X,Designated,Public record,2297,budesonide,5/17/2010,To slow the progression of immunoglobulin A nephropathy & delay kidney failure in patients affected by the disease.,Designated/Approved,,"to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) > or = 1.5 g/g",12/15/2021,12/15/2028,"to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) > or = 1.5 g/g",Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,,,Sweden,305710
RG-2833,17V14R89EU,Designated/Withdrawn,Public record,2300,N-(6-2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide,5/17/2010,Treatment of Friedreich's ataxia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Repligen Corporation,"Building 1, Suite 100",,Waltham,Massachusetts,2453,United States,306110
PITOLISANT,4BC83L4PIY,Designated,Public record,2301,Pitolisant,5/17/2010,Treatment of narcolepsy,Designated/Approved,,WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy,8/14/2019,8/14/2026,For the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy,"Harmony Biosciences, LLC",630 W Germantown Pike,Suite 215,Plymouth Meeting,Pennsylvania,19462,United States,307210
PITOLISANT,4BC83L4PIY,Designated,Public record,2302,pitolisant,5/17/2010,Treatment of narcolepsy,Designated/Approved,,treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy,10/13/2020,10/13/2027,treatment of cataplexy in adult patients with narcolepsy,"Harmony Biosciences, LLC",630 W Germantown Pike,Suite 215,Plymouth Meeting,Pennsylvania,19462,United States,307210
TELATINIB,18P7197Q7J,Designated,Public record,2303,telatinib,5/17/2010,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,ACT Biotech Inc.,717 market St #650,Suite 650,San Francisco,California,94103,United States,307410
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,D7RD81HE4W,Designated,Public record,2304,anti-thymocyte globulin [rabbit],5/25/2010,Prophylaxis of acute organ rejection in patients receiving renal transplants,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,308710
TEREVALEFIM,GG91UXK2M5,Designated,Public record,2305,refanalin,5/25/2010,To improve renal function and prevent delayed graft function following renal transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Angion Biomedica Corporation,1050 Stewart Avenue,,Garden City,New York,11530,United States,307510
TOL-101,28X0AGG6P8,Designated,Public record,2306,"anti-TCR murine monoclonal antibody (MAb, type IgM)",6/7/2010,Treatment of patients 16 years of age and younger with immune-mediated T1DM and preserved pancreatic beta cell function,Designated,Not FDA Approved for Orphan Indication,,,,,"Tolera Therapeutics, Inc.",350 E. Michigan Avenue,,Kalamazoo,Michigan,49001,United States,293209
BOSENTAN,Q326023R30,Designated/Withdrawn,Public record,2307,bosentan,6/7/2010,Reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Actelion Ltd.,Gewerbestrasse 16,,Allschwil,,,Switzerland,292209
PLASMINOGEN,1EF190B6M7,Designated,Public record,2309,human plasminogen,6/7/2010,Treatment of ligneous conjunctivitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Kedrion, S.p.A.",Loc. ai Conti,55051 Castelvecchio Pascoli,Barga (Lucca),,,Italy,309210
TELBERMIN,22G76ZW50X,Designated,Public record,2310,recombinant human vascular endothelial growth factor,6/7/2010,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,NeuroNova AB,Fiskartorpsvagen 15 A-D,,Stockholm,,,Sweden,309010
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,2311,angiotensin 1-7,6/17/2010,"To accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and aneima)in hematopoietic stem cell transplants.",Designated,Not FDA Approved for Orphan Indication,,,,,"Tarix Pharmaceuticals, Ltd.",12 Bow Street,,Cambridge,Massachusetts,2138,United States,308810
DASIPROTIMUT-T,,Designated,Public record,2312,dasiprotimut-T,6/17/2010,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Biovest International, Inc.",324 S. Hyde Park Avenue,Suite 350,Tampa,Florida,33606,United States,309710
GLYCOPYRROLATE,V92SO9WP2I,Designated,Public record,2313,glycopyrrolate 2%,6/17/2010,Treatment of Frey's syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Wellesley Therapeutics, Inc.","200 Gerrard St., East",,Toronto,,,Canada,309810
OCTREOTIDE,RWM8CCW8GP,Designated,Public record,2314,octreotide (oral),6/17/2010,For the oral treatment of acromegaly,Designated/Approved,,Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.,6/26/2020,,,Amryt Pharmaceutical DAC,45 Mespil Road,,Dublin 4,,,Ireland,309310
TREPROSTINIL,RUM6K67ESG,Designated/Approved,Public record,2315,treprostinil inhalation powder,6/17/2010,Treatment of pulmonary arterial hypertension,Designated/Approved,,Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability,5/23/2022,,,United Therapeutics Corporation,PO Box 14186,55 TW Alexander Drive,Research Triangle Park,North Carolina,27709,United States,189104
TREPROSTINIL,RUM6K67ESG,Designated/Approved,Public record,2316,treprostinil inhalation solution,6/17/2010,Treatment of pulmonary arterial hypertension,Designated/Approved,,"Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance",7/30/2009,7/30/2016,,United Therapeutics Corporation,PO Box 14186,55 TW Alexander Drive,Research Triangle Park,North Carolina,27709,United States,189104
SAPACITABINE,W335P73C3L,Designated,Public record,2317,1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine,6/24/2010,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Cyclacel Limited,Dundee Technopole,1 James Lindsay Place,Dundee,,,United Kingdom,263408
SAPACITABINE,W335P73C3L,Designated,Public record,2318,1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine,6/24/2010,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Cyclacel Limited,Dundee Technopole,1 James Lindsay Place,Dundee,,,United Kingdom,263508
SEBELIPASE ALFA,K4YTU42T8G,Designated/Approved,Public record,2319,sebelipase alfa,7/1/2010,Treatment of lysosomal acid lipase deficiency,Designated/Approved,,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency,12/8/2015,12/8/2022,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency,Alexion Pharmaceuticals,100 College Street,,New Haven,Connecticut,6510,United States,309410
PERIFOSINE,2GWV496552,Designated/Withdrawn,Public record,2320,perifosine,7/9/2010,Treatment of neuroblastoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Aeterna Zentaris GmbH,Weismuellerstrasse 50,D-60314 Frankfurt Am Main,Frankfurt Am Main,,,Germany,310010
GEVOKIZUMAB,QX3JU54GYQ,Designated,Public record,2321,gevokizumab,7/27/2010,Treatment of Behcet's disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC,2910 Seventh St.,,Berkeley,California,94710,United States,310810
STX-100,JD43Y6YF3N,Designated,Public record,2323,humanized monoclonal antibody against human integrin alphaVbeta6,8/5/2010,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen Idec, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,2142,United States,311310
MOMELOTINIB,6O01GMS00P,Designated,Public record,2324,momelotinib,8/5/2010,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,GSK,Upper Providence,1250 S. Collegeville Road,Collegeville,Pennsylvania,19426,United States,311610
NIFURTIMOX,M84I3K7C2O,Designated,Public record,2325,nifurtimox,8/5/2010,Treatment of Chagas disease (American Typanosomiasis)caused by T. cruzi,Designated/Approved,,"LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi",8/6/2020,8/6/2027,indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi,"Bayer HealthCare Pharmaceuticals, Inc.",100 BAYER BLVD,,WHIPPANY,New Jersey,7981,United States,310110
OCTREOTIDE,RWM8CCW8GP,Designated,Public record,2326,octreotide,8/5/2010,Treatment of neuroendocrine tumors,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health laza,,East Hanover,New Jersey,7936,United States,310710
MYCOBACTERIUM VACCAE,I639ME27W5,Designated/Withdrawn,Public record,2328,mycobacterium vaccae,8/6/2010,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immodulon Therapeutics Ltd.,22 Devonshire Place,,London,,,United Kingdom,312810
BECAPLERMIN,1B56C968OA,Designated/Withdrawn,Public record,2329,recombinant human platelet derived growth factor-BB,8/6/2010,Treatment of osteochondritis dissecans,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biomimetic Therapeutics, Inc.",389-A Nichol Mill Lane,,Franklin,Tennessee,37067,United States,310410
UBLITUXIMAB,U59UGK3IPC,Designated,Public record,2330,ublituximab,8/6/2010,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,8837,United States,296609
EFMITERMANT ALFA,566QNS333V,Designated,Public record,2332,ActRIIB-IgG1),8/16/2010,Treatment of Duchenne muscular dystrophy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Acceleron Pharma, Inc.",128 Sidney St.,,Cambridge,Massachusetts,2139,United States,312310
GLUTATHIONE,GAN16C9B8O,Designated,Public record,2333,Glutathione pegylated liposomal doxorubicin hydrochloride,8/16/2010,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,to-BBB technologies BV,Niels Bohrweg 11,,Leiden,,,Netherlands,311910
DOXORUBICIN HYDROCHLORIDE,82F2G7BL4E,Designated,Public record,2333,Glutathione pegylated liposomal doxorubicin hydrochloride,8/16/2010,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,to-BBB technologies BV,Niels Bohrweg 11,,Leiden,,,Netherlands,311910
LORVOTUZUMAB MERTANSINE,0IVD6ASY0W,Designated/Withdrawn,Public record,2334,Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901,8/17/2010,Treatment of small cell lung cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,2451,United States,311010
ANAKINRA,9013DUQ28K,Designated/Approved,Public record,2335,anakinra,8/19/2010,Treatment of cryopyrin-associated periodic syndromes,Designated/Approved,,Treatment of neonatal-onset multisystem inflammatory disease (NOMID),12/21/2012,12/21/2019,,Swedish Orphan Biovitrum AB (publ),SE-011276,,Stockholm,,,Sweden,312110
MYCOBACTERIUM VACCAE,I639ME27W5,Designated,Public record,2336,mycobacterium vaccae,8/20/2010,Treatment of tuberculosis,Designated,Not FDA Approved for Orphan Indication,,,,,Immodulon Therapeutics Ltd,22 Devonshire Place,B2,London,,,United Kingdom,312710
RALOXIFENE HYDROCHLORIDE,4F86W47BR6,Designated,Public record,2337,raloxifene hydrochloride,8/20/2010,Treatment of hereditary hemorrhagic telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,Consejo Superior de Investigaciones Cientificas,C/ Serrano 142,,Madrid,,,Spain,309910
REVEGLUCOSIDASE ALFA,E86R97M8XQ,Designated,Public record,2338,reveglucosidase alfa,8/20/2010,Treatment of Pompe disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,94949,United States,308310
INTERMEDINE,OVF025LA77,Designated,Public record,2339,alpha melanotropin,9/2/2010,Treatment of chronic beryllium disease,Designated,Not FDA Approved for Orphan Indication,,,,,mondoBIOTECH Laboratories AG,Herrengasse 21,,Furstentum Liechtenstein,,,Germany,308910
DICHLORPHENAMIDE,VVJ6673MHY,Designated/Approved,Public record,2340,dichlorphenamide,9/2/2010,Treatment of primary periodic paralyses,Designated/Approved,,"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants",8/7/2015,8/7/2022,"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants","Xeris Pharmaceuticals, Inc.","180 N La Salle Street, Suite 1600",,Chicago,Illinois,60601,United States,314210
EPITALON,O65P17785G,Designated/Withdrawn,Public record,2341,Epitalon,9/2/2010,Treatment of retinitis pigmentosa,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,BioDiem Ltd,"Level 10, South Tower",Victoria 3000,Melbourne,,,Australia,312010
MEXILETINE,1U511HHV4Z,Designated,Public record,2342,mexiletine,9/2/2010,Treatment of nondystrophic myotonia,Designated,Not FDA Approved for Orphan Indication,,,,,University of Rochester Medical Center,1351 Mt. Hope Ave.,Suite 203,Rochester,New York,14620,United States,314410
RECOMBINANT HUMAN LECITHIN:CHOLESTEROL ACYLTRANSFERASE,XBA7E67HMJ,Designated,Public record,2343,recombinant human lecithin:cholesterol acyltransferase (rhLCAT),9/2/2010,Treatment of familial lecithin-cholesterol acyltransferase deficiency (FLD).,Designated,Not FDA Approved for Orphan Indication,,,,,MedImmune,1 Medimmune Way,,Gaithersburg,Maryland,20878,United States,314010
CRIZOTINIB,53AH36668S,Designated/Approved,Public record,2345,crizotinib; crizotinib,9/13/2010,"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",Designated/Approved,,Treatment of patients with locally advanced or metastatic non-small cell lungcancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapprovedtest,8/26/2011,8/26/2018,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,310610
CRIZOTINIB,53AH36668S,Designated/Approved,Public record,2346,crizotinib; crizotinib,9/13/2010,"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",Designated/Approved,,Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive,3/11/2016,3/11/2023,Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,310610
DARINAPARSIN,9XX54M675G,Designated,Public record,2347,Darinaparsin,9/13/2010,Treatment of peripheral T-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Solasia Pharma K.K.,"3F, Shiodome Building",,Toyko 105-0022,,,Japan,313810
PENTAMIDINE,673LC5J4LQ,Designated/Withdrawn,Public record,2348,pentamidine,9/13/2010,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Oncozyme Pharma, Inc.",555 Rene-Levesque West - 9th Floor,,Montreal,,,Canada,279709
ROZROLIMUPAB,S134V96RPQ,Designated,Public record,2349,rozrolimupab,9/13/2010,Treatment of primary immune thrombocytopenia.,Designated,Not FDA Approved for Orphan Indication,,,,,Symphogen A/S,Pederstrupvej 93,,Ballerup,,,Denmark,312610
CPP-115,0285I2MVUA,Designated,Public record,2350,"(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride",9/15/2010,Treatment of infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 1250,Coral Gables,Florida,33134,United States,300410
Amphotericin B,7XU7A7DROE,Designated,Public record,2352,amphotericin B,9/15/2010,Treatment of visceral leishmaniasis.,Designated,Not FDA Approved for Orphan Indication,,,,,iCo Therapeutics Inc.,760-777 Hornby Street,,Vancouver,,,Canada,315310
MULTIPOTENT ADULT PROGENITOR CELLS (BONE MARROW DERIVED),WNR9FH307P,Designated,Public record,2353,Multistem,9/15/2010,Prophylaxis of graft vs host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Athersys, Inc.",3201 Carnegie Avenue,,Cleveland,Ohio,44115,United States,314710
AT-300,,Designated,Public record,2354,Peptide that inhibits mechanosensitive ion channel (MSC) activity,9/15/2010,Treatment of Duchenne Muscular Dystrophy (DMD.),Designated,Not FDA Approved for Orphan Indication,,,,,Rose Pharmaceuticals,8210 Godlen Oak Circle,,Williamsville,New York,14221,United States,315710
ACYCLOVIR,X4HES1O11F,Designated/Withdrawn,Public record,2355,acyclovir,9/16/2010,Treatment of herpetic keratitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,One Franklin Plaza,,Philadelphia,Pennsylvania,19101,United States,313210
VITAMIN A ACETATE C20-D3,JN7W3M3OI7,Designated,Public record,2356,C20-D3-retinyl acetate,9/16/2010,Treatment of Stargardt's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Alkeus pharmaceuticals, Inc.",2103 Massachusetts Avenue,,Cambridge,Massachusetts,2140,United States,317210
DEFLAZACORT,KR5YZ6AE4B,Designated,Public record,2357,deflazacort,9/16/2010,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,University of Rochester Medical Center,1351 Mt. Hope Avenue,Suite 203,Rochester,New York,14620,United States,315110
EVEROLIMUS,9HW64Q8G6G,Designated/Withdrawn,Public record,2358,everolimus,9/16/2010,Treatment of Waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,315410
UNOPROSTONE ISOPROPYL,5M161S5O5P,Designated/Withdrawn,Public record,2359,unoprostone isopropyl,9/16/2010,Treatment of retinitis pigmentosa,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"R-Tech Ueno, Ltd.","Kobe Hybrid Business Center, 3F",Chuo-ku,Kobe City,Hyogo,,Japan,314810
SETANAXIB,45II35329V,Designated,Public record,2360,"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",9/21/2010,Treatment of idiopathic pulmonary fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics Suisse SA,Chemin des Aulx 16,,Plan-les-Ouates,,1228,Switzerland,316110
POMALIDOMIDE,D2UX06XLB5,Designated/Withdrawn,Public record,2361,pomalidomide,9/21/2010,Treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,308610
ECOPIPAM HYDROCHLORIDE,5X1J3190JI,Designated,Public record,2362,ecopipam hydrochloride,9/29/2010,Treatment of pediatric patients with Tourette's syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Emalex Biosciences, Inc.","1033 Skokie Bulevard, Suite 600",,Northbrook,Illinois,60062,United States,308210
SOMATROGON,6D848RA61B,Designated,Public record,2363,MOD-423 hGH analogue,9/29/2010,Treatment of growth hormone deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Pfizer Ireland Pharmaceuticals,Operations Support Group Building,,Ringaskiddy,Co. Cork,,Ireland,313410
MOXIDECTIN,NGU5H31YO9,Designated,Public record,2364,moxidectin,9/29/2010,Treatment of onchocerciasis volvulus in children and adults,Designated/Approved,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older,6/13/2018,6/13/2025,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older,Medicines Development Limited,"Level 1, 18 Kevanagh Street",Southbank VIC 3006,Melbourne,,,Australia,316510
TECOVIRIMAT,F925RR824R,Designated,Public record,2365,tecovirimat,9/29/2010,Treatment of orthopoxvirus infections.,Designated,Not FDA Approved for Orphan Indication,,,,,"SIGA Technologies, Inc.",4575 SW Research Way,,Corvallis,Oregon,97333,United States,316210
TLC-388,D47234N30N,Designated,Public record,2366,"(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2"",4"",5"",7""-tetranitro-9""-fluorenylideneaminooxy)propionyl]- 1H-pyrano[3',4',6',7',] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride",10/6/2010,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TLC Biopharmaceuticals, Inc.",432 N Canal St,Suite 20,South San Francisco,California,94080,United States,317610
PRX-08066,92E9B7675Y,Designated/Withdrawn,Public record,2367,"5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate",10/21/2010,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Forest Laboratories, Inc.",Harborside Financial Center,Plaza V,Jersey City,New Jersey,7311,United States,308510
ALGENPANTUCEL-L,I6HAD3HP89,Designated/Withdrawn,Public record,2368,algenpantucel-L,10/21/2010,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,NewLink Genetics Corporation,2503 S. Loop Drive,,Ames,Iowa,50010,United States,315810
VATIQUINONE,6O85FK9I0X,Designated,Public record,2369,alpha-tocotrienol quinone,10/21/2010,Treatment of inherited mitochondrial respiratory chain diseases,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,316310
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,2371,bevacizumab,10/21/2010,Treatment of hereditary hemorrhagic telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD",UCSD Medical Center,,San Diego,California,92103,United States,317510
ENSITUXIMAB,F988K568V2,Designated,Public record,2372,ensituximab,10/21/2010,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Neogenix Oncology, Inc.",9700 Great Seneca Highway,,Rockville,Maryland,20850,United States,320210
FRESOLIMUMAB,375142VBIA,Designated/Withdrawn,Public record,2373,fresolimumab,10/21/2010,Treatment of primary focal segmental glomerulosclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genzyme, a Sanofi Company",200 Crossing Boulevard,,Framingham,Massachusetts,1702,United States,313510
IPILIMUMAB,6T8C155666,Designated/Withdrawn,Public record,2374,human monoclonal anti-PA antibody,10/21/2010,For post-exposure prophylaxis and treatment of inhalation anthrax.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Emergent Product Development Gaithersburg, Inc.",300 Professional Drive,,Gaithersburg,Maryland,20879,United States,317710
LUCINACTANT,5BSH2G9BH8,Designated,Public record,2375,Lucinactant,10/21/2010,Treatment of cystic fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Windtree Therapeutics, Inc.",2600 Kelly Road,Suite 100,Warrington,Pennsylvania,18976,United States,318910
ACETYLCYSTEINE,WYQ7N0BPYC,Designated/Withdrawn,Public record,2376,N-acetylcysteine,10/21/2010,Treatment of apnea of prematurity,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Galleon Pharmaceuticals,213 Witmer Road,,Horsham,Pennsylvania,19044,United States,309110
CHLOROPYRAMINE,2K3L8O9SOV,Designated,Public record,2378,chloropyramine,10/22/2010,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"CurFAKtor Pharmaceuticals, LLC",14 Rock Dove Lane,,Orchard Park,New York,14127,United States,321110
OPAGANIB,DRG21OQ517,Designated,Public record,2379,4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide,11/2/2010,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Apogee Biotechnology Corporation,Hershey Center for Applied Research,Suite 1016,Hummelstown,Pennsylvania,17036,United States,318110
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,2380,bevacizumab,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,317810
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,2381,bevacizumab,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical rese",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,317810
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,2382,bevacizumab,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regi",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,317810
MENATETRENONE,27Y876D139,Designated,Public record,2383,menatetrenone,11/2/2010,Treatment of hepatocellular carcinoma (HCC).,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,319910
MENATETRENONE,27Y876D139,Designated,Public record,2384,menatetrenone,11/2/2010,Treatment of acute promyelocytic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,320810
MOGAMULIZUMAB,YI437801BE,Designated,Public record,2385,mogamulizumab,11/2/2010,Treatment of patients with cutaneous T-cell lymphoma.,Designated/Approved,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.,8/8/2018,8/8/2025,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.,Kyowa Kirin Pharmaceutical Development Inc.,212 Carnegie Center # 101,,Princeton,New Jersey,8540,United States,322010
MOGAMULIZUMAB,YI437801BE,Designated,Public record,2386,mogamulizumab,11/2/2010,Treatment of peripheral T-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.",212 Carnegie Center #101,,Princeton,New Jersey,8540,United States,313710
TRIENTINE HYDROCHLORIDE,HC3NX54582,Designated,Public record,2388,trientine hydrochloride,11/2/2010,Treatment of manganism,Designated,Not FDA Approved for Orphan Indication,,,,,"Cerberus Princeton, LLC",c/o Cerberus Capital Management L.P.,875 Third Avenue,New York,New York,10022,United States,301210
GABAPENTIN,6CW7F3G59X,Designated/Approved,Public record,2389,gabapentin,11/8/2010,Management of postherpetic neuralgia,Designated/Approved,,For the management of postherpetic neuralgia,1/28/2011,1/28/2018,,Golf Acquiror LLC,44 Whippany Road,Suite 300,Morristown,New Jersey,7960,United States,236506
EFMOROCTOCOG ALFA,7PCM518YLR,Designated/Approved,Public record,2390,"antihemophilic factor (recombinant), Fc fusion protein",11/23/2010,Treatment of hemophilia A,Designated/Approved,,"Indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.",6/6/2014,6/6/2021,"Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","Bioverativ Therapeutics, Inc.",225 2nd Avenue,,Waltham,Massachusetts,2451,United States,321610
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,2391,bevacizumab,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,318010
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,2392,bevacizumab,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,318010
BEVACIZUMAB,2S9ZZM9Q9V,Designated/Approved,Public record,2393,bevacizumab,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical rese",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,318010
CYCLOSPORINE,83HN0GTJ6D,Designated,Public record,2394,cyclosporine; ciclosporin,11/23/2010,Treatment of moderate to severe traumatic brain injury.,Designated,Not FDA Approved for Orphan Indication,,,,,NeuroVive Pharmaceutical AB,Medicon Village,SE-223 81,Lund,,,Sweden,319710
EFLORNITHINE,ZQN1G5V6SR,Designated,Public record,2395,eflornithine,11/23/2010,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Cancer Prevention Pharmaceuticals,1760 E. River Road,Suite 250,Tucson,Alaska,85718,United States,319610
ENTOLIMOD,R1UQ6D1ECM,Designated,Public record,2396,entolimod,11/23/2010,Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster,Designated,Not FDA Approved for Orphan Indication,,,,,"Statera BioPharma, Inc.",2537 Research Boulevard,Suite 201,Ft. Collins,Colorado,80526,United States,310910
GANITUMAB,CK1441RCZ8,Designated,Public record,2397,ganitumab,11/23/2010,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc., a wholly-owned subsidiary of ImmunityBio, Inc.",9920 Jefferson Boulevard,,Culver City,California,90232,United States,321510
NALOXONE,36B82AMQ7N,Designated,Public record,2398,naloxone,11/23/2010,Topical treatment of pruritus associated with mycosis fungoides,Designated,Not FDA Approved for Orphan Indication,,,,,"Elorac, Inc.",100 Fairway Drive,,Vernon Hills,Illinois,60061,United States,280209
VONICOG ALFA,5PKM8P0G5I,Designated/Approved,Public record,2400,recombinant von Willebrand factor (rhVWF),11/23/2010,Treatment of von Willebrand disease,Designated/Approved,,For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy,1/28/2022,1/28/2029,For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,322210
VONICOG ALFA,5PKM8P0G5I,Designated/Approved,Public record,2401,recombinant von Willebrand factor (rhVWF),11/23/2010,Treatment of von Willebrand disease,Designated/Approved,,Indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease (VWD),12/8/2015,12/8/2022,Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD),"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,322210
VONICOG ALFA,5PKM8P0G5I,Designated/Approved,Public record,2402,recombinant von Willebrand factor (rhVWF),11/23/2010,Treatment of von Willebrand disease,Designated/Approved,,Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding,4/13/2018,4/13/2025,Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,322210
CABOZANTINIB,1C39JW444G,Designated/Approved,Public record,2403,cabozantinib,11/29/2010,"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",Designated/Approved,,"Treatment of progressive, metastatic medullary thyroid cancer (MTC).",11/29/2012,11/29/2019,,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,94502,United States,297109
CABOZANTINIB,1C39JW444G,Designated/Approved,Public record,2404,cabozantinib,11/29/2010,"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",Designated/Approved,,Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible,9/17/2021,9/17/2028,Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,94502,United States,297109
FILOCICLOVIR,EAO0TD9B13,Designated,Public record,2405,filociclovir,11/29/2010,Treatment of active cytomegalovirus infections,Designated,Not FDA Approved for Orphan Indication,,,,,"Microbiotix, Inc.",One Innovation Drive,,Worcester,Massachusetts,1605,United States,319010
LORVOTUZUMAB MERTANSINE,0IVD6ASY0W,Designated/Withdrawn,Public record,2406,maytansinoid DM1-conjugated humanized monoclonal antibody N901,11/29/2010,Treatment of multiple myeloma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,2451,United States,322610
Sodium dichloroacetate,42932X67B5,Designated,Public record,2407,sodium dichloroacetate,11/29/2010,For pulmonary arterial hypertension.,Designated,Not FDA Approved for Orphan Indication,,,,,"Peter W. Stackpoole, PhD, MD",University of FL College of Medicine,P. O. Box 100226,Gainesville,Florida,32611,United States,313010
USTEKINUMAB,FU77B4U5Z0,Designated,Public record,2408,ustekinumab,11/29/2010,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC,902 Route 202 South,Room 1654,Raritan,New Jersey,8869,United States,314510
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,2410,sodium thiosulfate,12/2/2010,Treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,322410
ZURETINOL ACETATE,2K3YP54BYU,Designated,Public record,2411,zuretinol acetate,12/2/2010,Treatment of retinitis pigmentosa,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Retinagenix LLC,1815 Purdy Avenue,,Miami Beach,Florida,33139,United States,324410
ZURETINOL ACETATE,2K3YP54BYU,Designated,Public record,2412,zuretinol acetate,12/2/2010,Treatment of inherited retinal dystrophies caused by confirmed biallelic RPE65 or LRAT mutations,Designated,Not FDA Approved for Orphan Indication,,,,,"Eluminex Biosciences, Inc.","611 Gateway Boulevard, Suite 120",,South San Francisco,California,94080,United States,320410
ACYCLOVIR,X4HES1O11F,Designated,Public record,2413,acyclovir,12/13/2010,Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2,Designated/Approved,,AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.,3/29/2019,3/29/2026,AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.,Fera Pharmaceuticals,134 Birch Hill Road,,Locust Valley,New York,11560,United States,325010
CEDIRANIB,NQU9IPY4K9,Designated,Public record,2414,cediranib,12/13/2010,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,National Institutes of Health,National Cancer Institute,9609 Medical Center Dr.,Bethesda,Maryland,20892,United States,310510
FIDAXOMICIN,Z5N076G8YQ,Designated,Public record,2417,fidaxomicin,12/13/2010,Treatment of pediatric Clostridium difficile infection,Designated/Approved,,DIFICID® is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).,1/24/2020,1/24/2027,Dificid (fidaxomicin) is indicated for pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).,"Cubist Pharmaceuticals LLC, a subsidiary of Merck Sharp & Dohme LLC",20 Weystrasse,,Luzern,Luzern,,Switzerland,325210
IFERANSERIN,NWR3BEB8PA,Designated,Public record,2418,iferanserin (S-MPEC),12/13/2010,For use in pulmonary arterial hypertension.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sam Amer & Company, Inc.",P. O. Box 5685,,Montecito,California,93150,United States,315910
LITHIUM CITRATE,5Z6E9K79YV,Designated,Public record,2419,lithium citrate tetrahydrate (in reverse micelle formulation),12/13/2010,Treatment of Huntington's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Medesis Pharma,L'Oree des Mas,,Baillargues,,,France,325510
BLEOMYCIN,40S1VHN69B,Designated,Public record,2422,Bleomycin,12/20/2010,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,CIRJ Company Ltd.,1800 Loma Vista St.,,Pasadena,California,91004,United States,326510
RISPERIDONE,L6UH7ZF8HC,Designated,Public record,2423,calcium benzoate and risperidone,12/20/2010,Treatment of pediatric patients with schizophrenia,Designated,Not FDA Approved for Orphan Indication,,,,,"University of California, Los Angeles",Dept. of Psychiarty,"HH212, 1000 W. Carson Street",Torrance,California,90509,United States,326110
CALCIUM BENZOATE,3QDE968MKD,Designated,Public record,2423,calcium benzoate and risperidone,12/20/2010,Treatment of pediatric patients with schizophrenia,Designated,Not FDA Approved for Orphan Indication,,,,,"University of California, Los Angeles",Dept. of Psychiarty,"HH212, 1000 W. Carson Street",Torrance,California,90509,United States,326110
CRENOLANIB BESYLATE,MC4B01024K,Designated,Public record,2424,crenolanib besylate,12/20/2010,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"AROG Pharmaceuticals, LLC",Two Lincoln Centre,Suite 410,Dallas,Texas,75240,United States,320910
DENOSUMAB,4EQZ6YO2HI,Designated/Approved,Public record,2425,denosumab,12/20/2010,Treatment of patients with giant cell tumor of bone,Designated/Approved,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,6/13/2013,6/13/2020,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91320,United States,324110
DINUTUXIMAB,7SQY4ZUD30,Designated/Approved,Public record,2426,dinutuximab,12/20/2010,Treatment of neuroblastoma,Designated/Approved,,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prio",3/10/2015,3/10/2022,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prio",United Therapeutics Corporation,55 TW Alexander Drive,,Research Triangle Park,North Carolina,27709,United States,324210
TRAMETINIB,33E86K87QN,Designated/Approved,Public record,2429,trametinib,12/20/2010,Treatment of Stage IIb through Stage IV melanoma,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.,5/29/2013,5/29/2020,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,325410
VEMURAFENIB,207SMY3FQT,Designated/Approved,Public record,2430,vemurafenib,12/20/2010,Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation,Designated/Approved,,Treatment of unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test.,8/17/2011,8/17/2018,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,325310
TRANILAST,HVF50SMY6E,Designated,Public record,2432,tranilast,12/23/2010,Prevention of scarring following glaucoma filtration surgery,Designated,Not FDA Approved for Orphan Indication,,,,,Altacor Ltd,St. John's Innovation Centre,,Cambridge CB4 0WS,,,United Kingdom,311810
4-IODOPHENYLALANINE I-131,606VTF676Y,Designated,Public record,2433,4-[131I]iodo-L-phenylalanine,1/4/2011,Treatment of glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,Telix Pharmaceuticals (US) Inc.,10475 Crosspoint Boulevard,Suite 250,Indianapolis,Indiana,46256,United States,328710
BORTEZOMIB,69G8BD63PP,Designated,Public record,2434,bortezomib,1/4/2011,Treatment of follicular non-Hodgkin lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,328610
TOL-101,28X0AGG6P8,Designated,Public record,2436,"anti-TCR murine monoclonal antibody (MAB, type IgM)",1/12/2011,Treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age,Designated,Not FDA Approved for Orphan Indication,,,,,"Tolera Therapeutics, Inc.",350 E. Michigan Ave.,,Kalamazoo,Michigan,49008,United States,329310
CRIDANIMOD,X91E9EME19,Designated,Public record,2437,cridanimod,1/12/2011,Treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Xenetic Biosciences, Inc.",99 Hayden Avenue,Suite 230,Lexington,Massachusetts,2421,United States,328910
DABRAFENIB,QGP4HA4G1B,Designated/Approved,Public record,2438,dabrafenib,1/12/2011,Treatment BRAF V600 mutation positive Stage IIB through IV melanoma,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.,5/29/2013,5/29/2020,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,329610
PIMASERTIB HYDROCHLORIDE,6GS1ULF5HV,Designated,Public record,2441,"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride",1/12/2011,Treatment of acute myeloid leukemia (AML).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,328110
REGORAFENIB ANHYDROUS,24T2A1DOYB,Designated/Approved,Public record,2442,regorafenib,1/12/2011,Treatment gastrointestinal stromal tumors,Designated/Approved,,"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",2/25/2013,2/25/2020,"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.","Bayer HealthCare Pharmaceuticals, Inc.",P. O. Box 1000,,Montvale,New Jersey,7045,United States,329410
RESLIZUMAB,35A26E427H,Designated,Public record,2443,reslizumab,1/12/2011,Treatment of hypereosinophilic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC",145 Brandywine Pkwy.,,West Chester,Pennsylvania,19380,United States,328510
FLUCYTOSINE,D83282DT06,Designated,Public record,2444,vocimagene amiretrorepvec and flucytosine,1/12/2011,Treatment of malignant glioma in addition to glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"Tocagen, Inc.",4242 Campus Point Court,Suite 500,San Diego,California,92121,United States,327910
MITOMYCIN,50SG953SK6,Designated,Public record,2445,mitomycin,1/13/2011,Prevention of recurrence of pterygium after its surgical excision.,Designated,Not FDA Approved for Orphan Indication,,,,,"Mobius Therapeutics, LLC",4041 Forest Park Avenue,,St. Louis,Missouri,63108,United States,312510
FLUTICASONE PROPIONATE,O2GMZ0LF5W,Designated,Public record,2446,fluticasone propionate,1/19/2011,Treatment of pediatric and adult eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,Ellodi Pharmaceuticals,"325 Sentry Parkway, Building 5 West, Suite 200",,Blue Bell,Pennsylvania,19422,United States,319410
NEROFE,SR717JCM7M,Designated,Public record,2449,D-peptide,2/4/2011,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Immune System Key, Ltd",POB 23365,,Jerusalem,,,Israel,331210
EFLORNITHINE,ZQN1G5V6SR,Designated,Public record,2450,eflornithine,2/4/2011,Treatment of Familial Adenomatous Polyposis,Designated,Not FDA Approved for Orphan Indication,,,,,Cancer Prevention Pharmaceuticals,1760 E. River Road #250,,Tucson,Alaska,85718,United States,321210
MENATETRENONE,27Y876D139,Designated,Public record,2453,menatetrenone,2/4/2011,Treatment of myelodysplastic syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,319110
PEVONEDISTAT,S3AZD8D215,Designated,Public record,2455,MLN4924-Inhibitor of Nedd8-activating enzyme (NAE),2/4/2011,Treatment of acute myelogenous leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,331510
PEVONEDISTAT,S3AZD8D215,Designated,Public record,2456,MLN4924-Inhibitor of Nedd8-activating enzyme (NAE),2/4/2011,Treatment of Myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,331310
SUTEZOLID,3A71182L8P,Designated,Public record,2457,"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide",2/4/2011,Treatment of tuberculosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sequella, Inc.",9610 Medical Center Drive,Suite 200,Rockville,Maryland,20820,United States,328210
THYMOPENTIN,O3Y80ZF13F,Designated,Public record,2460,thymopentin,2/4/2011,Treatment of sarcoidosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Mondobiotech Laboratories AG,Herrengasse 21,,Furstentum Liechtenstein,,,Germany,330010
GO-203-2C,5YSY733NA3,Designated/Withdrawn,Public record,2463,acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide,2/18/2011,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genus Oncology, LLC",2458 N. Racine Avenue,,Chicago,Illinois,60614,United States,333311
TAGRAXOFUSP,8ZHS5657EH,Designated,Public record,2464,human interleukin-3 genetically conjugated to diphtheria toxin protein,2/18/2011,Treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Stemline Therapeutics, Inc.",750 Lexington Avenue,,New York,New York,10022,United States,332811
IXAZOMIB CITRATE,46CWK97Z3K,Designated/Approved,Public record,2465,ixazomib citrate,2/18/2011,Treatment of multiple myeloma,Designated/Approved,,Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy,11/20/2015,11/20/2022,Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,330510
METENKEFALIN,9JEZ9OD3AS,Designated,Public record,2466,met-enkephalin; Met-N,2/18/2011,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,333011
PATIDEGIB,JT96FPU35X,Designated/Withdrawn,Public record,2468,oral potent and selective antagonist,2/18/2011,Treatment of patients with chondrosarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Infinity Pharmaceuticals, Inc.",780 Memorial Drive,,Cambridge,Massachusetts,2139,United States,333511
CYCLOPHOSPHAMIDE,8N3DW7272P,Designated,Public record,2469,Revimmune,2/18/2011,Treatment of autoimmune hemolytic anemia.,Designated,Not FDA Approved for Orphan Indication,,,,,Accentia Biopharmaceuticals,324 South Hyde Park Avenue #350,,Tampa,Florida,33606,United States,333711
ACADESINE,53IEF47846,Designated,Public record,2470,acadesine,3/3/2011,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Avanced In Vitro Cell Technologies, S.L.",(Advancell),,Barcelona,,,Spain,203105
GANDOTINIB,ANC71R916O,Designated,Public record,2471,Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase,3/3/2011,"Treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)",Designated,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,334211
LOMITAPIDE,82KUB0583F,Designated,Public record,2472,lomitapide,3/3/2011,Treatment of Familial Chylomicronemia,Designated,Not FDA Approved for Orphan Indication,,,,,Amryt Pharmaceutical DAC,45 Mespil Road,,Dublin,,4,Ireland,332110
OMBRABULIN,82JB1524Q6,Designated,Public record,2473,"ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethozyphenyl)vinyl]phenyl}-L-serinamide hydrochloride",3/3/2011,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Sanofi-Aventis U.S., Inc.",55 Corporate Drive,,Bridgewater,New Jersey,8807,United States,334511
PYRIDOXINE,KV2JZ1BI6Z,Designated,Public record,2474,pyridoxine; vitamin B6,3/3/2011,Treatment of pyridoxine dependent seizures.,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,334311
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,2475,sodium thiosulfate,3/3/2011,Treatment of sulfur mustard poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,335311
ICOSAPENT,AAN7QOV9EA,Designated,Public record,2476,eicosapentaenoic acid,3/8/2011,Treatment of familial adenomatous polyposis,Designated,Not FDA Approved for Orphan Indication,,,,,S.L.A. Pharma Ltd. (UK),Elite House,,"Leavesden, Watford",,,United Kingdom,283409
.ALPHA.-TOCOPHEROL,H4N855PNZ1,Designated,Public record,2477,coenzyme Q10 and d-alpha-tocopherol,3/14/2011,Treatment of Friedreich's Ataxia.,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,335111
UBIDECARENONE,EJ27X76M46,Designated,Public record,2477,coenzyme Q10 and d-alpha-tocopherol,3/14/2011,Treatment of Friedreich's Ataxia.,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,335111
TALIMOGENE LAHERPAREPVEC,07730V90L6,Designated/Approved,Public record,2478,talimogene laherparepvec,3/14/2011,Treatment of stage IIb-stage IV melanoma,Designated/Approved,,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery",10/27/2015,10/27/2022,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery","BioVex, Inc. (subsidiary of Amgen)",Amgen,Mail Stop 17-2-B,Thousand Oaks,California,91320,United States,334011
"""(SAR9,MET(O2)11)SUBSTANCE P""",8V0QAFPRXV,Designated,Public record,2479,"Sar9, Met(O2)11-Substance P",3/16/2011,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,New Amsterdam Sciences,"14358 N. Frank Llyod Wright Blvd., Suite 3",,Scottsdale,Alaska,85260,United States,304110
HYDRALAZINE,26NAK24LS8,Designated,Public record,2481,hydralazine - magnesium valproate,3/17/2011,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Neolpharma S.A.DE C.V.,Boulevard de los Ferrocarriles 277,Azcapotalco,Mexico City,,,Mexico,334611
VALPROATE MAGNESIUM,Q400352CM2,Designated,Public record,2482,hydralazine - magnesium valproate,3/17/2011,Treatment of cutaneous T-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Neolpharma S.A.DE C.V.,Boulevard de los Ferrocarriles 277,Azcapotalco,Mexico City,,,Mexico,334411
MENATETRENONE,27Y876D139,Designated,Public record,2483,menatetrenone,3/17/2011,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,319210
OK-432,2F42BH7X2L,Designated,Public record,2484,picibanil,3/17/2011,Treatment of lymphatic malformations,Designated,Not FDA Approved for Orphan Indication,,,,,Protara Therapeutics Inc.,"345 Park Avenue South, 3rd Floor",,New York,New York,10010,United States,335811
NRC-AN-019,K6W49JL148,Designated,Public record,2485,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide",3/18/2011,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,NATCO Pharma Limited,Natco House,,Hyderabad 500033,,,India,337011
NRC-AN-019,K6W49JL148,Designated,Public record,2486,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide",3/18/2011,Treatment of chronic myelogenous leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,NATCO Pharma Limited,Natco House,,Hyderabad-500033,,,India,336911
NRC-AN-019,K6W49JL148,Designated,Public record,2487,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019",3/18/2011,Treatment of Glioma,Designated,Not FDA Approved for Orphan Indication,,,,,NATCO Pharma Limited,Natco House,,Hyderabad-500033,,,India,336811
ACETYLCARNITINE,6DH1W9VH8Q,Designated/Withdrawn,Public record,2488,acetyl-l-carnitine (ALC),3/18/2011,Treatment of Rett syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd.,Suite 500,Gaithersburg,Maryland,20878,United States,329010
BRIVANIB ALANINATE,U2Y5OFN795,Designated/Withdrawn,Public record,2489,brivanib alaninate,3/18/2011,Treatment of hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,P. O. Box 4000,,Princeton,New Jersey,8543,United States,336311
CRENOLANIB,LQF7I567TQ,Designated,Public record,2490,crenolanib,3/18/2011,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"AROG Pharmaceuticals, LLC",12400 Coit Road,Suite 570,Dallas,Texas,75251,United States,335911
TZ-101,K2X1EE8C73,Designated,Public record,2491,FTV1+GDP-fucose,3/18/2011,To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"America Stem Cell, Inc.",11014 Bar X Trail,,Helotes,Texas,78023,United States,321010
GUANOSINE 5'-DIPHOSPHO-.BETA.-L-FUCOSE,SM108QK2IH,Designated,Public record,2491,FTV1+GDP-fucose,3/18/2011,To improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"America Stem Cell, Inc.",11014 Bar X Trail,,Helotes,Texas,78023,United States,321010
RIGOSERTIB,67DOW7F9GL,Designated,Public record,2493,rigosertib,3/18/2011,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc",375 Pheasant Run,,Newtown,Pennsylvania,18940,United States,333611
LENALIDOMIDE,F0P408N6V4,Designated,Public record,2494,lenalidomide,3/28/2011,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,333811
PRADIGASTAT,2U23G6VNUZ,Designated,Public record,2495,selective deacylglycerol acyltransferase 1 inhibitor,3/28/2011,"Treatment of hypertriglyceridemia in the setting of Type I hyperlipoproteinemia, also known as Familial Chylomicronemia Syndrome",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,335711
BMS-986020,38CTP01B4L,Designated,Public record,2496,(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt,4/15/2011,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 4000,,Princeton,New Jersey,8543,United States,327810
MCD-386CR,6P87MRR8OA,Designated,Public record,2497,"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride",4/18/2011,Treatment of progressive supranuclear palsy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Mithridion, Inc.",505 Science Drive,,Madison,Wisconsin,53711,United States,327510
TPI-287,A2VM2V569A,Designated,Public record,2498,abeotaxane inhibitor of microtubules,4/18/2011,Treatment of pediatric neuroblastoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Cortice Biosciences,1345 Avenue of the Americas,42nd Floor,New York,New York,10105,United States,335611
ALDOXORUBICIN,C28MV4IM0B,Designated,Public record,2499,Aldoxorubicin,4/18/2011,Treatment of adenocarcinoma of the pancreas.,Designated,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,90232,United States,337211
ETIRINOTECAN PEGOL,LJ16641SFT,Designated,Public record,2502,etirinotecan pegol,4/18/2011,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Nektar Therapeutics,"455 Mission Bay Blvd, South",,San Francisco,California,94158,United States,338011
FIRTECAN PEGOL,WC4978T687,Designated,Public record,2503,firtecan pegol,4/18/2011,Treatment of neuroblastoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Enzon Pharmaceuticals, Inc.",20 Kingsbridge Road,,Piscataway,New Jersey,8854,United States,338311
LONAFARNIB,IOW153004F,Designated,Public record,2504,lonafarnib,4/18/2011,Treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies,Designated/Approved,,in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with e,11/20/2020,11/20/2027,in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with,"Eiger BioPharmaceuticals, Inc.",2155 Park Boulevard,,Palo Alto,California,94306,United States,333411
EP-217609,R6464792NG,Designated,Public record,2505,"Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-?-aspararginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-ox",4/18/2011,Prevention of ischemia reperfusion injury associated wth solid organ transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Endotis Pharma,"102, avenue Gaston Roussel",,93230 Romainville,,,France,336211
NUSINERSEN,5Z9SP3X666,Designated/Approved,Public record,2506,nusinersen,4/18/2011,Treatment of spinal muscular atrophy,Designated/Approved,,Treatment of spinal muscular atrophy in pediatric and adult patients,12/23/2016,12/23/2023,Treatment of spinal muscular atrophy in pediatric and adult patients,"Biogen, Inc",225 Binney Street,,Cambridge,Massachusetts,2142,United States,336711
PEPTIDE YY HUMAN,T2670C12I5,Designated,Public record,2507,peptide YY,4/18/2011,Treatment of hepatocellular carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Mondobiotech Laboratories AG,Herrengasse 21,,Furstentum Liechtenstein,,,Germany,338911
PERILLYL ALCOHOL,319R5C7293,Designated,Public record,2508,perillyl alcohol,4/18/2011,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.",10524 South La Cienega Blvd.,,Inglewood,California,90304,United States,340411
SIMTUZUMAB,11Z5AIU653,Designated/Withdrawn,Public record,2509,Recombinant humanized anti-LOXL2 monoclonal antibody,4/18/2011,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine St.,,Seattle,Washington,98102,United States,336611
"""DISODIUM 4,5,6,7-TETRACHLORO-2',4',5',7'-TETRAIODOFLUORESCEIN""",U1PBKAJVAD,Designated,Public record,2511,rose bengal disodium,4/18/2011,Treatment of hepatocellular carcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Provectus BioPharmaceuticals, Inc.",10025 Investment Drive,Suite 250,Knoxville,Tennessee,37932,United States,339611
ALTEPLASE,1RXS4UE564,Designated,Public record,2512,Tissue Plasminogen activator,4/18/2011,Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.,Designated,Not FDA Approved for Orphan Indication,,,,,"Catherine Amlie-Lefond, MD",University of Washington,4800 Sand Point Way NE - M/S B5552,Seattle,Washington,98105,United States,331410
RIFABUTIN,1W306TDA6S,Designated,Public record,2513,"clarithromycin, rifabutin, clofazimine",4/26/2011,Treatment of pediatric Crohn's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a Street,Tel Aviv-Yafo,Tel Aviv District,,,Israel,338811
CLARITHROMYCIN,H1250JIK0A,Designated,Public record,2513,"clarithromycin, rifabutin, clofazimine",4/26/2011,Treatment of pediatric Crohn's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a Street,Tel Aviv-Yafo,Tel Aviv District,,,Israel,338811
CLOFAZIMINE,D959AE5USF,Designated,Public record,2513,"clarithromycin, rifabutin, clofazimine",4/26/2011,Treatment of pediatric Crohn's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a Street,Tel Aviv-Yafo,Tel Aviv District,,,Israel,338811
LEVOTHYROXINE SODIUM,9J765S329G,Designated,Public record,2515,levothyroxine sodium,4/26/2011,The preservation of organ function in brain-dead organ donors.,Designated,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,11560,United States,334711
METRONIDAZOLE,140QMO216E,Designated,Public record,2516,metronidazole,4/26/2011,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,S.L.A. Pharma Limited (UK),Elite House,,"Watford, Hertfordshire.",,,United Kingdom,339111
FERUMOXYTOL,,Designated,Public record,2517,ferumoxytol,4/29/2011,For use in MR imaging for the mangement of brain tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Covis Pharma GmbH,Grafenauweg 12,,Zug,,6300,Switzerland,338411
ONTUXIZUMAB,0M2XT000YC,Designated,Public record,2518,Humanized monoclonal antibody to TumorEndothelial Marker-1,4/29/2011,Treatment of soft tissue sarcoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,155 Tice Boulevard,,Woodcliff Lake,New Jersey,7677,United States,337311
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated/Approved,Public record,2519,immune globulin intravenous (human),4/29/2011,Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia),Designated/Approved,,Idiopathic thrombocytopenic purpura,3/8/2013,,,Bio Products Laboratory,Dagger Lane,Hertfordshire,England,,,United Kingdom,335211
SOBETIROME,XQ31741E9Q,Designated,Public record,2520,sobetirome,4/29/2011,Treatment of X-linked adrenoleukodystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Naftali Kaminski, MD","Department of Medicine, Yale School of Medicine",300 Cedar Street,New Haven,Connecticut,6520,United States,334811
ACADESINE,53IEF47846,Designated,Public record,2521,acadesine,5/4/2011,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Advancell-Advanced In Vitro Cell Technologies S.A.,"Via Augusta 59, 3rd floor, door 313",,Barcelona,,,Spain,341011
ADALIMUMAB,FYS6T7F842,Designated,Public record,2523,adalimumab,5/11/2011,Treatment of pediatric patients with ulcerative colitis,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers,2/24/2021,2/24/2028,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers,"AbbVie, Inc.",1 North Waukegan Rd,Dept PA72; Bldg AP30-4,North Chicago,Illinois,60064,United States,340911
SIMTUZUMAB,11Z5AIU653,Designated/Withdrawn,Public record,2525,"recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)",5/17/2011,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St.,,Seattle,Washington,98102,United States,339311
CAMOSTAT,0FD207WKDU,Designated,Public record,2526,camostat,5/18/2011,Treatment of chronic pancreatitis,Designated,Not FDA Approved for Orphan Indication,,,,,NIXS Corporation,"Nichi-Iko Pharmaceutical Co., Ltd.",7th Floor - NOF Nihonbashi Honcho Bldg,Tokyo,,,Japan,338211
EVEROLIMUS,9HW64Q8G6G,Designated/Withdrawn,Public record,2527,everolimus,5/24/2011,Treatment of gastric cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,340111
OCARATUZUMAB,NTY9893GD0,Designated,Public record,2528,humanized IgG1 monoclonal anti-CD20 antibody,5/26/2011,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"MENTRIK Biotech, LLC",12400 Coit Rd,,Dallas,Texas,75251,United States,341111
EPOETIN,64FS3BFH5W,Designated,Public record,2529,recombinant human erythropoietin (rHuEPO),5/26/2011,Treatment of mutliple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"XTL Biopharmaceuticals, Ltd",85 Medinat Hayehudim St.,,Herzliya Pituach 46766,,,Israel,341711
CIPROFLOXACIN,5E8K9I0O4U,Designated,Public record,2531,ciprofloxacin,6/1/2011,The management of bronchiectasis,Designated,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"6836 Bee Cave Road, Building 3, Suite 200",,Austin,Texas,78746,United States,339911
AVEXITIDE,5313W10MYT,Designated,Public record,2532,exendin-(9-39),6/1/2011,Treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children,Designated,Not FDA Approved for Orphan Indication,,,,,The Children's Hospital of Philadelphia,Children's Hospital of Phil. Research Institute,Abramson Research Center,Philadelphia,Pennsylvania,19104,United States,321310
MITOMYCIN,50SG953SK6,Designated,Public record,2533,mitomycin,6/1/2011,Prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy,Designated,Not FDA Approved for Orphan Indication,,,,,"Mobius Therapeutics, LLC",1141 South 7th Street,,St. Louis,Missouri,63104,United States,305610
SIMTUZUMAB,11Z5AIU653,Designated/Withdrawn,Public record,2534,"Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)",6/1/2011,Treatment of myelofibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St.,,Seattle,Washington,98102,United States,340511
CYCLOPHOSPHAMIDE,8N3DW7272P,Designated,Public record,2537,cyclophosphamide,6/7/2011,Treatment of systemic sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Accentia Biopharmaceuticals, Inc.","324 South Hyde Avenue, Suite 350",,Tampa,Florida,33606,United States,333911
GABAPENTIN ENACARBIL,75OCL1SPBQ,Designated/Approved,Public record,2538,gabapentin enacarbil,6/7/2011,Treatment of postherpetic neuralgia,Designated/Approved,,Management of postherpetic neuralgia in adults.,6/6/2012,6/6/2019,,"Arbor Pharmaceuticals, LLC",6 Concourse Parkway,Suite 1800,Atlanta,Georgia,30328,United States,330710
MARIBAVIR,PTB4X93HE1,Designated,Public record,2539,maribavir,6/7/2011,Treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.,Designated/Approved,,"Treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valgan",11/23/2021,11/23/2028,"Treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valgan","Takeda Pharmaceuticals USA, Inc.",650 East Kendall Street,,Cambridge,Massachusetts,2142,United States,332210
MUBODINA,5JUR4M77U7,Designated/Withdrawn,Public record,2540,recombinant human minibody against complement component,6/7/2011,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A,Via Zurigo 46,6900 Lugano,,,,Switzerland,269908
7.BETA.-HYDROXYCHOLESTERYL 3-OLEATE,A59FMD985O,Designated,Public record,2541,7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester,6/15/2011,Treatment of gliomas.,Designated,Not FDA Approved for Orphan Indication,,,,,Intsel Chimos SA,1 rue Royale,,91123 Saint-Cloud Cedex,,,France,343511
CYCLOPHOSPHAMIDE,8N3DW7272P,Designated,Public record,2542,cyclophosphamide,6/17/2011,Prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant,Designated,Not FDA Approved for Orphan Indication,,,,,"Accentia Biopharmaceuticals, Inc.",324 S. Hyde Park Avenue,,Tampa,Florida,33606,United States,343611
CYTOCHROME C,Q5ED5J76AX,Designated,Public record,2543,"cytochrome C, flavin mononucleotide and thiamin diphosphate",6/17/2011,Treatment of mitochondrial disorders,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,342311
COCARBOXYLASE,Q57971654Y,Designated,Public record,2543,"cytochrome C, flavin mononucleotide and thiamin diphosphate",6/17/2011,Treatment of mitochondrial disorders,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,342311
RIBOFLAVIN 5'-PHOSPHATE,7N464URE7E,Designated,Public record,2543,"cytochrome C, flavin mononucleotide and thiamin diphosphate",6/17/2011,Treatment of mitochondrial disorders,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,342311
PENTETIC ACID,7A314HQM0I,Designated,Public record,2544,NanoDTPA(tm),6/17/2011,"Treatment of known or suspected cases of internal contamination with plutonium, americium, or curium",Designated,Not FDA Approved for Orphan Indication,,,,,NanoSHIFT LLC,10454 Northwest 132nd Drive,,Alachua,Florida,32615,United States,335511
ALDOXORUBICIN,C28MV4IM0B,Designated,Public record,2546,Aldoxorubicin,6/29/2011,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,90232,United States,339711
AMBROXOL,200168S0CL,Designated,Public record,2547,ambroxol,6/29/2011,Treatment of Gaucher disease,Designated,Not FDA Approved for Orphan Indication,,,,,Zywie LLC,155 Lambert Drive,,Princeton,New Jersey,8540,United States,262308
DENILEUKIN DIFTITOX,25E79B5CTM,Designated,Public record,2549,denileukin diftitox,6/29/2011,Treatment of peripheral T-cell lymphoma (PTCL),Designated,Not FDA Approved for Orphan Indication,,,,,"Citius Pharmaceuticals, Inc.","11 Commerce Drive, 1st Floor",,Cranford,New Jersey,7016,United States,342611
CP-12,SM5MFZ7FKP,Designated,Public record,2550,Fibronectin Peptide,6/29/2011,"Prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.",Designated,Not FDA Approved for Orphan Indication,,,,,"NeoMatrix Therapeutics, Inc.",Long Island High Tech Incubator,25 Health Sciences Drive,Stony Brook,New York,11790,United States,311510
GUSPERIMUS TRIHYDROCHLORIDE,QZS4144IO0,Designated,Public record,2551,gusperimus trihydrochloride,6/29/2011,Treatment of Wegener's granulomatosis,Designated,Not FDA Approved for Orphan Indication,,,,,Nordic Group B.V.,Siriusdreef 22,,2132 WT Hoofdorp,,,Netherlands,342711
NINTEDANIB,G6HRD2P839,Designated/Approved,Public record,2552,nintedanib,6/29/2011,Treatment of patients with idiopathic pulmonary fibrosis.,Designated/Approved,,Treatment of idiopathic pulmonary fibrosis,10/15/2014,10/15/2021,Treatment of idiopathic pulmonary fibrosis,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,344511
RESMINOSTAT,1578EUB98L,Designated,Public record,2553,resminostat,6/29/2011,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,4SC AG,Am Klopferspitz 19a,,Martinsried,,,Germany,345511
CORIFUNGIN,L26BTK4791,Designated,Public record,2554,corifungin,7/6/2011,Treatment of visceral leishmaniasis,Designated,Not FDA Approved for Orphan Indication,,,,,Sandler Center for Drug Discovery,"University of CA, San Francisco",1700 4th Street,San Francisco,California,94158,United States,342211
DEXTRAN SULFATE SODIUM (5000 MW),V5LWP0C2L5,Designated,Public record,2555,low molecular weight dextran sulfate,7/6/2011,Treatment to mobilze progenitor cells prior to stem cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,TikoMed AB,P.O. Box 81 (Karlsfaltsvagen 349),"SE-263 03, Viken",Viken,,,Sweden,344711
MEPOLIZUMAB,90Z2UF0E52,Designated/Approved,Public record,2556,mepolizumab,7/14/2011,Treatment of Churg-Strauss Syndrome,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).,6/6/2019,,,GlaxoSmithKline LLC,Corporation Service Company,1250 S. Collegeville Rd.,Collegeville,Pennsylvania,19426,United States,345111
MEPOLIZUMAB,90Z2UF0E52,Designated/Approved,Public record,2557,mepolizumab,7/14/2011,Treatment of Churg-Strauss Syndrome,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),12/12/2017,12/12/2024,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC,Corporation Service Company,1250 S. Collegeville Rd.,Collegeville,Pennsylvania,19426,United States,345111
MOGAMULIZUMAB,YI437801BE,Designated,Public record,2558,mogamulizumab,7/14/2011,Treatment of adult T-cell leukemia/lymphoma (ATLL).,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.",212 Carnegie Center,Suite 101,Princeton,New Jersey,8540,United States,345311
IRINOTECAN,7673326042,Designated/Approved,Public record,2559,irinotecan liposome injection,7/21/2011,Treatment of pancreatic cancer,Designated/Approved,,"For use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy",10/22/2015,10/22/2022,"For use in combination with 5-fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy","Ipsen Bioscience,Inc.",650 East Kendall Street,,Cambridge,Massachusetts,2142,United States,344311
HUMAN LAMININ-111,QJK0WC9NHE,Designated,Public record,2560,laminin-111 (human),7/21/2011,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Prothelia, Inc.",30 Haven Street,,Milford,Massachusetts,1757,United States,337411
SMILAGENIN,GQE3Q7YMVZ,Designated,Public record,2561,smilagenin,7/21/2011,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Junaxo, Inc.",First Canadian Place,Suite 5600,Toronto,,,Canada,345811
TRANSCROCETINATE SODIUM,YP57637WMX,Designated,Public record,2562,trans sodium crocetinate,7/21/2011,Treatment of glioblastoma in conjunction with radiotherapy,Designated,Not FDA Approved for Orphan Indication,,,,,"Diffusion Pharmaceuticals, LLC",2020 Avon Court,Suite 4,Charlottesville,Virginia,22902,United States,345911
ILORASERTIB,6L5D03D975,Designated/Withdrawn,Public record,2563,"1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)",7/28/2011,Treatment of acute myelogenous leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,337811
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,2564,alpha-1 proteinase inhibitor (human),7/28/2011,Treatment of patients with recent onset (,Designated,Not FDA Approved for Orphan Indication,,,,,"Kamada, Ltd.",2 Holtzman Street,,Rehovot,,,Israel,344111
PLERIXAFOR,S915P5499N,Designated/Withdrawn,Public record,2565,plerixafor,7/28/2011,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,346111
SILDENAFIL,3M7OB98Y7H,Designated,Public record,2566,sildenafil,7/28/2011,Treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension,Designated/Approved,,"treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old to improve exercise ability and, in pediatric patients too young to perform standard exercise testing, pulmonary hemodynamics thought to underly impro",1/31/2023,,,Viatris Specialty LLC,3711 Collins Ferry Road,,Morgantown,West Virginia,26505,United States,344211
PYRIMETHAMINE,Z3614QOX8W,Designated,Public record,2567,pyrimethamine,8/16/2011,Treatment of GM-2 gangliosidoses (Tay-Sachs disease and Sandhoff disease).,Designated,Not FDA Approved for Orphan Indication,,,,,ExSAR Corporation,11 Deer Park Drive,,Monmouth Junction,New Jersey,8852,United States,232206
DEVIMISTAT,E76113IR49,Designated,Public record,2568,"6,8-bis-benzylsulfanyl-octanoic acid",8/22/2011,Treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,8512,United States,349911
CORIFUNGIN,L26BTK4791,Designated,Public record,2570,corifungin,8/22/2011,Treatment of amebic meningoencephalitis.,Designated,Not FDA Approved for Orphan Indication,,,,,Ctr for Discovery & Innovation in Parasitic Diseas,"University of CA, San Francisco","Byers Hall Room 508B, QB3",San Francisco,California,94158,United States,348811
MENATETRENONE,27Y876D139,Designated,Public record,2571,menatetrenone and Vitamin D3,8/22/2011,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,348111
Cholecalciferol,1C6V77QF41,Designated,Public record,2571,menatetrenone and Vitamin D3,8/22/2011,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,59718,United States,348111
SODIUM CHLORITE,G538EBV4VF,Designated,Public record,2572,sodium chlorite,8/22/2011,For slowing the progression of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuraltus Pharmaceuticals, Inc.",1111 Bayhill Drive,Suite 210,San Bruno,California,94066,United States,343311
TRABEDERSEN,98OYR854NY,Designated,Public record,2573,trabedersen,8/22/2011,Treatment of Stage IIB through Stage IV malignant melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Oncotelic Inc.,29397 Agoura Road,Suite 107,Agoura Hills,California,91301,United States,346011
TIOMOLIBDATE CHOLINE,FD57A79R4P,Designated,Public record,2574,choline tetrathiomolybdate,8/25/2011,Treatment of Wilson's disease,Designated,Not FDA Approved for Orphan Indication,,,,,Alexion Pharmaceutical Inc.,121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,346511
DINACICLIB,4V8ECV0NBQ,Designated,Public record,2575,dinaciclib,8/25/2011,Treatment of chronic lymphocytic leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme Ltd.,"Hertford Road, Hoddesdon",,Hertfordshire,,,United Kingdom,347211
IDELALISIB,YG57I8T5M0,Designated,Public record,2576,idelalisib,8/25/2011,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St.,,Seattle,Washington,98102,United States,347511
LANREOTIDE ACETATE,IEU56G3J9C,Designated/Approved,Public record,2577,lanreotide acetate,8/25/2011,Treatment of neuroendocrine tumors,Designated/Approved,,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival",12/16/2014,12/16/2021,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival","Ipsen Biopharmaceuticals, Inc.",106 Allen Road,,Basking Ridge,New Jersey,7920,United States,347811
AVATROMBOPAG MALEATE,GDW7M2P1IS,Designated,Public record,2578,avatrombopag maleate,9/1/2011,Treatment of idiopathic thrombocytopenic purpura,Designated/Approved,,DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment,6/26/2019,6/26/2026,For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment,"Sobi, Inc.",240 Leigh Farm Road,Suite 245,Durham,North Carolina,27707,United States,325110
DEFERIPRONE,2BTY8KH53L,Designated,Public record,2579,deferiprone,9/1/2011,Treatment of superficial siderosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,340011
ELOTUZUMAB,1351PE5UGS,Designated/Approved,Public record,2580,elotuzumab,9/1/2011,Treatment of multiple myeloma,Designated/Approved,,EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.,11/6/2018,11/6/2025,"Indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, excluding adult patients covered by Em",Bristol-Myers Squibb Co.,P.O. Box 5326,,Princeton,New Jersey,8543,United States,348411
ELOTUZUMAB,1351PE5UGS,Designated/Approved,Public record,2581,elotuzumab,9/1/2011,Treatment of multiple myeloma,Designated/Approved,,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,11/30/2015,11/30/2022,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,Bristol-Myers Squibb Co.,P.O. Box 5326,,Princeton,New Jersey,8543,United States,348411
L-3972-T,06HG6YW0HK,Designated,Public record,2582,HPV16 E6/E7 synthetic long peptides vaccine,9/1/2011,Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.,Designated,Not FDA Approved for Orphan Indication,,,,,ISA Therapeutics BV,J.H. Oortweg 19,2333 CH Leiden,CH Leiden,,,Netherlands,324310
D-3082-L,LF9Q4TT8ZW,Designated,Public record,2582,HPV16 E6/E7 synthetic long peptides vaccine,9/1/2011,Treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.,Designated,Not FDA Approved for Orphan Indication,,,,,ISA Therapeutics BV,J.H. Oortweg 19,2333 CH Leiden,CH Leiden,,,Netherlands,324310
DOMPERIDONE,5587267Z69,Designated,Public record,2583,domperidone,9/2/2011,"Treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding",Designated,Not FDA Approved for Orphan Indication,,,,,Texas Tech University Health Sciences Center,1400 S Coulter St.,,Amarillo,Texas,79106,United States,336111
RIBAVIRIN ELAIDATE,4LU13X0I13,Designated,Public record,2584,ribavirin elaidate,9/2/2011,"Treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer",Designated,Not FDA Approved for Orphan Indication,,,,,"Translational Therapeutics, Inc.",163 Scituate Street,,Arlington,Massachusetts,2476,United States,344011
RIBOFLAVIN,TLM2976OFR,Designated/Approved,Public record,2585,riboflavin ophthalmic solution & ultraviolet A,9/2/2011,Treatment of keratoconus,Designated/Approved,,Indicated for use in corneal collagen crosslinking in combination with the KXL¿ System for the treatment of progressive keratoconus,4/15/2016,4/15/2023,Treatment of progressive keratoconus,"Avedro, Inc.",230 Third Avenue,,Waltham,Massachusetts,2451,United States,344911
LANREOTIDE ACETATE,IEU56G3J9C,Designated/Approved,Public record,2586,lanreotide acetate,9/8/2011,Treatment of carcinoid syndrome,Designated/Approved,,"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy",9/15/2017,9/15/2024,"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy","Ipsen Biopharmaceuticals, Inc.",106 Allen Road,,Basking Ridge,New Jersey,7920,United States,347111
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,2587,Angiotensin-(1-7),9/13/2011,Treatment of pulmonary arterial hypertension.,Designated,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,93401,United States,345411
CARDIOTROPHIN 1,AJ7U77BR8I,Designated,Public record,2588,cardiotrophin-1,9/13/2011,Treatment of acute liver failure,Designated,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,,Spain,350711
CIBINETIDE,9W5677JKDA,Designated,Public record,2589,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,9/13/2011,Treatment of neuropathic pain in patients with sarcoidosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Araim Pharmaceuticals, Inc.",712 Kitchawan Raod,,Ossining,New York,10562,United States,349111
ROMILKIMAB,O8HNJ174XS,Designated/Withdrawn,Public record,2590,bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13),9/14/2011,Treatment of idiopathic pulmonary fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sanofi US Services, Inc., A SANOFI COMPANY",55 Corporate Drive,Mailstop: 55C-300,Bridgewater,New Jersey,8807,United States,342811
NIMODIPINE,57WA9QZ5WH,Designated/Approved,Public record,2591,nimodipine,9/16/2011,Treatment of subarachnoid hemorrhage.,Designated/Approved,,"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hu",5/10/2013,5/10/2020,"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hu","Arbor Pharmaceuticals, Inc.",6 Concourse Parkway,Suite 1800,Atlanta,Georgia,30328,United States,338611
PENTOSAN POLYSULFATE SODIUM,914032762Y,Designated,Public record,2592,pentosan polysulfate sodium,9/16/2011,Treatment of sickle cell disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.",108 Eagle Trace Drive,,Half Moon Bay,California,94019,United States,352311
RESMINOSTAT,1578EUB98L,Designated,Public record,2593,resminostat,9/16/2011,Treatment of Hodgkin's lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,4SC AG,Am Klopferspitz 19a,,Martinsried,,,Germany,351411
TANZISERTIB,M5O06306UO,Designated/Withdrawn,Public record,2594,"4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol",9/23/2011,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,348911
ACENEURAMIC ACID,GZP2782OP0,Designated,Public record,2595,aceneuramic acid,9/23/2011,Treatment of hereditary inclusion body myopathy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,Suite 200,Novato,California,94949,United States,351511
HUMAN LAMININ-111,QJK0WC9NHE,Designated,Public record,2597,human laminin-111,9/23/2011,Treatment of merosin (laminin-alpha2) deficient congential muscular dystrophy type 1A.,Designated,Not FDA Approved for Orphan Indication,,,,,"Prothelia, Inc.",30 Haven Street,,Milford,Massachusetts,1757,United States,351811
PERETINOIN,11ALM7A4RV,Designated,Public record,2598,peretinoin,9/23/2011,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Kowa Pharmaceutical Europe GmbH,Duiburger Landstassa,,Dusseldorf,,,Germany,352011
P-2745,ZGL5E40F57,Designated,Public record,2599,"4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol",10/4/2011,Treatment of chronic myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Piramal Enterprises Limited,1 Nirlon Complex,Goregaon (East),Mumbai,Maharashtra,,India,349611
LACTOBACILLUS BREVIS,268IL53Q7O,Designated,Public record,2600,lactobacillus brevis CD2,10/4/2011,Treatment Behcet's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"VSL Pharmaceuticals, Inc.",100 West Road,,Towson,Maryland,21204,United States,351711
TPI-287,A2VM2V569A,Designated,Public record,2601,abeotaxane inhibitor of microtubules,10/7/2011,Treatment of gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,Cortice Biosciences,1345 Avenue of the Americas,42nd Floor,New York,New York,10105,United States,352811
FERUMOXYTOL,,Designated,Public record,2602,ferumoxytol,10/7/2011,For use in magnetic resonance imaging in brain metastases,Designated,Not FDA Approved for Orphan Indication,,,,,Covis Pharma GmbH,Grafenauweg 12,,Zug,,6300,Switzerland,350111
MAVOGLURANT,GT0I9SV4F6,Designated,Public record,2603,"(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester",10/12/2011,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Stalicla SA,Campus Biotech Innovation Park,Avenue de Secheron 15,Geneve,,1202,Switzerland,353611
RELTECIMOD,U00J02UY29,Designated,Public record,2604,reltecimod,10/12/2011,Treatment of necrotizing soft tissue infections (NSTI),Designated,Not FDA Approved for Orphan Indication,,,,,"Atox Bio, Inc.",3 Golda Meir St.,,Ness Ziona,,,Israel,352211
SARCOSINE,Z711V88R5F,Designated,Public record,2605,sarcosine,10/12/2011,Treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"Guochuan Emil Tsai, MD, PhD","David Geffen School of Medicine, UCLA","1000 W., Carson St.",Torrance,California,90502,United States,346611
HALOFUGINONE HYDROBROMIDE,PTC2969MV1,Designated,Public record,2606,halofuginone hydrobromide,10/13/2011,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Akashi Therapeutics, Inc.",245 First Street,18th Floor,Cambridge,Massachusetts,2142,United States,352711
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,2607,sodium thiosulfate,10/13/2011,Prevention of platinum-induced ototoxicity in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,353311
ECULIZUMAB,A3ULP0F556,Designated,Public record,2609,eculizumab,10/18/2011,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,354511
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,2610,sodium 4-phenylbutyrate,10/18/2011,Treatment of spinal muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,GMP-Orphan SAS,"7, rue du Pasteur Wagner",F-75011,Paris,,,France,354011
INTERFERON GAMMA,P050J5FWC5,Designated,Public record,2612,interferon gamma,11/4/2011,Treatment of Friedreich's ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,"Roberto Testi, MD",School of Medicine,via Michelini-Tocci 82,Rome,,,Italy,354711
RAMUCIRUMAB,D99YVK4L0X,Designated,Public record,2613,ramucirumab,11/4/2011,Treatment of hepatocellular carcinoma,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",5/10/2019,5/10/2026,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,353911
SIROLIMUS,W36ZG6FT64,Designated,Public record,2614,sirolimus,11/4/2011,"Treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (NICUPS).",Designated,Not FDA Approved for Orphan Indication,,,,,Santen Inc.,"6401 Hollis Street, Suite 125",,Emeryville,California,94608,United States,327210
UREA,8W8T17847W,Designated,Public record,2615,urea,11/7/2011,"Treatment of rare congenital ichthyoses (CHILD syndrome, collodion baby, congenital ichthyosform erythroderma, Conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, KID syndrome, lamellar ichthyosis, Nether",Designated,Not FDA Approved for Orphan Indication,,,,,"Orenova Group, LLC",10 New King Street,Suite 106,White Plains,New York,10604,United States,346211
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,2616,sodium thiosulfate,11/9/2011,Treatment of uremic and non-uremic calciphylaxis,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,352611
OTLERTUZUMAB,2MZ3L2664T,Designated,Public record,2617,humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains),11/17/2011,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Aptevo Therapeutics, Inc.",2401 Fourth Avenue,Suite 1050,Seattle,Washington,98121,United States,353411
EZUTROMID,645R07LF0D,Designated,Public record,2618,5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole,11/22/2011,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Summit (Oxford) Limited,136a Eastern Avenue,Milton Park,Abingdon,,,United Kingdom,351111
MCMV-3068A,I4SA959J1V,Designated/Withdrawn,Public record,2619,MCMV5322A/MCMV3068A,11/22/2011,Prevention of maternal-fetal transmission of congenital CMV in pregnant women who acquire CMV infection during pregnancy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genentech,1 DNA Way,MS#241B,South San Francisco,California,94080,United States,355911
OPIUM TINCTURE,,Designated,Public record,2620,opium tincture,12/2/2011,Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment,Designated,Not FDA Approved for Orphan Indication,,,,,"Valeant Pharmaceuticals International, Inc.",400 Somerset Corporate Blvd,,Bridgewater,New Jersey,8807,United States,307710
PORFIMER SODIUM,Y3834SIK5F,Designated,Public record,2621,porfimer sodium,12/2/2011,Treatment of malignant mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Concordia Laboratories, Inc., Sarl",8-10 Avenue de la Gare - L-1610,,Luxembourg,Grand Duchy of Luxembourg,,Luxembourg,357011
RIBOFLAVIN,TLM2976OFR,Designated/Approved,Public record,2622,riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation,12/2/2011,Treatment of corneal ectasia following refractive surgery,Designated/Approved,,Treatment of corneal ectasia following refractive surgery,7/15/2016,7/15/2023,Treatment of corneal ectasia following refractive surgery,"Avedro, Inc.",230 Third Avenue,,Waltham,Massachusetts,2451,United States,352511
VAMOROLONE,8XP29XMB43,Designated,Public record,2623,vamorolone,12/2/2011,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Santhera Pharmaceuticals Ltd.,Hohenrainstrasse 24,,Pratteln,,4133,Switzerland,343111
TOMARALIMAB,P45C2W27DU,Designated,Public record,2624,humanized IgG4 monoclonal antibody,12/12/2011,Prevention of ischemia/reperfusion injury associated with solid organ tranplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuramedy Co., Ltd.","Rm408, Convergence Research Bldg",Seoul National University College of Medicine,Seoul,Jongro-gu,,South Korea,355311
LETERMOVIR,1H09Y5WO1F,Designated/Approved,Public record,2625,letermovir,12/12/2011,Prevention of human cytomegalovirus viremia and disease in at risk populations,Designated/Approved,,prophylaxis of CMV disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]),6/5/2023,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,340211
LETERMOVIR,1H09Y5WO1F,Designated/Approved,Public record,2626,letermovir,12/12/2011,Prevention of human cytomegalovirus viremia and disease in at risk populations,Designated/Approved,,Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).,11/8/2017,11/8/2024,Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,340211
LOSARTAN,JMS50MPO89,Designated,Public record,2627,losartan,12/12/2011,Treatment of Marfan Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,National Marfan Foundation,22 Manhhasset Avenue,,Port Washington,New York,11050,United States,357211
SORAFENIB,9ZOQ3TZI87,Designated/Approved,Public record,2629,sorafenib,12/12/2011,"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer",Designated/Approved,,"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.",11/22/2013,11/22/2020,"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.","Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd.,PO Box 915,Whippany,New Jersey,7981,United States,320310
ESUBERAPROST SODIUM,6C8TLD4Q9K,Designated,Public record,2631,beraprost sodium 314d,12/22/2011,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Lung Biotechnology PBC,1040 Spring Street,,Silver Spring,Maryland,20910,United States,355711
CBP-501 ACETATE,8HSP55450P,Designated,Public record,2632,H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt,12/22/2011,For use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,"CanBas Company, Ltd.",2-2-1 Otemachi,,Numazu City,Shizuoka,,Japan,358411
CLOZAPINE,J60AR2IKIC,Designated,Public record,2634,sodium benzoate and clozapine,12/22/2011,Treatment of treatment-resistant schizophrenia,Designated,Not FDA Approved for Orphan Indication,,,,,SyneuRx International Corp.,"20F-9 99 Section 1, Xintaiwu Road",Xizhi District,New Taipei City,,,Taiwan,357411
Sodium benzoate,OJ245FE5EU,Designated,Public record,2634,sodium benzoate and clozapine,12/22/2011,Treatment of treatment-resistant schizophrenia,Designated,Not FDA Approved for Orphan Indication,,,,,SyneuRx International Corp.,"20F-9 99 Section 1, Xintaiwu Road",Xizhi District,New Taipei City,,,Taiwan,357411
USTEKINUMAB,FU77B4U5Z0,Designated/Withdrawn,Public record,2635,ustekinumab; human monocloncal antibody to interkeukin 12p40,12/22/2011,Treatment of primary biliary cirrhosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,19355,United States,343811
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,2636,nitric oxide,12/28/2011,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Bellerophon Therapeutics,53 Frontage Road,Suite 301,Hampton,New Jersey,8827,United States,340811
USTEKINUMAB,FU77B4U5Z0,Designated/Withdrawn,Public record,2637,ustekinumab,12/28/2011,Treatment of chronic sarcoidosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",800 & 850 Ridgeview Drive,,Horsham,Pennsylvania,19044,United States,358111
POCAPAVIR,4ILA3VOV97,Designated,Public record,2638,"1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene",1/9/2012,Treatment of poliovirus infection.,Designated,Not FDA Approved for Orphan Indication,,,,,"ViroDefense, Inc.",155 Gibbs Street,Suite 529,Rockville,Maryland,20850,United States,357811
Sodium nitrite,M0KG633D4F,Designated,Public record,2639,sodium nitrite,1/9/2012,Treatment of chlorine gas poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,359111
REC-2282,E0GG29V0AQ,Designated,Public record,2641,N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide,1/13/2012,Treatment of Schwannoma of the central nervous system,Designated,Not FDA Approved for Orphan Indication,,,,,Recursion Pharmaceuticals Inc.,41 S. Rio Grande Street,,Salt Lake City,Utah,84101,United States,355611
REC-2282,E0GG29V0AQ,Designated,Public record,2642,N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide,1/13/2012,Treatment of meningioma,Designated,Not FDA Approved for Orphan Indication,,,,,Recursion Pharmaceuticals Inc.,41 S. Rio Grande Street,,Salt Lake City,Utah,84101,United States,355511
DIANHYDROGALACTITOL,4S465RYF7M,Designated,Public record,2643,"1,2:5,6-Dianhdrogalactitol",1/31/2012,Treatment of malignant gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"DelMar Pharmaceuticals, Inc.",3475 Edison Way,Suite R,Menlo Park,California,94025,United States,361311
PHENYLEPHRINE,1WS297W6MV,Designated,Public record,2645,phenylephrine,1/31/2012,Treatment of Tetralogy of Fallot,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,11967,United States,359011
DIGOXIN IMMUNE FAB (OVINE),,Designated,Public record,2646,digoxin immune fab (ovine),2/3/2012,Treatment of severe preeclampsia and eclampsia,Designated,Not FDA Approved for Orphan Indication,,,,,"AMAG Pharmaceuticals, Inc.",1100 Winter Street,,Waltham,Massachusetts,2451,United States,343911
OVINE DIGOXIN IMMUNE FAB,YB12NQZ1YN,Designated,Public record,2646,digoxin immune fab (ovine),2/3/2012,Treatment of severe preeclampsia and eclampsia,Designated,Not FDA Approved for Orphan Indication,,,,,"AMAG Pharmaceuticals, Inc.",1100 Winter Street,,Waltham,Massachusetts,2451,United States,343911
RAMUCIRUMAB,D99YVK4L0X,Designated/Approved,Public record,2647,ramucirumab,2/16/2012,Treatment of gastric cancer,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.",4/21/2014,4/21/2021,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company,33 ImClone Drive,,Branchburg,New Jersey,8876,United States,359711
RAMUCIRUMAB,D99YVK4L0X,Designated/Approved,Public record,2648,ramucirumab,2/16/2012,Treatment of gastric cancer,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.",11/5/2014,,,Eli Lilly and Company,33 ImClone Drive,,Branchburg,New Jersey,8876,United States,359711
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,2649,Sodium Thiosulfate,2/16/2012,Treatment of uremic and non-uremic calciphylaxis,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",800 Adams Avenue,Suite 100,Norristown,Pennsylvania,19403,United States,356511
VESTRONIDASE ALFA,7XZ4062R17,Designated/Approved,Public record,2650,vestronidase alfa-vjbk,2/16/2012,"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",Designated/Approved,,"Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).",11/15/2017,11/15/2024,"Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).","Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,,Novato,California,94949,United States,359811
BIRTAMIMAB,VXQ2SK8I3P,Designated,Public record,2651,birtamimab,2/17/2012,Treatment of AA amyloidosis and AL amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,Prothena Therapeutics Limited,Treasury Building,Lower Grand Canal Street,Dublin,2,,Ireland,361411
NAMODENOSON,Z07JR07J6C,Designated,Public record,2652,2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide,2/17/2012,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Can-Fite BioPharma Ltd.,10 Bareket Street,P. O. Box 7537,Petah-Tikva,,,Israel,363512
NEOSTIGMINE METHYLSULFATE,98IMH7M386,Designated,Public record,2654,neostigmine methylsulfate,2/17/2012,Treatment of Myasthenia Gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",1000 Madison Ave,,Norristown,Pennsylvania,19403,United States,359611
OBINUTUZUMAB,O43472U9X8,Designated,Public record,2655,obinutuzumab,2/17/2012,Treatment of diffuse large B cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group",1 DNA Way,MS #355e,South San Francisco,California,94080,United States,360011
OBINUTUZUMAB,O43472U9X8,Designated/Approved,Public record,2656,obinutuzumab,2/17/2012,Treatment of chronic lymphocytic leukemia,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).",11/1/2013,11/1/2020,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group",1 DNA Way,,South San Francisco,California,94080,United States,359911
ZINPENTRAXIN ALFA,F68WAH6N5E,Designated,Public record,2657,recombinant human Pentraxin-2; recombinant human Serum Amyloid P,2/17/2012,Treatment of idiopathic pulmonary fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,Building 45,South San Francisco,California,94080,United States,361111
DEPATUXIZUMAB,W984C353CG,Designated/Withdrawn,Public record,2658,Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor,2/17/2012,Treatment of glioblastoma multiforme,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,361811
Salicylic acid,O414PZ4LPZ,Designated,Public record,2659,salicylic acid 6%,2/17/2012,Treatment of rare congenital ichthyoses.,Designated,Not FDA Approved for Orphan Indication,,,,,"Orenova Group, LLC",10 New King Street,Suite 106,White Plains,New York,10604,United States,359211
SILIBININ DIHEMISUCCINATE DISODIUM,57LSQ377IE,Designated,Public record,2660,"Silibinin-C-2',3-dihydrogensuccinate, disodium salt",2/17/2012,Prevention of recurrent hepatitis C in liver transplant patients,Designated,Not FDA Approved for Orphan Indication,,,,,Mylan Specialty LP,781 Chestnut Ridge Road,P. O. Box 4310,Morgantown,West Virginia,26505,United States,362811
TAFAMIDIS MEGLUMINE,ZU7CF08A1A,Designated,Public record,2662,tafamidis meglumine,2/17/2012,Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.,Designated/Approved,,VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.,5/3/2019,5/3/2026,VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.,"FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.",445 Eastern Point Road,,Groton,Connecticut,6340,United States,363312
EVOFOSFAMIDE,8A9RZ3HN8W,Designated,Public record,2663,"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate",3/9/2012,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Threshold Pharmaceuticals, Inc.",170 Harbor Way,Suite 300,South San Francisco,California,94080,United States,365812
IXAZOMIB CITRATE,46CWK97Z3K,Designated,Public record,2664,"2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)",3/9/2012,Treatment of systemic light chain (AL) amyloidosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,361911
BASIMGLURANT,3110E3AO8S,Designated,Public record,2666,basimglurant,3/9/2012,Treatment of Fragile X Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,7110,United States,333211
PEGINTERFERON ALFA-2A,Q46947FE7K,Designated,Public record,2667,Hanferon,3/9/2012,Treatment of Behcet's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"HanAll BioPharma Co., Ltd.",Jamsil I-Space Building 6F,138 420,Seoul,,,South Korea,362911
LEVOKETOCONAZOLE,2DJ8R0NT7K,Designated,Public record,2669,levoketoconazole,3/9/2012,Treatment of endogenous Cushing's syndrome,Designated/Approved,,Treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative,12/30/2021,12/30/2028,Treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative,Strongbridge Dublin Limited,"Suite 206, Fitzwilliam Hall",,Dublin 2,,,Ireland,364412
LINSITINIB,15A52GPT8T,Designated/Withdrawn,Public record,2670,linsitinib,3/9/2012,Treatment of adrenocortical carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,362311
NEVANIMIBE HYDROCHLORIDE,TK694ZFS57,Designated,Public record,2671,nevanimibe HCL,3/9/2012,Treatment of adrenocortical carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millendo Therapeutics, Inc.",301 North Main Street,Suite 100,Ann Arbor,Michigan,48104,United States,364712
TELOTRISTAT ETIPRATE,3T25U84H4U,Designated/Approved,Public record,2672,telotristat etiprate,3/9/2012,Treatment of carcinoid syndrome in patients with neuroendocrine tumors,Designated/Approved,,Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,2/28/2017,2/28/2024,Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,"TerSera Therapeutics, LLC","520 Lake Cook Road, Suite 500",,Deerfield,Illinois,60015,United States,266308
VERTEPORFIN,0X9PA28K43,Designated,Public record,2673,verteporfin,3/9/2012,Treatment of chronic or recurrent central serous chorioretinopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America LLC,700 Route 202/206 North,,Bridgewater,New Jersey,8807,United States,350511
CARISBAMATE,P7725I9V3Z,Designated,Public record,2674,carisbamate,3/16/2012,Management of patients with infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,"SK Life Science, Inc.",22-10 Route 208 South,,Fair Lawn,New Jersey,7410,United States,362511
ALCOHOL,3K9958V90M,Designated,Public record,2675,dehydrated alcohol,3/16/2012,Treatment of trigeminal neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,11967,United States,361611
GOLIMUMAB,91X1KLU43E,Designated,Public record,2676,golimumab,3/16/2012,Treatment of pediatric ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",1400 McKean Road,,Spring House,Pennsylvania,19477,United States,365112
ILORASERTIB,6L5D03D975,Designated/Withdrawn,Public record,2677,ilorasertib,3/16/2012,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,364212
JS-K,80P1Q21652,Designated,Public record,2678,"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate",3/16/2012,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"JSK Therapeutics, Inc.",1567 W. Silver Springs Road,,Park City,Utah,84098,United States,363412
RIGOSERTIB,67DOW7F9GL,Designated,Public record,2679,rigosertib,3/16/2012,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc.",375 Pheasant Run,,Newton,Pennsylvania,18940,United States,366412
TALAROZOLE,XKD9N5CJ6W,Designated/Withdrawn,Public record,2681,talarazole,3/16/2012,Treatment of congenital ichthyosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Stiefel Laboratories, Inc.",20 T.W. Alexander Drive,,Research Triangle Park,North Carolina,27709,United States,365412
IBRUTINIB,1X70OSD4VX,Designated/Withdrawn,Public record,2682,ibrutinib,3/27/2012,Treatment of chronic lymphocytic leukemia (CLL).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,366212
ROPEGINTERFERON ALFA-2B,981TME683S,Designated/Approved,Public record,2684,ropeginterferon alfa-2b-njft,4/2/2012,Treatment of polycythemia vera,Designated/Approved,,Treatment of adults with polycythemia vera,11/12/2021,11/12/2028,Treatment of adults with polycythemia vera,PharmaEssentia,"13F, No. 3, YuanQu St.",,Taipei,Taiwan,,Taiwan,367012
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,2685,alpha1-proteinase inhibitor (human),4/6/2012,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",8368 US 70 BUS Hwy W.,,Clayton,North Carolina,27520,United States,368112
EMERAMIDE,4U7K5X4ANS,Designated,Public record,2686,emeramide,4/6/2012,Treatment of mercury toxicity,Designated,Not FDA Approved for Orphan Indication,,,,,NBMI Science Limited,c/o Philip Lee Solicitors,119 Burnside Drive,Nicholasville,,,Ireland,367312
FERUMOXYTOL,,Designated,Public record,2687,ferumoxytol,4/6/2012,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC",38 Frederick Street,,Newton,Massachusetts,2460,United States,365212
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,2688,ibrutinib,4/6/2012,Treatment of chronic lymphocytic leukemia (CLL),Designated/Approved,,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion,7/28/2014,7/28/2021,Treatment of chronic lymphocytic leukemia with 17p deletion who have not received at least one prior therapy,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,368012
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,2689,ibrutinib,4/6/2012,Treatment of chronic lymphocytic leukemia (CLL),Designated/Approved,,Indicated for the treatment of patients with chronic lymphocytic leukemia,3/4/2016,3/4/2023,Indicated for the treatment of patients with chronic lymphocytic leukemia without 17p deletion who have not received at least one prior therapy (first line therapy).,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,368012
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,2690,ibrutinib,4/6/2012,Treatment of chronic lymphocytic leukemia (CLL),Designated/Approved,,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy,2/12/2014,2/12/2021,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,368012
ILOPROST,JED5K35YGL,Designated,Public record,2691,iloprost,4/6/2012,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Algorithum Sciences, LLC",World Trade Center Delaware,702 West Street,Wilmington,Delaware,19801,United States,324610
TOLVAPTAN,21G72T1950,Designated,Public record,2692,tolvaptan,4/6/2012,Treatment of autosomal dominant polycystic kidney disease,Designated/Approved,,JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD),4/23/2018,4/23/2025,JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD),"Otsuka Pharmaceutical Company, Ltd.","2-9, Kanda-Tsukasamachi",,Tokyo,,,Japan,347311
EPTIFIBATIDE,NA8320J834,Designated,Public record,2694,eptifibatide and iloprost,4/20/2012,Treatment of purpura fulminans,Designated,Not FDA Approved for Orphan Indication,,,,,Thrombologic,COBIS/Ole Maaloesvej 3,,2200 Copenhagen,,,Denmark,364012
ILOPROST,JED5K35YGL,Designated,Public record,2694,eptifibatide and iloprost,4/20/2012,Treatment of purpura fulminans,Designated,Not FDA Approved for Orphan Indication,,,,,Thrombologic,COBIS/Ole Maaloesvej 3,,2200 Copenhagen,,,Denmark,364012
ALBUTREPENONACOG ALFA,A57KX1VL5P,Designated/Approved,Public record,2695,recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP),4/27/2012,Treatment of patients with congenital factor IX deficiency (hemophilia B).,Designated/Approved,,"Indicated in children and adults with hemophilia B (congenital Factor IX deficiency) for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequenc",3/4/2016,3/4/2023,"Indicated for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","CSL Behring, LLC",1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,19406,United States,366712
SIROLIMUS,W36ZG6FT64,Designated,Public record,2696,sirolimus in an implantable collagen matrix,5/10/2012,"Prevention of arteriovenous(AV) fistula or AV graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis",Designated,Not FDA Approved for Orphan Indication,,,,,"Vascular Therapies, LLC",105 Union Avenue,,Cresskill,New Jersey,7626,United States,184304
ALISERTIB,T66ES73M18,Designated/Withdrawn,Public record,2697,alisertib,5/14/2012,Treatment of peripheral T-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,369112
COPPER HISTIDINE,9078K3MO9U,Designated,Public record,2698,copper histidinate,5/14/2012,Treatment of Menkes disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Cyprium Therapeutics, Inc.",2 Gansevoort Street,9th Floor,New York,New York,10014,United States,366312
ERIBULIN MESYLATE,AV9U0660CW,Designated/Approved,Public record,2699,eribulin mesylate,5/14/2012,Treatment of soft tissue sarcoma,Designated/Approved,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen,1/28/2016,1/28/2023,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,,United States,367112
GOLIMUMAB,91X1KLU43E,Designated/Withdrawn,Public record,2702,golimumab,5/21/2012,Treatment of sarcoidosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",200 Great Vallley Parkway,,Malvern,Pennsylvania,19355,United States,368412
BORTEZOMIB,69G8BD63PP,Designated/Approved,Public record,2704,bortezomib,5/30/2012,Treatment of mantle cell lymphoma.,Designated/Approved,,Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.,12/8/2006,12/8/2013,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,226106
BORTEZOMIB,69G8BD63PP,Designated/Approved,Public record,2705,bortezomib,5/30/2012,Treatment of mantle cell lymphoma.,Designated/Approved,,Treatment of patients with mantle cell lymphoma.,10/8/2014,10/8/2021,Treatment of patients with mantle cell lymphoma who have not received at least 1 prior therapy,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,226106
CIPROFLOXACIN,5E8K9I0O4U,Designated,Public record,2707,liposomal ciprofloxacin plus ciprofloxacin,6/1/2012,For the management of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"6836 Bee Cave Road, Building 3, Suite 200",,Austin,Texas,78746,United States,369812
RECILISIB SODIUM,1068SXU525,Designated,Public record,2708,recilisib sodium,6/1/2012,Prevention of acute radiation syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc.",375 Pheasant Run,,Newtown,Pennsylvania,18940,United States,350311
PATISIRAN,50FKX8CB2Y,Designated/Approved,Public record,2710,patisiran,6/14/2012,Treatment of transthyretin-mediated amyloidosis,Designated/Approved,,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,8/10/2018,8/10/2025,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,"Alnylam Pharmaceuticals, Inc.",300 Third Street,,Cambridge,Maryland,2142,United States,371112
PENTOXIFYLLINE,SD6QCT3TSU,Designated,Public record,2711,pentoxifylline,6/14/2012,Treatment of Behcet's disease,Designated,Not FDA Approved for Orphan Indication,,,,,Silk Road Therapeutics,641 S Street Northwest,3rd Floor,Washington,District of Columbia,20001,United States,369712
PERHEXILINE MALEATE,K7V8Y90G0H,Designated,Public record,2712,perhexiline maleate,6/14/2012,Treatment of moderate to severe symptomatic hypertrophic cardiomyopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Heart Metabolics, Limited.",88 Harcourt Street,,Dublin,,,Ireland,360211
BIMAGRUMAB,N15SW1DIV8,Designated,Public record,2713,bimagrumab,6/18/2012,Treatment of inclusion body myositis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,369012
CYCLOCREATINE,6732XGX1RK,Designated,Public record,2715,cyclocreatine,6/18/2012,Treatment of creatine transporter deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Lumos Pharma,4200 Marathon Blvd.,Suite 200,Austin,Texas,78756,United States,362711
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,2716,nitric oxide,6/18/2012,Treatment of persistent pulmonary hypertension in newborns,Designated/Approved,,GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmon,12/20/2019,,,VERO BIOTECH,"387 Technology Circle, Suite 125",,Atlanta,Georgia,30313,United States,368512
RILOTUMUMAB,51WEW898IJ,Designated/Withdrawn,Public record,2717,rilotumumab,6/18/2012,Treatment of gastric cancer including gastroesophageal junction adenocarcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,M/S 17-2-B,Thousand Oaks,California,91320,United States,369412
ANETUMAB RAVTANSINE,M170940PMI,Designated,Public record,2718,antimesothelin-ADC (antibody drug conjugate),7/5/2012,Treatment of mesothelioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",340 Changebridge Road,,Pine Brook,New Jersey,7058,United States,370112
Benzoic acid,8SKN0B0MIM,Designated,Public record,2721,benzoate,7/6/2012,Treatment of pediatric schizophrenia,Designated,Not FDA Approved for Orphan Indication,,,,,SyneuRx International (Taiwan) Corp.,1380 S. Marengo Ave,,Pasadena,California,91106,United States,365712
"""BLOOD CELLS, RED""",2K524Y8G0J,Designated,Public record,2723,L-asparaginase encapsulated in red blood cells,7/6/2012,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,ERYTECH Pharma,Batiment Adenine,60 Avenue Rockefeller,lyon,,,France,370712
MOTIXAFORTIDE,DA9G065962,Designated,Public record,2724,motixafortide,7/6/2012,For use to mobilize hematopoietic stem cells (HSCs) from the marrow to peripheral blood for collection for autologous or allogeneic transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"BioLineRx, Ltd.",Modi'in Technology Park,2 HaMa'ayan Street,Modi'in,,,Israel,371912
PAMREVLUMAB,QS5F6VTS0O,Designated,Public record,2725,pamrevlumab,7/6/2012,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.",409 Illinois Street,,San Francisco,California,94158,United States,351211
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,2726,tacrolimus,7/6/2012,Treatment of hemorrhagic cystitis,Designated,Not FDA Approved for Orphan Indication,,,,,Lipella Pharmaceuticals Inc.,"400 N. Lexington Ave, LL105",,Pittsburgh,Pennsylvania,15208,United States,314310
ACETYLCYSTEINE,WYQ7N0BPYC,Designated,Public record,2727,N-acetylcysteine,7/19/2012,Prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD",3181 SW Sam Jackson Park Road,,Portland,Oregon,97239,United States,370012
EVEROLIMUS,9HW64Q8G6G,Designated,Public record,2728,everolimus,7/23/2012,Treatment of hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,374012
MECASERMIN RINFABATE,NZ8M50KKRG,Designated,Public record,2730,mecasermin rinfabate,7/23/2012,Treatment of amyotropic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"PCUT BioPartners, Inc.",2196 Glenkirk Drive,,San Jose,California,95124,United States,364312
ACETYLCARNITINE,6DH1W9VH8Q,Designated/Withdrawn,Public record,2731,acetyl-l-carnitine,7/24/2012,Treatment of Fragile X syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd.,Suite 500,Gaithersburg,Maryland,20878,United States,373112
AUTOLOGOUS CORD BLOOD,VDX0F5H4FP,Designated,Public record,2733,autologous umbilical cord blood,7/24/2012,Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury,Designated,Not FDA Approved for Orphan Indication,,,,,Duke University,2301 Erwin Road,,Durham,North Carolina,27710,United States,372312
CANTHARIDIN,IGL471WQ8P,Designated,Public record,2734,cantharidin,7/24/2012,"Treatment of perforating diseases, including Kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa",Designated,Not FDA Approved for Orphan Indication,,,,,"Orenova Group, LLC",10 New King Street,Suite 106,White Plains,New York,10604,United States,359311
DEXAMETHASONE SODIUM PHOSPHATE,AI9376Y64P,Designated,Public record,2735,dexamethasone sodium phosphate encapsulated in autologous erythrocytes,7/24/2012,Treatment of ataxia-telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,EryDel S.p.A.,Via Sasso 36,,61029 Urbino (PU),,,Italy,373212
INOTERSEN,0IEO0F56LV,Designated/Approved,Public record,2738,Inotersen,7/24/2012,Treatment of transthyretin amyloidosis (ATTR amyloidosis),Designated/Approved,,TEGSEDI¿ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,10/5/2018,10/5/2025,TEGSEDI¿ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,"Akcea Therapeutics, Inc.",22 Boston Wharf Road,9th Floor,Boston,Massachusetts,2210,United States,374512
METHYLENE BLUE,T42P99266K,Designated,Public record,2739,methylene blue,7/24/2012,Treatment of methemoglobinemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,11560,United States,345711
MIDAZOLAM,R60L0SM5BC,Designated,Public record,2740,midazolam,7/24/2012,Treatment of nerve agent-induced seizures,Designated,Not FDA Approved for Orphan Indication,,,,,"Meridian Medical Technologies, Inc.","6350 Stevens Forest Rd, Suite 301",,Columbia,Maryland,21046,United States,373912
OXALOACETIC ACID,2F399MM81J,Designated,Public record,2741,oxaloacetate,7/24/2012,Treatment of gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,Terra Biological LLC,3830 Valley Centre Drive,Suite 705-561,San Diego,California,92130,United States,370412
ASUNERCEPT,F333OQQ9UV,Designated,Public record,2742,Recombinant Fusion Protein,7/24/2012,Treatment of Myelodysplastic Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Apogenix GmbH,Im Neuenheimer Feld 584,,Heidelberg,,,Germany,371612
DOMAGROZUMAB,516MD5WQ24,Designated,Public record,2743,recombinant human anti-GDF-8 monoclonal antibody,7/24/2012,Treatment of Duchenne Muscular Dystrophy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",500 Arcola Road,,Collegeville,Pennsylvania,19426,United States,373412
TRALOKINUMAB,GK1LYB375A,Designated/Withdrawn,Public record,2744,tralokinumab,7/24/2012,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,MedImmune Ltd.,Milstein Building,Granta Park,Cambridge,,,United Kingdom,373812
BRILLIANT BLUE G,M1ZRX790SI,Designated,Public record,2745,Brilliant Blue G Ophthalmic Solution 0.025%,7/31/2012,For use as an aid in ophthalmic surgery by selectively staining the internal limiting membrane,Designated/Approved,,TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is indicated to selectively stain the internal limiting membrane (ILM).,12/20/2019,12/20/2026,Indicated to selectively stain the internal limiting membrane (ILM),Dutch Ophthalmic Research Center International BV,P.O. Box 43,,Zuidland,,,Netherlands,341811
DIAZEPAM,Q3JTX2Q7TU,Designated,Public record,2746,diazepam (intranasal),7/31/2012,Management of patients with acute repetitive seizures,Designated,Not FDA Approved for Orphan Indication,,,,,SK Life Sciences Inc.,22-10 New Jersey 208,,Fair Lawn,New Jersey,7410,United States,334911
RUCAPARIB,8237F3U7EH,Designated/Approved,Public record,2748,rucaparib,7/31/2012,Treatment of ovarian cancer,Designated/Approved,,"For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.",4/6/2018,4/6/2025,For the maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in complete or partial response to platinum-based chemotherapy.,"Clovis Oncology, Inc.",5500 Flatiron Parkway,Suite 100,Boulder,Colorado,80301,United States,374712
RUCAPARIB,8237F3U7EH,Designated/Approved,Public record,2749,rucaparib,7/31/2012,Treatment of ovarian cancer,Designated/Approved,,As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies,12/19/2016,12/19/2023,As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies,"Clovis Oncology, Inc.",5500 Flatiron Parkway,Suite 100,Boulder,Colorado,80301,United States,374712
TOCILIZUMAB,I031V2H011,Designated/Approved,Public record,2750,tocilizumab,7/31/2012,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,Designated/Approved,,ACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older,5/11/2018,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,367812
TOCILIZUMAB,I031V2H011,Designated/Approved,Public record,2751,tocilizumab,7/31/2012,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,Designated/Approved,,ACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older,4/29/2013,4/29/2020,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,367812
METHYLENE BLUE,T42P99266K,Designated,Public record,2752,methylene blue injection,8/11/2012,Treatment of congenital and acquired methemoglobinemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,11967,United States,357111
GEVOKIZUMAB,QX3JU54GYQ,Designated,Public record,2753,gevokizumab,8/20/2012,"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC,2910 Seventh St.,,Berkeley,California,94710,United States,364512
LURBINECTEDIN,2CN60TN6ZS,Designated,Public record,2754,lurbinectedin,8/20/2012,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"PharmaMar USA, Inc.",205 East 42nd St.,Suite 15003,New York,New York,10017,United States,376512
MERCAPTOPURINE,E7WED276I5,Designated/Approved,Public record,2755,mercaptopurine oral solution,8/20/2012,Treatment of acute lymphoblastic leukemia in pediatric patients,Designated/Approved,,Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen.,4/28/2014,4/28/2021,Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen (in pediatric patients).,Nova Laboratories Limited,Martin House,,Leicester,Wigston,,United Kingdom,373512
PANOBINOSTAT,9647FM7Y3Z,Designated/Approved,Public record,2757,panobinostat,8/20/2012,Treatment of multiple myeloma,Designated/Approved,,"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent",2/23/2015,2/23/2022,"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent",zr pharma& GmbH,Rauhensteingasse 10/14,,Wien,,1010,Austria,376212
SOLRIAMFETOL HYDROCHLORIDE,K7RO88SP7A,Designated,Public record,2758,Solriamfetol,8/20/2012,Treatment of narcolepsy,Designated/Approved,,SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy,6/17/2019,6/17/2026,To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy,"Axsome Malta, Ltd.","78 Mill Street, Zone 5, Central Business District",,Qormi,,,Malta,375112
TRIPTORELIN PAMOATE,08AN7WA2G0,Designated/Approved,Public record,2759,triptorelin pamoate,8/20/2012,Treatment of central precocious puberty,Designated/Approved,,Treatment of pediatric patients 2 years of age and older with central precocious puberty,6/29/2017,6/29/2024,Treatment of pediatric patients 2 years of age and older with central precocious puberty,"Arbor Pharmaceuticals, LLC",6 Concourse Parkway,Suite 1800,Atlanta,Georgia,30328,United States,376012
CAFFEINE,3G6A5W338E,Designated,Public record,2760,caffeine and sodium benzoate,8/22/2012,Treatment of seizure prolongation in patients undergoing electroconvulsive therapy,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,11967,United States,367512
Sodium benzoate,OJ245FE5EU,Designated,Public record,2760,caffeine and sodium benzoate,8/22/2012,Treatment of seizure prolongation in patients undergoing electroconvulsive therapy,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,11967,United States,367512
CANAKINUMAB,37CQ2C7X93,Designated/Approved,Public record,2761,canakinumab,9/4/2012,Treatment of TNF-receptor associated periodic syndrome (TRAPS),Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,376912
MENAQUINONE,12V8PA4WCH,Designated,Public record,2762,menaquinone,9/4/2012,Treatment of calciphylaxis,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC",428 East Thunderbird Road,Suite 510,Phoenix,Alaska,85022,United States,357311
RECILISIB SODIUM,1068SXU525,Designated,Public record,2763,recilisib sodium,9/4/2012,Treatment of acute radiation syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc.",375 Pheasant Run,,Newton,Pennsylvania,18940,United States,350411
ALFIMEPRASE,GPN9HBH1HS,Designated,Public record,2764,alfimeprase,9/20/2012,Treatment of ST-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention,Designated,Not FDA Approved for Orphan Indication,,,,,"Niche Therapeutics, LLC",2009 Morton Avenue,,Ann Arbor,Michigan,48104,United States,370512
L-LEUCYL-L-PROLYL-L-PROLYL-L-SERYL-L-ARGININE,HFL33E395I,Designated,Public record,2765,H-Leu-Pro-Pro-Ser-Arg-OH,9/20/2012,Treatment of Kaposi sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Immuno Tech, Inc.","6329 256th Street, NE",,Arlington,Washington,98223,United States,375312
MECASERMIN RINFABATE,NZ8M50KKRG,Designated,Public record,2766,mecasermin rinfabate,9/20/2012,Prevention of retinopathy of prematurity in premature infants born at risk for the disease,Designated,Not FDA Approved for Orphan Indication,,,,,OHB Neonatology Ltd,"3rd Floor, 1 Ashley Road",,Altrincham,Cheshire,,Uk,372612
MILCICLIB MALEATE,82W826FL6S,Designated,Public record,2767,milciclib maleate,9/20/2012,Treatment of thymic epithelial tumors.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Tiziana Life Sciences PLC,18 South Street,W1K 1DG,London,,,United Kingdom,375512
DINUTUXIMAB,7SQY4ZUD30,Designated,Public record,2768,mouse-human chimeric monoclonal anti-GD2 IgG1 antibody,9/20/2012,Treatment of neuroblastoma.,Designated,Not FDA Approved for Orphan Indication,,,,,EUSA Pharma (UK) Limited,Breakspear Park,Breakspear Way,,England,,United Kingdom,377712
PACLITAXEL POLIGLUMEX,TQ64FZ98ZN,Designated,Public record,2769,paclitaxel poliglumex,9/20/2012,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,CTI BioPharma Corporation,3101 Western Ave,Suite 600,Seattle,Washington,98119,United States,377312
DABRAFENIB,QGP4HA4G1B,Designated/Approved,Public record,2770,trametinib and dabrafenib,9/20/2012,Treatment of Stage IIb through IV melanoma.,Designated/Approved,,MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable respon,1/8/2014,1/8/2021,MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable respon,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,376812
TRAMETINIB,33E86K87QN,Designated/Approved,Public record,2770,trametinib and dabrafenib,9/20/2012,Treatment of Stage IIb through IV melanoma.,Designated/Approved,,MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable respon,1/8/2014,1/8/2021,MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable respon,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,376812
DABRAFENIB,QGP4HA4G1B,Designated/Approved,Public record,2771,trametinib and dabrafenib,9/20/2012,Treatment of Stage IIb through IV melanoma.,Designated/Approved,,"MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",4/30/2018,4/30/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) indicated in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete rese",Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,376812
TRAMETINIB,33E86K87QN,Designated/Approved,Public record,2771,trametinib and dabrafenib,9/20/2012,Treatment of Stage IIb through IV melanoma.,Designated/Approved,,"MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",4/30/2018,4/30/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) indicated in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete rese",Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,376812
DABRAFENIB,QGP4HA4G1B,Designated/Approved,Public record,2772,trametinib and dabrafenib,9/20/2012,Treatment of Stage IIb through IV melanoma.,Designated/Approved,,"TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",4/30/2018,4/30/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) indicated in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete rese",Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,376812
TRAMETINIB,33E86K87QN,Designated/Approved,Public record,2772,trametinib and dabrafenib,9/20/2012,Treatment of Stage IIb through IV melanoma.,Designated/Approved,,"TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",4/30/2018,4/30/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) indicated in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete rese",Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,376812
DABRAFENIB,QGP4HA4G1B,Designated/Approved,Public record,2773,trametinib and dabrafenib,9/20/2012,Treatment of Stage IIb through IV melanoma.,Designated/Approved,,TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable respon,1/8/2014,1/8/2021,TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable respon,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,376812
TRAMETINIB,33E86K87QN,Designated/Approved,Public record,2773,trametinib and dabrafenib,9/20/2012,Treatment of Stage IIb through IV melanoma.,Designated/Approved,,TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable respon,1/8/2014,1/8/2021,TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable respon,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,376812
VANCOMYCIN HYDROCHLORIDE,71WO621TJD,Designated,Public record,2774,vancomycin hydrochloride (inhalational),9/20/2012,Treatment of persistent methicillin-resistant S. aureus lung infection in patients with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Savara Pharmaceuticals, Inc.","6836 Bee Cave Road, Building 3, Suite 201",,Austin,Texas,78746,United States,374212
VENETOCLAX,N54AIC43PW,Designated/Approved,Public record,2775,venetoclax,9/20/2012,Treatment of chronic lymphocytic leukemia,Designated/Approved,,"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy",4/11/2016,4/11/2023,"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy","AbbVie, Inc",1 North Waukegan Road,"Dept. PA72, Bldg. AP30",North Chicago,Illinois,60064,United States,375612
VENETOCLAX,N54AIC43PW,Designated/Approved,Public record,2776,venetoclax,9/20/2012,Treatment of chronic lymphocytic leukemia,Designated/Approved,,"VENCLEXTA® (venetoclax) indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.",6/8/2018,6/8/2025,"For treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), without 17p deletion, who have received at least one prior therapy.","AbbVie, Inc",1 North Waukegan Road,"Dept. PA72, Bldg. AP30",North Chicago,Illinois,60064,United States,375612
VENETOCLAX,N54AIC43PW,Designated/Approved,Public record,2777,venetoclax,9/20/2012,Treatment of chronic lymphocytic leukemia,Designated/Approved,,VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).,5/15/2019,5/15/2026,Treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),"AbbVie, Inc",1 North Waukegan Road,"Dept. PA72, Bldg. AP30",North Chicago,Illinois,60064,United States,375612
DANTROLENE SODIUM,287M0347EV,Designated,Public record,2778,dantrolene sodium,9/25/2012,Treatment of heat stroke,Designated,Not FDA Approved for Orphan Indication,,,,,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,7677,United States,377512
JAPANESE ENCEPHALITIS VIRUS STRAIN SA 14-14-2 ANTIGEN (FORMALDEHYDE INACTIVATED),DZ854I04ZE,Designated/Approved,Public record,2779,"Japanese encephalitis vaccine, inactivated, adsorbed",9/25/2012,Prevention of Japanese encephalitis virus in pediatric patients.,Designated/Approved,,IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.,5/17/2013,5/17/2020,"To extend the age range to include infants, children, and adolescents 2 months to less than 17 years of age for active immunization for the prevention of disease caused by Japanese encephalitis virus.",Intercell AG,Campus Vienna Biocenter 3,A-1030,Vienna,,,Austria,376112
METYRAPONE,ZS9KD92H6V,Designated,Public record,2780,metyrapone,9/25/2012,Treatment of Cushing's syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,HRA Pharma Rare Diseases,"200, Avenue de Paris",,Chatillon,,92320,France,377212
REPARIXIN LYSINE,4RZ9P05120,Designated,Public record,2781,reparixin,9/25/2012,Prevention of graft loss in pancreatic islet transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Dompe S.p.A.,Via Campo di Pile,,L'Aquila,,,Italy,373312
REPARIXIN,U604E1NB3K,Designated,Public record,2781,reparixin,9/25/2012,Prevention of graft loss in pancreatic islet transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Dompe S.p.A.,Via Campo di Pile,,L'Aquila,,,Italy,373312
INTERLEUKIN-7 HUMAN RECOMBINANT,418XB47Y71,Designated,Public record,2783,glycosylated recombinant human interleukin-7,9/27/2012,Treatment of progressive multifocal leukoencephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Cytheris, Inc.",1700 Rockville Pike,Suite 230,Rockville,Maryland,20852,United States,379112
AMATUXIMAB,6HP0354G04,Designated,Public record,2785,amatuximab,9/28/2012,Treatment of mesothelioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,155 Tice Boulevard,,Woodcliff Lake,New Jersey,7677,United States,241607
CARBON MONOXIDE,7U1EE4V452,Designated,Public record,2786,carbon monoxide,9/28/2012,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Hillhurst Biopharmaceuticals, Inc.",2029 Verdugo Blvd,Suite 125,Montrose,California,91020,United States,379612
CRIZOTINIB,53AH36668S,Designated,Public record,2787,crizotinib,9/28/2012,Treatment of anaplastic large cell lymphoma,Designated/Approved,,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive",1/14/2021,1/14/2028,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.","Pfizer, Inc.",10646 Science Center Drive,,San Diego,California,92121,United States,379712
QUINACRINE,H0C805XYDE,Designated,Public record,2789,quinacrine,9/28/2012,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur",73 High Street,,Buffalo,New York,14203,United States,379912
PRALMORELIN DIHYDROCHLORIDE,R4AVR27MM8,Designated,Public record,2790,pralmorelin hydrochloride,10/18/2012,As a diagnostic agent for the detection of growth hormone deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Sella Pharmaceuticals, Inc.",412 Wister Road,,Wynnewood,Pennsylvania,19096,United States,372912
ODEVIXIBAT,2W150K0UUC,Designated,Public record,2791,"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",10/31/2012,Treatment of primary biliary cirrhosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Albireo AB c/o Albireo Pharma, Inc.","53 State Street, 19th Floor",,Boston,Massachusetts,2109,United States,371012
LSP-GR3,DAGM66PSEW,Designated,Public record,2792,2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3',10/31/2012,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,LifeSplice Pharma LLC,1 Great Valley Parkway,Suite 20,Malvern,Pennsylvania,19355,United States,380012
AVI-7537,0P93LDFNTU,Designated,Public record,2793,5'-GCCATGGTTTTTTCTCAGG-3',10/31/2012,Prophylaxis for patients following documented or suspected exposure to ebolavirus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,2142,United States,347611
COAGULATION FACTOR IX RECOMBINANT HUMAN,382L14738L,Designated/Approved,Public record,2795,coagulation factor IX (recombinant); coagulation factor IX (recombinant),10/31/2012,Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding),Designated/Approved,,"Adults with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",6/26/2013,6/26/2020,Adults with Hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,377412
COAGULATION FACTOR IX RECOMBINANT HUMAN,382L14738L,Designated/Approved,Public record,2796,coagulation factor IX (recombinant); coagulation factor IX (recombinant),10/31/2012,Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding),Designated/Approved,,"Adults and children with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis",9/12/2014,9/12/2021,Children with hemophilia B for routine prophylaxis.,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,377412
CRENOLANIB,LQF7I567TQ,Designated,Public record,2797,crenolanib,10/31/2012,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"AROG Pharmaceuticals, LLC",12400 Coit Road,Suite 570,Dallas,Texas,75251,United States,363812
CRIZOTINIB,53AH36668S,Designated,Public record,2798,crizotinib,10/31/2012,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,379812
ODEVIXIBAT,2W150K0UUC,Designated,Public record,2799,odevixibat,10/31/2012,Treatment of progressive familial intrahepatic cholestasis,Designated/Approved,,Treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use: BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete abse,7/20/2021,7/20/2028,Treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use: BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete abse,"Albireo AB c/o Albireo Pharma, Inc.",10 Post Office Square,Suite 1000,Boston,Massachusetts,2109,United States,370912
MOLGRAMOSTIM,B321AL142J,Designated,Public record,2800,"recombinant human GM-CSF, molgramostim",10/31/2012,Treatment of pulmonary alveolar proteinosis,Designated,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"6836 Bee Cave Road, Building 3, Suite 201",,Austin,Texas,78746,United States,377912
SIROLIMUS,W36ZG6FT64,Designated/Approved,Public record,2801,sirolimus,10/31/2012,Treatment of lymphangioleiomyomatosis,Designated/Approved,,Treatment of lymphangioleiomyomatosis (LAM),5/28/2015,5/28/2022,Treatment of lymphangioleiomyomatosis (LAM),"Pfizer, Inc.",500 Arcola Road,,Collegeville,Pennsylvania,19426,United States,379312
SODIUM SULFATE,0YPR65R21J,Designated,Public record,2802,"sodium sulfate, potassium sulfate, and magnesium sulfate",10/31/2012,For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents,Designated/Approved,,for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older,8/5/2020,8/5/2027,for cleansing of the colon as a preparation for colonoscopy in pediatric patients 12 years of age and older.,"Braintree Laboratories, Inc.",60 Columbian Street West,PO Box 850929,Braintree,Massachusetts,2185,United States,379212
"""MAGNESIUM SULFATE, UNSPECIFIED FORM""",DE08037SAB,Designated,Public record,2802,"sodium sulfate, potassium sulfate, and magnesium sulfate",10/31/2012,For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents,Designated/Approved,,for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older,8/5/2020,8/5/2027,for cleansing of the colon as a preparation for colonoscopy in pediatric patients 12 years of age and older.,"Braintree Laboratories, Inc.",60 Columbian Street West,PO Box 850929,Braintree,Massachusetts,2185,United States,379212
Potassium sulfate,1K573LC5TV,Designated,Public record,2802,"sodium sulfate, potassium sulfate, and magnesium sulfate",10/31/2012,For cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents,Designated/Approved,,for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older,8/5/2020,8/5/2027,for cleansing of the colon as a preparation for colonoscopy in pediatric patients 12 years of age and older.,"Braintree Laboratories, Inc.",60 Columbian Street West,PO Box 850929,Braintree,Massachusetts,2185,United States,379212
COSYNTROPIN HEXAACETATE,H86HJ92K8Y,Designated,Public record,2803,tetracosactide hexaacetate (beta 1-24-corticotrophin),10/31/2012,Treatment of infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,"Cerium Pharmaceuticals, Inc.",817-B Linsdale Street,,Gaithersburg,Maryland,20878,United States,378212
FUNAPIDE,A5595LHJ2L,Designated,Public record,2805,"1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one",11/19/2012,Treatment of erythromelalgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Flexion Therapeutics, Inc.","10 Mall Road, Suite 301",,Burlington,Massachusetts,1803,United States,378012
BECLOMETHASONE DIPROPIONATE,5B307S63B2,Designated,Public record,2807,"beclomethasone 17,21-dipropionate",11/19/2012,Prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc","29 Emmons Drive, Suite B-10",,Princeton,New Jersey,8540,United States,356311
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated/Approved,Public record,2808,brentuximab vedotin,11/19/2012,Treatment of mycosis fungoides,Designated/Approved,,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,11/9/2017,11/9/2024,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,362611
OXI-4503,JH6Z94GLUD,Designated,Public record,2809,combretastatin A 1 diphosphate,11/19/2012,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Blvd,Suite 210,South San Francisco,California,94080,United States,382412
SORGHUM,CUL9PN8ELJ,Designated,Public record,2810,extract of sorghum bicolor extract,11/19/2012,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Invenux, LLC",1550 Main Street,Suite A3,Windsor,Colorado,80550,United States,358811
MELPHALAN,Q41OR9510P,Designated,Public record,2811,melphalan,11/19/2012,Treatment of retinoblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"EyePoint Pharmaceuticals, Inc.","480 Pleasant Street, B300",,Watertown,Massachusetts,2472,United States,378112
MELPHALAN,Q41OR9510P,Designated,Public record,2812,melphalan,11/19/2012,Treatment of Stage IIB through IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"OncoTx, LLC",9 Brandeis Road,,Newton,Massachusetts,2459,United States,381412
PEMBROLIZUMAB,DPT0O3T46P,Designated/Approved,Public record,2813,pembrolizumab,11/19/2012,Treatment of Stage IIB through IV malignant melanoma,Designated/Approved,,"adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection",12/3/2021,12/3/2028,"adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection, and adjuvant treatment of pediatric (12 years and older) patients with Stage III melanoma following complete resection",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,381012
PEMBROLIZUMAB,DPT0O3T46P,Designated/Approved,Public record,2814,pembrolizumab,11/19/2012,Treatment of Stage IIB through IV malignant melanoma,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.",9/4/2014,9/4/2021,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,381012
PEMBROLIZUMAB,DPT0O3T46P,Designated/Approved,Public record,2815,pembrolizumab,11/19/2012,Treatment of Stage IIB through IV malignant melanoma,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma.,12/18/2015,12/18/2022,Initial treatment of patients with unresectable or metastatic melanoma,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,381012
PEMBROLIZUMAB,DPT0O3T46P,Designated/Approved,Public record,2816,pembrolizumab,11/19/2012,Treatment of Stage IIB through IV malignant melanoma,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,2/15/2019,2/15/2026,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,381012
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,2817,sodium thiosulfate,11/19/2012,Treatment of calciphylaxis,Designated,Not FDA Approved for Orphan Indication,,,,,Edinburg BioQuarter,University Medical School 47,EH16 4TJ,Edinburgh,,,United Kingdom,381912
TABALUMAB,PQP8VH3MJW,Designated/Withdrawn,Public record,2818,tabalumab,11/19/2012,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,381612
Zolbetuximab,TF5MPQ8WGY,Designated,Public record,2819,chimeric monoclonal antibody to claudin 18 splice variant 2,11/20/2012,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,60062,United States,383312
MARZEPTACOG ALFA (ACTIVATED),J5LT149M79,Designated,Public record,2820,marzeptacog alfa (activated),11/30/2012,Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Biosciences, Inc.",260 Littlefield Avenue,,South San Francisco,California,94080,United States,377612
HEXASODIUM PHYTATE,ZBX50UG81V,Designated,Public record,2821,hexasodium phytate,12/2/2012,Treatment of calciphylaxis,Designated,Not FDA Approved for Orphan Indication,,,,,"Vifor Pharma, Inc.",200 Cardinal Way,,Redwood City,California,94063,United States,380412
AFATINIB,41UD74L59M,Designated/Approved,Public record,2822,afatinib,12/3/2012,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).,Designated/Approved,,First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,7/12/2013,7/12/2020,First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,375712
AFATINIB,41UD74L59M,Designated/Approved,Public record,2823,afatinib,12/3/2012,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).,Designated/Approved,,GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.,1/12/2018,1/12/2025,GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations other than exon 19 deletions or exon 21 (L858R) substiution,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,375712
DIAZOXIDE,O5CB12L4FN,Designated,Public record,2825,diazoxide,12/3/2012,Treatment of Prader Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Sedogen, LLC",1701 East Lake Avenue,Suite260,Glenview,Illinois,60025,United States,383712
HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX,5T6B772R4Q,Designated,Public record,2826,human coagulation factor VIII,12/3/2012,Immune tolerance induction in hemophilia A patients with inhibitors,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OCTAPHARMA USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,7030,United States,382812
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,2827,ibrutinib,12/3/2012,Treatment of mantle cell lymphoma,Designated/Approved,,Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,11/13/2013,11/13/2020,Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,383112
SOMATROPIN,NQX9KB6PCL,Designated,Public record,2829,recombinant human gowth hormone in an ocular delivery system,12/3/2012,Treatment of persistent corneal epithelial defects,Designated,Not FDA Approved for Orphan Indication,,,,,Jade Therapeutics LLC,7585 Ranch Club Trail,,Park City,Utah,84098,United States,384012
MK-4721,L0505LPC7O,Designated/Withdrawn,Public record,2830,recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen,12/3/2012,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,383812
TRANSCROCETINATE SODIUM,YP57637WMX,Designated,Public record,2831,trans sodium crocetinate,12/3/2012,Treatment of brain metastasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Diffusion Pharmaceuticals, LLC",1317 Carlton Ave,Suite 200,Charlottesville,Virginia,22902,United States,378312
Glucagon,76LA80IG2G,Designated,Public record,2833,glucagon,12/5/2012,Prevention of hypoglycemia in the congenital hyperinsulinism population,Designated,Not FDA Approved for Orphan Indication,,,,,"Biodel, Inc.",100 Saw Mill Road,,Danbury,Connecticut,6810,United States,366812
PERAMPANEL,H821664NPK,Designated,Public record,2834,perampanel,12/7/2012,Treatment of Lennox-Gastaut Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,,United States,380912
METHYLENE BLUE,T42P99266K,Designated/Approved,Public record,2836,methylene blue0.5%,12/18/2012,Treatment of hereditary and acquired methemoglobinemia,Designated/Approved,,For treatment of pediatric and adult patients with acquired methemoglobinemia.,4/8/2016,4/8/2023,For treatment of pediatric and adult patients with acquired methemoglobinemia.,Provepharm SAS,Technopote de Chateau-Combert,,Marseille,,,France,385512
LENVATINIB,EE083865G2,Designated/Approved,Public record,2838,lenvatinib,12/27/2012,"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer",Designated/Approved,,"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer",2/13/2015,2/13/2022,"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer","Eisai, Inc.",200 Metro Blvd.,,Nutley,New Jersey,,United States,378412
PROTEIN C,3Z6S89TXPW,Designated/Approved,Public record,2840,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",4/29/2013,4/29/2020,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
PROTEIN S HUMAN,90J3F6N5FN,Designated/Approved,Public record,2840,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",4/29/2013,4/29/2020,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
COAGULATION FACTOR VII HUMAN,4156XVB4QD,Designated/Approved,Public record,2840,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",4/29/2013,4/29/2020,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
COAGULATION FACTOR X HUMAN,0P94UQE6SY,Designated/Approved,Public record,2840,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",4/29/2013,4/29/2020,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
COAGULATION FACTOR IX (HUMAN),,Designated/Approved,Public record,2840,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",4/29/2013,4/29/2020,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
PROTHROMBIN,8FB1K07F16,Designated/Approved,Public record,2840,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",4/29/2013,4/29/2020,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
PROTEIN C,3Z6S89TXPW,Designated/Approved,Public record,2841,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.",12/13/2013,12/13/2020,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
PROTEIN S HUMAN,90J3F6N5FN,Designated/Approved,Public record,2841,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.",12/13/2013,12/13/2020,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
COAGULATION FACTOR VII HUMAN,4156XVB4QD,Designated/Approved,Public record,2841,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.",12/13/2013,12/13/2020,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
COAGULATION FACTOR X HUMAN,0P94UQE6SY,Designated/Approved,Public record,2841,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.",12/13/2013,12/13/2020,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
COAGULATION FACTOR IX (HUMAN),,Designated/Approved,Public record,2841,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.",12/13/2013,12/13/2020,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
PROTHROMBIN,8FB1K07F16,Designated/Approved,Public record,2841,prothrombin complex concentrate (human),12/27/2012,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.",12/13/2013,12/13/2020,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,305310
Vancomycin,6Q205EH1VU,Designated,Public record,2842,vancomycin,12/27/2012,Treatment of endophthalmitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,11560,United States,361211
S-NITROSOGLUTATHIONE,78RRI89ZTO,Designated,Public record,2843,S-nitrosoglutathione,12/28/2012,Treatment of severe preeclampsia,Designated,Not FDA Approved for Orphan Indication,,,,,Salupont Consulting Ltd,"The Old Quarters, Hazells Hall","Everton Road, Sandy",Bedfordshire SG19 2DD,,,United Kingdom,358511
TIPRELESTAT,78I8295690,Designated,Public record,2844,tiprelestat,12/28/2012,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,tiakis Biotech AG,Am Kiel Kanal 44,,Kiel,,,Germany,241007
PACLITAXEL,P88XT4IS4D,Designated,Public record,2845,paclitaxel nanoparticles,1/2/2013,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"CIRJ Co., Ltd.",1800 Loma Vista Street,,Pasadena,California,91104,United States,384912
EZATIOSTAT HYDROCHLORIDE,D59N834676,Designated,Public record,2846,ezatiostat hydrochloride,1/9/2013,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Hessian Pharmaceuticals, Inc.","1111 Broadway, 3rd Floor",Suite 03-138,Oakland,California,94607,United States,382312
RILONACEPT,8K80YB5GMG,Designated,Public record,2848,rilonacept,1/9/2013,Treatment of familial Mediterranean fever,Designated,Not FDA Approved for Orphan Indication,,,,,"Philip J Hashkes, MD, MSc.","Head, Section of Pediatric Rheumatology",9500 Euclid Avenue,Cleveland,Ohio,44195,United States,292509
AMINOLEVULINIC ACID,88755TAZ87,Designated/Approved,Public record,2849,5-aminolevulinic acid,1/15/2013,Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV),Designated/Approved,,Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery,6/6/2017,6/6/2024,Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery,NX Development Corporation,1827 South Bayshore Lane,,Miami,Florida,33133,United States,387312
BELORANIB,FI471K8BU6,Designated/Withdrawn,Public record,2850,beloranib,1/15/2013,Treatment of Prader-Willi syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Zafgen, Inc.",175 Portland Street,4th Floor,Boston,Massachusetts,2114,United States,385012
BGP-15,RLN2GTG4YS,Designated,Public record,2852,O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride,1/15/2013,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Vudbenk Life Science Kft.,Rizling utca 3,,Balatonvilagos,,8171,Hungary,386512
TAFENOQUINE,262P8GS9L9,Designated,Public record,2853,tafenoquine,1/15/2013,Treatment of malaria,Designated/Approved,,KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.,7/20/2018,7/20/2025,KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.,GlaxoSmithKline Intellectual Property Development Ltd. England,980 Great West Road,,"Brentford, Middlesex",England,,United Kingdom,385812
SOLNATIDE,17ZS80333G,Designated,Public record,2854,synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys,1/16/2013,Treatment of high altitude pulmonary edema,Designated,Not FDA Approved for Orphan Indication,,,,,Apeptico Forschung und Entwicklung GmbH,c/o mingo bueros,,Vienna,,,Austria,382912
"""APREMILAST, (?)-""",N5UK68MGDZ,Designated,Public record,2855,apremilast,1/17/2013,Treatment of Behcet's disease,Designated/Approved,,OTEZLA is indicated for the treatment of adult patients with oral ulcers associated with Behçet¿s Disease.,7/19/2019,7/19/2026,For the treatment of adult patients with oral ulcers associated with Behçet¿s disease,Amgen Inc.,One Amgen Center Drive,Mailstop: 27-2-D,Thousand Oaks,California,91320,United States,384812
LISURIDE,E0QN3D755O,Designated,Public record,2856,lisuride,1/17/2013,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Sinoxa Pharma GmbH,Thomasiusstr.13,,Berlin,,,Germany,316610
VOSORITIDE,7SE5582Q2P,Designated,Public record,2857,vosoritide,1/17/2013,Treatment of achondroplasia,Designated/Approved,,To increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses,11/19/2021,11/19/2028,To increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,94949,United States,386012
SULINDAC,184SNS8VUH,Designated,Public record,2858,eflornithine plus sulindac,1/22/2013,Treatment of familial adenomatous polyposis,Designated,Not FDA Approved for Orphan Indication,,,,,"Panbela Therapeutics, Inc.",712 Vista Blvd #305,,Waconia,Minnesota,55387,United States,387012
EFLORNITHINE,ZQN1G5V6SR,Designated,Public record,2858,eflornithine plus sulindac,1/22/2013,Treatment of familial adenomatous polyposis,Designated,Not FDA Approved for Orphan Indication,,,,,"Panbela Therapeutics, Inc.",712 Vista Blvd #305,,Waconia,Minnesota,55387,United States,387012
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,2864,nivolumab,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",12/22/2014,12/22/2021,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,8543,United States,387612
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,2865,nivolumab,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,12/20/2017,12/20/2024,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,8543,United States,387612
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,2866,nivolumab,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,"As a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma",2/15/2023,2/15/2030,Treatment of pediatric patients 12 years and older with unresectable or metastatic melanoma,Bristol-Myers Squibb,3401 Princeton Pike,,Lawrenceville,New Jersey,8648,United States,387612
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,2867,nivolumab,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,adjuvant treatment of adult and pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,2/15/2023,2/15/2030,adjuvant treatment of pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.,3401 Princeton Pike,,Lawrenceville,New Jersey,8648,United States,387612
ONARTUZUMAB,MS1J9720WC,Designated/Withdrawn,Public record,2868,onartuzumab,1/23/2013,Treatment of gastric cancer including gastroesophageal cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS# 241B,South San Francisco,California,94080,United States,387712
METENKEFALIN,9JEZ9OD3AS,Designated,Public record,2869,[met5]-enkephalin,1/24/2013,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Statera BioPharma, Inc.",2537 Research Boulevard,Suite 201,Ft. Collins,Colorado,80526,United States,388312
ENALAPRIL MALEATE,9O25354EPJ,Designated/Withdrawn by OPD,Public record,2870,enalapril maleate (powder for oral solution),1/30/2013,Treatment of hypertension in pediatric patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Silvergate Pharmaceuticals, Inc.",5371 Gordon Way,,Dublin,Ohio,43017,United States,376712
IDURSULFASE BETA,5GCF8EPY6R,Designated,Public record,2872,idursulfase beta,2/11/2013,Treatment of Hunter Syndrome (mucopolysaccharidoses),Designated,Not FDA Approved for Orphan Indication,,,,,Green Cross Corp.,"303 Bojeong-dong, Giheung-gu",,Gyunggi-Do 446-770,,,South Korea,385712
TESTOSTERONE UNDECANOATE,H16A5VCT9C,Designated,Public record,2873,testosterone undecanoate (oral),2/13/2013,Treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age),Designated,Not FDA Approved for Orphan Indication,,,,,"Marius Pharmaceuticals, LLC",8601 Six Forks Road,Suite 630,Raleigh,North Carolina,27615,United States,366012
ADRABETADEX,8W6Q67R6NX,Designated,Public record,2874,2-hydroxypropyl-B-cyclodextrin,2/18/2013,"Treatment of Niemann Pick disease, type C.",Designated,Not FDA Approved for Orphan Indication,,,,,Mandos LLC,9200 Sunset Blvd.,Suite 1010,West Hollywood,California,90069,United States,386412
MINNELIDE,1CIV2UMO40,Designated,Public record,2876,Minnelide,2/18/2013,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Minneamrita Therapeutics, LLC",6 Hickory Court,,Rock Island,Illinois,61201,United States,388512
BROMOPYRUVATE,63JMV04GRK,Designated,Public record,2877,3-bromopyruvate,3/5/2013,Treatment of liver and intrahepatic bile duct cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"KoDiscovery, LLC",Columbus Center,701 East Pratt Street,Baltimore,Maryland,21202,United States,390013
PLASMINOGEN,1EF190B6M7,Designated,Public record,2878,"plasminogen, human-tvmh",3/5/2013,"Treatment of hypoplasminogenemia, or type I plasminogen deficiency",Designated/Approved,,Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).,6/4/2021,6/4/2028,Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia),"ProMetic BioTherapeutics, Inc.",1330 Piccard Drive,Suite 201,Rockville,Maryland,20850,United States,389112
TRALESINIDASE ALFA,AA60A4ST8X,Designated,Public record,2879,recombinant human Naglu- insulin-like growth factor II,3/5/2013,Treatment of mucopolysaccharidosis type IIIB (Sanfilippo syndrome type B),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc.",300 Shire Way,,Lexington,Massachusetts,2421,United States,388712
Beractant,S866O45PIG,Designated,Public record,2881,aerosolized beractant,3/11/2013,Treatment of respiratory distress syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Beena G. Sood, MD, MS",Wayne State University School of Medicine,Children's Hospital fo %i,Detroit,Michigan,48201,United States,390113
MIPSAGARGIN,Q032I35QMX,Designated,Public record,2882,C66H100N6O27,3/11/2013,Treatment of of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"GenSpera, Inc.",2511 North Loop 1604 W,Suite 204,San Antonio,Texas,78258,United States,389613
ONL-1204,XNA75YDV3F,Designated,Public record,2883,His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr,3/11/2013,Treatment of retinal detachment,Designated,Not FDA Approved for Orphan Indication,,,,,"ONL Therapeutics, Inc",1600 Huron Parkway,Second Floor,Ann Arbor,Michigan,48109,United States,390313
SOTATERCEPT,0QI90BTJ37,Designated,Public record,2884,Luspatercept-aamt,3/11/2013,Treatment of B-thalassemia,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,11/8/2019,11/8/2026,Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,389813
GALUNISERTIB,3OKH1W5LZE,Designated,Public record,2885,transforming growth factor-beta receptor 1 kinase inhibitor,3/11/2013,Treatment of glioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,389412
BETIBEGLOGENE AUTOTEMCEL,MEE8487RTP,Designated/Approved,Public record,2886,betibeglogene autotemcel,3/18/2013,Treatment of B-thalassemia major and intermedia,Designated/Approved,,Treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions,8/17/2022,8/17/2029,Treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions,"bluebird bio, Inc.",455 Grand Union Blvd,,Somerville,Massachusetts,2145,United States,390513
NONACOG BETA PEGOL,27Y83O992Q,Designated,Public record,2889,"Coagulation Factor IX (Recombinant), GlycoPEGylated",3/18/2013,Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease),Designated/Approved,,Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital Factor IX deficiency),7/29/2022,,,"Novo Nordisk, Inc.",100 College Road West,,Princeton,,8540,United States,276509
SOTATERCEPT,0QI90BTJ37,Designated,Public record,2890,Luspatercept,3/18/2013,Treatment of myelodysplastic syndrome,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts,4/3/2020,4/3/2027,For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS),Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,387112
NEOSTIGMINE,3982TWQ96G,Designated,Public record,2891,neostigmine,3/18/2013,Treatment of acute colonic pseudo-obstruction,Designated,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,11967,United States,388812
TIPRELESTAT,78I8295690,Designated,Public record,2892,recombinant elafin,3/18/2013,Prevention of inflammatory complications of transthoracic esophagectomy,Designated,Not FDA Approved for Orphan Indication,,,,,tiakis Biotech AG,Sophienblatt 40,,Kiel,,,Germany,364612
SIROLIMUS,W36ZG6FT64,Designated,Public record,2893,sirolimus,3/18/2013,Treatment of pachyonychia congenita,Designated,Not FDA Approved for Orphan Indication,,,,,"Palvella Therapeutics, Inc.",125 Strafford Avenue,Suite #360,Wayne,Pennsylvania,19087,United States,391013
FEDRATINIB HYDROCHLORIDE,UH9J2HBQWJ,Designated,Public record,2894,Fedratinib,3/21/2013,Treatment of polycythemia vera,Designated,Not FDA Approved for Orphan Indication,,,,,Impact Biomedicines,12526 High Bluff Drive,Suite 260,San Diego,California,92130,United States,390913
ACAMPROSATE,N4K14YGM3J,Designated,Public record,2895,acamprosate,3/25/2013,Treatment of fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Confluence Pharmaceuticals, LLC",Box 528,351 West 10th Street,Indianapolis,Indiana,46202,United States,392413
INOTUZUMAB OZOGAMICIN,P93RUU11P7,Designated/Approved,Public record,2896,inotuzumab ozogamicin,3/25/2013,Treatment of B-cell acute lymphoblastic leukemia,Designated/Approved,,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),8/17/2017,8/17/2024,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),"Pfizer, Inc.",10646 Science Center Drive,,San Diego,California,92121,United States,391413
AMIKACIN,84319SGC3C,Designated,Public record,2897,liposomal amikacin,3/25/2013,Treatment of infections caused by non-tuberculous mycobacteria,Designated/Approved,,Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy,9/28/2018,9/28/2025,Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy,Insmed Incorporated,10 Finderne Avenue,Building 10,Bridgewater,New Jersey,8807,United States,342011
NERIDRONIC ACID,8U27U3RIN4,Designated,Public record,2898,neridronate,3/25/2013,"Treatment of complex regional pain syndrome (CRPS-1, CRPS-II, CRPS-NOS)",Designated,Not FDA Approved for Orphan Indication,,,,,"NovaPharm, LLC",526 Park Ridge Drive,,Wayne,Pennsylvania,19087,United States,372412
CERLIPONASE ALFA,X8R2D92QP1,Designated/Approved,Public record,2901,cerliponase alfa,4/1/2013,Treatment of neuronal ceroid lipofuscinosis type 2,Designated/Approved,,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.",4/27/2017,4/27/2024,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.","BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,94949,United States,391913
CREATINE MONOHYDRATE,9603LN7R2Q,Designated,Public record,2902,Kre-Celazine,4/1/2013,Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population,Designated,Not FDA Approved for Orphan Indication,,,,,All American Pharmaceutical & Natural Foods Corpor,2376 Main Street,,Billings,Montana,59105,United States,298309
CETYL MYRISTOLEATE,87P8K33Q5X,Designated,Public record,2902,Kre-Celazine,4/1/2013,Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population,Designated,Not FDA Approved for Orphan Indication,,,,,All American Pharmaceutical & Natural Foods Corpor,2376 Main Street,,Billings,Montana,59105,United States,298309
CETYL OLEATE,78K2L26L8N,Designated,Public record,2902,Kre-Celazine,4/1/2013,Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population,Designated,Not FDA Approved for Orphan Indication,,,,,All American Pharmaceutical & Natural Foods Corpor,2376 Main Street,,Billings,Montana,59105,United States,298309
CETYL PALMITOLEATE,962I97113K,Designated,Public record,2902,Kre-Celazine,4/1/2013,Treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population,Designated,Not FDA Approved for Orphan Indication,,,,,All American Pharmaceutical & Natural Foods Corpor,2376 Main Street,,Billings,Montana,59105,United States,298309
GALUNISERTIB,3OKH1W5LZE,Designated,Public record,2903,transforming growth factor-beta receptor 1 kinase inhibitor,4/1/2013,Treatment of hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,378712
ANTI INHIBITOR COAGULANT COMPLEX,,Designated/Approved,Public record,2904,anti-inhibitor coagulant complex,4/12/2013,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,Designated/Approved,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,12/16/2013,12/16/2020,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,"Baxalta US, Inc.",One Baxter Way,,West Lake Village,California,91362,United States,393913
GIVINOSTAT,5P60F84FBH,Designated,Public record,2905,givinostat,4/12/2013,Treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Italfarmaco SpA,"Via dei Lavoratori, 54",,20092 Cinisello Balsamo,,,Italy,391613
MELATONIN,JL5DK93RCL,Designated,Public record,2906,melatonin,4/12/2013,Treatment of neonatal hypoxic ischemic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Scharper S.p.A.,Viale Ortles 12,,Milan,,,Italy,391313
LDN-193189 MONOHYDROCHLORIDE,PLH51K438W,Designated,Public record,2908,"4-(6-(4-(piperazin-1-yl)phenyl_pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride",4/15/2013,Treatment of fibrodysplasia ossificans progressiva,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"La Jolla Pharmaceutical Company, Inc.","10182 Telesis Court, Suite 600",,San Diego,California,92121,United States,393513
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated,Public record,2909,brentuximab vedotin,4/15/2013,"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,394013
DAUNORUBICIN CITRATE,5L84T2Z6NP,Designated/Withdrawn,Public record,2910,daunorubicin citrate liposome,4/15/2013,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Galen Limited,Seagoe Industrial Estate,,"Graigavon, BT63 5UA",,,United Kingdom,393413
DUVELISIB,610V23S0JI,Designated,Public record,2911,duvelisib,4/15/2013,Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,Designated/Approved,,Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies,9/24/2018,9/24/2025,Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies,"Secura Bio, Inc.",1995 Village Center Cir.,,Las Vegas,Nevada,,United States,394413
REMETINOSTAT,37NT056AT4,Designated,Public record,2912,methylparaben suberohydroxamic acid phenyl ester,4/15/2013,Treatment of cutaneous T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Medivir AB,Box 1086s,,Huddinge,,,Sweden,292109
PROLACTIN G129R,Y88638Q24R,Designated,Public record,2913,prolactin receptor antagonist,4/15/2013,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolix, Inc.",14405 Walters Road,Suite 780,Houston,Texas,77014,United States,392613
LESINIDASE ALFA,61A4G0P3IB,Designated/Withdrawn,Public record,2914,recombinant human alpha-N-acetylglucosaminidase,4/15/2013,Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",100 College Street,,Hew Haven,Connecticut,6510,United States,394113
SODIUM ASCORBATE,S033EH8359,Designated,Public record,2916,sodium ascorbate and menadione sodium bisulfite,4/15/2013,Treatment of autosomal dominant polycystic liver disease,Designated,Not FDA Approved for Orphan Indication,,,,,IC-Medtech Corporation,9902 Indian Creek Lane,,El Cajon,California,92021,United States,395413
MENADIONE SODIUM BISULFITE,6XF3C2HK77,Designated,Public record,2916,sodium ascorbate and menadione sodium bisulfite,4/15/2013,Treatment of autosomal dominant polycystic liver disease,Designated,Not FDA Approved for Orphan Indication,,,,,IC-Medtech Corporation,9902 Indian Creek Lane,,El Cajon,California,92021,United States,395413
MENADIONE SODIUM BISULFITE,6XF3C2HK77,Designated,Public record,2917,sodium ascorbate and menadione sodium bisulfite,4/15/2013,Treatment of autosomal dominant polycystic kidney disease,Designated,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,92021,United States,394313
SODIUM ASCORBATE,S033EH8359,Designated,Public record,2917,sodium ascorbate and menadione sodium bisulfite,4/15/2013,Treatment of autosomal dominant polycystic kidney disease,Designated,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,92021,United States,394313
METENKEFALIN,9JEZ9OD3AS,Designated,Public record,2918,opioid growth factor,4/16/2013,Treatment of liver and intrahepatic bile duct cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Primocure Pharma, Inc.",1732 1st Avenue,#23222,New York,New York,10128,United States,392213
TOCILIZUMAB,I031V2H011,Designated,Public record,2919,tocilizumab,4/17/2013,Treatment of systemic sclerosis,Designated/Approved,,slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease,3/4/2021,3/4/2028,slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,381212
BUDESONIDE,Q3OKS62Q6X,Designated,Public record,2922,budesonide,5/6/2013,Treat of ulcerative colitis in pediatric patients aged 0 through 16 years.,Designated,Not FDA Approved for Orphan Indication,,,,,"Santarus, Inc.","3611 Valley Centre Drive, Suite 400",,San Diego,California,92130,United States,394613
DARATUMUMAB,4Z63YK6E0E,Designated/Approved,Public record,2923,daratumumab,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refracto,6/27/2019,,,"Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,8869,United States,397113
DARATUMUMAB,4Z63YK6E0E,Designated/Approved,Public record,2924,daratumumab,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,11/16/2015,11/16/2022,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,8869,United States,397113
DARATUMUMAB,4Z63YK6E0E,Designated/Approved,Public record,2925,daratumumab,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethas",5/7/2018,5/7/2025,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,8869,United States,397113
DARATUMUMAB,4Z63YK6E0E,Designated/Approved,Public record,2926,daratumumab,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients",11/21/2016,11/21/2023,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,8869,United States,397113
DARATUMUMAB,4Z63YK6E0E,Designated/Approved,Public record,2927,daratumumab,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexametha",6/16/2017,6/16/2024,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded","Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,8869,United States,397113
DARATUMUMAB,4Z63YK6E0E,Designated/Approved,Public record,2928,daratumumab,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who,9/26/2019,9/26/2026,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,8869,United States,397113
DARATUMUMAB,4Z63YK6E0E,Designated/Approved,Public record,2929,daratumumab,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,Treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy,8/20/2020,,,"Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,8869,United States,397113
ISAVUCONAZONIUM SULFATE,31Q44514JV,Designated/Approved,Public record,2931,isavuconazonium sulfate,5/6/2013,Treatment of invasive aspergillosis,Designated/Approved,,Treatment of invasive aspergillosis in patients 18 years of age and older,3/6/2015,3/6/2022,Treatment of invasive aspergillosis in patients 18 years of age and older,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,60062,United States,394913
PAZOPANIB,7RN5DR86CK,Designated,Public record,2932,pazopanib,5/6/2013,Treatment of ovarian cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 337/B17.5F",,East Hanover,New Jersey,7936,United States,383912
PEXASTIMOGENE DEVACIREPVEC,K82DG47I0G,Designated,Public record,2933,pexastimogene devacirepvec,5/6/2013,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"SillaJen Biotherapeutics, Inc.",450 Sansome Street,Suite 200,San Francisco,California,94111,United States,394213
TEPROTUMUMAB,Y64GQ0KC0A,Designated,Public record,2935,teprotumumab,5/6/2013,Treatment of active thyroid eye disease,Designated/Approved,,TEPEZZA is indicated for the treatment of Thyroid Eye Disease.,1/21/2020,1/21/2027,For the treatment of active Thyroid Eye Disease,Horizon Therapeutics Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin,Ireland,,Ireland,387812
ZOLEDRONIC ACID,6XC1PAD3KF,Designated,Public record,2936,zoledronic acid,5/6/2013,Treatment of complex regional pain syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Axsome Therapeutics, Inc.","25 Broadway, 9th Floor",Suite 2000,New York,New York,10004,United States,374112
FIPAXALPARANT,Y76WZ464EY,Designated,Public record,2937,2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid,5/14/2013,Treatment of patients with systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Horizon Therapeutics Ireland DAC,70 St. Stephen’s Green,,Dublin 2,,,Ireland,393813
"""3,5-DIIODOTHYROPROPIONIC ACID""",1HTO2X0SJ9,Designated,Public record,2938,"3,5-diiodothyropropionic acid",5/14/2013,Treatment of Allan-Herndon-Dudley syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Zarion Pharmaceuticals P/L,8 Grandview Grove,Sassafras 3787,Victoria,,,Australia,395613
NERINETIDE,D45TI2TWMA,Designated,Public record,2940,H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH,5/14/2013,Treatment of subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,"NoNO, Inc.",399 Bathurst Street,,Toronto,,,Canada,377812
ROCILETINIB,72AH61702G,Designated,Public record,2941,rociletinib,5/14/2013,Treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor,Designated,Not FDA Approved for Orphan Indication,,,,,"Clovis Oncology, Inc.",5500 Flatiron Parkway,Suite 100,Boulder,Colorado,80301,United States,380212
IBRUTINIB,1X70OSD4VX,Designated,Public record,2943,ibrutinib,5/16/2013,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,397313
TERGURIDE,21OJT43Q88,Designated,Public record,2944,terguride,5/17/2013,Treatment of systemic sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Medac GmbH,TheaterstraBe 6+,,Wedel,,,Germany,380512
ABATACEPT,7D0YB67S97,Designated,Public record,2945,abatacept,5/30/2013,Treatment of type 1 diabetes mellitus patients with residual beta cell function,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC,64 Aspinwall Avenue,,Brookline,Massachusetts,2446,United States,395713
DIAZEPAM,Q3JTX2Q7TU,Designated,Public record,2946,diazepam auto-injector,5/30/2013,"Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity",Designated,Not FDA Approved for Orphan Indication,,,,,"Meridian Medical Technologies, Inc.","6350 Stevens Forest Rd, Suite 301",,Columbia,Maryland,21046,United States,384112
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,2947,ibrutinib,5/30/2013,Treatment of small lymphocytic lymphoma,Designated/Approved,,Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) with 17p deletion.,5/6/2016,5/6/2023,For treatment of patients with small lymphocytic lymphoma (SLL),"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,395513
EVOFOSFAMIDE,8A9RZ3HN8W,Designated,Public record,2949,"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate",6/5/2013,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,EMD Serono,One Technology Place,,Rockland,Massachusetts,2370,United States,396513
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,2950,sodium phenylbutyrate,6/6/2013,Treatment of urea cycle disorders,Designated/Approved,,"As adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamy",6/17/2022,,,Medunik Canada Inc,950 Boulevard Michèle-Bohec,,Blainville,,,Canada,372112
TAGRAXOFUSP,8ZHS5657EH,Designated,Public record,2951,Tagraxofusp-erzs,6/6/2013,Treatment of blastic plasmacytoid dendritic cell neoplasm,Designated/Approved,,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,12/21/2018,12/21/2025,ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,"Stemline Therapeutics, Inc.",750 Lexington Avenue,11th floor,New York,New York,10022,United States,397413
PVX-410 COMPONENT XBP1 SP367-375 (YLFPQLISV),7AS3WP8FO8,Designated,Public record,2952,Multi-peptide cancer vaccine,6/23/2013,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"OncoPep, Inc.",520 Boston Street,,North Andover,Massachusetts,1845,United States,392313
PVX-410 COMPONENT CS1 239-247(SLFVLGLFL),EHT3VE7CI1,Designated,Public record,2952,Multi-peptide cancer vaccine,6/23/2013,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"OncoPep, Inc.",520 Boston Street,,North Andover,Massachusetts,1845,United States,392313
PVX-410 COMPONENT CD138 260-268(GLVGLIFAV),V1QJC0TIE6,Designated,Public record,2952,Multi-peptide cancer vaccine,6/23/2013,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"OncoPep, Inc.",520 Boston Street,,North Andover,Massachusetts,1845,United States,392313
PVX-410 COMPONENT XBP1 US184-192(YISPWILAV),W7QU8GP4UY,Designated,Public record,2952,Multi-peptide cancer vaccine,6/23/2013,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"OncoPep, Inc.",520 Boston Street,,North Andover,Massachusetts,1845,United States,392313
VELDOREOTIDE ACETATE,9F2286627L,Designated,Public record,2953,"cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonly-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt",6/24/2013,Treatment of acromegaly,Designated,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceuticals, lnc.","180 N La Salle Street, Suite 1600",,Chicago,Illinois,60601,United States,397713
ECULIZUMAB,A3ULP0F556,Designated,Public record,2954,eculizumab,6/24/2013,Treatment of neuromyelitis optica,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,6/27/2019,6/27/2026,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,398713
FLUNARIZINE,R7PLA2DM0J,Designated/Withdrawn,Public record,2955,flunarizine,6/24/2013,Treatment of alternating hemiplegia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Marathon Pharmaceuticals, LLC",1033 Skokie Blvd.,Suite 600,Northbrook,Illinois,60062,United States,398513
BUSULFAN,G1LN9045DK,Designated,Public record,2957,liposomal busulfan,6/24/2013,For use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,,,Sweden,394513
NAXITAMAB,9K8GNJ2874,Designated,Public record,2958,naxitamab-gqgk,6/24/2013,Treatment of neuroblastoma,Designated/Approved,,"in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demon",11/25/2020,11/25/2027,"treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy","Y-mAbs Therapeutics, Inc.",750 3rd Avenue,9th Floor,New York,New York,10017,United States,399613
ULIXERTINIB HYDROCHLORIDE,3K792HRQ8B,Designated,Public record,2959,Ulixertinib,6/24/2013,Treatment of Stage IIb through Stage IV BRAF mutant melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"BioMed Valley Discoveries, Inc.",4435 Main Street,Suite 550,Kansas City,Missouri,64111,United States,398213
CARBAMAZEPINE,33CM23913M,Designated/Approved,Public record,2961,intravenous carbamazepine,6/27/2013,Treatment of epilepsy patients who cannot take anything by mouth (NPO),Designated/Approved,,"Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed",10/7/2016,10/7/2023,"Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed",Lundbeck LLC,"3530 Toringdon Way, Suite 200",,Charlotte,North Carolina,28277,United States,265508
MOXETUMOMAB PASUDOTOX,2NDX4B6N8F,Designated,Public record,2962,moxetumomab pasudotox,6/28/2013,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike PO Box 8355,,Wilmington,Delaware,,United States,396813
Corticotropin,K0U68Q2TXA,Designated,Public record,2963,repository corticortropin injection,6/28/2013,Treatment of amyotrophic lateral sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mallinckrodt Pharmaceuticals, Inc.",Perryville III Corporate Park,P. O. Box 9001,Hampton,New Jersey,8827,United States,399113
ALISERTIB,T66ES73M18,Designated,Public record,2964,alisertib,7/12/2013,Treatment of small cell lung cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,400313
BREXANOLONE,S39XZ5QV8Y,Designated,Public record,2965,allopregnanolone,7/12/2013,"Treatment of Neimann-Pick disease, type C",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"La Jolla Pharmaceutical Company, Inc.",10182 Telesis Court,"6th Floor, Suite 600",San Diego,California,92121,United States,399013
DENILEUKIN DIFTITOX,25E79B5CTM,Designated,Public record,2966,denileukin diftitox,7/12/2013,Treatment of cutaneous T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Citius Pharmaceuticals, Inc.","11 Commerce Drive, 1st Floor",,Cranford,New Jersey,7016,United States,341311
PERTUZUMAB,K16AIQ8CTM,Designated,Public record,2967,pertuzumab,7/12/2013,"Treatment of gastric cancer, including gastroesophageal junction cancer",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,400713
DEFACTINIB HYDROCHLORIDE,L2S469LM49,Designated,Public record,2968,N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride,7/18/2013,Treatment of mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Verastem, Inc.",117 Kendrick Street,Suite 500,Needham,Massachusetts,2494,United States,393313
BEZAFIBRATE,Y9449Q51XH,Designated,Public record,2969,bezafibrate,7/24/2013,For therapeutic treatment of Barth syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Barth Sydrome Foundation, Inc.",P. O. Box 618,,Larchmont,New York,10538,United States,400013
Hydroxyurea,X6Q56QN5QC,Designated/Approved,Public record,2971,hydroxycarbamide (hydroxyurea),7/24/2013,Treatment of sickle cell disease in patients under 18 years of age,Designated/Approved,,"To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crisis",12/21/2017,12/21/2024,"To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age amd older, with sickle cell anemia with recurrent moderate to severe painful crisis",Addmedica Laboratories,37 rue de Caumartin,,Paris,,,France,400413
TOPIRAMATE,0H73WJJ391,Designated,Public record,2972,topiramate injection,7/24/2013,Treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate,Designated,Not FDA Approved for Orphan Indication,,,,,"CURx Pharmaceuticals, Inc.",3210 Merryfield Row,,San Diego,California,92121,United States,283909
VIXOTRIGINE HYDROCHLORIDE,7L3OLR4M8T,Designated,Public record,2973,vixotrigine,7/24/2013,Treatment of trigeminal neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",300 Binney Street,,Cambridge,Massachusetts,2142,United States,401613
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,2974,angiotensin (1-7)[A(1-7)],7/25/2013,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Constant Therapeutics LLC,"303 Congress St, c/o Casner & Edwards",,Boston,Massachusetts,2210,United States,400813
SULTHIAME,I00Q766CZ2,Designated/Withdrawn,Public record,2975,sulthiame,7/25/2013,Treatment of patients with benign epilepsy of childhood with centrotemporal spikes (BECTS) also known as rolandic epilepsy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Marathon Pharmaceuticals, LLC","1033 Skokie Blvd.,",Suite 600,Northbrook,Illinois,60062,United States,401213
DUVELISIB,610V23S0JI,Designated,Public record,2976,duvelisib,8/1/2013,Treatment of follicular lymphoma,Designated/Approved,,Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies (Indication withdrawn),9/24/2018,12/17/2021,Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies (Indication withdrawn),"Secura Bio, Inc.",1995 Village Center Cir.,Suite 128,Las Vegas,Nevada,,United States,399913
Limosilactobacillus reuteri,9913I24QEE,Designated,Public record,2977,L. reuteri,8/1/2013,"Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams",Designated,Not FDA Approved for Orphan Indication,,,,,Infant Bacterial Therapeutics,Kungsbroplan 3A,P. O. Box 3242,Stockholm,,,Sweden,393013
FERROHEME,42VZT0U6YR,Designated,Public record,2979,Human Hemin,8/6/2013,Prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Borders Technology Management Ltd,2 Broomlee Mains Court,,Peeblesshire,Scotland,,United Kingdom,402413
MM-111,6IJ4CQY76O,Designated,Public record,2980,bispecific antibody (monoclonal antibody),8/8/2013,Treatment of HER2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.",888 7th Avenue,Suite 30,New York,New York,10106,United States,401413
MM-111,6IJ4CQY76O,Designated,Public record,2981,bispecific antibody (monoclonal antibody),8/8/2013,Treatment of HER2-expressing adenocarcinoma of the esophagus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.",888 7th Avenue,Suite 30,New York,New York,10106,United States,401113
PINOMETOSTAT,8V9YR09EF3,Designated,Public record,2983,small molecule inhibitor of histone methyltransferase DOT1L,8/8/2013,Treatment of acute lymphoblastic leukemia (ALL),Designated,Not FDA Approved for Orphan Indication,,,,,Epizyme Inc.,"400 Technology Square, 4th Floor",,Cambridge,Massachusetts,2139,United States,402213
URIDINE TRIACETATE,2WP61F175M,Designated/Approved,Public record,2984,uridine triacetate,8/9/2013,Treatment of hereditary orotic aciduria,Designated/Approved,,Treatment of hereditary orotic aciduria,9/4/2015,9/4/2022,Treatment of hereditary orotic aciduria,"Wellstat Therapeutics, Inc.",14200 Shady Grove Road,Suite 600,Rockville,Maryland,20850,United States,401013
AXALIMOGENE FILOLISBAC,NY7PTD1862,Designated,Public record,2985,ADXS11-001,8/12/2013,Treatment of HPV-positive associated anal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Advaxis, Inc.",305 College Road East,,Princeton,New Jersey,8540,United States,401813
PENTAMIDINE,673LC5J4LQ,Designated/Withdrawn,Public record,2986,pentamidine,8/12/2013,Treatment of liver and intrahepatic bile duct cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Verlyx Pharma, Inc.","555 Rene-Levesque West, 9th Floor",,Montreal,,,Canada,389312
PENTAMIDINE,673LC5J4LQ,Designated/Withdrawn,Public record,2987,pentamidine,8/12/2013,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Oncozyme Pharma, Inc.",555 Rene-Levesque West,,Montreal,,,Canada,389212
PINOMETOSTAT,8V9YR09EF3,Designated,Public record,2989,small molecule inhibitor of histone methyltransferase DOT1L,8/15/2013,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Epizyme Inc.,"400 Technology Square, 4th Floor",,Cambridge,Massachusetts,2139,United States,402113
DANTROLENE SODIUM,287M0347EV,Designated/Approved,Public record,2990,dantrolene sodium suspension for injection,8/16/2013,Treatment of malignant hyperthermia syndrome,Designated/Approved,,Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.,7/22/2014,7/22/2021,Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,7677,United States,179703
DEFLAZACORT,KR5YZ6AE4B,Designated/Approved,Public record,2991,deflazacort,8/16/2013,Treatment of Duchenne muscular dystrophy,Designated/Approved,,Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older,2/9/2017,2/9/2024,Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,403413
DEFLAZACORT,KR5YZ6AE4B,Designated/Approved,Public record,2992,deflazacort,8/16/2013,Treatment of Duchenne muscular dystrophy,Designated/Approved,,EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.,6/7/2019,6/7/2026,For the treatment of Duchene muscular dystrophy in patients 2 years of age to less than 5 years of age,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,403413
RUXOLITINIB,82S8X8XX8H,Designated,Public record,2993,ruxolitinib,8/16/2013,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,400613
POMALIDOMIDE,D2UX06XLB5,Designated/Withdrawn,Public record,2996,pomalidomide,8/22/2013,Treatment of systemic sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,363212
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,2997,angiotensin (1-7),8/30/2013,Treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (CD34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor,Designated,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,93401,United States,402713
TREBANANIB,X8Y5U6NC7E,Designated,Public record,2998,trebananib,8/30/2013,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91320,United States,403313
MARALIXIBAT CHLORIDE,V78M04F0XC,Designated,Public record,2999,"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride",9/4/2013,Treatment of primary biliary cirrhosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,94404,United States,406113
MARALIXIBAT CHLORIDE,V78M04F0XC,Designated,Public record,3000,"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride",9/4/2013,Treatment of primary sclerosing cholangitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,94404,United States,406213
FENRETINIDE,187EJ7QEXL,Designated,Public record,3001,fenretinide,9/4/2013,Treatment of peripheral T-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"CerRx, Inc.",Reese Technology Center,"9801 Reese Blvd, Suite 104",Lubbock,Texas,79416,United States,404013
FENRETINIDE,187EJ7QEXL,Designated,Public record,3002,fenretinide,9/4/2013,Treatment of cutaneous T-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"CerRx, Inc.",Reese Technology Center,"9801 Reese Blvd, Suite 104",Lubbock,Texas,79416,United States,409913
MARALIXIBAT CHLORIDE,V78M04F0XC,Designated,Public record,3003,maralixibat,9/4/2013,Treatment of alagille syndrome,Designated/Approved,,Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older,9/29/2021,9/29/2028,Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,94404,United States,401513
MARALIXIBAT CHLORIDE,V78M04F0XC,Designated,Public record,3004,maralixibat,9/4/2013,Treatment of alagille syndrome,Designated/Approved,,treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older,3/13/2023,3/13/2030,treatment of cholestatic pruritus in patients 3 months of age to less than 1 year of age with Alagille syndrome (ALGS),"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,94404,United States,401513
MARALIXIBAT,UYB6UOF69L,Designated,Public record,3005,maralixibat,9/4/2013,Treatment of progressive familial intrahepatic cholestasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,94404,United States,406013
SODIUM SULFATE,0YPR65R21J,Designated,Public record,3006,"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride",9/4/2013,For use in cleansing of the colon in preparation for colonoscopy in children and adolescents,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,403513
Potassium sulfate,1K573LC5TV,Designated,Public record,3006,"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride",9/4/2013,For use in cleansing of the colon in preparation for colonoscopy in children and adolescents,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,403513
POLYETHYLENE GLYCOL 3350,G2M7P15E5P,Designated,Public record,3006,"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride",9/4/2013,For use in cleansing of the colon in preparation for colonoscopy in children and adolescents,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,403513
Potassium chloride,660YQ98I10,Designated,Public record,3006,"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride",9/4/2013,For use in cleansing of the colon in preparation for colonoscopy in children and adolescents,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,403513
"""MAGNESIUM SULFATE, UNSPECIFIED FORM""",DE08037SAB,Designated,Public record,3006,"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride",9/4/2013,For use in cleansing of the colon in preparation for colonoscopy in children and adolescents,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,403513
SODIUM BICARBONATE,8MDF5V39QO,Designated,Public record,3006,"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride",9/4/2013,For use in cleansing of the colon in preparation for colonoscopy in children and adolescents,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,403513
Sodium chloride,451W47IQ8X,Designated,Public record,3006,"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride",9/4/2013,For use in cleansing of the colon in preparation for colonoscopy in children and adolescents,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,403513
LISTERIA MONOCYTOGENES,3O44K14A86,Designated,Public record,3007,listeria monocytogenes,9/5/2013,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Aduro BioTech, Inc.",740 Heinz Avenue,,Berkeley,California,94710,United States,386212
MOTIXAFORTIDE,DA9G065962,Designated,Public record,3008,motixafortide,9/5/2013,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"BioLineRx, Ltd.",Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,,,Israel,403213
UBLITUXIMAB,U59UGK3IPC,Designated,Public record,3009,ublituximab,9/5/2013,"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)",Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New York,8837,United States,403813
UBLITUXIMAB,U59UGK3IPC,Designated,Public record,3010,ublituximab,9/5/2013,Treatment of Nodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,8837,United States,410913
BENDAMUSTINE HYDROCHLORIDE,981Y8SX18M,Designated,Public record,3011,bendamustine hydrochloride with betadex sulfobutyl ether sodium,9/10/2013,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,BendaRx Corp.,1000 De La Gauchetiere W,Ste 2400,Montréal,,,Canada,386612
BETADEX SULFOBUTYL ETHER SODIUM,2PP9364507,Designated,Public record,3011,bendamustine hydrochloride with betadex sulfobutyl ether sodium,9/10/2013,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,BendaRx Corp.,1000 De La Gauchetiere W,Ste 2400,Montréal,,,Canada,386612
CYSTEAMINE,5UX2SD1KE2,Designated,Public record,3012,cysteamine,9/11/2013,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,,Lake Forest,Illinois,60045,United States,404613
ALCOHOL,3K9958V90M,Designated,Public record,3013,dehydrated alcohol,9/11/2013,Treatment of hypertrophic obstructive cardiomyopathy,Designated/Approved,,ABLYSINOL® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.,6/21/2018,6/21/2025,ABLYSINOL® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.,"Belcher Pharmaceuticals, LLC",6911 Bryan Dairy Road,,Largo,Florida,33777,United States,402513
DENOSUMAB,4EQZ6YO2HI,Designated/Approved,Public record,3014,denosumab,9/11/2013,Treatment of hypercalcemia in malignancy,Designated/Approved,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,12/5/2014,12/5/2021,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.",One Amgen Center Drive,MS 17-2-C,Thousand Oaks,California,91320,United States,404213
DIMETHYL FUMARATE,FO2303MNI2,Designated,Public record,3015,dimethyl fumarate,9/11/2013,Treatment of Friedreich's Ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,"Ixchel Pharma, LLC",608 12th Street,,Davis,California,95616,United States,406713
DUSQUETIDE,IKX7W49NLN,Designated,Public record,3017,L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide,9/11/2013,Treatment of acute radiation syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,8540,United States,395913
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,3018,nitric oxide,9/11/2013,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Novoteris, LLC",7245 Garden Grove Blvd.,Suite C,Garden Grove,California,92841,United States,403613
EVOLOCUMAB,LKC0U3A8NJ,Designated/Approved,Public record,3020,evolocumab,9/12/2013,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,"As an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C",9/24/2021,9/24/2028,to reduce LDL-C in pediatric patients aged 10 to less than 13 years with homozygous familial hypercholesterolemia (HoFH),Amgen Inc.,One Amgen Center Drive,M/S 17 2 B,Thousand Oaks,California,91320,United States,404113
EVOLOCUMAB,LKC0U3A8NJ,Designated/Approved,Public record,3021,evolocumab,9/12/2013,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",8/27/2015,8/27/2022,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.,One Amgen Center Drive,M/S 17 2 B,Thousand Oaks,California,91320,United States,404113
AUTOLOGOUS EX VIVO EXPANDED CD4+-ENRICHED LEUKOCYTES TREATED WITH THE DE-METHYLATING AGENT 5-AZA-DEOXYCYTIDINE,B2NUS89036,Designated,Public record,3023,autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2â??-deoxycytidine,9/13/2013,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,CytoVac A/S,Science & Technology Park Scion DTU,,Horsholm,,,Denmark,405513
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated,Public record,3024,brentuximab vedotin,9/13/2013,Treatment of patients with angioimmunoblastic T-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,404913
MELARSOPROL,ZF3786Q2E8,Designated,Public record,3025,melarsoprol-hydroxypropylbetadex,9/13/2013,Treatment of human African trypanosomiasis (sleeping sickness),Designated,Not FDA Approved for Orphan Indication,,,,,"Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,",Glasgow University Department of Neurology,,Glasgow,,,United Kingdom,406613
OSILODROSTAT,5YL4IQ1078,Designated,Public record,3026,osilodrostat,9/13/2013,Treatment of Cushing's disease,Designated/Approved,,ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing¿s disease for whom pituitary surgery is not an option or has not been curative.,3/6/2020,3/6/2027,For the treatment of adult patients with Cushing¿s disease for whom pituitary surgery is not an option or has not been curative.,"Recordati Rare Diseases, Inc",100 Corporate Drive,,Lebanon,New Jersey,8833,United States,405113
LENALIDOMIDE,F0P408N6V4,Designated,Public record,3027,lenalidomide,9/17/2013,Treatment of follicular lymphoma,Designated/Approved,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma (FL).,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,390813
RIOCIGUAT,RU3FE2Y4XI,Designated/Approved,Public record,3028,riociguat,9/19/2013,Treatment of pulmonary arterial hypertension.,Designated/Approved,,"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.",10/8/2013,10/8/2020,"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.","Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd.,,Whippany,New Jersey,7981,United States,392113
RIOCIGUAT,RU3FE2Y4XI,Designated/Approved,Public record,3029,riociguat,9/19/2013,Treatment of chronic thromboembolic pulmonary hypertension,Designated/Approved,,"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class",10/8/2013,10/8/2020,"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class","Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd.,,Whippany,New Jersey,7981,United States,406913
Z-160,TX3R141LEP,Designated/Withdrawn,Public record,3031,"1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one",9/26/2013,Management of postherpetic neuralgia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Zalicus Pharmaceuticals Ltd.,245 First Street,,Cambridge,Massachusetts,2142,United States,387412
DEVIMISTAT,E76113IR49,Designated,Public record,3032,"6,8-bis-benzylsulfanyl-octanoic acid",9/26/2013,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,8512,United States,406813
DOVITINIB,I35H55G906,Designated,Public record,3035,dovitinib,9/26/2013,Treatment of adenoid cystic carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Oncology Venture ApS,1 Venlighedsvej,,Hørsholm,,,Denmark,388012
ETHIODIZED OIL,KZW0R0686Q,Designated/Approved,Public record,3036,ethiodized oil injection,9/26/2013,Management of patients with known hepatocellular carcinoma (HCC),Designated/Approved,,Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC),4/4/2014,4/4/2021,Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC),Guerbet LLC,"120 West 7th St., Suite 108",,Bloomington,Indiana,47404,United States,400113
IDELALISIB,YG57I8T5M0,Designated,Public record,3037,idelalisib,9/26/2013,Treatment of lymphoplasmacytic lymphoma with or without Walenstrom's macroglobulinemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,98102,United States,405713
IDELALISIB,YG57I8T5M0,Designated/Approved,Public record,3038,idelalisib,9/26/2013,Treatment of follicular lymphoma,Designated/Approved,,Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies.,7/23/2014,7/23/2021,Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,98102,United States,405813
ALANINE,OF5P57N2ZX,Designated,Public record,3039,manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption),9/26/2013,Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be admini,Designated,Not FDA Approved for Orphan Indication,,,,,Ascelia Pharma AB,Scion DTU,DK-2800 Lyngby,Lund,,,Sweden,342911
Cholecalciferol,1C6V77QF41,Designated,Public record,3039,manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption),9/26/2013,Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be admini,Designated,Not FDA Approved for Orphan Indication,,,,,Ascelia Pharma AB,Scion DTU,DK-2800 Lyngby,Lund,,,Sweden,342911
MANGANESE CHLORIDE,QQE170PANO,Designated,Public record,3039,manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption),9/26/2013,Use as a targeted contrast agent for diagnostic MRI for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be admini,Designated,Not FDA Approved for Orphan Indication,,,,,Ascelia Pharma AB,Scion DTU,DK-2800 Lyngby,Lund,,,Sweden,342911
MELPHALAN HYDROCHLORIDE,1VXP4V453T,Designated,Public record,3040,melphalan hydrochloride,9/26/2013,Treatment of patients with hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,10019,United States,405413
CERITINIB,K418KG2GET,Designated/Approved,Public record,3042,ceritinib,9/27/2013,Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive,Designated/Approved,,ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic nonsmall cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.,4/29/2014,4/29/2021,Treatment of patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,405213
CERITINIB,K418KG2GET,Designated/Approved,Public record,3043,ceritinib,9/27/2013,Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive,Designated/Approved,,Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test,5/26/2017,5/26/2024,Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,405213
Tovorafenib,ZN90E4027M,Designated,Public record,3045,6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamide,10/15/2013,Treatment of stage IIb-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,410813
DECTREKUMAB,764HZ2554D,Designated,Public record,3046,human monoclonal antibody againt human interleukin 13 (IL-13),10/15/2013,Treatment of eosinophilic esophagitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporaton,One Health Plaza,,East Hanover,New Jersey,7936,United States,408513
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,3047,ibrutinib,10/15/2013,Treatment of Waldenstrom's macroglobulinemia,Designated/Approved,,Treatment of patients with Waldenstrom's macroglobulinemia,1/29/2015,1/29/2022,Treatment of patients with Waldenstrom's macroglobulinemia,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,407413
IDELALISIB,YG57I8T5M0,Designated/Approved,Public record,3048,idelalisib,10/15/2013,Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,Designated/Approved,,"Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and Zydelig is indicated for",7/23/2014,7/23/2021,"(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who hav","Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,98102,United States,405913
IDELALISIB,YG57I8T5M0,Designated,Public record,3049,idelalisib,10/15/2013,Treatment of extranodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,98102,United States,405613
IDELALISIB,YG57I8T5M0,Designated,Public record,3050,idelalisib,10/15/2013,Treatment of nodal marginal zone lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,98102,United States,412513
IDELALISIB,YG57I8T5M0,Designated,Public record,3051,idelalisib,10/15/2013,Treatment of splenic marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,98102,United States,412613
INEBILIZUMAB,74T7185BMM,Designated,Public record,3052,anifrolumab,10/16/2013,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,19803,United States,299209
ONATASERTIB,I8RA3543SY,Designated,Public record,3053,mTOR kinase inhibitor (CC-223),10/16/2013,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,407913
Olaparib,WOH1JD9AR8,Designated/Approved,Public record,3054,olaparib,10/16/2013,Treatment of ovarian cancer,Designated/Approved,,"Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in comple",12/19/2018,12/19/2025,Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian cancer who are in complete or partial response to first-line p,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,409213
Olaparib,WOH1JD9AR8,Designated/Approved,Public record,3055,olaparib,10/16/2013,Treatment of ovarian cancer,Designated/Approved,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemot",5/8/2020,5/8/2027,"LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemo",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,409213
Olaparib,WOH1JD9AR8,Designated/Approved,Public record,3056,olaparib,10/16/2013,Treatment of ovarian cancer,Designated/Approved,,Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy,12/19/2014,12/19/2021,Use as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,409213
Olaparib,WOH1JD9AR8,Designated/Approved,Public record,3057,olaparib,10/16/2013,Treatment of ovarian cancer,Designated/Approved,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.",8/17/2017,8/17/2024,"Maintenance treatment of adult patients with recurrent epithelial ovarian cancer, who are in a complete or partial response to platinum-based chemotherapy.",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,409213
SOMAVARATAN,4Y05SI704S,Designated,Public record,3058,somavaratan,10/16/2013,Treatment of growth hormone deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Versartis, Inc.",275 Shoreline Drive,Suite 450,Redwood City,,94065,United States,379412
TIVANTINIB,PJ4H73IL17,Designated/Withdrawn,Public record,3059,tivantinib,10/16/2013,Treatment of hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Daiichi Sankyo Pharma Development,399 Thornall Street,,Edison,New Jersey,8837,United States,407513
IBRUTINIB,1X70OSD4VX,Designated,Public record,3060,ibrutinib,10/23/2013,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,409713
SODIUM,9NEZ333N27,Designated,Public record,3061,phenobarbitol sodium injection,10/23/2013,Treatment of hypoxic-ischemic encephalopathy to prevent siezures in neonates,Designated,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,11560,United States,408413
FUSIDATE SODIUM,J7P3696BCQ,Designated,Public record,3062,sodium fusidate,10/23/2013,Treatment of patients with prosthetic joint infections,Designated,Not FDA Approved for Orphan Indication,,,,,"Cempra Pharmaceuticals, Inc.",6340 Quadrangle Drive,Suite 100,Chapel Hill,North Carolina,27517,United States,400513
TIGECYCLINE,70JE2N95KR,Designated,Public record,3063,tigecycline,10/23/2013,Treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Trillium Therapeutics, Inc.",96 Skyway Avenue,,Toronto,,,Canada,406313
TROFINETIDE,Z2ME8F52QL,Designated,Public record,3064,Trofinetide,10/23/2013,Treatment of Fragile X Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,ACADIA Pharmaceuticals Inc.,3611 Valley Centre Drive,Suite 300,San Diego,California,92130,United States,409013
F-15599,83481Y1YCX,Designated,Public record,3065,3-chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone,10/25/2013,Treatment of Rett syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Neurolixis, Inc.",3210 Merryfield Row,,San Diego,California,92121,United States,410613
FLUBENDAZOLE,R8M46911LR,Designated/Withdrawn,Public record,3066,flubendazole,10/25/2013,Treatment of onchocerciasis caused by Onchocerca volvulus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,396713
EDOTREOTIDE GALLIUM GA-68,Y68179SY2L,Designated,Public record,3067,Gallium-68 (DOTA0-Phel-Tyr3)octreotide,10/25/2013,The management of neuroendocrine tumors,Designated/Approved,,Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.,8/21/2019,,Exclusivity waived by sponsor,University of Iowa Hospital & Clinics,Department of Radiology/PET Imaging Center,200 Hawkins Drive,Iowa City,Iowa,52242,United States,409513
ISAVUCONAZONIUM SULFATE,31Q44514JV,Designated/Approved,Public record,3068,isavuconazonium sulfate,10/25/2013,Treatment of zygomycosis,Designated/Approved,,Treatment of invasive mucormycosis in patients 18 years of age and older,3/6/2015,3/6/2022,Treatment of invasive mucormycosis in patients 18 years of age and older,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,60062,United States,395013
OLEYLPHOSPHOCHOLINE,Z46GXL23LX,Designated,Public record,3069,oleylphosphocholine,10/25/2013,Treatment of leishmaniasis,Designated,Not FDA Approved for Orphan Indication,,,,,Oblita Therapeutics bvba,Rogendijk 40,,Zoersel,,,Belgium,410313
TRASTUZUMAB EMTANSINE,SE2KH7T06F,Designated/Withdrawn,Public record,3073,trastuzumab emtansine,10/25/2013,For the treatment of gastric cancer including gastroesophageal junction cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.",1 DNA Way,,south San Francisco,California,94080,United States,412213
TREHALOSE,B8WCK70T7I,Designated,Public record,3074,trehalose,10/25/2013,Treatment of occulopharyngeal muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Seelos Therapeutics,300 Park Avenue,,New York,New York,10022,United States,410713
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,3075,TXA127,10/25/2013,Treament of acute radiation syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,93401,United States,411813
ELTROMBOPAG,S56D65XJ9G,Designated/Approved,Public record,3078,eltrombopag,11/8/2013,Treatment of aplastic anemia,Designated/Approved,,PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.,11/16/2018,11/16/2025,PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,410213
ELTROMBOPAG,S56D65XJ9G,Designated/Approved,Public record,3079,eltrombopag,11/8/2013,Treatment of aplastic anemia,Designated/Approved,,Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.,8/26/2014,8/26/2021,Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,410213
POLOXAMER 188,LQA7B6G8JG,Designated,Public record,3080,poloxamer 188,11/8/2013,Treatment of Acute Limb Ischemia,Designated,Not FDA Approved for Orphan Indication,,,,,Mast Therapeutics Inc.,3611 Valley Centre rive,Suite 500,San Diego,California,92130,United States,408113
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3081,cannabidiol,11/14/2013,Treatment of Dravet syndrome,Designated/Approved,,"treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.",7/31/2020,7/31/2027,treatment of seizures associated with Dravet syndrome (DS) in patients between 1 and 2 years of age,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,409313
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3082,cannabidiol,11/14/2013,Treatment of Dravet syndrome,Designated/Approved,,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.,9/28/2018,9/28/2025,EPIDIOLEX is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older.,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,409313
AVALGLUCOSIDASE ALFA,EO144CP0X9,Designated,Public record,3084,avalglucosidase alfa-ngpt,11/19/2013,Treatment of Pompe Disease,Designated/Approved,,Treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency),8/6/2021,,,"Genzyme Corporation, a Sanofi Company",50 Binney Street,,Cambridge,Massachusetts,2142,United States,411913
Binimetinib,181R97MR71,Designated,Public record,3085,binimetinib,11/19/2013,Treatment Stage IIB-IV melanoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc.",125 Cambridge Park Drive,Suite 301,Cambridge,Massachusetts,2140,United States,411513
ENCORAFENIB,8L7891MRB6,Designated,Public record,3086,encorafenib,11/19/2013,Treatment of Stage IIB-IV melanoma positive for BRAF mutation,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc.",125 Cambridge Park Drive,Suite 301,Cambridge,Massachusetts,2140,United States,411413
ENCORAFENIB,8L7891MRB6,Designated,Public record,3087,encorafenib + binimetinib,11/19/2013,Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.,Designated/Approved,,"BRAFTOVI¿ is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test",6/27/2018,6/27/2025,"BRAFTOVI¿ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","Array BioPharma, Inc.",100 Cambridgepark Drive,Suite 505,Cambridge,Massachusetts,2140,United States,411613
Binimetinib,181R97MR71,Designated,Public record,3087,encorafenib + binimetinib,11/19/2013,Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.,Designated/Approved,,"BRAFTOVI¿ is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test",6/27/2018,6/27/2025,"BRAFTOVI¿ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","Array BioPharma, Inc.",100 Cambridgepark Drive,Suite 505,Cambridge,Massachusetts,2140,United States,411613
ENCORAFENIB,8L7891MRB6,Designated,Public record,3088,encorafenib + binimetinib,11/19/2013,Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.,Designated/Approved,,"MEKTOVI® is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test",6/27/2018,6/27/2025,"BRAFTOVI¿ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","Array BioPharma, Inc.",100 Cambridgepark Drive,Suite 505,Cambridge,Massachusetts,2140,United States,411613
Binimetinib,181R97MR71,Designated,Public record,3088,encorafenib + binimetinib,11/19/2013,Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.,Designated/Approved,,"MEKTOVI® is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test",6/27/2018,6/27/2025,"BRAFTOVI¿ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","Array BioPharma, Inc.",100 Cambridgepark Drive,Suite 505,Cambridge,Massachusetts,2140,United States,411613
Haptoglobulin 1/1 (Plasma Derived),4AUM9TX5RP,Designated,Public record,3089,human haptoglobin,11/19/2013,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,BioProducts Laboratory Limited,"Dagger Lane, Elstree",,Herts,,,United Kingdom,359511
LONAFARNIB,IOW153004F,Designated,Public record,3090,lonafarnib,11/19/2013,Treatment of Hepatitis Delta Virus (HDV)infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Eiger Biopharmaceuticals, Inc.",PO Box 430,,San Carlos,California,94070,United States,411713
PIRFENIDONE,D7NLD2JX7U,Designated,Public record,3091,pirfenidone,11/19/2013,Treatment of systemic sclerosis (including the associated interstitial lung disease),Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,411113
EMRICASAN,P0GMS9N47Q,Designated,Public record,3092,emricasan,11/20/2013,Treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease,Designated,Not FDA Approved for Orphan Indication,,,,,Conatus Pharmaceuticals Inc.,16745 W. Bernardo Drive,Suite 200,San Diego,California,92127,United States,396113
FILGRASTIM,PVI5M0M1GW,Designated/Approved,Public record,3093,filgrastim,11/20/2013,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,3/30/2015,3/30/2022,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.",One Amgen Center Drive,M/S 17-1-C,Thousand Oaks,California,91320,United States,413113
LENADOGENE NOLPARVOVEC,X0R16875YD,Designated,Public record,3094,lenadogene nolparvovec,11/20/2013,Treatment of Leber Hereditary Optic Neuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,Gensight Biologics,74 Rue du Faubourg Saint Antoine,,Paris,,75012,France,412013
PEGFILGRASTIM,3A58010674,Designated/Approved,Public record,3095,Pegfilgrastim,11/20/2013,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome),11/13/2015,11/13/2022,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome),"Amgen, Inc.",One Amgen Center Drive,M/S 17-1-C,Thousand Oaks,California,91320,United States,413013
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,3096,Angiotensin (1-7),11/26/2013,Treatment of limb-girdle muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Constant Therapeutics LLC,"303 Congress St, c/o Casner & Edwards",,Boston,Massachusetts,2210,United States,412313
BENDAMUSTINE HYDROCHLORIDE,981Y8SX18M,Designated/Approved,Public record,3097,bendamustine hydrochloride,11/26/2013,"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively",Designated/Approved,,Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.,10/31/2008,10/31/2015,,"Cephalon, Inc.",A wholly owned subsidiary of Teva Pharmaceuticals,PO Box 4011,Frazer,Pennsylvania,19355,United States,253107
LANADELUMAB,2372V1TKXK,Designated/Approved,Public record,3099,lanadelumab-flyo,11/26/2013,Treatment of angioedema,Designated/Approved,,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older,2/3/2023,2/3/2030,prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients aged 2 years to less than 12 years,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,397213
LANADELUMAB,2372V1TKXK,Designated/Approved,Public record,3100,lanadelumab-flyo,11/26/2013,Treatment of angioedema,Designated/Approved,,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,8/23/2018,8/23/2025,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,397213
KX2-361 BESYLATE,A718CYC1N0,Designated,Public record,3101,N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate,11/26/2013,Treatment of gliomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Kinex Pharmaceuticals, Inc.",701 Ellicott Street,,Buffalo,New York,14203,United States,413513
Siponimod,RR6P8L282I,Designated,Public record,3102,Siponimod,11/26/2013,Treatment of polymyositis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,413413
VEMURAFENIB,207SMY3FQT,Designated,Public record,3103,vemurafenib,11/26/2013,Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,M/S 241B,South San Francisco,California,94080,United States,399213
SACITUZUMAB GOVITECAN,M9BYU8XDQ6,Designated,Public record,3104,sacituzumab govitecan,11/27/2013,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,415413
CANAKINUMAB,37CQ2C7X93,Designated/Approved,Public record,3105,canakinumab,12/5/2013,Treatment of familial mediterranean fever,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,412813
CANAKINUMAB,37CQ2C7X93,Designated/Approved,Public record,3106,canakinumab,12/5/2013,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,412913
SOTATERCEPT,0QI90BTJ37,Designated,Public record,3107,sotatercept,12/5/2013,Treatment of beta-thalassemia intermedia and major,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,413713
MARIZOMIB,703P9YDP7F,Designated,Public record,3108,marizomib,12/13/2013,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene International II S?,4 Rue des Moulins,,Couvet,Neuchâtel,,Switzerland,414313
JS-K,80P1Q21652,Designated,Public record,3109,"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate",12/13/2013,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"JSK Therapeutics, Inc.",85 Fort Douglas Boulevard,P.O. Box 58986,Salt Lake City,Utah,84158,United States,414013
NARSOPLIMAB,FT24ZQQ5RP,Designated,Public record,3110,Human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2 (MASP-2),12/16/2013,Prevention (inhibition) of complement-mediated thrombotic microangiopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Avenue West,,Seattle,Washington,98119,United States,397813
METADOXINE,EJQ7M98H5J,Designated,Public record,3111,metadoxine,12/16/2013,Treatment of Fragile X Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Alcobra, Inc.",2 Weizman Street,,Tel-Aviv,,,Israel,414513
ONARTUZUMAB,MS1J9720WC,Designated/Withdrawn,Public record,3112,onartuzumab (MetMab),12/16/2013,Treatment of hepatocellular carcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,417113
VINTAFOLIDE,36O410ZD4I,Designated,Public record,3113,vintafolide,12/16/2013,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Endocyte, Inc.",3000 Kent Avenue,Suite A1-100,West Lafayette,Indiana,47906,United States,415513
ERDOSTEINE,76J0853EKA,Designated,Public record,3115,erdosteine,12/20/2013,Treatment of bronchiectasis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Alitair Pharmaceuticals, Inc.",55 Madison Avenue,Suite 400,Morristown,New Jersey,7960,United States,417413
FENFLURAMINE HYDROCHLORIDE,3KC089243P,Designated,Public record,3116,fenfluramine HCI,12/20/2013,For the Treatment of Dravet Syndrome,Designated/Approved,,Fintepla (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.,6/25/2020,6/25/2027,For the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.,"Zogenix, Inc.",5959 Horton Street,Suite 500,Emeryville,California,94608,United States,414613
TACROLIMUS,WM0HAQ4WNM,Designated/Approved,Public record,3117,tacrolimus,12/20/2013,Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant,Designated/Approved,,Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants,7/10/2015,7/10/2022,Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants,"Veloxis Pharmaceuticals, Inc.",1001 Winstead Drive,Suite 310,Cary,North Carolina,27513,United States,407113
TACROLIMUS,WM0HAQ4WNM,Designated/Approved,Public record,3118,tacrolimus,12/20/2013,Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant,Designated/Approved,,ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.,12/19/2018,,,"Veloxis Pharmaceuticals, Inc.",1001 Winstead Drive,Suite 310,Cary,North Carolina,27513,United States,407113
ACID CERAMIDASE,QK6ZKF2EPJ,Designated,Public record,3119,recombinant human acid ceramidase,12/24/2013,Treatment of Farber disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Aceragen, Inc.",15 TW Alexander Drive,,Durham,North Carolina,27709,United States,415313
TOLCAPONE,CIF6334OLY,Designated,Public record,3120,Tolcapone,12/24/2013,Treatment of transthyretin amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Corino Therapeutics, Inc.",57 West 57th Street,18th Floor,New York,New York,10019,United States,413913
EDOTREOTIDE GALLIUM GA-68,Y68179SY2L,Designated/Approved,Public record,3121,"Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide",12/31/2013,Diagnostic for the clinical management of neuroendocrine tumors,Designated/Approved,,"For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.",6/1/2016,6/1/2023,A radioactive diagnostic agent indicated for use with with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.,"Advanced Accelerator Applications, USA",57 East Willow Street,,Millburn,New Jersey,7041,United States,413613
ACETYLCYSTEINAMIDE,4N69717RKW,Designated,Public record,3122,N-acetyl cysteine amide,12/31/2013,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Nacuity Pharmaceuticals, Inc.",Fort Worth Club Building,306 W 17th Street,Fort Worth,Texas,76106,United States,417513
NIFURTIMOX,M84I3K7C2O,Designated,Public record,3123,nifurtimox,12/31/2013,Treatment of Chagas disease,Designated,Not FDA Approved for Orphan Indication,,,,,"MetronomX Therapeutics, LLC",7000 Fannin Street,Suite 1960,Houston,Texas,77030,United States,419213
ACLERASTIDE,YYD6UT8T47,Designated,Public record,3124,NorLeu3-Angiontensin(1-7)) [NorLeu3-A(1-7)],12/31/2013,Treatment of leakage from the surgical site following penetrating keratoplasty,Designated,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,93401,United States,414813
GALLIUM OXODOTREOTIDE GA-68,9L17Y0H71P,Designated,Public record,3125,radiolabeled somastatin analog,12/31/2013,Diagnostic for the management of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"RadioMedix, Inc.",9701 Richmond Avenue,Suite 222,Houston,Texas,77042,United States,404813
THYMOSIN .BETA.-4,549LM7U24W,Designated,Public record,3126,thymosin beta 4,12/31/2013,Treatment of patients with neurotrophic keratopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"ReGenTree, LLC",116 Village Blvd,Suite 200,Princeton,New Jersey,8540,United States,416613
ECULIZUMAB,A3ULP0F556,Designated,Public record,3127,eculizumab,1/10/2014,Prevention of delayed graft function after renal transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,417213
EMICIZUMAB,7NL2E3F6K3,Designated/Approved,Public record,3128,emicizumab-kxwh,1/10/2014,Treatment of hemophilia A,Designated/Approved,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors,11/16/2017,11/16/2024,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors,Genentech,1 DNA Way,MS 355e,South San Francisco,California,94080,United States,416913
EMICIZUMAB,7NL2E3F6K3,Designated/Approved,Public record,3129,emicizumab-kxwh,1/10/2014,Treatment of hemophilia A,Designated/Approved,,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.,10/4/2018,10/4/2025,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.,Genentech,1 DNA Way,MS 355e,South San Francisco,California,94080,United States,416913
Amphotericin B,7XU7A7DROE,Designated,Public record,3130,enchochleate amphotericin B,1/10/2014,Treatment of visceral leishmaniasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Matinas BioPharma Nanotechnologies, Inc","1545 Route 206 South, Suite 302",,Bedminister,New Jersey,7921,United States,416113
NAXITAMAB,9K8GNJ2874,Designated,Public record,3132,monoclonal antibody Hu3F8,1/10/2014,Treatment of osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Y-mAbs Therapeutics A/S,Agern Allé 11,,Hørsholm,,2970,Denmark,416313
MONOETHANOLAMINE,5KV86114PT,Designated,Public record,3135,ethanolamine,1/17/2014,Prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding,Designated,Not FDA Approved for Orphan Indication,,,,,"QOL Medical, LLC","4445 North Highway A1A, 241",,Vero Beach,Florida,32963,United States,416713
PAQUINIMOD,HB76GLG27V,Designated,Public record,3136,paquinimod,1/17/2014,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Active Biotech AB,Scheelevagen 22,SE-220 07,LUND,,,Sweden,356911
AEOL-10150,KPKO7W46E8,Designated,Public record,3137,tetra substituted prophyrin derivative containing manganese (III),1/17/2014,For use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Aeolus Pharmaceuticals, Inc.",26361 Crown Valley Parkway,Suite 150,Mission Viejo,California,92691,United States,354611
FLUBENDAZOLE,R8M46911LR,Designated/Withdrawn,Public record,3138,flubendazole,1/23/2014,"Treatment of lymphatic filariasis caused by nematodes of the family Filariodidea, in children and adults.",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,399813
TISAGENLECLEUCEL,Q6C9WHR03O,Designated/Approved,Public record,3139,(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19,1/31/2014,For the treatment of Acute Lymphoblastic Leukemia,Designated/Approved,,Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse,8/30/2017,8/30/2024,Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse,Novartis Pharmaceuticals Corporation,"One Health Plaza,",Bldg 315 - Room 3650B,East Hanover,New Jersey,7936,United States,415113
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated,Public record,3140,brentuximab vedotin,1/31/2014,Treatment of patients with diffuse large B-cell lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,418713
COBIMETINIB,ER29L26N1X,Designated/Approved,Public record,3141,cobimetinib,1/31/2014,"Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation",Designated/Approved,,"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. Limitations of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.",11/10/2015,11/10/2022,"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma","Genentech, Inc.","1 DNA Way, MS 241A",,South San Francisco,California,94080,United States,419513
ACLERASTIDE,YYD6UT8T47,Designated,Public record,3142,NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)],1/31/2014,Treatment of dermal injury due to nuclear/radiation incident,Designated,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,93401,United States,414713
VATIQUINONE,6O85FK9I0X,Designated,Public record,3144,vatiquinone,1/31/2014,Treatment of Friedreich's ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,418413
ALDAFERMIN,IK9NYN31ZM,Designated,Public record,3146,Engineered variant of recombinant human fibroblast growth factor 19,2/6/2014,Treatment of primary biliary cirrhosis,Designated,Not FDA Approved for Orphan Indication,,,,,"NGM Biopharmaceuticals, Inc.",630 Gateway Blvd,,South San Francisco,California,94080,United States,415813
GEMCABENE,B96UX1DDKS,Designated,Public record,3147,gemcabene,2/6/2014,Treatment of homozygous familial hypercholesterolemia,Designated,Not FDA Approved for Orphan Indication,,,,,"NeuroBo Pharmaceuticals, Inc.",200 Berkeley Street,FL 19,Boston,Massachusetts,2116,United States,419313
P-2045 RE-188,2H4MY43GJD,Designated,Public record,3148,Re188 P2045 somatostatin analog,2/6/2014,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Andarix Pharmaceuticals,"141 Powderhouse Blvd, Suite 1",,Somerville,Massachusetts,2144,United States,403013
IR-401,VYD9GJM8HP,Designated,Public record,3149,"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine",2/6/2014,Treatment of Pediatric Multiple Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Immune Response BioPharma, Inc.",244 5th Avenue,Suite 1727,New York,New York,10001,United States,385412
IR-208,6532E45BS6,Designated,Public record,3149,"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine",2/6/2014,Treatment of Pediatric Multiple Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Immune Response BioPharma, Inc.",244 5th Avenue,Suite 1727,New York,New York,10001,United States,385412
IR-901,VS2A96444Q,Designated,Public record,3149,"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine",2/6/2014,Treatment of Pediatric Multiple Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Immune Response BioPharma, Inc.",244 5th Avenue,Suite 1727,New York,New York,10001,United States,385412
SPEBRUTINIB,DRU6NG543J,Designated/Withdrawn,Public record,3150,Bruton's tyrosine kinase inhibitor,2/10/2014,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,400 Connell Drive,Suite 700,Berkeley Heights,New Jersey,7922,United States,408313
SOTALOL HYDROCHLORIDE,HEC37C70XX,Designated,Public record,3151,sotalol hydrochloride,2/10/2014,Treatment of life-threatening ventricular arrhythmias in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Arbor Pharmaceuticals, LLC",980 Hammond Drive,"Bldg Two, Suite 1250",Atlanta,Georgia,30328,United States,397613
BISANTRENE HYDROCHLORIDE,74GNV897RO,Designated,Public record,3152,bisantrene HCl,2/14/2014,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Race Oncology, Ltd",50 Kings Park Road,Level 2,West Perth,WA,,Australia,419613
DOXOFYLLINE,MPM23GMO7Z,Designated,Public record,3154,doxofylline,2/14/2014,Treatment of bronchiectasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Alitair Pharmaceuticals, Inc.",55 Madison Avenue,Suite 400,Morristown,New Jersey,7960,United States,399413
PEXIDARTINIB HYDROCHLORIDE,YS6WAI3XN7,Designated,Public record,3155,pexidartinib,2/14/2014,Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath,Designated/Approved,,TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.,8/2/2019,8/2/2026,For the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,7920,United States,419913
ROSUVASTATIN,413KH5ZJ73,Designated/Approved,Public record,3158,rosuvastatin,2/14/2014,For the treatment of pediatric homozygous familial hypercholesterolemia,Designated/Approved,,"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).",5/27/2016,5/27/2023,"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).","iPR Pharmaceuticals, Inc.",1 MedImmune Way,,Gaithersburg,Maryland,20878,United States,420513
KRN-5500,8VH13L5K20,Designated/Withdrawn,Public record,3159,"(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)",2/21/2014,"Parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"DARA Therapeutics, Inc.",8601 Six Forks Road,Suite 160 (Forum 1),Raleigh,North Carolina,27615,United States,385312
GEVOKIZUMAB,QX3JU54GYQ,Designated,Public record,3160,gevokizumab,2/21/2014,Treatment of pyoderma gangrenosum,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC,2910 Seventh St.,,Berkeley,California,94710,United States,419113
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3162,cannabidiol,2/27/2014,Treatment of Lennox-Gastaut syndrome,Designated/Approved,,"treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of age and older.",7/31/2020,7/31/2027,treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients between 1 and 2 years of age,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,421213
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3163,cannabidiol,2/27/2014,Treatment of Lennox-Gastaut syndrome,Designated/Approved,,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.,9/28/2018,9/28/2025,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,421213
ALIRINETIDE,6BK9OEG8CC,Designated,Public record,3165,oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH),2/27/2014,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Genervon Biopharmaceuticals, LLC",1055 E. Colorado Blvd,Suite 500,Pasadena,California,91106,United States,424714
PRACINOSTAT,GPO2JN4UON,Designated,Public record,3166,pracinostat,2/27/2014,Treatment of acute myeloid leulemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Helsinn Healthcare SA,P.O. Box 357,,Pambio-Noranco,Lugano,6915,Switzerland,421313
FECAL MICROBIOTA,Q805XO2F7C,Designated,Public record,3167,"fecal microbiota, live - jslm",3/10/2014,Prevention of recurrent Clostridium difficile infection (CDI) in individuals with recurrent Clostridium difficile infection,Designated/Approved,,prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI,11/30/2022,11/30/2029,prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI,"Ferring Pharmaceuticals, Inc.",100 Interpace Parkway,,Parsippany,New Jersey,7054,United States,421013
TISAGENLECLEUCEL,Q6C9WHR03O,Designated,Public record,3169,Tisagenlecleucel,3/14/2014,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,"One Health Plaza,",Bldg 315 - Room 3650B,East Hanover,New Jersey,7936,United States,422013
SORBITOL,506T60A25R,Designated,Public record,3170,"(RS)-baclofen, naltrexone and D-sorbitol",3/17/2014,Treatment of Charcot-Marie-Tooth disease type 1A,Designated,Not FDA Approved for Orphan Indication,,,,,Pharnext SA,"11, rue des Peupliers",,Issey-les-Moulineaux,,,France,422914
NALTREXONE,5S6W795CQM,Designated,Public record,3170,"(RS)-baclofen, naltrexone and D-sorbitol",3/17/2014,Treatment of Charcot-Marie-Tooth disease type 1A,Designated,Not FDA Approved for Orphan Indication,,,,,Pharnext SA,"11, rue des Peupliers",,Issey-les-Moulineaux,,,France,422914
BACLOFEN,H789N3FKE8,Designated,Public record,3170,"(RS)-baclofen, naltrexone and D-sorbitol",3/17/2014,Treatment of Charcot-Marie-Tooth disease type 1A,Designated,Not FDA Approved for Orphan Indication,,,,,Pharnext SA,"11, rue des Peupliers",,Issey-les-Moulineaux,,,France,422914
LENVATINIB,EE083865G2,Designated,Public record,3173,lenvatinib,3/26/2014,Treatment of stage IIB to Stage IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",200 Metro Blvd.,,Nutley,New Jersey,,United States,423614
VENETOCLAX,N54AIC43PW,Designated,Public record,3174,"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",3/27/2014,Treatment of diffuse large B-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie,Research and Development,1 North Waukegan Road,North Chicago,Illinois,60064,United States,423814
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated/Approved,Public record,3175,axicabtagene ciloleucel,3/27/2014,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cel",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lin","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,90404,United States,423914
GEFITINIB,S65743JHBS,Designated/Approved,Public record,3176,gefitinib,8/26/2014,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test,7/13/2015,7/13/2022,For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,443014
ZINPENTRAXIN ALFA,F68WAH6N5E,Designated,Public record,3177,recombinant human Pentraxin-2,8/26/2014,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS 241B,South San Francisco,California,94080,United States,416013
VEMURAFENIB,207SMY3FQT,Designated,Public record,3178,vemurafenib,8/26/2014,Treatment of hairy cell leukemia (HCL).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,M/S 241B,South San Francisco,California,94080,United States,444114
VENGLUSTAT,BLP1XA3FZA,Designated,Public record,3179,Venglustat,8/26/2014,Treatment of Fabry's disease,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,1242,United States,439814
SPANLECORTEMLOCEL,D8O38M043D,Designated,Public record,3180,Spanlecortemlocel,8/27/2014,Hematopoietic support in patients with acute lymphoblastic leukemia (ALL),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,443514
RALINEPAG,CQY12ZJN6E,Designated,Public record,3181,"2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid",8/28/2014,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,United Therapeutics Corporation,55 T.W. Alexander Drive,P.O. Box 14186,Research Triangle Park,North Carolina,27708,United States,440214
METHOTREXATE,YL5FZ2Y5U1,Designated,Public record,3182,Methotrexate,8/28/2014,Treatment of Myasthenia Gravis,Designated,Not FDA Approved for Orphan Indication,,,,,The Universtiy of Kanasa Medical Center,3901 Rainbow Blvd,MSN 2012,Kanasa City,Kansas,66160,United States,440314
MEBENDAZOLE,81G6I5V05I,Designated/Approved,Public record,3183,mebendazole,9/3/2014,"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm).",Designated/Approved,,treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm),10/19/2016,,,"Janssen Pharmaceutical Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,397013
PBT-1033 HYDROCHLORIDE,24Z79C941B,Designated,Public record,3184,"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride",9/4/2014,Treatment of Huntington's disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Prana Biotechnology Limited,"Level 2, 369 Royal Parade",,Parkville,Victoria,,Australia,353711
PF-04447943,7N969W8Y4O,Designated,Public record,3185,"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one",9/4/2014,Treatment of sickle cell disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cardurion Pharmaceuticals, Inc.","78 Blanchard Road, Suite 200",,Burlington,Massachusetts,1803,United States,440514
OSIMERTINIB,3C06JJ0Z2O,Designated/Approved,Public record,3189,osimertinib,9/4/2014,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,"adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",12/18/2020,12/18/2027,"adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,19803,United States,445214
OSIMERTINIB,3C06JJ0Z2O,Designated/Approved,Public record,3190,osimertinib,9/4/2014,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy",11/13/2015,11/13/2022,"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy",AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,19803,United States,445214
OSIMERTINIB,3C06JJ0Z2O,Designated/Approved,Public record,3191,osimertinib,9/4/2014,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,"TAGRISSO® is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",4/18/2018,4/18/2025,"TAGRISSO® is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,19803,United States,445214
IBRUTINIB,1X70OSD4VX,Designated,Public record,3192,ibrutinib,9/8/2014,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,94085,United States,444414
MITOMYCIN,50SG953SK6,Designated,Public record,3193,mitomycin,9/8/2014,Treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter),Designated/Approved,,JELMYTO¿ is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC),4/15/2020,4/15/2027,Indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).,"UroGen Pharma, Ltd.","9 Ha'Ta'asiya St., POB 2397",,Ra'anana,,,Israel,445114
VEMURAFENIB,207SMY3FQT,Designated,Public record,3194,vemurafenib,9/8/2014,Treatment of patients with non-small cell lung cancer (NSCLC) with BRAF V600 mutation,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,444314
SARUPLASE,U5NH2JV64T,Designated,Public record,3195,single chain urokinase plasminogen activator,9/11/2014,Treatment of empyema (pleural),Designated,Not FDA Approved for Orphan Indication,,,,,"Lung Therapeutics, Inc.",P. O. Box 150183,,Austin,Texas,78715,United States,442514
CYSTEAMINE,5UX2SD1KE2,Designated,Public record,3196,Cysteamine,9/11/2014,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,NovaBiotics Ltd.,Cruickshank Building,,Craibstone,Aberdeen,,United Kingdom,368712
SILIBININ DIHEMISUCCINATE DISODIUM,57LSQ377IE,Designated,Public record,3198,"silibinin-C-2',3-dihydrogensuccinate, disodium salt",9/11/2014,"Treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure",Designated,Not FDA Approved for Orphan Indication,,,,,Mylan Specialty LP,781 Chestnut Ridge Road,P. O. Box 4310,Morgantown,West Virginia,26504,United States,444214
VENGLUSTAT,BLP1XA3FZA,Designated,Public record,3199,venglustat,9/11/2014,Treatment of Gaucher disease,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme,500 Kendall Street,,Cambridge,Massachusetts,2142,United States,443414
TECHNETIUM TC-99M TILMANOCEPT,8IHI69PQTC,Designated/Approved,Public record,3200,technetium Tc 99m tilmanocept,9/17/2014,"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck",Designated/Approved,,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.",6/13/2014,6/13/2021,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.","Cardinal Health 414, LLC",7200 Cardinal Pl,,Dublin,Ohio,43017,United States,427814
RODUCITABINE,0Z4A82I0JO,Designated,Public record,3201,"4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one",9/23/2014,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Processa Pharmaceuticals, Inc.","7380 Coca Cola Drive, Suite 106",,Hanover,Maryland,21076,United States,447314
IMM-101,IZT740JY57,Designated,Public record,3202,heat killed whole cell mycobacterium obuense,9/23/2014,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Immodulon Therapeutics Limited,22 Devonshire Place,"B2,",London,,,United Kingdom,446114
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,3204,nitric oxide,9/23/2014,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Inhalation Therapies, Ltd.",2 Ilan Ramon Street,,Ness Ziyona,,,Israel,443914
ALDOXORUBICIN,C28MV4IM0B,Designated,Public record,3205,aldoxorubicin,9/24/2014,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,90232,United States,446814
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated/Approved,Public record,3206,axicabtagene ciloleucel,3/27/2014,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular l","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,90404,United States,423914
ASPARAGINASE,G4FQ3CKY5R,Designated,Public record,3207,L-asparaginase,3/27/2014,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,ERYTECH Pharma S.A.,Batiment Adenine,"60, avenue Rockefeller",Lyon,,,France,424114
LAROMUSTINE,14J2G0U3NQ,Designated,Public record,3208,Laromustine,3/27/2014,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,NanoSHIFT LLC,10454 Northwest 132nd Drive,,Alachua,Florida,32615,United States,424014
LENVATINIB,EE083865G2,Designated,Public record,3209,lenvatinib,3/27/2014,Treatment of hepatocellular carcinoma,Designated/Approved,,LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC),8/15/2018,8/15/2025,LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC),Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,,United States,423714
ISOTRETINOIN,EH28UP18IF,Designated,Public record,3210,isotretinoin,4/10/2014,Treatment of congenital ichthyosis,Designated,Not FDA Approved for Orphan Indication,,,,,Timber Pharmaceuticals,50 Tice Blvd,Suite A35,Woodcliff Lake,New Jersey,7677,United States,424614
ROPEGINTERFERON ALFA-2B,981TME683S,Designated,Public record,3211,pegylated proline interferon alpha-2b,4/10/2014,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,PharmaEssentia,"13F, No 3, YuanQu Street",,Taipei,,,Taiwan,424414
MOTOLIMOD,WP6PY72ZH3,Designated/Withdrawn,Public record,3212,"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide",4/10/2014,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,425014
"""ANTHRAX VACCINE, ADSORBED""",,Designated/Approved,Public record,3213,Anthrax Vaccine Adsorbed,4/11/2014,For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure,Designated/Approved,,"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",11/23/2015,11/23/2022,"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",Emergent BioDefense Operations Lansing LLC,300 Proessional Drive,,Gaithersburg,Maryland,20879,United States,424914
CARBETOCIN,88TWF8015Y,Designated,Public record,3214,carbetocin (nasal spray),4/11/2014,Treatment of Prader Willi syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Acadia Pharmaceuticals Inc.,"12830 El Camino Real, Suite 400",,San Diego,Illinois,92310,United States,423014
NERINETIDE,D45TI2TWMA,Designated,Public record,3215,H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH,4/11/2014,Treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset,Designated,Not FDA Approved for Orphan Indication,,,,,"NoNO, Inc.",399 Bathurst Street,Suite 4W-435,Toronto,,,Canada,412713
ROPEGINTERFERON ALFA-2B,981TME683S,Designated,Public record,3216,pegylated proline interferon alpha-2b,4/11/2014,Treatment of essential thrombocythemia,Designated,Not FDA Approved for Orphan Indication,,,,,PharmaEssentia,"13F, No 3, YuanQu Street",,Taipei,,,Taiwan,424514
BENZNIDAZOLE,YC42NRJ1ZD,Designated/Approved,Public record,3217,benznidazole,4/14/2014,Treatment of Chagas disease,Designated/Approved,,"Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.",8/29/2017,8/29/2024,"Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.","Chemo Research, S.L.",Edificio Nectar,"c/Quintanapalla, 2, 3 planta",Madrid,,,Spain,425214
ENTOSPLETINIB DIMESYLATE,4N0Q3I064C,Designated,Public record,3218,entospletinib,4/14/2014,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Kronos Bio, Inc.","1300 S. El Camino Real, Suite 400",,San Mateo,California,94402,United States,426714
NALTREXONE,5S6W795CQM,Designated,Public record,3219,naltrexone/clonidine combination,4/14/2014,Treatment of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,Allodynic Therapeutics LLC,1785 NE 123rd Street,,North Miami,Florida,33181,United States,425614
CLONIDINE,MN3L5RMN02,Designated,Public record,3219,naltrexone/clonidine combination,4/14/2014,Treatment of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,Allodynic Therapeutics LLC,1785 NE 123rd Street,,North Miami,Florida,33181,United States,425614
VOLASERTIB,6EM57086EA,Designated,Public record,3220,volasertib,4/14/2014,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,415913
CIPROFLOXACIN,5E8K9I0O4U,Designated,Public record,3221,ciprofloxacin dry powder inhaler,4/17/2014,Treatment of non-cystic fibrosis bronchiectasis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",P. O. Box 1000,,Montville,New Jersey,7045,United States,422314
TERIPARATIDE,10T9CSU89I,Designated,Public record,3222,teriparatide,4/18/2014,Treatment of hypoparathyroidism,Designated,Not FDA Approved for Orphan Indication,,,,,"Entera Bio, Ltd.","Kiryat Hadassah Minrav Bldg, 5th Floor",P. O. Box 12117,Jeusalem,,,Israel,425814
BREXANOLONE,S39XZ5QV8Y,Designated,Public record,3223,allopregnanolone,4/20/2014,Treatment of status epilepticus,Designated,Not FDA Approved for Orphan Indication,,,,,Sage Therapeutics,215 First Street,Suite 220,Cambridge,Massachusetts,2142,United States,426114
PEGCETACOPLAN,TO3JYR3BOU,Designated/Approved,Public record,3224,pegcetacoplan,4/20/2014,Treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH),5/14/2021,5/14/2028,Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH),"Apellis Pharmaceuticals, Inc.",100 Fifth Avenue,,Waltham,Massachusetts,2451,United States,427614
ALVOCIDIB,45AD6X575G,Designated,Public record,3225,alvocidib,4/21/2014,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Dainippon Pharma Oncology, Inc.",640 Memorial Drive,,Cambridge,Massachusetts,2139,United States,426214
TEZACAFTOR,8RW88Y506K,Designated,Public record,3226,Tezacaftor,4/24/2014,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,427414
SOTATERCEPT,0QI90BTJ37,Designated,Public record,3227,sotatercept,4/28/2014,Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,428614
Omidubicel,ET4JC4S66E,Designated,Public record,3228,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,4/28/2014,For the treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd,PO Box 34670,,Jerusalem,,,Israel,426814
BROMOPYRUVATE,63JMV04GRK,Designated,Public record,3229,3-bromopyruvate,4/29/2014,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"PreScience Labs, LLC",9500 Reach Road,,Potomac,Maryland,20854,United States,430514
TAFASITAMAB,QQA9MLH692,Designated,Public record,3231,humanized Fc engineered monoclonal antibody against CD19,4/29/2014,Treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,MorphoSys AG,Semmelweisstrasse 7,82152 Planegg,Planegg,,,Germany,427914
REBISUFLIGENE ETISPARVOVEC,V28L3Q0LVZ,Designated,Public record,3232,recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase,4/29/2014,Treatment of mucopolysaccharidosis type III-A (Sanfilippo Syndrome Type A),Designated,Not FDA Approved for Orphan Indication,,,,,Ultragenyx Pharmaceutical Inc.,60 Leveroni Court,,Novato,California,94949,United States,433714
VLX-1570,K6067N5M6N,Designated,Public record,3233,"(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne",4/30/2014,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,VivoLux AB,Uppsala Science Park,SE-751 83,Uppsala,,,Sweden,428714
IOPOFOSINE I-124,08W354EC17,Designated,Public record,3234,18-(p-[124I]-iodophenyl)octadecyl phosphocholine,4/30/2014,Diagnostic for the management of glioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,53716,United States,429514
DEMCIZUMAB,SF168W7FW0,Designated/Withdrawn,Public record,3235,demcizumab,4/30/2014,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.",800 Chesapeake Drive,,Redwood City,California,94063,United States,427314
IPATASERTIB,524Y3IB4HQ,Designated/Withdrawn,Public record,3237,Ipatasertib,4/30/2014,For the treatment of gastric cancer including cancer of the gastro-esophageal junction.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,429714
MOXIFLOXACIN HYDROCHLORIDE,C53598599T,Designated/Withdrawn,Public record,3238,moxifloxacin hydrochloride,4/30/2014,Treatment of tuberculosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Whippany,New Jersey,7981,United States,428014
FILANESIB,8A49OSO368,Designated,Public record,3242,filanesib,5/6/2014,Treatment of multiple myeloma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma, Inc.",3200 Walnut Street,,Boulder,Colorado,80301,United States,431114
IMATINIB MESYLATE,8A1O1M485B,Designated,Public record,3243,imatinib mesylate,5/6/2014,Treatment of progressive multifocal leukencephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Inhibikase Therapeutics, Inc.",3350 Riverwood Parkway,,Atlanta,Georgia,30339,United States,428914
ADALIMUMAB,FYS6T7F842,Designated/Approved,Public record,3245,adalimumab,5/13/2014,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",9/28/2018,9/28/2025,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,318510
ADALIMUMAB,FYS6T7F842,Designated/Approved,Public record,3246,adalimumab,5/13/2014,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",6/30/2016,6/30/2023,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,318510
DIAZOXIDE CHOLINE,2U8NRZ7P8L,Designated,Public record,3247,diazoxide choline,5/13/2014,Treatment of Prader-Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Soleno Therapeutics, Inc.",1235 Radio Road,Suite 110,Redwood City,California,94065,United States,428214
PEMZIVIPTADIL,200AW54D93,Designated,Public record,3248,vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein,5/13/2014,"Treatment of pulmonary arterial hypertension, WHO Group 1",Designated,Not FDA Approved for Orphan Indication,,,,,ImmunoForge Co. Ltd.,"#1704, Ace Hansol Tower, 58, Gasan Digital 1-ro",Geumcheon-gu,Seoul,,,South Korea,397513
TETULOMAB TETRAXETAN LU-177,CPW7BR9UY7,Designated,Public record,3249,177Lu-tetraxetan-tetulomab,5/14/2014,Treatment of Follicular Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Nordic Nanovector AS,Anniken Hagen,"Kjelsasveien 168B, NO-0884",Oslo,,,Norway,433014
AFAMELANOTIDE,QW68W3J66U,Designated,Public record,3250,afamelanotide,5/14/2014,Treatment of familial benign chronic pemphigus (Hailey-Hailey disease),Designated,Not FDA Approved for Orphan Indication,,,,,"Clinuvel, Inc.",40 Worth Street,10th Floor - Suite 1053,New York,New York,10013,United States,430014
INECALCITOL,05FZV98342,Designated,Public record,3251,Inecalcitol,5/14/2014,Treatment of chronic lymphocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Hybrigenics, S.A.",3-5 Impasse Reille,75014,Paris,,,France,432914
MENADIONE SODIUM BISULFITE,6XF3C2HK77,Designated,Public record,3252,Menadione Sodium Bisulfite,5/14/2014,For the treatment of autosomal dominant polycystic kidney disease,Designated,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,92021,United States,429014
MENADIONE SODIUM BISULFITE,6XF3C2HK77,Designated,Public record,3253,menadione sodium bisulfite,5/14/2014,Treatment of autosomal dominant polycystic liver disease,Designated,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,92021,United States,430114
EMACTUZUMAB,6FY6EI1X8R,Designated/Withdrawn,Public record,3254,recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages,5/14/2014,Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,431614
SELINEXOR,31TZ62FO8F,Designated,Public record,3255,selinexor,5/14/2014,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.",85 Wells Avenue,,Newton,Massachusetts,2459,United States,432414
SELINEXOR,31TZ62FO8F,Designated,Public record,3256,selinexor,5/14/2014,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.",6/22/2020,6/22/2027,"For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy","Karyopharm Therapeutics, Inc.",2 Mercer Road,,Natick,Massachusetts,1760,United States,436414
PACLITAXEL TREVATIDE,8P77G99D3P,Designated,Public record,3258,[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr,5/14/2014,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"Angiochem, Inc.",201 President-Kennedy Avenue,,Montreal,,,Canada,432514
IDASANUTLIN,QSQ883V35U,Designated,Public record,3259,"4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid",5/19/2014,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, A member of the Roche Group",F. Hoffmann-La Roche Ltd.,430 East 29th Street,New York,New York,10016,United States,429614
OCU-100,I460W8FA7S,Designated,Public record,3260,recombinant lens epithelium derived growth factor 1-326,5/19/2014,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Ocugen, Inc.",5 Great Valley Parkway,Suite 160,Malvern,Pennsylvania,19355,United States,432314
DOCONEXENT,ZAD9OKH9JC,Designated,Public record,3261,"all-cis-docosa-4,7,10,13,16,19-hexaenoic acid",5/21/2014,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Natac Pharma, S.L.",C/ Faraday 7,28049,Madrid,,,Spain,432814
ISATUXIMAB,R30772KCU0,Designated,Public record,3263,isatuximab-irfc,5/22/2014,Treatment of multiple myeloma,Designated/Approved,,"in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy",3/31/2021,3/31/2028,"treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 prior line of therapy, and for treatment of adult patients with relapsed or refractory multiple myeloma who have received 2 to 3 prior therapies excluding patient","Sanofi U.S. Services, Inc.",50 Binney St.,,Cambridge,Massachusetts,2142,United States,431914
ISATUXIMAB,R30772KCU0,Designated,Public record,3264,isatuximab-irfc,5/22/2014,Treatment of multiple myeloma,Designated/Approved,,"SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.",3/2/2020,3/2/2027,"Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.","Sanofi U.S. Services, Inc.",50 Binney St.,,Cambridge,Massachusetts,2142,United States,431914
MICONAZOLE,7NNO0D7S5M,Designated,Public record,3265,miconazole,5/22/2014,Treatment of fungal otitis externa (otomycosis),Designated,Not FDA Approved for Orphan Indication,,,,,"Hill Dermaceuticals, Inc.",2650 S. Mellonville Ave.,,Sanford,Florida,32773,United States,406413
SPIRONOLACTONE,27O7W4T232,Designated,Public record,3266,spironolactone,5/22/2014,Use in pediatric patients with primary hyperaldosteronism,Designated,Not FDA Approved for Orphan Indication,,,,,"CMP Pharma, Inc.",PO Box 147,8026 US Highway 264A,Farmville,North Carolina,27828,United States,430614
EMPRUMAPIMOD,4JG61K4659,Designated,Public record,3267,p38 mitogen-activated kinase inhibitor,5/27/2014,"Treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin A/C gene mutations",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma, Inc.",3200 Walnut Street,,Boulder,Colorado,80301,United States,431714
DEPATUXIZUMAB MAFODOTIN,F3R7A4P04N,Designated,Public record,3269,Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F,5/29/2014,Treatment of glioblastoma multiforme,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,60064,United States,433214
METFORMIN,9100L32L2N,Designated,Public record,3270,metformin,5/29/2014,Treatment of pediatric polycystic ovary syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,EffRx Pharmaceuticals SA,Wolleraustrass 41 B,,8807 Freienbach (SZ),,,Switzerland,432214
SACITUZUMAB GOVITECAN,M9BYU8XDQ6,Designated,Public record,3271,sacituzumab govitecan,5/29/2014,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,433514
VON WILLEBRAND FACTOR HUMAN,ZE22NE22F1,Designated,Public record,3272,von Willebrand Factor Human Concentrate,5/29/2014,Treatment of Von Willebrand Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"LFB USA, Inc.",175 Crossing Blvd,,Framingham,Massachusetts,1702,United States,424814
MARDEPODECT SUCCINATE,TJ5KAZ8T5G,Designated,Public record,3273,2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid,6/2/2014,Treatment of Huntington's disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,445 Eastern Point Road,,Groton,Connecticut,6340,United States,429914
AVACOPAN,O880NM097T,Designated,Public record,3274,avacopan,6/2/2014,"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome).",Designated/Approved,,As an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy includin,10/7/2021,10/7/2028,As an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]),"ChemoCentryx, Inc.","835 Industrial Road, Suite 600",,San Carlos,California,94070,United States,432014
ECHOTHIOPHATE IODIDE,BA9QH3P00T,Designated,Public record,3275,echothiophate iodide,6/2/2014,Treatment of Stargardt's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Makindus, Inc.",3805 Old Easton Road,,Doylestown,Pennsylvania,18902,United States,430914
EVEROLIMUS,9HW64Q8G6G,Designated,Public record,3276,everolimus,6/2/2014,Treatment of diffuse large B-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,431214
AFATINIB,41UD74L59M,Designated,Public record,3277,afatinib,6/4/2014,Treatment of malignant brain and central nervous system tumors,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,433414
VATIQUINONE,6O85FK9I0X,Designated,Public record,3278,vatiquinone,6/4/2014,Treatment of Leigh Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,435014
TRIFAROTENE,0J8RN2W0HK,Designated,Public record,3279,trifarotene,6/6/2014,Treatment of congenital ichthyosis,Designated,Not FDA Approved for Orphan Indication,,,,,Mayne Pharma LLC.,1240 Sugg Parkway,,Greenville,North Carolina,27834,United States,431014
KRN-5500,8VH13L5K20,Designated/Withdrawn,Public record,3281,"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine",6/12/2014,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"DARA Therapeutics, Inc.",8601 Six Forks Road,Suite 160 (Forum 1),Raleigh,North Carolina,27615,United States,434414
ECULIZUMAB,A3ULP0F556,Designated/Approved,Public record,3282,eculizumab,6/12/2014,Treatment of Myasthenia Gravis,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,10/23/2017,10/23/2024,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,434214
ENASIDENIB,3T1SS4E7AG,Designated/Approved,Public record,3283,enasidenib,6/12/2014,Treatment of acute myelogenous leukemia,Designated/Approved,,Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test,8/1/2017,8/1/2024,Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test,Celgene Corporation,9225 Indian Creek Parkway,Suite 900,Overland Park,Kansas,66210,United States,434514
MOCETINOSTAT,A6GWB8T96J,Designated,Public record,3285,Mocetinostat,6/12/2014,Treatment of myelodysplastic syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",9363 Towne Center Drive,Suite 200,San Diego,California,92121,United States,435414
ECULIZUMAB,A3ULP0F556,Designated/Approved,Public record,3286,ravulizumab-cwvz,6/12/2014,Treatment of myasthenia gravis,Designated/Approved,,Treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive,4/27/2022,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,434214
COTI-2,2BTA1O65BR,Designated,Public record,3287,small molecule normalizing the p53 function,6/12/2014,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Critical Outcome Technologies, Inc.",700 Collip Circle,Suite 213,London,,,Canada,434314
CARGLUMIC ACID,5L0HB4V1EW,Designated,Public record,3288,carglumic acid,6/17/2014,Treatment of organic acidemias,Designated/Approved,,in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA),1/22/2021,1/22/2028,in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA),Recordati Rare Diseases,Immeuble Le Wilson,70 avenue du General de Gaulle,Puteaux,,,France,352111
BI-836858,JA7I0QFJ17,Designated,Public record,3289,human fully IgG1 antibody specific for CD33,6/19/2014,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,435614
P-2045 RE-188,2H4MY43GJD,Designated,Public record,3290,Re188 P2045 somatostatin peptide analogue,6/19/2014,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Andarix Pharmaceuticals, Inc.",141 Powderhouse Blvd,Suite 1,Somerville,Massachusetts,2144,United States,434914
TPI-287,A2VM2V569A,Designated,Public record,3291,"(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1""S)-7,9-acrolein acetal-11(15-1)-abeotaxane",6/23/2014,Treatment of progressive supranuclear palsy,Designated,Not FDA Approved for Orphan Indication,,,,,"Cortice Biosciences, Inc.",1345 Avenue of the Americas,42nd Floor,New York,New York,10105,United States,436014
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3292,cannabidiol,6/23/2014,Treatment of Lennox-Gastaut syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.",1333 S. Spectrum Blvd,Suite 100,Chandler,Alaska,85286,United States,438214
ZELPULTIDE ALFA,96HS6QEW3X,Designated,Public record,3294,recombinant human surfactant protein D,6/23/2014,Prevention of bronchopulmonary dysplasia,Designated,Not FDA Approved for Orphan Indication,,,,,Airway Therapeutics LLC,11804 Conrey Road,Suite 175,Cincinnati,Ohio,45249,United States,347011
CLOFAZIMINE,D959AE5USF,Designated,Public record,3295,clofazimine,6/25/2014,Treatment of active tuberculosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,436314
SIROLIMUS,W36ZG6FT64,Designated,Public record,3296,sirolimus,6/25/2014,Treatment of lymphangioleiomyomatosis,Designated,Not FDA Approved for Orphan Indication,,,,,"LAM Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,6437,United States,434114
LUMACAFTOR,EGP8L81APK,Designated/Approved,Public record,3297,lumacaftor and ivacaftor,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene,9/2/2022,9/2/2029,Treatment of cystic fibrosis (CF) in patients aged 1 year to less than 2 years who are homozygous for the F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,434814
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,3297,lumacaftor and ivacaftor,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene,9/2/2022,9/2/2029,Treatment of cystic fibrosis (CF) in patients aged 1 year to less than 2 years who are homozygous for the F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,434814
LUMACAFTOR,EGP8L81APK,Designated/Approved,Public record,3298,lumacaftor/ivacaftor,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene.,8/7/2018,8/7/2025,ORKAMBI (lumacaftor/ivacaftor) oral granules indicated for the treatment of cystic fibrosis (CF) in patients age 2 through 5 years old who are homozygous for the F508del mutation in the CFTR gene.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,434814
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,3298,lumacaftor/ivacaftor,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene.,8/7/2018,8/7/2025,ORKAMBI (lumacaftor/ivacaftor) oral granules indicated for the treatment of cystic fibrosis (CF) in patients age 2 through 5 years old who are homozygous for the F508del mutation in the CFTR gene.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,434814
LUMACAFTOR,EGP8L81APK,Designated/Approved,Public record,3299,lumacaftor/ivacaftor,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene,7/2/2015,7/2/2022,Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,434814
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,3299,lumacaftor/ivacaftor,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene,7/2/2015,7/2/2022,Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,434814
LUMACAFTOR,EGP8L81APK,Designated/Approved,Public record,3300,lumacaftor/ivacaftor,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene,9/28/2016,9/28/2023,Treatment of cystic fibrosis (CF) in patients age 6-11 years old who are homozygous for the F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,434814
IVACAFTOR,1Y740ILL1Z,Designated/Approved,Public record,3300,lumacaftor/ivacaftor,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene,9/28/2016,9/28/2023,Treatment of cystic fibrosis (CF) in patients age 6-11 years old who are homozygous for the F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,434814
TOCILIZUMAB,I031V2H011,Designated,Public record,3302,satralizumab-mwge,6/30/2014,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,Designated/Approved,,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,8/14/2020,8/14/2027,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Genentech, Inc.",1 DNA WAY,,SOUTH SAN FRANCISCO,California,94080,United States,436114
ENMD-2076,KXQ762CQTH,Designated,Public record,3303,2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,7/1/2014,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"CASI Pharmaceuticals, Inc.",9620 Medical Center Drive,Suite 300,Rockville,Maryland,20850,United States,437214
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3304,cannabidiol,7/1/2014,Treatment of Dravet syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.",1333 S. Spectrum Blvd,Suite 100,Chandler,Alaska,85286,United States,439414
BENDAMUSTINE,9266D9P3PQ,Designated/Approved,Public record,3305,bendamustine for 50 ml admixture,7/2/2014,Treatment of chronic lymphocytic leukemia,Designated/Approved,,Treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.,12/7/2015,12/7/2022,Treatment of patients with CLL,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,7677,United States,431814
BENDAMUSTINE,9266D9P3PQ,Designated/Approved,Public record,3306,bendamustine for 50ml admixture,7/2/2014,"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively",Designated/Approved,,Treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.,12/7/2015,12/7/2022,Treatment of patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,7677,United States,430314
CARBENOXOLONE,MM6384NG73,Designated,Public record,3307,carbenoxolone,7/2/2014,Treatment of Huntington's Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Oxalys Pharmaceuticals, Inc.",4 Mollard Road,,Toronto,,,Canada,429414
ADALIMUMAB,FYS6T7F842,Designated,Public record,3308,adalimumab,7/10/2014,Treatment of Behcet's disease,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora,32b Eisenberg St,,Rehovot 7628810,,,Israel,436714
Siponimod,RR6P8L282I,Designated,Public record,3309,siponimod,7/10/2014,Treatment of dermatomyositis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,437614
Mirvetuximab Soravtansine,98DE7VN88D,Designated,Public record,3310,mirvetuximab soravtansine-gynx,7/14/2014,Treatment of ovarian cancer,Designated/Approved,,"treatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based",11/14/2022,11/14/2029,"treatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian cancer, as detected by an FDA-approved test, who have received one to three prior systemic treatment regimens","ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,2451,United States,435214
OXFENDAZOLE,OMP2H17F9E,Designated,Public record,3311,oxfendazole,7/14/2014,Treatment of cysticercosis (including neurocysticercosis),Designated,Not FDA Approved for Orphan Indication,,,,,"Robert H. Gilman, MD, DTMH and",Johns Hopkins School of Public Health,"615 N. Wolfe St, Room W5515",Baltimore,Maryland,21205,United States,435514
PACLITAXEL,P88XT4IS4D,Designated,Public record,3312,paclitaxel-coated buttress,7/15/2014,For use as local administration at the time of curative surgery in the treatment of stage 0 to III non-small cell lung cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Cook Biotech Incorporated,1425 Innovation Place,,West Lafayette,Indiana,47906,United States,394813
BIRABRESIB DIHYDRATE,4Q356KA5V2,Designated,Public record,3313,"2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate",7/16/2014,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,OncoEthix GmbH (Merck Subsidiary),Weystrasse 20,,Lucerne,,,Switzerland,433914
INDUSATUMAB VEDOTIN,3F0FR4W3H8,Designated/Withdrawn,Public record,3315,antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E,7/21/2014,Treatment of gastric cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,437914
PALOVAROTENE,28K6I5M16G,Designated,Public record,3316,palovarotene,7/21/2014,Treatment of fibrodysplasia ossificans progressiva,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.","One Main Street, 7th Floor",,Cambridge,Massachusetts,2142,United States,438714
PEGARGIMINASE,0B7PYQ9YRT,Designated,Public record,3317,pegargiminase,7/21/2014,Treatment of mesothelioma.,Designated,Not FDA Approved for Orphan Indication,,,,,Polaris Group,"Polaris Pharmaceuticals, Inc.","9373 Town Centre Dr., Suite 150",San Diego,California,92121,United States,437014
RIOCIGUAT,RU3FE2Y4XI,Designated,Public record,3319,riociguat,7/24/2014,Treatment of systemic sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd,P. O. Box 915,Whippany,New Jersey,7981,United States,439514
LIFASTUZUMAB VEDOTIN,7IUT83FK6S,Designated/Withdrawn,Public record,3320,Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E,7/29/2014,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,440714
INDUSATUMAB VEDOTIN,3F0FR4W3H8,Designated/Withdrawn,Public record,3321,monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C,7/29/2014,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,438014
Binimetinib,181R97MR71,Designated,Public record,3322,binimetinib,7/31/2014,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc.",3200 Walnut Street,,Boulder,Colorado,80301,United States,440414
PIRFENIDONE,D7NLD2JX7U,Designated,Public record,3323,pirfenidone,7/31/2014,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Avalyn Pharma, Inc.",701 Pike Street,Suite 1500,Seattle,Washington,98101,United States,436914
Roseburia hominis,M881HBT4WO,Designated,Public record,3324,Roseburia hominis,8/4/2014,Treatment of ulcerative colitis in pediatric patients age 0 through 16 years,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,4D Pharma Research Ltd,Life Sciences Innovation Bldg,Cornhill Road,Scotland,,,United Kingdom,439114
BETULA PENDULA/PUBESCENS BARK,6NQM402G7Y,Designated,Public record,3326,dry extract from Betulae Cortex (birch bark),8/7/2014,Treatment of epidermolysis bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Amryt Research, Ltd.",90,,Dublin 2,,,Ireland,438114
MOCETINOSTAT,A6GWB8T96J,Designated,Public record,3327,mocetinostat,8/7/2014,Treatment of diffuse large B-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",9363 Towne Center Drive,Suite 200,San Diego,California,92121,United States,441514
Ivospemin,775S1NC70I,Designated,Public record,3328,"N1,N14,-diethyl-3,12,-dihydroxyhomospermine",8/7/2014,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Sun BioPharma, Inc.",712 Vista Blvd,Suite 305,Waconia,Minnesota,55387,United States,441214
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,3329,nivolumab,8/7/2014,Treatment of Hodgkin lymphoma,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT,4/25/2017,4/25/2024,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing appro",Bristol-Myers Squibb Company,Route 206 & Province Line Road,P. O. Box 4000,Princeton,New Jersey,8543,United States,442614
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,3330,nivolumab,8/7/2014,Treatment of Hodgkin lymphoma,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,5/17/2016,5/17/2023,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company,Route 206 & Province Line Road,P. O. Box 4000,Princeton,New Jersey,8543,United States,442614
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated,Public record,3331,"Immune Globulin Subcutaneous (Human), 20% Liquid",8/18/2014,Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP),Designated/Approved,,Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.,3/15/2018,3/15/2025,Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,439914
DORNASE ALFA,953A26OA1Y,Designated,Public record,3332,recombinant human deoxyribonuclease I,8/18/2014,Treatment of graft-vs-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"CLS Therapeutics, Inc.",180 Varick Street,,New York,New York,10014,United States,447114
DORNASE ALFA,953A26OA1Y,Designated,Public record,3333,recombinant human deoxyribonuclease I (DNase I),8/18/2014,Prevention of graft-vs-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"CLS Therapeutics, Inc.",180 Varick Street,,New York,New York,10014,United States,439614
ALTIRATINIB,T678746713,Designated,Public record,3334,altiratinib,8/19/2014,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"Deciphera Pharmaceuticals, LLC",643 Massachusetts,Suite 200,Lawrence,Kansas,66044,United States,441714
DEXRAZOXANE HYDROCHLORIDE,5346058Q7S,Designated,Public record,3335,dexrazoxane hydrochloride,8/19/2014,Prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines,Designated,Not FDA Approved for Orphan Indication,,,,,"Satiscor, LLC",45 Marine Road,,Boston,Massachusetts,2127,United States,441314
OTILIMAB,Y8127R3VCH,Designated,Public record,3336,Lacnotuzumab,8/19/2014,"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath",Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp,One Health Plaza,,East Hanover,New Jersey,7936,United States,439314
OLAPTESED PEGOL,MTM792B442,Designated,Public record,3337,olaptesed pegol,8/19/2014,Treatment of glioblastoma in conjunction with radiotherapy.,Designated,Not FDA Approved for Orphan Indication,,,,,Noxxon Pharma AG,Max-Dohrn0Strasse,,Berlin,,,Germany,443114
QUILSECONAZOLE,7WJ1XH4Z6A,Designated,Public record,3338,selective inhibitor of fungal lanosterol demethylase,8/19/2014,Treatment of cryptococcal meningitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Viamet Pharmaceuticals, Inc.",4505 Emperor Blvd,Suit 300,Durham,North Carolina,27703,United States,439214
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,3339,sodium phenylbutyrate,8/19/2014,Treatment of maple syrup urine disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Acer Therapeutics, Inc.",One Gateway Center,"300 Washington Street, Suite 351",Newton,Massachusetts,2458,United States,439714
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3340,cannabidiol,8/20/2014,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,78665,United States,444814
PORGAVIXIMAB,07EY0HWO2M,Designated,Public record,3341,"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus",8/25/2014,Treatment of Ebola virus infection,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LeafBio, Inc.",6160 Lusk Blvd.,Suite C105,San Diego,California,90121,United States,440914
LARCAVIXIMAB,181UPT812X,Designated,Public record,3341,"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus",8/25/2014,Treatment of Ebola virus infection,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LeafBio, Inc.",6160 Lusk Blvd.,Suite C105,San Diego,California,90121,United States,440914
COSFROVIXIMAB,820CI2BHRP,Designated,Public record,3341,"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus",8/25/2014,Treatment of Ebola virus infection,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LeafBio, Inc.",6160 Lusk Blvd.,Suite C105,San Diego,California,90121,United States,440914
OPROZOMIB,MZ37792Y8J,Designated,Public record,3342,oprozomib,8/25/2014,Treatment of Waldenstrom's macroglobulinemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Onyx Therapeutics, Inc.",249 E. Grand Avenue,,South San Francisco,California,94080,United States,443614
ALDOXORUBICIN,C28MV4IM0B,Designated,Public record,3343,aldoxorubicin,9/24/2014,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,90232,United States,446914
ALDOXORUBICIN,C28MV4IM0B,Designated,Public record,3344,aldoxorubicin,9/24/2014,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,90232,United States,447014
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3345,cannabidiol,9/24/2014,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,78665,United States,450814
SATOREOTIDE TRIZOXETAN GALLIUM GA-68,ZP2ODR0UR3,Designated,Public record,3346,satoreotide tetraxetan,9/24/2014,Management of gastroenteropancreatic neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,SatoSea Oncology GmbH,c/o LSP Services Deutschland GmbH,Dachauer Str. 65,München,,80335,Germany,449514
Glucagon,76LA80IG2G,Designated,Public record,3347,glucagon infusion,9/25/2014,"Prevention of chronic, severe hypoglycemia related to congential hyperinsulinism",Designated,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceuticals, Inc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,60607,United States,427514
ONASEMNOGENE ABEPARVOVEC,MLU3LU3EVV,Designated/Approved,Public record,3348,onasemnogene abeparvovec,9/30/2014,Treatment of spinal muscular atrophy,Designated/Approved,,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,5/24/2019,5/24/2026,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,"AveXis, Inc.",2275 Half Day Road,Suite 200,Bannockburn,Illinois,60015,United States,444714
INTERFERON GAMMA-1B,21K6M2I7AG,Designated,Public record,3350,interferon gamma-1b,10/1/2014,Treatment of Friedreich's Ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,Horizon Therapeutic Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin 4,,,Ireland,445514
PEGVORHYALURONIDASE ALFA,P01I4980ZS,Designated,Public record,3351,PEGylated recombinant human hyaluronidase PH20,10/1/2014,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Halozyme Therapeutics, Inc.",11388 Sorrento Valley Road,,San Diego,California,92121,United States,447914
NODAGA-THERANOST GA-68,5EKN6H63OA,Designated,Public record,3352,Theranost 68 Ga RGD,10/1/2014,A Diagnostic for the management of Moyamoya disease (MMD),Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC (AIP)",3651 FAU Blvd.,,Boca Raton,Florida,33467,United States,452214
RIPRETINIB,9XW757O13D,Designated,Public record,3354,Ripretinib,10/2/2014,Treatment of gastrointestinal stromal tumors (GIST),Designated/Approved,,"QINLOCK (ripretinib) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.",5/15/2020,5/15/2027,"Indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.","Deciphera Pharmaceuticals, LLC",200 Smith Street,,Waltham,Massachusetts,2451,United States,447414
RESIMMUNE,P7MQ9ZOQ82,Designated,Public record,3355,A-dmDT390-bisFv(UCHT1),10/9/2014,Treatment of cutaneous T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Angimmune, LLC",American Red Cross Holland Laboratory,15601 Crabbs Branch Way,Rockville,Maryland,20855,United States,448114
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,3356,Combination of nivolumab and ipilimumab,10/9/2014,Treatment of Stage IIb to Stage IV melanoma,Designated/Approved,,"Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma",9/30/2015,9/30/2022,"Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma",Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,6492,United States,445014
IPILIMUMAB,6T8C155666,Designated/Approved,Public record,3356,Combination of nivolumab and ipilimumab,10/9/2014,Treatment of Stage IIb to Stage IV melanoma,Designated/Approved,,"Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma",9/30/2015,9/30/2022,"Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma",Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,6492,United States,445014
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,3357,ipilimumab,10/9/2014,Treatment of Stage IIb to Stage IV melanoma,Designated/Approved,,"as a single agent or in combination with nivolumab, for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older",2/15/2023,,,Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,6492,United States,445014
IPILIMUMAB,6T8C155666,Designated/Approved,Public record,3357,ipilimumab,10/9/2014,Treatment of Stage IIb to Stage IV melanoma,Designated/Approved,,"as a single agent or in combination with nivolumab, for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older",2/15/2023,,,Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,6492,United States,445014
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,3358,nivolumab,10/9/2014,Treatment of Stage IIb to Stage IV melanoma,Designated/Approved,,"as a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma",2/15/2023,,,Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,6492,United States,445014
IPILIMUMAB,6T8C155666,Designated/Approved,Public record,3358,nivolumab,10/9/2014,Treatment of Stage IIb to Stage IV melanoma,Designated/Approved,,"as a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma",2/15/2023,,,Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,6492,United States,445014
OLARATUMAB,TT6HN20MVF,Designated/Approved,Public record,3359,olaratumab,10/9/2014,Treatment of soft tissue sarcoma,Designated/Approved,,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or",10/19/2016,2/25/2020,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or",Eli Lilly and Company,"Lilly Corporate Center, Drop Code 2543",,Indianapolis,Indiana,46285,United States,448414
AMY-101,4Z4DFR9BX7,Designated,Public record,3360,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",10/9/2014,Treatment of paroxysmal nocturnal hemoglobinuria (PNH),Designated,Not FDA Approved for Orphan Indication,,,,,Amyndas Pharmaceuticals,Kyprou 27,,Glyfada,,16675,Greece,446714
DIACEREIN,4HU6J11EL5,Designated,Public record,3361,diacerein,10/15/2014,Treatment of epidermolysis bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,"TWi Biotechnology, Inc.","8F, No.41, Lane 221, Kang Chien Rd.",Nei Hu Dist,Taipei,,,Taiwan,448614
PTI-110,YI3H6V056C,Designated,Public record,3362,"N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide",10/15/2014,Treatment of AL Amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"ProtaMed, Inc.","14241 Woodinville Duvall Road, Suite # 370",,Woodinville,Washington,98072,United States,434014
(NORTH)-METHANOCARBATHYMIDINE,LTM5S02010,Designated,Public record,3363,N-Methanocarbathymidine,10/15/2014,Treatment of neonatal herpes,Designated,Not FDA Approved for Orphan Indication,,,,,"N & N Pharmaceuticals, Inc.",2400 Research Blvd,Suite 310,Rockville,Maryland,20850,United States,426014
CARDIOTROPHIN 1,AJ7U77BR8I,Designated,Public record,3364,cardiotrophin-1,10/16/2014,Prevention of ischemia-reperfusion injury in kidney transplant recipients,Designated,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,,Spain,432714
ALTEPLASE,1RXS4UE564,Designated,Public record,3365,alteplase,10/20/2014,Treatment of plastic bronchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor",University of %i,428 Church St.,Ann Arbor,Michigan,48109,United States,431414
DABRAFENIB,QGP4HA4G1B,Designated,Public record,3366,dabrafenib,10/20/2014,Treatment of patients with BRAF mutation positive non-small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,1 Health Plaza,,East Hanover,New Jersey,7936,United States,448214
IBALIZUMAB,LT369U66CE,Designated/Approved,Public record,3367,ibalizumab,10/20/2014,Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy,Designated/Approved,,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretro",3/6/2018,3/6/2025,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretro",Theratechnologies Inc.,2015 Peel Street,5th Floor,Montreal,,,Canada,321910
ISAVUCONAZONIUM SULFATE,31Q44514JV,Designated,Public record,3368,isavuconazonium sulfate,10/20/2014,Treatment of invasive candidiasis/candidemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,447814
RST-001,4C78HMB6T8,Designated,Public record,3369,non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein,10/20/2014,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,92623,United States,447714
TIPELUKAST,08379P260O,Designated,Public record,3370,tipelukast,10/20/2014,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"MediciNova, Inc.",4275 Executive Square,Suite 300,La Jolla,California,92037,United States,448914
SYD-003,TE3ESF890C,Designated,Public record,3371,"[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone",10/20/2014,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Synovo GmbH,Paul-Ehrlich-Str. 15,,D-72076 Tubingen,,,Germany,449814
AMG-900 BISMESYLATE DIHYDRATE,E717YSV70L,Designated,Public record,3373,N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate,10/21/2014,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,Mail Stop 17-2-B,Thousand Oaks,California,91320,United States,450414
TRIHEPTANOIN,2P6O7CFW5K,Designated,Public record,3374,triheptanoin,10/21/2014,Treatment of glucose transporter type-1 deficiency syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,,Novato,California,94949,United States,426414
AUTOLOGOUS ADIPOSE DERIVED MESENCHYMAL STEM CELLS (MSCS),KA0IJR9DZ7,Designated,Public record,3375,autologous adipose derived mesenchymal stromal cells,10/22/2014,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Mayo Clinic,200 First Street SW,,Rochester,Minnesota,55905,United States,427014
Rildinadstrocel,3ME9TTI5QB,Designated,Public record,3375,autologous adipose derived mesenchymal stromal cells,10/22/2014,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Mayo Clinic,200 First Street SW,,Rochester,Minnesota,55905,United States,427014
ISTIRATUMAB,XLR461MD3M,Designated,Public record,3377,Istiratumab,10/22/2014,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Merrimack Pharmaceuticals, Inc.",One Kendall Square,Suite B7201,Cambridge,Massachusetts,2139,United States,450314
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,3378,alpha-1 proteinase inhibitor (human),10/23/2014,Treatment of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.,2 Holtsman Street,,Rehovot,Center District,,Israel,448014
CLENBUTEROL,XTZ6AXU7KN,Designated,Public record,3379,clenbuterol,10/27/2014,Adjunctive therapy with enzyme replacement therapy in the treatment of Pompe disease,Designated,Not FDA Approved for Orphan Indication,,,,,Duke University Medical Center,Department of Pediatrics,Box 103856,Durham,North Carolina,27710,United States,451614
OPROZOMIB,MZ37792Y8J,Designated,Public record,3380,oprozomib,10/28/2014,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Onyx Therapeutics, Inc.",249 E. Grand Avenue,,South San Francisco,California,94080,United States,449614
PRITUMUMAB,Z6Q90D1G53,Designated,Public record,3381,pritumumab,10/28/2014,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.",10246 Parkdale Avenue,,San Diego,California,92126,United States,448514
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,3382,sodium thiosulfate,10/28/2014,Treatment of dermatomyositis,Designated,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,85260,United States,450114
BEMCENTINIB,0ICW2LX8AS,Designated,Public record,3383,"(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine",11/5/2014,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,BerGenBio AS,Jonas Lies vei 91,,Bergen,,,Norway,452314
DEUTETRABENAZINE,P341G6W9NB,Designated/Approved,Public record,3385,"d6-tetrabenazine, deutetrabenazine",11/5/2014,Treatment of Huntington's Disease,Designated/Approved,,Treatment of chorea associated with Huntington¿s disease,4/3/2017,4/3/2024,Treatment of chorea associated with Huntington¿s disease,"Teva Branded Pharmaceutical Products R&D, Inc.",3333 N. Torrey Pines Court,Suite 400,La Jolla,California,92037,United States,383212
TEMOZOLOMIDE,YF1K15M17Y,Designated,Public record,3387,(S)-perillyl alcohol temozolomide,11/12/2014,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.","8335 Sunset Blvd., #240",,Los Angeles,California,90069,United States,453314
PERILLA ALCOHOL,3UL4QIY642,Designated,Public record,3387,(S)-perillyl alcohol temozolomide,11/12/2014,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.","8335 Sunset Blvd., #240",,Los Angeles,California,90069,United States,453314
WHARTON JELLY DERIVED UMBILICAL CORD MESENCHYMAL STEM CELLS,3FXW1IW7WT,Designated,Public record,3389,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,11/13/2014,Treatment of myelodysplastic syndrome.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,,Israel,455314
WHARTON JELLY DERIVED UMBILICAL CORD MESENCHYMAL STEM CELLS,3FXW1IW7WT,Designated,Public record,3390,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,11/13/2014,Treatment of acute lymphoblastic leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,,Israel,454414
WHARTON JELLY DERIVED UMBILICAL CORD MESENCHYMAL STEM CELLS,3FXW1IW7WT,Designated,Public record,3391,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,11/13/2014,Treatment of Hodgkin lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,,Israel,454514
SERALUTINIB,3P63ZTE3OY,Designated,Public record,3392,"(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium",11/17/2014,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"GB002, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.",3013 Science Park Road,Suite 200,San Diego,California,92121,United States,441914
SONLICROMANOL HYDROCHLORIDE,858M8246UL,Designated,Public record,3393,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",11/17/2014,Treatment of inherited mitochondrial respiratory chain diseases,Designated,Not FDA Approved for Orphan Indication,,,,,Khondrion BV,Philips van Leydenlaan 15,,Ex Nijmegen,,6525,Netherlands,450714
AVACOPAN,O880NM097T,Designated,Public record,3395,avacopan,11/17/2014,Treatment of atypical hemolytic uremic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"ChemoCentryx, Inc.",850 Maude Avenue,,Mountain View,California,94043,United States,443714
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3396,cannabidiol,11/17/2014,Treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,78655,United States,452614
EDASALONEXENT,AF3Z6434KS,Designated,Public record,3397,Edasalonexent,11/17/2014,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Catabasis Pharmaceuticals, Inc.","One Kendall Square, Suite B14202",Suite B14202,Cambridge,Massachusetts,2139,United States,453714
BN-201,KCN37L7EIH,Designated,Public record,3398,N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide,11/17/2014,Treatment of optic neuritis,Designated,Not FDA Approved for Orphan Indication,,,,,Bionure Farma SL,Dalmases 27,,Barcelona,,,Spain,440014
N-9-METHOXYNONYLDEOXYNOJIRIMYCIN HYDROCHLORIDE,R3Y2198MRP,Designated,Public record,3399,N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride,11/17/2014,"Treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Emergent Virology, LLC",400 Professional Drive,,Gaithersburg,Maryland,20879,United States,442714
SIROLIMUS,W36ZG6FT64,Designated,Public record,3401,sirolimus,11/17/2014,Treatment of lymphangioleiomyomatosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Cote Orphan Consulting, LLC","8630 Fenton St., #222",,Silver Spring,Maryland,20910,United States,453114
TREHALOSE,B8WCK70T7I,Designated,Public record,3402,trehalose,11/17/2014,Treatment of spinal cerebellar ataxia type 3 (also known as SCA3 or Machado Joseph disease),Designated,Not FDA Approved for Orphan Indication,,,,,"Seelos Therapeutics, Inc.",300 Park Avenue,,New York,New York,10022,United States,442014
VATIQUINONE,6O85FK9I0X,Designated,Public record,3403,vatiquinone,11/17/2014,Treatment of Rett syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,453014
VELTUZUMAB,BPD4DGQ314,Designated,Public record,3404,veltuzumab,11/17/2014,Treatment of pemphigus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 The American Rd.,,Morris Plains,New Jersey,7950,United States,454714
Oxytocin,1JQS135EYN,Designated,Public record,3405,oxytocin,11/24/2014,Treatment of Prader-Willi syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,OT4B,109 Avenue de Lespinet,,Toulouse,,31400,France,453614
IMT-504,8A805B1IH6,Designated,Public record,3406,PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCATTTTGTCATT 3',11/24/2014,Treatment of rabies virus infections,Designated,Not FDA Approved for Orphan Indication,,,,,"Mid-Atlantic BioTherapeutics, Inc.",3805 Old Easton Rd.,,Doylestown,Pennsylvania,18902,United States,451914
LINTUZUMAB SATETRAXETAN AC-225,V860J30J9N,Designated,Public record,3407,225Ac-lintuzumab,11/25/2014,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Actinium Pharmaceuticals, Inc.",379 Thornall Avenue,6th Floor,Edison,New Jersey,8837,United States,451714
TRALESINIDASE ALFA,AA60A4ST8X,Designated,Public record,3408,chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2,11/25/2014,"Treatment of mucopolysaccharidosis III Type B (MPS IIIB, Sanfilippo Syndrome Type B)",Designated,Not FDA Approved for Orphan Indication,,,,,Allievex Corporation,P.O. Box 1056,,Marblehead,Massachusetts,1945,United States,450014
TAFASITAMAB,QQA9MLH692,Designated,Public record,3409,tafasitamab,12/1/2014,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"MONJUVI® is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible",7/31/2020,7/31/2027,"indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autolog",MorphoSys AG,Semmelweisstrasse 7,,Plannegg,,,Germany,456014
IOPOFOSINE I-131,R048696O9L,Designated,Public record,3410,1 8-(p[131I]-iodophenyl)octadecyl phosphocholine,12/3/2014,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,53716,United States,455614
IMIQUIMOD,P1QW714R7M,Designated,Public record,3411,Imiquimod,12/3/2014,Treatment of carcinoma in situ (CIS) of the urinary bladder,Designated,Not FDA Approved for Orphan Indication,,,,,UroGen Pharma Ltd,9 Ha'Ta'asiya Street,P. O. Box 2397,Ra'anana,,,Israel,425314
PACLITAXEL,P88XT4IS4D,Designated,Public record,3412,liposome encapsulated paclitaxel,12/3/2014,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,78665,United States,454014
XENON,3H3U766W84,Designated,Public record,3414,xenon gas,12/3/2014,Treatment of hypoxic ischemic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Neuroprotexeon,Imperial Innovations,London SW7 2PG,London,,,United Kingdom,455714
Anpocogin,3TTT9ZD93F,Designated,Public record,3415,recombinant nematode anticoagulant protein c2 (rNAPc2),12/8/2014,Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola),Designated,Not FDA Approved for Orphan Indication,,,,,"ARCA Biopharma, Inc.",11080 Circle Point Rd.,Suite 140,Westminster,Colorado,80020,United States,329810
NODAGA-THERANOST GA-68,5EKN6H63OA,Designated,Public record,3416,theranost 68Ga-RGD,12/8/2014,Diagnostic for clinical management of patients with neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",Florida Atlantic University Research Park,3651 FAU Blvd,Boca Raton,Florida,33431,United States,454814
ATALUREN,K16AME9I3V,Designated/Withdrawn,Public record,3417,ataluren,12/10/2014,Treatment of mucopolysaccharidosis type I,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,455814
PCO-371,TE53TU0WSQ,Designated,Public record,3418,non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I,12/15/2014,Treatment of hypoparathyroidism,Designated,Not FDA Approved for Orphan Indication,,,,,"Chugai Pharma USA, LLC",300 Connell Drive,Suite 300,Berkeley Heights,New Jersey,7922,United States,455914
DOCONEXENT,ZAD9OKH9JC,Designated,Public record,3420,"docosahexaenoic acid, DHA",12/17/2014,Treatment of primary sclerosing cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Micelle BioPharma, Inc.","3874 Fiscal Ct., #200",,Riviera Beach,Florida,33404,United States,456414
VELIPARIB,01O4K0631N,Designated,Public record,3422,veliparib,12/17/2014,Treatment of brain metastases when used in combination with DNA-damaging agents,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,456514
CHROMIUM HISTIDINATE,1BY3EP7D99,Designated,Public record,3423,chromium picolinate and chromium histidinate,12/22/2014,Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"JDS Therapeutics, LLC",3 Manhattanville Rd,Suite 201,Purchase,New York,10577,United States,456814
CHROMIUM PICOLINATE,S71T8B8Z6P,Designated,Public record,3423,chromium picolinate and chromium histidinate,12/22/2014,Treatment of pediatic polycystic ovary syndrome (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"JDS Therapeutics, LLC",3 Manhattanville Rd,Suite 201,Purchase,New York,10577,United States,456814
ENTRECTINIB,L5ORF0AN1I,Designated,Public record,3424,entrectinib,12/22/2014,Treatment of neuroblastoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,94080,United States,462414
MANF,5R3OV3AM5M,Designated,Public record,3425,"human recombinant mesencephalic, astrocyte derived neurotrophic factor",12/22/2014,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Amarantus BioScience Holdings, Inc.",655 Montgomery Street,Suite 900,San Francisco,California,94111,United States,457514
PLECONARIL,9H4570Q89D,Designated,Public record,3427,pleconaril,12/22/2014,Treatment of symptomatic enteroviral infection in the neonate,Designated,Not FDA Approved for Orphan Indication,,,,,"NES Therapeutics, Inc.",7 Ardsley Ct.,,Princeton,New Jersey,8550,United States,457214
AVORALSTAT,UX17773O15,Designated/Withdrawn,Public record,3428,3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid,12/23/2014,Prevention of acute attacks of angioedema in individuals with hereditary angioedema,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"BioCryst Pharmaceuticals, Inc.",4505 Emperor Blvd,Suite 200200,Durham,North Carolina,27703,United States,457114
BAZLITORAN,2U46M95B5M,Designated,Public record,3429,"antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9",12/23/2014,Treatment of Waldenstrom's macroglobulinemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Idera Pharmaceuticals, Inc.",505 Eagleview Boulevard,Suite 212,Exton,Pennsylvania,19341,United States,417813
PAFOLACIANINE,F7BD3Z4X8L,Designated,Public record,3431,pafolacianine,12/23/2014,Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer),Designated/Approved,,As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer,11/29/2021,11/29/2028,As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer,"On Target Laboratories, LLC",1282 Win Hentschel Blvd,,West Lafayette,Indiana,47906,United States,458714
AMIKACIN SULFATE,N6M33094FD,Designated,Public record,3432,amikacin sulfate,1/5/2015,Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections,Designated,Not FDA Approved for Orphan Indication,,,,,PlumeStars s.r.l.,Via Lago Scuro11,,Parma,,,Italy,458114
CELIPROLOL,DRB57K47QC,Designated,Public record,3433,celiprolol,1/5/2015,Treatment of Ehlers-Danlos syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Acer Therapeutics, Inc.",222 Third Street,Suite 2240,Cambridge,Massachusetts,2142,United States,456714
PENTOSAN POLYSULFATE SODIUM,914032762Y,Designated,Public record,3434,pentosan polysulfate sodium,1/5/2015,Treatment of mucopolysaccharidosis (MPS) type VI,Designated,Not FDA Approved for Orphan Indication,,,,,Paradigm Biopharmaceuticals Ltd.,"Level 15, 500 Collins Street",,Melbourne,Victoria,,Australia,458614
PYRVINIUM,6B9991FLU3,Designated,Public record,3435,pyrvinium,1/5/2015,Treatment of familial adenomatous polyposis,Designated,Not FDA Approved for Orphan Indication,,,,,"StemSynergy Therapeutics, Inc.",1951 NW 7th Avenue,Suite 300,Miami,Florida,33136,United States,458314
SELINEXOR,31TZ62FO8F,Designated,Public record,3436,selinexor,1/5/2015,Treatment of multiple myeloma,Designated/Approved,,XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibi,7/3/2019,7/3/2026,"Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at l","Karyopharm Therapeutics, Inc.","85 Wells Avenue, Suite 210",,Newton,Massachusetts,2459,United States,459014
SELINEXOR,31TZ62FO8F,Designated,Public record,3437,selinexor,1/5/2015,Treatment of multiple myeloma,Designated/Approved,,in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy,12/18/2020,12/18/2027,"for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, excluding adult patients covered by Xpovio's previous indication for multiple myeloma approved on July 3, 2019","Karyopharm Therapeutics, Inc.","85 Wells Avenue, Suite 210",,Newton,Massachusetts,2459,United States,459014
SIMTUZUMAB,11Z5AIU653,Designated/Withdrawn,Public record,3438,simtuzumab,1/5/2015,Treatment of primary sclerosing cholangitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,458214
SPARSENTAN,9242RO5URM,Designated,Public record,3439,sparsentan,1/5/2015,Treatment of Focal Segmental Glomerulosclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Travere Therapeutics, Inc.","3611 Valley Centre Drive, Suite 300",,San Diego,California,92130,United States,410113
CM-101,YW45RY9QD4,Designated,Public record,3440,monoclonal antibody targeting eotaxin-2,1/6/2015,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"ChemomAb, Ltd.",6 Hanehoset St.,,Tel Aviv,,,Israel,442214
NEVANIMIBE HYDROCHLORIDE,TK694ZFS57,Designated,Public record,3441,"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt",1/7/2015,For the treatment of Cushing's Syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millendo Therapeutics, Inc.",301 North Main St.,Suite 100,"Ann Arbor,",Michigan,48104,United States,414913
ULOCUPLUMAB,7KNP87L4X4,Designated,Public record,3442,ulocuplumab,1/12/2015,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,"3401 Princeton Pike, B-3043C",,Lawrence Township,New Jersey,8648,United States,457414
ARIMOCLOMOL CITRATE,Q85FFY6179,Designated,Public record,3444,arimoclomol citrate,1/13/2015,"Treatment of Neimann-Pick disease, type C",Designated,Not FDA Approved for Orphan Indication,,,,,Zevra Denmark A/S,Ole Maaloes Vej 3,,Copenhagen,København,2200,Denmark,458814
DEUTETRABENAZINE,P341G6W9NB,Designated,Public record,3445,deutetrabenazine,1/13/2015,Treatment of Tourette syndrome in the pediatric population (defined as 0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,TEVA Pharmaceuticals,3366 North Torrey Pines Court,Suite 225,LaJolla,California,92037,United States,442314
NALTREXONE,5S6W795CQM,Designated,Public record,3446,naltrexone,1/13/2015,Treatment of autoimmune hepatitis,Designated,Not FDA Approved for Orphan Indication,,,,,"TaiwanJ Pharmaceuticals Co., Ltd.","Room 204 A, Bldg 53","195 Chung Hsing Rd., Sec 4","Chutung, Hsinchu",,,Taiwan,460314
BALIFORSEN,DR9CF3915M,Designated/Withdrawn,Public record,3448,synthetic oligomer of 16 nucleotides,1/13/2015,Treatment of myotonic dystrophy Type I,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Ct.,,Carlsbad,California,92010,United States,457914
VERUCERFONT,X60608B091,Designated/Withdrawn,Public record,3449,"2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-",1/15/2015,Treatment of congenital adrenal hyperplasia (CAH),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Neurocrine Biosciences, Inc.",12780 El Camino Real,,San Diego,California,92130,United States,399713
SELONSERTIB,NS3988A2TC,Designated,Public record,3450,"5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide",1/15/2015,Treatment pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,459114
PALOMID 529,XV9409EWG4,Designated,Public record,3453,8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one,1/21/2015,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"Diffusion Pharmaceuticals, Inc.",2020 Avon Court,Suite 4,Charlottesville,Virginia,22902,United States,463714
ANTROQUINONOL,AX9P92T7JZ,Designated,Public record,3454,antroquinonol,1/21/2015,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Golden Biotechnology Corp.,"10F., No. 9, Ln 3",Tamsui Dist.,New Taipei City 251,,,Taiwan,460814
PACLITAXEL,P88XT4IS4D,Designated,Public record,3455,liposomal encapsulated paclitaxel,1/21/2015,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,78665,United States,454114
LAS-191954,1MK0TQ597B,Designated,Public record,3457,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",1/26/2015,Treatment of pemphigus vulgaris,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Almirall S.A.,"Ronda General Mitre, 151",,Barcelona,,,Spain,444614
IOFLUPANE F-18,NT4P0L3OCX,Designated,Public record,3458,18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane,1/26/2015,Diagnostic to be used in the management of multiple system atrophy (MSA),Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,451114
ITACITINIB ADIPATE,XZG407XE0Y,Designated,Public record,3459,"2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-l-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate",1/26/2015,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,462014
A-16L,0UHG2WF4HP,Designated,Public record,3461,human leukocyte antigen-A2 restricted peptides,1/26/2015,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Stemline Therapeutics, Inc.",750 Lexington Avenue,11 th Floor,New York,New York,10022,United States,433614
ACEBILUSTAT,J64RI4D29U,Designated,Public record,3462,leukotriene A4 hydrolase inhibitor,1/26/2015,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Celltaxis, LLC",3060 Peachtree Road,"NW, Suite 1425",Atlanta,Georgia,30305,United States,432114
TAREXTUMAB,333YMY788E,Designated/Withdrawn,Public record,3463,tarextumab,1/26/2015,Treatment of small cell lung cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.",800 Chesapeake Drive,,Redwood City,California,94063,United States,461314
TAREXTUMAB,333YMY788E,Designated/Withdrawn,Public record,3464,tarextumab,1/26/2015,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.",800 Chesapeake Drive,,Redwood City,California,94063,United States,461414
NODAGA-THERANOST GA-68,5EKN6H63OA,Designated,Public record,3465,Theranost 68Ga RGD,1/26/2015,Diagnostic for the clinical management of patients with tuberculosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",3651 FAU Blvd.,,Boca Raton,Florida,33467,United States,461514
ALECTINIB,LIJ4CT1Z3Y,Designated/Approved,Public record,3466,alectinib,1/27/2015,Treatment of ALK-positive non-small cell lung cancer,Designated/Approved,,"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",11/6/2017,11/6/2024,"Treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small-cell lung cancer (NSCLC) as detected by an FDA-approved test, excluding patients who have progressed on or are intolerant to crizotinib.","Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)","1 DNA Way, MS #355E",,South San Francisco,California,94080,United States,462814
ALECTINIB,LIJ4CT1Z3Y,Designated/Approved,Public record,3467,alectinib,1/27/2015,Treatment of ALK-positive non-small cell lung cancer,Designated/Approved,,"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.",12/11/2015,12/11/2022,"Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib","Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)","1 DNA Way, MS #355E",,South San Francisco,California,94080,United States,462814
FILGRASTIM,PVI5M0M1GW,Designated,Public record,3468,filgrastim,1/27/2015,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH,Emil-Geis Str. 4,,Grunwald,,,Germany,461814
LISINOPRIL,E7199S1YWR,Designated/Withdrawn by OPD,Public record,3469,lisinopril oral solution,1/27/2015,Treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"BioRamo, LLC",5319 NW 35th Terrace,,Ft. Lauderdale,Florida,33309,United States,365512
TZ-101,K2X1EE8C73,Designated,Public record,3470,recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose,1/27/2015,To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"TargaZyme, Inc.",2100 Palomar Airport Road,Suite 214-219,Carlsbad,California,92011,United States,459214
GUANOSINE 5'-DIPHOSPHO-.BETA.-L-FUCOSE,SM108QK2IH,Designated,Public record,3470,recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose,1/27/2015,To increase the activity of regulatory T-cells (Tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"TargaZyme, Inc.",2100 Palomar Airport Road,Suite 214-219,Carlsbad,California,92011,United States,459214
BORTEZOMIB,69G8BD63PP,Designated,Public record,3472,bortezomib,2/3/2015,Treatment of acute lymphoblastic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,464014
ENTRECTINIB,L5ORF0AN1I,Designated,Public record,3473,entrectinib,2/3/2015,"Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer",Designated/Approved,,ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,8/15/2019,8/15/2026,For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,"Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,94080,United States,462914
SAPOSIN C (RECOMBINANT HIS TAGGED),QT2JK7C5U6,Designated,Public record,3474,saposin C,2/3/2015,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"Bexion Pharmaceuticals, LLC",632 Russell St.,,Covington,Kentucky,41011,United States,463814
"""1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHO-L-SERINE""",KJ401H4834,Designated,Public record,3474,saposin C,2/3/2015,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"Bexion Pharmaceuticals, LLC",632 Russell St.,,Covington,Kentucky,41011,United States,463814
TISAGENLECLEUCEL,Q6C9WHR03O,Designated,Public record,3475,tisagenlecleucel-T,2/3/2015,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cel,5/1/2018,5/1/2025,For treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma after two or more lines of systemic therapy.,Novartis Pharmaceuticals Corporation,"One Health Plaza,",Bldg 315 - Room 3650B,East Hanover,New Jersey,7936,United States,463114
COPANLISIB,WI6V529FZ9,Designated/Approved,Public record,3476,copanlisib,2/5/2015,Treatment of follicular lymphoma,Designated/Approved,,Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies,9/14/2017,9/14/2024,Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies,Bayer US LLC,100 Bayer Boulevard,P. O. Box 915,Hanover,New Jersey,7981,United States,463314
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,3477,ibrutinib,2/5/2015,Treatment of splenic marginal zone lymphoma,Designated/Approved,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.,1/18/2017,1/18/2024,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.,"Pharmacyclics, LLC",1000 Gateway Blvd,,South San Francisco,California,94080,United States,462314
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,3478,ibrutinib,2/5/2015,Treatment of nodal marginal zone lymphoma,Designated/Approved,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.,1/18/2017,1/18/2024,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.,"Pharmacyclics, LLC",1000 Gateway Blvd,,South San Francisco,California,94080,United States,462214
VS-5584,W71J4X250V,Designated/Withdrawn,Public record,3480,5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine,2/10/2015,Treatment of malignant mesothelioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Verastem, Inc.",117 Kendrick Street,Suite 500,Needham,Massachusetts,2494,United States,463614
MIRIDESAP,WO97N24A47,Designated,Public record,3482,carboxy pyrrolidine hexanoyl pyrrolidine carboxylate,2/10/2015,Treatment of AL amyloidosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Glaxo Group Limited, England d/b/a GlaxoSmithKline",980 Great West Road,,"Middlesex, TW8 9GS",,,United Kingdom,462614
LEVOMEFOLATE CALCIUM,A9R10K3F2F,Designated,Public record,3483,levomefolate calcium,2/10/2015,Treatment of megaloblastic anemia caused by folate deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Cox Biosciences LLC,"267 West 71st Street, #3F",,New York,New York,10023,United States,428514
LANSOPRAZOLE,0K5C5T2QPG,Designated,Public record,3484,omeprazole-lansoprazole with buffer,2/10/2015,Treatment of esophageal ulcers,Designated,Not FDA Approved for Orphan Indication,,,,,"Effexus Pharmaceuticals, LLC",10901 Granada Lane,Suite 101,Leawood,Kansas,66211,United States,446014
OMEPRAZOLE,KG60484QX9,Designated,Public record,3484,omeprazole-lansoprazole with buffer,2/10/2015,Treatment of esophageal ulcers,Designated,Not FDA Approved for Orphan Indication,,,,,"Effexus Pharmaceuticals, LLC",10901 Granada Lane,Suite 101,Leawood,Kansas,66211,United States,446014
PELAREOREP,S9J80L3D1U,Designated,Public record,3485,pelareorep,2/10/2015,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,,Canada,464414
DEZAMIZUMAB,6U3F28IT58,Designated,Public record,3486,recombinant monoclonal antibody to human serum amyloid P component,2/10/2015,Treatment of AL amyloidosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Glaxo Group Limited, England d/b/a GlaxoSmithKline",980 Great West Road,,"Middlesex, TW8, 9GS",,,United Kingdom,462714
SETOGEPRAM SODIUM,R05571KE07,Designated,Public record,3487,3-pentylbenzenacetic acid sodium salt,2/11/2015,Treatment of idiopathic pulmonary fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Liminal BioSciences Limited,"Unit 1, Iconix Park, London Road",Sawston,Cambridge,,,United Kingdom,464214
PAROMOMYCIN,61JJC8N5ZK,Designated,Public record,3488,paromomycin,2/11/2015,Treatment of cutaneous leishmaniasis (Old World and New World),Designated,Not FDA Approved for Orphan Indication,,,,,Appili Therapeutics Inc.,21-1344 Summer Street,,Halifax,Nova Scotia,,Canada,464314
PELAREOREP,S9J80L3D1U,Designated,Public record,3489,pelareorep,2/11/2015,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,,Canada,464514
CENDAKIMAB,O8R9U9ZUVN,Designated,Public record,3490,recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody,2/11/2015,Treatment of eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,3033 Science Park Road,Suite 300,San Diego,California,92121,United States,443314
TROFINETIDE,Z2ME8F52QL,Designated,Public record,3491,trofinetide,2/11/2015,Treatment of Rett syndrome,Designated/Approved,,treatment of Rett syndrome in adults and pediatric patients 2 years of age and older,3/10/2023,3/10/2030,treatment of Rett syndrome in adults and pediatric patients 2 years of age and older,Acadia Pharmaceuticals Inc.,3611 Valley Centre Drive,Suite 300,San Diego,California,92130,United States,363111
DEFACTINIB,53O87HA2QU,Designated,Public record,3492,defactinib,2/12/2015,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Verastem, Inc.",117 Kendrick Street,Suite 500,Needham,Massachusetts,2494,United States,463514
ENTRECTINIB,L5ORF0AN1I,Designated,Public record,3493,"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide",2/12/2015,"Treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive, or ALK-positive colorectal cancer",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,94080,United States,463014
"""LACTOFERRIN, BOVINE""",KG21X1090A,Designated,Public record,3494,bovine lactoferrin,2/19/2015,Prevention of late-onset sepsis in very low birth weight infants,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC",2502 Avenue I,,Brooklyn,New York,11210,United States,460514
POLIDOCANOL,0AWH8BFG9A,Designated,Public record,3495,polidocanol,2/19/2015,Treatment of congenital venous malformations,Designated,Not FDA Approved for Orphan Indication,,,,,Provensis Ltd,5 Fleet Place,,London,,,United Kingdom,464614
"""LACTOFERRIN, BOVINE""",KG21X1090A,Designated,Public record,3496,bovine lactoferrin,2/23/2015,Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC",2502 Avenue I,,Brooklyn,New York,11210,United States,460714
ANDEXANET ALFA,BI009E452R,Designated,Public record,3497,"Coagulation factor Xa (recombinant), inactivated-zhzo",2/23/2015,For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery,Designated/Approved,,"Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding",5/3/2018,5/3/2025,"Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding","Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,437414
NALTREXONE,5S6W795CQM,Designated,Public record,3498,naltrexone,2/23/2015,Treatment of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,Allodynic Therapeutics LLC,1785 NE 123rd Street,,North Miami,Florida,33181,United States,465614
RITUXIMAB,4F4X42SYQ6,Designated,Public record,3499,rituximab,2/23/2015,Treatment of pemphigus vulgaris.,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,6/7/2018,6/7/2025,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,465014
ACETYLCYSTEINE,WYQ7N0BPYC,Designated/Approved,Public record,3500,acetylcysteine effervescent tablets for oral solution,2/24/2015,Preventing hepatic injury from acetaminophin overdose,Designated/Approved,,Indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion,1/29/2016,,,"Arbor Pharmaceuticals, Inc.",6 Concourse Parkway,Suite 1800,Atlanta,Georgia,30328,United States,401713
DEFERASIROX,V8G4MOF2V9,Designated/Approved,Public record,3501,deferasirox,2/24/2015,Treatment of chronic iron overload in alpha-thalassemia,Designated/Approved,,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a,5/18/2017,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,354411
DEFERASIROX,V8G4MOF2V9,Designated/Approved,Public record,3502,deferasirox,2/24/2015,Treatment of chronic iron overload in alpha-thalassemia,Designated/Approved,,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and s,1/23/2013,1/23/2020,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and s,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,354411
PELAREOREP,S9J80L3D1U,Designated,Public record,3503,pelareorep,2/24/2015,Treatment of fallopian tube cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,,Canada,470115
PELAREOREP,S9J80L3D1U,Designated,Public record,3504,pelareorep,2/24/2015,Treatment of primary peritoneal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,,Canada,470215
ETODOLAC,2M36281008,Designated,Public record,3505,propranolol hydrochloride and etodolac,2/24/2015,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,7960,United States,454614
PROPRANOLOL HYDROCHLORIDE,F8A3652H1V,Designated,Public record,3505,propranolol hydrochloride and etodolac,2/24/2015,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,7960,United States,454614
KETOTIFEN,X49220T18G,Designated,Public record,3506,ketotifen,2/25/2015,Treatment of mastocytosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Valcrest Pharmaceuticals, LLC",520 White Plains Road,Suite 500,Tarrytown,New York,10591,United States,464714
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,3507,alpha1-proteinase inhibitor (human),3/3/2015,Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",8368 US Business Hwy 70 West,,Clayton,North Carolina,27520,United States,418913
AMIFAMPRIDINE PHOSPHATE,8HF8FIN815,Designated,Public record,3508,amifampridine phosphate,3/3/2015,Treatment of congenital myasthenic syndromes,Designated,Not FDA Approved for Orphan Indication,,,,,Catalyst Pharmaceuticals,"(dba Catalyst Pharmaceutical Partner, Inc)",Suite 1500,Coral Gables,Florida,33134,United States,464814
DACOMITINIB,5092U85G58,Designated,Public record,3509,dacomitinib,3/3/2015,"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.",Designated/Approved,,For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R,9/27/2018,9/27/2025,For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,435114
PF-05230907,W1DT53SAN0,Designated,Public record,3510,recombinant activated Factor X variant,3/3/2015,Treatment of intracerebral hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,439014
PMX-205 ACETATE,7P258240O5,Designated,Public record,3512,hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO),3/9/2015,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Alsonex Pty Ltd,210 Alice Street,"OLD, 4000",Brisbane,,,Australia,469014
LEBRIKIZUMAB,U9JLP7V031,Designated,Public record,3513,lebrikizumab,3/9/2015,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,381112
EDARAVONE,S798V6YJRP,Designated,Public record,3514,edaravone,3/12/2015,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Treeway B.V.,Sevillaweg 142,,Rotterdam,,,Netherlands,465514
PONATINIB,4340891KFS,Designated/Withdrawn,Public record,3515,ponatinib,3/12/2015,Treatment of gastrointestinal stromal tumors (GIST).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ARIAD Pharmaceuticals, Inc.",26 Landsdowne Street,,Cambridge,Massachusetts,2339,United States,466714
Hydroxyurea,X6Q56QN5QC,Designated,Public record,3516,hydroxyurea,3/16/2015,"Treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.",Designated,Not FDA Approved for Orphan Indication,,,,,Ebelle D'Ebelle Pharmaceuticals LLC,5 Witherwood Drive,,Hamburg,New Jersey,7419,United States,463414
MELPHALAN FLUFENAMIDE HYDROCHLORIDE,3412470A0V,Designated,Public record,3517,melphalan flufenamide,3/16/2015,"Treatment of plasma cell myeloma, also referred to as multiple myeloma",Designated/Approved,,"Treatment, in combination with dexamethasone, of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory",2/26/2021,2/26/2028,"Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monocl",Oncopeptides AB,Vastra Tradgardsgatan 15,,Stockholm,,,Sweden,465314
NAPROXCINOD,V24GR4LI3I,Designated,Public record,3518,naproxcinod,3/16/2015,Treatment of Duchenne muscular dystrophy.,Designated,Not FDA Approved for Orphan Indication,,,,,Nicox SA,2105 route des Dolines,Drakkar bat D-CS 10313,Valbonne,,,France,467414
PEGZILARGINASE,4YV4KW88GD,Designated,Public record,3519,pegzilarginase,3/16/2015,Treatment of arginase I deficiency (hyperargininemia).,Designated,Not FDA Approved for Orphan Indication,,,,,"Aeglea Biotherapeutics, Inc.",805 Las Cimas Parkway,Suite 100,Austin,Texas,78746,United States,466614
BN-82451,531B661QBY,Designated/Withdrawn,Public record,3520,"phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride",3/16/2015,Treatment of Huntington's disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.",106 Allen Road,3rd Floor,Basking Ridge,New Jersey,7920,United States,468314
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,3521,tacrolimus,3/16/2015,Treatment of pulmonary arterial hypertension.,Designated,Not FDA Approved for Orphan Indication,,,,,"VIVUS, Inc.",900 East Hamilton Avenue,Suite 550,Campbell,California,95008,United States,468214
AEOL-10150,KPKO7W46E8,Designated,Public record,3522,tetra-substituted porphyrin derivative containing manganese (III),3/16/2015,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Aeolus Pharmaceuticals,26361 Crown Valley Parkway,Suite 150,Mission Viejo,California,92691,United States,465414
SEVUPARIN,7C17NQF03M,Designated,Public record,3524,sevuparin,3/17/2015,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,Modus Therapeutics,Sankt Eriksgatan 117,SE-113 43,Stockholm,,,Sweden,467314
SELADELPAR LYSINE,N1429130KR,Designated,Public record,3525,2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate,3/18/2015,Treatment of homozygous familial hypercholesterolemia (HoFH),Designated,Not FDA Approved for Orphan Indication,,,,,"CymaBay Therapeutics, Inc.",7999 Gateway Blvd,Suite 130,Newark,California,94560,United States,429214
HYDROCORTISONE,WI4X0X7BPJ,Designated,Public record,3526,hydrocortisone modified release capsules,3/18/2015,Treatment of congenital adrenal hyperpasia,Designated,Not FDA Approved for Orphan Indication,,,,,Diurnal Limited,Cardiff Medicentre,,Cardiff,,,United Kingdom,467014
MASITINIB MESYLATE,ZK89EG3A18,Designated,Public record,3527,masitinib mesylate,3/18/2015,Treatment of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenuve George V",75008,Paris,,,France,469415
METHOTREXATE,YL5FZ2Y5U1,Designated,Public record,3528,methotrexate oral liquid formulation,3/18/2015,Treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.,Designated,Not FDA Approved for Orphan Indication,,,,,Chesapeake Therapeutics,1498-M Reistertown Road,Suite 313,Pikesville,Maryland,21208,United States,469315
TREMELIMUMAB,QEN1X95CIX,Designated,Public record,3529,tremelimumab,3/18/2015,Treatment of malignant mesothelioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC",One MedImmune Way,,Gaithersburg,Maryland,20878,United States,466014
VORETIGENE NEPARVOVEC-RZYL,,Designated/Approved,Public record,3530,voretigene neparvovec-rzyl,3/18/2015,Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations,Designated/Approved,,an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician,12/19/2017,12/19/2024,Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal distrophy. Patients must have viable retinal cells determined by a treating physician.,"Spark Therapeutics, Inc.",3737 Market Street,Suite 1300,Philadelphia,Pennsylvania,19104,United States,466414
CLADRIBINE,47M74X9YT5,Designated,Public record,3531,cladribine,3/19/2015,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,Designated,Not FDA Approved for Orphan Indication,,,,,Chord Therapeutics S.a.r.l.,15 Avenue De Secheron,,Geneva,,,Switzerland,467214
ELAPEGADEMASE,9R3D3Y0UHS,Designated,Public record,3532,elapegademase-lvlr,3/19/2015,Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.,Designated/Approved,,Treatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID).,10/5/2018,10/5/2025,treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.,Chiesi USA Inc.,175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,467514
RONEPARSTAT,1J0593208B,Designated,Public record,3533,roneparstat,3/19/2015,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Leadiant Biosciences S.p.A,Via Sudafrica 20,,Roma,,,Italy,468914
SONIDEGIB,0RLU3VTK5M,Designated,Public record,3534,sonidegib,3/23/2015,Treatment of medulloblastoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,468814
QUINOLINE,E66400VT9R,Designated,Public record,3535,4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid,3/24/2015,Prevention of scarring post ab externo glaucoma surgery,Designated,Not FDA Approved for Orphan Indication,,,,,Clanotech AB,Fogdevreten 2,,Solna,,,Sweden,468714
"""AMYLOPECTIN, UNSPECIFIED SOURCE""",4XO4QFV777,Designated,Public record,3536,amylopectin,3/24/2015,Treatment of glycogen storage disease types Ia and Ib,Designated,Not FDA Approved for Orphan Indication,,,,,"Voltera Pharmaceuticals, LLC",9322 SW 41st Ln,,Gainesville,Florida,32608,United States,469515
AVICIN D,69451KN1RO,Designated,Public record,3537,avicin d,3/24/2015,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Avicin Therapeutics Ltd.,Westpark Corporate Center,4634 S. Alston Avenue,Durham,North Carolina,27713,United States,467714
GANAXOLONE,98WI44OHIQ,Designated,Public record,3538,ganaxolone,3/24/2015,Treatment of Protocadherin 19 (PCDH19) female epilepsy.,Designated,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",3 Radnor Corporate Center,Suite 304,Radnor,Pennsylvania,19087,United States,473515
BIFIDOBACTERIUM ANIMALIS LACTIS,5307V7XW8I,Designated,Public record,3539,Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis,3/24/2015,Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams,Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd.,Suite 500,Gaithersburg,Maryland,20878,United States,422414
LACTOBACILLUS ACIDOPHILUS,1PRR1V42V5,Designated,Public record,3539,Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis,3/24/2015,Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams,Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd.,Suite 500,Gaithersburg,Maryland,20878,United States,422414
CRS-207,JJX4JHS4PO,Designated,Public record,3540,Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38,3/24/2015,Treatment of mesothelioma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Aduro BioTech, Inc.",740 Heinz Avenue,,Berkeley,California,94710,United States,468614
MITAPIVAT SULFATE,N4JTA67V3O,Designated,Public record,3541,mitapivat,3/24/2015,Treatment of pyruvate kinase deficiency,Designated/Approved,,Treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency,2/17/2022,2/17/2029,Treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency,"Agios Pharmaceuticals, Inc.",88 Sidney Street,,Cambridge,Massachusetts,2139,United States,442814
BI-836826,LB090AB8DB,Designated,Public record,3542,"mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37",3/24/2015,Treatment of chronic lymphocytic leukemia (CLL).,Designated,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.","900 Ridgebury Rd., PO Box 368",,Ridgefield,Connecticut,6877,United States,451514
BARDOXOLONE,7HT68L8941,Designated,Public record,3543,bardoxolone,3/30/2015,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Dr.,Suite 150,Irving,Texas,75063,United States,456114
MINNELIDE,1CIV2UMO40,Designated,Public record,3544,C21H27O10P,3/30/2015,Treatment of gastric cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Minneamrita Therapeutics, LLC",6 Hickory Court,,Rock Island,Illinois,61201,United States,471615
DALBAVANCIN,808UI9MS5K,Designated,Public record,3545,dalbavancin,3/30/2015,Treatment of acute osteomyelitis in children (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,Durata Therapeutics International B.V.,"Spaces Zuidas II, Kantoor 4.03",,Amsterdam,,,Netherlands,459714
LANIFIBRANOR,28Q8AG0PYL,Designated,Public record,3546,1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid,3/31/2015,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Inventiva Pharma,50 rue de Dijon,,Daix 21121,,,France,470315
BAZLITORAN SODIUM,1NLR4WAG4U,Designated,Public record,3547,5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+,3/31/2015,Treatment of diffuse large B-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Idera Pharmaceuticals, Inc.",505 Eagleview Boulevard,Suite 212,Exton,Pennsylvania,19341,United States,472615
BRYOSTATIN 1,37O2X55Y9E,Designated,Public record,3548,bryostatin 1,3/31/2015,Treatment of Fragile X Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Synaptogenix, Inc.",50 Park Place,Suite 1401,Newark,New Jersey,7102,United States,471415
MYRCLUDEX B,JA8K50N04H,Designated,Public record,3549,bulevirtide,3/31/2015,Treatment of hepatitis D virus infection.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,470915
FIMEPINOSTAT,3S9RX35S5X,Designated,Public record,3550,C24H28N8O7S2,4/2/2015,Treatment of diffuse large B-cell lymphoma (DLBCL).,Designated,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.",4 Maguire Road,,Lexington,Massachusetts,2421,United States,467814
GOLIMUMAB,91X1KLU43E,Designated,Public record,3551,golimumab,4/2/2015,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older,9/29/2020,9/29/2027,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC",1400 McKean Road,,Spring House,Pennsylvania,19477,United States,325610
TANESPIMYCIN,4GY0AVT3L4,Designated,Public record,3552,"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)",4/2/2015,Treatment of angiosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Co-D Therapeutics, Inc.",1625 Kings Mill Way,Suite 205,Madison,Wisconsin,53718,United States,469915
PACLITAXEL,P88XT4IS4D,Designated,Public record,3552,"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)",4/2/2015,Treatment of angiosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Co-D Therapeutics, Inc.",1625 Kings Mill Way,Suite 205,Madison,Wisconsin,53718,United States,469915
SIROLIMUS,W36ZG6FT64,Designated,Public record,3552,"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)",4/2/2015,Treatment of angiosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Co-D Therapeutics, Inc.",1625 Kings Mill Way,Suite 205,Madison,Wisconsin,53718,United States,469915
DOXORUBICIN,80168379AG,Designated,Public record,3553,doxorubicin,4/6/2015,Treatment of cutaneous T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Louis D. Falo, Jr.","University of Pittsburgh, Dep. of Dermatology",3500 Fifth Avenue,Pittsburgh,Pennsylvania,15213,United States,469215
INSULIN HUMAN,1Y17CTI5SR,Designated,Public record,3554,human insulin (rDNA),4/6/2015,Treatment of short bowel syndrome (SBS).,Designated,Not FDA Approved for Orphan Indication,,,,,ELGAN Pharma Ltd.,13 wadi el hadj,,Nazareth,,17111,Israel,469115
EFLORNITHINE HYDROCHLORIDE,4NH22NDW9H,Designated,Public record,3555,eflornithine HCL,4/7/2015,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Cancer Prevention Pharmaceuticals, Inc.",1760 East River Road,Suite 250,Tucson,Alaska,85718,United States,472715
FLUCICLOVINE F-18,38R1Q0L1ZE,Designated,Public record,3556,"fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)",4/7/2015,For the diagnosis of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Blue Earth Diagnostics Ltd.,215 Euston Rd.,NW1 2BE,London,,,United Kingdom,465814
TREOSULFAN,CO61ER3EPI,Designated,Public record,3558,treosulfan,4/8/2015,Conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases in adults and pediatric patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Medac GmbH,TheaterstraBe 6,,Wedel,,,Germany,468014
PREXASERTIB MESYLATE MONOHYDRATE,S4D3L195S4,Designated,Public record,3559,"2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate",4/9/2015,Treatment of anal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Acrivon Therapeutics, Inc.","480 Arsenal Way, Suite 100",,Watertown,Massachusetts,2472,United States,472015
AMANTADINE HYDROCHLORIDE,M6Q1EO9TD0,Designated/Approved,Public record,3560,Amantadine hydrochloride,4/9/2015,Treatment of levodopa-induced dyskinesia,Designated/Approved,,treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications,8/24/2017,8/24/2024,treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications,"Adamas Pharmaceuticals, Inc.",1900 Powell Street,Suite 750,Emeryville,California,94608,United States,413213
SODIUM ASCORBATE,S033EH8359,Designated,Public record,3561,sodium ascorbate and menadione sodium bisulfite,4/9/2015,Treatment of noninfected painful total joint without mechanical complication,Designated,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,92021,United States,392513
MENADIONE SODIUM BISULFITE,6XF3C2HK77,Designated,Public record,3561,sodium ascorbate and menadione sodium bisulfite,4/9/2015,Treatment of noninfected painful total joint without mechanical complication,Designated,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,92021,United States,392513
SELADELPAR LYSINE,N1429130KR,Designated,Public record,3562,2-[4-[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate,4/15/2015,Treatment of patients with Frederickson Type I or V hyperlipoproteinemia,Designated,Not FDA Approved for Orphan Indication,,,,,"CymaBay Therapeutics, Inc.",7999 Gateway Blvd,Suite 130,Newark,California,94560,United States,470715
DIPHENCYPRONE,I7G14NW5EC,Designated,Public record,3563,Diphenylcyclopropenone gel,4/15/2015,Treatment of malignant melanoma stage IIB to IV,Designated,Not FDA Approved for Orphan Indication,,,,,RXi Pharmaceuticals Corp.,257 Simarano Drive,Suite 101,Marlborough,Massachusetts,1752,United States,473615
OBINUTUZUMAB,O43472U9X8,Designated/Approved,Public record,3564,obinutuzumab,4/15/2015,Treatment of follicular lymphoma,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen",2/26/2016,2/26/2023,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group",1 DNA Way,,South San Francisco,California,94080,United States,473415
OBINUTUZUMAB,O43472U9X8,Designated/Approved,Public record,3565,obinutuzumab,4/15/2015,Treatment of follicular lymphoma,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherap",11/16/2017,11/16/2024,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group",1 DNA Way,,South San Francisco,California,94080,United States,473415
PELAREOREP,S9J80L3D1U,Designated,Public record,3566,pelareorep,4/15/2015,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,,Canada,472915
SELUMETINIB,6UH91I579U,Designated/Withdrawn,Public record,3567,selumetinib,4/15/2015,Treatment of uveal melanoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,471015
TRIHEPTANOIN,2P6O7CFW5K,Designated,Public record,3568,triheptanoin,4/15/2015,Treatment of fatty acid oxidation disorders,Designated/Approved,,DOJOLVI is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).,6/30/2020,6/30/2027,Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,,Novato,California,94949,United States,474015
"""ZOLEDRONATE D,L-LYSINE MONOHYDRATE""",IL1N7FSO1U,Designated,Public record,3569,"zoledronate D,L-lysine monohydrate (ZLM)",4/15/2015,Treatment of complex regional pain syndrome (CRPS),Designated,Not FDA Approved for Orphan Indication,,,,,"Thar Pharma, LLC",150 Gamma Dr.,,Pittsburgh,Pennsylvania,15238,United States,461014
PACLITAXEL TREVATIDE,8P77G99D3P,Designated,Public record,3570,[Î±â¿¿N-(2â¿¿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr,4/15/2015,Treatment of breast cancer patients with brain metastases,Designated,Not FDA Approved for Orphan Indication,,,,,"Angiochem, Inc.",201 President Kennedy,,Montreal,,,Canada,446614
TRX-E-002-1,5DVS457HEG,Designated,Public record,3572,cantrixil,4/20/2015,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Kazia Therapeutics Limited,20 George Street,Suite 207,Hornsby,New South Wales,,Australia,474815
CAP-1002,ZM7OCV7H6H,Designated,Public record,3573,allogeneic cardiosphere-derived cells,4/21/2015,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Capricor, Inc.",8840 Wilshire Boulevard,2nd Floor,Beverly HIlls,California,90211,United States,474615
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3574,cannabidiol,4/22/2015,Treatment of neonatal hypoxic ischemic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,GW Pharma Ltd.,15 T.W. Alexander Drive,P. O. Box 13547,Research Triangle Park,North Carolina,27709,United States,471815
ATYR-1940,WS7U5TQ7ZJ,Designated,Public record,3575,recombinant human histidyl tRNA synthetase,4/22/2015,Treatment of facioscapulohumeral muscular dystrophy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"aTyr Pharma, Inc.",3545 John Hopkins Court,Suite 250,San Diego,California,92121,United States,474215
DOCONEXENT,ZAD9OKH9JC,Designated,Public record,3577,docosahexaenoic acid,4/27/2015,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Micelle BioPharma, Inc.","3874 Fiscal Ct., #200",,Riviera Beach,Florida,33404,United States,454314
PROPRANOLOL,9Y8NXQ24VQ,Designated,Public record,3579,propranolol and etodolac,4/27/2015,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,7960,United States,475715
ETODOLAC,2M36281008,Designated,Public record,3579,propranolol and etodolac,4/27/2015,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,7960,United States,475715
DEZAPELISIB,2K59L7G59M,Designated,Public record,3580,"(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one",4/29/2015,Treatment of Hodgkin lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,476215
LENALIDOMIDE,F0P408N6V4,Designated,Public record,3581,lenalidomide,4/29/2015,Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,Designated/Approved,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated extranodal marginal zone lymphoma,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,476115
ANTROQUINONOL,AX9P92T7JZ,Designated,Public record,3582,antroquinonol,4/30/2015,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Golden Biotechnology Corporation,"10F, No. 9, Ln. 3, Sec. 1, Zhong-Zheng E. Rd",,New Taipei City 251,,,Taiwan,476315
ELECLAZINE,PUY08529FK,Designated/Withdrawn,Public record,3583,"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one",5/4/2015,Treatment of congenital long QT syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,446214
PHOSPHOPANTOTHENIC ACID,1SCE5NG3E8,Designated,Public record,3585,pantothenate phosphate,5/4/2015,Treatment of pantothenate kinase associated neurodegeneration (PKAN).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Retrophin, Inc.",777 Third Avenue,22nd Floor,New York,New York,10017,United States,427114
PELAREOREP,S9J80L3D1U,Designated,Public record,3586,pelareorep,5/4/2015,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,,Canada,478315
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,3587,tacrolimus,5/4/2015,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Stanford University School of Medicine,300 Pasteur Drive,Room H3143,Stanford,California,94305,United States,472815
TADALAFIL,742SXX0ICT,Designated,Public record,3588,tadalafil,5/4/2015,Treatment of Duchenne Muscular Dystrophy (DMD),Designated,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,476415
TALACOTUZUMAB,X8JR0I7JE1,Designated,Public record,3589,humanized monoclonal antibody that targets the a-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473),5/5/2015,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,478715
EDARAVONE,S798V6YJRP,Designated/Approved,Public record,3591,edaravone,5/12/2015,Treatment of amyotrophic lateral sclerosis,Designated/Approved,,Treatment of amyotrophic lateral sclerosis (ALS),5/12/2022,,,Mitsubishi Tanabe Pharma Corporation,"17-10, Nihonbashi-Koamicho",,Tokyo,,,Japan,478215
EDARAVONE,S798V6YJRP,Designated/Approved,Public record,3592,edaravone,5/12/2015,Treatment of amyotrophic lateral sclerosis,Designated/Approved,,Treatment of amyotrophic lateral sclerosis (ALS),5/5/2017,5/5/2024,Treatment of amyotrophic lateral sclerosis (ALS),Mitsubishi Tanabe Pharma Corporation,"17-10, Nihonbashi-Koamicho","Chuo-ku,",Tokyo,,,Japan,478215
N-T-BUTYLHYDROXYLAMINE,BQ5JE2DA91,Designated,Public record,3593,N-t-butylhydroxylamine,5/12/2015,Treatment of infantile neuronal ceroid lipofuscinosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Andrew Lim,California Institute of Technology,1200 East California Blvd.,Pasadena,California,91125,United States,478615
FDL169,49PN4S4FDH,Designated,Public record,3594,2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide,5/13/2015,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Flatley Discovery Lab,529 Main Street,Suite 115,Charlestown,Massachusetts,2129,United States,479115
ACALABRUTINIB,I42748ELQW,Designated,Public record,3595,acalabrutinib,5/13/2015,Treatment of chronic lymphocytic leukemia (CLL).,Designated/Approved,,Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),8/4/2022,,,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,94080,United States,477415
ACALABRUTINIB,I42748ELQW,Designated,Public record,3596,acalabrutinib,5/13/2015,Treatment of chronic lymphocytic leukemia (CLL).,Designated/Approved,,CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).,11/21/2019,11/21/2026,Indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,94080,United States,477415
ADALIMUMAB,FYS6T7F842,Designated/Approved,Public record,3597,adalimumab,5/13/2015,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa,9/9/2015,9/9/2022,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,446414
ADALIMUMAB,FYS6T7F842,Designated/Approved,Public record,3598,adalimumab,5/13/2015,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.,10/16/2018,10/16/2025,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,446414
GOSURANEMAB,09FZ7Q0PQZ,Designated,Public record,3599,Anti-eTau Humanized IgG4 Monoclonal Antibody,5/13/2015,Treatment of Progressive Supranuclear Palsy,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",225 Binney Street,,Cambridge,Massachusetts,2142,United States,477515
UPROLESELAN SODIUM,17ZJN0Q4CJ,Designated,Public record,3600,E-selectin antagonist,5/13/2015,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,"GlycoMimetics, Inc.",401 Professional Drive,Suite 250,Gaithersburg,Maryland,20879,United States,475315
HYDROCORTISONE,WI4X0X7BPJ,Designated,Public record,3601,Hydrocortisone,5/13/2015,Treatment of pediatric adrenal insufficiency (0 through 16 years of age).,Designated/Approved,,ALKINDI® SPRINKLE is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency,9/29/2020,,,"Eton Pharmaceuticals, Inc.","21925 West Field Parkway, Suite 235",,Deer Park,Illinois,60010,United States,441614
REVUSIRAN,ZE6EHM8Z3A,Designated,Public record,3603,revusiran,5/18/2015,Treatment of transthyretin amyloidosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alnylam Pharmaceuticals, Inc.",300 Third Street,,Cambridge,Massachusetts,2142,United States,477615
XENON,3H3U766W84,Designated,Public record,3604,xenon gas,5/18/2015,To improve neurological outcome in hospitalized cardiac arrest patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Neuroprotexeon,Imperial Innovations,London SW7 2PG,London,,,United Kingdom,461914
CHLOROQUINE,886U3H6UFF,Designated,Public record,3605,chloroquine,5/20/2015,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"DualTpharma B.,V.",Boschstraat 111-D01,,Maastricht,,,Netherlands,475015
ECHINOMYCIN,TG824J6RQT,Designated,Public record,3606,echinomycin,5/21/2015,Treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"OncoC4, Inc.",9640 Medical Center Drive,,Rockville,Maryland,20850,United States,479815
Lutetium Lu177 Edotreotide,RGO812Q0C8,Designated,Public record,3607,lutetium (177Lu)-edotreotide,5/21/2015,Treatment of gastro-entero-pancreatic neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,ITM Solucin GmbH,Lichtenbergstrasse 1,,Garching,,,Germany,479215
PRASUGREL HYDROCHLORIDE,G89JQ59I13,Designated,Public record,3609,prasugrel hydrochloride,5/26/2015,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,Eli Lilly,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,473015
IDARUCIZUMAB,97RWB5S1U6,Designated/Approved,Public record,3611,idarucizumab,5/28/2015,To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure,Designated/Approved,,For use in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding,10/16/2015,10/16/2022,For use in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding,"Boehringer Ingelheim Pharmaceuticals, Inc.",PO Box 368,900 Ridgebury Road,Ridgefield,Connecticut,6877,United States,445714
NIMODIPINE,57WA9QZ5WH,Designated,Public record,3612,intraventricular nimodipine,5/28/2015,Treatment of subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,"Edge Therapeutics, Inc.",211 Warren Street,,Newark,New Jersey,7103,United States,343711
METHOTREXATE,YL5FZ2Y5U1,Designated/Approved,Public record,3613,methotrexate oral solution,5/28/2015,Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age),Designated/Approved,,Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen,4/25/2017,4/25/2024,Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen,"Silvergate Pharmaceuticals, Inc.",6251 Greenwood Plaza Blvd.,Suite 101,Greenwood Village,Colorado,80111,United States,479615
HYDROXYPROGESTERONE CAPROATE,276F2O42F5,Designated,Public record,3614,17-a-hydroxyprogesterone caporate (oral formulation),6/1/2015,Prevention of preterm birth in women with a singleton pregnancy,Designated,Not FDA Approved for Orphan Indication,,,,,"Lipocine, Inc.",675 Arapeen Drive,Suite 202,Salt Lake City,Utah,84108,United States,445314
APTO-253,WB59MRW00U,Designated,Public record,3615,"2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline",6/1/2015,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Aptose Biosciences, Inc.",5955 Airport Road,Suite 228,"Mississauga,",,,Canada,480415
DOCONEXENT,ZAD9OKH9JC,Designated,Public record,3616,docosahexaenoic acid,6/1/2015,Treatment of short bowel syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Micelle BioPharma, Inc.","3874 Fiscal Ct., #200",,Riviera Beach,Florida,33404,United States,450214
IBUDILAST,M0TTH61XC5,Designated,Public record,3617,ibudilast,6/1/2015,Treatment of Krabbe disease,Designated,Not FDA Approved for Orphan Indication,,,,,"MediciNova, Inc.",4275 Executive Square,Suite 300,La Jolla,California,92037,United States,480015
REGORAFENIB ANHYDROUS,24T2A1DOYB,Designated/Approved,Public record,3619,regorafenib,6/4/2015,Treatment of hepatocellular carcinoma,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.,4/27/2017,4/27/2024,Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd,P. O. Box 915,Whippany,New Jersey,7981,United States,478015
Ersodetug,QD87BSP58N,Designated,Public record,3623,fully human IgG2 monoclonal antibody that binds insulin receptors,6/9/2015,Treatment of congenital hyperinsulinism,Designated,Not FDA Approved for Orphan Indication,,,,,"Rezolute, Inc.",201 Redwood Shores Parkway,,Redwood City,California,94065,United States,430714
IVOSIDENIB,Q2PCN8MAM6,Designated,Public record,3624,ivosidenib,6/9/2015,Treatment of acute myeloid leukemia (AML),Designated/Approved,,TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.,7/20/2018,7/20/2025,Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,481515
IVOSIDENIB,Q2PCN8MAM6,Designated,Public record,3625,ivosidenib,6/9/2015,Treatment of acute myeloid leukemia (AML),Designated/Approved,,"In combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have",5/25/2022,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,481515
IVOSIDENIB,Q2PCN8MAM6,Designated,Public record,3626,ivosidenib,6/9/2015,Treatment of acute myeloid leukemia (AML),Designated/Approved,,TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities th,5/2/2019,5/2/2026,TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities th,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,481515
LENABASUM,OGN7X90BT8,Designated,Public record,3629,"(6aR, 10aR)-3-(1â¿¿,1â¿¿-dimethylheptyl)-Î¿8-tetrahydro-cannabinol-9-carboxylic acid",6/10/2015,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Corbus Pharmaceuticals, Inc.",500 River Ridge Drive,Second Floor,Norwood,Massachusetts,2062,United States,480715
BEVIFIMOD,PNV0H3A73B,Designated,Public record,3630,staphylococcal aureus protein A,6/10/2015,Treatment of immune thrombocytopenic purpura,Designated,Not FDA Approved for Orphan Indication,,,,,"Protalex, Inc.",131 Columbia Turnpike,Suite 1,Florham Park,New Jersey,7932,United States,427714
IMETELSTAT,F60NE4XB53,Designated,Public record,3631,imetelstat,6/11/2015,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Geron Corporation,"919 E. Hillsdale Blvd., Suite 250",,Foster City,California,94404,United States,481315
OBINUTUZUMAB,O43472U9X8,Designated/Withdrawn,Public record,3632,obinutuzumab,6/11/2015,Treatment of splenic marginal zone lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS# 214A,South San Francisco,California,94080,United States,473315
ABEQUOLIXRON,Q26B92650V,Designated,Public record,3633,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",6/16/2015,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Rgenix, Inc.",310 East 67th Street,Suite 1-12,New York,New York,10065,United States,483115
ABEQUOLIXRON,Q26B92650V,Designated,Public record,3634,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",6/16/2015,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"Rgenix, Inc.",310 East 67th Street,Suite 1-12,New York,New York,10065,United States,483215
PEMBROLIZUMAB,DPT0O3T46P,Designated/Approved,Public record,3635,pembrolizumab,6/16/2015,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated/Approved,,"in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma",5/5/2021,5/5/2028,"for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, excluding patients covered by Keytruda's previous indication for gastric or GEJ adenocarcino",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,481715
PEMBROLIZUMAB,DPT0O3T46P,Designated/Approved,Public record,3636,pembrolizumab,6/16/2015,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with",9/22/2017,9/22/2024,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,481715
IMMUCIN,YRY1GG3QHU,Designated,Public record,3638,synthetic signal peptide of human mucin-1 (amino acids 1-21),6/16/2015,Treatment of multiple myeloma.,Designated,Not FDA Approved for Orphan Indication,,,,,Vaxil Bio Therapeutics Ltd.,"13 Einstein St., Building 13A",,Nes-Ziona,,,Israel,482115
SXR-1096,BDQ30W2KTS,Designated,Public record,3639,"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one",6/18/2015,Treatment of Netherton syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Sixera Pharma AB,Erik Dahlbergsgaten 11a2t,,Vastra Gotaland 41126,,,Sweden,481815
ABEQUOLIXRON,Q26B92650V,Designated,Public record,3640,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",6/23/2015,Treatment of malignant melanoma stages IIB to IV.,Designated,Not FDA Approved for Orphan Indication,,,,,"Rgenix, Inc.",310 East 67th Street,Suite 1-12,New York,New York,10065,United States,483015
TOZULERISTIDE,835UH424TU,Designated,Public record,3641,chlorotoxin conjugated to indocyanine green dye,6/23/2015,Diagnostic for the management of malignant brain tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Blaze Bioscience, Inc.","530 Fairview Avenue, North",Suite 1400,Seattle,Washington,98109,United States,482615
LORLATINIB,OSP71S83EU,Designated,Public record,3642,Lorlatinib; lorlatinib,6/23/2015,Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer,Designated/Approved,,LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or al,11/2/2018,11/2/2025,LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or al,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,481015
LORLATINIB,OSP71S83EU,Designated,Public record,3643,Lorlatinib; lorlatinib,6/23/2015,Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer,Designated/Approved,,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.,3/3/2021,3/3/2028,"Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test, excluding patients whose disease has progressed on crizotinib and at least one o","Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,481015
VOLANESORSEN SODIUM,6JON30SLDT,Designated,Public record,3644,"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide",6/23/2015,treatment of familial chylomicronemia syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Akcea Therapeutics, Inc.",22 Boston Wharf Road,9th Floor,Boston,Massachusetts,2210,United States,480815
VOLANESORSEN,2O4BE0K238,Designated,Public record,3644,"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide",6/23/2015,treatment of familial chylomicronemia syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Akcea Therapeutics, Inc.",22 Boston Wharf Road,9th Floor,Boston,Massachusetts,2210,United States,480815
GEMCITABINE,B76N6SBZ8R,Designated,Public record,3645,gemcitabine ready-to-use,6/24/2015,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sun Pharmaceutical Industries Ltd.,Acme Plaza,,"Andheri (East), Mumbai 400059",,,India,477015
GEMCITABINE,B76N6SBZ8R,Designated,Public record,3646,gemcitabine ready-to-use,6/24/2015,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sun Pharmaceutical Industries Ltd.,Acme Plaza,,"Andheri (East), Mumbai 400059",,,India,476915
EDOTREOTIDE GALLIUM GA-68,Y68179SY2L,Designated,Public record,3647,Gallium (68Ga) edotreotide,7/1/2015,Diagnostic for the clinical management of neuroendocrine tumors.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Advanced Accelerator Applications, USA",57 East Willow Street,,Millburn,New Jersey,7041,United States,483915
SARIZOTAN,467LU0UCUW,Designated,Public record,3649,sarizotan,7/7/2015,Treatment of Rett syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Newron Pharmaceuticals US, Inc.",89 Headquarter Plaza North,Suite 1438,Morristown,New Jersey,7960,United States,484015
CB-5083,591IV6UL6J,Designated/Withdrawn,Public record,3650,"1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide",7/8/2015,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cleave Biosciences, Inc.",866 Malcolm Road,Suite 100,Burlingame,California,94010,United States,483815
PROPRANOLOL,9Y8NXQ24VQ,Designated,Public record,3651,propranolol and etodolac,7/8/2015,Treatment of malignant glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,7960,United States,484315
ETODOLAC,2M36281008,Designated,Public record,3651,propranolol and etodolac,7/8/2015,Treatment of malignant glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,7960,United States,484315
"""3,3',5,5'-TETRAIODOTHYROACETIC ACID""",PA7UX1FFYQ,Designated,Public record,3652,nano-diamino-tetraiodothyroacetic acid,7/9/2015,Treatment of glioblastoma multiforme (GBM),Designated,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,12144,United States,485115
"""3-(4-(1,5-NAPTHRYDINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)))""",1G7DB33DC7,Designated,Public record,3653,"3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)",7/14/2015,Treatment of fibrodysplasia ossificans progressiva.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"La Jolla Pharmaceutical Company, Inc.",10182 Telesis Court,Suite 600,San Diego,California,92121,United States,484615
"""3-(4-(8-FLUOROQUINOLINE)IMIDAZOLE(1,2-A)PYRIDINE-7-(1-PHENYL-4-(1-(4-METHYL PIPERAZINE)""",0PD95Q5DD1,Designated,Public record,3654,"3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)",7/14/2015,Treatment of fibrodysplasia ossificans progressiva.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"La Jolla Pharmaceutical Company, Inc.",10182 Telesis Court,Suite 600,San Diego,California,92121,United States,484915
ATM-3507,MC4FSR36T2,Designated,Public record,3656,anisina,7/14/2015,Treatment of neuroblastoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Novogen Ltd,16-20 Edgeworth David Avenue,,Hornsbsy,,,Australia,485815
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3657,cannabidiol,7/14/2015,Prevention of Graft versus Host Disease (GVHD).,Designated,Not FDA Approved for Orphan Indication,,,,,"Kalytera Therapeutics Israel, Ltd.",Technological Building,Road 4 Katzrin,Qatsrin,,,Israel,482315
MELPHALAN,Q41OR9510P,Designated,Public record,3659,melphalan,7/14/2015,Treatment of cholangiocarcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1633 Broadway,Suite 22C,New York,New York,10019,United States,485515
4-ISOTHIOUREIDOBUTYRONITRILE,C3059TG1KN,Designated,Public record,3661,thioureidobutyronitrile,7/14/2015,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Innovation Pharmaceuticals, Inc.",100 Cummings Center,Suite 151-B,Beverly,Massachusetts,1915,United States,485615
VITAMIN A PALMITATE,1D1K0N0VVC,Designated,Public record,3662,vitamin A palmitate,7/14/2015,Prevention of bronchopulmonary dysplasia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Advent Therapeutics, Inc.",6500 Old Carversville Road,,Lumberville,Pennsylvania,18933,United States,483315
OMBITASVIR,2302768XJ8,Designated,Public record,3664,ombitasvir/paritaprevir/ritonavir and dasabuvir,7/16/2015,Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"Abbvie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,484715
PARITAPREVIR,OU2YM37K86,Designated,Public record,3664,ombitasvir/paritaprevir/ritonavir and dasabuvir,7/16/2015,Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"Abbvie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,484715
RITONAVIR,O3J8G9O825,Designated,Public record,3664,ombitasvir/paritaprevir/ritonavir and dasabuvir,7/16/2015,Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"Abbvie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,484715
DASABUVIR,DE54EQW8T1,Designated,Public record,3664,ombitasvir/paritaprevir/ritonavir and dasabuvir,7/16/2015,Treatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"Abbvie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,484715
ANDECALIXIMAB,571045EIM4,Designated,Public record,3665,recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4,7/16/2015,Treatment of gastric cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St.,,Seattle,Washington,98102,United States,473815
AMANTADINE HYDROCHLORIDE,M6Q1EO9TD0,Designated,Public record,3666,Amantadine HCl,7/20/2015,Treatment of levodopa-induced dyskinesia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Osmotica Pharmaceutical Corporation,"Regulatory, Clinical Operations & Legal","Lumina Station #2, Suite 209-A",Wilmington,North Carolina,28403,United States,257608
MONGERSEN,O1VIU3R1NE,Designated,Public record,3667,mongersen,7/20/2015,Treatment of pediatric Crohn's disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,484215
ANTROQUINONOL,AX9P92T7JZ,Designated,Public record,3669,antroquinonol,7/23/2015,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Golden Biotechnology Corporation,"10F, No. 9, Ln. 3","Tamsui Dist.,",New Taipei City 251,,,Taiwan,488115
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3670,cannabidiol,7/23/2015,Treatment of infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",950 Winter Street,,Waltham,Massachusetts,2451,United States,486115
PAC-1,9LIS8N0B2C,Designated,Public record,3671,procaspase-activating compound 1,7/23/2015,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanquish Oncology, Inc.",2001 S. First Street,Suite 201,Champaign,Illinois,61820,United States,486615
VELTUZUMAB,BPD4DGQ314,Designated,Public record,3672,veltuzumab,7/28/2015,Treatment of immune thrombocytopenic purpura.,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,7950,United States,486915
AFATINIB,41UD74L59M,Designated/Approved,Public record,3673,afatinib,8/3/2015,Treatment of non-small cell lung cancer with squamous histology.,Designated/Approved,,"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy",4/15/2016,4/15/2023,"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy","Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,484115
INECALCITOL,05FZV98342,Designated,Public record,3674,inecalcitol,8/3/2015,Treatment of acute myeloid leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Hybrigenics, S.A.",3-5 Impasse Reille,75014,Paris,,,France,479715
3-BUTYLIDENEPHTHALIDE,S9178G4B3F,Designated,Public record,3675,butylidenephthalide,8/5/2015,Treatment of Malignant Glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Everfront Biotech, Inc.","11F., No. 31, Ln. 169, Kangning St.",,New Taipei City 221,,,Taiwan,485715
VALPROATE SODIUM,5VOM6GYJ0D,Designated,Public record,3676,sodium valproate,8/5/2015,Treatment of Wolfram syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,The University of Birmingham,Birmingham Research Park - Vincent Drive,,Birmingham,,,United Kingdom,486515
VARLITINIB,846Y8197W1,Designated,Public record,3677,varlitinib,8/5/2015,treatment of biliary tract cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"ASLAN Pharmaceuticals Pte, Ltd.",83 Clemenceau Avenue,#12-03,Singapore,,,Singapore,485915
DARATUMUMAB,4Z63YK6E0E,Designated,Public record,3678,daratumumab,8/6/2015,Treatment of follicular lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,487415
DARATUMUMAB,4Z63YK6E0E,Designated,Public record,3680,daratumumab,8/20/2015,Treatment of mantle cell lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,488615
MAGROLIMAB,90YIEHRFJ9,Designated,Public record,3681,humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47,8/20/2015,Treatment of acute myeloid (myelogenous) leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,488515
FOSTAMATINIB DISODIUM,86EEZ49YVB,Designated,Public record,3683,fostamatinib disodium hexahydrate,8/25/2015,Treatment of immune thrombocytopenic purpura,Designated/Approved,,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.,4/17/2018,4/17/2025,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.,"Rigel Pharmaceuticals, Inc.",1180 Veterans Boulevard,,South San Francisco,California,94080,United States,487715
ABTL-0812 SODIUM,X1840C8161,Designated,Public record,3684,sodium 2-hydroxylinoleate,8/25/2015,Treatment of neuroblastoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Ability Pharmaceuticals, SL","Edifici Eureka, Campus de la UAB",,Bellaterra,,8193,Spain,489315
METHOTREXATE,YL5FZ2Y5U1,Designated/Approved,Public record,3685,methotrexate oral solution,8/27/2015,Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy.,Designated/Approved,,"Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-infl",4/25/2017,4/25/2024,Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant or of had an inadequate response to first-line therapy.,"Silvergate Pharmaeuticals, Inc.",6251 Greenwood Plaza Blvd,Suite 101,Greenwood Village,Colorado,80111,United States,479515
NIVOLUMAB,31YO63LBSN,Designated,Public record,3686,nivolumab,8/27/2015,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co,P. O. Box 4000,,Princeton,New Jersey,8543,United States,469615
LAROTRECTINIB SULFATE,RDF76R62ID,Designated,Public record,3687,Larotrectinib,8/31/2015,Treatment of soft tissue sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare Pharmaceuticals Inc.,100 Bayer Boulevard,,Whippany,New Jersey,7981,United States,490115
ACETYLCYSTEINE,WYQ7N0BPYC,Designated,Public record,3688,N-acetylcysteine and sodium thiosulfate,8/31/2015,Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD",3181 SW Sam Jackson Park Road,,Portland,Oregon,97239,United States,479415
SODIUM THIOSULFATE,HX1032V43M,Designated,Public record,3688,N-acetylcysteine and sodium thiosulfate,8/31/2015,Prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD",3181 SW Sam Jackson Park Road,,Portland,Oregon,97239,United States,479415
UDENAFIL,L5IB4XLY36,Designated,Public record,3689,udenafil,8/31/2015,Treatment of single ventricle congenital heart disease with Fontan physiology,Designated,Not FDA Approved for Orphan Indication,,,,,Mezzion Pharma Co. Ltd.,3rd Floor C & H Building,Gangnam-gu 135-879,Seoul,,,South Korea,449714
ATALUREN,K16AME9I3V,Designated,Public record,3690,ataluren,9/1/2015,Treatment of aniridia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,490215
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,3693,nivolumab; nivolumab,9/2/2015,Treatment of hepatocellular carcinoma,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Indication withdrawn),9/22/2017,7/23/2021,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Indication withdrawn),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,,United States,489915
NIVOLUMAB,31YO63LBSN,Designated/Approved,Public record,3694,nivolumab; nivolumab,9/2/2015,Treatment of hepatocellular carcinoma,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.",3/10/2020,,,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,,United States,489915
HYDROCORTISONE,WI4X0X7BPJ,Designated,Public record,3695,hydrocortisone modified release capsules,9/3/2015,Treatment of adrenal insufficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,Diurnal Limited,Cardiff Medicentre,,Cardiff,,,United Kingdom,487515
NIMOTUZUMAB,6NS400BXKH,Designated,Public record,3696,nimotuzumab,9/8/2015,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,InnoCIMab Pte Ltd,21 Bukit Batok Crescent,,WCEGA Tower #14-78,,,Singapore,487915
PENTETRAZOL,WM5Z385K7T,Designated,Public record,3697,pentetrazol,9/9/2015,Treatment of idiopathic hypersomnia,Designated,Not FDA Approved for Orphan Indication,,,,,"Balance Therapeutics, Inc.",1250 Bayhill Drive,Suite 125,San Bruno,California,94066,United States,488815
ICERGUASTAT ACETATE,JDD15DX7JF,Designated,Public record,3698,2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate,9/10/2015,Treatment of Charcot-Marie Tooth disease.,Designated,Not FDA Approved for Orphan Indication,,,,,InFlectis BioScience,21 rue de la Noue Bras de Fer,44200,Nantes,,,France,488415
EVEROLIMUS,9HW64Q8G6G,Designated,Public record,3699,everolimus ointment,9/10/2015,Topical treatment of Tuberous Sclerosis Complex-related skin lesions,Designated,Not FDA Approved for Orphan Indication,,,,,"Aucta Pharmaceuticals, LLC",675 US Highway One,,North Brunswick,New Jersey,8902,United States,489715
IMLIFIDASE,UVJ7NL8S2P,Designated,Public record,3700,immunoglobulin G degrading enzyme of Streptococcus pyogenes,9/10/2015,Prevention of antibody mediated organ rejection in solid organ transplant patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Hansa Medical AB,"Scheelevägen 22, P. O. Box 785",SE-220 07,Lund,,,Sweden,455114
MANF,5R3OV3AM5M,Designated,Public record,3701,"mesencephalic, astrocyte-derived neurotrophic factor",9/10/2015,Treatment of retinal artery occlusion.,Designated,Not FDA Approved for Orphan Indication,,,,,"Amarantus BioScience Holdings, Inc.",655 Montgomery Street,Suite 900,San Francisco,California,94111,United States,466314
MASITINIB MESYLATE,ZK89EG3A18,Designated,Public record,3702,masitinib mesylate,9/14/2015,Treatment of gastric cancer including cancer of the gastroesophageal junction,Designated,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue George V",,Paris,,,France,490815
BLU-9931,FQK825B5DX,Designated,Public record,3703,small molecule FGFR4 inhibitor,9/14/2015,Treatment of hepatocellular cancer (HCC).,Designated,Not FDA Approved for Orphan Indication,,,,,Blueprint Medicines Corporation,38 Sidney Street,Suite 200,Cambridge,Massachusetts,2139,United States,490915
ANAKINRA,9013DUQ28K,Designated,Public record,3704,interleukin-1 receptor antagonist anakinra,9/15/2015,Treatment of Still's disease including systemic juvenile idiopathic arithritis and adult-onset Still's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB,SE-112,75 Stockholm,Stockholm,,,Sweden,488715
NIVOLUMAB,31YO63LBSN,Designated,Public record,3706,nivolumab,9/15/2015,Treatment of small cell lung cancer.,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Indication withdrawn),8/16/2018,12/29/2020,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Indication withdrawn),Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,6492,United States,491415
REMDESIVIR,3QKI37EEHE,Designated,Public record,3707,Remdesivir,9/18/2015,Treatment of Ebola virus disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,490515
UPADACITINIB TARTRATE,7KCW9IQM02,Designated,Public record,3708,upadacitinib,9/18/2015,Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA,Designated,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,485415
ACALABRUTINIB,I42748ELQW,Designated/Approved,Public record,3709,acalabrutinib,9/21/2015,Treatment of mantle cell lymphoma.,Designated/Approved,,treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,10/31/2017,10/31/2024,treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,94080,United States,488915
ACALABRUTINIB,I42748ELQW,Designated/Approved,Public record,3710,acalabrutinib,9/21/2015,Treatment of mantle cell lymphoma.,Designated/Approved,,Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,8/4/2022,,,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,94080,United States,488915
AVELUMAB,KXG2PJ551I,Designated/Approved,Public record,3712,avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1),9/21/2015,Treatment of merkel cell carcinoma.,Designated/Approved,,Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma,3/23/2017,3/23/2024,Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma,"EMD Serono Research and Development Institute, Inc.",45A Middlesex Turnpike,,Billerica,Massachusetts,1821,United States,491815
MARIZOMIB,703P9YDP7F,Designated,Public record,3713,marizomib,9/21/2015,Treatment of malignant glioma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene International II S?,Rue du Pre-Jorat 14,,Couvet,Neuchâtel,,Switzerland,490015
MECASERMIN,7GR9I2683O,Designated,Public record,3714,"mecasermin, recombinant human insulin-like growth factor-1",9/21/2015,Treatment of Rett Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences,535 Watson Drive,,Claremont,California,91711,United States,491915
SETMELANOTIDE,N7T15V1FUY,Designated,Public record,3715,setmelanotide,9/21/2015,Treatment of Prader-Willi Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Rhythm Metabolics, Inc.",855 Boylston Street,11th Floor,Boston,Massachusetts,2116,United States,480615
RO-6870810,TA3QN7788D,Designated,Public record,3716,"2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide",9/29/2015,Treatment of nuclear protein in testis (NUT) midline carcinoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc (a Roche Group Member)",1 DNA Way,M/S# 35-5e,South San Francisco,California,94080,United States,492615
TEMPOL,U78ZX2F65X,Designated,Public record,3717,"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",9/29/2015,Treatment of cerebral cavernous malformation.,Designated,Not FDA Approved for Orphan Indication,,,,,"Recursion Pharmaceuticals, LLC",383 S. Colorow Drive,,Salt Lake City,Utah,84108,United States,487815
GLYBURIDE,SX6K58TVWC,Designated,Public record,3719,glyburide,9/29/2015,Treatment of acute spinal cord injury,Designated,Not FDA Approved for Orphan Indication,,,,,"Remedy Pharmaceuticals, Inc.","233 Broadway, Suite 1750",,New York,New York,10279,United States,491215
GUADECITABINE,2KT4YN1DP7,Designated,Public record,3720,guadecitabine,9/29/2015,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,94588,United States,492515
MOCRAVIMOD HYDROCHLORIDE,3YH0N35CE3,Designated/Withdrawn,Public record,3721,"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3-propanediol hydrochloride",10/6/2015,Prevention of graft versus host disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,491315
PACLITAXEL,P88XT4IS4D,Designated,Public record,3722,nanoparticulate paclitaxel,10/6/2015,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"NanOlogy, LLC",231 Bonetti Drive,,San Luis Obispo,California,93401,United States,482015
RODATRISTAT ETHYL,507FY6OL37,Designated,Public record,3723,rodatristat ethyl,10/6/2015,Treatment of pulmonary arterial hypertension (PAH).,Designated,Not FDA Approved for Orphan Indication,,,,,Altavant Sciences GmbH,8 Viaduktstrasse,,Basel,Basel-Stadt,,Switzerland,492715
BETAMETHASONE,9842X06Q6M,Designated,Public record,3724,betamethasone,10/7/2015,Treatment of Ataxia Telangiectasia.,Designated,Not FDA Approved for Orphan Indication,,,,,Acasti Pharma Inc.,"3009 Boulevard De la Concorde E., Suite 102",,Laval,Quebec,,Canada,492415
LENABASUM,OGN7X90BT8,Designated,Public record,3727,"(6aR, 10aR)-3-(1¿,1¿-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid",10/13/2015,Treatment of cystic fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Corbus Pharmaceuticals, Inc.",500 River Ridge Drive,Second floor,Norwood,Massachusetts,2062,United States,493415
SETANAXIB,45II35329V,Designated,Public record,3728,"(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione)",10/14/2015,Treatment of systemic sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics Suisse SA,Chemin des Aulx 16,,Plan-les-Ouates,,1228,Switzerland,493115
STM-434,7G4D2B5AC8,Designated,Public record,3729,human soluble receptor-Fc fusion protein that targets human activin A,10/14/2015,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Atara Biotherapeutics,4360 Park Terrace Drive,Suite 100,Westlake Village,California,91361,United States,489415
LISINOPRIL,E7199S1YWR,Designated/Withdrawn by OPD,Public record,3730,lisinopril oral solution,10/14/2015,Treatment of hypertension in pediatric patients 0 through 16 years of age.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Silvergate Pharmaceuticals, Inc.",6251 Greenwood Plaza Blvd.,Suite 101,Greenwood Village,Colorado,80111,United States,481915
ONDANSETRON,4AF302ESOS,Designated,Public record,3731,ondansetron inhalation powder,10/14/2015,Prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .,Designated,Not FDA Approved for Orphan Indication,,,,,"Luxena Pharmaceuticals, Inc.",1400 Coleman Avenue,Suite D27,Santa Clara,California,95050,United States,491115
ACALABRUTINIB,I42748ELQW,Designated,Public record,3732,acalabrutinib,10/22/2015,Treatment of Waldenstrom macroglobulinemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,94080,United States,489015
BUCILLAMINE,R80LRA5WTF,Designated,Public record,3733,bucillamine,10/22/2015,Treatment of cystinuria,Designated,Not FDA Approved for Orphan Indication,,,,,"Revive Therapeutics, Ltd.",5 Director Court,Suite 105,Vaughan,,,Canada,493615
DEFLAZACORT,KR5YZ6AE4B,Designated,Public record,3734,deflazacort,10/22/2015,Treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (JIA) International League of Associations for Rheumatology (ILAR) categories excluding systemic JIA.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,491715
PARICALCITOL,6702D36OG5,Designated/Approved,Public record,3735,paricalcitol,10/27/2015,Treatment of pediatric hyperparathyroidism,Designated/Approved,,Indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal di,10/18/2016,10/18/2023,Indicated in pediatric patients ages 10 -16 years for treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and pediatric patients ages 10-16 years for treatment of secondary hyperparathyroidism associated,"Abbvie, inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,492815
BACLOFEN,H789N3FKE8,Designated,Public record,3737,baclofen,10/28/2015,Treatment of complex regional pain syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Piramal Critical Care, Inc.",261 Brodhead Road,Suite 221,Bethlehem,Pennsylvania,18017,United States,493915
VALSARTAN,80M03YXJ7I,Designated/Withdrawn by OPD,Public record,3739,valsartan oral solution,10/28/2015,Treatment of hypertension in pediatric patients 0 through 16 years of age,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Carmel Biosciences,5673 Peachtree Dunwoody Road,Suite 440,Atlanta,Georgia,30342,United States,494115
TRAMETINIB,33E86K87QN,Designated/Approved,Public record,3740,dabrafenib and trametinib,10/29/2015,Treatment of patients with BRAF mutation positive non-small cell lung cancer.,Designated/Approved,,"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",6/22/2017,6/22/2024,"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test; AND Tafinlar in combination with trametinib, for the treatment of patie",Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,495915
DABRAFENIB,QGP4HA4G1B,Designated/Approved,Public record,3740,dabrafenib and trametinib,10/29/2015,Treatment of patients with BRAF mutation positive non-small cell lung cancer.,Designated/Approved,,"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",6/22/2017,6/22/2024,"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test; AND Tafinlar in combination with trametinib, for the treatment of patie",Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,495915
LUCERASTAT,GVS3YDM418,Designated,Public record,3741,lucerastat,10/29/2015,Treatment of Fabry Disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Idorsia Pharmaceuticals US Inc.,1820 Chapel Avenue West,Suite 150,Cherry Hill,New Jersey,8002,United States,495815
CM-101,YW45RY9QD4,Designated,Public record,3742,monoclonal antibody targeting eotaxin-2,10/29/2015,Treatment of idiopathic pulmonary fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"ChemomAb, Ltd.",6 Hanehoset St.,,Tel Aviv,,,Israel,494615
AQ-13 FREE BASE,4K7VT5621X,Designated,Public record,3743,"N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine",10/29/2015,Treatment of malaria.,Designated,Not FDA Approved for Orphan Indication,,,,,"Donald J. Krogstad, MD","1430 Tulane Ave., #8317",J.B. Johnson Building,New Orleans,Louisiana,70112,United States,494715
ARSENIC TRIOXIDE,S7V92P67HO,Designated,Public record,3745,arsenic trioxide capsule (oral),11/2/2015,Treatment of acute promyelocytic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Syros Pharmaceuticals, Inc.","35 CambridgePark Drive, 4th Floor",,Cambridge,Massachusetts,2140,United States,496415
CISPLATIN,Q20Q21Q62J,Designated,Public record,3746,Cisplatin ChemoThin Wafer,11/3/2015,"Treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)",Designated,Not FDA Approved for Orphan Indication,,,,,Privo Technologies,13 Bristol Street,Unit #1,Cambridge,Massachusetts,2141,United States,447514
BENDAMUSTINE,9266D9P3PQ,Designated,Public record,3748,Bendamustine oral doseage formulation,11/5/2015,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Exinda Theapeutics LLC,"3941 Park Drive, Suite 20-740",,El Dorado Hills,California,95762,United States,486215
MIRANSERTIB,T1DQI1B52Y,Designated,Public record,3749,"3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate",11/9/2015,Treatment of Proteus Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,497115
DARATUMUMAB,4Z63YK6E0E,Designated,Public record,3750,daratumumab,11/9/2015,Treatment of diffuse large B-cell lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring hOuse,Pennsylvania,19477,United States,496815
EDETIC ACID,9G34HU7RV0,Designated,Public record,3752,sodium nitrite and EDTA,11/10/2015,Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Arch Biopartners, Inc.",27 Saint Clair Avenue East,P. O. Box 305,Toronto,,,Canada,495615
Sodium nitrite,M0KG633D4F,Designated,Public record,3752,sodium nitrite and EDTA,11/10/2015,Treatment of Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Arch Biopartners, Inc.",27 Saint Clair Avenue East,P. O. Box 305,Toronto,,,Canada,495615
VADASTUXIMAB TALIRINE,T13V17U431,Designated,Public record,3753,vadastuximab talirine,11/10/2015,Treatment of acute myeloid leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,494515
DIAZEPAM,Q3JTX2Q7TU,Designated,Public record,3755,diazepam (intranasal),11/16/2015,Management of acute repetitive seizures,Designated/Approved,,"Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 6 years of age and older.",1/10/2020,1/10/2027,"Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 6 years of age and older.","Neurelis Pharmaceuticals, Inc.",11682 El Camino Reall,Suite 255,San Diego,California,92130,United States,382512
AMY-101,4Z4DFR9BX7,Designated,Public record,3757,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide",11/16/2015,Treatment of C3 glomerulopathy.,Designated,Not FDA Approved for Orphan Indication,,,,,Amyndas Pharmaceuticals S.A,Kyprou 27,,Glyfada,,16675,Greece,494915
4-ISOTHIOUREIDOBUTYRONITRILE,C3059TG1KN,Designated,Public record,3758,thioureidobutyronitrile,11/17/2015,Treatment of retinoblastoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Innovation Pharmaceuticals, Inc.",100 Cummings Center,Suite 151-B,Beverly,Massachusetts,1915,United States,502515
ARM-210 HEMIFUMARATE,ZHR6WM1ADJ,Designated,Public record,3759,"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate",11/18/2015,Treatment of patients with Duchenne Muscular Dystrophy.,Designated,Not FDA Approved for Orphan Indication,,,,,"ARMGO Pharma, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,501515
OXALOACETIC ACID,2F399MM81J,Designated,Public record,3761,oxaloacetic acid,11/18/2015,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Terra Biological LLC,3830 Valley Centre Drive,Suite 705-561,San Diego,California,92130,United States,488015
DERAZANTINIB HYDROCHLORIDE,U6B7J0L31Q,Designated,Public record,3762,"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride",11/19/2015,Treatment of cholangiocarcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Basilea Pharmaceutical International Ltd.,Grenzacherstrasse 487,P.O. Box,Basel,,,Switzerland,497615
UBENIMEX,I0J33N5627,Designated,Public record,3763,ubenimex,11/19/2015,Treatment of pulmonary arterial hypertension.,Designated,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.",350 Cambridge Avenue,Suite 350,Palo Alto,California,94306,United States,498115
PEMZIVIPTADIL,200AW54D93,Designated,Public record,3764,Vasomera,11/19/2015,"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP).",Designated,Not FDA Approved for Orphan Indication,,,,,ImmunoForge Co. Ltd.,"#1704, Ace Hansol Tower, 58, Gasan Digital 1-ro",Geumcheon-gu,Seoul,,,South Korea,492215
NECITUMUMAB,2BT4C47RUI,Designated/Approved,Public record,3765,necitumumab,11/20/2015,Treatment of squamous non-small cell lung cancer,Designated/Approved,,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.",11/24/2015,11/24/2022,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer",Eli Lilly and Company,33 ImClone Drive,,Branchburg,New Jersey,8876,United States,418213
GO-203-2C,5YSY733NA3,Designated,Public record,3766,acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylmaide disulfide,11/24/2015,Treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Genus Oncology, LLC",2458 N. Racine Avenue,,Chicago,Illinois,60614,United States,494415
TEMOZOLOMIDE,YF1K15M17Y,Designated,Public record,3767,temozolomide,11/25/2015,Treatment glioblastoma multiforme in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"AmpliPharm Pharmaceuticals, LLC",970 Peachtree Industrial Boulevard,Suite 100,Suwanee,Georgia,30024,United States,497215
TIRAPAZAMINE,1UD32YR59G,Designated,Public record,3768,tirapazamine,11/30/2015,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Teclison Limited,28 Baltusrol Way,,Short Hills,New Jersey,7078,United States,498815
AZURIN-P28,H4QZU9L323,Designated,Public record,3769,Azurin-p28,12/2/2015,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"CDG Therapeutics, Inc.",840 South Wood Street,M/C 820,Chicago,Illinois,60612,United States,507415
PERFLENAPENT,483AU1Y5CZ,Designated,Public record,3770,dodecafluoropentane emulsion (DDFPe),12/2/2015,Radiosensitizer to be used during radiation treatment of glioblastoma multiforme (GBM).,Designated,Not FDA Approved for Orphan Indication,,,,,NuvOx Pharma,1635 East 18th Street,,Tucson,Alaska,85719,United States,497715
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3771,delta-9-tetrahydrocannibinol and cannabidiol,12/3/2015,Treatment of glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,498215
DRONABINOL,7J8897W37S,Designated,Public record,3771,delta-9-tetrahydrocannibinol and cannabidiol,12/3/2015,Treatment of glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,498215
FLINDOKALNER,J57O328W4W,Designated,Public record,3774,"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one",12/9/2015,Treatment of Fragile X Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Centre National de la Recherche Scientifique (CNRS),3 Rue Michel-Ange,,Paris,,,France,497515
CROMOLYN SODIUM,Q2WXR1I0PK,Designated,Public record,3775,cromolyn sodium for inhalation,12/9/2015,Treatment of mastocytosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Patara Pharma, LLC",11455 El Camino Real,Suite 460,San Diego,California,92130,United States,497415
PROPAGERMANIUM,1Q2P9TO9Q7,Designated,Public record,3776,propagermanium and irbesartan,12/9/2015,Treatment of focal segmental glomerulosclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Dimerix Bioscience Ltd.,"Level 2, 25 Flinders Lane",,Melbourne,Victoria,,Australia,496715
IRBESARTAN,J0E2756Z7N,Designated,Public record,3776,propagermanium and irbesartan,12/9/2015,Treatment of focal segmental glomerulosclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Dimerix Bioscience Ltd.,"Level 2, 25 Flinders Lane",,Melbourne,Victoria,,Australia,496715
Carbon dioxide,142M471B3J,Designated,Public record,3778,carbon dioxide,12/17/2015,Treatment of trigeminal neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Capnia, Inc.",3 Twin Dolphin Drive,Suite 160,Redwood City,California,94065,United States,465114
ROVALPITUZUMAB TESIRINE,P256HB60FF,Designated,Public record,3779,rovalpituzumab tesirine,12/22/2015,Treatment of small cell lung cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,500315
TELACEBEC,55G92WGH3X,Designated,Public record,3780,Substituted imidazopyridine amide,12/22/2015,Treatment of active tuberculosis (TB).,Designated,Not FDA Approved for Orphan Indication,,,,,"The Global Alliance for TB Drug Development, Inc.","80 Pine Street, 20th Floor",,New York,New York,10005,United States,499015
GALINPEPIMUT-S,12R66419FZ,Designated,Public record,3781,Human Wilms tumor protein 1 peptides,12/23/2015,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,SELLAS Life Sciences Group,75 Baarerstrasse,,Zug,Zug,,Switzerland,500915
IMETELSTAT,F60NE4XB53,Designated,Public record,3782,imetelstat,12/23/2015,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Geron Corporation,"919 E. Hillsdale Blvd., Suite 250",,Foster City,California,94404,United States,501415
TP-252,QDG62BO0C2,Designated,Public record,3783,magnesium lysinate bis eicosapentaenoate,12/23/2015,Treatment of familial adenomatous polyposis.,Designated,Not FDA Approved for Orphan Indication,,,,,Thetis Pharmaceuticals,167 Old Post Road,2nd Floor,Southport,Connecticut,6890,United States,501115
VL-2397,E39B3691TD,Designated,Public record,3785,Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III),12/29/2015,Treatment of invasive aspergillosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gravitas Therapeutics, Inc.",P.O. Box 8155,,Rancho Santa Fe,California,92067,United States,498415
DIPRAGLURANT,CV8JZR21A1,Designated,Public record,3786,dipraglurant,12/29/2015,Treatment of levodopa-induced dyskinesias,Designated,Not FDA Approved for Orphan Indication,,,,,Addex Pharma SA,Chemin des Aulx 14,1228 Plan-Les-Ouates,Geneva,,,Switzerland,485215
FLUTICASONE PROPIONATE,O2GMZ0LF5W,Designated,Public record,3787,fluticasone propionate,12/29/2015,Treatment of eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Banner Life Sciences, LLC",4125 Premier Drive,,High Point,North Carolina,27265,United States,499815
FOSBRETABULIN TROMETHAMINE,GBW044919E,Designated,Public record,3788,fosbretabulin tromethamine,12/29/2015,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Blvd,Suite 210,South San Francisco,California,94080,United States,500715
NOSCAPINE,8V32U4AOQU,Designated,Public record,3789,noscapine,12/29/2015,Treatment of amyotrophic lateral sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,KineMed Inc.,5980 Horton Street,Suite 470,Emeryville,California,94608,United States,500615
OZANIMOD,Z80293URPV,Designated,Public record,3790,ozanimod,12/29/2015,Treatment of pediatric (0 through 16 years of age) ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,3033 Science Park Road,Suite 300,San Diego,California,92121,United States,499515
TOMINERSEN,7QI41X9QWC,Designated,Public record,3792,Tominersen,12/29/2015,Treatment of Huntington's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,499215
TREPROSTINIL SODIUM,7JZ75N2NT6,Designated,Public record,3793,"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump",12/29/2015,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,SteadyMed Therapeutics,2603 Camino Ramon,Suite 350,San Ramon,California,94583,United States,478815
VOXELOTOR,3ZO554A4Q8,Designated,Public record,3794,voxelotor,12/29/2015,Treatment of sickle cell disease,Designated/Approved,,treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older,12/17/2021,12/17/2028,treatment of sickle cell disease (SCD) in pediatric patients 4 years of age to less than 12 years of age,"Global Blood Therapeutics, Inc.",181 Oyster Point Blvd,,South San Francisco,California,94080,United States,499715
VOXELOTOR,3ZO554A4Q8,Designated,Public record,3795,voxelotor,12/29/2015,Treatment of sickle cell disease,Designated/Approved,,OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.,11/25/2019,11/25/2026,Indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.,"Global Blood Therapeutics, Inc.",181 Oyster Point Blvd,,South San Francisco,California,94080,United States,499715
GEMCITABINE,B76N6SBZ8R,Designated,Public record,3796,gemcitabine,12/30/2015,Treatment of upper tract urothelial carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,TARIS Biomedical LLC,113 Hartwell Avenue,,Lexington,Massachusetts,2421,United States,502015
PEMBROLIZUMAB,DPT0O3T46P,Designated/Approved,Public record,3797,pembrolizumab,12/30/2015,Treatment of Hodgkin lymphoma.,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.",3/14/2017,3/14/2024,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rathway,Pennsylvania,7065,United States,502415
CAMSIRUBICIN HYDROCHLORIDE,QFO4NOX87K,Designated,Public record,3798,5-imino-13-deoxydoxorubicin HCl,12/31/2015,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Monopar Therapeutics, Inc.",5 Revere Drive,Suite 200,Northbrook,Illinois,60062,United States,490315
Catequentinib Hydrochloride,A3749M6582,Designated,Public record,3800,anlotinib hydrochloride,12/31/2015,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Advenchen Laboratories, LLC",887 Patriot Drive,Suite A,Moorpark,California,93021,United States,502715
FLUOROMISONIDAZOLE F-18,8MSY49469G,Designated,Public record,3801,1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole,1/6/2016,"As a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma.",Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,509715
AVAPRITINIB,513P80B4YJ,Designated,Public record,3802,avapritinib,1/6/2016,Treatment of gastrointestinal stromal tumors,Designated/Approved,,"Treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations",1/9/2020,1/9/2027,"Treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations",Blueprint Medicines Corporation,45 Sidney Street,Suite 200,Cambridge,Massachusetts,2139,United States,500415
BALORAMOTIDE,9T6PW6J6MA,Designated,Public record,3804,recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A,1/6/2016,Treatment of soft tissue sarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immune Design Corp.,1616 Eastlake Ave. E,Suite 310,Seattle,Washington,98102,United States,497815
LAPRETOLIMOD AMMONIUM,A1O9D5VN5D,Designated,Public record,3804,recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A,1/6/2016,Treatment of soft tissue sarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immune Design Corp.,1616 Eastlake Ave. E,Suite 310,Seattle,Washington,98102,United States,497815
CABIRALIZUMAB,5FJL6W0640,Designated,Public record,3805,Cabiralizumab,1/11/2016,Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Five Prime Therapeutics, Inc.",111 Oyster Point Boulevard,,South San Francisco,California,94080,United States,502315
GEMCITABINE,B76N6SBZ8R,Designated,Public record,3806,gemcitabine,1/11/2016,Treatment of cholangiocarcinoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"InnoPharmax, Inc.","9F, No. 22, Lane 478",Rueiguang Road,Taipei,Neihu District,,Taiwan,504815
CAVOSONSTAT,O2Z8Q22ZE4,Designated/Withdrawn,Public record,3807,S-nitrosoglutathione reductase inhibitor,1/13/2016,Treatment of cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Alpine Immune Sciences,201 Elliott Ave. West,Suite 230,Seattle,Washington,98119,United States,435714
ONL-1204,XNA75YDV3F,Designated,Public record,3808,His-His- Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2,1/13/2016,Treatment of retinal detachment,Designated,Not FDA Approved for Orphan Indication,,,,,"ONL Therapeutics, Inc",1600 Huron Parkway,"NCRC Bldg. 520, 2nd Floor",Ann Arbor,Michigan,48109,United States,501215
ALBUSOMATROPIN,88C1D8R8JW,Designated,Public record,3809,recombinant human serum albumin human growth hormone,1/13/2016,Treatment of growth hormone deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"TEVA Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,410513
MIFEPRISTONE,320T6RNW1F,Designated,Public record,3810,mifepristone,1/14/2016,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,94025,United States,506015
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,3811,pembrolizumab,1/14/2016,Treatment of primary mediastinal B cell lymphoma.,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy",6/13/2018,6/13/2025,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,495415
EDOTREOTIDE YTTRIUM Y-90,ABF7OG3FA3,Designated,Public record,3812,90Y-DOTA-tyr3-Octreotide,1/20/2016,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"M. Sue O'Dorisio, MD, PhD","2519 JPP, 200 Hawkins Drive",,Iowa City,Iowa,52242,United States,504015
CAROTUXIMAB,YB2EWE6139,Designated,Public record,3813,Human/Murine Chimeric Monoclonal antibody to Endoglin,1/20/2016,Treatment of soft tissue sarcoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Tracon Pharmaceuticals, Inc.",4350 LaJolla Village Dr.,Suite 800,San Diego,California,92122,United States,504715
4-ISOTHIOUREIDOBUTYRONITRILE,C3059TG1KN,Designated,Public record,3814,thioureidobutyronitrile,1/20/2016,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Innovation Pharmaceuticals, Inc.",100 Cummings Center,Suite 151-B,Beverly,Massachusetts,1915,United States,503815
AVAPRITINIB,513P80B4YJ,Designated,Public record,3815,avapritinib,1/21/2016,Treatment of mastocytosis,Designated/Approved,,"Treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).",6/16/2021,6/16/2028,"Treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).",Blueprint Medicines Corporation,45 Sidney Street,,Cambridge,Massachusetts,2139,United States,506515
AVAPRITINIB,513P80B4YJ,Designated,Public record,3816,avapritinib,1/21/2016,Treatment of mastocytosis,Designated/Approved,,Treatment of adult patients with indolent systemic mastocytosis (ISM). Limitations of Use: Ayvakit is not recommended for the treatment of patients with ISM with platelet counts of less than 50 X 109/L,5/22/2023,,,Blueprint Medicines Corporation,45 Sidney Street,,Cambridge,Massachusetts,2139,United States,506515
BQ-788,44OLL8XEJ4,Designated,Public record,3817,Endothelin receptor B antagonist,1/21/2016,Treatment of malignant melanoma Stages IIB to IV.,Designated,Not FDA Approved for Orphan Indication,,,,,"ENB Therapeutics, LLC",166 5th Avenue,2nd Floor,New York,New York,10010,United States,506215
TEBENTAFUSP,N658GY6L3E,Designated,Public record,3818,tebentafusp-tebn,1/21/2016,Treatment of uveal melanoma,Designated/Approved,,treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma,1/25/2022,1/25/2029,treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma,Immunocore Ltd,Milton Park,90 Park Drive,Milton,,,United Kingdom,503615
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,3819,bevacizumab,1/27/2016,Treatment of mesothelioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,505115
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,3820,ibrutinib,2/2/2016,Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma),Designated/Approved,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.,1/18/2017,1/18/2024,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.,"Pharmacyclics, LLC",1000 Gateway Blvd,,South San Francisco,California,94080,United States,462114
AFAMELANOTIDE,QW68W3J66U,Designated,Public record,3822,afamelanotide,2/4/2016,Treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease),Designated,Not FDA Approved for Orphan Indication,,,,,Clinuvel Inc.,40 Worth Street,Suite 1053,New York,New York,10013,United States,502815
ABBV-257,MA59O0RPES,Designated/Withdrawn,Public record,3823,human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A,2/4/2016,Treatment of pediatric patients 0 to,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,503715
MIDAZOLAM,R60L0SM5BC,Designated,Public record,3824,midazolam,2/4/2016,Treatment of status epilepticus,Designated/Approved,,SEIZALAM is indicated for the treatment of status epilepticus in adults.,9/14/2018,9/14/2025,SEIZALAM is indicated for the treatment of status epilepticus in adults.,Meridian Medical Technologies,6350 Stevens Forest Road,Suite 301,Columbia,Maryland,21046,United States,508215
SOLNATIDE,17ZS80333G,Designated,Public record,3825,solnatide,2/4/2016,Treatment of primary graft dysfunction following lung transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Apeptico Forschung und Entwicklung GmbH,c/o mingo bueros,,Vienna,,,Austria,504415
SOR-C13,C79B5A73C4,Designated,Public record,3827,Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH,2/4/2016,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Soricimed Biopharma Inc.,18 Botsford Street,Suite 201,Moncton,,,Canada,505215
TABELECLEUCEL,G3NJ7M8N4H,Designated,Public record,3828,tabelecleucel,2/4/2016,Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders,Designated,Not FDA Approved for Orphan Indication,,,,,"ATARA Biotherapeutics, Inc.",4360 Park Terrace Drive,Suite 100,Westlake Village,California,91361,United States,487015
TAZEMETOSTAT,Q40W93WPE1,Designated,Public record,3829,tazemetostat,2/4/2016,Treatment of malignant rhabdoid tumors (MRTs),Designated,Not FDA Approved for Orphan Indication,,,,,Epizyme Inc.,400 Technology Square,4th Floor,Cambridge,Massachusetts,2139,United States,508415
VENETOCLAX,N54AIC43PW,Designated,Public record,3830,venetoclax,2/4/2016,Treatment of acute myeloid leukemia.,Designated/Approved,,"VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensi",11/21/2018,11/21/2025,"VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensi",AbbVie Inc.,1 North Waukegan Road,"Dept PA72, Bldg. AP30-4",North Chicago,Illinois,60064,United States,506815
"""4-((2E)-1-OXO-3-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2-PROPEN-1-YL)-1-PIPERAZINECARBOXAMIDE""",BC9KBY85WY,Designated/Withdrawn,Public record,3831,"4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide",2/8/2016,Treatment of retinitis pigmentosa,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Shire HGT, Inc.",300 Shire Way,,Lexington,Massachusetts,2421,United States,506615
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,3832,Angiotensin (1-7),2/8/2016,Treatment of LAMA2-related muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Constant Therapeutics LLC,"303 Congress St, c/o Casner & Edwards",,Boston,Massachusetts,2210,United States,508815
DABRAFENIB,QGP4HA4G1B,Designated,Public record,3833,dabrafenib,2/8/2016,Treatment of malignant glioma with BRAF V600 mutation,Designated/Approved,,"in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy",3/16/2023,3/16/2030,treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,506415
ELTOPRAZINE HYDROCHLORIDE,5275JY4PKD,Designated,Public record,3834,eltoprazine HCl,2/8/2016,Treatment of levodopa-induced dyskinesia associated with Parkinson's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Amarantus BioScience Holdings, Inc.",655 Montgomery St.,Suite 900,San Francisco,California,94111,United States,504215
EVINACUMAB,T8B2ORP1DW,Designated,Public record,3835,evinacumab-dgnb,2/8/2016,Treatment of homozygous familial hypercholesterolemia.,Designated/Approved,,"as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH)",3/21/2023,3/21/2030,"as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of pediatric patients, aged 5 years to less than 12 years, with homozygous familial hypercholesterolemia (HoFH)","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,,United States,507815
EVINACUMAB,T8B2ORP1DW,Designated,Public record,3836,evinacumab-dgnb,2/8/2016,Treatment of homozygous familial hypercholesterolemia.,Designated/Approved,,"adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)",2/11/2021,2/11/2028,"adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,,United States,507815
GLYBURIDE,SX6K58TVWC,Designated,Public record,3837,glyburide,2/8/2016,Treatment of acute subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,"Remedy Pharmaceuticals, Inc.","233 Broadway, Suite 1750",,New York,New York,10279,United States,502615
LUMASIRAN,RZT8C352O1,Designated,Public record,3838,lumasiran,2/8/2016,Treatment of primary hyperoxaluria type 1,Designated/Approved,,Treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients,10/6/2022,10/6/2029,Treatment of primary hyperoxaluria type 1 (PH1) to lower plasma oxalate levels in pediatric and adult patients,Alnylam Pharmaceuticals,300 Third Street,,Cambridge,Massachusetts,2142,United States,505315
LUMASIRAN,RZT8C352O1,Designated,Public record,3839,lumasiran,2/8/2016,Treatment of primary hyperoxaluria type 1,Designated/Approved,,treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients,11/23/2020,11/23/2027,treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients,"Alnylam Pharmaceuticals, Inc.",300 Third Street,,Cambridge,Massachusetts,2142,United States,505315
MIDAZOLAM,R60L0SM5BC,Designated,Public record,3840,midazolam,2/8/2016,Treatment of seizures induced by organophosporous insecticide poisoning.,Designated,Not FDA Approved for Orphan Indication,,,,,"Meridian Medical Technologies, Inc.","6350 Stevens Forest Rd, Suite 301",,Columbia,Maryland,21046,United States,507615
ECHINOCANDIN B,CNW0ZW8ZTQ,Designated,Public record,3841,rezafungin,2/8/2016,Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.,Designated/Approved,,in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis,3/22/2023,3/22/2030,in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis,"Cidara Therapeutics, Inc.","6310 Nancy Ridge Drive, Suite 101",,San Diego,California,92121,United States,507215
SOLNATIDE,17ZS80333G,Designated,Public record,3842,solnatide,2/8/2016,Treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB),Designated,Not FDA Approved for Orphan Indication,,,,,Apeptico Forschung und Entwicklung GmbH (APEPTICO),Mariahilferstrabe 136,Top 1150,Vienna,,,Austria,504515
INEBILIZUMAB,74T7185BMM,Designated,Public record,3843,inebilizumab,2/10/2016,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders,Designated/Approved,,Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,6/11/2020,6/11/2027,Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,Horizon Therapeutics Ireland DAC,70St. Stephen’s Green,,Dublin 2,,,Ireland,490415
USL-311,2BTG5MX2Q2,Designated,Public record,3844,"6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide",2/11/2016,Treatment of glioblastoma multiforme (GBM).,Designated,Not FDA Approved for Orphan Indication,,,,,"Proximagen, LLC",505 Waterford Park,Hwy 169 North,Plymouth,Minnesota,55441,United States,503415
PERFLENAPENT,483AU1Y5CZ,Designated,Public record,3845,dodecafluoropentane emulsion,2/11/2016,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,NuvOx Pharma,1635 East 18th Street,,Tucson,Alaska,85719,United States,507515
EPACADOSTAT,71596A9R13,Designated,Public record,3846,epacadostat,2/11/2016,Treatment of stage IIB-IV melanoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,493015
ASC-JM-17,5VLL140BN9,Designated,Public record,3847,"1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",2/17/2016,Treatment of spinal and bulbar muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,AnnJi Pharmaceutical Co. Ltd.,"B405, No. 18, Siyuan St., Zhongzheng Dist.",,Taipei City 100,,,Taiwan,509315
DANTROLENE SODIUM,287M0347EV,Designated,Public record,3848,dantrolene sodium,2/17/2016,Treatment of Wolfram Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Washington University in St. Louis,660 S. Euclid Avenue,Campus Box 8127,St. Louis,Missouri,63110,United States,474515
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,3849,pembrolizumab,2/17/2016,Treatment of multiple myeloma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.",One Merck Drive,,Whitehouse Station,New Jersey,8889,United States,513115
RIMIDUCID,H564L1W5J2,Designated,Public record,3850,CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid,2/18/2016,Replacement T-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bellicum Pharmaceuticals, Inc.",2130 West Holcombe Boulevard,,Houston,Texas,77030,United States,496915
MIDAZOLAM,R60L0SM5BC,Designated,Public record,3851,midazolam,2/18/2016,Treatment of status epilepticus,Designated,Not FDA Approved for Orphan Indication,,,,,"Laboratorios Lesvi, S.L.",Avda. Barcelona 69,,Sant Joan Despí,Barcelona,8970,Spain,514115
FLAG-003 FREE BASE,LB2951OCS5,Designated,Public record,3852,"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine",2/18/2016,Treatment of glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Flag Therapeutics, Inc.",9168 Wooden Road,,Raleigh,North Carolina,27617,United States,509015
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3853,cannabidiol,2/23/2016,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Zynerba Pharmaceuticals, Inc.",80 West Lancaster Avenue,Suite 300,Devon,Pennsylvania,19333,United States,488315
SOMATORELIN,4UR7N9Z9MM,Designated,Public record,3854,"growth hormone releasing hormone, 1-44 human amide",2/23/2016,Treatment of growth hormone deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Hollenbeck Pharmaceuticals, Inc.",P. O. Box 429,,Falls Village,Connecticut,6031,United States,436814
RILUZOLE,7LJ087RS6F,Designated,Public record,3856,riluzole,2/23/2016,Treatment of spinocereballar ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceutical Holding Company, Ltd.",215 Church Street,,New Haven,Connecticut,6510,United States,510015
PARITAPREVIR,OU2YM37K86,Designated,Public record,3857,Ombitasvir/Paritaprevir/Ritonavir,2/24/2016,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,509215
OMBITASVIR,2302768XJ8,Designated,Public record,3857,Ombitasvir/Paritaprevir/Ritonavir,2/24/2016,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,509215
RITONAVIR,O3J8G9O825,Designated,Public record,3857,Ombitasvir/Paritaprevir/Ritonavir,2/24/2016,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,509215
SIROLIMUS,W36ZG6FT64,Designated,Public record,3858,rapamycin,2/24/2016,Treatment of facial angiofibromas (FA) associated with tuberous sclerosis complex (TSC).,Designated,Not FDA Approved for Orphan Indication,,,,,AFT Pharmaceuticals Ltd.,129 Hurstmere Road,"Level 1, Nielsen Building",Takapuna,Auckland,,New Zealand,508515
RELOXALIASE,48OB405WWC,Designated,Public record,3861,Bacillus subtilis oxalate decarboxylase,2/29/2016,Treatment of pediatric hyperoxaluria,Designated,Not FDA Approved for Orphan Indication,,,,,"Allena Pharmaceuticals, Inc.",1 Executive Park Drive,Suite 202,Newton,Massachusetts,2462,United States,508015
SETRUSUMAB,FPW3780T3E,Designated,Public record,3862,human monoclonal antibody targeting human sclerostin,2/29/2016,Treatment of osteogenesis imperfecta.,Designated,Not FDA Approved for Orphan Indication,,,,,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Ct,,Novato,California,94949,United States,508615
TESEVATINIB,F6XM2TN5A1,Designated,Public record,3863,Tesevatinib,3/1/2016,Treatment of patients with autosomal recessive polycystic kidney disease (ARPKD),Designated,Not FDA Approved for Orphan Indication,,,,,"Kadmon Corporation, LLC",450 East 29th Street,,New York,New York,10016,United States,506715
AMIKACIN,84319SGC3C,Designated,Public record,3864,encochleated amikacin,3/3/2016,Treatment of non-tuberculous mycobacteria (NTM) infections,Designated,Not FDA Approved for Orphan Indication,,,,,"Matinas BioPharma Nanotechnologies, Inc","1545 Route 206 South, Suite 302",,Bedminster Township,New Jersey,7921,United States,507715
VT-1598,AV9K9X720D,Designated,Public record,3865,selective inhibitor of fungal CYP51,3/3/2016,Treatment of coccidioidomycosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"NQP 1598, Ltd.","P.O. Box 309, Ugland House",,Grand Cayman,KYl-1004,,Cayman Islands,511515
DIANHYDROGALACTITOL,4S465RYF7M,Designated,Public record,3866,"1,2:5,6-dianhydrogalactitol",3/10/2016,Treatment of medulloblastoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"DelMar Pharmaceuticals, Inc.",3475 Edison Way,Suite R,Menlo Park,California,94025,United States,512515
ANFIBATIDE,DCG29J773G,Designated,Public record,3869,anfibatide,3/10/2016,Treatment of thrombotic thrombocytopenic purpura.,Designated,Not FDA Approved for Orphan Indication,,,,,Lee's Pharmaceutical (Hong Kong) Limited,"Unit 110-11, Bio-Informatics Centre",Hong Kong Science Park,"Shatin, Hong Kong",,,China,471215
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,3870,bevacizumab,3/10/2016,Treatment of Coat's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.",Bar Yehuda Street,,Nesher,Haifa District,,Israel,512215
ROSOMIDNAR,2X4LQG2T5U,Designated/Withdrawn,Public record,3872,Rosomidnar,3/10/2016,Treatment of diffuse large B-cell lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ProNAi Therapeutics, Inc.",46701 Commerce Center Drive,,Plymouth,Michigan,48170,United States,512415
TRIENTINE TETRAHYDROCHLORIDE,7360URE56Q,Designated,Public record,3873,trientine tetrahydrochloride,3/10/2016,Treatment of Wilson's disease excluding patients intolerant to penicillamine,Designated/Approved,,Treatment of adult patients with stable Wilson¿s disease who are de-coppered and tolerant to penicillamine,4/28/2022,4/28/2029,Treatment of adult patients with stable Wilson¿s disease who are de-coppered and tolerant to penicillamine,Orphalan,226 boulevard Voltaire,,Paris,,75011,France,492915
AMPHETAMINE,CK833KGX7E,Designated,Public record,3875,guanfacine and amphetamine,3/17/2016,Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"KemPharm, Inc.",1180 Celebration Boulevard,Suite 103,Celebration,Florida,34747,United States,405313
GUANFACINE,30OMY4G3MK,Designated,Public record,3875,guanfacine and amphetamine,3/17/2016,Treatment of pediatric patients with Tourette's syndrome (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"KemPharm, Inc.",1180 Celebration Boulevard,Suite 103,Celebration,Florida,34747,United States,405313
IVABRADINE,3H48L0LPZQ,Designated,Public record,3876,ivabradine,3/23/2016,Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.,Designated/Approved,,"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.",4/22/2019,4/22/2026,"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.","Amgen, Inc.,",1 Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,91320,United States,511915
IODINE I-131 APAMISTAMAB,71RR81V666,Designated,Public record,3878,131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I,3/28/2016,Treatment of Acute Myeloid Leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,"Actinium Pharmaceuticals, Inc.",379 Thornall Avenue,6th Floor,Edison,New Jersey,8837,United States,510615
ELRAGLUSIB,ND1SOF0DLU,Designated,Public record,3880,"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione",3/29/2016,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Actuate Therapeutics,1751 River Run,Suite 400,Fort Worth,Texas,76107,United States,513815
GENTAMICIN C2,3P99H114B8,Designated,Public record,3881,gentamicin C2 congener,3/29/2016,Treatment of cystic fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceuticals Company,10182 Telesis Court,Suite 600,San Diego,California,92121,United States,513215
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated,Public record,3882,immune globulin infusion 10% (human) with recombinant human hyaluronidase),3/31/2016,Treatment of chronic inflammatory demyelinating polyneuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,514315
HYALURONIDASE (HUMAN RECOMBINANT),743QUY4VD8,Designated,Public record,3882,immune globulin infusion 10% (human) with recombinant human hyaluronidase),3/31/2016,Treatment of chronic inflammatory demyelinating polyneuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,514315
FEXINIDAZOLE,306ERL82IR,Designated,Public record,3883,fexinidazole,4/4/2016,Treatment of human African trypanosomiasis (HAT) or sleeping sickness,Designated/Approved,,Treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Limitations of use: Due to t,7/16/2021,7/16/2028,Treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Limitations of use: Due to t,"Sanofi US Services Inc., A SANOFI COMPANY",55 Corporate Drive,,Bridgewater,New Jersey,,United States,513915
SETMELANOTIDE,N7T15V1FUY,Designated,Public record,3884,setmelanotide,4/4/2016,Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene,Designated/Approved,,"chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing dem",11/25/2020,11/25/2027,"chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing dem","Rhythm Pharmaceuticals, Inc.",222 Berkeley St. Suite 1200,,Boston,Massachusetts,2116,United States,514815
METRONIDAZOLE,140QMO216E,Designated,Public record,3885,metronidazole,4/5/2016,Treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).,Designated,Not FDA Approved for Orphan Indication,,,,,"Appili Therapeutics, Inc.",1344 Summer Street,Suite 415,Halifax,,,Canada,514715
CEREBROLYSIN,37KZM6S21G,Designated,Public record,3886,peptide fraction derived from porcine brain protein,4/5/2016,"Treatment of frontotemporal dementia, including all subvariants",Designated,Not FDA Approved for Orphan Indication,,,,,EVER Neuro Pharma GmbH,3 Oberburgau,,4866 Unterach,Salzburg,,Austria,513315
POLYHEXAMETHYLENEGUANIDINE,KYU75D2TUQ,Designated,Public record,3887,"poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine",4/5/2016,"Treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,Burkholderia cepacia and other bacteria",Designated,Not FDA Approved for Orphan Indication,,,,,"TGV-Inhalonix, Inc.",303 5th Avenue,Suite 2012,New York,New York,10016,United States,511215
AF-710B,AAE07Z061B,Designated,Public record,3888,"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one",4/6/2016,Treatment of frontotemporal dementia.,Designated,Not FDA Approved for Orphan Indication,,,,,Anavex Life Sciences Corp.,51 West 52nd Street,7th Floor,New York,New York,10019,United States,512615
FLUOROMISONIDAZOLE F-18,8MSY49469G,Designated,Public record,3889,1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol; 1H-1-(3-[18F]fluoro-2-hydroxypropyl0-2-nitroimidazole (18F-Misonidazole),4/6/2016,Diagnostic for management of glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,521116
PRITUMUMAB,Z6Q90D1G53,Designated,Public record,3890,pritumumab,4/6/2016,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.",8400 Miramar Road,Suite 247,San Diego,California,92126,United States,476615
7-ETHYL-10-HYDROXYCAMPTOTHECIN,0H43101T0J,Designated,Public record,3891,7-ethyl-10-hydroxycamptothecin (EHC),4/13/2016,Treatment of small cell lung cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Nippon Kayaku Co., Ltd.","1-1, Marunouchi 2-chome",,Chiyoda,Tokyo,,Japan,513715
Xevinapant,N65WC8PXDD,Designated,Public record,3892,"(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxyamide",4/14/2016,Treatment of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc., a business of Merck Healthcare KGaA",1 Technology Pl,,Rockland,Massachusetts,2370,United States,515315
GANAXOLONE,98WI44OHIQ,Designated,Public record,3893,ganaxolone,4/14/2016,Treatment of status epilepticus.,Designated,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",Three Radnor Corporate Center,100 Matsonford Road,Radnor,Pennsylvania,19087,United States,489215
DIANHYDROGALACTITOL,4S465RYF7M,Designated,Public record,3894,"1,2:5,6-dianhydrogalactitol",4/19/2016,Treatment of ovarian cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"DelMar Pharmaceuticals, Inc. (Clinical Operations)",3475 Edison Way,Suite R,Menlo Park,California,94025,United States,514915
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3896,cannabidiol,4/19/2016,Treatment of tuberous sclerosis complex.,Designated/Approved,,"treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older",7/31/2020,7/31/2027,treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,510716
VELEDIMEX,ASU841TV0X,Designated,Public record,3897,HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex,4/19/2016,Treatment of localized scleroderma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Castle Creek Biosciences, LLC",405 Eagleview Blvd,,Exton,Pennsylvania,19341,United States,493815
"""APHIDICOLIN, (?)-""",6B3F8QW8TU,Designated,Public record,3899,aphidicolin,4/20/2016,Treatment of Ebola virus infection,Designated,Not FDA Approved for Orphan Indication,,,,,Biospherics.net LLC,Department of Pharmaceutical Sciences,University of Kentucky,Nicholasville,Kentucky,40356,United States,472415
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated/Approved,Public record,3900,axicabtagene ciloleucel,4/20/2016,Treatment of primary mediastinal B-cell lymphoma.,Designated/Approved,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular l","Kite Pharma, inc.",2400 Broadway,,Santa Monica,California,90404,United States,515915
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated/Approved,Public record,3901,axicabtagene ciloleucel,4/20/2016,Treatment of primary mediastinal B-cell lymphoma.,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cel",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lin","Kite Pharma, inc.",2400 Broadway,,Santa Monica,California,90404,United States,515915
BREXUCABTAGENE AUTOLEUCEL,4MD2J2T8SJ,Designated/Approved,Public record,3902,brexucabtagene autoleucel,4/20/2016,Treatment of acute lymphoblastic leukemia (ALL),Designated/Approved,,Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL),10/1/2021,10/1/2028,Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL),"Kite Pharma, Inc.",2225 Colorado Avenue,,Santa Monica,California,90404,United States,515815
BREXUCABTAGENE AUTOLEUCEL,4MD2J2T8SJ,Designated/Withdrawn,Public record,3903,brexucabtagene autoleucel,4/20/2016,Treatment of chronic lymphocytic leukemia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2225 Colorado Avenue,,Santa Monica,California,90404,United States,516015
AJOENE,99A0041VG8,Designated,Public record,3904,"(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)",4/21/2016,Treatment of Pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Neem Biotech Ltd.,Units G & H,Roseheyworth Business Park,Blaenau Gwent,,,United Kingdom,516316
AVA-4746 SODIUM,TGC4U44G07,Designated,Public record,3905,"(3S)-3-[({1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl}amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt",4/25/2016,For mobilization of hematopoietic stem cells,Designated,Not FDA Approved for Orphan Indication,,,,,"Aviara Pharmaceuticals, Inc/",3331 Green Tree Park,,Houston,Texas,77027,United States,515216
PIRLINDOLE LACTATE,PRE19MC9Y9,Designated,Public record,3905,"(3S)-3-[({1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl}amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt",4/25/2016,For mobilization of hematopoietic stem cells,Designated,Not FDA Approved for Orphan Indication,,,,,"Aviara Pharmaceuticals, Inc/",3331 Green Tree Park,,Houston,Texas,77027,United States,515216
Propionic acid,JHU490RVYR,Designated,Public record,3905,"(3S)-3-[({1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl}amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt",4/25/2016,For mobilization of hematopoietic stem cells,Designated,Not FDA Approved for Orphan Indication,,,,,"Aviara Pharmaceuticals, Inc/",3331 Green Tree Park,,Houston,Texas,77027,United States,515216
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated/Approved,Public record,3906,axicabtagene ciloleucel,4/25/2016,Treatment of follicular lymphoma.,Designated/Approved,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular l","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,90404,United States,515615
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated/Approved,Public record,3907,axicabtagene ciloleucel,4/25/2016,Treatment of follicular lymphoma.,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cel",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lin","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,90404,United States,515615
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated/Approved,Public record,3908,axicabtagene ciloleucel,4/25/2016,Treatment of follicular lymphoma.,Designated/Approved,,Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,3/5/2021,3/5/2028,"Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, excluding patients with diffuse large B-cell lymphoma arising from follicular lymphoma.","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,90404,United States,515615
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,3909,lisocabtagene maraleucel,4/27/2016,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"Treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma,",6/24/2022,6/24/2029,"Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) , primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line che","Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue North,,Seattle,Washington,98109,United States,516115
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,3910,lisocabtagene maraleucel,4/27/2016,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade",2/5/2021,2/5/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue North,,Seattle,Washington,98109,United States,516115
MAVACAMTEN,QX45B99R3J,Designated,Public record,3911,mavacamten,4/27/2016,Treatment of symptomatic hypertrophic cardiomyopathy,Designated/Approved,,Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms,4/28/2022,4/28/2029,Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms,"MyoKardia, Inc. (A Wholly-Owned Subsidiary of Bristol Myers Squibb)",1000 Sierra Point Parkway,,Brisbane,California,94005,United States,515015
BREXUCABTAGENE AUTOLEUCEL,4MD2J2T8SJ,Designated/Approved,Public record,3912,brexucabtagene autoleucel,4/28/2016,Treatment of mantle cell lymphoma.,Designated/Approved,,TECARTUS¿ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL),7/24/2020,7/24/2027,TECARTUS¿ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL),"Kite Pharma, Inc.",199 E Blaine St,,Seattle,Washington,98102,United States,515715
BRIGATINIB,HYW8DB273J,Designated/Approved,Public record,3913,brigatinib,4/28/2016,"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).",Designated/Approved,,ALUNBRIG (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.,5/22/2020,5/22/2027,"For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, not including patients who have progressed on or are intolerant to crizotinib.","Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,505415
BRIGATINIB,HYW8DB273J,Designated/Approved,Public record,3914,brigatinib,4/28/2016,"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).",Designated/Approved,,Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,4/28/2017,4/28/2024,Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,505415
ACYCLOVIR,X4HES1O11F,Designated,Public record,3917,acyclovir,5/3/2016,Treatment of herpetic keratitis.,Designated,Not FDA Approved for Orphan Indication,,,,,Cumulus Pharmaceuticals LLC,1712 Pioneer Avenue,Suite 1377,Cheyenne,Wyoming,82001,United States,513615
HUMAN RECOMBINANT BONE MORPHOGENETIC PROTEIN 4,08RQ4CQ601,Designated,Public record,3919,human recombinant bone morphogenetic protein 4,5/4/2016,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"HyperStem Therapeutics, Inc.",13223-1 Black Mountain Road,,San Diego,California,92129,United States,520216
ATESIDORSEN SODIUM,F3H59ON671,Designated,Public record,3920,2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide,5/10/2016,Treatment of acromegaly,Designated,Not FDA Approved for Orphan Indication,,,,,Antisense Therapeutics Limited,6 Wallace Avenue,TOORAK VIC 3142,Trevose,,,Australia,517016
CLOTRIMAZOLE,G07GZ97H65,Designated,Public record,3922,clotrimazole otic solution,5/10/2016,Treatment of fungal otitis externa (otomycosis),Designated,Not FDA Approved for Orphan Indication,,,,,Laboratorios SALVAT S.A.,"C/ Gall, 30-36",Esplugues de Llobregat,Barcelona,Catalunya,,Spain,520516
IBREXAFUNGERP,A92JFM5XNU,Designated,Public record,3923,"enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor",5/10/2016,"Treatment of invasive Candida infections, including candidemia",Designated,Not FDA Approved for Orphan Indication,,,,,"SCYNEXIS, Inc.","One Evertrust Plaza, 13th Floor",,Jersey City,New Jersey,7302,United States,519616
NOMACOPAN,79V7Q9VIWQ,Designated,Public record,3924,Recombinant protein inhibitor of complement factor 5,5/10/2016,Treatment of Guillain-Barre Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc,24 West 40th Street,8th Floor,New York,New York,10018,United States,520316
SELUMETINIB,6UH91I579U,Designated,Public record,3925,selumetinib,5/10/2016,Adjuvant treatment of patients with stage III or stage IV differentiated thyroid cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,19803,United States,475815
BPR-0L075,W918223VQ6,Designated,Public record,3926,"6-methoxy-3-(3',4',5'-trimethoxybenzoyl) indole",5/11/2016,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,SynCore Biotechnology Co. Ltd.,"4F, 69 Dongxing Road",XinYi Dist,,Taipei City,,Taiwan,524516
FLORILGLUTAMIC ACID,954ZFH0S16,Designated,Public record,3927,florilglutamic acid,5/11/2016,Diagnostic for the management of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"Iceni Centre, Warwick Technology Park",,Warwick,,,United Kingdom,517616
CECLAZEPIDE,99B5ZR9276,Designated,Public record,3929,Ceclazepide,5/12/2016,Treatment of gastric neuroendocrine tumors (gastric NETs).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Trio Medicines Ltd.,Pavillion View,19 New Road,Brighton,,,United Kingdom,520116
NARATUXIMAB EMTANSINE,WE1X5A83B9,Designated,Public record,3930,Naratuximab emtansine,5/12/2016,Treatment of diffuse large B-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Debiopharm International S.A.,"Forum ""apres-demain""","Chemin Messidor 5-7, CP 5911",,,,Switzerland,518016
TAUROLIDINE,8OBZ1M4V3V,Designated,Public record,3931,taurolidine,5/16/2016,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Geistlich Pharma NA, Inc.",202 Carnegie Center Drive,,Princeton,New Jersey,8540,United States,500015
BLARCAMESINE HYDROCHLORIDE,1M49V1PBPL,Designated,Public record,3932,"(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride",5/18/2016,Treatment of Rett Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Anavex Life Sciences Corporation,51 West 52nd Street,7th Floor,New York,New York,10019,United States,520816
TRORILUZOLE HYDROCHLORIDE,BQ5F77DZS3,Designated,Public record,3933,2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride,5/18/2016,Treatment of spinocerebellar ataxia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceuticals, Inc.",215 Church Street,,New Haven,Connecticut,6510,United States,520016
ZANIDATAMAB,Z20OC92TDI,Designated,Public record,3934,anti-HER2 bispecific antibody,5/18/2016,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Zymeworks Inc.,"1385 West 8th Street, Suite 540",,Vancouver,BC,,Canada,519516
COPPER GLUCONATE,RV823G6G67,Designated,Public record,3935,combination of disulfiram and copper gluconate,5/18/2016,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cantex Pharmaceuticals, Inc.",1792 Bell Tower Lane,,Weston,Florida,33326,United States,522516
DISULFIRAM,TR3MLJ1UAI,Designated,Public record,3935,combination of disulfiram and copper gluconate,5/18/2016,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cantex Pharmaceuticals, Inc.",1792 Bell Tower Lane,,Weston,Florida,33326,United States,522516
COPPER OXODOTREOTIDE CU-64,N3858377KC,Designated,Public record,3936,copper Cu 64 dotatate,5/18/2016,Diagnostic for the management of neuroendocrine tumors.,Designated/Approved,,indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients,9/3/2020,9/3/2027,indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients,RadioMedix Inc.,"9701 Richmond Avenue, Suite 222",,Houston,Texas,77042,United States,520716
GLUTATHIONE,GAN16C9B8O,Designated,Public record,3937,liposomal glutathione,5/18/2016,Treatment of Dengue Virus infection.,Designated,Not FDA Approved for Orphan Indication,,,,,"Your Energy Systems, LLC",555 Bryant Street #305,,Palo Alto,California,94301,United States,519216
MARSTACIMAB,0UB3OA67O7,Designated,Public record,3938,marstacimab,5/18/2016,"Treatment of hemophilia A and hemophilia B patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia A and hemophilia B patients.",Designated,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,521916
USTEKINUMAB,FU77B4U5Z0,Designated,Public record,3939,ustekinumab,5/18/2016,Treatment of pediatric Crohn's disease (0 through 16 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,520916
ITRACONAZOLE,304NUG5GF4,Designated,Public record,3940,Itraconazole,5/19/2016,Treatment of basal cell carcinoma nevus syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Mayne Pharma LLC,1240 Sugg Parkway,,Greenville,North Carolina,27834,United States,473715
ROPIDOXURIDINE,3HX21A3SQF,Designated,Public record,3941,ropidoxuridine,5/19/2016,Radiosensitizer to be used during radiation treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"EMEK, Inc.",196 Channel View,,Warwick,Rhode Island,2889,United States,519016
"""TETRANDRINE, (+)-""",29EX23D5AJ,Designated,Public record,3942,tetrandrine,5/19/2016,Treatment of chronic myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Escend Pharmaceuticals, Inc.",3475 Edison Way,Suite R,Menlo Park,California,94025,United States,518916
DEULINOLEATE ETHYL,24B102R86P,Designated,Public record,3943,"9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester",5/23/2016,Treatment of Friedreich's Ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,"Retrotope, Inc.",4300 El Camino Real,Suite 201,Los Altos,California,94022,United States,492315
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated,Public record,3944,brentuximab vedotin,5/23/2016,Treatment of adult T-cell leukemia/lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,521716
DIAZEPAM,Q3JTX2Q7TU,Designated,Public record,3948,diazepam subcutaneous injection,5/26/2016,Treatment of acute repetitive seizures.,Designated,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceuticals, Inc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,60607,United States,518316
BUPIVACAINE HYDROCHLORIDE,7TQO7W3VT8,Designated,Public record,3950,bupivacaine hydrochloride,5/31/2016,treatment of pain associated with postherpetic neuralgia.,Designated,Not FDA Approved for Orphan Indication,,,,,Acasti Pharma Inc.,"3009 Boulevard De la Concorde E., Suite 102",,Laval,Quebec,,Canada,510515
ESMETHADONE,S95RZH8AMH,Designated,Public record,3951,d-methadone,6/2/2016,Treatment of postherpetic neuralgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Relmada Therapeutics, Inc.",750 Third Avenue,9th Floor,New York,New York,10017,United States,499915
LIOTHYRONINE SODIUM,GCA9VV7D2N,Designated,Public record,3953,methimazole and liothyronine sodium,6/2/2016,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,Musli Thyropeutics Ltd,6 HaGefen Street,,zur Moshe,Center District,,Israel,523216
METHIMAZOLE,554Z48XN5E,Designated,Public record,3953,methimazole and liothyronine sodium,6/2/2016,Treatment of glioblastoma multiforme.,Designated,Not FDA Approved for Orphan Indication,,,,,Musli Thyropeutics Ltd,6 HaGefen Street,,zur Moshe,Center District,,Israel,523216
TESTOSTERONE,3XMK78S47O,Designated,Public record,3954,oral testosterone,6/2/2016,Treatment of constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age.,Designated,Not FDA Approved for Orphan Indication,,,,,"TesoRx Pharma, LLC",3670 West Temple Avenue,Suite 270,Pomona,California,91768,United States,523916
GLU-ILE-TRP-THR-PHE-SER-THR-LYS-VAL,AYW9KM2EPO,Designated,Public record,3956,Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val,6/8/2016,Treatment (including prevention of recurrence) of ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Galena Biopharma, Inc.",Crow Canyon Place,Suite 380,San Ramon,California,94583,United States,528616
FOSBRETABULIN TROMETHAMINE,GBW044919E,Designated,Public record,3957,fosbretabulin tromethamine,6/8/2016,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Boulevard,Suite 210,South San Francisco,California,94080,United States,524816
GLYBURIDE,SX6K58TVWC,Designated,Public record,3958,glibentek (glibenclamide oral suspension),6/8/2016,Treatment of neonatal diabetes (monogenic forms of diabetes that present in infancy),Designated,Not FDA Approved for Orphan Indication,,,,,AMMTeK,15 Rue Béranger,,Paris,Île-de-France,,France,518816
HER-902,BA99H4C2PR,Designated,Public record,3959,recombinant human cerebral dopamine neurotrophic factor,6/8/2016,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Herantis Pharma Plc,4 Viikinkaari,,Helsinki,,,Finland,515515
CANNABIDIOL,19GBJ60SN5,Designated,Public record,3961,cannabidiol,6/13/2016,Treatment of infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,521416
CIBINETIDE,9W5677JKDA,Designated,Public record,3962,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,6/13/2016,Treatment to increase survival and improve functioning of pancreatic islets following transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Araim Pharmaceuticals, Inc.",580 White Plains Road,Suite 210,Tarrytown,New York,10591,United States,523116
CIBINETIDE,9W5677JKDA,Designated,Public record,3963,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,6/13/2016,Treatment of sarcoidosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Araim Pharmaceuticals, Inc.",580 White Plains Road,Suite 210,Tarrytown,New York,10591,United States,523816
HYDROMORPHONE HYDROCHLORIDE,L960UP2KRW,Designated,Public record,3965,hydromorphone hydrochloride (intrathecal infusion),6/16/2016,Treatment of complex regional pain syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Piramal Critical Care, Inc.",3950 Schelden Circle,,Bethlehem,Pennsylvania,18017,United States,499415
NAPABUCASIN,Z1HHM49K7O,Designated,Public record,3966,napabucasin,6/20/2016,Treatment of gastric cancer including gastroesophageal junction cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boston Biomedical, Inc.",640 Memorial Drive,,Cambridge,Massachusetts,2139,United States,526116
BLARCAMESINE HYDROCHLORIDE,1M49V1PBPL,Designated,Public record,3967,"tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride",6/20/2016,Treatment of infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,Anavex Life Sciences Corp.,51 West 52nd Street,7th Floor,New York,New York,10019,United States,524416
VARLITINIB,846Y8197W1,Designated,Public record,3968,varlitinib,6/20/2016,Treatment of gastric cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,ASLAN Pharmaceuticals,10A Bukit Pasoh Road,,,,,Singapore,524216
SIROLIMUS,W36ZG6FT64,Designated,Public record,3969,sirolimus,6/21/2016,Treatment of beta-thalassemia.,Designated,Not FDA Approved for Orphan Indication,,,,,Rare Partners srl Impresa Sociale,31 Corso Magenta,,Milano,Lombardia,,Italy,524916
Dordaviprone dihydrochloride,53VG71J90J,Designated,Public record,3971,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one*2HCl",6/23/2016,Treatment of glioblastoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Chimerix, Inc.","2505 Meridian Parkway, Suite 100",,Durham,North Carolina,27713,United States,527916
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,3972,ibrutinib,6/23/2016,Treatment of chronic Graft versus Host disease,Designated/Approved,,Treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy,8/24/2022,8/24/2029,Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy,"Pharmacyclics, LLC",995 East Arques Avenue,,Sunnyvale,California,94085,United States,525616
IBRUTINIB,1X70OSD4VX,Designated/Approved,Public record,3973,ibrutinib,6/23/2016,Treatment of chronic Graft versus Host disease,Designated/Approved,,Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.,8/2/2017,8/2/2024,Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.,"Pharmacyclics, LLC",995 East Arques Avenue,,Sunnyvale,California,94085,United States,525616
ZANUBRUTINIB,AG9MHG098Z,Designated,Public record,3974,zanubrutinib,6/23/2016,Treatment of mantle cell lymphoma,Designated/Approved,,BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.,11/14/2019,11/14/2026,Indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,94403,United States,527416
TRICLABENDAZOLE,4784C8E03O,Designated,Public record,3976,triclabendazole,6/27/2016,Treatment of fascioliasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Tropicalis Pharmaceuticals, LLC",22345 Bracketts Road,,Excelsior,Minnesota,55331,United States,525416
SOR-C13,C79B5A73C4,Designated,Public record,3977,Peptide consisting of L-amino acids with the sequence H-lys-glu-phe-leu-his-pro-ser-lys-val-asp-leu-pro-arg-OH,6/29/2016,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Soricimed Biopharma, Inc.",18 Botsford Street,Suite 201,Moncton,,,Canada,526016
BEMARITUZUMAB,RJW23BQ0KW,Designated,Public record,3978,"recombinant, glycoenfineered humanized IgG1 kappa monoclonal antibody directed against Fibroblast Growth Factor Receptor 2b",6/29/2016,Treatment of gastric cancer including cancer of the gastroesophageal junction.,Designated,Not FDA Approved for Orphan Indication,,,,,"Five Prime Therapeutics, Inc.",2 Corporate Drive,,South San Francisco,California,94080,United States,527716
ZANUBRUTINIB,AG9MHG098Z,Designated,Public record,3979,zanubrutinib,6/29/2016,Treatment of Waldenstrom's macroglobulinemia,Designated/Approved,,Treatment of adult patients with Waldenstrom¿s macroglobulinemia (WM),8/31/2021,8/31/2028,Treatment of adult patients with Waldenstrom¿s macroglobulinemia (WM),"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,94403,United States,527616
BORTEZOMIB,69G8BD63PP,Designated,Public record,3983,bortezomib,7/5/2016,Treatment of neurofibromatosis type 2 (NF2),Designated,Not FDA Approved for Orphan Indication,,,,,BioXcel Corporation,780 East Main Street,Suite 2,Branford,Connecticut,6405,United States,525816
ZANIDATAMAB ZOVODOTIN,HKH2GV9PVO,Designated/Withdrawn,Public record,3985,anti-HER2 bispecific antibody drug conjugate,7/6/2016,Treatment of ovarian cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Zymeworks Inc.,18 West Mercer Street,Suite 370,Seattle,Washington,98119,United States,522616
MAZINDOL,C56709M5NH,Designated,Public record,3986,mazindol,7/6/2016,Treatment of narcolepsy,Designated,Not FDA Approved for Orphan Indication,,,,,NLS-0 Pharma AG,10 Breitenweg,CH-6370,Stans NW,Nidwalden,,Switzerland,526816
ALB-185357,IZB8PZ86FH,Designated,Public record,3987,"metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide",7/6/2016,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Avenzoar Pharmaceuticals, Inc.",662 Encinitas Blvd,Suite 248,Encinitas,California,92024,United States,526216
NINTEDANIB,G6HRD2P839,Designated,Public record,3988,nintedanib,7/6/2016,Treatment of systemic sclerosis (including the associated interstitial lung disease).,Designated/Approved,,OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).,9/6/2019,9/6/2026,Indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,528516
JBPOS-0101,D7NM51C3GU,Designated,Public record,3989,1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane,7/7/2016,Treatment of status epilepticus,Designated,Not FDA Approved for Orphan Indication,,,,,"Bio-Pharm Solutions Co., Ltd.",Advanced Institute of Convergence Technology,"6F, C Bldg",Yeongtong Suwon,Gyeonggi-do,,South Korea,528216
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated,Public record,3990,brentuximab vedotin,7/7/2016,Treatment of enteropathy-associated T-cell lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,528716
DEOXYCYTIDINE 5'-MONOPHOSPHATE,W7A9174XQL,Designated,Public record,3991,deoxythymidine monophosphate and deoxycytidine monophosphate,7/7/2016,Treatment of thymidine kinase 2 deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,"Modis Therapeutics, Inc. (wholly owned subsidiary of Zogenix Therapeutics Inc.)","409 13th Street, Suite 700",,Oakland,California,94612,United States,532716
THYMIDINE 5'-MONOPHOSPHATE,43W3021X6C,Designated,Public record,3991,deoxythymidine monophosphate and deoxycytidine monophosphate,7/7/2016,Treatment of thymidine kinase 2 deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,"Modis Therapeutics, Inc. (wholly owned subsidiary of Zogenix Therapeutics Inc.)","409 13th Street, Suite 700",,Oakland,California,94612,United States,532716
SELINEXOR,31TZ62FO8F,Designated,Public record,3992,selinexor,7/7/2016,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.",85 Wells Avenue,,Newton,Massachusetts,2459,United States,527816
TVN-102,20ZC7Q59K8,Designated,Public record,3993,recombinant human biglycan,7/13/2016,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Tivorsan Pharmaceuticals, Inc.",3 Davol Square,A340,Providence,Rhode Island,2903,United States,526416
TOLFENAMIC ACID,3G943U18KM,Designated,Public record,3994,tolfenamic acid,7/13/2016,Treatment of Frontotemporal Dementia,Designated,Not FDA Approved for Orphan Indication,,,,,Nasser H. Zawia,83 Castle Rocks Road,,Warwick,Rhode Island,2886,United States,517816
TOLFENAMIC ACID,3G943U18KM,Designated,Public record,3995,tolfenamic acid,7/13/2016,Treatment of progressive supranuclear palsy,Designated,Not FDA Approved for Orphan Indication,,,,,Nasser H. Zawia,83 Castle Rocks Road,,Warwick,Rhode Island,2886,United States,517916
FLORILGLUTAMIC ACID F-18,92T1Y5X038,Designated,Public record,3996,[F18] florilglutamic acid,7/13/2016,Diagnostic for the management of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"Iceni Centre, Warwick Technology Park",,Warwick,,,United Kingdom,538716
FLORILGLUTAMIC ACID F-18,92T1Y5X038,Designated,Public record,3997,[F18] florilglutamic acid,7/13/2016,For the diagnosis of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"Iceni Centre, Warwick Technology Park",,Warwick,,,United Kingdom,517516
ODESIVIMAB,UY9LQ8P6HW,Designated,Public record,3998,"atoltivimab, maftivimab, and odesivimab-ebgn",7/14/2016,Treatment of ebola virus infection,Designated/Approved,,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",10/14/2020,10/14/2027,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,536316
ATOLTIVIMAB,FJZ07Q63VY,Designated,Public record,3998,"atoltivimab, maftivimab, and odesivimab-ebgn",7/14/2016,Treatment of ebola virus infection,Designated/Approved,,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",10/14/2020,10/14/2027,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,536316
MAFTIVIMAB,KOP95331M4,Designated,Public record,3998,"atoltivimab, maftivimab, and odesivimab-ebgn",7/14/2016,Treatment of ebola virus infection,Designated/Approved,,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",10/14/2020,10/14/2027,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,536316
PEGILODECAKIN,5Z9850I25F,Designated,Public record,3999,pegylated recombinant human interleukin-10,7/18/2016,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,528416
RUXOLITINIB,82S8X8XX8H,Designated,Public record,4000,Ruxolitinib,7/18/2016,Treatment of acute lymphoblastic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-off,,Wilmington,Delaware,19803,United States,529116
FLUNARIZINE,R7PLA2DM0J,Designated,Public record,4001,flunarizine,7/20/2016,Treatment of hemiplegic migraine,Designated,Not FDA Approved for Orphan Indication,,,,,"Xenon Pharmaceuticals, Inc.",3650 Gilmore Way,,Burnaby,,,Canada,528116
ZANUBRUTINIB,AG9MHG098Z,Designated,Public record,4002,zanubrutinib,7/20/2016,Treatment of chronic lymphocytic leukemia,Designated/Approved,,treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),1/19/2023,1/19/2030,treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),"BeiGene USA, Inc.","1840 Gateway Drive, 3rd floor",,San Mateo,California,94404,United States,527516
SUTIMLIMAB,GNWE7KJ995,Designated,Public record,4004,sutimlimab-jome,7/27/2016,Treatment of autoimmune hemolytic anemia,Designated/Approved,,To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),2/4/2022,2/4/2029,To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),Bioverativ USA Inc. (a fully owned subsidiary of Sanofi),951 Gateway Boulevard,,South San Francisco,California,94080,United States,506115
SUTIMLIMAB,GNWE7KJ995,Designated,Public record,4005,sutimlimab-jome,7/27/2016,Treatment of autoimmune hemolytic anemia (AIHA),Designated/Approved,,treatment of hemolysis in adults with cold agglutinin disease (CAD),1/25/2023,,,Bioverativ USA Inc. (a fully owned subsidiary of Sanofi),951 Gateway Boulevard,,South San Francisco,California,94080,United States,506115
VEMURAFENIB,207SMY3FQT,Designated/Approved,Public record,4007,vemurafenib,8/2/2016,Treatment of Erdheim-Chester Disease,Designated/Approved,,Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation,11/6/2017,11/6/2024,Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,529616
VEDOLIZUMAB,9RV78Q2002,Designated,Public record,4008,vedolizumab,8/4/2016,Prevention of graft versus host disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,523516
VITAMIN A PALMITATE,1D1K0N0VVC,Designated,Public record,4010,Retinol palmitate,8/8/2016,Prevention of bronchopulmonary dysplasia.,Designated,Not FDA Approved for Orphan Indication,,,,,Orphanix GmbH,41 Peter-Rosegger-Straße,,Ried im Innkreis,Oberösterreich,,Austria,525116
DUSQUETIDE,IKX7W49NLN,Designated,Public record,4011,dusquetide,8/10/2016,Treatment of macrophage activation syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,8540,United States,528016
CARBON MONOXIDE,7U1EE4V452,Designated,Public record,4012,carbon monoxide,8/16/2016,Treatment of idiopathic pulmonary fibrosis (IPF).,Designated,Not FDA Approved for Orphan Indication,,,,,"Proterris, Inc.",197 West Springfield Street,,Boston,Massachusetts,2118,United States,530816
PEPINEMAB,BPZ4A29SYE,Designated,Public record,4013,humanized IgG4 monoclonal antibody that binds to the SEMA4D antigen,8/16/2016,Treatment of Huntington's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Vaccinex, Inc.",1895 Mount Hope Avenue,,Rochester,New York,14620,United States,530916
ITRACONAZOLE,304NUG5GF4,Designated,Public record,4014,itraconazole inhalation powder,8/16/2016,Treatment of pulmonary fungal infections in patients with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Pulmatrix, Inc",99 Hayden Avenue,,Lexington,Massachusetts,2421,United States,509515
PROPOFOL HEMISUCCINATE,OIC0UYZ1W6,Designated,Public record,4015,propofol hemisuccinate,8/19/2016,Treatment of acute repetitive seizures,Designated,Not FDA Approved for Orphan Indication,,,,,EpaleX Corporation,305 Lytton Avenue,,Palo Alto,California,94301,United States,530016
IBREXAFUNGERP,A92JFM5XNU,Designated,Public record,4016,"(1,3)-ß-D-glucan synthesis inhibitor",8/22/2016,Treatment of invasive Aspergillus infections,Designated,Not FDA Approved for Orphan Indication,,,,,"SCYNEXIS, Inc.","One Evertrust Plaza, 13th Floor",,Jersey City,New Jersey,7302,United States,531716
"""AMBRISENTAN, (?)-""",7B43003091,Designated/Withdrawn,Public record,4017,ambrisentan/tadalafil fixed combination,8/22/2016,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,528316
TADALAFIL,742SXX0ICT,Designated/Withdrawn,Public record,4017,ambrisentan/tadalafil fixed combination,8/22/2016,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,528316
DISUFENTON SODIUM,7M1J3HN9VO,Designated,Public record,4019,disufenton sodium,8/22/2016,Treatment of glioblastoma multiforme,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Oblato, Inc.",116 Village Boulevard,,Princeton,New Jersey,8540,United States,531616
ETROLIZUMAB,I2A72G2V3J,Designated,Public record,4020,etrolizumab,8/22/2016,Treatment of pediatric patients with ulcerative colitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 Dna Way,,South San Francisco,California,94080,United States,531116
NIVOLUMAB,31YO63LBSN,Designated,Public record,4022,nivolumab,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",4/16/2021,4/16/2028,"treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,531016
NIVOLUMAB,31YO63LBSN,Designated,Public record,4023,nivolumab,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",6/10/2020,6/10/2027,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,531016
NIVOLUMAB,31YO63LBSN,Designated,Public record,4024,nivolumab,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,"In combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)",5/27/2022,5/27/2029,First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,531016
NIVOLUMAB,31YO63LBSN,Designated,Public record,4025,nivolumab,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,"In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)",5/27/2022,5/27/2029,First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,531016
NIVOLUMAB,31YO63LBSN,Designated,Public record,4026,nivolumab,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),5/20/2021,5/20/2028,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,531016
INTERLEUKIN-12 HUMAN RECOMBINANT,02FXP10O2U,Designated,Public record,4027,recombinant human interleukin-12,8/22/2016,Treatment of acute radiation syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Neumedicines, Inc.",133 Altadena Drive,Suite 133,Pasadena,California,91107,United States,531916
HYALURONIDASE (HUMAN RECOMBINANT),743QUY4VD8,Designated/Approved,Public record,4028,rituximab and recombinant human hyaluronidase,8/22/2016,Treatment of chronic lymphocytic leukemia (CLL),Designated/Approved,,Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide,6/22/2017,6/22/2024,Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,545616
RITUXIMAB,4F4X42SYQ6,Designated/Approved,Public record,4028,rituximab and recombinant human hyaluronidase,8/22/2016,Treatment of chronic lymphocytic leukemia (CLL),Designated/Approved,,Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide,6/22/2017,6/22/2024,Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,545616
RITUXIMAB,4F4X42SYQ6,Designated/Approved,Public record,4029,rituximab and recombinant human hyaluronidase,8/22/2016,Treatment of follicular lymphoma,Designated/Approved,,"Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in",6/22/2017,6/22/2024,"Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,529816
HYALURONIDASE (HUMAN RECOMBINANT),743QUY4VD8,Designated/Approved,Public record,4029,rituximab and recombinant human hyaluronidase,8/22/2016,Treatment of follicular lymphoma,Designated/Approved,,"Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in",6/22/2017,6/22/2024,"Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,529816
SULFORAPHANE,GA49J4310U,Designated,Public record,4030,stabilized sulforaphane,8/22/2016,Treatment of subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,Evgen Pharma PLC,146 Brownlow Hill,,Liverpool,,,United Kingdom,530616
UMBRALISIB,38073MQB2A,Designated,Public record,4031,umbralisib,8/23/2016,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,8837,United States,533016
TIMOLUMAB,UJO03RO3K6,Designated,Public record,4032,"recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1)",8/25/2016,Treatment of primary sclerosing cholangitis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Acorda Therapeutics, Inc.",420 Saw Mill River Road,,Ardsley,New York,10502,United States,531516
UBLITUXIMAB,U59UGK3IPC,Designated,Public record,4033,ublituximab,8/25/2016,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,8837,United States,533116
OMBURTAMAB I-131,B6PMV8U3C4,Designated,Public record,4034,131-I-8H9 monoclonal antibody,8/29/2016,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Y-mAbs Therapeutics, Inc.",750 3rd Avenue,9th Floor,New York,New York,10017,United States,535716
Berberine Ursodeoxycholate,VM8KQ3W8GM,Designated,Public record,4035,"9,10-dimethoxy-5,6-dihydro-[1,3] dioxolo[4,5-g]isoquinolino[3,2-alpha]isoquinolin-7-ium(R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyhexadecahydro-1H-cyclopenta[alpha]",8/29/2016,Treatment of primary sclerosing cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,HighTide Biopharma Pty. Ltd.,1 Melissa Street,,Mount Waverley,Victoria,,Australia,509915
Givosiran,ROV204583W,Designated,Public record,4037,givosiran,8/29/2016,Treatment of acute hepatic porphyria,Designated/Approved,,GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).,11/20/2019,11/20/2026,Indicated for the treatment of adults with acute hepatic porphyria (AHP).,"Alnylam Pharmaceuticals, Inc.",101 Main Street,,Cambridge,Massachusetts,2142,United States,535516
S-ETHYLISOTHIURONIUM DIETHYL PHOSPHATE,CTD25O6OBI,Designated,Public record,4038,S-ethylisothiourea diethylphosphate,8/29/2016,"Treatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period.",Designated,Not FDA Approved for Orphan Indication,,,,,"TrioxBio, Inc.",P. O. Box 1000,,Wilmington,Delaware,19801,United States,514615
VENETOCLAX,N54AIC43PW,Designated,Public record,4039,venetoclax,8/29/2016,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regualtory Affairs,1 North Waukegan Road,North Chicago,Illinois,60064,United States,536116
TOMARALIMAB,P45C2W27DU,Designated,Public record,4040,humanized IgG4 monoclonal antibody to Toll-Like Receptor 2 (TLR2),8/30/2016,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"TLR Therapeutics, Inc.",902 Brigham Young Drive,,Claremont,California,91711,United States,455014
AMIFAMPRIDINE PHOSPHATE,8HF8FIN815,Designated,Public record,4041,amifampridine phosphate,8/31/2016,Treatment of myasthenia gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 1250,Coral Gables,Florida,33134,United States,534916
ANGIOTENSIN 1-7,IJ3FUK8MOF,Designated,Public record,4044,Angiotensin (1-7),9/1/2016,Treatment of recessive dystrophic epidermolysis bullosa (RDEB).,Designated,Not FDA Approved for Orphan Indication,,,,,Constant Therapeutics LLC,"303 Congress St, c/o Casner & Edwards",,Boston,Massachusetts,2210,United States,546416
TRAMETINIB,33E86K87QN,Designated,Public record,4045,dabrafenib and trametinib,9/1/2016,Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.,Designated/Approved,,"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",5/4/2018,5/4/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) in combination, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",Novartis Pharmaceuticals Corporation,1 Health Plaza,Building 337,East Hanover,New Jersey,7936,United States,521616
DABRAFENIB,QGP4HA4G1B,Designated,Public record,4045,dabrafenib and trametinib,9/1/2016,Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.,Designated/Approved,,"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",5/4/2018,5/4/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) in combination, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",Novartis Pharmaceuticals Corporation,1 Health Plaza,Building 337,East Hanover,New Jersey,7936,United States,521616
TRAMETINIB,33E86K87QN,Designated,Public record,4046,dabrafenib and trametinib,9/1/2016,Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.,Designated/Approved,,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",5/4/2018,5/4/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) in combination, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",Novartis Pharmaceuticals Corporation,1 Health Plaza,Building 337,East Hanover,New Jersey,7936,United States,521616
DABRAFENIB,QGP4HA4G1B,Designated,Public record,4046,dabrafenib and trametinib,9/1/2016,Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.,Designated/Approved,,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",5/4/2018,5/4/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) in combination, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",Novartis Pharmaceuticals Corporation,1 Health Plaza,Building 337,East Hanover,New Jersey,7936,United States,521616
GABOXADOL,K1M5RVL18S,Designated,Public record,4049,"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol",9/6/2016,Treatment of Angelman syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,Ovid Therapeutics,1460 Broadway,,New York,New York,10036,United States,533816
CISPLATIN,Q20Q21Q62J,Designated,Public record,4051,Cisplatin,9/6/2016,Treatment of anal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Privo Technologies,13 Bristol Street,Unit #1,Cambridge,Massachusetts,2141,United States,536616
FIMEPINOSTAT,3S9RX35S5X,Designated,Public record,4052,mesylate synthetic small molecule inhibitor of HDAC and PI3K,9/6/2016,Treatment of nuclear protein in testis (NUT) midline carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.",4 Maguire Road,,Lexington,Massachusetts,2421,United States,482415
FLUORODOPA F-18,2C598205QX,Designated,Public record,4053,"6-fluoro-(18F)-L-3,4-dihydroxyphenylalanine",9/7/2016,A diagnostic for management of patients with Lesch-Nyhan syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,543716
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated,Public record,4055,Brentuximab vedotin,9/7/2016,Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders,Designated/Approved,,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,11/9/2017,11/9/2024,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,536516
CINACALCET,UAZ6V7728S,Designated,Public record,4056,cinacalcet,9/7/2016,Treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,"Bldg 17, 1A-4-4, Mail Stop 17-1-B",Thousand Oaks,California,91320,United States,511315
HYALURONIDASE (BOVINE),8KOG53Z5EM,Designated/Approved,Public record,4057,rituximab and recombinant human hyaluronidase,9/7/2016,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens",6/22/2017,6/22/2024,"Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,546516
RITUXIMAB,4F4X42SYQ6,Designated/Approved,Public record,4057,rituximab and recombinant human hyaluronidase,9/7/2016,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens",6/22/2017,6/22/2024,"Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,546516
NOMACOPAN,79V7Q9VIWQ,Designated,Public record,4058,Coversin,9/8/2016,Treatment of paroxysmal nocturnal hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc,24 West 40th Street,8th Floor,New York,New York,10018,United States,533916
TERLIPRESSIN,7Z5X49W53P,Designated,Public record,4059,terlipressin,9/8/2016,Treatment of ascites due to all etiologies except cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Bio Vie Inc.,100 Cummings Center,Suite 247-C,Beverly,Massachusetts,1915,United States,534216
EMODEPSIDE,YZ647Y5GC9,Designated,Public record,4060,emodepside,9/13/2016,"Treatment of onchocerhiasis (""river blindness"") caused by the filarial nematode onchocerca volvulus",Designated,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Whippany,New Jersey,7981,United States,535416
RILUZOLE,7LJ087RS6F,Designated,Public record,4062,riluzole oral suspension,9/15/2016,Treatment of amyotrophic lateral sclerosis (ALS).,Designated/Approved,,TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).,9/5/2018,,,Italfarmaco SpA,54 Via dei Lavoratori,,Cinisello Balsamo,Lombardia,20092,Italy,508715
RILUZOLE,7LJ087RS6F,Designated,Public record,4063,riluzole oral suspension,9/15/2016,Treatment of amyotrophic lateral sclerosis (ALS).,Designated/Approved,,TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).,12/13/2019,,,Italfarmaco SpA,54 Via dei Lavoratori,,Cinisello Balsamo,Lombardia,20092,Italy,508715
AVADOMIDE HYDROCHLORIDE,6CX4AEX3KR,Designated,Public record,4064,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",9/19/2016,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,536816
DECITABINE,776B62CQ27,Designated,Public record,4066,decitabine and tetrahydrouridine,9/19/2016,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Inc.,800 Scudders Mill Rd.,P.O. Box 846,Plainsboro,New Jersey,8536,United States,537716
TETRAHYDROURIDINE,0NIZ8H6OL8,Designated,Public record,4066,decitabine and tetrahydrouridine,9/19/2016,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Inc.,800 Scudders Mill Rd.,P.O. Box 846,Plainsboro,New Jersey,8536,United States,537716
FLECAINIDE,K94FTS1806,Designated,Public record,4068,fixed dose combination of modafinil and flecainide,9/19/2016,Treatment of narcolepsy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Theranexus S.A,86 Rue de Paris,,Orsay,Île-de-France,,France,536716
MODAFINIL,R3UK8X3U3D,Designated,Public record,4068,fixed dose combination of modafinil and flecainide,9/19/2016,Treatment of narcolepsy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Theranexus S.A,86 Rue de Paris,,Orsay,Île-de-France,,France,536716
METHYLPREDNISOLONE,X4W7ZR7023,Designated,Public record,4069,methylprednisolone oral suspension,9/19/2016,Treatment of adrenal insufficiency in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,Generic Specialty Pharma,"Unit 10, Block 3",City North Business Campus,Stamullin,Meath,,Ireland,531816
TOFERSEN,2NU6F9601K,Designated,Public record,4072,tofersen,9/19/2016,Treatment of amyotrophic lateral sclerosis,Designated/Approved,,treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene,4/25/2023,4/25/2030,treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene,Biogen Inc.,225 Binney St.,,Cambridge,Massachusetts,2142,United States,537216
TENOFOVIR DISOPROXIL FUMARATE,OTT9J7900I,Designated,Public record,4074,tenofovir disoproxil fumarate,9/27/2016,Prevention of mother to child transmission of hepatitis B virus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,538416
ATRASENTAN,V6D7VK2215,Designated,Public record,4077,Atrasentan,9/29/2016,Treatment of pediatric nephrotic syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regulatory Affairs,1 North Waukegan Road,North Chicago,Illinois,60044,United States,537116
POSACONAZOLE,6TK1G07BHZ,Designated,Public record,4079,posaconazole,10/4/2016,Treatment of invasive aspergillosis,Designated/Approved,,Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older,6/17/2021,6/17/2028,Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,539016
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,4080,tacrolimus,10/4/2016,"Prevention of rejection in kidney, liver or heart transplant in pediatric patients",Designated/Approved,,"For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.",5/24/2018,5/24/2025,"For the prophylaxis of organ rejection in pediatric patients receiving allogeneic kidney transplant and heart transplant, in combination with other immunosuppressants.","Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,534516
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,4081,tacrolimus,10/4/2016,"Prevention of rejection in kidney, liver or heart transplant in pediatric patients",Designated/Approved,,"For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.",5/24/2018,5/24/2025,"For the prophylaxis of organ rejection in pediatric patients receiving allogeneic kidney transplant and heart transplant, in combination with other immunosuppressants.","Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,534516
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,4082,tacrolimus,10/4/2016,"Prevention of rejection in kidney, liver or heart transplant in pediatric patients",Designated/Approved,,"For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.",5/24/2018,5/24/2025,For the prophylaxis of organ rejection in pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants.,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,534516
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,4083,tacrolimus extended-release capsules,10/4/2016,"Prevention of rejection in kidney, liver or heart transplant in pediatric patients",Designated/Approved,,prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients.,11/29/2018,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,534516
IBUDILAST,M0TTH61XC5,Designated,Public record,4084,ibudilast,10/6/2016,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"MediciNova, Inc.",4275 Executive Square,Suite 300,La Jolla,California,92037,United States,445814
ECULIZUMAB,A3ULP0F556,Designated/Withdrawn,Public record,4085,Recombinant human monoclonal antibody against human complement component C5a,10/6/2016,Treatment of acute graft versus host disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",100 College Street,,New Haven,Connecticut,6510,United States,539416
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,4086,pembrolizumab,10/11/2016,Treatment of nasopharyngeal carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,511715
LEDIPASVIR,013TE6E4WV,Designated/Approved,Public record,4087,ledipasvir/sofosbuvir,10/12/2016,Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients,Designated/Approved,,"HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated",8/28/2019,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,535916
SOFOSBUVIR,WJ6CA3ZU8B,Designated/Approved,Public record,4087,ledipasvir/sofosbuvir,10/12/2016,Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients,Designated/Approved,,"HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated",8/28/2019,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,535916
LEDIPASVIR,013TE6E4WV,Designated/Approved,Public record,4088,ledipasvir/sofosbuvir,10/12/2016,Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients,Designated/Approved,,"Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis",4/7/2017,4/7/2024,"Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,535916
SOFOSBUVIR,WJ6CA3ZU8B,Designated/Approved,Public record,4088,ledipasvir/sofosbuvir,10/12/2016,Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients,Designated/Approved,,"Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis",4/7/2017,4/7/2024,"Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,535916
LEDIPASVIR,013TE6E4WV,Designated/Approved,Public record,4089,ledipasvir/sofosbuvir,10/12/2016,Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients,Designated/Approved,,"HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated",8/28/2019,8/28/2026,"For treatment of pediatric patients between 3 years of age and 12 years of age or weighing 35 kg with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; (2) treatment of pediatric patients 3 y","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,535916
SOFOSBUVIR,WJ6CA3ZU8B,Designated/Approved,Public record,4089,ledipasvir/sofosbuvir,10/12/2016,Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients,Designated/Approved,,"HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated",8/28/2019,8/28/2026,"For treatment of pediatric patients between 3 years of age and 12 years of age or weighing 35 kg with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; (2) treatment of pediatric patients 3 y","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,535916
VINORELBINE TARTRATE,253GQW851Q,Designated,Public record,4090,liposomal vinorelbine,10/12/2016,Treatment of cutaneous t-cell lymphoma (CTCL),Designated,Not FDA Approved for Orphan Indication,,,,,"Taiwan Liposome Company, Ltd.","11F-1, No. 3, Yuanqu Street",,Taipei City,Nangang District,,Taiwan,540716
VINORELBINE,Q6C979R91Y,Designated,Public record,4090,liposomal vinorelbine,10/12/2016,Treatment of cutaneous t-cell lymphoma (CTCL),Designated,Not FDA Approved for Orphan Indication,,,,,"Taiwan Liposome Company, Ltd.","11F-1, No. 3, Yuanqu Street",,Taipei City,Nangang District,,Taiwan,540716
MICROBIAL COLLAGENASE,FY14NZH2SF,Designated,Public record,4091,Vibrio alginolyticus collagenase,10/12/2016,Treatment of advanced Dupuytren's disease (Dupuytren's contracture),Designated,Not FDA Approved for Orphan Indication,,,,,Fidia Farmaceutici S.p.A.,"Via Ponte della Fabbrica, 3/A",,Abano Terme PD,,,Italy,539616
ATEZOLIZUMAB,52CMI0WC3Y,Designated,Public record,4092,atezolizumab,10/13/2016,Treatment of small cell lung cancer (SCLC),Designated/Approved,,"TECENTRIQ®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",3/18/2019,3/18/2026,"TECENTRIQ®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,541216
VORINOSTAT,58IFB293JI,Designated,Public record,4094,vorinostat,10/13/2016,"Treatment of advanced melanoma (stages IIb, IIc, III, and IV)",Designated,Not FDA Approved for Orphan Indication,,,,,Qameleon Therapeutics,Moslaan 32,1433 WJ,Kudelstaart,Noord-Holland,,Netherlands,540116
EXALUREN SULFATE,DZ671709NT,Designated,Public record,4095,"6-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate",10/18/2016,Treatment of mucopolysaccharidosis type 1 (MPS I),Designated,Not FDA Approved for Orphan Indication,,,,,"Eloxx Pharmaceuticals, Ltd.",Weizmann Science Park,7 Golda Meir Street,Ness Ziona,Center District,,Israel,540816
FOSMANOGEPIX,1XQ871489P,Designated,Public record,4096,fosmanogepix,10/19/2016,Treatment of invasive candidiasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Amplyx Pharmaceuticals, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,538616
TADALAFIL,742SXX0ICT,Designated,Public record,4097,"macitentan and tadalafil, a fixed dose combination formulation",10/19/2016,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Actelion Pharmaceuticals US, Inc.","1125 Trenton-Harbourton Road,",1st Floor/B-Wing,Titusville,New Jersey,8560,United States,509615
MACITENTAN,Z9K9Y9WMVL,Designated,Public record,4097,"macitentan and tadalafil, a fixed dose combination formulation",10/19/2016,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Actelion Pharmaceuticals US, Inc.","1125 Trenton-Harbourton Road,",1st Floor/B-Wing,Titusville,New Jersey,8560,United States,509615
SER-100,VJ98TJ922K,Designated,Public record,4098,Partial agonist at the opioid receptor-like 1 receptor with amino acid sequence Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-Lys-NH2,10/19/2016,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Serodus ASA,Gaustadalléen 21,,Oslo,Oslo,,Norway,541316
SIROLIMUS,W36ZG6FT64,Designated,Public record,4099,rapamycin,10/20/2016,Treatment of pulmonary arterial hypertention,Designated,Not FDA Approved for Orphan Indication,,,,,Lam Therapeutics,530 Old Whitfield Street,,Guilford,Connecticut,6437,United States,540516
NAPABUCASIN,Z1HHM49K7O,Designated,Public record,4100,napabucasin,10/25/2016,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Dainippon Pharma Oncology, Inc.",640 Memorial Drive,,Cambridge,Massachusetts,2139,United States,542316
SOFOSBUVIR,WJ6CA3ZU8B,Designated/Approved,Public record,4101,sofosbuvir,10/25/2016,Treatment of pediatric chronic hepatitis C virus infection,Designated/Approved,,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin,4/7/2017,4/7/2024,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,541716
SOFOSBUVIR,WJ6CA3ZU8B,Designated/Approved,Public record,4102,sofosbuvir,10/25/2016,Treatment of pediatric chronic hepatitis C virus infection,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin,8/28/2019,8/28/2026,For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,541716
SOFOSBUVIR,WJ6CA3ZU8B,Designated/Approved,Public record,4103,sofosbuvir,10/25/2016,Treatment of pediatric chronic hepatitis C virus infection,Designated/Approved,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin,8/28/2019,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,541716
FOSMANOGEPIX,1XQ871489P,Designated,Public record,4104,fosmanogepix,10/26/2016,Treatment of invasive aspergillosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Amplyx Pharmaceuticals, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,551416
FOSMANOGEPIX,1XQ871489P,Designated,Public record,4105,fosmanogepix,11/2/2016,"Treatment of invasive rare mold infections caused by scedosporium spp., fusarium spp., and mucorales fungi (including mucor spp., and rhizopus spp.)",Designated,Not FDA Approved for Orphan Indication,,,,,"Amplyx Pharmaceuticals, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,554916
EXALUREN SULFATE,DZ671709NT,Designated,Public record,4106,"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate",11/3/2016,Treatment of Rett syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Eloxx Pharmaceuticals, Ltd.",Weizmann Science Park,7 Golda Meir Street,Ness Ziona,Center District,,Israel,541516
FOSMANOGEPIX,1XQ871489P,Designated,Public record,4107,fosmanogepix,11/3/2016,Treatment of coccidioidomycosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Amplyx Pharmaceuticals, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,555016
AP-102,EW91FWW4HC,Designated,Public record,4108,H-(4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2,11/3/2016,Treatment of acromegaly,Designated,Not FDA Approved for Orphan Indication,,,,,Amryt Research Ltd.,18 Fitzwilliam Place,,Dublin,Dublin,,Ireland,540916
MELATONIN,JL5DK93RCL,Designated,Public record,4109,melatonin,11/3/2016,Treatment of smith-magenis syndrome in combination with a beta-blocker,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,541016
RUXOLITINIB,82S8X8XX8H,Designated,Public record,4110,ruxolitinib,11/3/2016,Treatment of graft versus host disease,Designated/Approved,,Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.,5/24/2019,5/24/2026,Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,542716
RUXOLITINIB,82S8X8XX8H,Designated,Public record,4111,ruxolitinib,11/3/2016,Treatment of graft versus host disease,Designated/Approved,,Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older,9/22/2021,9/22/2028,Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,542716
VELIPARIB,01O4K0631N,Designated,Public record,4112,veliparib,11/3/2016,Treatment of squamous non-small cell lung cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,542916
AGANIRSEN,0N3FY8225K,Designated,Public record,4113,aganirsen,11/7/2016,Prevention of corneal graft rejection.,Designated,Not FDA Approved for Orphan Indication,,,,,Gene Signal International SA,Route Cantonale,,Lausanne,Vaud,,Switzerland,500515
SELADELPAR LYSINE,N1429130KR,Designated,Public record,4114,seladelpar,11/7/2016,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,CymaBay Therapeutics,7999 Gateway Boulevard,Suite 130,Newark,California,94560,United States,543416
VITAMIN E POLYETHYLENE GLYCOL SUCCINATE,O03S90U1F2,Designated,Public record,4115,riboflavin-vitamin E-TPGS topical solution,11/8/2016,Treatment of keratoconus in patients undergoing crosslinking procedure,Designated,Not FDA Approved for Orphan Indication,,,,,Institute of Refractive & Ophthalmic Surgery,"Via Andrea D'Isernia 31,",,Napoli,,,Italy,468414
RIBOFLAVIN,TLM2976OFR,Designated,Public record,4115,riboflavin-vitamin E-TPGS topical solution,11/8/2016,Treatment of keratoconus in patients undergoing crosslinking procedure,Designated,Not FDA Approved for Orphan Indication,,,,,Institute of Refractive & Ophthalmic Surgery,"Via Andrea D'Isernia 31,",,Napoli,,,Italy,468414
BRILAROXAZINE HYDROCHLORIDE,I440YY0HX0,Designated,Public record,4116,"6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride",11/9/2016,Treatment of pulmonary arterial hypertension (WHO Group 1),Designated,Not FDA Approved for Orphan Indication,,,,,"Reviva Pharmaceuticals, Inc.",3900 Freedom Circle,Suite 101,Santa Clara,California,95054,United States,541616
Omidubicel,ET4JC4S66E,Designated,Public record,4119,NiCord (cord blood-derived exvivo expanded CD34+ cells and the non-expanded cell fraction of the same cord blood unit),11/9/2016,Treatment of chronic myelogenous leukemia (CML),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,,Israel,544116
RITUXIMAB,4F4X42SYQ6,Designated,Public record,4121,rituximab,11/9/2016,Treatment of Rasmussen's encephalitis,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences,535 Watson Drive,,Claremont,California,91711,United States,542416
SARGRAMOSTIM,5TAA004E22,Designated,Public record,4122,sargramostim,11/9/2016,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),Designated/Approved,,LEUKINE® is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).,3/29/2018,3/29/2025,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.",19 Muzzey Street,,Lexington,Massachusetts,2421,United States,541816
DIAZEPAM,Q3JTX2Q7TU,Designated,Public record,4123,diazepam buccal soluble film,11/10/2016,"Treatment of selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (AED) and who require intermittent use of diazepam to control bouts of increased seizure activity (acute repetitive seizures)",Designated,Not FDA Approved for Orphan Indication,,,,,Aquestive Therapeutics,30 Technology Drive South,,Warren,New Jersey,7059,United States,543516
BIMIRALISIB,6Z3QHB00LB,Designated,Public record,4124,"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-pyridin-2-amine",11/21/2016,Treatment of primary central nervous system lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Torqur AG, a subsidiary of Swiss Rockets AG",Rittergasse 3,,Basel,,4051,Switzerland,543116
"""ISOINDOLIN-1,3-DITHIONE""",7R978066MK,Designated,Public record,4125,"Isoindolin-1,3-Di Thione",11/21/2016,Treatment of Frontotemporal dementia,Designated,Not FDA Approved for Orphan Indication,,,,,"P2D, Inc.",10101 Alliance Road,Suite 105,Cincinnati,Ohio,45242,United States,542616
ABTL-0812 SODIUM,X1840C8161,Designated,Public record,4127,sodium 2-hydroxylinoleate,11/23/2016,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Ability Pharmaceuticals, SL",Edifici Eureka,Campus de la UAB,Bellaterra,,8193,Spain,543816
CITARINOSTAT,441P620G3P,Designated,Public record,4128,(2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide),11/29/2016,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Acetylon Pharmaceuticals, Inc.",(Celgene Subsidiary),86 Morris Avenue,Summit,New Jersey,7901,United States,544316
CANNABIDIOL,19GBJ60SN5,Designated,Public record,4130,cannabidiol,11/29/2016,Treatment of Graft versus Host Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Kalytera Therapeutics Israel, Ltd.",Technological Building,Road 4 Katzrin,Qatsrin,,,Israel,545316
ZOLEDRONIC ACID,6XC1PAD3KF,Designated,Public record,4132,nanoparticles containing Zoledronic acid,11/29/2016,Treatment of Glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA,Via Licinio 11,,Erba (CO),Lombardia,,Italy,543616
RISANKIZUMAB,90ZX3Q3FR7,Designated,Public record,4133,risankizumab,11/29/2016,Treatment of pediatric Crohn's disease,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regulatory Affair,1 North Waukegan Road,North Chicago,Illinois,60044,United States,544716
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated,Public record,4134,C1 esterase inhibitor (Human),11/30/2016,Treatment of acute antibody mediated rejection following kidney transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,510415
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated,Public record,4134,C1 esterase inhibitor (Human),11/30/2016,Treatment of acute antibody mediated rejection following kidney transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,510415
CANNABIDIVARIN,I198VBV98I,Designated,Public record,4135,cannabidivarin,11/30/2016,Treatment of Rett syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,549216
Lactiplantibacillus plantarum,QFC21096ON,Designated,Public record,4136,lactobacillus plantarum,11/30/2016,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,"New Biotic, LLC",19546 Rogan Court,,Rowland Heights,California,91748,United States,550016
RILUZOLE,7LJ087RS6F,Designated,Public record,4137,riluzole orally disolving tablet,11/30/2016,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceutical Holding Company, Ltd",215 Church Street,,New Haven,Connecticut,6510,United States,509415
VK-0214,6FGG71NJ3Y,Designated,Public record,4139,"((4-(3-benzyl-4-hydroxybenzyl)-3,5-dimethylphenoxy)methyl)phosphonic acid",12/5/2016,Treatment of X-linked adrenoleukodystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Viking Therapeutics, Inc.","9920 Pacific Heights Blvd, Suite 350",,San Diego,California,92121,United States,494215
QUABODEPISTAT,1PQN78P4S3,Designated,Public record,4140,"5-{[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy}-8-fluoro-3,4-dihydroquinolin-2(1H)-one",12/5/2016,Treatment of active tuberculosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Otsuka Pharmaceutical Company, Ltd","2-9, Kanda-Tsukasamachi",,Tokyo,,,Japan,547216
MILTEFOSINE,53EY29W7EC,Designated,Public record,4141,miltefosine,12/6/2016,Treatment of primary amebic encephalitis (PAM),Designated,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,32822,United States,540216
MILTEFOSINE,53EY29W7EC,Designated,Public record,4142,miltefosine,12/6/2016,Treatment of Acanthamoeba keratitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,32822,United States,565016
AVEXITIDE,5313W10MYT,Designated,Public record,4143,avexitide,12/8/2016,Treatment of hyperinsulinemic hypoglycemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.",350 Cambridge Avenue,Suite 350,Palo Alto,California,94306,United States,522116
GLUTATHIONE,GAN16C9B8O,Designated,Public record,4144,ascorbic acid,12/12/2016,Treatment of lung dysfunction following lung transplant,Designated,Not FDA Approved for Orphan Indication,,,,,"Renovion, Inc.",2 Briar Bridge Lane,,Chapel Hill,North Carolina,27516,United States,545816
IMMUNE GLOBULIN (HUMAN),,Designated,Public record,4145,immune globulin (human),12/12/2016,Treatment of Myasthenia Gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",79 TW Alexander Drive,,Research Triangle Park,North Carolina,27709,United States,544616
NINTEDANIB,G6HRD2P839,Designated,Public record,4146,Nintedanib,12/12/2016,Treatment of mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,547916
POLATUZUMAB VEDOTIN,KG6VO684Z6,Designated,Public record,4147,polatuzumab vedotin-piiq,12/12/2016,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.",6/10/2019,6/10/2026,"In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.","Genentech, Inc.",1 DNA Way,MS# 40?N8?5,South San Francisco,California,,United States,547416
POLATUZUMAB VEDOTIN,KG6VO684Z6,Designated,Public record,4148,polatuzumab vedotin-piiq,12/12/2016,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymp",4/19/2023,4/19/2030,"treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) and who have an International Prognostic Index score of 2 or greater","Genentech, Inc.",1 DNA Way,MS# 40?N8?5,South San Francisco,California,,United States,547416
SGS-742,GBZ5UC0RME,Designated,Public record,4149,3-aminopropyl-butyl phosphinic acid,12/13/2016,Treatment of succinic semialdehyde dehydrogenase deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,"Speragen, Inc.",13492 Research Boulevard,Suite 120-475,Austin,Texas,78750,United States,545416
"""TETRANDRINE, (+)-""",29EX23D5AJ,Designated,Public record,4150,tetrandrine,12/13/2016,Treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Escend Pharmaceuticals, Inc.",3475 Edison Way,Suite R,Menlo Park,California,94025,United States,545716
EFLORNITHINE,ZQN1G5V6SR,Designated,Public record,4151,eflornithine,12/14/2016,Treatment of pancreatic cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cancer Prevention Pharmaceutical, Inc.",1760 East River Road,Suite 250,Tucson,Alaska,85718,United States,547716
NIVOLUMAB,31YO63LBSN,Designated,Public record,4152,nivolumab,12/20/2016,Treatment of gastric cancer and gastro-esophageal junction cancer,Designated/Approved,,"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",4/16/2021,4/16/2028,"treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,545016
NIVOLUMAB,31YO63LBSN,Designated,Public record,4153,nivolumab,12/20/2016,Treatment of gastric cancer and gastro-esophageal junction cancer,Designated/Approved,,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),5/20/2021,5/20/2028,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,545016
IPILIMUMAB,6T8C155666,Designated,Public record,4154,Nivolumab and Ipilimumab,12/20/2016,Treatment of gastric cancer and gastric-esophageal junction cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,545116
FLOTETUZUMAB,0AHT0IC02G,Designated,Public record,4155,flotetuzumab,12/22/2016,Treatment of acute myeloid leukemia (AML),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.",9704 Medical Center Drive,,Rockville,Maryland,20850,United States,563516
SILMITASERTIB,C6RWP0N0L2,Designated,Public record,4156,Silmitasertib,12/22/2016,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Senhwa Biosciences, Inc.","No. 205-1, Peihsin Road",Section 3,New Taipei City,Hsintien District,,Taiwan,548516
GANAXOLONE,98WI44OHIQ,Designated,Public record,4157,ganaxolone,12/28/2016,Treatment of Fragile X Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Marinus Pharmaceuticals,170 North Radnor Chester Road,Suite 250,Radnor,Pennsylvania,19087,United States,547116
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,4158,pembrolizumab,12/28/2016,Treatment of Merkel cell carcinoma,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,12/19/2018,12/19/2025,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,548216
EMIXUSTAT,02DZ1HBF0M,Designated,Public record,4160,emixustat,1/4/2017,Treatment of Stargardt disease (STGD),Designated,Not FDA Approved for Orphan Indication,,,,,Acucela Inc.,1301 2nd Avenue,Suite 4200,Seattle,Washington,98101,United States,548816
LENALIDOMIDE,F0P408N6V4,Designated,Public record,4161,lenalidomide,1/4/2017,Treatment of splenic marginal zone lymphoma,Designated/Approved,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated splenic marginal zone lymphoma,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,475915
LENALIDOMIDE,F0P408N6V4,Designated,Public record,4162,lenalidomide,1/4/2017,Treatment of nodal marginal zone lymphoma,Designated/Approved,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated nodal marginal zone lymphoma,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,476015
PYRIDOXAL PHOSPHATE,5V5IOJ8338,Designated,Public record,4163,pyridoxal-5¿ phosphate monohydrate (P5P),1/4/2017,Treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Medicure International Inc.,2-1250 Waverley Street,,Winnipeg,,,Canada,557116
RAVULIZUMAB,C3VX249T6L,Designated,Public record,4164,ravulizumab-cwvz,1/4/2017,Treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,10/9/2020,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,513015
RAVULIZUMAB,C3VX249T6L,Designated,Public record,4165,ravulizumab-cwvz,1/4/2017,Treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,12/21/2018,12/21/2025,ULTOMIRIS¿ is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,513015
RAVULIZUMAB,C3VX249T6L,Designated,Public record,4166,ravulizumab-cwvz,1/4/2017,Treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,Treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH),6/7/2021,6/7/2028,Treatment of pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH),"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,513015
RAVULIZUMAB,C3VX249T6L,Designated,Public record,4167,ravulizumab-cwvz,1/4/2017,Treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,Treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH),7/22/2022,,,"Alexion Pharmaceuticals, Inc.",100 College Street,,New Haven,Connecticut,6510,United States,513015
RISDIPLAM,76RS4S2ET1,Designated,Public record,4168,risdiplam,1/4/2017,Treatment of spinal muscular atrophy,Designated/Approved,,Treatment of spinal muscular atrophy (SMA) in pediatric and adult patients,5/27/2022,5/27/2029,Treatment of spinal muscular atrophy (SMA) in pediatric patients between birth and 2 months of age,"Genentech, Inc., a Member of the Roche Group",1 DNA Way,,South San Francisco,California,94080,United States,548116
RISDIPLAM,76RS4S2ET1,Designated,Public record,4169,risdiplam,1/4/2017,Treatment of spinal muscular atrophy,Designated/Approved,,treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older,8/7/2020,8/7/2027,treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.,"Genentech, Inc., a Member of the Roche Group",1 DNA Way,,South San Francisco,California,,United States,548116
LAS-191954,1MK0TQ597B,Designated,Public record,4170,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",1/5/2017,Treatment of epidermolysis bullosa acquisita,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Almirall, S.A.","Ctra. Laurea Miro, 408-410",Sant Feliu de Llobregat,Barcelona,Catalunya,,Spain,548916
CELECOXIB,JCX84Q7J1L,Designated,Public record,4171,Celecoxib oral liquid suspension,1/5/2017,Treatment of pediatric juvenile idiopathic arthritis,Designated,Not FDA Approved for Orphan Indication,,,,,"NuBioPharma, LLC",111 Dennis Drive,Suite 121,Sanford,North Carolina,27330,United States,549716
ECHINOMYCIN,TG824J6RQT,Designated,Public record,4173,echinomycin,1/5/2017,Treatment of graft-versus-host disease (GVHD),Designated,Not FDA Approved for Orphan Indication,,,,,"OncoC4, Inc.",9640 Medical Center Drive,,Rockville,Maryland,20850,United States,549016
UMBRALISIB,38073MQB2A,Designated,Public record,4174,umbralisib in combination with ublituximab,1/5/2017,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,8837,United States,554216
UBLITUXIMAB,U59UGK3IPC,Designated,Public record,4174,umbralisib in combination with ublituximab,1/5/2017,Treatment of chronic lymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,8837,United States,554216
CLENBUTEROL,XTZ6AXU7KN,Designated,Public record,4176,Clenbuterol,1/9/2017,Treatment of Pompe disease (glycogen storage disease type II),Designated,Not FDA Approved for Orphan Indication,,,,,"Dwight D. Koeberl, MD, PhD",Duke University Medical Center,"Pediatrics Dept., Div. of Genetics",Durham,North Carolina,27710,United States,546316
GLECAPREVIR,K6BUU8J72P,Designated,Public record,4177,glecaprevir and pibrentasvir,1/9/2017,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Approved,,"MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).",4/30/2019,4/30/2026,"For the treatment of pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and also for the treatment of","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60044,United States,550516
PIBRENTASVIR,2WU922TK3L,Designated,Public record,4177,glecaprevir and pibrentasvir,1/9/2017,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Approved,,"MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).",4/30/2019,4/30/2026,"For the treatment of pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and also for the treatment of","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60044,United States,550516
GLECAPREVIR,K6BUU8J72P,Designated,Public record,4178,glecaprevir and pibrentasvir,1/9/2017,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Approved,,"treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment of adult and pediatric patients 3 years an",6/10/2021,6/10/2028,"treatment of pediatric patients 3 years of age to less than 12 years of age weighing less than 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment o","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60044,United States,550516
PIBRENTASVIR,2WU922TK3L,Designated,Public record,4178,glecaprevir and pibrentasvir,1/9/2017,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Approved,,"treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment of adult and pediatric patients 3 years an",6/10/2021,6/10/2028,"treatment of pediatric patients 3 years of age to less than 12 years of age weighing less than 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment o","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60044,United States,550516
CITRULLINE,29VT07BGDA,Designated,Public record,4179,L-citrulline,1/9/2017,Prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Asklepion Pharmaceuticals, LLC",729 East Pratt Street,Suite 360,Baltimore,Maryland,21202,United States,544216
TOBRAMYCIN SULFATE,HJT0RXD7JK,Designated,Public record,4180,Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer,1/9/2017,Treatment of periprosthetic joint infection,Designated,Not FDA Approved for Orphan Indication,,,,,Joint Purification Systems LLC,c/o Cor Medical Ventures LLC,215 S. Highway 101,Solana Beach,California,92075,United States,536416
VANCOMYCIN HYDROCHLORIDE,71WO621TJD,Designated,Public record,4180,Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer,1/9/2017,Treatment of periprosthetic joint infection,Designated,Not FDA Approved for Orphan Indication,,,,,Joint Purification Systems LLC,c/o Cor Medical Ventures LLC,215 S. Highway 101,Solana Beach,California,92075,United States,536416
K-777,320A4L58IZ,Designated,Public record,4181,4-methylpiperazine-1-carboxylic acid [1-(3-benzenesufonyl-1-phenethylallyl-carbamoyl)-2-phenylethyl] amide,1/11/2017,Treatment of Chagas disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Center for Discovery & Innovation in Parasitic Diseases,"University of CA, San Francisco",9500 Gilman Drive,LaJolla,California,92093,United States,550316
AD-114,TWM9C4NTQ6,Designated/Withdrawn,Public record,4182,human single domain antibody-like protein inhibitor of the chemokine receptor type 4,1/11/2017,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,AdAlta Limited,15/2 Park Drive,,Bundoora,Victoria,,Australia,535816
RITONAVIR,O3J8G9O825,Designated/Approved,Public record,4186,Ritonavir powder for oral suspension,1/11/2017,Use with other antiretroviral agents for the treatment of pediatric HIV-1 infection,Designated/Approved/Withdrawn,,Used in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection,6/7/2017,,,AbbVie Inc.,Regulatory Affairs,1 Waukegan Road,North Chicago,Illinois,60044,United States,549816
Seclidemstat Mesylate,BD6N473ZLF,Designated,Public record,4187,(E)-N¿-(1-(5-Chloro-2-hydroxy phenyl)Ethylidene)-3-((4-Methyl Piperazin-1-yl) Sulfonyl) Benzohydrazide Mesylate,1/12/2017,Treatment of Ewing's sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Salarius Pharmaceuticals,2450 Holcombe Boulevard,Suite J-608,Houston,Texas,77021,United States,571316
NNC0114-0006,L1SQ55DADE,Designated,Public record,4188,anti-interleukin 21 (NNC0114-0006) in combination with liraglutide,1/12/2017,Treatment of Type I Diabetes Mellitus with residual beta cell function.,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",800 Scudders Mill Road,P. O. Box 846,,New Jersey,8536,United States,529716
LIRAGLUTIDE,839I73S42A,Designated,Public record,4188,anti-interleukin 21 (NNC0114-0006) in combination with liraglutide,1/12/2017,Treatment of Type I Diabetes Mellitus with residual beta cell function.,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",800 Scudders Mill Road,P. O. Box 846,,New Jersey,8536,United States,529716
GLYBURIDE,SX6K58TVWC,Designated,Public record,4189,Glyburide,1/12/2017,Treatment of severe cerebral edema in patients with acute ischemic stroke,Designated,Not FDA Approved for Orphan Indication,,,,,Biogen Chesapeake LLC,225 Binney Street,,Cambridge,Massachusetts,2142,United States,539316
METHYLDOPA,56LH93261Y,Designated,Public record,4190,methyldopa,1/12/2017,Treatment of type 1 diabetes in DQ8 positive patients with residual beta cell function,Designated,Not FDA Approved for Orphan Indication,,,,,IM Therapeutics LLC,11001 West 120th Avenue,Suite 400,Broomfield,Colorado,80021,United States,548616
TADEKINIG ALFA,3G6834I4PF,Designated,Public record,4191,tadekinig alfa,1/12/2017,Treatment of hemophagocytic lymphohistiocytosis,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd,EPFL Innovation Park,Building B,Lausanne,Vaud,,Switzerland,543916
VILTOLARSEN,SXA7YP6EKX,Designated,Public record,4192,viltolarsen,1/12/2017,Treatment of Duchenne Muscular Dystrophy,Designated/Approved,,VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,8/12/2020,8/12/2027,VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"NS Pharma, Inc.","140 East Ridgewood Avenue, Suite 280S",,Paramus,New Jersey,7652,United States,565616
METHIONINE C-11,ED857BWP29,Designated,Public record,4193,"2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S methyl[11C]methionine",1/17/2017,Diagnostic agent for the Clinical Management of Medulloblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,566416
3-(3-(6-GUANIDINO-1-OXOISOINDOLIN-2YL)PROPANAMIDO)-3-(PYRIDINE-3YL)PROPANOIC ACID DIHYDROCHLORIDE,BJM92K3NGH,Designated,Public record,4194,3-[3-(6-guanidino-1-oxoisoindolin-2yl) propanamido]-3-(pyridine-3yl) propanoic acid dihydrochloride,1/17/2017,Treatment of retinopathy of prematurity,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,566316
DEUTIVACAFTOR,SHA6U5FJZL,Designated,Public record,4195,D9-ivacaftor,1/18/2017,Treatment of cystic fibrosis (CF),Designated,Not FDA Approved for Orphan Indication,,,,,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,2210,United States,551016
HYALURONIC ACID,S270N0TRQY,Designated,Public record,4196,hyaluronic acid,1/18/2017,Treatment of emphysema due to alpha1-antitrypsin deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gerard M. Turino, MD","Division of Pulmonary, Critical Care & Sleep Medicine",Mt. Sinai Roosevelt Hospital Center,New York,New York,10019,United States,550716
HYALURONIC ACID (NON-ANIMAL STABILIZED),B7SG5YV2SI,Designated,Public record,4196,hyaluronic acid,1/18/2017,Treatment of emphysema due to alpha1-antitrypsin deficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gerard M. Turino, MD","Division of Pulmonary, Critical Care & Sleep Medicine",Mt. Sinai Roosevelt Hospital Center,New York,New York,10019,United States,550716
TAGATOSE,T7A20Y888Y,Designated,Public record,4197,D-tagatose,1/19/2017,Treatment of Prader-Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Biospherics.net LLC,Department of Pharmaceutical Sciences,University of Kentucky,Nicholasville,Kentucky,40356,United States,459614
GARETOSMAB,KR9ZSKO5QE,Designated,Public record,4198,Human monoclonal antibody directed against human Activin A,1/19/2017,Treatment of fibrodysplasia ossificans progressiva,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,547016
ANX-005,N5WBB45U8L,Designated,Public record,4199,humanized IgG4 monoclonal antibody binding to human C1q,1/19/2017,Treatment of Guillain-Barre Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Annexon, Inc.",180 Kimball Way,,South San Francisco,California,94080,United States,550416
UMBRALISIB,38073MQB2A,Designated,Public record,4200,umbralisib in combination with ublituximab,1/19/2017,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,8837,United States,552216
UBLITUXIMAB,U59UGK3IPC,Designated,Public record,4200,umbralisib in combination with ublituximab,1/19/2017,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,8837,United States,552216
CHF-6333,Q0656F336Y,Designated,Public record,4201,"(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate",1/25/2017,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,26A Via Palermo,,Parma,Emilia-Romagna,,Italy,551216
Buloxibutid sodium,Y151F1Q61I,Designated,Public record,4202,3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt,1/25/2017,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vicore Pharma AB,Kornhamnstorg 53,,Stockholm,,,Sweden,550816
INTERLEUKIN-12 HUMAN RECOMBINANT,02FXP10O2U,Designated,Public record,4204,Dendritic cell/tumor cell fusion vaccine + recombinant human interleukin 12,1/25/2017,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,CyTIX Inc.,"7F Terada Bldg, 2-3-3 Shibakoen",,Minato-ku,Tokyo,,Japan,552316
MELATONIN,JL5DK93RCL,Designated,Public record,4205,melatonin,1/25/2017,Treatment of necrotizing enterocolitis,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,552016
NICOTINAMIDE RIBOSIDE,0I8H2M0L7N,Designated,Public record,4206,nicotinamide riboside,1/25/2017,"Treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS)",Designated,Not FDA Approved for Orphan Indication,,,,,Rejuvenation Therapeutics,774 Mays Boulevard,10-509 PMB,Incline Village,Nevada,89451,United States,548716
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,4207,nitric oxide,1/25/2017,Treatment of pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn,Designated,Not FDA Approved for Orphan Indication,,,,,"GeNo, LLC",2941 Oxbow Circle,,Cocoa,Florida,32926,United States,551616
VIXOTRIGINE HYDROCHLORIDE,7L3OLR4M8T,Designated,Public record,4208,"(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide, hydrochloride",1/30/2017,Treatment of erythromelalgia,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",300 Binney Street,,Cambridge,Massachusetts,2142,United States,553016
LERIGLITAZONE,K824X25AYA,Designated,Public record,4210,hydroxypioglitazone,1/30/2017,Treatment of X-linked adrenoleukodystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Minoryx Therapeutics S.L.,TecnoCampus Mataro-Maresme. TCM3 602,"Av. Ernest Lluch, 32.",Mataró,Catalunya,,Spain,552716
P-TOLUENESULFONAMIDE,I8266RI90M,Designated,Public record,4211,Para-toluenesulfonamide,1/30/2017,Treatment of adenoid cystic carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,PTS International Inc.,2211 Newoak Pk,,San Antonio,Texas,78230,United States,553516
TOVINONTRINE,W248Y1AKOR,Designated,Public record,4212,"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one",1/31/2017,Treatment of sickle cell disease (SCD),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Imara Inc.,700 Technology Square,3rd Floor,Cambridge,Massachusetts,2139,United States,564316
LAQUINIMOD SODIUM,4H914M0CSP,Designated,Public record,4213,laquinimod sodium,1/31/2017,Treatment of Huntington's Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Active Biotech AB,Scheelevagen 22,Box 724,Lund,Scania,,Sweden,466114
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,4214,nitric oxide,1/31/2017,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,VERO Biotech,387 Technology Circle,Suite 125,Atlanta,Georgia,30313,United States,551716
ZANIDATAMAB,Z20OC92TDI,Designated,Public record,4216,Anti-HER2 bispecific antibody,2/6/2017,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,Not FDA Approved for Orphan Indication,,,,,Zymeworks Inc.,"1385 West 8th Street, Suite 540",,Vancouver,BC,,Canada,554716
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated,Public record,4217,Brentuximab vedotin,2/6/2017,Treatment of cutaneous T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,550916
Dordaviprone,9U35A31JAI,Designated,Public record,4218,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one-2HCL",2/7/2017,Treatment of mantle cell lymphoma (MCL),Designated,Not FDA Approved for Orphan Indication,,,,,"Chimerix, Inc.","2505 Meridian Parkway, Suite 100",,Durham,North Carolina,27713,United States,553316
BOMEDEMSTAT TOSYLATE,2PYF2U9JNF,Designated,Public record,4219,bomedemstat,2/7/2017,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","126 E. Lincoln Avenue, PO Box 2000",RY34B-332,Rahway,New Jersey,,United States,553716
COPANLISIB,WI6V529FZ9,Designated,Public record,4220,copanlisib,2/7/2017,Treatment of splenic marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Hanover,New Jersey,7981,United States,552616
COPANLISIB,WI6V529FZ9,Designated,Public record,4221,copanlisib,2/7/2017,Treatment of nodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Hanover,New Jersey,7981,United States,552516
COPANLISIB,WI6V529FZ9,Designated,Public record,4222,copanlisib,2/7/2017,Treatment of extranodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Hanover,New Jersey,7981,United States,552416
ATEZOLIZUMAB,52CMI0WC3Y,Designated,Public record,4224,Atezolizumab,2/13/2017,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS 35-5E,South San Francisco,California,94080,United States,574817
ATEZOLIZUMAB,52CMI0WC3Y,Designated,Public record,4225,atezolizumab,2/13/2017,"Treatment of Stage llb, llc, lll and IV melanoma",Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,7/30/2020,7/30/2027,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.",1 DNA Way,MS 35-5E,South San Francisco,California,94080,United States,550616
MILADEMETAN TOSYLATE MONOHYDRATE,4Y0K58UFU2,Designated,Public record,4226,milademetan,2/13/2017,Treatment of liposarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Rain Oncology Inc.,"8000 Jarvis Rd., Suite 204",,Newark,California,94560,United States,555416
SIROLIMUS,W36ZG6FT64,Designated,Public record,4227,sirolimus,2/13/2017,Treatment of tuberous sclerosis complex-related facial angiofibromas,Designated,Not FDA Approved for Orphan Indication,,,,,"Aucta Pharmaceuticals, Inc.",675 US Highway One,,North Brunswick,New Jersey,8902,United States,555516
MIVAVOTINIB CITRATE,6ZJ8V3Q0H1,Designated,Public record,4228,"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate",2/14/2017,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,556916
DEXTROMETHORPHAN HYDROBROMIDE,9D2RTI9KYH,Designated,Public record,4229,dextromethorphan hydrobromide/quinidine sulfate,2/14/2017,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,Avanir Pharmaceuticals,30 Enterprise,Suite 400,Aliso Viejo,California,92656,United States,556716
QUINIDINE SULFATE,J13S2394HE,Designated,Public record,4229,dextromethorphan hydrobromide/quinidine sulfate,2/14/2017,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,Avanir Pharmaceuticals,30 Enterprise,Suite 400,Aliso Viejo,California,92656,United States,556716
DOXORUBICIN,80168379AG,Designated,Public record,4230,EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tumor with sequences from Vectibix and mouse monoclonal antibody,2/14/2017,Treatment glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,EnGeneIC Ltd,25 Sirius Road,Building 2,Lane Cove West,New South Wales,,Australia,553116
LAPRETOLIMOD AMMONIUM,A1O9D5VN5D,Designated,Public record,4231,Glucopyranosyl lipid A stable emulsion,2/14/2017,Treatment of follicular lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immune Design Corp.,1616 Eastlake Ave. E,Suite 310,Seattle,Washington,98102,United States,554616
MELATONIN,JL5DK93RCL,Designated,Public record,4232,melatonin,2/14/2017,Treatment of short bowel syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,551916
NELFINAVIR,HO3OGH5D7I,Designated,Public record,4233,nelfinavir,2/14/2017,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Swiss Group for Clinical Cancer Research (SAKK),Effingerstrasse 33,,Bern,Bern,,Switzerland,554316
TETRAHYDROURIDINE,0NIZ8H6OL8,Designated,Public record,4234,"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one",2/16/2017,Treatment of thalassemia,Designated,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Inc.,800 Scudders Mill Rd.,P.O. Box 846,Plainsboro,New Jersey,8536,United States,555916
DECITABINE,776B62CQ27,Designated,Public record,4234,"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one",2/16/2017,Treatment of thalassemia,Designated,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Inc.,800 Scudders Mill Rd.,P.O. Box 846,Plainsboro,New Jersey,8536,United States,555916
ABATACEPT,7D0YB67S97,Designated,Public record,4235,abatacept,2/22/2017,Treatment of idiopathic inflammatory myopathy (IIM),Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development,Marketed Products Development - Regulatory Strategy,P.O. Box 5326,Princeton,New Jersey,8543,United States,556216
ABATACEPT,7D0YB67S97,Designated,Public record,4236,Abatacept,2/22/2017,Treatment of giant cell arteritis,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development,Marketed Products Development - Regulatory Strategy,P.O. Box 5326,Princeton,New Jersey,8543,United States,556316
VELPATASVIR,KCU0C7RS7Z,Designated,Public record,4237,sofosbuvir and velpatasvir,2/22/2017,Treatment of pediatric chronic hepatitis C virus (HCV) infection,Designated/Approved,,"EPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or wi",3/19/2020,3/19/2027,"For the treatment of pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for u","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,554816
SOFOSBUVIR,WJ6CA3ZU8B,Designated,Public record,4237,sofosbuvir and velpatasvir,2/22/2017,Treatment of pediatric chronic hepatitis C virus (HCV) infection,Designated/Approved,,"EPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or wi",3/19/2020,3/19/2027,"For the treatment of pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for u","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,554816
VELPATASVIR,KCU0C7RS7Z,Designated,Public record,4238,sofosbuvir and velpatasvir,2/22/2017,Treatment of pediatric chronic hepatitis C virus (HCV) infection,Designated/Approved,,"treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ri",6/10/2021,6/10/2028,"treatment of pediatric patients 3 years of age to less than 6 years of age weighing less than 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhos","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,554816
SOFOSBUVIR,WJ6CA3ZU8B,Designated,Public record,4238,sofosbuvir and velpatasvir,2/22/2017,Treatment of pediatric chronic hepatitis C virus (HCV) infection,Designated/Approved,,"treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ri",6/10/2021,6/10/2028,"treatment of pediatric patients 3 years of age to less than 6 years of age weighing less than 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhos","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,554816
USTEKINUMAB,FU77B4U5Z0,Designated,Public record,4239,ustekinumab,2/22/2017,Treatment of pediatric ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",1400 McKean Road,,Spring House,Pennsylvania,19477,United States,537516
TOMIVOSERTIB,U2H19X4WBV,Designated,Public record,4240,"6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5a]pyridine]-1',5'-dione hydrochloride",2/23/2017,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,eFFECTOR Therapeutics,11180 Roselle Street,Suite A,San Diego,California,92121,United States,554516
ATYR-1940,WS7U5TQ7ZJ,Designated,Public record,4241,Recombinant human histidyl-tRNA synthetase,2/23/2017,Treatment of patients with limb girdle muscular dystrophy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,aTyr Pharma,3545 John Hopkins Court,Suite 250,San Diego,California,92121,United States,548416
ASCIMINIB,L1F3R18W77,Designated,Public record,4243,asciminib,2/27/2017,Treatment of chronic myelogenous leukemia,Designated/Approved,,Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation,10/29/2021,10/29/2028,Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation,Novartis Pharmaceutical Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,556416
ASCIMINIB,L1F3R18W77,Designated,Public record,4244,asciminib,2/27/2017,Treatment of chronic myelogenous leukemia,Designated/Approved,,"Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)",10/29/2021,10/29/2028,"Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)",Novartis Pharmaceutical Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,556416
BI-836858,JA7I0QFJ17,Designated,Public record,4245,Fully human IgG1 antibody specific for CD33,2/27/2017,Treatment of myelodysplastic syndromes (MDS),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,555316
NEO-212,237TB781D9,Designated,Public record,4246,(s)-perillyl alcohol temozolomide carbamate,2/28/2017,Treatment of intracranially located metastases from breast cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.","8335 Sunset Blvd., #240",,Los Angeles,California,90069,United States,557316
SETOGEPRAM SODIUM,R05571KE07,Designated,Public record,4247,3-pentylbenzeneacetic acid sodium salt,2/28/2017,Treatment of Alström syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Liminal BioSciences Limited,"Unit 1, Iconix Park, London Road",Sawston,Cambridge,,,United Kingdom,557016
CABOZANTINIB,1C39JW444G,Designated,Public record,4248,cabozantinib,3/2/2017,Treatment of hepatocellular carcinoma.,Designated/Approved,,CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.,1/14/2019,1/14/2026,CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,94502,United States,552916
Hydroxyurea,X6Q56QN5QC,Designated,Public record,4249,Hydroxyurea,3/2/2017,Treatment of sickle cell anemia in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,Nova Laboratories Limited,Martin House,Gloucester Crescent,Leicester,Wigston,,United Kingdom,555116
MELATONIN,JL5DK93RCL,Designated,Public record,4250,melatonin,3/2/2017,Treatment of acute acetaminophen overdose,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,557416
LIOTHYRONINE,06LU7C9H1V,Designated,Public record,4251,fixed dose combination of methimazole and liothyronine,3/6/2017,Treatment of brain metastases in patients with primary lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Musli Thyropeutics Ltd.,6 Hagefen Street,P. O. Box 529,Zur Moshe,,,Israel,539116
METHIMAZOLE,554Z48XN5E,Designated,Public record,4251,fixed dose combination of methimazole and liothyronine,3/6/2017,Treatment of brain metastases in patients with primary lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Musli Thyropeutics Ltd.,6 Hagefen Street,P. O. Box 529,Zur Moshe,,,Israel,539116
PENTETRAZOL,WM5Z385K7T,Designated,Public record,4254,pentetrazol,3/16/2017,Treatment of narcolepsy,Designated,Not FDA Approved for Orphan Indication,,,,,"Balance Therapeutics, Inc.",533 Airport Blvd.,Suite 400,Burlingame,California,94010,United States,558716
RECOMBINANT HUMAN PLACENTAL GROWTH FACTOR (PLGF-131),NOV5VI05MF,Designated,Public record,4255,Recombinant human placental growth factor,3/16/2017,Treatment of severe preeclampsia,Designated,Not FDA Approved for Orphan Indication,,,,,"Aggamin, LLC",3960 Broadway,Suite 330B,New York,New York,10032,United States,559716
TALABOSTAT,KZ1O2SH88Z,Designated,Public record,4257,Talabostat,3/16/2017,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,BioXcel Corporation,780 East Main Street,Suite 2,Branford,Connecticut,6405,United States,559616
JBPOS-0101,D7NM51C3GU,Designated,Public record,4258,1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane,3/20/2017,Treatment of infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,"Bio-Pharm Solutions, Co., Ltd.","6F, C Bldg., Advanced Institute of Convergence Technology","145 Gwanggyo-Ro, Yeongtong-Gu",Suwon,Gyeonggi-Do,,South Korea,555216
AVACOPAN,O880NM097T,Designated,Public record,4259,avacopan,3/20/2017,Treatment of C3 glomerulopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"ChemoCentryx, Inc.",850 Maude Avenue,,Mountain View,California,94043,United States,559016
ANNAMYCIN,SNU299M83Q,Designated,Public record,4261,liposomal annamycin,3/20/2017,Treatment of acute myeloid leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.",2575 West Bellfort Avenue,Suite 333,Houston,Texas,77054,United States,550116
EZEPROGIND DISULFATE,7L8UKH84T0,Designated,Public record,4262,N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt,3/20/2017,Treatment of progressive supranuclear palsy,Designated,Not FDA Approved for Orphan Indication,,,,,Alzprotect sas,85C Rue Nelson Mandela,Parc Eurasanté – Le Galénis,Loos,Hauts-de-France,,France,504115
TALABOSTAT,KZ1O2SH88Z,Designated,Public record,4263,Talabostat,3/20/2017,Treatment of stages IIb through IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,BioXcel Corporation,780 East Main Street,Suite 2,Branford,Connecticut,6405,United States,559416
GANITUMAB,CK1441RCZ8,Designated,Public record,4264,ganitumab,3/21/2017,Treatment of Ewing sarcoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc., a wholly-owned subsidiary of ImmunityBio, Inc.",9920 Jefferson Boulevard,,Culver City,California,90232,United States,578217
VEDOLIZUMAB,9RV78Q2002,Designated,Public record,4265,Vedolizumab,3/21/2017,Treatment of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,558216
(+)-a-Dihydrotetrabenazine,IFRYDMLSGE,Designated,Public record,4267,(+)-a-dihydrotetrabenazine,3/30/2017,Treatment pediatric patients with Tourette's syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Adeptio Pharmaceuticals, Ltd",22 Bedford Row,WC1R 4JS,London,,,United Kingdom,498715
AMIFAMPRIDINE,RU4S6E2G0J,Designated,Public record,4268,"3,4-diaminopyridine",3/30/2017,Treatment of congenital myasthenic syndrome (CMS),Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 801,Coral Gables,Florida,33134,United States,556516
OPAGANIB,DRG21OQ517,Designated,Public record,4269,4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide,3/30/2017,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a Street,,Tel Aviv-Yafo,Tel Aviv District,,Israel,559116
OXALIPLATIN,04ZR38536J,Designated,Public record,4270,liposomal oxaliplatin,3/30/2017,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"KC Specialty Therapeutics, LLC",2002 West 39th Avenue,,Kansas City,Arkansas,66103,United States,561716
COBOMARSEN SODIUM,27193E2Y44,Designated,Public record,4271,MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p,3/30/2017,Treatment of mycosis fungoides,Designated,Not FDA Approved for Orphan Indication,,,,,"miRagen Therapeutics, Inc.",6200 Lookout Road,Suite 100,Boulder,Colorado,80301,United States,560316
VALPROIC ACID,614OI1Z5WI,Designated,Public record,4272,Valproic acid,3/30/2017,Treatment of diffuse large B-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Valcuria AB,Scheelevägen 2,,Lund,Skåne län,,Sweden,563116
LEVOSIMENDAN,C6T4514L4E,Designated,Public record,4274,levosimendan,4/10/2017,Treatment of amyotrophic lateral sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Orion Corporation,Orionintie 1,,Espoo,,,Finland,495515
MERESTINIB,5OGS5K699E,Designated,Public record,4275,merestinib,4/10/2017,Treatment of biliary tract cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,563316
RHCC10,MRS7SR55LQ,Designated,Public record,4276,recombinant human club cell protein,4/10/2017,Treatment of bronchiolitis obliterans,Designated,Not FDA Approved for Orphan Indication,,,,,"Trove Therapeutics, Inc.",9430 Key West Avenue,,Rockville,Maryland,20850,United States,550216
TASQUINIMOD,756U07KN1R,Designated,Public record,4277,Tasquinimod,4/10/2017,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Active Biotech AB,Scheelevägen 22,P.O. Box 724,Lund,Skåne län,,Sweden,561916
HUPERZINE A,0111871I23,Designated,Public record,4279,Huperzine A,4/12/2017,Treatment of Dravet syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Supernus Pharmaceuticals, Inc.",9715 Key West Avenue,,Rockville,Maryland,20850,United States,559916
REDAPORFIN,ZP3QP1H44W,Designated,Public record,4280,Redaporfin,4/12/2017,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Luzitin, S.A.",Edificio Bluepharma,S Martinho do Bispo,Coimbra,Coimbra District,,Portugal,556616
REPROXALAP,F0GIZ22IJH,Designated,Public record,4281,2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol,4/17/2017,Treatment of congenital ichthyosis,Designated,Not FDA Approved for Orphan Indication,,,,,Aldeyra Therapeutics,131 Hartwell Avenue,Suite 320,Lexington,Massachusetts,2421,United States,530116
ITACITINIB,19J3781LPM,Designated,Public record,4283,itacitinib,4/17/2017,Treatment of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,562716
LORCASERIN,637E494O0Z,Designated,Public record,4284,lorcaserin,4/17/2017,Treatment of Dravet syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 East Ridgewood Avenue,Suite 415 South Tower,Paramus,New Jersey,7652,United States,565816
TRICLABENDAZOLE,4784C8E03O,Designated,Public record,4286,triclabendazole,4/17/2017,Treatment of fascioliasis,Designated/Approved,,EGATEN¿ is indicated for the treatment of fascioliasis in patients 6 years of age and older.,2/13/2019,2/13/2026,EGATEN¿ is indicated for the treatment of fascioliasis in patients 6 years of age and older.,Novartis Pharmaceuticals Corporation,1 Health Plaza,,East Hanover,New Jersey,7936,United States,564216
TRIFLURIDINE,RMW9V5RW38,Designated,Public record,4287,trifluridine/tipiracil,4/17/2017,Treatment of gastric cancer including cancer of the gastroesophageal junction,Designated/Approved,,"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or",2/22/2019,2/22/2026,"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or","Taiho Oncology, Inc.",101 Carnegie Center,Suite 101,Princeton,New Jersey,8540,United States,564116
TIPIRACIL,NGO10K751P,Designated,Public record,4287,trifluridine/tipiracil,4/17/2017,Treatment of gastric cancer including cancer of the gastroesophageal junction,Designated/Approved,,"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or",2/22/2019,2/22/2026,"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or","Taiho Oncology, Inc.",101 Carnegie Center,Suite 101,Princeton,New Jersey,8540,United States,564116
CLEMIZOLE,T97CB3796L,Designated,Public record,4288,clemizole,4/19/2017,Treatment of Dravet syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 East Ridgewood Avenue,Suite 415 South Tower,Paramus,New Jersey,7652,United States,566116
HUMAN IMMUNOGLOBULIN G,66Y330CJHS,Designated,Public record,4289,Immune Globulin Intravenous (Human),4/19/2017,Treatment of dermatomyositis,Designated/Approved,,Treatment of dermatomyositis in adults,7/15/2021,7/15/2028,Treatment of dermatomyositis in adults,"OCTAPHARMA USA, Inc.",117 West Century Road,,Paramus,New Jersey,7652,United States,564716
SULANEMADLIN,6BGF28R54M,Designated,Public record,4290,Peptide inhibiting murine double minute 2 (MDM2) and murine double minute X (MDMX),4/19/2017,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Aileron Therapeutics, Inc.",81 Albany Street,,Cambridge,Massachusetts,2139,United States,565316
TRICIRIBINE PHOSPHATE,5L5GE3DV88,Designated,Public record,4291,Triciribine phosphate,4/24/2017,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Prescient Therapeutics LTD,2644 North Kitty Hawk Drive,,Palm Springs,California,92262,United States,558516
IVOSIDENIB,Q2PCN8MAM6,Designated,Public record,4293,ivosidenib,4/26/2017,Treatment of cholangiocarcinoma,Designated/Approved,,"Treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test",8/25/2021,8/25/2028,"Treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test",Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,562216
OLUTASIDENIB,0T4IMT8S5Z,Designated,Public record,4294,olutasidenib,4/27/2017,Treatment of acute myeloid leukemia,Designated/Approved,,treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,12/1/2022,12/1/2029,treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,"Rigel Pharmaceuticals, Inc.",611 Gateway Boulevard,Suite 900,South San Francisco,California,94080,United States,565716
CISPLATIN,Q20Q21Q62J,Designated,Public record,4295,Cisplatin loaded hyaluronate film for implant,5/2/2017,Treatment of mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,PlumeStars s.r.l.,Via Lago Scuro11,,Parma,,,Italy,557716
OBEXELIMAB,RM16A4BA8R,Designated,Public record,4299,"humanized anti-CD19, Fc engineered, monoclonal antibody with enhanced binding to FcyRIIb",5/9/2017,Treatment of immunoglobulin G4-related disease,Designated,Not FDA Approved for Orphan Indication,,,,,Zenas BioPharma (USA) LLC.,1000 Winter Street,"North Building, Suite 1200",Waltham,Massachusetts,2451,United States,566516
LAROTRECTINIB,PF9462I9HX,Designated,Public record,4300,larotrectinib,5/9/2017,Treatment of solid tumors with NTRK-fusion proteins,Designated/Approved,,VITRAKVI® is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is lik,11/26/2018,11/26/2025,VITRAKVI® is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is lik,Bayer HealthCare Pharmaceuticals Inc.,100 Bayer Boulevard,,Whippany,New Jersey,7981,United States,578317
RILONACEPT,8K80YB5GMG,Designated,Public record,4301,rilonacept,5/9/2017,Treatment of deficiency of interleukin-1 receptor antagonist (DIRA),Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,561616
RELDESEMTIV,4S0HBYW6QE,Designated,Public record,4303,fast skeletal muscle troponin activator,5/11/2017,Treatment of spinal muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Cytokinetics, Inc.",280 East Grand Avenue,,South San Francisco,California,94080,United States,516215
POVIDONE-IODINE,85H0HZU99M,Designated,Public record,4304,povidone-iodine 0.5% (w/w) in dimethylsulfoxide 44% (w/w),5/11/2017,Treatment of microbial keratitis (which includes Acanthamoeba keratitis).,Designated,Not FDA Approved for Orphan Indication,,,,,"Veloce BioPharma, LLC",7315 Wisconsin Avenue,Suite 400W,Chevy Chase,Maryland,20815,United States,566216
RITANSERIN,145TFV465S,Designated,Public record,4305,Ritanserin,5/11/2017,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,The University of Virginia/Benjamin Purow,1215 Lee Street,,Charlottesville,Virginia,22908,United States,575017
EXENATIDE,9P1872D4OL,Designated,Public record,4306,exenatide,5/16/2017,Treatment of idiopathic intracranial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Boyd Consultants Ltd,"6th Floor, South Bank House, Barrow Street",,Dublin,,4,Ireland,530516
EMTRICITABINE,G70B4ETF4S,Designated,Public record,4307,"bictegravir, emtricitabine, and tenofovir alafenamide",5/17/2017,Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients,Designated/Approved,,BIKTARVY® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiret,6/18/2019,6/18/2026,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are v,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,559316
TENOFOVIR DISOPROXIL FUMARATE,OTT9J7900I,Designated,Public record,4307,"bictegravir, emtricitabine, and tenofovir alafenamide",5/17/2017,Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients,Designated/Approved,,BIKTARVY® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiret,6/18/2019,6/18/2026,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are v,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,559316
BICTEGRAVIR,8GB79LOJ07,Designated,Public record,4307,"bictegravir, emtricitabine, and tenofovir alafenamide",5/17/2017,Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients,Designated/Approved,,BIKTARVY® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiret,6/18/2019,6/18/2026,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are v,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,559316
EMTRICITABINE,G70B4ETF4S,Designated,Public record,4308,"bictegravir, emtricitabine, and tenofovir alafenamide",5/17/2017,Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients,Designated/Approved,,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in thos,10/7/2021,10/7/2028,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing 14 kg to less than 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,559316
TENOFOVIR DISOPROXIL FUMARATE,OTT9J7900I,Designated,Public record,4308,"bictegravir, emtricitabine, and tenofovir alafenamide",5/17/2017,Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients,Designated/Approved,,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in thos,10/7/2021,10/7/2028,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing 14 kg to less than 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,559316
BICTEGRAVIR,8GB79LOJ07,Designated,Public record,4308,"bictegravir, emtricitabine, and tenofovir alafenamide",5/17/2017,Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients,Designated/Approved,,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in thos,10/7/2021,10/7/2028,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing 14 kg to less than 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,559316
SIROLIMUS,W36ZG6FT64,Designated,Public record,4309,sirolimus,5/17/2017,Treatment of angiofibroma associated with tuberous sclerosis,Designated/Approved,,treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older,3/22/2022,3/22/2029,treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older,"NobelPharma Co., LTD",12-10 Nihonbashi-kobunacho,,Chuo-ku,Tokyo-to,,Japan,568416
IRINOTECAN,7673326042,Designated,Public record,4312,irinotecan liposome injection,5/24/2017,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Bioscience, Inc.",650 East Kendall Street,,Cambridge,Massachusetts,2142,United States,567516
RESIQUIMOD,V3DMU7PVXF,Designated,Public record,4313,resiquimod,5/24/2017,Treatment of cutaneous T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Galderma Research and Development, LLC",14501 North Freeway,,Fort Worth,Texas,76177,United States,569016
ETELCALCETIDE,60ME133FJB,Designated,Public record,4315,etelcalcetide,5/31/2017,Treatment of pediatric hyperparathyroidism,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",1 Amgen Center Drive,,Thousand Oaks,California,91320,United States,567616
FLUORODOPA F-18,2C598205QX,Designated,Public record,4316,"L-3,4-Dihydroxy-6-[18F]fluorophenylalanine",5/31/2017,Diagnostic agent for the management of patients with aromatic L-amino acid decarboxylase deficiency (AADC).,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,567816
RECIFERCEPT,620C079F3I,Designated,Public record,4317,Recombinant human fibroblast growth factor receptor 3,6/2/2017,Treatment of achondroplasia.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,235 East 42nd Street,,New York,New York,10017,United States,567916
Tirabrutinib Hydrochloride,U374135N48,Designated,Public record,4318,"6-Amino-9-[(3R)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one monohydrochloride",6/5/2017,Treatment of chronic lymphocytic leukemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine Street,,Seattle,Washington,98102,United States,571116
TIOMOLIBDATE CHOLINE,FD57A79R4P,Designated,Public record,4319,bis-choline tetrathiomolybdate,6/5/2017,Treatment of Amyotrophic Lateral Sclerosis (ALS),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Alexion Pharmaceutical Inc.,121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,569516
RECOMBINANT HUMAN PALMITOYL-PROTEIN THIOESERASE-1,PQ6XU2SD3M,Designated,Public record,4320,recombinant human palmitoyl-protein thioeserase-1 (rhPPT1),6/5/2017,Treatment of PPT1-deficient neuronal ceroid lipofuscinoses,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.",840 Main Campus Drive,Lab 3510,Raleigh,North Carolina,27606,United States,570116
SODIUM STIBOGLUCONATE ANHYDROUS,V083S0159D,Designated,Public record,4321,Sodium Stibogluconate,6/5/2017,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,BioXcel Corporation,780 East Main Street,Suite 2,Branford,Connecticut,6405,United States,572516
TUCATINIB,234248D0HH,Designated,Public record,4322,tucatinib,6/5/2017,Treatment of breast cancer patients with brain metastases.,Designated/Approved,,"TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-H",4/17/2020,4/17/2027,"For use in combination with trastuzumab and capecitabine for treatment of adult patients with metastatic HER2-positive breast cancer and brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,570716
TYLOSIN,YEF4JXN031,Designated,Public record,4323,4¿-(p-fluorobenzyl)tylosin A,6/6/2017,Treatment of lymphatic filariasis,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regulatory Affairs,1 Waukegan Road,North Chicago,Illinois,60044,United States,572916
CANNABIDIVARIN,I198VBV98I,Designated,Public record,4324,Cannabidivarin,6/6/2017,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,,United Kingdom,572416
EMTRICITABINE,G70B4ETF4S,Designated,Public record,4326,emtricitabine and tenofovir alafenamide,6/6/2017,Treatment of HIV-1 infection in pediatric patients under 12 years of age,Designated/Approved,,"DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination with other antiretroviral agents other than protease inhib",9/28/2017,9/28/2024,"¿ In combination with other antiretroviral agents, for the treatment of HIV-1 infection in pediatric patients under 12 years of age weighing at least 35kg; and ¿ In combination with other antiretroviral agents other than protease inhibitors that require a","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,569716
TENOFOVIR ALAFENAMIDE,EL9943AG5J,Designated,Public record,4326,emtricitabine and tenofovir alafenamide,6/6/2017,Treatment of HIV-1 infection in pediatric patients under 12 years of age,Designated/Approved,,"DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination with other antiretroviral agents other than protease inhib",9/28/2017,9/28/2024,"¿ In combination with other antiretroviral agents, for the treatment of HIV-1 infection in pediatric patients under 12 years of age weighing at least 35kg; and ¿ In combination with other antiretroviral agents other than protease inhibitors that require a","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,569716
EMTRICITABINE,G70B4ETF4S,Designated,Public record,4327,emtricitabine and tenofovir alafenamide,6/6/2017,Treatment of HIV-1 infection in pediatric patients under 12 years of age,Designated/Approved,,Treatment of HIV-1 infection in pediatric patients weighing at least 14 kg and less than 35 kg in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor,1/7/2022,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,569716
TENOFOVIR ALAFENAMIDE,EL9943AG5J,Designated,Public record,4327,emtricitabine and tenofovir alafenamide,6/6/2017,Treatment of HIV-1 infection in pediatric patients under 12 years of age,Designated/Approved,,Treatment of HIV-1 infection in pediatric patients weighing at least 14 kg and less than 35 kg in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor,1/7/2022,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,569716
ODRONEXTAMAB,8R5CM46UIO,Designated,Public record,4328,human IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody,6/6/2017,Treatment of diffuse large b-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,569816
MACITENTAN,Z9K9Y9WMVL,Designated,Public record,4330,macitentan,6/6/2017,Treatment of Fontan-Palliated patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1820 Chapel Avenue West,Suite 300,Cherry Hill,New Jersey,8002,United States,574917
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,4331,pembrolizumab,6/6/2017,Treatment of follicular lymphoma.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp",1 Merck Access Road,,Whitehouse Station,New Jersey,8889,United States,570816
LORECIVIVINT,42EK42WHI5,Designated,Public record,4332,small molecule inhibitor of the Wnt pathway,6/6/2017,Treatment of idiopathic pulmonary fibrosis (IPF).,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biosplice Therapeutics, Inc.",9360 Towne Centre Drive,,San Diego,California,92121,United States,568516
ZIRITAXESTAT,I02418V13W,Designated,Public record,4333,"2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile",6/8/2017,Treatment of idiopathic pulmonary fibrosis.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Galapagos NV,Generaal De Wittelaan,L11 A3,Mechelen,,,Belgium,570616
FLUBENTYLOSIN,HXL1F57P8O,Designated,Public record,4335,4¿-(p-fluorobenzyl)tylosin A,6/8/2017,Treatment of onchocerciasis,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regulatory Affairs,1 Waukegan Road,North Chicago,Illinois,60044,United States,573016
SPARTALIZUMAB,QOG25L6Z8Z,Designated,Public record,4336,humanized monoclonal antibody against human PD-1,6/8/2017,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,7936,United States,576417
LONCASTUXIMAB TESIRINE,7K5O7P6QIU,Designated,Public record,4337,Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linker,6/8/2017,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,ADC Therapeutics SA,"Route de la Corniche, 3B",,Epalinges,Vaud,,Switzerland,572816
LONCASTUXIMAB TESIRINE,7K5O7P6QIU,Designated,Public record,4338,loncastuximab tesirine-lpyl,6/8/2017,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cel",4/23/2021,4/23/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy,ADC Therapeutics SA,"Route de la Corniche, 3B",,Epalinges,Vaud,,Switzerland,572716
OLEIC MONOETHANOLAMIDE,1HI5J9N8E6,Designated,Public record,4339,Oleoylethanolamide,6/8/2017,Treatment of Prader-Willi syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"NutriForward, LLC","1520 Luna Road, # 120",,Carrollton,Texas,75006,United States,577117
IT-139,7OSJ9KS483,Designated,Public record,4340,sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)],6/8/2017,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Bold Therapeutics Inc.,170 - 422 Richards St.,,Vancouver,British Columbia,,Canada,573817
RELOXALIASE,48OB405WWC,Designated,Public record,4343,Bacillus subtilis oxalate decarboxylase,6/12/2017,Treatment of primary hyperoxaluria,Designated,Not FDA Approved for Orphan Indication,,,,,"Allena Pharmaceuticals, Inc.",1 Executive Park Drive,Suite 202,Newton,Massachusetts,2462,United States,578917
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,4344,Human alpha-1-antitrypsin,6/12/2017,Treatment of acute graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,20814,United States,576717
IBRUTINIB,1X70OSD4VX,Designated,Public record,4345,ibrutinib,6/12/2017,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 East Arques Avenue,,Sunnyvale,California,94085,United States,574317
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,4346,pembrolizumab,6/12/2017,Treatment of hepatocellular carcinoma (HCC),Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,11/9/2018,11/9/2025,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,576917
TAK-075,N9LP5QC07K,Designated,Public record,4347,Active calcium sensing receptor antagonist derived from tetrahydropyrazolopyrimidine,6/13/2017,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Centre Europe, Ltd.",61 Aldwych,,London,England,,United Kingdom,568816
NANDROLONE DECANOATE,H45187T098,Designated,Public record,4348,nandrolone,6/13/2017,Treatment of Duchenne and Becker Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,25 Störtloppsvägen,,Hägersten-Liljeholmen,Stockholms län,,Sweden,569116
LACUTAMAB,N8O7MY0VNS,Designated,Public record,4350,humanized IgG1 monoclonal antibody targeting KIR3DL2,6/14/2017,Treatment of cutaneous T-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma,117 Avenue de Luminy,BP 30191,Marseille,Provence-Alpes-Côte d'Azur,,France,574717
VACTOSERTIB,6T4O391P5Y,Designated,Public record,4351,"N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline",6/14/2017,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"MedPacto, Inc.",145 Gwanggyo-ro,Advanced Institutes of Convergence Technology,Suwon,Gyeonggi-do,,South Korea,575617
UPADACITINIB,4RA0KN46E0,Designated,Public record,4352,"(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate",6/15/2017,Treatment of Pediatric Crohn's disease,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie,1 North Waukegan Road,,North Chicago,Illinois,60044,United States,575517
ALIROCUMAB,PP0SHH6V16,Designated,Public record,4353,alirocumab,6/15/2017,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,as an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C,4/1/2021,4/1/2028,as an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,580617
RIVOCERANIB MESYLATE,TK02X14ASJ,Designated,Public record,4354,apatinib mesylate,6/15/2017,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevar Therapeutics, Inc.",2825 E Cottonwood Parkway,Suite 180,Salt Lake City,Utah,84121,United States,579117
BUROSUMAB,G9WJT6RD29,Designated,Public record,4355,burosumab-twza,6/15/2017,Treatment of tumor-induced osteomalacia (TIO) syndrome,Designated/Approved,,Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.,6/18/2020,6/18/2027,For the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older,"Kyowa Kirin, Inc.",135 US Highway 202 206,Suite 6,Bedminster Township,New Jersey,7921,United States,576217
COBICISTAT,LW2E03M5PG,Designated,Public record,4356,cobicistat,6/15/2017,Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients,Designated/Approved,,TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg,8/22/2019,8/22/2026,Indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg.,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,577917
COBICISTAT,LW2E03M5PG,Designated,Public record,4357,cobicistat,6/15/2017,Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients,Designated/Approved,,TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg co,10/3/2019,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,577917
DEFERIPRONE,2BTY8KH53L,Designated,Public record,4359,deferiprone,6/15/2017,Treatment of neurodegeneration with brain iron accumulation (NBIA),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,581217
ENTOSPLETINIB,6I3O3W6O3B,Designated,Public record,4360,entospletinib,6/15/2017,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Kronos Bio, Inc.","1300 S. El Camino Real, Suite 400",,San Mateo,California,94402,United States,569616
MIRIKIZUMAB,Z7HVY03PHP,Designated,Public record,4362,humanized immunoglobulin G4-variant monoclonal antibody directed against the p19 subunit of interleukin (IL)-23,6/15/2017,Treatment of ulcerative colitis in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,Eli Lilly & Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,577817
IBUTAMOREN MESYLATE,R90JB6QJ2B,Designated,Public record,4363,ibutamoren mesylate,6/15/2017,Treatment of growth hormone deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Lumos Pharma,4200 Marathon Blvd.,Suite 200,Austin,Texas,78756,United States,579617
MACITENTAN,Z9K9Y9WMVL,Designated,Public record,4364,macitentan,6/15/2017,Treatment of chronic thromboembolic pulmonary hypertension (CTEPH),Designated,Not FDA Approved for Orphan Indication,,,,,"Actelion Clinical Research, Inc.",1820 Chapel Avenue West,Suite 300,Cherry Hill,New Jersey,8002,United States,580117
ELAPEGADEMASE,9R3D3Y0UHS,Designated,Public record,4365,monomethoxypolyethylene glycol recombinant adenosine deaminase,6/15/2017,Treatment of systemic sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiesi USA Inc.,175 Regency Woods Place,Suite 600,Cary,North Carolina,27518,United States,570316
RRX-001,7RPW6SU9SC,Designated,Public record,4366,"N-(bromoacetyl)-3,3-dinitroazetidine",6/15/2017,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"EpicentRx, Inc.",4445 Eastgate Mall,Suite 200,San Diego,California,92121,United States,579817
RRX-001,7RPW6SU9SC,Designated,Public record,4367,"N-(bromoacetyl)-3,3-dinitroazetidine",6/15/2017,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"EpicentRx, Inc.",4445 Eastgate Mall,Suite 200,San Diego,California,92121,United States,577317
Oxytocin,1JQS135EYN,Designated,Public record,4368,oxytocin,6/15/2017,Treatment of Prader-Willi syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Eric Hollander, MD",Montefiore Medical Center,Univ. Hosp for Albert Einstein College of Medicine,Bronx,New York,10467,United States,582717
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,4369,pembrolizumab,6/15/2017,Treatment of esophageal carcinoma,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or mo",7/30/2019,7/30/2026,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression a","Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,578717
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,4370,pembrolizumab,6/15/2017,Treatment of esophageal carcinoma,Designated/Approved,,Treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:- in,3/22/2021,,,"Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,578717
TAZEMETOSTAT,Q40W93WPE1,Designated,Public record,4371,tazemetostat,6/15/2017,Treatment of soft tissue sarcoma,Designated/Approved,,TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.,1/23/2020,1/23/2027,,"Epizyme, Inc.",400 Technology Square,4th Floor,Cambridge,Massachusetts,2139,United States,578417
TEZACAFTOR,8RW88Y506K,Designated,Public record,4372,tezacaftor/ivacaftor; ivacaftor,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,SYMDEKO? is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that i,6/21/2019,6/21/2026,For the treatment of patients with cystic fibrosis (CF) age 6 years to less than 12 years who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsi,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,577517
IVACAFTOR,1Y740ILL1Z,Designated,Public record,4372,tezacaftor/ivacaftor; ivacaftor,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,SYMDEKO? is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that i,6/21/2019,6/21/2026,For the treatment of patients with cystic fibrosis (CF) age 6 years to less than 12 years who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsi,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,577517
TEZACAFTOR,8RW88Y506K,Designated,Public record,4373,tezacaftor/ivacaftor; ivacaftor,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivaca,12/21/2020,12/21/2027,treatment of cystic fibrosis (CF) in patients age 6 years and older who have at least one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to tezacaftor/ivacaftor ba,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,577517
IVACAFTOR,1Y740ILL1Z,Designated,Public record,4373,tezacaftor/ivacaftor; ivacaftor,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivaca,12/21/2020,12/21/2027,treatment of cystic fibrosis (CF) in patients age 6 years and older who have at least one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to tezacaftor/ivacaftor ba,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,577517
TEZACAFTOR,8RW88Y506K,Designated,Public record,4374,tezacaftor/ivacaftor; ivacaftor,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembr",2/12/2018,2/12/2025,"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembr",Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,577517
IVACAFTOR,1Y740ILL1Z,Designated,Public record,4374,tezacaftor/ivacaftor; ivacaftor,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembr",2/12/2018,2/12/2025,"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembr",Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,577517
Catequentinib,GKF8S4C432,Designated,Public record,4375,Anlotinib,6/19/2017,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Advenchen Laboratories, LLC",887 Patriot Drive,Suite A,Moorpark,California,93021,United States,576017
FENFLURAMINE,2DS058H2CF,Designated,Public record,4376,fenfluramine,6/19/2017,Treatment of Lennox-Gastaut syndrome,Designated/Approved,,Treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older,3/25/2022,3/25/2029,Treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older,Zogenix Inc.,5959 Horton Street,Suite 500,Emeryville,California,94608,United States,584217
MILTEFOSINE,53EY29W7EC,Designated,Public record,4377,miltefosine,6/19/2017,Treatment of disseminated amebiasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,32822,United States,565216
MILTEFOSINE,53EY29W7EC,Designated,Public record,4378,miltefosine,6/19/2017,Treatment of granulomatous amebic encephalitis (GAE),Designated,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,32822,United States,565116
ELATIPEPIMUT-S,38184303XR,Designated,Public record,4379,NELATIMOTIDE AND ADEGRAMOTIDE combination,6/19/2017,Treatment of myelodysplastic syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,1752,United States,571516
ADEGRAPEPIMUT-S,4XQ7W02EQ0,Designated,Public record,4379,NELATIMOTIDE AND ADEGRAMOTIDE combination,6/19/2017,Treatment of myelodysplastic syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,1752,United States,571516
OMAVELOXOLONE,G69Z98951Q,Designated,Public record,4380,omaveloxolone,6/19/2017,Treatment of Friedreich's Ataxia,Designated/Approved,,treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older,2/28/2023,2/28/2030,treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older,"Reata Phamaceuticals, Inc.",5320 Legacy Drive,,Plano,Texas,75024,United States,461214
PAMREVLUMAB,QS5F6VTS0O,Designated,Public record,4381,pamrevlumab,6/19/2017,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.",409 Illinois Street,,San Francisco,California,94158,United States,581617
TIDEGLUSIB,Q747Y6TT42,Designated,Public record,4382,Tideglusib,6/19/2017,Treatment of myotonic dystrophy type 1 (DM1),Designated,Not FDA Approved for Orphan Indication,,,,,AMO Pharma Ltd.,Braebum,Grove Road,Godalming,Surrey,,United Kingdom,577417
H3B-8800,90YLS47BRX,Designated,Public record,4384,"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate",6/21/2017,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,Pharmavant 7 Sciences GmBH,Viaduktstr. 8,,Basel,,4051,Switzerland,581817
IDN-7314,WLA1SUY9N8,Designated,Public record,4385,"(S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid",6/21/2017,Treatment of primary sclerosing cholangitis (PSC),Designated,Not FDA Approved for Orphan Indication,,,,,Conatus Pharmaceuticals,16745 West Bernardo Drive,Suite 200,San Diego,California,92127,United States,583717
CITRIC ACID MONOHYDRATE,2968PHW8QP,Designated,Public record,4387,citric acid monohydrate,6/21/2017,Treatment of acute-on-chronic liver failure,Designated,Not FDA Approved for Orphan Indication,,,,,Versantis AG,7 Otto-Stern-Weg,HPL D16.2,Zürich,Zürich,,Switzerland,583217
TILSOTOLIMOD SODIUM,I6CNU8SY0F,Designated,Public record,4388,tilsotolimod sodium,6/21/2017,Treatment of melanoma stages IIb-IV.,Designated,Not FDA Approved for Orphan Indication,,,,,"Idera Pharmaceuticals, Inc.",505 Eagleview Boulevard,Suite 212,Exton,Pennsylvania,19341,United States,571016
H3B-8800,90YLS47BRX,Designated,Public record,4389,"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate",6/22/2017,Treatment of chronic myelomonocytic leukemia (CMML),Designated,Not FDA Approved for Orphan Indication,,,,,Pharmavant 7 Sciences GmBH,Viaduktstr. 8,,Basel,,4051,Switzerland,581717
BELANTAMAB MAFODOTIN,DB1041CXDG,Designated,Public record,4390,belantamab mafodotin-blmf,6/22/2017,Treatment of multiple myeloma,Designated/Approved,,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (indication withdrawn)",8/5/2020,2/6/2023,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (indication withdrawn)",GlaxoSmithKline Intellectual Property Development Ltd.,980 GREAT WEST ROAD,,BRENTFORD,MIDDLESEX,,United Kingdom,590517
BENDAMUSTINE,9266D9P3PQ,Designated,Public record,4391,bendamustine,6/22/2017,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,20814,United States,584417
CHRYSERIOL,Q813145M20,Designated,Public record,4392,chrysoeriol,6/22/2017,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Flavocure Biotech,701 East Pratt Street,Suite 2033,Baltimore,Maryland,21202,United States,582017
REPOTRECTINIB,08O3FQ4UNP,Designated,Public record,4393,repotrectinib,6/22/2017,Treatment of non-small cell lung adenocarcinomas with adenocarcinoma histology,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol Myers Squibb Company,3401 Princeton Pike,,Lawrenceville,New Jersey,8648,United States,573517
TIPIFARNIB,MAT637500A,Designated,Public record,4394,tipifarnib,6/22/2017,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,20814,United States,585317
BOMEDEMSTAT TOSYLATE,2PYF2U9JNF,Designated,Public record,4396,bomedemstat,6/26/2017,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","126 E. Lincoln Avenue, PO Box 2000",RY34B-332,Rahway,New Jersey,,United States,565516
ARPRAZIQUANTEL,WF15T5925V,Designated,Public record,4397,(R)-praziquantel,6/27/2017,Treatment of schistosomiasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Tongli Biomedical Co., Ltd. (TLB)",Guotaibei Road,"Room 401, Building D",Zhangjiagang,Jiangsu,,China,584317
HYDROCORTISONE ACETATE,3X7931PO74,Designated,Public record,4398,hydrocortisone acetate,6/27/2017,Treatment of pediatric ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Cristcot HCA, LLC",555 Virginia Road,Suite 202,Concord,Massachusetts,1742,United States,568616
LCL-161,6TNS415Y3P,Designated,Public record,4400,"(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide",6/28/2017,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,20814,United States,582917
SOBI-003,ZS87P77DQC,Designated,Public record,4402,chemically modified recombinant sulfamidase,6/28/2017,Treatment of mucopolysaccharidosis type IIIA (MPS IIIA),Designated,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ),DÄNSKEBO,,Linköping SV,Östergötlands län,,Sweden,583617
GANAXOLONE,98WI44OHIQ,Designated,Public record,4403,ganaxolone,6/28/2017,Treatment of cyclin-dependent kinase-like 5 (CDKL5) gene-related early-onset infantile epileptic encephalopathy,Designated/Approved,,Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older,6/1/2022,6/1/2029,Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older,Marinus Pharmaceuticals,170 North Radnor Chester Road,Suite 250,Radnor,Pennsylvania,19087,United States,578017
GLASDEGIB,K673DMO5H9,Designated,Public record,4404,Glasdegib,6/28/2017,Treatment of acute myeloid leukemia (AML),Designated/Approved,,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.",11/21/2018,11/21/2025,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.","Pfizer, Inc.",445 Eastern Point Road,,Groton,Connecticut,6340,United States,585517
Vamotinib,I8C3R768IZ,Designated,Public record,4406,oral tyrosine kinase inhibitor,6/28/2017,Treatment of chronic myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Fusion Pharma, LLC",Territory of the Skolkovo innovation center,Nobelya St. 7,,Moscow,,Russia,585217
VITAMIN A PALMITATE,1D1K0N0VVC,Designated,Public record,4407,retinol palmitate (vitamin A palmitate),6/28/2017,Prevention of retinopathy of prematurity (ROP),Designated,Not FDA Approved for Orphan Indication,,,,,orphanix GmbH,41 Peter-Rosegger-Straße,,Ried im Innkreis,Oberösterreich,,Austria,583417
RILZABRUTINIB,NWN58M4F5T,Designated,Public record,4408,Small Molecule Bruton's Agammaglobulinemia Tyrosine Kinase (BKT) Inhibitor,6/29/2017,Treatment of Pemphigus Vulgaris,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Principia Biopharma Inc.,400 East Jamie Court,,South San Francisco,California,94080,United States,582517
AVADOMIDE HYDROCHLORIDE,6CX4AEX3KR,Designated,Public record,4409,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",7/3/2017,Treatment of hepatocellular carcinoma (HCC),Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,585117
PF-4136309,3M2595V4KT,Designated/Withdrawn,Public record,4411,antagonist of chemokine Ligand-2,7/3/2017,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",300 Technology Square,,Cambridge,Massachusetts,2139,United States,570416
BARDOXOLONE METHYL,CEG1Q6OGU1,Designated,Public record,4414,bardoxolone methyl,7/3/2017,Treatment of Alport Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Dr.,Suite 150,Irving,Texas,75063,United States,568016
SIRUKUMAB,640443FU93,Designated,Public record,4415,sirukumab,7/3/2017,Treatment of juvenile idiopathic arthritis (JIA) in pediatric patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,19477,United States,575217
TADEKINIG ALFA,3G6834I4PF,Designated,Public record,4416,tadekinig alfa,7/3/2017,"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)",Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd,EPFL Innovation Park,Building B,Lausanne,Vaud,,Switzerland,585017
BENZNIDAZOLE,YC42NRJ1ZD,Designated,Public record,4417,benznidazole,7/5/2017,Treatment of Chagas disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Humanigen, Inc.",533 Airport Boulevard,Suite 400,Burlingame,California,94010,United States,586517
ENTRECTINIB,L5ORF0AN1I,Designated,Public record,4418,entrectinib,7/5/2017,Treatment of NTRK fusion-positive solid tumors,Designated/Approved,,"ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where",8/15/2019,8/15/2026,"For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is","Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,94080,United States,587117
Etrinabdione,KTJCIKNF3F,Designated,Public record,4419,"(1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione",7/6/2017,Treatment of systemic scleroderma (SSc),Designated,Not FDA Approved for Orphan Indication,,,,,Emerald Health Pharmaceuticals Inc.,5820 Nancy Ridge Drive,,San Diego,California,92121,United States,585717
LARSUCOSTEROL SODIUM,71A5JOPBE8,Designated,Public record,4420,"5-cholesten-3ß, 25-diol 3-sulfate sodium salt (25HC3S)",7/6/2017,Treatment of primary sclerosing cholangitis (PSC),Designated,Not FDA Approved for Orphan Indication,,,,,DURECT Corporation,10260 Bubb Road,,Cupertino,California,95014,United States,586317
BLINATUMOMAB,4FR53SIF3A,Designated,Public record,4421,blinatumomab,7/6/2017,Treatment of diffuse large B-cell lymphoma (DLBCL),Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,91320,United States,585917
COSYNTROPIN,72YY86EA29,Designated,Public record,4422,cosyntropin,7/6/2017,Treatment of Duchenne muscular dystrophy.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt ARD Inc.,675 McDonnell Boulevard,,Hazelwood,Missouri,63042,United States,545216
MIRIKIZUMAB,Z7HVY03PHP,Designated,Public record,4423,humanized immunoglobulin G4-variant monoclonal antibody directed against the p19 subunit of interleukin (IL)-23,7/6/2017,Treatment of pediatric Crohn's disease,Designated,Not FDA Approved for Orphan Indication,,,,,Eli Lilly & Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,584617
TBO-FILGRASTIM,,Designated,Public record,4425,tbo-filgrastim,7/10/2017,For the mobilization of peripheral blood progenitor cells (PBPCs) in healthy donors prior to allogeneic PBPC transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Sicor Biotech UAB,5 Moletu pl. 5,,Vilnius,Vilniaus apskritis,,Lithuania,577617
AR-67,3YEA04NV6H,Designated,Public record,4426,(20S)-7-tert-butyldimethysilyl-10-hydroxycamptothecin,7/13/2017,Treatment of glioblastoma multiforme (GBM),Designated,Not FDA Approved for Orphan Indication,,,,,"Vivacitas Oncology, Inc.",1990 North California Boulevard,8th Floor,Walnut Creek,California,94596,United States,586917
EPIRUBICIN,3Z8479ZZ5X,Designated,Public record,4428,epirubicin-conjugated polymer micelles,7/13/2017,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"NanoCarrier Co., Ltd",Chuou 144-15,226-39 Wakashiba,Kashiwa,Chiba,,Japan,588517
ETROLIZUMAB,I2A72G2V3J,Designated,Public record,4429,etrolizumab,7/13/2017,Treatment of pediatric Crohn's disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 Dna Way,,South San Francisco,California,94080,United States,531216
GILTERITINIB,66D92MGC8M,Designated,Public record,4430,gilteritinib,7/13/2017,Treatment of acute myeloid leukemia (AML),Designated/Approved,,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,11/28/2018,11/28/2025,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,"Astellas Pharma US, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,587217
VINORELBINE TARTRATE,253GQW851Q,Designated,Public record,4431,liposomal vinorelbine,7/13/2017,Treatment of soft tissue carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Taiwan Liposome Company, Ltd.",3 Yuanqu Street,,,Taipei City,,Taiwan,588417
VINORELBINE,Q6C979R91Y,Designated,Public record,4431,liposomal vinorelbine,7/13/2017,Treatment of soft tissue carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Taiwan Liposome Company, Ltd.",3 Yuanqu Street,,,Taipei City,,Taiwan,588417
RANPIRNASE,ZE15FIT23E,Designated,Public record,4432,Ranpirnase,7/14/2017,Treatment of Ebola virus disease (EVD),Designated,Not FDA Approved for Orphan Indication,,,,,"Tamir Biotechnology, Inc.",51 John F Kennedy Parkway,1st Floor West,Short Hills,New Jersey,7078,United States,596317
FILGOTINIB MALEATE,JG8OB4UL9Y,Designated,Public record,4433,filgotinib maleate,7/18/2017,Treatment of pediatric Crohn's disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine Street,,Seattle,Washington,98102,United States,588017
USTEKINUMAB,FU77B4U5Z0,Designated,Public record,4435,ustekinumab,7/18/2017,Treatment of pediatric systemic lupus erythematosus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",800 & 850 Ridgeview Drive,,Horsham,Pennsylvania,19044,United States,586217
DELPAZOLID,43EP6XV33E,Designated,Public record,4436,"(R)-3-[3-Fluoro-4-(1-methyl-1,4,5,6-tetrahydro-1,2,4-triazin-4-yl)phenyl]-5(R)-(hydroxymethyl)oxazolidin-2-one",7/19/2017,Treatment of tuberculosis,Designated,Not FDA Approved for Orphan Indication,,,,,"LegoChem Biosciences, Inc.",8-26 Munpyeongseo-ro,,Daejeon,Daedeok-gu,,South Korea,590317
ARTEMISONE,796LMW5BUZ,Designated,Public record,4437,artemisone,7/19/2017,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Artemis Therapeutics, Inc.",18 East 16th Street,Suite 307,New York,New York,10003,United States,590117
NOMLABOFUSP,V6S49GL5GS,Designated,Public record,4438,Fusion protein linking human frataxin to a cell-penetrant peptide,7/19/2017,Treatment of Friedreich's ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,"Larimar Therapeutics, Inc.",Three Bala Plaza East,Suite 506,Bala Cynwyd,Pennsylvania,19004,United States,590617
PATIDEGIB,JT96FPU35X,Designated,Public record,4439,patidegib,7/19/2017,Treatment of nevoid basal cell carcinoma syndrome (Gorlin syndrome),Designated,Not FDA Approved for Orphan Indication,,,,,"Sol-Gel Technologies, Ltd.",7 Golda Meir St.,,Weizmann Scíence Park,Ness-Ziona,7403650,Israel,587917
ZILUCOPLAN,YG391PK0CC,Designated,Public record,4442,Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol palmitoylated linker,7/19/2017,Treatment of paroxysmal nocturnal hemoglobinuria (PNH),Designated,Not FDA Approved for Orphan Indication,,,,,"Ra Pharmaceuticals, Inc.",87 Cambridge Park Drive,,Cambridge,Massachusetts,2140,United States,589717
THALIDOMIDE,4Z8R6ORS6L,Designated,Public record,4443,thalidomide,7/19/2017,Treatment of hereditary hemorrhagic telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,PlumeStars s.r.l.,Via Lago Scuro11,,Parma,,,Italy,585417
EPI-589,I4ZSB1Q2DU,Designated,Public record,4444,"(R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl) butanamide",7/27/2017,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,592517
NEO-212,237TB781D9,Designated,Public record,4445,(s)-perillyl alcohol temozolomide carbamate,7/27/2017,Treatment of nasopharyngeal carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.","8335 Sunset Blvd., #240",,Los Angeles,California,90069,United States,575117
BEDAQUILINE,78846I289Y,Designated,Public record,4447,Bedaquiline,7/27/2017,Treatment of Nontuberculosis Mycobacteria infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",125 Trenton-Harbourton Road,,Titusville,New Jersey,8560,United States,589917
CIPARGAMIN,Z7Q4FWA04P,Designated,Public record,4448,Cipargamin,7/27/2017,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,20814,United States,595417
"""POLYETHYLENE GLYCOL, UNSPECIFIED""",3WJQ0SDW1A,Designated,Public record,4450,humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA) and CD3 epsilon chain (CD3e) on T-cells,7/27/2017,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS 35-5E,South San Francisco,California,94080,United States,589817
PICROPODOPHYLLIN,0F35AOI227,Designated,Public record,4451,Picropodophyllin,7/27/2017,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,MAX Kemikonsult AB,c/o Magnus Axelson,"Hanna Nilssons vag 6, Lgh 1301",Jarfalla,Stockholms län,,Sweden,593617
PRO-PRO-THR-VAL-PRO-THR-ARG,CU50CY5QP5,Designated,Public record,4452,Pro-Pro-Thr-Val-Pro-Thr-Arg,7/27/2017,Treatment of xeroderma pigmentosum,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ProGeLife S.A.S,8 Rue Sainte-Barbe,,Marseille,Provence-Alpes-Côte d'Azur,,France,587417
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,4453,sodium phenylbutyrate and taurursodiol,7/27/2017,Treatment of amyotrophic lateral sclerosis (ALS),Designated/Approved,,Treatment of amyotrophic lateral sclerosis (ALS) in adults,9/29/2022,9/29/2029,Treatment of amyotrophic lateral sclerosis (ALS) in adults,"Amylyx Pharmaceuticals, Inc.",43 Thorndike St.,,Cambridge,Massachusetts,2141,United States,588117
TAURURSODIOL DIHYDRATE,U7XRV7RZ1I,Designated,Public record,4453,sodium phenylbutyrate and taurursodiol,7/27/2017,Treatment of amyotrophic lateral sclerosis (ALS),Designated/Approved,,Treatment of amyotrophic lateral sclerosis (ALS) in adults,9/29/2022,9/29/2029,Treatment of amyotrophic lateral sclerosis (ALS) in adults,"Amylyx Pharmaceuticals, Inc.",43 Thorndike St.,,Cambridge,Massachusetts,2141,United States,588117
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,4454,alpha-1 proteinase inhibitor (human),7/31/2017,Prevention of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Kamada, Ltd.",2 Holtzman Street,,Rehovot,,,Israel,590417
CANAKINUMAB,37CQ2C7X93,Designated,Public record,4455,canakinumab,7/31/2017,Treatment of adult-onset Still's Disease,Designated/Approved,,"ILARIS is indicated for the treatment of active Still¿s disease, including Adult-Onset Still¿s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.",6/16/2020,6/16/2027,For the treatment of active adult-onset Still¿s Disease (AOSD).,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,591317
TOCILIZUMAB,I031V2H011,Designated/Approved,Public record,4457,tocilizumab,8/1/2017,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,8/30/2017,8/30/2024,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group",1 DNA Way,MS #355e,South San Francisco,California,94080,United States,589317
CT-179 DIMESYLATE,FG4454219O,Designated,Public record,4458,"1-{2-[3-(3,4-Dichlorophenyl)ureido]-6-methyl-pyrimidin-4-yl}-amino-3(dimethylamino)propane Di methansulfonate",8/2/2017,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Curtana Pharmaceuticals, Inc.",1624 Headway Circle,,Austin,Texas,78754,United States,599417
CARISBAMATE,P7725I9V3Z,Designated,Public record,4459,carisbamate,8/2/2017,Treatment of Lennox-Gastaut syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"SK Life Sciences, Inc.",22-10 New Jersey 208 South,,Fair Lawn,New Jersey,7410,United States,594117
COSYNTROPIN,72YY86EA29,Designated,Public record,4460,cosyntropin,8/2/2017,Treatment of infantile spasms.,Designated,Not FDA Approved for Orphan Indication,,,,,"West Therapeutic Development, LLC",540 Ziegler Drive,,Grayslake,Illinois,60030,United States,594017
CROFELEMER,PY79D6C8RX,Designated,Public record,4461,crofelemer,8/2/2017,Treatment of short bowel syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.",201 Mission Street,Suite 2375,San Francisco,California,94105,United States,592017
GEMFIBROZIL,Q8X02027X3,Designated,Public record,4462,gemfibrozil,8/2/2017,Treatment of neuronal ceroid lipofuscinoses,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.",140 East Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,7652,United States,591917
GEMFIBROZIL,Q8X02027X3,Designated,Public record,4462,gemfibrozil,8/2/2017,Treatment of neuronal ceroid lipofuscinoses,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.",140 East Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,7652,United States,591917
MILTEFOSINE,53EY29W7EC,Designated,Public record,4463,miltefosine,8/2/2017,Treatment of schistosomiasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,32822,United States,590217
U-0126,8027P94HLL,Designated,Public record,4465,"1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene",8/3/2017,Treatment of subarachnoid hemorrhage (SAH),Designated,Not FDA Approved for Orphan Indication,,,,,Edvince AB,Medicon Village,Scheelevägen 2,Lund,Skåne län,,Sweden,593217
Efanesoctocog Alfa,WH7BHQ0RB4,Designated,Public record,4466,"antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl",8/3/2017,Treatment of hemophilia A,Designated/Approved,,in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding,2/22/2023,2/22/2030,in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding,"Bioverativ Therapeutics, Inc.",225 Second Avenue,,Waltham,Massachusetts,2451,United States,591217
BRIMONIDINE,E6GNX3HHTE,Designated,Public record,4467,brimonidine,8/3/2017,Treatment of ocular graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Ocugen, Inc.",5 Great Valley Parkway,Suite 160,Malvern,Pennsylvania,19355,United States,564016
ACT-1 PEPTIDE,LQO3A9PGE4,Designated,Public record,4468,Granexin® gel (aCTI peptide),8/3/2017,Treatment of cutaneous radiation injury due to radiation disaster,Designated,Not FDA Approved for Orphan Indication,,,,,"FirstString Research, Inc.",300 West Coleman Boulevard,Suite 203,Mount Pleasant,South Carolina,29464,United States,573217
NARSOPLIMAB,FT24ZQQ5RP,Designated,Public record,4469,human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2,8/3/2017,Treatment of immunoglobulin A nephropathy (IgAN),Designated,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Avenue West,,Seattle,Washington,98119,United States,561516
ODIPARCIL,FIK1414ZI8,Designated,Public record,4470,odiparcil,8/3/2017,Treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome),Designated,Not FDA Approved for Orphan Indication,,,,,Inventiva SA,50 rue de Dijon,,Daix,,21121,France,592317
PAPAVERINE,DAA13NKG2Q,Designated,Public record,4471,papaverine,8/3/2017,Treatment of mesenteric ischemia,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,161 Jefferson Avenue,,Tenafly,New Jersey,7670,United States,581417
SELETALISIB,64CW205BDD,Designated,Public record,4472,seletalisib,8/3/2017,Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive,,Smyrna,Georgia,30080,United States,579917
TESEVATINIB,F6XM2TN5A1,Designated,Public record,4473,tesevatinib,8/3/2017,Treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations,Designated,Not FDA Approved for Orphan Indication,,,,,"Kadmon Corporation, LLC",450 East 29th Street,,New York,New York,10016,United States,584917
SELETALISIB,64CW205BDD,Designated,Public record,4474,apolipoprotein E mimetic peptide (AEM-28(R)-14),8/7/2017,Treatment of homozygous familial hypercholesterolemia (HoFH),Designated,Not FDA Approved for Orphan Indication,,,,,"LipimetiX Development, LLC",5 Commonwealth Road,Suite 2A,Natick,Massachusetts,1760,United States,596517
BLISIBIMOD,114VP6C6ES,Designated,Public record,4475,blisibimod,8/7/2017,Treatment of patients with immunoglobulin A nephropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Anthera Pharmaceuticals, Inc.",25801 Industrial Boulevard,Suite B,Hayward,California,94545,United States,560216
RIPRETINIB,9XW757O13D,Designated,Public record,4476,KIT and PDGFR inhibitor,8/7/2017,Treatment of glioblastoma multiforme and anaplastic astrocytomas,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Deciphera Pharmaceuticals, LLC",200 Smith Street,,Waltham,Massachusetts,2451,United States,597617
BLISIBIMOD,114VP6C6ES,Designated,Public record,4477,Leu-Lys-Gly-Gln-Leu-Arg-Cys-Ile,8/7/2017,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Kalos Therapeutics, Inc.",6351 W. Lone Cactus Drive,,Glendale,Alaska,85308,United States,593517
NIVOLUMAB,31YO63LBSN,Designated,Public record,4478,nivolumab,8/7/2017,Treatment of anal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,591617
OXFENDAZOLE,OMP2H17F9E,Designated,Public record,4479,oxfendazole,8/7/2017,Treatment of cysticercosis,Designated,Not FDA Approved for Orphan Indication,,,,,Oxfendazole Development Group,736 Cathcart Road,,Blue Bell,Pennsylvania,19422,United States,597217
CADAZOLID,2OEA2UN10Y,Designated,Public record,4480,cadazolid,8/8/2017,Treatment of clostridium difficile infection in pediatric patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Actelion Pharmaceuticals Ltd,16 Gewerbestrasse,,Allschwil,Basel-Landschaft,,Switzerland,592917
COBITOLIMOD,328101264R,Designated,Public record,4481,cobitolimod,8/8/2017,Treatment of ulcerative colitis in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,InDex Pharmaceuticals AB,23a Tomtebodavägen,,Hagalund,Stockholms län,,Sweden,594417
DASIGLUCAGON,AD4J2O47FQ,Designated,Public record,4482,dasiglucagon,8/10/2017,Treatment of hypoglycemia in patients with congenital hyperinsulinism (CH),Designated,Not FDA Approved for Orphan Indication,,,,,Zealand Pharma A/S,36 Smedeland,,Glostrup,,,Denmark,569416
ENTOSPLETINIB,6I3O3W6O3B,Designated,Public record,4483,entospletinib,8/10/2017,Prevention of chronic graft-versus-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Kronos Bio, Inc.","1300 S. El Camino Real, Suite 400",,San Mateo,California,94402,United States,510115
NIMODIPINE,57WA9QZ5WH,Designated,Public record,4484,nimodipine intravenous,8/10/2017,Treatment of subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,Acasti Pharma Inc.,"3009 Boulevard De la Concorde E., Suite 102",,Laval,Quebec,,Canada,566016
BIRCH TRITERPENES,BX09B0RQR0,Designated,Public record,4485,Recombinant human antibody directed against human misfolded superoxide dismutase 1,8/10/2017,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,AL-S Pharma SA,13 Wagistrasse,,Schlieren,Zürich,,Switzerland,596417
ARAZASETRON BESYLATE,UXP39EQ477,Designated,Public record,4488,(R)-Azasetron besylate,8/16/2017,Prevention of platinum-induced ototoxicity in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,Sensorion SA,375 Rue du Professeur Joseph Blayac,,Montpellier,Languedoc-Roussillon,,France,593417
BITOPERTIN,Q8L6AN59YY,Designated,Public record,4489,bitopertin,8/16/2017,Treatment of ß-thalassemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Hoffmann-La Roche Inc.,"c/o Genentech, Inc.",1 DNA Way,South San Francisco,California,94080,United States,596717
NIVOLUMAB,31YO63LBSN,Designated,Public record,4490,nivolumab,8/16/2017,Treatment of mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,595817
IPILIMUMAB,6T8C155666,Designated,Public record,4491,nivolumab and ipilimumab,8/16/2017,Treatment of mesothelioma,Designated/Approved,,"YERVOY® (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",10/2/2020,10/2/2027,YERVOY® (ipilimumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,595917
NIVOLUMAB,31YO63LBSN,Designated,Public record,4491,nivolumab and ipilimumab,8/16/2017,Treatment of mesothelioma,Designated/Approved,,"YERVOY® (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",10/2/2020,10/2/2027,YERVOY® (ipilimumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,595917
IPILIMUMAB,6T8C155666,Designated,Public record,4492,nivolumab and ipilimumab,8/16/2017,Treatment of mesothelioma,Designated/Approved,,"OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",10/2/2020,10/2/2027,OPDIVO (nivolumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,595917
NIVOLUMAB,31YO63LBSN,Designated,Public record,4492,nivolumab and ipilimumab,8/16/2017,Treatment of mesothelioma,Designated/Approved,,"OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",10/2/2020,10/2/2027,OPDIVO (nivolumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,8543,United States,595917
TAMIBAROTENE,08V52GZ3H9,Designated,Public record,4493,tamibarotene,8/16/2017,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,"Syros Pharmaceuticals, Inc.",620 Memorial Drive,Suite 300,Cambridge,Massachusetts,2139,United States,596017
RESVERATROL,Q369O8926L,Designated,Public record,4494,trans-resveratrol,8/16/2017,Treatment of Friedreich’s Ataxia (FRDA),Designated,Not FDA Approved for Orphan Indication,,,,,Jupiter Orphan Therapeutics,601 Heritage Drive,,Jupiter,Florida,33458,United States,597817
UPADACITINIB,4RA0KN46E0,Designated,Public record,4495,upadacitinib,8/16/2017,Treatment of pediatric systemic juvenile idiopathic arthritis,Designated,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,522916
SUTIMLIMAB,GNWE7KJ995,Designated,Public record,4496,"humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s)",8/17/2017,Treatment of bullous pemphigoid (BP).,Designated,Not FDA Approved for Orphan Indication,,,,,Bioverativ USA Inc.,225 Second Avenue,,Waltham,Massachusetts,2451,United States,597117
NEVANIMIBE,VK9OS8R205,Designated,Public record,4497,nevanimibe HCL,8/17/2017,Treatment of congenital adrenal hyperplasia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Millendo Therapeutics, Inc.",301 North Main Street,Suite 100,Ann Arbor,Michigan,48104,United States,497315
OBINUTUZUMAB,O43472U9X8,Designated,Public record,4498,obinutuzumab,8/17/2017,Treatment of splenic marginal zone lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group",1 DNA Way,MS #355e,South San Francisco,California,94080,United States,592717
VIXTIMOTAMAB,56FUB33G5M,Designated,Public record,4499,tetravalent tandem diabody binding both CD3 and CD33,8/17/2017,Treatment of patients with acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,"Amphivena Therapeutics, Inc.",601 Gateway Boulevard,Suite 350,South San Francisco,California,94080,United States,593317
DSM-265,0Q42P4YI6B,Designated,Public record,4500,"2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-¿{6}-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",8/18/2017,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,20814,United States,598417
ELRAGLUSIB,ND1SOF0DLU,Designated,Public record,4501,"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5 f]indol-7-yl)-pyrrole-2,5-dione",8/18/2017,Treatment of Neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Actuate Therapeutics,1751 River Run,Suite 400,Fort Worth,Texas,76107,United States,598217
RELATLIMAB,AF75XOF6W3,Designated,Public record,4502,nivolumab and relatlimab-rmbw,8/18/2017,Treatment of stage IIb to IV melanoma,Designated/Approved,,Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma,3/18/2022,3/18/2029,Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,,United States,595017
NIVOLUMAB,31YO63LBSN,Designated,Public record,4502,nivolumab and relatlimab-rmbw,8/18/2017,Treatment of stage IIb to IV melanoma,Designated/Approved,,Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma,3/18/2022,3/18/2029,Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,,United States,595017
TRAZODONE,YBK48BXK30,Designated,Public record,4504,trazodone,8/18/2017,Treatment of Dravet syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 E. Ridgewood Avenue,Suite 415 South Tower,Paramus,New Jersey,7652,United States,593917
PEGINTERFERON LAMBDA-1A,0T0250N43U,Designated,Public record,4505,Peginterferon lambda-1a,8/25/2017,Treatment of hepatitis Delta virus infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.",350 Cambridge Avenue,Suite 350,Palo Alto,California,94306,United States,594817
VENETOCLAX,N54AIC43PW,Designated,Public record,4509,venetoclax,8/31/2017,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,600117
ARTESUNATE,60W3249T9M,Designated,Public record,4510,Artesunate,9/5/2017,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Guilin Pharmaceutical Co., Ltd.",No. 43 Qilidian Road,,Guilin Guangxi,Shanghai Shi,,China,598517
DARATUMUMAB,4Z63YK6E0E,Designated,Public record,4511,daratumumab,9/5/2017,Treatment of systemic amyloid light-chain (AL) amyloidosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,536216
DUPILUMAB,420K487FSG,Designated,Public record,4512,dupilumab,9/5/2017,Treatment of eosinophilic esophagitis,Designated/Approved,,"Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)",5/20/2022,5/20/2029,"Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,599317
ELAMIPRETIDE,87GWG91S09,Designated,Public record,4513,elamipretide,9/5/2017,Treatment of primary mitochondrial myopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Stealth BioTherapeutics,140 Kendrick Street,Building C-West,Needham,Massachusetts,2494,United States,597417
OLAFERTINIB,708TLB8J3Y,Designated,Public record,4514,"N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide",9/5/2017,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC),Designated,Not FDA Approved for Orphan Indication,,,,,"Checkpoint Therapeutics, Inc.",2 Gansevoort Street,9th Floor,New York,New York,10014,United States,599817
OMAVELOXOLONE,G69Z98951Q,Designated,Public record,4515,omaveloxolone,9/5/2017,Treatment of stage IIb through IV malignant melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Dr.,Suite 150,Irving,Texas,75063,United States,461114
CROVALIMAB,H9KH1GP3UU,Designated,Public record,4516,recombinant humanized anti-complement component 5 monoclonal antibody,9/5/2017,Treatment of paroxysmal nocturnal hemoglobinuria (PNH),Designated,Not FDA Approved for Orphan Indication,,,,,Hoffmann-La Roche Inc.,"c/o Genentech, Inc.",1 DNA Way,South San Francisco,California,94080,United States,590717
BEPRANEMAB,9M1GV6L389,Designated,Public record,4517,recombinant humanized IgG4P monoclonal antibody with specificity for human tau,9/5/2017,Treatment of progressive supranuclear palsy (PSP),Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive,,Smyrna,Georgia,30080,United States,598117
H3B-6527,4HTE364XIK,Designated,Public record,4519,"(N-{2-[(6-{[(2,6-Dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4- yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide)",9/7/2017,Treatment of hepatocellular carcinoma (HCC),Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,,United States,597717
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,4521,lisocabtagene maraleucel,9/7/2017,Treatment of follicular lymphoma (FL),Designated/Approved,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade",2/5/2021,2/5/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",86 Morris Ave,,Summit,New Jersey,7901,United States,600517
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,4522,lisocabtagene maraleucel,9/7/2017,Treatment of follicular lymphoma (FL),Designated/Approved,,"Treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma,",6/24/2022,6/24/2029,"Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chem","Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",86 Morris Ave,,Summit,New Jersey,7901,United States,600517
RUSALATIDE ACETATE,9J556O9JPD,Designated,Public record,4523,rusalatide acetate,9/7/2017,Treatment of acute radiation syndrome (ARS),Designated,Not FDA Approved for Orphan Indication,,,,,"Chrysalis BioTherapeutics, Inc.",2200 Market Street,Suite 609,Galveston,Texas,77550,United States,601417
AGALSIDASE ALFA,2HLC17MX9G,Designated,Public record,4526,recombinant human acid a-glucosidase co-administered with N-butyl-deoxynojirimycin (recombinant human acid a-glucosidase/miglustat),9/13/2017,Treatment of Pompe disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Amicus Therapeutics, Inc.",3675 Market Street,,Philadelphia,Pennsylvania,19104,United States,601617
MIGLUSTAT,ADN3S497AZ,Designated,Public record,4526,recombinant human acid a-glucosidase co-administered with N-butyl-deoxynojirimycin (recombinant human acid a-glucosidase/miglustat),9/13/2017,Treatment of Pompe disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Amicus Therapeutics, Inc.",3675 Market Street,,Philadelphia,Pennsylvania,19104,United States,601617
ICLAPRIM,42445HUU0O,Designated,Public record,4527,iclaprim,9/14/2017,Treatment of Staphylococus aureus lung infections in patients with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Motif Bio PLC,330 Madison Avenue,6th Floor,New York,New York,10017,United States,514415
OXALIPLATIN,04ZR38536J,Designated,Public record,4529,liposomal oxaliplatin,9/18/2017,Treatment of pancreatic adenocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"KC Specialty Therapeutics, LLC",2002 West 39th Avenue,,Kansas City,Arkansas,66103,United States,560816
LIXIVAPTAN,8F5X4B082E,Designated,Public record,4530,lixivaptan,9/18/2017,Treatment of autosomal dominant polycystic kidney disease (ADPKD),Designated,Not FDA Approved for Orphan Indication,,,,,"Palladio Biosciences, Inc.",12 Penns Trail,Unit A,Newtown,Pennsylvania,18940,United States,589617
OXALIPLATIN,04ZR38536J,Designated,Public record,4531,mRNA encoding human argininosuccinate lyase,9/18/2017,Treatment of argininosuccinate lyase deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"PhaseRx, Inc.",410 West Harrison Street,Suite 300,Seattle,Washington,98119,United States,605617
ADEGRAPEPIMUT-S,4XQ7W02EQ0,Designated,Public record,4532,nelatimotide and adegramotide (DSP-7888 dosing emulsion),9/18/2017,Treatment of brain cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,1752,United States,603617
ELATIPEPIMUT-S,38184303XR,Designated,Public record,4532,nelatimotide and adegramotide (DSP-7888 dosing emulsion),9/18/2017,Treatment of brain cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,1752,United States,603617
PRILIXIMAB,TW5DE23BLM,Designated,Public record,4533,priliximab,9/18/2017,Treatment of mycosis fungoides (MF),Designated,Not FDA Approved for Orphan Indication,,,,,"Onco Therapies, Inc.",2265 East Foothill Boulevard,,Pasadena,California,91107,United States,600717
TUCATINIB,234248D0HH,Designated,Public record,4534,tucatinib,9/18/2017,Treatment of HER2+ colorectal cancer,Designated/Approved,,"in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemother",1/19/2023,1/19/2030,"treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy",Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,98021,United States,571216
TINLAREBANT,63WI9S8P1M,Designated,Public record,4535,"1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-6-yl)ethan-1-one",9/19/2017,Treatment of Stargardt disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Belite Bio, LLC",3210 Merryfield Row,,San Diego,California,92121,United States,601217
MIPICOLEDINE,1S83F4T2WE,Designated,Public record,4536,4-demethyl-4-cholesteryloxycarbonylpenclomedine,9/19/2017,Treatment of non-small cell lung cancer with CNS metastases,Designated,Not FDA Approved for Orphan Indication,,,,,"DEKK-TEC, Inc.",725 Topaz Street,,New Orleans,Louisiana,70124,United States,604017
TUCATINIB,234248D0HH,Designated,Public record,4538,non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA,9/19/2017,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Nationwide Children's Hospital,Drug and Device Development Services,700 Children's Drive,Columbus,Ohio,43205,United States,603217
RIMEPORIDE,QH6B4V5743,Designated,Public record,4540,rimeporide,9/19/2017,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,EspeRare Foundation,"14, Ch des Aulx",,Plan-les-Ouates,Genève,,Switzerland,602717
DALCINONACOG ALFA,BDB9DD09QX,Designated,Public record,4541,Dalcinonacog Alfa,9/20/2017,Treatment for hemophilia B,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Biosciences, Inc.",260 Littlefield Avenue,,South San Francisco,California,94080,United States,596217
EFGARTIGIMOD ALFA,961YV2O515,Designated,Public record,4542,efgartigimod alfa-fcab,9/20/2017,Treatment of myasthenia gravis,Designated/Approved,,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,12/17/2021,12/17/2028,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,argenx BV,Industriepark Zwijnaarde 7,,Zwijnaarde,,9052,Belgium,527316
MITOXANTRONE HYDROCHLORIDE,U6USW86RD0,Designated,Public record,4544,Mitoxantrone hydrochloride liposome,9/20/2017,Treatment of peripheral T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.","., a subsidiary company within CSPC Pharmaceutical Group, Ltd",226 Huanghe Avenue,Shijiazhuang Shi,Hebei Sheng,,China,602317
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,4545,Nitric oxide,9/26/2017,Treatment of non-tuberculosis mycobacterial (NTM) infections,Designated,Not FDA Approved for Orphan Indication,,,,,Advanced Inhalation Therapies Ltd.,2 Ilan Ramon Street,Ness Ziona,,,,Israel,603917
ROFECOXIB,0QTW8Z7MCR,Designated,Public record,4546,rofecoxib,9/26/2017,Treatment of hemophilic arthropathy (HA),Designated,Not FDA Approved for Orphan Indication,,,,,"Tremeau Pharmaceuticals, Inc.",1 Broadway,14th Floor,Cambridge,Massachusetts,2142,United States,601917
FIMAPORFIN,3UVT27C76J,Designated,Public record,4549,fimaporfin,9/27/2017,Treatment of cholangiocarcinoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,PCI Biotech AS,64 Ullernchausseen,,Ullern,Oslo,,Norway,574217
ONVANSERTIB,67RM91WDHQ,Designated,Public record,4550,"1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt",9/28/2017,Treatment of Acute Myeloid Leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cardiff Oncology, Inc.",11055 Flintkote Avenue,,San Diego,California,92121,United States,602617
GIVINOSTAT,5P60F84FBH,Designated,Public record,4552,Givinostat,9/28/2017,Treatment of polycythemia vera (PV),Designated,Not FDA Approved for Orphan Indication,,,,,Italfarmaco SpA,54 Via dei Lavoratori,,Cinisello Balsamo,Lombardia,,Italy,604917
FB-825,YO4XL7781V,Designated,Public record,4553,Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE),9/28/2017,Treatment of hyperimmunoglobulin E syndrome (HIES),Designated,Not FDA Approved for Orphan Indication,,,,,"Oneness Biotech Co., Ltd.","11F., No.236, Sec 4","Xinyi Road, Da'an District","Taipei City 106, Taiwan",,,Taiwan,606617
TAZEMETOSTAT,Q40W93WPE1,Designated,Public record,4554,tazemetostat,9/28/2017,Treatment of mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,Epizyme Inc.,400 Technology Square,4th Floor,Cambridge,Massachusetts,2139,United States,544416
MIVAVOTINIB CITRATE,6ZJ8V3Q0H1,Designated,Public record,4555,"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate",10/3/2017,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,606817
GABOXADOL,K1M5RVL18S,Designated,Public record,4557,Gaboxadol,10/3/2017,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Ovid Therapeutics,1460 Broadway,,New York,New York,10036,United States,605517
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,4558,pembrolizumab,10/3/2017,Treatment of Small Cell Lung Cancer,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. (Indication withdrawn),6/17/2019,3/30/2021,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. (Indication withdrawn),"Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,605417
LERONLIMAB,Y1J4NP8FF0,Designated,Public record,4559,humanized monoclonal antibody to CCR5,10/4/2017,Prevention of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"CytoDyn, Inc.",1111 Main Street,Suite 660,Vancouver,Washington,98660,United States,516516
BELUMOSUDIL MESYLATE,6MX7XE1M0U,Designated,Public record,4561,belumosudil,10/5/2017,Treatment of graft versus host disease (GVHD),Designated/Approved,,Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy,7/16/2021,7/16/2028,Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy,"Kadmon Pharmaceuticals, LLC","55 Cambridge Parkway, Suite 300E",,Cambridge,Massachusetts,2142,United States,606717
FILGOTINIB MALEATE,JG8OB4UL9Y,Designated,Public record,4562,filgotinib maleate,10/5/2017,Treatment of pediatric ulcerative colitis (UC),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine Street,,Seattle,Washington,98102,United States,604517
AVELUMAB,KXG2PJ551I,Designated,Public record,4564,avelumab,10/11/2017,Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ),Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.",45A Middlesex Turnpike,,Billerica,Massachusetts,1821,United States,604117
CARMUSTINE,U68WG3173Y,Designated,Public record,4565,carmustine,10/11/2017,Conditioning treatment prior to hematopoietic progenitor cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A.,"Via Zurigo, 46",,Lugano,,,Switzerland,606517
LIVOLETIDE,9VHD7J6363,Designated,Public record,4567,synthetic cyclic 8 amino acid analog of human unacylated ghrelin,10/12/2017,Treatment of Prader-Willi syndrome (PWS),Designated,Not FDA Approved for Orphan Indication,,,,,"Millendo Therapeutics, Inc.",301 North Main Street,Suite 100,Ann Arbor,Michigan,48104,United States,603317
UPAMOSTAT,S5M7KW6U17,Designated,Public record,4570,upamostat,10/16/2017,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a Street,,Tel Aviv-Yafo,Tel Aviv District,,Israel,608417
VATIQUINONE,6O85FK9I0X,Designated,Public record,4574,vatiquinone,10/18/2017,Treatment of pontocerebellar hypoplasia,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,606317
Valbenazine,54K37P50KH,Designated,Public record,4575,valbenazine,10/19/2017,Treatment of pediatric patients with Tourette syndrome (TS).,Designated,Not FDA Approved for Orphan Indication,,,,,"Neurocrine Biosciences, Inc.",12780 El Camino Real,,San Diego,California,92130,United States,608317
GLASDEGIB,K673DMO5H9,Designated,Public record,4576,glasdegib,10/20/2017,Treatment of myelodysplastic syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",445 Eastern Point Road,,Groton,Connecticut,6340,United States,608617
GLEPAGLUTIDE,4M3C1913N6,Designated,Public record,4577,glepaglutide,10/20/2017,Treatment of short bowel syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Zealand Pharma A/S,36 Smedeland,,Glostrup,,,Denmark,539216
DEULINOLEATE ETHYL,24B102R86P,Designated,Public record,4578,"9-cis,12-cis-11,11-D2-linoleic acid ethyl ester",10/24/2017,Treatment of PLA2G6-associated neurodegeneration,Designated,Not FDA Approved for Orphan Indication,,,,,"Retrotope, Inc.",4300 El Camino Real,Suite 201,Los Altos,California,94022,United States,607717
CANNABIDIOL,19GBJ60SN5,Designated,Public record,4579,cannabidiol (CBD),10/24/2017,Treatment of Lennox-Gastaut syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,27262,United States,610117
DOPAMINE HYDROCHLORIDE,7L3E358N9L,Designated,Public record,4580,dopamine hydrochloride,10/24/2017,Prevention of intraventricular hemorrhage in hypotensive premature neonates,Designated,Not FDA Approved for Orphan Indication,,,,,"Brepco Biopharma, Ltd.",1785 Old Mill Road,,Bethlehem,Pennsylvania,18015,United States,578817
DCLL-9718S,YCH5V86R73,Designated,Public record,4581,"THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer",10/24/2017,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,"mail stop: B-35, 355d",South San Francisco,California,94080,United States,609217
PHENOBARBITAL,YQE403BP4D,Designated,Public record,4583,phenobarbital,10/25/2017,Treatment of neonatal seizures,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Renaissance SSA, LLC",411 South State Street,Suite E100,Newtown,Pennsylvania,18940,United States,601717
SERIBANTUMAB,1N3L70MDFX,Designated,Public record,4584,seribantumab,10/25/2017,Treatment of heregulin-positive non-small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.",888 7th Avenue,Suite 30,New York,New York,10106,United States,545516
CUPRIC SULFATE,LRX7AJ16DT,Designated,Public record,4585,copper sulfate,10/26/2017,Treatment of keratoconus,Designated,Not FDA Approved for Orphan Indication,,,,,Glaukos Corporation,One Glaukos Way,,Aliso Viejo,California,92656,United States,586117
INDOXIMOD,TX5CYN1KMZ,Designated,Public record,4586,indoximod,10/26/2017,Treatment of Stage IIB to IV melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Lumos Pharma, Inc.","2503 South Loop Drive, Suite 5100",,Ames,Iowa,50010,United States,608917
RAVULIZUMAB,C3VX249T6L,Designated,Public record,4587,ravulizumab-cwvz,10/27/2017,Treatment of atypical hemolytic uremic syndrome (aHUS),Designated/Approved,,Treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA),7/22/2022,,,"Alexion Pharmaceuticals, Inc.",100 College Street,,New Haven,Connecticut,6510,United States,606917
Florzolotau F-18,51M993JIQ4,Designated,Public record,4588,"1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol",11/1/2017,A diagnostic for the management of progressive supranuclear palsy,Designated,Not FDA Approved for Orphan Indication,,,,,Aprinoia Therapeutics,"17F, No. 3 Yuanqu Street",Nangang District,Taipei City,,11503,Taiwan,610917
BEROTRALSTAT HYDROCHLORIDE,88SH1NBL2B,Designated,Public record,4589,berotralstat,11/1/2017,Treatment of C1-inhibitor-dependent angioedema (including prevention and treatment of attacks),Designated/Approved,,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older,12/3/2020,12/3/2027,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older,"BioCryst Pharmaceuticals, Inc.",4505 Emperor Blvd,Suite 200,Durham,North Carolina,27703,United States,607617
OZANIMOD,Z80293URPV,Designated,Public record,4590,ozanimod,11/1/2017,Treatment of pediatric Crohn’s disease,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene International II Sarl,4 Rue des Moulins,,Val-de-Travers,Neuchâtel,,Switzerland,611517
COSYNTROPIN,72YY86EA29,Designated,Public record,4592,vigabatrin and cosyntropin,11/1/2017,Treatment of infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,"West Therapeutic Development, LLC",540 Ziegler Drive,,Grayslake,Illinois,60030,United States,609817
VIGABATRIN,GR120KRT6K,Designated,Public record,4592,vigabatrin and cosyntropin,11/1/2017,Treatment of infantile spasms,Designated,Not FDA Approved for Orphan Indication,,,,,"West Therapeutic Development, LLC",540 Ziegler Drive,,Grayslake,Illinois,60030,United States,609817
DANICOPAN,JM8C1SFX0U,Designated,Public record,4593,"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide",11/2/2017,Treatment of paroxysmal nocturnal hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc",300 George Street,,New Haven,Connecticut,6511,United States,512715
ARIMOCLOMOL,EUT3557RT5,Designated,Public record,4594,arimoclomol,11/2/2017,Treatment of inclusion body myositis,Designated,Not FDA Approved for Orphan Indication,,,,,KemPharm Denmark A/S,Ole Maaloes Vej 3,,Copenhagen,København,2200,Denmark,611317
BARICITINIB,ISP4442I3Y,Designated,Public record,4595,baricitinib,11/2/2017,Treatment of pediatric systemic lupus erythematosus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,610017
BEREMAGENE GEPERPAVEC,AQN7K24KQU,Designated,Public record,4596,beremagene geperpavec-svdt,11/2/2017,Treatment of dystrophic epidermolysis bullosa,Designated/Approved,,treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene,5/19/2023,5/19/2030,treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene,"Krystal Biotech, LLC",2100 Wharton Street,Suite 701,Pittsburgh,Pennsylvania,15203,United States,558816
ALANYL GLUTAMINE,U5JDO2770Z,Designated,Public record,4598,alanyl-glutamine dipeptide,11/6/2017,Prevention of complications associated with peritoneal dialysis (PD) treatment in end stage renal disease (ESRD),Designated,Not FDA Approved for Orphan Indication,,,,,Zytoprotec GmbH,28/2 Mariannengasse,,Vienna,Wien,,Austria,611617
PALOVAROTENE,28K6I5M16G,Designated,Public record,4599,palovarotene,11/6/2017,Treatment of multiple osteochondromas,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Clementia Pharmaceuticals, Inc.","1000 De La Gauchetiere West, Suite 1200",,Montreal,,,Canada,612117
POLIHEXANIDE,322U039GMF,Designated,Public record,4600,polyhexanide,11/6/2017,Treatment of Acanthamoeba keratitis,Designated,Not FDA Approved for Orphan Indication,,,,,Società Industria Farmaceutica Italiana S.p.A.,36 Via Ercole Patti,,Lavinaio,Sicilia,,Italy,610317
ACT-001 FUMARATE,KM6239D2QV,Designated,Public record,4601,"(3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate",11/8/2017,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,Accendatech USA Incorporated,3730 Kirby Drive,Suite 1200,Houston,Texas,77098,United States,610217
OCX-0191,U4XIL4091C,Designated,Public record,4602,3-aminopyridine-2-carboxaldehyde thiosemicarbazone,11/8/2017,Treatment of stage 1B to IV cervical cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"National Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD)",9609 Medical Center Drive,"Room 5-W520, MSC 9740",Rockville,Maryland,20850,United States,588817
TILDACERFONT,09QCEV5481,Designated,Public record,4603,corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring,11/8/2017,Treatment of congenital adrenal hyperplasia,Designated,Not FDA Approved for Orphan Indication,,,,,Spruce Biosciences,548 Market Street,Suite 74598,San Francisco,California,94104,United States,612217
UBIDECARENONE,EJ27X76M46,Designated,Public record,4604,ubidecarenone,11/8/2017,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Berg, LLC",500 Old Connecticut Path,Building B,Framingham,Massachusetts,1701,United States,610717
Alintegimod,NX38VST3GU,Designated,Public record,4605,VLA-4 and LFA-1 integrin activator,11/8/2017,Treatment of malignant melanoma stages IIB to IV,Designated,Not FDA Approved for Orphan Indication,,,,,"7 Hills Pharma, LLC",8285 El Rio Street,Suite 130,Houston,Texas,77054,United States,611917
TAZEMETOSTAT,Q40W93WPE1,Designated,Public record,4608,tazemetostat,11/14/2017,Treatment of follicular lymphoma,Designated/Approved,,TAZVERIK (tazemetostat) is indicated for: the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior,6/18/2020,6/18/2027,"For the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for the treatment of adul","Epizyme, Inc.",400 Technology Square,4th Floor,Cambridge,Massachusetts,2139,United States,607017
CHOLERA ENTEROTOXIN SUBUNIT B,1FKD81GIZJ,Designated,Public record,4609,cholera toxin B subunit,11/16/2017,Treatment of ulcerative colitis in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,Aliment Wellness LLC,9462 Brownsboro Road,Suite 340,Louisville,Kentucky,40241,United States,603817
DaxibotulinumtoxinA-LANM,,Designated,Public record,4610,daxibotulinumtoxinA,11/16/2017,Treatment of cervical dystonia,Designated,Not FDA Approved for Orphan Indication,,,,,"Revance Therapeutics, Inc.",7555 Gateway Boulevard,,Newark,California,94560,United States,579317
ONTAMALIMAB,6LGI7RV4PB,Designated,Public record,4611,human IgG2 anti-monoclonal antibody directed against mucosal addressin cell adhesion molecule (MAdCAM),11/16/2017,Treatment of pediatric patients with Ulcerative Colitis (UC),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc. (Shire)",300 Shire Way,,Lexington,Massachusetts,2421,United States,608217
IMIFOPLATIN,F5I3T42BXC,Designated,Public record,4613,"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)",11/22/2017,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Phosplatin Therapeutics LLC,1350 6th Avenue,3rd Floor,New York,New York,10019,United States,613617
EFLORNITHINE,ZQN1G5V6SR,Designated,Public record,4614,eflornithine,11/22/2017,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"USWM, LLC",4441 Springdale Rd,,Louisville,Kentucky,40241,United States,613217
PREIMPLANTATION FACTOR,3K6A6FJ98O,Designated,Public record,4615,Synthetic PreImplantation Factor (H-Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser-Asp-Asp-OH,11/22/2017,Treatment of autoimmune hepatitis (AIH),Designated,Not FDA Approved for Orphan Indication,,,,,"BioIncept, LLC",140 East 40th Street,Suite 11E,New York,New York,10016,United States,613417
POVIDONE-IODINE,85H0HZU99M,Designated,Public record,4616,povidone iodine,11/27/2017,Treatment of endophthalmitis,Designated,Not FDA Approved for Orphan Indication,,,,,Veloce BioPharma LLC,7008 Lafayette Avenue,,Fort Washington,Pennsylvania,19034,United States,564916
SETMELANOTIDE,N7T15V1FUY,Designated,Public record,4619,setmelanotide,11/27/2017,Treatment of leptin receptor deficiency,Designated/Approved,,"Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing dem",11/25/2020,11/25/2027,"Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing dem","Rhythm Pharmaceuticals, Inc.",222 Berkeley St. Suite 1200,,Boston,Massachusetts,2116,United States,613717
SOTICLESTAT,1766MU795L,Designated,Public record,4620,cholesterol 24S-hydroxylase inhibitor,11/29/2017,Treatment of Dravet syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",Takeda Parkway,,Deerfield,Illinois,60015,United States,614917
IDASANUTLIN,QSQ883V35U,Designated,Public record,4622,idasanutlin,11/29/2017,Treatment of polycythemia vera,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Hoffmann-La Roche Inc.,430 East 29th Street,,New York,New York,10016,United States,615017
METHYL BACTERIOPURPURINIMIDE,E7DBJ0SBC7,Designated,Public record,4623,3-(1¿-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-N-butylimide methyl ester,12/6/2017,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Photolitec, LLC",6220 Creekhaven Drive,,East Amherst,New York,14051,United States,615317
SOTICLESTAT,1766MU795L,Designated,Public record,4624,cholesterol 24S-hydroxylase inhibitor,12/6/2017,Treatment of Lennox-Gastaut syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",Takeda Parkway,,Deerfield,Illinois,60015,United States,615817
LUVADAXISTAT,76IC00YRVR,Designated,Public record,4625,D-amino acid oxidase inhibitor,12/6/2017,Treatment of Friedreich's ataxia (FRDA),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",Takeda Parkway,,Deerfield,Illinois,60015,United States,615417
GEMFIBROZIL,Q8X02027X3,Designated,Public record,4626,gemfibrozil and vitamin A,12/6/2017,Treatment of neuronal ceroid lipofuscinoses,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.",140 East Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,7652,United States,546216
VITAMIN A,81G40H8B0T,Designated,Public record,4626,gemfibrozil and vitamin A,12/6/2017,Treatment of neuronal ceroid lipofuscinoses,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.",140 East Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,7652,United States,546216
DANICOPAN,JM8C1SFX0U,Designated,Public record,4628,"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide",12/14/2017,Treatment of C3 glomerulopathy (C3G),Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc",300 George Street,,New Haven,Connecticut,6511,United States,617117
LPT-99,A2Y8E9P363,Designated,Public record,4629,"2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl) acetamide",12/14/2017,Prevention of platinum-induced ototoxicity in pediatric patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Spiral Therapeutics,1467 Dolores Street,,San Francisco,California,94110,United States,618517
METFORMIN,9100L32L2N,Designated,Public record,4631,metformin,12/14/2017,Treatment of progressive myoclonus epilepsy type 2 (Lafora disease),Designated,Not FDA Approved for Orphan Indication,,,,,"Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)",Monforte de Lemos,3-5 Pabellon 11,Madrid,Comunidad de Madrid,,Spain,616117
PLASMINOGEN,1EF190B6M7,Designated,Public record,4632,plasminogen (Human),12/14/2017,Treatment of idiopathic pulmonary fibrosis (IPF),Designated,Not FDA Approved for Orphan Indication,,,,,"ProMetic BioTherapeutics, Inc.",1330 Piccard Drive,Suite 201,Rockville,Maryland,20850,United States,609317
TENALISIB,2261HH611H,Designated,Public record,4633,(S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one),12/18/2017,Treatment of peripheral T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Rhizen Pharmaceuticals SA,40 Rue Fritz-Courvoisier,,La Chaux-de-Fonds,Neuchâtel,,Switzerland,616417
ATSM COPPER (II),0YDK1H9L3A,Designated,Public record,4634,diacetyl(N(4)-methylthiosemicarbazonato) copper (II),12/18/2017,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,Collaborative Medicinal Development Pty. Ltd. (CMD),c/o Shaw Downie,Level 11,Sydney,New South Wales,,Australia,611117
FENRETINIDE,187EJ7QEXL,Designated,Public record,4635,fenretinide,12/19/2017,Treatment of cutaneous T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"SciTech Development, LLC",281 Kercheval Avenue,,Grosse Pointe Farms,Michigan,48236,United States,615217
DANAVOREXTON,1QMD83K4YN,Designated,Public record,4636,"methyl (2R,3S)-3-[(methylsulfonyl)amino]-2-{[(cis-4-phenylcyclohexyl)oxy]methyl}piperidine-1-carboxylate",12/19/2017,Treatment of narcolepsy,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,616717
MOSEDIPIMOD,88928BS57E,Designated,Public record,4637,mosedipimod,12/19/2017,Treatment of acute radiation syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Enzychem Lifesciences Corporation,"59, Bio valley-ro",,Jecheon-si,Chungcheongbuk-do,,South Korea,616517
SODIUM SULFATE,0YPR65R21J,Designated,Public record,4638,"sodium sulfate, magnesium sulfate, potassium chloride",12/19/2017,For the cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,616817
"""MAGNESIUM SULFATE, UNSPECIFIED FORM""",DE08037SAB,Designated,Public record,4638,"sodium sulfate, magnesium sulfate, potassium chloride",12/19/2017,For the cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,616817
Potassium chloride,660YQ98I10,Designated,Public record,4638,"sodium sulfate, magnesium sulfate, potassium chloride",12/19/2017,For the cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,2185,United States,616817
CANNABIDIOL,19GBJ60SN5,Designated,Public record,4640,cannabidiol,12/21/2017,Treatment of Dravet syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,27262,United States,617417
SIROLIMUS,W36ZG6FT64,Designated,Public record,4641,sirolimus protein-bound particles for injectable suspension (albumin-bound),12/21/2017,Treatment of perivascular epithelioid cell tumors (PEComa),Designated/Approved,,treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa),11/22/2021,11/22/2028,treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa),"Aadi Bioscience, Inc.","17383 Sunset Blvd, A250",,Pacific Palisades,California,90272,United States,616217
PLATELET RICH PLASMA,ZW1U5HYZ1A,Designated,Public record,4643,trafermin in combination with plasma and platelet rich plasma,12/21/2017,Treatment of alopecia areata in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"HCell, Inc.",314 East Highland Mall Boulevard,Suite 406,Austin,Texas,78752,United States,595317
TRAFERMIN,333OX80X87,Designated,Public record,4643,trafermin in combination with plasma and platelet rich plasma,12/21/2017,Treatment of alopecia areata in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"HCell, Inc.",314 East Highland Mall Boulevard,Suite 406,Austin,Texas,78752,United States,595317
HUMAN PLASMA,T74K1VTI2X,Designated,Public record,4643,trafermin in combination with plasma and platelet rich plasma,12/21/2017,Treatment of alopecia areata in pediatric patients,Designated,Not FDA Approved for Orphan Indication,,,,,"HCell, Inc.",314 East Highland Mall Boulevard,Suite 406,Austin,Texas,78752,United States,595317
FENRETINIDE,187EJ7QEXL,Designated,Public record,4644,fenretinide,12/22/2017,Treatment of peripheral T-cell lymphoma (including follicular T-cell lymphoma),Designated,Not FDA Approved for Orphan Indication,,,,,"SciTech Development, LLC",281 Kercheval Avenue,,Grosse Pointe Farms,Michigan,48236,United States,621117
SORAPRAZAN,5XB3671655,Designated,Public record,4645,soraprazan,12/22/2017,Treatment of Stargardt Disease (StD),Designated,Not FDA Approved for Orphan Indication,,,,,Katairo GmbH,21 Lederstraße,,Kusterdingen,Baden-Württemberg,,Germany,617617
"""1-(3-FLUORO-4-(7-(5-METHYL-1H-IMIDAZOL-2-YL)-1-OXO-2,3-DIHYDRO-1H-ISOINDO-1-4-YL)-PHENYL)-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA""",7W3FGR71NN,Designated,Public record,4646,"Urea, N-[4-[2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl]-3-fluorophenyl]-N¿-(2,4,6-trifluorophenyl)-",12/22/2017,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,"Aptose Biosciences, Inc.",12770 High Bluff Drive,Suite 120,San Diego,California,92130,United States,618417
ABATACEPT,7D0YB67S97,Designated,Public record,4647,abatacept,12/26/2017,Prevention of graft versus host disease,Designated/Approved,,"prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 a",12/15/2021,12/15/2028,prophylaxis of acute graft versus host disease (aGVHD) in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor,Bristol-Myers Squibb Co.,P. O. Box 5326,,Princeton,New Jersey,8543,United States,614117
"""2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1-(5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL)ETHANONE, (S)-""",5EJO0RJF9O,Designated,Public record,4648,Arylalkyl 3-ketoindole,12/26/2017,Treatment of dengue virus infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",125 Trenton-Harbourton Road,,Titusville,New Jersey,8560,United States,618217
RESATORVID,H2MZ648C31,Designated,Public record,4652,resatorvid,1/2/2018,Treatment of acute-on-chronic liver failure,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",One Takeda Parkway,,Deerfield,Illinois,60015,United States,503515
TAMRINTAMAB PAMOZIRINE,GM0RU5SU0E,Designated,Public record,4653,antibody drug conjugate targeting dipeptidase 3 (DPEP3),1/8/2018,"Treatment of DPEP3-positive ovarian, fallopian tube, and primary peritoneal cancers",Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"AbbVie Stemcentrx, LLC",1 North Waukegan Road,,Chicago,Illinois,60064,United States,555816
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,4654,atezolizumab + bevacizumab,1/8/2018,Treatment of hepatocellular carcinoma (HCC),Designated/Approved,,"AVASTIN, in combination with atezolizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.",5/29/2020,5/29/2027,AVASTIN for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.,"Genentech, Inc.",1 DNA Way,MS 451A,South San Francisco,California,94080,United States,619317
ATEZOLIZUMAB,52CMI0WC3Y,Designated,Public record,4654,atezolizumab + bevacizumab,1/8/2018,Treatment of hepatocellular carcinoma (HCC),Designated/Approved,,"AVASTIN, in combination with atezolizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.",5/29/2020,5/29/2027,AVASTIN for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.,"Genentech, Inc.",1 DNA Way,MS 451A,South San Francisco,California,94080,United States,619317
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,4655,atezolizumab + bevacizumab,1/8/2018,Treatment of hepatocellular carcinoma (HCC),Designated/Approved,,"TECENTRIQ, in combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.",5/29/2020,5/29/2027,TECENTRIQ for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.,"Genentech, Inc.",1 DNA Way,MS 451A,South San Francisco,California,94080,United States,619317
ATEZOLIZUMAB,52CMI0WC3Y,Designated,Public record,4655,atezolizumab + bevacizumab,1/8/2018,Treatment of hepatocellular carcinoma (HCC),Designated/Approved,,"TECENTRIQ, in combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.",5/29/2020,5/29/2027,TECENTRIQ for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.,"Genentech, Inc.",1 DNA Way,MS 451A,South San Francisco,California,94080,United States,619317
CANNABIDIOL,19GBJ60SN5,Designated,Public record,4656,cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC),1/8/2018,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,27262,United States,620417
DRONABINOL,7J8897W37S,Designated,Public record,4656,cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC),1/8/2018,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,27262,United States,620417
ALLOGENIC CRYOPRESERVED HUMAN UMBILICAL CORD TISSUE,83B48FLE3F,Designated,Public record,4657,cryopreserved human umbilical cord,1/8/2018,Treatment of spina bifida,Designated,Not FDA Approved for Orphan Indication,,,,,"TissueTech, Inc.",7300 Corporate Center Drive,Suite 700,Miami,Florida,33126,United States,611717
SULINDAC,184SNS8VUH,Designated,Public record,4658,eflornithine + sulindac,1/8/2018,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Cancer Prevention Pharmaceutical, Inc.",1760 East River Road,Suite 250,Tucson,Alaska,85718,United States,619917
EFLORNITHINE,ZQN1G5V6SR,Designated,Public record,4658,eflornithine + sulindac,1/8/2018,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Cancer Prevention Pharmaceutical, Inc.",1760 East River Road,Suite 250,Tucson,Alaska,85718,United States,619917
MILRINONE,JU9YAX04C7,Designated,Public record,4660,milrinone,1/8/2018,Treatment of right heart failure (RHF) in left ventricular assist device (LVAD) patients,Designated,Not FDA Approved for Orphan Indication,,,,,Hyloris Developments SA,1555 S Wasatch Dr.,,Salt Lake City,Utah,84108,United States,565916
SODIUM OXYBATE,7G33012534,Designated,Public record,4661,sodium oxybate,1/8/2018,Treatment of narcolepsy,Designated/Approved,,Treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy,5/1/2023,5/1/2030,Treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy,Flamel Ireland Limited dba Avadel Ireland,10 Earlsfort Terrace,,Dublin,Dublin,,Ireland,530216
ROSTAPORFIN,466G63QE7G,Designated,Public record,4663,tin ethyl etiopurpurin,1/16/2018,Treatment of basal cell carcinoma nevus syndrome (BCCNS),Designated,Not FDA Approved for Orphan Indication,,,,,"Adgero Biopharmaceuticals, Inc",4365 US Highway 1,Suite 211,Princeton,New Jersey,8540,United States,620517
"""APREMILAST, (?)-""",N5UK68MGDZ,Designated,Public record,4664,apremilast,1/17/2018,Treatment of pediatric patients with ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mailstop 27-2-D,Thousand Oaks,California,91320,United States,622417
CYCLOCREATINE,6732XGX1RK,Designated,Public record,4665,cyclocreatine phosphate,1/17/2018,Prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,"Nour Heart Therapeutics, LLC","121 Locust Street, SW",,Vienna,Virginia,22180,United States,495115
FLUORODOPA F-18,2C598205QX,Designated,Public record,4666,dihydroxyphenylalanine F 18/Fluorodopa (F18),1/22/2018,Diagnostic for the management of congenital hyperinsulinism,Designated,Not FDA Approved for Orphan Indication,,,,,Society of Nuclear Medicine and Molecular Imaging,1850 Samuel Morse Drive,,Reston,Virginia,20190,United States,621017
CIBISATAMAB,ZAM5J1ATF2,Designated,Public record,4667,humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA),1/22/2018,"Treatment of gastric cancer, including gastroesophageal junction cancer",Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS 35-5E,South San Francisco,California,94080,United States,618817
INCLISIRAN,UOW2C71PG5,Designated,Public record,4668,inclisiran,1/22/2018,Treatment of homozygous familial hypercholesterolemia (HoFH),Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7932,United States,618017
BRANAPLAM,P12R69543A,Designated,Public record,4670,branaplam,1/23/2018,Treatment of spinal muscular atrophy (SMA),Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,1 Health Plaza,Office #310-2132B,East Hanover,New Jersey,7936,United States,620117
OCTREOTIDE ACETATE,75R0U2568I,Designated,Public record,4671,octreotide acetate (intranasal),1/23/2018,Treatment of acromegaly,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Dauntless Pharmaceuticals, Inc.",12390 El Camino Real,Suite 170,San Diego,California,92130,United States,606217
RILUZOLE,7LJ087RS6F,Designated,Public record,4672,riluzole oral film,1/23/2018,Treatment of amyotrophic lateral sclerosis (ALS),Designated/Approved,,EXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS).,11/22/2019,,,Aquestive Therapeutics,30 Technology Drive South,,Warren,New Jersey,7059,United States,563216
CALFACTANT,Q4K217VGA9,Designated,Public record,4673,SF-RI-1 bovine surfactant for inhalation,1/23/2018,Treatment of respiratory distress syndrome (RDS),Designated,Not FDA Approved for Orphan Indication,,,,,Aerogen Pharma Corporation,1660 South Amphlett Boulevard,,San Mateo,California,94402,United States,593817
Glucagon,76LA80IG2G,Designated,Public record,4674,glucagon (ready-to-use),1/24/2018,Treatment of hyperinsulinemic hypoglycemia (%h),Designated,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceuticals, Inc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,60607,United States,616317
DEVIMISTAT,E76113IR49,Designated,Public record,4675,"6,8-bis(benzylthio)octanoic acid",1/25/2018,Treatment of Burkitt’s Lymphoma (BL),Designated,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,8512,United States,621617
ODRONEXTAMAB,8R5CM46UIO,Designated,Public record,4676,humanized IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody,1/25/2018,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,623317
NEIHULIZUMAB,615637S5PE,Designated,Public record,4677,neihulizumab,1/25/2018,Treatment of acute graft-versus-host disease (aGvHD),Designated,Not FDA Approved for Orphan Indication,,,,,"AltruBio Inc. (formerly AbGenomics International, Inc.)",5050 El Camino Real,Suite #105,Los Altos,California,94022,United States,622617
LENIOLISIB,L22772Z9CP,Designated,Public record,4678,leniolisib,1/30/2018,"Treatment of activated P13Kdelta Syndrome/p110delta-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency",Designated/Approved,,treatment of activated phosphoinositide 3-kinase delta (PI3K delta) syndrome (APDS) in adult and pediatric patients 12 years of age and older,3/24/2023,3/24/2030,treatment of activated phosphoinositide 3-kinase delta (PI3K delta) syndrome (APDS) in adult and pediatric patients 12 years of age and older,Pharming Technologies B.V.,Darwinweg 24,,Leiden,,,Netherlands,504315
MIDAZOLAM,R60L0SM5BC,Designated,Public record,4679,midazolam,1/30/2018,Treatment of status epilepticus,Designated,Not FDA Approved for Orphan Indication,,,,,Crossject SA,6 Rue Pauline Kergomard,,Dijon,Bourgogne Franche-Comté,,France,622817
MURLENTAMAB,ZN0DUZ3M4L,Designated,Public record,4680,recombinant humanized monoclonal antibody targeting the anti-müllerian hormone receptor II,1/30/2018,Treatment of Anti -Mullerian Hormone Receptor II (AMHRII)-expressing ovarian cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,94502,United States,578617
FOSTAMATINIB,SQ8A3S5101,Designated,Public record,4681,fostamatinib disodium,1/31/2018,Treatment of autoimmune hemolytic anemia (AIHA),Designated,Not FDA Approved for Orphan Indication,,,,,"Rigel Pharmaceuticals, INc.",1180 Veterans Blvd,,South San Francisco,California,94080,United States,544516
CYCLOHEXADIENEDIONE (MIXED ISOMERS),3X2WQ5ZIW6,Designated,Public record,4682,"2-(3,7-Dimethyl-octa-2, 6-dienyl)¿6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone",2/1/2018,Treatment of Huntington’s Disease (HD),Designated,Not FDA Approved for Orphan Indication,,,,,Emerald Health Pharmaceuticals Inc.,5820 Nancy Ridge Drive,,San Diego,California,92121,United States,623717
EFOCIPEGTRUTIDE,TUI1MDD9F6,Designated,Public record,4685,glucagon analog conjugated with human immunoglobulin G4 fragment,2/1/2018,Treatment of congenital hyperinsulinism (CHI),Designated,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Company, Ltd.","14, Wiryeseong-daero,",Songpa-gu,Seoul,5545,,South Korea,620717
LIRENTELIMAB,SWS48LJU3T,Designated,Public record,4686,humanized non-fucosylated Anti-Siglec-8 Monoclonal Antibody (IgG1),2/1/2018,Treatment of eosinophilic gastroenteritis,Designated,Not FDA Approved for Orphan Indication,,,,,"Allakos, Inc.",75 Shoreway Road,Suite A,San Carlos,California,94070,United States,623017
LIRENTELIMAB,SWS48LJU3T,Designated,Public record,4687,humanized non-fucosylated anti-siglec-8 monoclonal antibody (IgG1),2/1/2018,Treatment of eosinophilic gastritis,Designated,Not FDA Approved for Orphan Indication,,,,,"Allakos, Inc.",75 Shoreway Road,Suite A,San Carlos,California,94070,United States,628417
IBRUTINIB,1X70OSD4VX,Designated,Public record,4688,ibrutinib,2/1/2018,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 East Arques Avenue,,Sunnyvale,California,94085,United States,622317
ONTAMALIMAB,6LGI7RV4PB,Designated,Public record,4690,human IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule,2/7/2018,Treatment of Crohn’s Disease (CD) in the pediatric population,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc. (Shire)",300 Shire Way,,Lexington,Massachusetts,2421,United States,608117
TILORONE HYDROCHLORIDE,BJ507J4LKY,Designated,Public record,4691,tilorone dihydrochloride,2/7/2018,Treatment of Ebola infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.",840 Main Campus Drive,Lab 3510,Raleigh,North Carolina,27606,United States,624717
IMLIFIDASE,UVJ7NL8S2P,Designated,Public record,4694,imlifidase,2/14/2018,Treatment of Guillain-Barre Syndrome (GBS),Designated,Not FDA Approved for Orphan Indication,,,,,Hansa Medical AB,"Scheelevägen 22, P. O. Box 785",SE-220 07,Lund,,,Sweden,623817
TEMELIMAB,T32CR1A69R,Designated,Public record,4695,recombinant humanized IgG4 monoclonal antibody against pHERV-W Envelope protein,2/14/2018,Treatment of chronic inflammatory demyelinating polyradiculoneuropathy/polyneuropathy (CIDP),Designated,Not FDA Approved for Orphan Indication,,,,,GeNeuro S.A.,3 Chemin du Pré-Fleuri,,Plan-les-Ouates,Genèva,,Switzerland,625517
SELUMETINIB,6UH91I579U,Designated,Public record,4696,selumetinib,2/14/2018,Treatment of Neurofibromatosis Type 1,Designated/Approved,,"KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)",4/10/2020,4/10/2027,"Indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,19803,United States,624017
COAGULATION FACTOR XIA,Y42G5XID5M,Designated,Public record,4698,human coagulation factor XI,2/15/2018,Treatment of congenital factor XI deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Bio Products Laboratory Limited,Dagger Lane,,Elstree,Hertfordshire,,United Kingdom,625417
SIPLIZUMAB,KUW1QG1ZM3,Designated,Public record,4702,Siplizumab,2/15/2018,Prevention of solid organ transplant rejection,Designated,Not FDA Approved for Orphan Indication,,,,,ITB-MED AB,15 Västra Trädgårdsgatan,,Norrmalm,Stockholms län,,Sweden,623917
TENOFOVIR EXALIDEX,K7J545MEMA,Designated,Public record,4703,tenofovir exalidex,2/20/2018,Treatment of pediatric chronic hepatitis B infection (age 0 through 11 years of age),Designated,Not FDA Approved for Orphan Indication,,,,,"ContraVir Pharmaceuticals, Inc.",399 Thornall Street,First Floor,Edison,New Jersey,8837,United States,583917
PAXALISIB,P5DKZ70636,Designated,Public record,4704,"5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine",2/21/2018,Treatment of glioblastoma multiforme (GBM),Designated,Not FDA Approved for Orphan Indication,,,,,Kazia Therapeutics Limited,20 George Street,Suite 207,Hornsby,New South Wales,,Australia,624217
DAVUNETIDE,GF00K3IIWE,Designated,Public record,4706,davunetide,2/22/2018,Treatment of Activity-Dependent Neuroprotective Protein (ADNP) Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Ramot at Tel Aviv University Ltd.,PO Box 39296,,Tel-Aviv,,6139201,Israel,624317
ACETYLLEUCINE,K76S41V71X,Designated,Public record,4707,N-acetyl-DL-leucine,2/22/2018,"Treatment of Niemann-Pick disease, type C",Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,626218
TAUROLIDINE,8OBZ1M4V3V,Designated,Public record,4708,taurolidine,2/22/2018,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"CorMedix, Inc.",1430 U.S. 206,Suite 200,Bedminster Township,New Jersey,7921,United States,528816
DEVIMISTAT,E76113IR49,Designated,Public record,4709,"6,8-bis(benzylthio)octanoic acid",2/28/2018,Treatment of Peripheral T-cell Lymphoma (PTCL),Designated,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,8512,United States,623117
FECAL MICROBIOTA,Q805XO2F7C,Designated,Public record,4710,allogeneic Fecal Microbiota,2/28/2018,Treatment of Graft-Versus-Host Disease,Designated,Not FDA Approved for Orphan Indication,,,,,MaaT Pharma,317 Avenue Jean Jaurès,,Lyon-7E-Arrondissement,Auvergne-Rhône-Alpes,,France,627418
BUTYLPHTHALIDE,822Q956KGM,Designated,Public record,4711,DL-3-n-butylphthalide,2/28/2018,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,"CSPC NBP Pharmaceutical Co, Ltd, subsidiary of CSPC Pharma Group",No. 88 Yangzi Road,,Shijiazhuang Shi,Hebei Sheng,,China,623217
RUSFERTIDE,XM71MYX0IQ,Designated,Public record,4712,hepcidin mimetic peptide,3/1/2018,Treatment of B-thalassemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Protagonist Therapeutics,521 Cottonwood Drive,Suite 100,Milpitas,California,95035,United States,584117
NTP-42,2057H3EG0S,Designated,Public record,4713,"N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide",3/1/2018,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,ATXA Therapeutics Limited,75 Avoca Avenue,Avoca Avenue,Blackrock,County Dublin,,Ireland,628618
PESTICIDAL CRYSTAL PROTEIN CRY5BA,XZ3GBO97F9,Designated,Public record,4715,Bacillus thuringiensis crystal protein (Cry5B),3/7/2018,"Treatment of gastroinstestinal infections caused by ascaris lumbricoides (roundworm), trichuris trichiura (whipworm), ancylostoma duodenale, necator americanus, and ancylostoma ceylanicum (hookworms)",Designated,Not FDA Approved for Orphan Indication,,,,,University of Massachusetts Medical School,373 Plantation Street,"Two Biotech, Suite 219",Worcester,Massachusetts,1605,United States,562816
DRONABINOL,7J8897W37S,Designated,Public record,4716,delta-9-tetrahydrocannabinol and cannabidiol,3/7/2018,Treatment of complex regional pain syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,PhytoPain Pharma Inc.,9315-4466 Quebec Inc,1230 Boise Street,Boucherville,,,Canada,549616
CANNABIDIOL,19GBJ60SN5,Designated,Public record,4716,delta-9-tetrahydrocannabinol and cannabidiol,3/7/2018,Treatment of complex regional pain syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,PhytoPain Pharma Inc.,9315-4466 Quebec Inc,1230 Boise Street,Boucherville,,,Canada,549616
GRANATICIN B,JS606MEA30,Designated,Public record,4717,granaticin B,3/7/2018,Treatment of Acute Lymphoblastic Leukemia (ALL),Designated,Not FDA Approved for Orphan Indication,,,,,Lin BioScience,3210 Merryfield Row,"12F., No.68, Sec.5, Zhongxiao E. Rd.","Xinyi Dist., Taipei City 110",,,Taiwan,625017
NESOLICAFTOR,T2U4ZA62U4,Designated,Public record,4719,"N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide",3/7/2018,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Proteostasis Therapeutics, Inc.",200 Technology Square,,Cambridge,Massachusetts,2139,United States,544916
ONTORPACEPT,Q8A4U1Z9N2,Designated,Public record,4720,"1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer",3/8/2018,Treatment of Cutaneous T-Cell Lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Trillium Therapeutics Inc.,2488 Dunwin Drive,,Mississauga,,,Canada,624917
MELATONIN,JL5DK93RCL,Designated,Public record,4722,melatonin,3/8/2018,Treatment of perinatal asphyxia,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,628518
OLINVACIMAB,VFH55IZ5VI,Designated,Public record,4723,Recombinant Human Monoclonal Antibody To Vascular Endothelial Growth Factor Receptor-2,3/8/2018,Treatment of Glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,PharmAbcine Inc.,"#307, Daedeok Tech-Biz Center","593, Daedeok-daero",Yuseong-gu,Daejeon,,South Korea,628118
TIANEPTINE,0T493YFU8O,Designated,Public record,4724,tianeptine,3/8/2018,Treatment of Rett syndrome (RTT),Designated,Not FDA Approved for Orphan Indication,,,,,AMO Pharma Ltd.,Throwsters,The Street,Wonersh,England,,United Kingdom,627918
AVADOMIDE HYDROCHLORIDE,6CX4AEX3KR,Designated,Public record,4725,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2,6-dione hydrochloride",3/12/2018,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,629418
PEMIGATINIB,Y6BX7BL23K,Designated,Public record,4726,Pemigatinib,3/12/2018,Treatment of cholangiocarcinoma,Designated/Approved,,"PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",4/17/2020,4/17/2027,"For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.",Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,624117
SIROLIMUS,W36ZG6FT64,Designated,Public record,4727,sirolimus,3/13/2018,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,Rare Partners srl Impresa Sociale,31 Corso Magenta,,Milano,Lombardia,,Italy,628918
IOPOFOSINE I-131,R048696O9L,Designated,Public record,4728,18-(p-[131]-iodophenyl)octadecyl phosphocholine,3/15/2018,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,53716,United States,629018
BTZ-043,G55ZH52P57,Designated,Public record,4729,"2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one",3/15/2018,Treatment of Tuberculosis (TB),Designated,Not FDA Approved for Orphan Indication,,,,,Klinikum der Universität München,15 Marchioninistr.,,München,Bayern,,Germany,630318
CANNABIDIOL,19GBJ60SN5,Designated,Public record,4731,Cannabidiol and delta-9-tetrahydrocannabinol,3/15/2018,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,27262,United States,628818
DRONABINOL,7J8897W37S,Designated,Public record,4731,Cannabidiol and delta-9-tetrahydrocannabinol,3/15/2018,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,27262,United States,628818
DOXORUBICIN HYDROCHLORIDE,82F2G7BL4E,Designated,Public record,4732,PEGASEMP¿(doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31 aminoacid peptide targeting nucleolin),3/15/2018,Treatment of Mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,"TREAT U, S.A.",Parque Industrial de Taveiro,Lote 44,Taveiro,Coimbra,,Portugal,628318
TRIMETAZIDINE,N9A0A0R9S8,Designated,Public record,4733,Trimetazidine,3/15/2018,Treatment of acute-on-chronic liver failure,Designated,Not FDA Approved for Orphan Indication,,,,,"Martin Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,629618
PTEROSTILBENE,26R60S6A5I,Designated,Public record,4734,nicotinamide riboside and pterostilbene,3/19/2018,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Elysium Health Inc.,434 Broadway,Floor 2,New York,New York,10013,United States,628218
NICOTINAMIDE RIBOSIDE,0I8H2M0L7N,Designated,Public record,4734,nicotinamide riboside and pterostilbene,3/19/2018,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Elysium Health Inc.,434 Broadway,Floor 2,New York,New York,10013,United States,628218
ELAMIPRETIDE,87GWG91S09,Designated,Public record,4736,elamipretide,3/22/2018,Treatment of Barth syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Stealth Biotherapeutics, Inc.",140 Kendrick Street,Building C-West,Needham,Massachusetts,2494,United States,607817
APITEGROMAB,UZ54216N0Y,Designated,Public record,4737,fully human anti-proMyostatin monoclonal antibody of the IgG4/lambda isotype that binds to human pro- and latent myostatin with high affinity,3/22/2018,Treatment of spinal muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Scholar Rock,620 Memorial Drive,Suite E,Cambridge,Massachusetts,2139,United States,629218
PERFLUBRON,Q1D0Q7R4D9,Designated,Public record,4738,perfluorooctyl-bromide (PFOB),3/22/2018,Treatment of respiratory distress syndrome (RDS),Designated,Not FDA Approved for Orphan Indication,,,,,Children’s Hospital of Pennsylvania,Clinical Research Support,"Colket Translational Research Building, 11th Floor, Room 11101",Philadelphia,Pennsylvania,19104,United States,631018
MAX-40279 HEMIFUMARATE,JU19P2M2KM,Designated,Public record,4740,"7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl) thieno [3,2-d]pyrimidin-2-amine semi-fumarate",3/26/2018,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"MaxiNovel Pharmaceutical Co.,Ltd",Building A4-1005,181 Science Boulevard,Guangzhou,Guangdong Sheng,,China,629118
DEXAMETHASONE,7S5I7G3JQL,Designated,Public record,4742,dexamethasone,3/26/2018,Treatment of multiple myeloma (MM),Designated/Approved,,HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma,10/3/2019,10/3/2026,Indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM).,Dexcel Pharma Technologies Ltd,Dexcel Street,,Or Akiva,Haifa District,,Israel,626318
ACETYLLEUCINE,K76S41V71X,Designated,Public record,4743,N-acetyl-DL-leucine,3/26/2018,Treatment of GM2 Gangliosidosis,Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,631918
ZATOLMILAST,G786V328X6,Designated,Public record,4744,Small molecule allosteric inhibitor of the phosphodiesterase-4D enzyme,3/26/2018,Treatment of Fragile X Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Tetra Discovery Partners, Inc.",38 Fulton Street West,Suite 303,Grand Rapids,Michigan,49503,United States,631618
"""BENZENEACETAMIDE, 4-((2-(3-CHLOROPHENYL)-6-(TRIFLUOROMETHYL)-4-PYRIMIDINYL)AMINO)-""",3XKI17C2E2,Designated,Public record,4744,Small molecule allosteric inhibitor of the phosphodiesterase-4D enzyme,3/26/2018,Treatment of Fragile X Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Tetra Discovery Partners, Inc.",38 Fulton Street West,Suite 303,Grand Rapids,Michigan,49503,United States,631618
BOCIDELPAR SULFATE,LWF2PR5DHD,Designated,Public record,4745,(3R)-3-Methyl-6-[2-({5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl}methyl)phenoxy]hexanoic acid hemisulfate,3/28/2018,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.","1 Astellas Way, N4.203",,Northbrook,Illinois,60062,United States,633018
FLUASTERONE,R7M5UGD04G,Designated,Public record,4747,fluasterone,3/28/2018,"Treatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)",Designated,Not FDA Approved for Orphan Indication,,,,,"Sterotherapeutics, LLC",3805 Old Easton Road,,Doylestown,Pennsylvania,18902,United States,527116
SUTIMLIMAB,GNWE7KJ995,Designated,Public record,4748,"Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s",3/28/2018,Treatment of immune thrombocytopenia,Designated,Not FDA Approved for Orphan Indication,,,,,Bioverativ USA Inc.,225 2nd Avenue,,Waltham,Massachusetts,2451,United States,614317
MELATONIN,JL5DK93RCL,Designated,Public record,4749,melatonin,3/28/2018,Treatment of subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,600317
PHENOBARBITAL SODIUM,SW9M9BB5K3,Designated,Public record,4751,Phenobarbital sodium,3/28/2018,Treatment of neonatal seizures,Designated,Not FDA Approved for Orphan Indication,,,,,Genus Lifesciences,514 North 12th Street,,Allentown,Pennsylvania,18102,United States,633118
ETEVRITAMAB,WR4J8FV2SM,Designated,Public record,4752,anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct,4/2/2018,Treatment of glioblastoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop: 27-3-F,Thousand Oaks,California,91320,United States,634718
BREVENAL,ECX1L89MFR,Designated,Public record,4753,Brevenal,4/2/2018,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Silurian Pharmaceuticals, Inc.",6490 Doyle Street,,Emeryville,California,94608,United States,632318
ELAMIPRETIDE,87GWG91S09,Designated,Public record,4754,elamipretide,4/2/2018,Treatment of Leber’s Hereditary Optic Neuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,Stealth BioTherapeutics Inc.,140 Kendrick Street,Building C-West,Needham,Massachusetts,2494,United States,609417
TINOSTAMUSTINE HYDROCHLORIDE,QK4ZBS4FPO,Designated,Public record,4755,tinostamustine hydrochloride,4/2/2018,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Mundipharma EDO GmbH,74 Sankt Alban-Rheinweg,,Basel,Basel-Stadt,,Switzerland,634018
BRILAROXAZINE HYDROCHLORIDE,I440YY0HX0,Designated,Public record,4756,"6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,4] oxazin-3(4H)-one hydrochloride",4/4/2018,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Reviva Pharmaceuticals, Inc.","1250 Oakmead Parkway, Suite 210",,Sunnyvale,California,94085,United States,633718
Tegoprubart,EK87C62XNH,Designated,Public record,4757,"humanized anti-CD40LG IgG1, kappa monoclonal antibody with heavy chain C220S/C226S/C229S/P238S substitutions to attenuate effector function",4/4/2018,Treatment of Amyotrophic Lateral Sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,"Eledon Pharmaceuticals, Inc.",19900 MacArthur Blvd,Suite 550,Irvine,California,92612,United States,633818
POMALIDOMIDE,D2UX06XLB5,Designated,Public record,4758,pomalidomide,4/4/2018,Treatment of Kaposi sarcoma,Designated/Approved,,POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negati,5/14/2020,5/14/2027,Indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,635818
TENALISIB,2261HH611H,Designated,Public record,4759,tenalisib,4/4/2018,Treatment of Cutaneous T-Cell Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Rhizen Pharmaceuticals SA,40 Rue Fritz-Courvoisier,,La Chaux-de-Fonds,Neuchâtel,,Switzerland,630618
HUMAN C1-ESTERASE INHIBITOR,6KIC4BB60G,Designated,Public record,4760,"C1 esterase inhibitor, human",4/5/2018,Treatment of antibody mediated rejection (AMR) of solid organ transplants,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,602117
ORDESEKIMAB,EJ48MR05C3,Designated,Public record,4761,human immunoglobulin (IgG1K) monoclonal antibody that binds to interleukin 15,4/10/2018,Treatment of refractory celiac disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,91320,United States,574517
METHOTREXATE,YL5FZ2Y5U1,Designated,Public record,4765,methotrexate,4/11/2018,Prevention of proliferative vitreoretinopathy (PVR),Designated,Not FDA Approved for Orphan Indication,,,,,"Aldeyra Therapeutics, Inc.","131 Hartwell Avenue, Suite 320",,Lexington,Massachusetts,2421,United States,630518
PRALSETINIB,1WPE73O1WV,Designated,Public record,4766,pralsetinib,4/11/2018,"Treatment of rearranged during transfection (RET)-rearranged non-small cell lung cancer (NSCLC), JAK1/2-positive NSCLC, or TRKC-positive NSCLC.",Designated/Approved,,treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test,9/4/2020,9/4/2027,treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,634318
MONOMETHYL AURISTATIN E,V7I58RC5EJ,Designated,Public record,4767,antibody drug conjugate of metal-binding motif-introduced trastuzumab antibody variant and monomethyl auristatin E,7/30/2018,Treatment of Gastric Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Alteogen, Inc.",62 Yuseong-daero 1628beon-gil,Yuseong-gu,Daejeon,Daejeon,,South Korea,643918
ARSENIC TRIOXIDE,S7V92P67HO,Designated,Public record,4768,arsenic trioxide,7/30/2018,Treatment of Graft-versus-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,Medsenic,204 avenue de Colmar,,Strasbourg,Grand Est,,France,645318
ASCORBIC ACID,PQ6CK8PD0R,Designated,Public record,4769,ascorbic acid,7/30/2018,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Renovion, Inc.",112 South Duke Street,,Durham,North Carolina,27701,United States,645618
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,4770,human Alpha1-Proteinase inhibitor,7/30/2018,Prevention of graft-versus-host disease (GVHD),Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring LLC,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,644118
4'-THIO-FAC,R5B1HX1HUY,Designated,Public record,4771,"4-amino-1-[(2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl] pyrimidin-2(1H)-one",8/1/2018,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"FUJIFILM Pharmaceutical U.S.A., Inc.",1 Broadway,,Cambridge,Massachusetts,2142,United States,646118
CARBON MONOXIDE,7U1EE4V452,Designated,Public record,4773,carbon monoxide,8/1/2018,Prevention of delayed graft function in renal transplant recipients,Designated,Not FDA Approved for Orphan Indication,,,,,"Proterris, Inc.",197 West Springfield Street,,Boston,Massachusetts,2118,United States,573917
LENZUMESTROCEL,6YY2MY21JA,Designated,Public record,4774,lenzumestrocel,8/1/2018,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Corestem, Inc.","2F, 24, Pangyo-ro 255 beon-gil",Bundang-gu,Seongnam-si,Gyeonggi-do,,South Korea,646618
LURBINECTEDIN,2CN60TN6ZS,Designated,Public record,4775,lurbinectedin,8/1/2018,Treatment of small cell lung cancer (SCLC),Designated/Approved,,Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.,6/15/2020,6/15/2027,For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin,,,Ireland,646018
bexotegrast,QCV154PFT4,Designated,Public record,4776,small molecule inhibitor of integrins avb6 and avb1,8/1/2018,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Pliant Therapeutics, Inc.",260 Littlefield Avenue,,South San Francisco,California,94080,United States,646518
ANAKINRA,9013DUQ28K,Designated,Public record,4779,"interleukin-1 receptor antagonist (IL-1Ra, sequence-homologous anakinra)",8/7/2018,Treatment of Bronchiolitis Obliterans,Designated,Not FDA Approved for Orphan Indication,,,,,"Onspira Therapeutics, Inc.",101 Lindenwood Drive,Suite 400,Malvern,Pennsylvania,19355,United States,636118
MONOSIALOTETRAHEXOSYLGANGLIOSIDE SODIUM,G5WS9R9D50,Designated,Public record,4780,monosialotetrahexosylganglioside,8/7/2018,Treatment of Huntington’s Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Qilu Pharmaceutical Co., Ltd.",243 Gong Ye Bei Road Jinan,,,Shandong,,China,648018
TRIMETAZIDINE,N9A0A0R9S8,Designated,Public record,4782,trimetazidine,8/7/2018,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Martin Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,642918
NSI-189 PHOSPHATE,HX0VO60T62,Designated,Public record,4783,[(4-benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone]-phosphate,8/7/2018,Treatment of Angelman Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Seneca Biopharma, Inc.",20271 Goldenrod Lane,Suite 2024,Germantown,Maryland,20876,United States,647018
(1-HYDROXY-2-OXOPIPERIDIN-3-YL)PHOSPHONIC ACID,64T5RTG4MY,Designated,Public record,4784,(1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid,8/9/2018,Treatment of Glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,The University of Texas MD Anderson Cancer Center,1515 Holcombe Blvd #2,,Houston,Texas,77030,United States,646218
FARUDODSTAT,I58WE41H6X,Designated,Public record,4785,"2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid",8/16/2018,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"ASLAN Pharmaceuticals Pte, Ltd.",83 Clemenceau Avenue,#12-03,Singapore,,,Singapore,647118
ARM-210 HEMIFUMARATE,ZHR6WM1ADJ,Designated,Public record,4786,"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate",8/17/2018,Treatment of Ryanodine receptor type 1-related myopathies,Designated,Not FDA Approved for Orphan Indication,,,,,"ARMGO Pharma, Inc.",PMB #260,923 Saw Mill River Road,Ardsley,New York,10502,United States,558016
BERTILIMUMAB,60879E4NED,Designated,Public record,4787,bertilimumab,8/17/2018,Treatment of bullous pemphigoid,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,578517
CLOFAZIMINE,D959AE5USF,Designated,Public record,4788,clofazimine,8/17/2018,Treatment of Pulmonary Nontuberculous Mycobacterial Infections,Designated,Not FDA Approved for Orphan Indication,,,,,MannKind Corporation,1 Casper Street,,Danbury,Connecticut,6810,United States,646318
ATI-1013,6DX9Y74D3E,Designated,Public record,4790,fully human nicotine-specific monoclonal antibody,8/22/2018,Treatment of thromboangiitis obliterans (Buerger’s disease),Designated,Not FDA Approved for Orphan Indication,,,,,"Antidote Therapeutics, Inc.",708 Quince Orchard Rd.,Suite 250-C,Gaithersburg,Maryland,20878,United States,647218
ELEXACAFTOR,RRN67GMB0V,Designated,Public record,4791,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,10/21/2019,10/21/2026,Indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
TEZACAFTOR,8RW88Y506K,Designated,Public record,4791,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,10/21/2019,10/21/2026,Indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
IVACAFTOR,1Y740ILL1Z,Designated,Public record,4791,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,10/21/2019,10/21/2026,Indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
ELEXACAFTOR,RRN67GMB0V,Designated,Public record,4792,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,6/8/2021,6/8/2028,Treatment of cystic fibrosis (CF) in patients aged 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro dat,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
TEZACAFTOR,8RW88Y506K,Designated,Public record,4792,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,6/8/2021,6/8/2028,Treatment of cystic fibrosis (CF) in patients aged 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro dat,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
IVACAFTOR,1Y740ILL1Z,Designated,Public record,4792,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of cystic fibrosis,Designated/Approved,,Treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,6/8/2021,6/8/2028,Treatment of cystic fibrosis (CF) in patients aged 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro dat,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
ELEXACAFTOR,RRN67GMB0V,Designated,Public record,4793,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,4/26/2023,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
TEZACAFTOR,8RW88Y506K,Designated,Public record,4793,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,4/26/2023,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
IVACAFTOR,1Y740ILL1Z,Designated,Public record,4793,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,4/26/2023,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
ELEXACAFTOR,RRN67GMB0V,Designated,Public record,4794,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,12/21/2020,12/21/2027,treatment of cystic fibrosis in patients aged 12 years and older who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on in vitro data.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
TEZACAFTOR,8RW88Y506K,Designated,Public record,4794,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,12/21/2020,12/21/2027,treatment of cystic fibrosis in patients aged 12 years and older who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on in vitro data.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
IVACAFTOR,1Y740ILL1Z,Designated,Public record,4794,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",8/29/2018,Treatment of Cystic Fibrosis,Designated/Approved,,treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,12/21/2020,12/21/2027,treatment of cystic fibrosis in patients aged 12 years and older who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on in vitro data.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,647618
DISITAMAB VEDOTIN,RB3U3A1S27,Designated,Public record,4798,disitamab vedotin,9/10/2018,Treatment of Gastric Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.,21823 30th Drive SE,,Bothell,Washington,98021,United States,649418
ORILANOLIMAB,1LTT6HMX9N,Designated,Public record,4799,orilanolimab,9/10/2018,Treatment of pemphigus,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Blvd.,,Boston,Massachusetts,2210,United States,649018
VORASIDENIB,789Q85GA8P,Designated,Public record,4800,vorasidenib,9/10/2018,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,649318
ILACIRNON SODIUM,X39CM70JTQ,Designated,Public record,4801,"4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbonyl)-3-pyridinyl]-3-(trifluoromethyl)benzenesulfonamide, sodium salt",9/12/2018,Treatment of focal segmental glomerulosclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"ChemoCentryx, Inc.",850 Maude Avenue,,Mountain View,California,94043,United States,604317
DOCETAXEL,15H5577CQD,Designated,Public record,4802,docetaxel encapsulated in an albumin-stabilized liposome,9/12/2018,Treatment of small cell lung cancer (SCLC),Designated,Not FDA Approved for Orphan Indication,,,,,"Plus Therapeutics, Inc.",12500 Network Blvd #207,,San Antonio,Texas,78249,United States,649918
IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN),,Designated,Public record,4803,immune globulin subcutaneous (Human),9/12/2018,Treatment of Dermatomyositis,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,649518
IKT-001PRO,WQJ8L8YJ7U,Designated,Public record,4804,Methanesulfonate-1-sec-butoxycarbonyloxymethyl-1-methyl-4-{4-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-ium,9/13/2018,Treatment of chronic myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Inhibikase Therapeutics, Inc.",3350 Riverwood Parkway,,Atlanta,Georgia,30339,United States,591517
AST-3424,X6SH5T8H76,Designated,Public record,4805,"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide",9/17/2018,Treatment of Acute Lymphoblastic Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"OBI Pharma USA, Inc.","6020 Cornerstone Court W, Suite 200",,San Diego,California,92121,United States,650818
INGAVIRIN,3CM03MUJ69,Designated,Public record,4806,imidazolyl ethanamide pentandioic acid,9/17/2018,Treatment of Acute Radiation Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Myelo Therapeutics GmbH,Rheinsberger Str. 7,,Berlin,Berlin,,Germany,650218
CERDULATINIB,D1LXQ45S1O,Designated,Public record,4807,cerdulatinib,9/21/2018,Treatment of peripheral T-cell lymphoma (PTCL).,Designated,Not FDA Approved for Orphan Indication,,,,,"Portola Pharmaceuticals, Inc.",270 East Grand Avenue,,South San Francisco,California,94080,United States,651118
SELITRECTINIB,0J45910S3X,Designated,Public record,4808,"(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one",9/24/2018,Treatment of solid tumors with neurotrophic tyrosine receptor kinase (NTRK)-fusion proteins,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bayer Healthcare Pharmaceuticals, Inc.",100 Bayer Blvd.,,Whippany,New Jersey,7981,United States,651318
TEGAVIVINT,18AP231HUP,Designated,Public record,4809,tegavivint,4/11/2018,Treatment of Desmoid Tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Beta Cat Pharmaceuticals,"2450 Holcombe Blvd, Suite J606",,Houston,Texas,77021,United States,634118
KL-1333,NA2ZOL5UGM,Designated,Public record,4810,"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione",4/16/2018,Treatment of inherited mitochondrial respiratory chain disease,Designated,Not FDA Approved for Orphan Indication,,,,,Abliva AB,Medicon Village,,Lund,,,Sweden,621217
ENCEQUIDAR,K4I4I996O4,Designated,Public record,4811,Oraxol,4/16/2018,Treatment of angiosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Athenex, Inc. dba Kinex Pharmaceuticals, Inc.",1001 Main Street,Suite 600,Buffalo,New York,14203,United States,594217
PACLITAXEL,P88XT4IS4D,Designated,Public record,4811,Oraxol,4/16/2018,Treatment of angiosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Athenex, Inc. dba Kinex Pharmaceuticals, Inc.",1001 Main Street,Suite 600,Buffalo,New York,14203,United States,594217
UBIDECARENONE,EJ27X76M46,Designated,Public record,4812,ubidecarenone,4/16/2018,Treatment of Epidermolysis Bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Berg, LLC (BERG)",500 Old Connecticut Path,Building B,Framingham,Massachusetts,1701,United States,635318
CICLOPIROX,19W019ZDRJ,Designated,Public record,4813,Ciclopirox,4/17/2018,Treatment of congenital erythropoietic porphyria,Designated,Not FDA Approved for Orphan Indication,,,,,Atlas Molecular Pharma S.L.,Parque Tecnológico de Bizkaia,Building 800,Derio,,,Spain,629718
GEMCITABINE,B76N6SBZ8R,Designated,Public record,4814,gemcitabine intra-arterial infusion via the RenovoCath¿ RC120 catheter,4/24/2018,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,RenovoRx,4546 El Camino Real,Suite 203,Los Altos,California,94022,United States,620917
TAK-418,LVM0PK6IHG,Designated,Public record,4815,"5-{(1R,2R)-2-[(Cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride",4/26/2018,Treatment of Kabuki Syndrome,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",Takeda Parkway,,Deerfield,Illinois,60015,United States,635718
EXALUREN SULFATE,DZ671709NT,Designated,Public record,4816,"6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate",4/26/2018,Treatment of Cystinosis,Designated,Not FDA Approved for Orphan Indication,,,,,"ELOXX Pharmaceuticals, Inc.","950 Winter Street, North",,Waltham,Massachusetts,2451,United States,636218
URSODIOL,724L30Y2QR,Designated,Public record,4818,Ursodeoxycholic acid,4/26/2018,"Treatment of Niemann-Pick disease, type C",Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,636718
ST-101 (D-AMINO ACID PEPTIDE),CT77XS2YLT,Designated,Public record,4821,Cell-penetrating activating transcription factor 5 mimetic,4/30/2018,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Sapience Therapeutics, Inc","520 White Plains Road, 2nd Floor",,Tarrytown,New York,10591,United States,637418
Rozanolixizumab,P7186074QC,Designated,Public record,4822,Rozanolixizumab,4/30/2018,Treatment of immune thrombocytopenic purpura (ITP),Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive Building 2100,,Smyrna,Georgia,30080,United States,636618
IVOSIDENIB,Q2PCN8MAM6,Designated,Public record,4823,ivosidenib,5/1/2018,Treatment of glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,637718
VENGLUSTAT,BLP1XA3FZA,Designated,Public record,4824,venglustat,5/1/2018,Treatment of Autosomal Dominant Polycystic Kidney Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Genzyme Corporation, a SANOFI COMPANY",50 Binney Street,,Cambridge,Massachusetts,2142,United States,637218
IMGN-779,YE6R3UY9IV,Designated,Public record,4825,Indolino-benzodiazepine compound (sulfonated DGN462) conjugated to the humanized anti-CD33 monoclonal antibody (Z4681A) via the sulfo-SPDB linker,5/2/2018,Treatment of acute myeloid leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,2451,United States,635518
IOPOFOSINE I-131,R048696O9L,Designated,Public record,4826,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,5/8/2018,Treatment of soft tissue sarcomas including rhabdomyosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,53716,United States,638418
BUDESONIDE,Q3OKS62Q6X,Designated,Public record,4827,budesonide,5/8/2018,Treatment of eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,Dr. Falk Pharma GmbH,Leinenweberstrasse 5,,Freiburg,,79108,Germany,634418
GALINPEPIMUT-S,12R66419FZ,Designated,Public record,4828,galinpepimut-S,5/8/2018,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"SELLAS Life Sciences Group, Inc.",315 Madison Avenue,4th floor,New York,New York,10017,United States,636918
PREIMPLANTATION FACTOR,3K6A6FJ98O,Designated,Public record,4830,synthetic preImplantation factor,5/8/2018,Prevention of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"BioIncept, LLC",140 East 40th Street,Suite 11E,New York,New York,10016,United States,622517
20-HYDROXYECDYSONE,779A7KPL0Y,Designated,Public record,4831,20-hydroxyecdysone,5/10/2018,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Biophytis SA,14 Avenue de l’Opera,,Paris,,,France,639318
CARBOXYAMIDOTRIAZOLE OROTATE,776C212QQH,Designated,Public record,4832,carboxyamidotriazole orotate,5/10/2018,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Tactical Therapeutics, Inc.","48 Wall Street, 12th Floor",,New York,New York,10005,United States,637318
Diosmin,7QM776WJ5N,Designated,Public record,4833,diosmin,5/15/2018,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Primus Pharmaceuticals, Inc.",7373 North Scottsdale Road,Suite B-200,Scottsdale,Alaska,85253,United States,582417
Olaparib,WOH1JD9AR8,Designated,Public record,4834,olaparib,5/15/2018,Treatment of Fallopian Tube Cancer,Designated/Approved,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemot",5/8/2020,5/8/2027,"LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemo",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,417613
Olaparib,WOH1JD9AR8,Designated,Public record,4835,olaparib,5/15/2018,Treatment of Fallopian Tube Cancer,Designated/Approved,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected",8/17/2017,8/17/2024,Maintenance treatment of adult patients with recurrent fallopian tube cancer who are in a complete or partial response to platinum-based chemotherapy.,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,417613
Olaparib,WOH1JD9AR8,Designated,Public record,4836,olaparib,5/15/2018,Treatment of primary peritoneal cancer,Designated/Approved,,"Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in comple",12/19/2018,12/19/2025,Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced primary peritoneal cancer who are in complete or partial response to first-line p,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,419013
Olaparib,WOH1JD9AR8,Designated,Public record,4837,olaparib,5/15/2018,Treatment of Fallopian Tube Cancer,Designated/Approved,,"Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in comple",12/19/2018,12/19/2025,Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced fallopian tube cancer who are in complete or partial response to first-line plati,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,417613
Olaparib,WOH1JD9AR8,Designated,Public record,4838,olaparib,5/15/2018,Treatment of primary peritoneal cancer,Designated/Approved,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemot",5/8/2020,5/8/2027,"LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemo",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,419013
Olaparib,WOH1JD9AR8,Designated,Public record,4839,olaparib,5/15/2018,Treatment of primary peritoneal cancer,Designated/Approved,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected",8/17/2017,8/17/2024,Maintenance treatment of adult patients with recurrent primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,19803,United States,419013
ZELAVESPIB,06IVK87M04,Designated,Public record,4841,"8-(6-iodobenzo[1,3]dioxol-5-ylsufanyl)-9-(3-isopropylamino propyl)adenine dihydrochloride",5/16/2018,Treatment of Myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Samus Therapeutics, Inc.",10 South Main Street,,Topsfield,Massachusetts,1983,United States,638018
GOLODIRSEN,033072U4MZ,Designated,Public record,4843,golodirsen,5/22/2018,Treatment of Duchenne muscular dystrophy (DMD),Designated/Approved,,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.,12/12/2019,12/12/2026,Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,2142,United States,636818
DIAZEPAM,Q3JTX2Q7TU,Designated,Public record,4844,diazepam,5/23/2018,Treatment of Dravet syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceutical, Inc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,60607,United States,638118
FUTIBATINIB,4B93MGE4AL,Designated,Public record,4845,futibatinib,5/23/2018,Treatment of cholangiocarcinoma (CCA),Designated/Approved,,"Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements",9/30/2022,9/30/2029,"Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements","Taiho Oncology, Inc.","101 Carnegie Center, Suite 101",,Princeton,New Jersey,8540,United States,635018
AB-22,R228S06SOH,Designated,Public record,4846,"N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide",5/23/2018,Treatment of Idiopathic pulmonary fibrosis (IPF),Designated,Not FDA Approved for Orphan Indication,,,,,"Arroyo Biosciences, LLC",1812 Pelling Court,,Silver Spring,Maryland,20905,United States,618717
IVACAFTOR,1Y740ILL1Z,Designated,Public record,4848,"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor",5/23/2018,Treatment of Cystic Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,638618
BAMOCAFTOR POTASSIUM,VY7D8MTV72,Designated,Public record,4848,"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor",5/23/2018,Treatment of Cystic Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,638618
TEZACAFTOR,8RW88Y506K,Designated,Public record,4848,"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor",5/23/2018,Treatment of Cystic Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,2210,United States,638618
REBASTINIB,75017Q6I97,Designated,Public record,4849,rebastinib,5/23/2018,Treatment of Facioscapulohumeral Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Genea Biocells US Inc.,11099 North Torrey Pines Road,,San Diego,California,92037,United States,637018
TAZEMETOSTAT,Q40W93WPE1,Designated,Public record,4850,tazemetostat,5/23/2018,Treatment of chordoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Epizyme, Inc.",400 Technology Square,4th Floor,Cambridge,Massachusetts,2139,United States,637118
SNX-5422 MESYLATE,K3BO8V06RM,Designated,Public record,4851,"trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}amino)cyclohexyl glycinate mesylate",5/23/2018,Treatment of neuroendocrine tumors (NETs).,Designated,Not FDA Approved for Orphan Indication,,,,,Esanex Inc.,115 West Washington Street,South Tower Suite 1680,Indianapolis,Indiana,46240,United States,637818
2-(1-HEXYLOXYETHYL)-2-DEVINYLPYROPHEOPHORBIDE A,DOB7Y3RSX0,Designated,Public record,4852,photochlor,5/24/2018,Treatment of Esophageal Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC",701 Ellicott Street,Center of Excellence,Buffalo,New York,14203,United States,640418
ROMIPLOSTIM,GN5XU2DXKV,Designated,Public record,4853,romiplostim,5/24/2018,Treatment of patients acutely exposed to myelosuppressive doses of radiation following radiological/nuclear incident,Designated/Approved,,to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]),1/28/2021,1/28/2028,to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]),Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,91320,United States,639818
Teicoplanin,4U3D3YY81M,Designated,Public record,4854,teicoplanin,5/24/2018,Treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Neupharma srl,8 Piazza del Duomo,,Imola,Emilia-Romagna,,Italy,631418
VUTRISIRAN,GB4I2JI8UI,Designated/Approved,Public record,4855,vutrisiran,5/25/2018,Treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis),Designated/Approved,,Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,6/13/2022,6/13/2029,Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,Alnylam Pharmaceuticals,300 Third Street,,Cambridge,Massachusetts,2142,United States,637618
Dordaviprone,9U35A31JAI,Designated,Public record,4856,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one",6/4/2018,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Chimerix, Inc.","2505 Meridian Parkway, Suite 100",,Durham,North Carolina,27713,United States,640218
APOMORPHINE PALMITATE,622ULQ7RBO,Designated,Public record,4857,apomorphine palmitate,6/4/2018,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Leukos Biotech,"Muntaner 383, 3°2°",,Barcelona,Catalonia,,Spain,640618
LH-708,KS0Q58NC7L,Designated,Public record,4858,L-cystine bis(N'-methylpiperazide),6/4/2018,Treatment of cystinuria.,Designated,Not FDA Approved for Orphan Indication,,,,,PharmaKrysto Ltd,Rmt Accountants & Business Advisors Ltd.,Gosforth Park Avenue,,England,,United Kingdom,639418
.ALPHA.-D-MANNOSE 1-PHOSPHATE,KT83C2DH0W,Designated,Public record,4859,liposomal mannose-1-phosphate,6/4/2018,Treatment of Phosphomannomutase 2-Congenital Disorder of Glycosylation,Designated,Not FDA Approved for Orphan Indication,,,,,"Glycomine, Inc.",QB3@953,953 Indiana Street,San Francisco,California,94107,United States,640318
OLINCIGUAT,PD5F4ZXD21,Designated,Public record,4860,olinciguat,6/4/2018,Treatment of Sickle Cell Disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Cyclerion Therapeutics, Inc.",245 First Street,"Riverview II, 18th Floor",Cambridge,Massachusetts,2142,United States,639718
PALOPEGTERIPARATIDE,G2N64C3385,Designated,Public record,4861,TransCon Parathyroid Hormone (mPEG conjugated parathyroid hormone 1-34),6/4/2018,Treatment of hypoparathyroidism,Designated,Not FDA Approved for Orphan Indication,,,,,Ascendis Pharma Bone Diseases A/S,Tuborg Boulevard 5,DK-2900,Hellerup,,,Denmark,638818
BRINCIDOFOVIR,6794O900AX,Designated,Public record,4862,brincidofovir,6/5/2018,Treatment of smallpox,Designated/Approved,,"Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates",6/4/2021,6/4/2028,"Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates",Emergent BioDefense Operations Lansing LLC,3500 North Martin Luther King Jr. Blvd.,,Lansing,Michigan,48906,United States,640518
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,4863,nitric oxide,6/5/2018,Treatment of non-tuberculous mycobacterial lung disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Novoteris, LLC",7245 Garden Grove Blvd.,Suite C,Garden Grove,California,92841,United States,638918
ACETYLLEUCINE,K76S41V71X,Designated,Public record,4864,N-acetyl-DL-leucine,6/6/2018,Treatment of Spinocerebellar Ataxia (SCA),Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,640818
NIROGACESTAT,QZ62892OFJ,Designated,Public record,4865,nirogacestat,6/7/2018,Treatment of desmoid tumor (aggressive fibromatosis),Designated,Not FDA Approved for Orphan Indication,,,,,"SpringWorks Therapeutics, Inc.",100 Washington Boulevard,,Stamford,Connecticut,6902,United States,636518
Trastuzumab Botidotin,6HUZ008AZX,Designated,Public record,4866,Recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to Duostatin-5,6/7/2018,Treatment of gastric cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"Klus Pharma, Inc.",8 Clarke Drive,Suite 4,Cranbury Township,New Jersey,8512,United States,641118
INZ-701,8ZH1P9LXW1,Designated,Public record,4867,extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1,6/11/2018,Treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2),Designated,Not FDA Approved for Orphan Indication,,,,,Inozyme Pharma Inc.,700 Technology Square,,Cambridge,Massachusetts,2139,United States,637918
INDRALIN,ACF4F9H44I,Designated,Public record,4868,indralin,6/13/2018,Prevention of acute radiation syndrome (ARS),Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Innovative Partners, Inc.",7947 Brookside Court,,Lake Worth,Florida,33467,United States,636318
PCS-499,FLV771E8ZV,Designated,Public record,4869,deuterated S-lisofylline,6/18/2018,Treatment of Necrobiosis Lipoidica,Designated,Not FDA Approved for Orphan Indication,,,,,Processa Pharmaceuticals Inc,7380 Coca Cola Drive,Suite 106,Hanover,Maryland,21076,United States,640918
NIVOLUMAB,31YO63LBSN,Designated,Public record,4870,Fixed dose combination of relatlimab and nivolumab,6/18/2018,Treatment of gastric cancer (GC) and gastro-esophageal junction cancer (GEJ).,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,8543,United States,641718
RELATLIMAB,AF75XOF6W3,Designated,Public record,4870,Fixed dose combination of relatlimab and nivolumab,6/18/2018,Treatment of gastric cancer (GC) and gastro-esophageal junction cancer (GEJ).,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,8543,United States,641718
LATOZINEMAB,IKT0XSS2XB,Designated,Public record,4871,"recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody",6/18/2018,Treatment of Frontotemporal Dementia,Designated,Not FDA Approved for Orphan Indication,,,,,Alector,151 Oyster Point Boulevard,Suite 300,South San Francisco,California,94080,United States,605817
EZOGABINE,12G01I6BBU,Designated,Public record,4873,ezogabine,6/21/2018,Treatment of KCNQ2 epileptic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Xenon Pharmaceuticals, Inc.",200-3650 Gilmore Way,,Burnaby,,,Canada,639118
TONABACASE,6F1Q7D668G,Designated,Public record,4874,L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages,6/21/2018,Treatment of inhalational anthrax,Designated,Not FDA Approved for Orphan Indication,,,,,"iNtRON Biotechnology, Inc.","137 Sagimakgol-ro, Seongnam-si",,,Gyeonggi-do,,South Korea,642118
CANNABIDIOL,19GBJ60SN5,Designated,Public record,4877,cannabidiol,6/25/2018,Treatment of autoimmune hepatitis,Designated,Not FDA Approved for Orphan Indication,,,,,Revive Therapeutics Ltd.,5 Director Court,Suite 105,Vaughan,,,Canada,609617
CC-90001,JD5ZWE631K,Designated,Public record,4878,small molecule selective inhibitor of c-Jun N-terminal kinase,6/27/2018,Treatment of idiopathic pulmonary fibrosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,573116
IOPOFOSINE I-131,R048696O9L,Designated,Public record,4880,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,7/3/2018,Treatment of Ewing’s Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,53716,United States,646918
AST-3424,X6SH5T8H76,Designated,Public record,4881,"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide",7/3/2018,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"OBI Pharma USA, Inc.","6020 Cornerstone Court W, Suite 200",,San Diego,California,92121,United States,643218
EFMITERMANT ALFA,566QNS333V,Designated,Public record,4882,Follistatin291-IgG2 Fc fusion protein,7/3/2018,Treatment of facioscapulohumeral muscular dystrophy,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.,128 Sidney Street,,Cambridge,Massachusetts,2139,United States,573617
IMLIFIDASE,UVJ7NL8S2P,Designated,Public record,4883,Imlifidase,7/3/2018,Treatment of anti-glomerular basement membrane (anti-GBM) disease,Designated,Not FDA Approved for Orphan Indication,,,,,Hansa Medical AB,"Scheelevägen 22, P. O. Box 785",SE-220 07,Lund,,,Sweden,643118
DILANUBICEL,FR89SC8CT4,Designated,Public record,4884,Dilanubicel,7/9/2018,Reduction of morbidity and mortality associated with hematopoietic stem cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Nohla Therapeutics, Inc.",1616 Fairview Avenue East,Suite 100,Seattle,Washington,98102,United States,642818
IVABRADINE,3H48L0LPZQ,Designated,Public record,4885,ivabradine,7/9/2018,Treatment of post-cardiac transplant heart dysfunction,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.,",1 Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,91320,United States,631818
DARLEUKIN,2OQ3OPV2F8,Designated,Public record,4888,Daromun,7/10/2018,Treatment of Melanoma Stages IIb through IV.,Designated,Not FDA Approved for Orphan Indication,,,,,Philogen S.p.A.,La Lizza 7,I-53100 Siena,Siena,Tuscany,,Italy,640018
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,4889,lisocabtagene maraleucel,7/12/2018,Treatment of primary mediastinal large B-cell lymphoma,Designated/Approved,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade",2/5/2021,2/5/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma) after two or more lines of systemic therapy; treatment of adult patients with relapsed o,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Ave N,,Seattle,Washington,98109,United States,644018
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,4890,lisocabtagene maraleucel,7/12/2018,Treatment of primary mediastinal large B-cell lymphoma,Designated/Approved,,"Treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma,",6/24/2022,6/24/2029,"Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chem","Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Ave N,,Seattle,Washington,98109,United States,644018
LENABASUM,OGN7X90BT8,Designated,Public record,4893,lenabasum,7/18/2018,Treatment of dermatomyositis,Designated,Not FDA Approved for Orphan Indication,,,,,"Corbus Pharmaceuticals, Inc.",500 River Ridge Drive,Second Floor,Norwood,Massachusetts,2062,United States,643618
URABRELIMAB,W6284A5K8N,Designated,Public record,4894,anti-CD47 monoclonal antibody,7/30/2018,Treatment of multiple myeloma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Surface Oncology, Inc.","50 Hampshire St, 8th Floor",,Cambridge,Massachusetts,1239,United States,643718
IOPOFOSINE I-131,R048696O9L,Designated,Public record,4895,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,9/24/2018,Treatment of osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,53716,United States,651018
ASPIRIN,R16CO5Y76E,Designated,Public record,4899,fixed combination of dimethyl fumarate and aspirin (162mg),9/27/2018,Treatment of multiple sclerosis in patients who experience dimethyl fumarate flushing,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,10003,United States,607917
DIMETHYL FUMARATE,FO2303MNI2,Designated,Public record,4899,fixed combination of dimethyl fumarate and aspirin (162mg),9/27/2018,Treatment of multiple sclerosis in patients who experience dimethyl fumarate flushing,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,10003,United States,607917
PYRONARIDINE TETRAPHOSPHATE,2T289F9ACO,Designated,Public record,4900,fixed dose combination of pyronaridine tetraphosphate and artesunate,9/27/2018,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Shin Poong Pharmaceutical Co., Ltd.","161 Yoksam-Ro, Gangnam-Gu",,Seoul,Seoul,,South Korea,651218
ARTESUNATE,60W3249T9M,Designated,Public record,4900,fixed dose combination of pyronaridine tetraphosphate and artesunate,9/27/2018,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Shin Poong Pharmaceutical Co., Ltd.","161 Yoksam-Ro, Gangnam-Gu",,Seoul,Seoul,,South Korea,651218
RELACORILANT,2158753C7E,Designated,Public record,4901,relacorilant,9/27/2018,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,94025,United States,652118
ABTL-0812 SODIUM,X1840C8161,Designated,Public record,4902,sodium 2-hydroxylinoleate,9/27/2018,Treatment of biliary tract cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Ability Pharmaceuticals, SL",Edifici Eureka,Campus de la UAB,Bellaterra,,,Spain,652418
ACORAMIDIS,T12B44A1OE,Designated,Public record,4903,"3-(3-(3,5-Dimethyl-1H-pyrazol-4- yl)propoxy)-4-fluorobenzoic acid",10/2/2018,Treatment of transthyretin amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Eidos Therapeutics, Inc.",101 Montgomery Street,Suite 2550,San Francisco,California,94104,United States,593117
CLENBUTEROL,XTZ6AXU7KN,Designated,Public record,4904,clenbuterol,10/2/2018,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Duke University Medical Center,Department of Pediatrics,Box 103856,Durham,North Carolina,27710,United States,653918
IBUDILAST,M0TTH61XC5,Designated,Public record,4905,Ibudilast,10/2/2018,Treatment of Glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"MediciNova, Inc.",4275 Executive Square,Suite 300,La Jolla,California,92037,United States,587717
ACETYLLEUCINE,K76S41V71X,Designated,Public record,4906,N-Acetyl-Leucine,10/2/2018,Treatment of Ataxia Telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,653218
Progerinin,426P9HSR8I,Designated,Public record,4908,progerinin,10/2/2018,Treatment of Hutchinson-Gilford progeria syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"PRG S&T Co., Ltd.",306 Hyowon Industry-Cooperation Bldg.,Pusan National University,Geumjeong-gu,Busan,,South Korea,653718
"""APOMORPHINE, S-""",LH812IV7LI,Designated,Public record,4909,S-[+]-apomorphine,10/2/2018,Treatment of amyotrophic lateral sclerosis (ALS).,Designated,Not FDA Approved for Orphan Indication,,,,,Aclipse One Inc,170 North Radnor Chester Road,Suite 350,Wayne,Pennsylvania,19087,United States,652718
SELEXIPAG,5EXC0E384L,Designated,Public record,4910,selexipag,10/2/2018,Treatment of Chronic Thromboembolic Pulmonary Hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Janssen Research & Development LLC,1820 Chapel Ave West,Suite 300,Cherry Hill,New Jersey,8002,United States,652018
SPESOLIMAB,5IB2J79MCX,Designated,Public record,4911,spesolimab-sbzo,10/3/2018,Treatment of generalized pustular psoriasis,Designated/Approved,,Treatment of generalized pustular psoriasis (GPP) flares in adults,9/1/2022,9/1/2029,Treatment of generalized pustular psoriasis (GPP) flares in adults,"Boehringer Ingelheim Pharmaceuticals, Inc. (BI)",900 Ridgebury Road,P.O. Box 368,Ridgefield,Connecticut,6877,United States,651618
CLERVONAFUSP ALFA,I6M9Q08XBP,Designated,Public record,4912,clervonafusp alfa,10/4/2018,Treatment of Pompe Disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Valerion Therapeutics, LLC",100 Main Street,,Concord,Massachusetts,1742,United States,651518
SELPERCATINIB,CEGM9YBNGD,Designated,Public record,4913,"6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile",10/10/2018,Treatment of pancreatic cancer.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Loxo Oncology, Inc.","701 Gateway Blvd, Suite 420",,"South San Francisco,",California,94080,United States,652318
STRO-001,0D8BWL78LD,Designated,Public record,4914,antibody-drug conjugate comprised of a human aglycosylated anti-CD74 IgG1 antibody (SP7219) and two non-cleavable maytansinoid linker warheads,10/10/2018,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Sutro Biopharma, Inc.",111 Oyster Point,,South San Francisco,California,94080,United States,654118
PACANALOTAMAB,102VUR9WQE,Designated,Public record,4915,bispecific T-cell engager antibody with a single chain Fc moiety that binds to B cell maturation antigen surface receptor and CD3,10/10/2018,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop: 27-3-F,Thousand Oaks,California,91320,United States,644818
IMGN-779,YE6R3UY9IV,Designated,Public record,4916,Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A),10/10/2018,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,2451,United States,654018
LINPERLISIB,05HYK3CV9N,Designated,Public record,4917,N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-yl]methanesulfonamide,10/10/2018,Treatment Follicular Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Shanghai Yingli Pharmaceutical Co., Ltd.","No.1 Building, 998 Halei Road","Zhangiiang Hi-tech Park, Pudong New Area",Shanghai,Shanghai,,China,654518
MAVORIXAFOR,0G9LGB5O2W,Designated,Public record,4918,"N1-(1H-benzimidazol-2-ylmethyl)-N1-((S)-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine",10/10/2018,"Treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome",Designated,Not FDA Approved for Orphan Indication,,,,,"X4 Pharmaceuticals, Inc.",1 Broadway,14th Floor,Cambridge,Massachusetts,2142,United States,500115
DOTAMTATE PB-212,E9N7QV53AK,Designated,Public record,4920,Lead-212 DOTAMTATE,10/11/2018,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"RadioMedix, Inc.",9701 Richmond Avenue,Suite 222,Houston,Texas,77042,United States,653318
CM-101,YW45RY9QD4,Designated,Public record,4921,Monoclonal antibody targeting CCL24,10/11/2018,Treatment of primary sclerosing cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ChemomAb, Ltd.",6 Hanehoset St.,,Tel Aviv,,,Israel,618317
LINPERLISIB,05HYK3CV9N,Designated,Public record,4922,N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl) piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-]methanesulfonamide,10/11/2018,Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Shanghai Yingli Pharmaceutical Co., Ltd.","No.1 Building, 998 Halei Road","Zhangiiang Hi-tech Park, Pudong New Area",Shanghai,Shanghai,,China,654418
Olaparib,WOH1JD9AR8,Designated,Public record,4923,olaparib,10/11/2018,Treatment of pancreatic cancer,Designated/Approved,,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy r,12/27/2019,12/27/2026,Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Sele,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,19803,United States,655318
ODEVIXIBAT,2W150K0UUC,Designated,Public record,4924,"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",10/15/2018,Treatment of Alagille syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Albireo AB c/o Albireo Pharma, Inc.","53 State Street, 19th Floor",,Boston,Massachusetts,2109,United States,370812
GOFLIKICEPT,11DRN01OK2,Designated,Public record,4925,heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IgG1 and part of human IL1 receptor accessory protein,10/15/2018,Treatment of Schnitzler Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,R-Pharm Overseas,505 Cost Boulevard South,Suite #102,San Diego,California,92037,United States,657018
PABINAFUSP ALFA,TRF8S0U6ON,Designated,Public record,4926,Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase,10/15/2018,Treatment of Mucopolysaccharidosis Type II (MPS II) or Hunter Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"JCR Pharmaceuticals Co., Ltd.",2-4 Kasuga-cho,,Ashiya,Hyogo Prefecture,,Japan,652518
REBOXETINE,947S0YZ36I,Designated,Public record,4927,reboxetine,10/15/2018,Treatment of narcolepsy,Designated,Not FDA Approved for Orphan Indication,,,,,"Axsome Therapeutics, Inc.","25 Broadway, 9th Floor",Suite 2000,New York,New York,10004,United States,656118
RELACORILANT,2158753C7E,Designated,Public record,4929,relacorilant,10/15/2018,Treatment of endogenous Cushing syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,94025,United States,656518
RILZABRUTINIB,NWN58M4F5T,Designated,Public record,4930,rilzabrutinib,10/15/2018,Treatment of immune thrombocytopenic purpura (ITP),Designated,Not FDA Approved for Orphan Indication,,,,,Principia Biopharma Inc.,400 East Jamie Court,,South San Francisco,California,94080,United States,605717
"""(4-(4-(1-(2-(2-(2-(2-(2-(2-(2-(4-GUANIDINOMETHYL-PHENOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHOXY)-ETHYL)-1H-(1,2,3)TRIAZOL-4-YLMETHOXY)-3,5-DIIODO-PHENOXY)-3,5-DIIODO-PHENYL)-ACETIC ACID""",70JCV6CT08,Designated,Public record,4931,"[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid",10/17/2018,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,12144,United States,655018
SPARTALIZUMAB,QOG25L6Z8Z,Designated,Public record,4932,spartalizumab,10/18/2018,Treatment of Stage IIB-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,7936,United States,653418
CONCIZUMAB,68603V9EAF,Designated,Public record,4933,concizumab,10/22/2018,Treatment of hemophilia A,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",P.O Box 846,,Plainsboro,New Jersey,8536,United States,653618
NARSOPLIMAB,FT24ZQQ5RP,Designated,Public record,4934,human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2 (MASP-2),10/22/2018,Treatment of Hematopoietic Stem-Cell Transplant-Associated Thrombotic Microangiopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Avenue West,,Seattle,Washington,98119,United States,655418
MELATONIN,JL5DK93RCL,Designated,Public record,4935,melatonin,10/22/2018,Treatment of Acute Radiation Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,644918
SARGRAMOSTIM,5TAA004E22,Designated,Public record,4936,sargramostim,10/22/2018,Treatment of pulmonary alveolar proteinosis (PAP).,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.",19 Muzzey Street,,Lexington,Massachusetts,2421,United States,654318
IMIFOPLATIN,F5I3T42BXC,Designated,Public record,4937,"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)",10/25/2018,Treatment of thymoma and thymic carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Promontory Therapeutics, Inc.",1350 6th Avenue,3rd Floor,New York,New York,10019,United States,654818
CILOFEXOR TROMETHAMINE,Z7AR0KNS4A,Designated,Public record,4938,"2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid¿2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)",10/25/2018,Treatment of Primary Sclerosing Cholangitis (PSC),Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,658018
Tuspetinib monohydrate,1YT25M37WR,Designated,Public record,4939,"5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazine-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine·monohydrate",10/25/2018,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Company, Ltd.","14, Wiryeseong-daero",,Seoul,Songpa-gu,,South Korea,657918
Rildinadstrocel,3ME9TTI5QB,Designated,Public record,4940,adipose-derived mesenchymal stem cells in a hydrogel sheet,10/25/2018,Treatment of Epidermolysis Bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Anterogen Co., Ltd.","405, Namsung Plaza",130 Digital-ro,Seoul,Seoul,,South Korea,658218
MIRDAMETINIB,86K0J5AK6M,Designated,Public record,4944,"N-[(2R)-2,3 dihydroxypropoxyl]-3,4 difluro-2 -[(2-fluoro-4-iodophenyl)amino] benzamide",10/30/2018,Treatment of Neurofibromatosis type I,Designated,Not FDA Approved for Orphan Indication,,,,,"SpringWorks Therapeutics, Inc.","575 5th Avenue, 16th Floor",,New York,New York,10017,United States,655618
TRIMETAZIDINE,N9A0A0R9S8,Designated,Public record,4945,trimetazidine,10/30/2018,Treatment of dilated cardiomyopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Martin Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,658318
DIACEREIN,4HU6J11EL5,Designated,Public record,4947,Diacerein,11/2/2018,Treatment of epidermolysis bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,660318
ROSE BENGAL SODIUM,956575SN5L,Designated,Public record,4948,Rose bengal disodium,11/2/2018,Treatment of Neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Provectus BioPharmaceuticals, Inc.",10025 Investment Drive,Suite 250,Knoxville,Tennessee,37932,United States,657518
CANNABIDIOL,19GBJ60SN5,Designated,Public record,4949,cannabidiol,11/5/2018,Prevention of ischemia/reperfusion Injury resulting from solid organ transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Revive Therapeutics Ltd.,5 Director Court,Suite 105,Vaughan,,,Canada,656618
BOMEDEMSTAT TOSYLATE,2PYF2U9JNF,Designated,Public record,4950,bomedemstat,11/7/2018,Treatment of essential thrombocythemia.,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","126 E. Lincoln Avenue, PO Box 2000",RY34B-332,Rahway,New Jersey,,United States,660418
IPILIMUMAB,6T8C155666,Designated,Public record,4951,ipilimumab,11/7/2018,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,8543,United States,657418
BRENTUXIMAB VEDOTIN,7XL5ISS668,Designated,Public record,4952,brentuximab vedotin,11/13/2018,Treatment of extranodal NK/T-cell lymphoma (ENKTL),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,98021,United States,656818
MECBOTAMAB VEDOTIN,VF40YVX65F,Designated,Public record,4954,humanized IgG1 antibody specifific for the AXL tyrosine kinase conjugated to monomethyl auristatin E,11/19/2018,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,BioAtla LLC,11085 Torreyana Road,Suite 100,San Diego,California,92121,United States,659718
bexotegrast,QCV154PFT4,Designated,Public record,4955,small molecule inhibitor of integrins avß6 and avß1,11/19/2018,Treatment of primary sclerosing cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Pliant Therapeutics, Inc.",260 Littlefield Avenue,,South San Francisco,California,94080,United States,660718
Denfivontinib hydrochloride,01ZQ25VJAL,Designated,Public record,4956,"8-bromo-2-(1-methylpiperidin-4-yl) amino)-4-(4-phenoxyphenyl) amino) pyrido[4,3-d] pyrimidin-5(6H)-one hydrochloride",11/20/2018,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Oscotec Inc.,"Korea Bio-Park Bldg A, 9th Floor","700 Dawwangpangyo-ro, Bundang-gu",Seongnam-si,Gyeonggi-do,,South Korea,661018
FLUNARIZINE,R7PLA2DM0J,Designated,Public record,4957,flunarizine,11/20/2018,Treatment of Alternating Hemiplegia,Designated,Not FDA Approved for Orphan Indication,,,,,"Xenon Pharmaceuticals, Inc.",200-3650 Gilmore Way,,Burnaby,,,Canada,665818
OBI-888,JI5TBH62QP,Designated,Public record,4958,humanized anti-Globo H monoclonal antibody,11/20/2018,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"OBI Pharma USA, Inc.","6020 Cornerstone Court W, Suite 200",,San Diego,California,92121,United States,661218
HYDROMETHYLTHIONINE MESYLATE,3248SEF29D,Designated,Public record,4960,hydromethylthionine mesylate,11/20/2018,Treatment of frontotemporal dementia,Designated,Not FDA Approved for Orphan Indication,,,,,TauRx Therapeutics Ltd,395 King Street,,Aberdeen,Scotland,,United Kingdom,661118
NENDRATAREOTIDE UZATANSINE,L8993M383E,Designated,Public record,4961,"peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine",11/20/2018,Treatment of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Tarveda Therapeutics, Inc.",134 Coolidge Ave.,,Watertown,Massachusetts,2472,United States,630018
BENRALIZUMAB,71492GE1FX,Designated,Public record,4963,benralizumab,11/21/2018,Treatment of eosinophilic granulomatosis with polyangiitis,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,19803,United States,660018
TERLIPRESSIN,7Z5X49W53P,Designated,Public record,4964,terlipressin,11/21/2018,Treatment of hepatorenal syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,BioVie Inc.,100 Cummings Center,Suite 247-C,Beverly,Massachusetts,1915,United States,580417
UDONITRECTAG LYSINE,6C16I5288U,Designated,Public record,4965,"(1S, 4R, 5R, 7S)-3, 4-dibenzyl-2-oxo-6, 8-dioxa- 3-azabyciclo [3.2.1] octane-7-carboxylic acid-L-lysine",11/30/2018,Treatment of Neurotrophic keratopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Recordati Rare Diseases, SARL","Immeuble le ""Wilson""",70 Avenue du General de Gaulle,Puteaux,,,France,662818
DORANIDAZOLE,911XR034RX,Designated,Public record,4966,doranidazole,11/30/2018,radiosensitizer to be used during radiation treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Shuttle Pharmaceuticals, Inc.",1 Research Court,Suite 450,Rockville,Maryland,20850,United States,665218
POVIDONE-IODINE,85H0HZU99M,Designated,Public record,4967,povidone iodine,11/30/2018,Treatment of Endophthalmitis,Designated,Not FDA Approved for Orphan Indication,,,,,Cumulus Pharmaceutical LLC,1712 Pioneer Avenue,Suite 1377,Cheyenne,Wyoming,82001,United States,647518
(+)-a-Dihydrotetrabenazine,IFRYDMLSGE,Designated,Public record,4969,(+)-alpha-dihydrotetrabenazine,12/5/2018,Treatment of Huntington's disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Adeptio Pharmaceuticals, Ltd",22 Bedford Row,WC1R 4JS,London,,,United Kingdom,607417
"""99MTC-ETHYLENEDIAMINE N,N'-DIACETIC ACID/HYDRAZINONICOTINAMIDE-TYR3-OCTREOTIDE""",534I87AT7J,Designated,Public record,4970,"99mTc-HYNIC-[D-Phe1,Tyr3-Octreotide] trifluoroacetate",12/5/2018,Diagnostic for the management of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Narodowe Centrum Badan Jadrowych,ul. Andrzeja Soltana 7,,Otwock,Masovian Voivodeship,,Poland,661918
INTERLEUKIN-12 HUMAN RECOMBINANT,02FXP10O2U,Designated,Public record,4972,recombinant human interleukin 12,12/5/2018,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,TherapyX Inc.,108 Biomedical Research Building,3435 Main Street,Buffalo,New York,14214,United States,663218
BINTRAFUSP ALFA,NW9K8C1JN3,Designated,Public record,4975,transforming growth factor beta trap/anti-programmed death ligand-1 antibody bifunctional fusion protein,12/7/2018,Treatment of biliary tract cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.",45 Middlesex Turnpike,,Billerica,Massachusetts,1821,United States,663818
CORD BLOOD EXPANDED WITH UM-171,DBD2HM3I4V,Designated,Public record,4976,"((1r, 4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate)-Expanded cord blood",12/13/2018,Prevention of Graft-versus-Host-Disease,Designated,Not FDA Approved for Orphan Indication,,,,,ExCellThera Inc.,2950 chemin de Polythechnique,,Montreal,,,Canada,661418
UM-171 DIHYDROBROMIDE DIHYDRATE,9VB5UBJ45H,Designated,Public record,4976,"((1r, 4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate)-Expanded cord blood",12/13/2018,Prevention of Graft-versus-Host-Disease,Designated,Not FDA Approved for Orphan Indication,,,,,ExCellThera Inc.,2950 chemin de Polythechnique,,Montreal,,,Canada,661418
BMS-986278,4UN9AOU6G8,Designated,Public record,4977,"(1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid",12/17/2018,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 4000,3551 Lawrenceville Road,Princeton,New Jersey,8540,United States,668018
EPELEUTON,FA9BPX1T6V,Designated,Public record,4978,"15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester",12/17/2018,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Afimmune,Trintech Building,South County Business Park,Dublin,County Dublin,,Ireland,667918
CIRTUVIVINT,7T1PY32ZPH,Designated,Public record,4981,CDC-like kinase inhibitor of the Wnt Pathway,12/17/2018,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Biosplice Therapeutics, Inc.",9360 Towne Centre Drive,,San Diego,California,92121,United States,662318
MOSUNETUZUMAB,LDJ89SS0YG,Designated,Public record,4982,mosunetuzumab-axgb,12/17/2018,Treatment of follicular lymphoma,Designated/Approved,,treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,12/22/2022,12/22/2029,treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,663418
QUERCETIN,9IKM0I5T1E,Designated,Public record,4983,poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin,12/17/2018,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Cancer Research and Life Foundation,2015 Placentia Ave.,,Costa Mesa,California,92627,United States,664018
VENETOCLAX,N54AIC43PW,Designated,Public record,4984,venetoclax + idasanutlin,12/17/2018,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Genentech Inc. (A Member of the Roche Group),1 DNA Way,MS# 355d,South San Francisco,California,94080,United States,664118
IDASANUTLIN,QSQ883V35U,Designated,Public record,4984,venetoclax + idasanutlin,12/17/2018,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Genentech Inc. (A Member of the Roche Group),1 DNA Way,MS# 355d,South San Francisco,California,94080,United States,664118
OZURIFTAMAB VEDOTIN,BPM6YN0KLI,Designated,Public record,4986,conditionally active biologics-anti-ROR2-antibody drug conjugate consisting of a humanized IgG1 antibody specific for ROR2 tyrosine kinase conjugated to a peptide linker coupled with monomethyl auristatin E,12/18/2018,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,BioAtla LLC,11085 Torreyana Road,Suite 100,San Diego,California,92121,United States,663018
ONFEKAFUSP ALFA,6HXC0O6JMV,Designated,Public record,4987,Fibromun,12/18/2018,Treatment of Soft Tissue Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Philogen S.p.A.,La Lizza 7,I-53100 Siena,Siena,Tuscany,,Italy,662918
IBERDOMIDE,8V66F27X44,Designated,Public record,4988,iberdomide,12/19/2018,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,665718
PEGCETACOPLAN,TO3JYR3BOU,Designated,Public record,4989,PEGylated peptide inhibitor of complement C3,12/19/2018,Treatment of C3 glomerulopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.",6400 Westwind Way,Suite A,Crestwood,Kentucky,40014,United States,633418
PREIMPLANTATION FACTOR,3K6A6FJ98O,Designated,Public record,4991,Synthetic PreImplantation Factor,12/19/2018,Treatment of Acute Radiation Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"BioIncept, LLC",140 East 40th Street,Suite 11E,New York,New York,10016,United States,664918
APRAGLUTIDE,CVQ1IAY2G6,Designated,Public record,4992,apraglutide,12/20/2018,Treatment of short bowel syndrome (SBS),Designated,Not FDA Approved for Orphan Indication,,,,,VectivBio AG,36 Aeschenvorstadt,,Basel,Basel-Stadt,,Switzerland,639518
TARLATAMAB,74X82ST8Q1,Designated,Public record,4994,bispecific T-cell engager antibody consisting of 2 single chain variable fragment binding domains specific for antigen Delta-like protein 3 (DLL3) and for TCR-associated complex CD3,12/27/2018,Treatment of small cell lung cancer (SCLC),Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,91320,United States,665418
BROMELAINS,U182GP2CF3,Designated,Public record,4995,bromelain + acetylcysteine,12/27/2018,Treatment of pseudomyxoma peritonei with Bromelain and Acetylcysteine,Designated,Not FDA Approved for Orphan Indication,,,,,MUCPharm Pty Ltd.,13/53 High Street,,Malvern,Victoria,,Australia,664418
ACETYLCYSTEINE,WYQ7N0BPYC,Designated,Public record,4995,bromelain + acetylcysteine,12/27/2018,Treatment of pseudomyxoma peritonei with Bromelain and Acetylcysteine,Designated,Not FDA Approved for Orphan Indication,,,,,MUCPharm Pty Ltd.,13/53 High Street,,Malvern,Victoria,,Australia,664418
CUSATUZUMAB,RR5U4UFJ8L,Designated,Public record,4997,cusatuzumab,1/14/2019,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,8869,United States,614717
GALACTOSE,X2RN3Q8DNE,Designated,Public record,4998,D-Galactose,1/14/2019,Treatment of Phosphoglucomutase 1 Deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Avalo Therapeutics, Inc.",1500 Liberty Ridge Drive,Suite 321,Wayne,Pennsylvania,19087,United States,666818
Demannose,PHA4727WTP,Designated,Public record,4999,D-mannose,1/14/2019,Treatment of Mannose Phosphate Isomerase Deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Avalo Therapeutics, Inc.",1500 Liberty Ridge Drive,Suite 321,Wayne,Pennsylvania,19087,United States,666918
Elfucose,28RYY2IV3F,Designated,Public record,5000,L-fucose,1/14/2019,Treatment of Congenital Disorder of Glycosylation IIc,Designated,Not FDA Approved for Orphan Indication,,,,,"Avalo Therapeutics, Inc.",1500 Liberty Ridge Drive,Suite 321,Wayne,Pennsylvania,19087,United States,667018
RRX-001,7RPW6SU9SC,Designated,Public record,5002,"N-(bromoacetyl)-3,3-dinitroazetidine",1/16/2019,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,EpicentRx Inc.,"11099 North Torrey Pines Road, Suite 160",La Jolla,San Diego,California,92037,United States,666718
ODEVIXIBAT,2W150K0UUC,Designated,Public record,5003,odevixibat,1/16/2019,Treatment of Biliary Atresia,Designated,Not FDA Approved for Orphan Indication,,,,,"Albireo AB c/o Albireo Pharma, Inc.","53 State Street, 19th Floor",,Boston,Massachusetts,2109,United States,658118
ADONITOL,353ZQ9TVDA,Designated,Public record,5004,ribitol,1/16/2019,Treatment of limb-girdle muscular dystrophy type 2I,Designated,Not FDA Approved for Orphan Indication,,,,,"ML Bio Solutions, Inc.","1800 Owens Street, Suite C-1200",,San Francisco,California,94158,United States,666518
TIRATRICOL,29OQ9EU4R1,Designated,Public record,5005,tiratricol,1/16/2019,Treatment of Monocarboxylate 8 Transporter (MCT8) Deficiency (Allan-Herndon-Dudley-Syndrome),Designated,Not FDA Approved for Orphan Indication,,,,,Rare Thyroid Therapeutics,3 Teatergatan,SE-111 48,Stockholm,,,Sweden,666618
MITSUGUMIN-53,GPU59XZ1PZ,Designated,Public record,5006,recombinant Mitsugumin 53,1/17/2019,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Axolo Pharma, Inc.",6425 Nieman Road,,Shawnee,Arkansas,66203,United States,667618
FOSMANOGEPIX,1XQ871489P,Designated,Public record,5007,fosmanogepix,1/22/2019,Treatment of cryptococcosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Amplyx Pharmaceuticals, Inc.",66 Hudson Boulevard East,,New York,New York,10001,United States,667318
MEZAGITAMAB,0XMR8L9LOL,Designated,Public record,5008,Human IgG1 monoclonal antibody to human CD38,1/22/2019,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,667418
CLOFARABINE,762RDY0Y2H,Designated,Public record,5009,clofarabine,1/24/2019,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Boyen Therapeutics, Inc.","333 Section 1, Keelung Road",Suite 1212,Taipei,Taipei,110208,Taiwan,668118
PBT-434 MESYLATE,826P1VAG3U,Designated,Public record,5010,"5,7-Dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinazolin-4(3H)-one mesylate",1/29/2019,Treatment of multiple system atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Alterity Therapeutics, Limited",460 Bourke Street,,Melbourne,Victoria,,Australia,669118
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5011,delta-9-tetrahydrocannabinol and cannabidiol,1/29/2019,Treatment of Huntington's Disease,Designated,Not FDA Approved for Orphan Indication,,,,,MMJ International Holdings,1895 Preston White Drive,Suite 101,Reston,Virginia,20191,United States,668918
DRONABINOL,7J8897W37S,Designated,Public record,5011,delta-9-tetrahydrocannabinol and cannabidiol,1/29/2019,Treatment of Huntington's Disease,Designated,Not FDA Approved for Orphan Indication,,,,,MMJ International Holdings,1895 Preston White Drive,Suite 101,Reston,Virginia,20191,United States,668918
BI-1206,24S6PA0WXW,Designated,Public record,5012,Fully human immunoglobulin G1 monoclonal antibody that targets CD32b,1/29/2019,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,BioInvent International AB,Ideon Science Park,,Lund,Skåne County,,Sweden,669218
IRGD,Z8MXU5GH4Q,Designated,Public record,5013,internalized-arginylglycylaspartic acid cyclic peptide,1/29/2019,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Lisata Therapeutics, Inc.","110 Allen Road, Second Floor",,Basking Ridge,New Jersey,7920,United States,669518
LOSARTAN,JMS50MPO89,Designated,Public record,5014,Losartan,1/29/2019,Treatment of epidermolysis bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,Crowd Pharma Losartan GmbH & Co. KG,Merkurstr. 8,,Dobel,Pforzheim,75179,Germany,668618
WP-1066,63V8AIE65T,Designated,Public record,5015,(E)-3-(6-Bromo-pyridin-2-yl)-2-cyano-N-((S)-1-phenyl-ethyl)-acryl amide,2/1/2019,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.","5300 Memorial Drive,",Suite 950,Houston,Texas,77007,United States,671018
BENRALIZUMAB,71492GE1FX,Designated,Public record,5019,benralizumab,2/1/2019,Treatment of hypereosinophilic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,19803,United States,670518
BUDESONIDE,Q3OKS62Q6X,Designated,Public record,5020,budesonide,2/1/2019,Treatment of Autoimmune Hepatitis,Designated,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,,,Sweden,670118
CILTACABTAGENE AUTOLEUCEL,0L1F17908Q,Designated/Approved,Public record,5021,ciltacabtagene autoleucel,2/1/2019,Treatment of multiple myeloma (MM),Designated/Approved,,"Treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody",2/28/2022,2/28/2029,"Treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody","Janssen Research and Development, LLC",920 US Highway 202,P.O. Box 300,Raritan,New Jersey,8869,United States,672118
EFGARTIGIMOD ALFA,961YV2O515,Designated,Public record,5022,efgartigimod,2/1/2019,Treatment of Primary Immune Thrombocytopenia (ITP),Designated,Not FDA Approved for Orphan Indication,,,,,argenx BVBA,7 Industriepark-Zwijnaarde,,Gent,Vlaanderen,,Belgium,633218
ITOLIZUMAB,XQQ2RHV14N,Designated,Public record,5023,itolizumab,2/1/2019,Treatment of acute graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.",2223 Avenida De La Playa,Suite 108,San Diego,California,92037,United States,646718
KETAMINE,690G0D6V8H,Designated,Public record,5024,ketamine,2/1/2019,Treatment of Complex Regional Pain Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Bexson Biomedical, Inc.",856 Chelham Way,,Santa Barbara,California,93108,United States,669318
MOTIXAFORTIDE,DA9G065962,Designated,Public record,5025,motixafortide,2/1/2019,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"BioLineRx, Ltd.",Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,,,Israel,669818
NIVOLUMAB,31YO63LBSN,Designated,Public record,5026,nivolumab,2/1/2019,Treatment of primary mediastinal B-cell lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 4000,,Princeton,New Jersey,8543,United States,670918
PEGCETACOPLAN,TO3JYR3BOU,Designated,Public record,5027,pegcetacoplan,2/1/2019,Treatment of autoimmune hemolytic anemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.","100 Fifth Avenue, 3rd Floor",,Waltham,Massachusetts,2451,United States,627018
Rozanolixizumab,P7186074QC,Designated,Public record,5029,rozanolixizumab,2/1/2019,Treatment of myasthenia gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive Building 2100,,Smyrna,Georgia,30080,United States,669918
ITOLIZUMAB,XQQ2RHV14N,Designated,Public record,5030,itolizumab,2/5/2019,Prevention of acute graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.",2223 Avenida De La Playa,Suite 108,San Diego,California,92037,United States,676618
PAVURUTAMAB,GLR3JG8TZU,Designated,Public record,5032,Bispecific T-cell engager (BiTE) containing two single-chain variable fragment (scFv) domains directed against the B cell maturation antigen (BCMA) surface receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T-cells,2/8/2019,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91320,United States,669618
"""2,4-DINITROPHENOL""",Q13SKS21MN,Designated,Public record,5033,"2,4-dinitrophenol",2/11/2019,Treatment of Huntington disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Mitochon Pharmaceuticals, Inc.",970 Cross Lane,,Blue Bell,Pennsylvania,19422,United States,672818
SIMUROSERTIB HEMIHYDRATE,1E98KCJ6UB,Designated,Public record,5034,"2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate",2/11/2019,Treatment of esophageal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,673218
BUDESONIDE,Q3OKS62Q6X,Designated,Public record,5035,budesonide,2/11/2019,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,Stockholms län,,Sweden,673818
ETOPOSIDE TONIRIBATE,A59HL2Q48U,Designated,Public record,5036,etoposide toniribate,2/11/2019,Treatment of biliary tract cancer,Designated,Not FDA Approved for Orphan Indication,,,,,CellAct Pharma GmbH,Otto-Hahn str. 15,,Dortmund,,44227,Germany,671318
ROSE BENGAL SODIUM,956575SN5L,Designated,Public record,5038,rose bengal disodium,2/11/2019,Treatment of ocular melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Provectus BioPharmaceuticals, Inc.",10025 Investment Drive,Suite 250,Knoxville,Tennessee,37932,United States,670618
MURIZATOCLAX,BO0V7196L2,Designated,Public record,5039,A small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL 1),2/15/2019,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,,United States,675018
NENDRATAREOTIDE UZATANSINE,L8993M383E,Designated,Public record,5040,"peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine",2/15/2019,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Tarveda Therapeutics, Inc.",134 Coolidge Ave.,,Watertown,Massachusetts,2472,United States,673318
VERDIPERSTAT,TT3345YXVR,Designated,Public record,5042,verdiperstat,2/15/2019,Treatment of multiple system atrophy (MSA).,Designated,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceuticals, Inc.",215 Church Street,,New Haven,Connecticut,6510,United States,671418
Tividenofusp Alfa,QLD7UJN8CF,Designated,Public record,5043,enzyme transport vehicle specific for the transferrin receptor fused to iduronate 2-sulfatase,2/19/2019,Treatment of mucopolysaccharidosis type II,Designated,Not FDA Approved for Orphan Indication,,,,,Denali Therapeutics Inc.,"151 Oyster Point Blvd, Second Floor",,South San Francisco,California,94080,United States,671118
ANHYDROUS DEXTROSE,5SL0G7R0OK,Designated,Public record,5044,peritoneal dialysis solution containing combination of D-glucose and L-carnitine,2/21/2019,Treatment of patients with end stage renal disease who require peritoneal dialysis,Designated,Not FDA Approved for Orphan Indication,,,,,CoreQuest Sagl,Stabile Suglio Via Cantonale 18,,Manno TI,Tessin,,Switzerland,599517
CARNITINE,S7UI8SM58A,Designated,Public record,5044,peritoneal dialysis solution containing combination of D-glucose and L-carnitine,2/21/2019,Treatment of patients with end stage renal disease who require peritoneal dialysis,Designated,Not FDA Approved for Orphan Indication,,,,,CoreQuest Sagl,Stabile Suglio Via Cantonale 18,,Manno TI,Tessin,,Switzerland,599517
"""5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE""",X4D0G881CN,Designated,Public record,5045,"5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",2/25/2019,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Molecure S.A. (previously OncoArendi S.A.),"101 Zwirki i Wigury street,",,Warsaw,,,Poland,671618
MIVAVOTINIB CITRATE,6ZJ8V3Q0H1,Designated,Public record,5046,"6-{[(1R,2S)-2-aminocyclohexyl]amino-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate",2/25/2019,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,671718
DEXAMETHASONE,7S5I7G3JQL,Designated,Public record,5048,dexamethasone,2/26/2019,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Fera Pharmaceuticals,134 Birch Hill Road,,Locust Valley,New York,11560,United States,674718
MPT-0L055,U1DMN1EU6W,Designated,Public record,5051,"4-(((3-chloro-1,4-dioxo-1,4 dihydronaphthalen-2-yl)amino)methyl)-N-(pyridine-3-yl)benzamide",2/28/2019,Treatment of Multiple Myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Sino-American Cancer Foundation,4978 Santa Anita Ave,Suite 104,Temple City,California,91780,United States,678619
EFMITERMANT ALFA,566QNS333V,Designated,Public record,5054,efmitermant alfa,2/28/2019,Treatment of Charcot-Marie-Tooth disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.,128 Sidney Street,,Cambridge,Massachusetts,2139,United States,674918
MELATONIN,JL5DK93RCL,Designated,Public record,5056,melatonin,2/28/2019,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,677519
NANATINOSTAT,YTL7A418KQ,Designated,Public record,5057,nanatinostat and valganciclovir,2/28/2019,Treatment of plasmablastic lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,92007,United States,676118
VALGANCICLOVIR,GCU97FKN3R,Designated,Public record,5058,nanatinostat and valganciclovir,2/28/2019,Treatment of post-transplant lymphoproliferative disorder,Designated,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,92007,United States,676018
PYRONARIDINE TETRAPHOSPHATE,2T289F9ACO,Designated,Public record,5059,pyronaridine tetraphosphate,2/28/2019,Treatment of Ebola infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,27526,United States,677019
MURIZATOCLAX,BO0V7196L2,Designated,Public record,5060,small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL 1),2/28/2019,Treatment of Multiple Myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,,United States,674818
SORAFENIB,9ZOQ3TZI87,Designated,Public record,5061,sorafenib,2/28/2019,Treatment of desmoid tumors/aggressive fibromatosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P.O. Box 915,Whippany,New Jersey,7981,United States,675918
JAB-3068,V6Q7413SA8,Designated,Public record,5062,src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor JAB-3068,2/28/2019,Treatment of esophageal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Jacobio Pharmaceuticals Co., Ltd.","Bld-F2, No 88, 6th Kechuang St, BDA",,Beijing,,,China,676318
ACETIC ACID C-11,2A9OM7IPNW,Designated,Public record,5063,[11C]Acetic Acid,2/28/2019,Diagnostic for the management of hepatoblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,662018
TECARFARIN,WN1479YT50,Designated,Public record,5064,tecarfarin,3/7/2019,Prevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillation,Designated,Not FDA Approved for Orphan Indication,,,,,"Cadrenal Therapeutics, Inc.",830 North A1A #196,,Ponte Vedra,Florida,32082,United States,659818
SARACATINIB,9KD24QGH76,Designated,Public record,5065,saracatinib,3/11/2019,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"AstraZeneca Pharmaceuticals, LP","Emerging Innovations, AstraZeneca, R&D Boston",35 Gatehouse Drive,Waltham,Massachusetts,2451,United States,674218
CALMANGAFODIPIR,N0JZU0WGU5,Designated,Public record,5066,calmangafodipir,3/15/2019,Treatment of acetaminophen overdose.,Designated,Not FDA Approved for Orphan Indication,,,,,Egetis Therapeutics AB,Grev Turegatan 11c,,Stockholm,,,Sweden,676418
CAPMATINIB,TY34L4F9OZ,Designated,Public record,5067,capmatinib,3/15/2019,Treatment of non-small cell lung cancer with MET genomic tumor aberrations,Designated/Approved,,Tabrecta (capmatinib) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved te,5/6/2020,5/6/2027,For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,7936,United States,644518
CRINECERFONT,MFT24BX55I,Designated,Public record,5068,corticotropin releasing factor 1 receptor antagonist,3/15/2019,Treatment of congenital adrenal hyperplasia,Designated,Not FDA Approved for Orphan Indication,,,,,"Neurocrine Biosciences, Inc.",12780 El Camino Real,,San Diego,California,92130,United States,639018
DEFEROXAMINE,J06Y7MXW4D,Designated,Public record,5069,deferoxamine,3/15/2019,Treatment of sickle cell leg ulcers,Designated,Not FDA Approved for Orphan Indication,,,,,Theris Medical,604 Fifth Avenue,Suite D,Redwood City,California,94063,United States,633618
SIROLIMUS,W36ZG6FT64,Designated,Public record,5070,encapsulated rapamycin,3/15/2019,Treatment of familial adenomatous polyposis,Designated,Not FDA Approved for Orphan Indication,,,,,Emtora Biosciences Inc,16601 Blanco Road,Suite 120,San Antonio,Texas,78232,United States,678319
MEPOLIZUMAB,90Z2UF0E52,Designated,Public record,5071,meplazumab,3/15/2019,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Pacific-Meinuoke Bio-pharmaceutical Co., Ltd.","No. 128, Hehai West Rd",Xinbei District,Changzhou,Jiangsu,,China,676218
NANATINOSTAT,YTL7A418KQ,Designated,Public record,5072,nanatinostat and valganciclovir,3/15/2019,Treatment of angioimmunoblastic T-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,92007,United States,675818
VALGANCICLOVIR,GCU97FKN3R,Designated,Public record,5072,nanatinostat and valganciclovir,3/15/2019,Treatment of angioimmunoblastic T-cell lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,92007,United States,675818
TINOSTAMUSTINE HYDROCHLORIDE,QK4ZBS4FPO,Designated,Public record,5074,tinostamustine hydrochloride,3/15/2019,Treatment of T-cell prolymphocytic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Mundipharma EDO GmbH,St. Alban-Rheinweg 74,,Basel,Basel City,,Switzerland,636418
AVID-200,6EX05GL2VK,Designated,Public record,5075,Anti-transforming growth factor beta (TGF-ß) trap fusion protein,3/25/2019,Treatment of systemic sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,Formation Biologics,101 W 6th Street,Suite 501,Austin,Texas,8701,United States,678419
BEFOVACIMAB,8FFQ0L4R3B,Designated,Public record,5077,human monoclonal IgG2 antibody against tissue factor pathway inhibitor (TFPI),3/25/2019,Treatment of Hemophilia A,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare LLC,100 Bayer Boulevard,P.O. Box 915,Hanover,New Jersey,7981,United States,678219
METHOTREXATE,YL5FZ2Y5U1,Designated,Public record,5078,methotrexate,3/25/2019,Treatment of ectopic pregnancy,Designated,Not FDA Approved for Orphan Indication,,,,,"Antares Pharma, Inc",Princeton Crossroads Corporate Center,100 Princeton South Suite 300,"Ewing,",New Jersey,8628,United States,679019
VARESPLADIB,2Q3P98DATH,Designated,Public record,5079,Varespladib,3/25/2019,Treatment of snakebite,Designated,Not FDA Approved for Orphan Indication,,,,,"Ophirex, Inc.",5643 Paradise Dr #2,,Corte Madera,California,94925,United States,677919
.ALPHA.-TOCOPHEROL,H4N855PNZ1,Designated,Public record,5081,alpha tocopherol and ascorbic acid,3/28/2019,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,GenCo Pharmaceuticals LLC,371 Lake Surprise Road,,Cold Spring,New York,10516,United States,678719
ASCORBIC ACID,PQ6CK8PD0R,Designated,Public record,5081,alpha tocopherol and ascorbic acid,3/28/2019,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,GenCo Pharmaceuticals LLC,371 Lake Surprise Road,,Cold Spring,New York,10516,United States,678719
ESTETROL ANHYDROUS,ENB39R14VF,Designated,Public record,5082,estetrol,3/28/2019,Treatment of neonatal hypoxic ischemic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Mithra Pharmaceuticals S.A.,5-7 Rue St Georges,,Liège,,,Belgium,678119
Vodudeutentan sodium,AAY8R26VDX,Designated,Public record,5083,sodium bispiperidine-carboxamido-dimethylpenatnamido-methoxycarbonyl-indol-propanamidohexanoate,3/28/2019,Treatment of malignant melanoma stages IIB to IV,Designated,Not FDA Approved for Orphan Indication,,,,,"ENB Therapeutics, INC","Alexandria Center for Life Sciences, Launch Labs","430 E 29th St, 14th Floor",New York,New York,10016,United States,679519
EPRENETAPOPT,Z41TGB4080,Designated,Public record,5085,"2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one",4/11/2019,Treatment of Myelodysplastic Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Aprea Therapeutics AB,Nobels Vag 3,,"Solna,",,,Sweden,673518
CROMOLYN,Y0TK0FS77W,Designated,Public record,5086,cromolyn solution,4/11/2019,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Respivant Sciences, Inc.","11455 El Camino Real, Suite 460",,San Diego,California,92130,United States,602817
PAMREVLUMAB,QS5F6VTS0O,Designated,Public record,5087,pamrevlumab,4/11/2019,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.",409 Illinois Street,,San Francisco,California,94158,United States,680319
EFINEPTAKIN ALFA,3K3WC6MT6P,Designated,Public record,5088,Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc),4/11/2019,Treatment of Idiopathic CD4+ Lymphocytopenia.,Designated,Not FDA Approved for Orphan Indication,,,,,"NeoImmuneTech, Inc.",2400 Research Boulevard,Suite 250,Rockville,Maryland,20850,United States,666218
UMBRALISIB,38073MQB2A,Designated,Public record,5089,umbralisib,4/11/2019,Treatment of nodal marginal zone lymphoma,Designated/Approved,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",3020 Carrington Mill Blvd. Suite 475,,Morrisville,North Carolina,27560,United States,687519
UMBRALISIB,38073MQB2A,Designated,Public record,5090,umbralisib,4/11/2019,Treatment of extranodal marginal zone lymphoma,Designated/Approved,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",3020 Carrington Mill Blvd. Suite 475,,Morrisville,North Carolina,27560,United States,687419
UMBRALISIB,38073MQB2A,Designated,Public record,5091,umbralisib,4/11/2019,Treatment of splenic marginal zone lymphoma,Designated/Approved,,treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",3020 Carrington Mill Blvd. Suite 475,,Morrisville,North Carolina,27560,United States,680019
2-FLUORO-5-HYDROXY-L-PHENYLALANINE F-18,QKU5EC2X53,Designated,Public record,5093,6-[18F] fluoro-L-m-tyrosine,4/17/2019,Diagnostic for the management of Aromatic L-Amino Acid Decarboxylase Deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,686619
STG-001,IK88NC17OD,Designated,Public record,5097,"3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-pyrazol-1-yl) propanoic acid",4/22/2019,Treatment of Stargardt’s disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Stargazer Pharmaceuticals, Inc.",200 Clarendon Street,"45th Floor, Mailbox 30",Boston,Massachusetts,2116,United States,681519
DEXPRAMIPEXOLE,WI638GUS96,Designated,Public record,5098,Dexpramipexole,4/22/2019,Treatment of hypereosinophilic syndrome (HES),Designated,Not FDA Approved for Orphan Indication,,,,,Areteia Therapeutics,"1200 Morris Turnpike, Suite 3005",,Short Hills,New Jersey,7078,United States,681319
MELATONIN,JL5DK93RCL,Designated,Public record,5099,Melatonin,4/22/2019,Treatment of heat stroke,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,680719
VARDENAFIL,UCE6F4125H,Designated,Public record,5101,vardenafil,4/22/2019,Treatment of Pulmonary Arterial Hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Respira Therapeutics, Inc",5901 Indian School Road NE,#107,Albuquerque,New Mexico,87110,United States,679319
PHI-101,U2UY9TBQ8Z,Designated,Public record,5102,N-{2-[N-((3S)(3-piperidyl))carbamoyl]-5-[2-(3-fluorophenyl)ethynyl](3-thienyl)}aminoamide,4/29/2019,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharos iBio Co., Ltd.","#1408, 38, Heungan-daero 427 beon-gil","Gwanyang-dong, Sungji Starwith),",Dongan-gu,Anyang-si Gyeonggi-do,,South Korea,681819
SOTORASIB,2B2VM6UC8G,Designated,Public record,5107,sotorasib,5/1/2019,Treatment of KRAS p.G12C-positive non-small cell lung cancer,Designated/Approved,,"Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.",5/28/2021,5/28/2028,"Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.",Amgen Inc.,1 Amgen Center Drive,Mail Stop 27-3-A,Thousand Oaks,California,91320,United States,653818
OSUGACESTAT,DRL23N424R,Designated,Public record,5109,A potent and selective inhibitor of Gamma Secretase-mediated NOTCH signaling,5/8/2019,Treatment of Adenoid cystic carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Ayala Pharmaceuticals, Inc.","7 Oppenheimer St.,",,Rehovot,,,Israel,683819
ANSUVIMAB,TG8IQ19NG2,Designated,Public record,5110,ansuvimab-zykl,5/8/2019,Treatment of Ebola Virus Disease,Designated/Approved,,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",12/21/2020,12/21/2027,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",Emergent Manufacturing Operations Baltimore LLC,5901 East Lombard Street,,Baltimore,Maryland,21224,United States,683019
GOLD,79Y1949PYO,Designated,Public record,5112,faceted gold nanocrystals,5/8/2019,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Clene Nanomedicine, Inc.",3165 East Millrock Drive,Suite 325,Salt Lake City,Utah,84121,United States,682119
O-(2-FLUOROETHYL)-L-TYROSINE F-18,1326R5J1IA,Designated,Public record,5113,O-18F-fluoroethyl-L-tyrosine,5/8/2019,Diagnostic for the management of Malignant Rhabdoid Tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,33467,United States,683619
ILOPROST,JED5K35YGL,Designated,Public record,5117,iloprost,5/9/2019,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company",200 Four Falls Corporate Center,Suite 107,West Conshohocken,Pennsylvania,19528,United States,655118
ASC-JM-17,5VLL140BN9,Designated,Public record,5118,"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione OR [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",5/14/2019,Treatment of Huntington’s Disease,Designated,Not FDA Approved for Orphan Indication,,,,,AnnJi Pharmaceutical Co. Ltd.,"B405, 4F., No. 18, Siyuan St.",Zhongzheng District,Taipai City,,10087,Taiwan,686419
MEZIGDOMIDE,LA88IH4O02,Designated,Public record,5119,cereblon enzyme 3 (E3) ubiquitin ligase modulating agent,5/14/2019,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,685019
ASPACYTARABINE,JL7V54Z2BR,Designated,Public record,5120,cytarabine-beta-L-aspartic acid,5/14/2019,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,BioSight Ltd.,1 Hayarden St.,P.O.B 1083,Airport City,Lod,,Israel,684419
ESOMEPRAZOLE,N3PA6559FT,Designated,Public record,5121,esomeprazole,5/15/2019,Treatment of Eosinophilic Esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Adare Pharmaceuticals US, L.P.",Princeton Pike Corporate Center,"1200 Lenox Drive, Suite 100",Lawrenceville,New Jersey,8648,United States,684119
RIMTUZALCAP,USO2D5J77R,Designated,Public record,5123,"N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-amine",5/22/2019,Treatment of spinocerebellar ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Building 337/03/A13L1-22,East Hanover,New Jersey,7936,United States,686219
GOVORESTAT,6JLQ8K35KK,Designated,Public record,5124,"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",5/23/2019,Treatment of Galactosemia,Designated,Not FDA Approved for Orphan Indication,,,,,Applied Therapeutics Inc.,"340 Madison Avenue, 19th Floor",,"New York,",New York,10173,United States,685219
SOTORASIB,2B2VM6UC8G,Designated,Public record,5125,"6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one",5/23/2019,Treatment of KRAS (Kirsten rat sarcoma viral oncogene homolog) p.G12C-positive Colorectal Cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,Mail Stop 27-3-A,Thousand Oaks,California,91320,United States,654918
VODOBATINIB,N8Q12KU2SW,Designated,Public record,5126,4-Methyl-3-quinolin-3-ylethynylbenzoic acid N'-(2-chloro-6- methylbenzoyl) hydrazide,6/3/2019,Treatment of chronic myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Sun Pharma Advanced Research Company Ltd.,"17/B, Mahal Industrial Estate",Mahakali Caves Road,Andheri (E),Mumbai,,India,687119
BARDOXOLONE METHYL,CEG1Q6OGU1,Designated,Public record,5128,bardoxolone methyl,6/3/2019,Treatment of autosomal dominant polycystic kidney disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Dr.,Suite 150,Irving,Texas,75063,United States,687219
CASIMERSEN,X8UHF7SX0R,Designated,Public record,5132,casimersen,6/4/2019,Treatment of Duchenne muscular dystrophy,Designated/Approved,,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping,2/25/2021,2/25/2028,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,2142,United States,690019
DORNASE ALFA,953A26OA1Y,Designated,Public record,5133,dornase alfa,6/4/2019,Treatment of sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"SarcoMed USA, LLC",1300 Post Oak Boulevard,Suite 760,Houston,Texas,77056,United States,616617
FLUBROBENGUANE F-18,8LF7W971UM,Designated,Public record,5134,flubrobenguane (18F),6/4/2019,Diagnostic for the management of neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantheus Medical Imaging, Inc.",331 Treble Cove Road,,North Billerica,Massachusetts,1862,United States,695819
FOSGEMCITABINE PALABENAMIDE,I17GWP65CE,Designated,Public record,5137,fosgemcitabine palabenamide,6/11/2019,Treatment of biliary tract cancer,Designated,Not FDA Approved for Orphan Indication,,,,,NuCana plc,3 Lochside Way,,Edinburgh,Scotland,,United Kingdom,644618
VALILOXYBATE,9B8NWP8K91,Designated,Public record,5140,4-((L-valyl)oxy)butanoic acid,6/12/2019,Treatment of Narcolepsy,Designated,Not FDA Approved for Orphan Indication,,,,,XWPharma Incorporated,"19F-1, No. 99, Sec. 1",Xintai 5th Road,New Taipei City,Xizhi District,,Taiwan,669418
PARSACLISIB,OS7097575K,Designated,Public record,5141,parsaclisib,6/12/2019,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,688519
VENETOCLAX,N54AIC43PW,Designated,Public record,5142,Venetoclax,6/12/2019,Treatment of myelodysplastic syndromes,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,"Dept #PA72, Bldg. AP30-4",North Chicago,Illinois,60064,United States,689119
BALIPODECT,6650W303H0,Designated,Public record,5144,Balipodect,6/13/2019,Treatment of Fragile X Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,689319
VAMIFEPORT HYDROCHLORIDE,9DV8VO33JX,Designated,Public record,5145,"2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride",6/17/2019,Treatment of beta-thalassemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Vifor Pharma, Inc.",200 Cardinal Way,,Redwood City,California,94063,United States,688419
BALIPODECT,6650W303H0,Designated,Public record,5146,Balipodect,6/19/2019,Treatment of CDKL5 deficiency disorder,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,689219
REXLEMESTROCEL-L,4LS0IJZ59V,Designated,Public record,5148,rexlemestrocel-L,6/19/2019,Prevention of post-LVAD (left ventricular assist device) implantation mucosal bleeding,Designated,Not FDA Approved for Orphan Indication,,,,,Mesoblast,505 5th Avenue,3rd Floor,New York,New York,10017,United States,661518
GALLIUM CITRATE,HT6C49L0ZP,Designated,Public record,5150,gallium citrate,6/24/2019,Treatment of lung infections in patients with cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Aridis Pharmaceuticals, Inc.",5941 Optical Court,,San Jose,California,95138,United States,689419
ROPIDOXURIDINE,3HX21A3SQF,Designated,Public record,5151,5-iodo-2-pyrimidinone-2¿deoxyribose,6/25/2019,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Shuttle Pharmaceuticals, LLC",1 Research Court,Suite 450,Rockville,Maryland,20850,United States,690919
BEFOVACIMAB,8FFQ0L4R3B,Designated/Withdrawn,Public record,5153,Human monoclonal IgG2 antibody against tissue factor pathway inhibitor,6/25/2019,Treatment of Hemophilia B,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare LLC,100 Bayer Boulevard,P.O. Box 915,Hanover,New Jersey,7981,United States,685719
LM-030,31I6DBK5RW,Designated,Public record,5154,Kallikrein 7 and elastase 2 inhibitor,6/25/2019,Treatment of Netherton Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"LifeMax Laboratories, Inc.","1731 Embarcadero Road, Suite 200",,Palo Alto,California,94303,United States,695519
MOMETASONE FUROATE,04201GDN4R,Designated,Public record,5155,mometasone furoate,6/26/2019,Treatment of eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,EsoCap AG,Malzgasse 9,,Basel,,,Switzerland,691019
RIOCIGUAT,RU3FE2Y4XI,Designated,Public record,5157,riociguat,6/26/2019,Treatment of Fontan-palliated patients,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Bayer U.S. LLC,100 Bayer Boulevard,P.O. Box 915,Hanover,New Jersey,7981,United States,669718
APILIMOD MESYLATE,5G3P5OK11S,Designated,Public record,5158,apilimod dimesylate,7/1/2019,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"AI Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,6437,United States,691619
ELUVIXTAMAB,6Z4B5PJ4OP,Designated,Public record,5159,bispecific T-cell engager (BiTE) antibody targeting CD33 and CD3,7/1/2019,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 17-1-A,Thousand Oaks,California,91320,United States,691519
REGORAFENIB ANHYDROUS,24T2A1DOYB,Designated,Public record,5161,Regorafenib,7/1/2019,Treatment of glioblastoma multiforme,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P.O. Box 915,Whippany,New Jersey,7981,United States,690619
AFATINIB,41UD74L59M,Designated,Public record,5162,afatinib,7/9/2019,Treatment of pancreatic cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,6877,United States,690419
DURVALUMAB,28X28X9OKV,Designated,Public record,5163,durvalumab,7/10/2019,Treatment of small cell lung cancer,Designated/Approved,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",3/27/2020,3/27/2027,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,19803,United States,691319
LIRENTELIMAB,SWS48LJU3T,Designated,Public record,5165,humanized non-fucosylated anti-Siglec-8 monoclonal antibody (IgG1),7/15/2019,Treatment of Mastocytosis,Designated,Not FDA Approved for Orphan Indication,,,,,Allakos Inc.,"975 Island Drive, Suite 201",,Redwood City,California,94065,United States,693519
ZAMICASTAT,YLU32D0DNV,Designated,Public record,5167,Zamicastat,7/15/2019,Treatment of pulmonary arterial hypertension (PAH) (pulmonary hypertension WHO Group 1),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bial-Portela & Cª., S.A.",À Av. da Siderurgia Nacional,4745-457 S. Mamede do Coronado,Coronado,,,Portugal,693619
Ziftomenib,4MOD1F4ENC,Designated,Public record,5169,"(S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile",7/22/2019,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Kura Oncology,Clinical Development,55 Cambridge Parkway,Cambridge,Massachusetts,2142,United States,697819
ARIPIPRAZOLE,82VFR53I78,Designated,Public record,5171,Aripiprazole,7/22/2019,Treatment of N-glycanase 1 (NGLY1) deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Perlara PBC,"2625 Alcatraz Ave, #435",,Berkeley,California,94705,United States,694219
ARTESUNATE,60W3249T9M,Designated,Public record,5172,artesunate,7/22/2019,Treatment of malaria,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceutical Company,4550 Towne Centre Court,,"San Diego,",California,92121,United States,693719
CONCIZUMAB,68603V9EAF,Designated,Public record,5174,concizumab,7/22/2019,Treatment of hemophilia B,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",P.O Box 846,,Plainsboro,New Jersey,8536,United States,663618
DAZCAPISTAT,AX895U92WU,Designated,Public record,5176,"N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyloxazole-5-carboxamide",7/22/2019,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Blade Therapeutics, Inc.",442 Littlefield Avenue,,South San Francisco,California,94080,United States,698719
POZELIMAB,0JJ21K6L2I,Designated,Public record,5177,pozelimab,7/22/2019,Treatment of Paroxysmal Nocturnal Hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc,777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,660518
LATOZINEMAB,IKT0XSS2XB,Designated,Public record,5178,"recombinant human anti-human sortilin (SORT1) IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody",7/22/2019,Treatment of Frontotemporal Dementia,Designated,Not FDA Approved for Orphan Indication,,,,,"Alector, Inc.","151 Oyster Point Boulevard, Suite 300",,South San Francisco,California,94080,United States,680219
Mavodelpar sodium,XRP79L5C2X,Designated,Public record,5179,Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop-1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate,7/22/2019,Treatment of fatty acid oxidation disorders,Designated,Not FDA Approved for Orphan Indication,,,,,Reneo Pharma Ltd,"Innovation House, Office 12B","Discovery Park, Ramsgate Road",Sandwich,Kent,,United Kingdom,693819
AFLIBERCEPT,15C2VL427D,Designated,Public record,5181,aflibercept,7/23/2019,Treatment of Retinopathy of Prematurity,Designated/Approved,,treatment of retinopathy of prematurity (ROP),2/8/2023,2/8/2030,treatment of retinopathy of prematurity (ROP),"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,694319
LOCNARTECAN,56DL1J49LR,Designated,Public record,5183,"(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl)ethyl)piperidine-1-carboxylate",7/24/2019,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Tarveda Therapeutics, Inc.",134 Coolidge Ave.,,Watertown,Massachusetts,2472,United States,694919
TOPOTECAN,7M7YKX2N15,Designated,Public record,5184,Episcleral Topotecan,7/24/2019,Treatment of retinoblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Targeted Therapy Technologies, LLC., DBA: 3T Ophthalmics",3972 Barranca Parkway,Suite J-185,Irvine,California,92606,United States,694519
ELAFIBRANOR,2J3H5C81A5,Designated,Public record,5185,elafibranor,7/25/2019,Treatment of Primary Biliary Cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,Ipsen Bioscience Inc.,"One Main Street, 7th Floor",,Cambridge,Massachusetts,2142,United States,693919
HEPARIN SODIUM,ZZ45AB24CA,Designated,Public record,5186,heparin sodium,7/29/2019,Treatment of Cystic Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vectura Limited,One Prospect West,Chippenham,Wiltshire,,,United Kingdom,694019
OXYBATE,30IW36W5B2,Designated,Public record,5187,"calcium, magnesium, potassium, and sodium oxybates",7/31/2019,Treatment of idiopathic hypersomnia,Designated/Approved,,Treatment of idiopathic hypersomnia (IH) in adults,8/12/2021,8/12/2028,Treatment of idiopathic hypersomnia (IH) in adults,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin,,,Ireland,694619
SINBAGLUSTAT,T5Y7NB5M2U,Designated,Public record,5188,"(2S,3R,4R,5S)-2-(hydroxymethyl)-1-pentylpiperidine-3,4,5-triol",8/1/2019,Treatment of GM2 gangliosidosis,Designated,Not FDA Approved for Orphan Indication,,,,,Idorsia Pharmaceuticals Ltd,91 Hegenheimermattweg,,Allschwil,Basel-Landschaft,,Switzerland,701719
AB-8939,REU6L9A46J,Designated,Public record,5189,1-{4-[2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl]-phenyl}-imidazolidin-2-one,8/1/2019,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue George V",,Paris,,,France,695919
LERIGLITAZONE,K824X25AYA,Designated,Public record,5190,leriglitazone,8/1/2019,Treatment of Friedreich´s ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,Minoryx Therapeutics S.L.,TecnoCampus Mataro-Maresme. TCM3 602,"Av. Ernest Lluch, 32.",Mataró,Catalunya,,Spain,700919
TEMOZOLOMIDE,YF1K15M17Y,Designated,Public record,5191,Temozolomide,8/1/2019,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,ORPHELIA Pharma,85 Blvd Saint-Michel,,Paris,,,France,698519
BERSIPOROCIN HYDROCHLORIDE,Q1X50E5QJL,Designated,Public record,5192,"(2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol Hydrogen Chloride",8/5/2019,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Daewoong Pharmaceutical Co., Ltd.","12, Bongeunsa-ro 114 gil",Gangnam-gu,Seoul,Korea,,South Korea,701419
FIDRISERTIB SESQUISUCCINATE,WU1JNY62EH,Designated,Public record,5195,"(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl)pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate",8/8/2019,Treatment of fibrodysplasia ossificans progressiva,Designated,Not FDA Approved for Orphan Indication,,,,,"Clementia Pharmaceuticals, Inc.","1000 De La Gauchetiere West, Suite 1200",,Montreal,,,Canada,698319
PPI-1040,5J560A5O35,Designated,Public record,5196,"1-(((Z)-hexadec-1-en-1-yl)oxy)-3-((2-oxido-1,3,2-oxazaphospholidin-2-yl)oxy)propan-2-yl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate",8/8/2019,Treatment of Rhizomelic Chondrodysplasia Punctata,Designated,Not FDA Approved for Orphan Indication,,,,,"Med-Life Discoveries, LP",407-15 Innovation Boulevard,,Saskatoon,,,Canada,696219
CLAZAKIZUMAB,4S38Z8RA9O,Designated,Public record,5198,clazakizumab,8/8/2019,Treatment of chronic antibody-mediated rejection in kidney transplant recipients,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,19406,United States,612317
PERFLUBRON,Q1D0Q7R4D9,Designated,Public record,5200,perfluorooctyl-bromide,8/8/2019,Treatment of congenital pulmonary hypoplasia in infancy,Designated,Not FDA Approved for Orphan Indication,,,,,Children’s Hospital of Pennsylvania,Clinical Research Support,"Colket Translational Research Building, 11th Floor, Room 11101",Philadelphia,Pennsylvania,19104,United States,630718
SARGRAMOSTIM,5TAA004E22,Designated,Public record,5201,sargramostim,8/8/2019,Treatment of Stage IIb-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.",19 Muzzey Street,,Lexington,Massachusetts,2421,United States,674618
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5202,cannabidiol,8/15/2019,Treatment of childhood absence epilepsy,Designated,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",950 Winter Street,,Waltham,Massachusetts,2451,United States,696519
M-(18F)-FLUOROBENZYLGUANIDINE,CD7WXM716P,Designated,Public record,5206,18F-meta-fluorobenzylguanidine,8/21/2019,Diagnostic for the management of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Illumina Radiopharmaceuticals LLC,175 Elm Road,,Englewood,New Jersey,7631,United States,702419
PRAVIBISMANE,G3T79NDD38,Designated,Public record,5207,"Bismuth-1,2-ethanedithiol; 1,2-Bis-((1,3-dithia-2-bismolan)-2-yl) thioethane",8/21/2019,Treatment (management) of pulmonary infections in patients with Cystic Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Microbion Corporation,1102 West Babcock Street,Suite B,Bozeman,Montana,59715,United States,621817
DECITABINE,776B62CQ27,Designated,Public record,5208,cedazuridine and decitabine,8/21/2019,Treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia),Designated/Approved,,"Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed",7/7/2020,7/7/2027,"Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed","Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,94588,United States,697019
CEDAZURIDINE,39IS23Q1EW,Designated,Public record,5208,cedazuridine and decitabine,8/21/2019,Treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia),Designated/Approved,,"Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed",7/7/2020,7/7/2027,"Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed","Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,94588,United States,697019
DUPILUMAB,420K487FSG,Designated,Public record,5210,dupilumab,8/21/2019,Treatment of bullous pemphigoid,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,697319
PEMIGATINIB,Y6BX7BL23K,Designated,Public record,5211,pemigatinib,8/21/2019,"Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2",Designated/Approved,,Treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement,8/26/2022,8/26/2029,Treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,696419
ROMILKIMAB,O8HNJ174XS,Designated,Public record,5212,Romilkimab,8/21/2019,Treatment of systemic sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Sanofi U.S. Service Inc.,55 Corporate Drive,Mail Stop: 55C-300,Bridgewater,New Jersey,8807,United States,629518
MURIZATOCLAX,BO0V7196L2,Designated,Public record,5213,small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL1),8/21/2019,Treatment of Multiple Myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,,United States,698019
TALABOSTAT,KZ1O2SH88Z,Designated,Public record,5214,Talabostat,8/21/2019,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"BioXcel Therapeutics, Inc.",555 Long Wharf Drive,5th Floor,New Haven,Connecticut,6511,United States,697119
ASC-JM-17,5VLL140BN9,Designated,Public record,5215,"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",8/23/2019,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Allianz Pharmascience Limited,"7F-2, No. 77, Section 2, Duan Hua",,South Road,Taipei,,Taiwan,704319
PROPRANOLOL,9Y8NXQ24VQ,Designated,Public record,5216,Propranolol,8/23/2019,Treatment of retinopathy of prematurity,Designated,Not FDA Approved for Orphan Indication,,,,,"Recordati Rare Diseases, SARL","Immeuble le ""Wilson""",70 Avenue du General de Gaulle,Puteaux,,,France,703319
IVALTINOSTAT PHOSPHATE,QA3Y8EZG57,Designated,Public record,5217,(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate,8/26/2019,Treatment of Pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"CG Pharmaceuticals, Inc.","100-D, Bldg. D, Pine Grove Business Center",4 Orinda Way,Orinda,California,94563,United States,699019
BENRALIZUMAB,71492GE1FX,Designated,Public record,5218,benralizumab,8/26/2019,Treatment of eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,19803,United States,670018
NERATINIB,JJH94R3PWB,Designated,Public record,5219,neratinib,8/26/2019,Treatment of breast cancer patients with brain metastases,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Puma Biotechnology Inc.,"10880 Wilshire Blvd., Suite 2150",,Los Angeles,California,90024,United States,699119
SIROLIMUS,W36ZG6FT64,Designated,Public record,5220,sirolimus,8/26/2019,Treatment of tuberous sclerosis complex,Designated,Not FDA Approved for Orphan Indication,,,,,"AI Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,6437,United States,698619
ZILUCOPLAN,YG391PK0CC,Designated,Public record,5222,Zilucoplan,8/26/2019,Treatment of myasthenia gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"Ra Pharmaceuticals, Inc.",87 Cambridge Park Drive,,Cambridge,Massachusetts,2140,United States,699319
ALNUCTAMAB,7OSV6M6T4D,Designated,Public record,5223,"An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody",8/28/2019,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,CELGENE INTERNATIONAL II SARL,c/o Celgene Corporation,86 Morris Avenue,Summit,New Jersey,7901,United States,698119
NOMACOPAN,79V7Q9VIWQ,Designated,Public record,5226,nomacopan,8/28/2019,Treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc,24 West 40th Street,8th Floor,New York,New York,10018,United States,698219
FASUDIL,Q0CH43PGXS,Designated,Public record,5227,fasudil,9/5/2019,Treatment of subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,"Aneuryst, Inc.",211 East 43rd Street,Suite 710,New York,New York,,United States,700019
SOTATERCEPT,0QI90BTJ37,Designated,Public record,5229,sotatercept,9/5/2019,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.",126 East Lincoln Avenue,P.O. Box 2000,Rahway,New Jersey,7065,United States,700219
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,5231,"drug component, inhaled nitric oxide, of the inhaled nitric oxice/INOpulse® Device combination product",9/10/2019,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Bellerophon Therapeutics,184 Liberty Corner Road,Suite 302,Warren,New Jersey,7059,United States,621517
TRIBENZOIN,3LZY0X529Y,Designated,Public record,5232,glycerol tribenzoate,9/10/2019,Treatment of Huntington’s disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Curyx Bio, Inc.",140 E. Ridgewood Avenue,Suite 415 South Tower,Paramus,New Jersey,7652,United States,703419
PARSACLISIB,OS7097575K,Designated,Public record,5233,parsaclisib,9/10/2019,Treatment of splenic marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,688319
QUINACRINE,H0C805XYDE,Designated,Public record,5234,quinacrine,9/10/2019,Treatment of Ebola Infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,27526,United States,701119
ADH-503,THN3VQ67CA,Designated,Public record,5235,"2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate",9/11/2019,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Ategrin, Inc.","c/o 149 Bio, LLC, 1951 NW 7th Ave, Suite 600",,Miami,Florida,33136,United States,701219
GBR-1342,7H3Q0M9END,Designated,Public record,5237,bispecific Antibody simultaneously targeting CD38 and CD3,9/11/2019,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Ichnos Sciences, Inc.",One World Trade Center,"76th Floor, Suite D",New York,New York,10007,United States,700119
EMERFETAMAB,HOG226RYH1,Designated,Public record,5238,bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor,9/11/2019,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 17-1-A,Thousand Oaks,California,91320,United States,655818
INFIGRATINIB,A4055ME1VK,Designated,Public record,5239,infigratinib,9/11/2019,Treatment of cholangiocarcinoma,Designated/Approved,,"Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.",5/28/2021,5/28/2028,"Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.","QED Therapeutics, Inc.",8000 Marina Boulevard,Suite 400,Brisbane,California,94005,United States,707019
CXA-10,1N19AGY57Y,Designated,Public record,5240,10-nitro-9(E)-octadec-9-enoic acid,9/12/2019,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Complexa, Inc.",1055 Westlakes Dr,Suite 200,Berwyn,Pennsylvania,19312,United States,701019
NOMACOPAN,79V7Q9VIWQ,Designated,Public record,5241,nomacopan,9/12/2019,Treatment of bullous pemphigoid,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc,24 West 40th Street,8th Floor,New York,New York,10018,United States,669018
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,5242,tacrolimus,9/12/2019,Prevention of rejection in lung transplantation,Designated/Approved,,"Prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic kidney transplant, liver transplant, heart transplant, or lung transplant in combination with other immunosuppressants",7/16/2021,7/16/2028,Prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic lung transplant,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,701319
LINERIXIBAT,386012Z45S,Designated,Public record,5245,linerixibat,9/18/2019,Treatment of Primary Biliary Cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,1250 South Collegeville Road,"Building 4, Mail Stop 4400",Collegeville,Pennsylvania,19426,United States,701919
SETMELANOTIDE,N7T15V1FUY,Designated,Public record,5246,setmelanotide,9/19/2019,Treatment of Bardet-Biedl syndrome,Designated/Approved,,For chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS),6/16/2022,6/16/2029,For chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS),"Rhythm Pharmaceuticals, Inc.",222 Berkeley Street,Suite 1200,Boston,Massachusetts,2116,United States,700719
ASC-JM-17,5VLL140BN9,Designated,Public record,5247,"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",9/24/2019,Treatment of spinocerebellar ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,AnnJi Pharmaceutical Co. Ltd.,"B405, 4F., No. 18, Siyuan, St.,",Zhongzheng Dist,Taipei City,,10087,Taiwan,701819
CAFLANONE,PH8V5N670E,Designated,Public record,5249,Caflanone,9/25/2019,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Flavocure Biotech,701 East Pratt Street,Suite 2033,Baltimore,Maryland,21202,United States,702719
PARSACLISIB,OS7097575K,Designated,Public record,5250,Parsaclisib,9/25/2019,Treatment of Follicular Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,703919
DUVELISIB,610V23S0JI,Designated,Public record,5251,duvelisib,10/2/2019,Treatment of T-Cell Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Secura Bio, Inc.",1995 Village Center Cir.,,Las Vegas,Nevada,,United States,703019
PHENOBARBITAL,YQE403BP4D,Designated,Public record,5252,phenobarbital sodium,10/2/2019,Treatment of neonatal seizures,Designated/Approved,,treatment of neonatal seizures in term and preterm infants,11/17/2022,11/17/2029,treatment of neonatal seizures in term and preterm infants,Sun Pharma Advanced Research Company Ltd.,"17/B, Mahal Industrial Estate",,Andheri (E),Mumbai,,India,703819
Amphotericin B,7XU7A7DROE,Designated,Public record,5253,Encochleated oral Amphotericin B suspension,10/3/2019,Treatment of cryptococcosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Matinas BioPharma Nanobiotechnologies, Inc.",1545 Route 206 South,Suite 302,Bedminster Township,New Jersey,7921,United States,703119
PARSACLISIB,OS7097575K,Designated,Public record,5255,parsaclisib,10/7/2019,Treatment of nodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,707319
NNZ-2591,2T1HU6069S,Designated,Public record,5256,cyclo(-L-Glycyl-L-2-Allylproline),10/9/2019,Treatment of Angelman syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuren Pharmaceuticals, Ltd.","Ste 201, 697 Burke Rd",,Camberwel,,,Australia,705719
MELATONIN,JL5DK93RCL,Designated,Public record,5257,melatonin,10/9/2019,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,704519
PARSACLISIB,OS7097575K,Designated,Public record,5258,parsaclisib,10/9/2019,Treatment of extranodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,707419
PAZOPANIB,7RN5DR86CK,Designated,Public record,5259,pazopanib,10/9/2019,Treatment of hereditary hemorrhagic telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,HHT Foundation International (d/b/a Cure HHT),8 Henderson Hill Ct,,Monkton,Maryland,21111,United States,705819
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,5260,pembrolizumab,10/9/2019,Treatment of Biliary Tract Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme, LLC",126 East Lincoln Avenue,P.O. Box 2000,Rahway,New Jersey,7065,United States,705319
LOCNARTECAN,56DL1J49LR,Designated,Public record,5261,"(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl)ethyl)piperidine-1-carboxylate",10/10/2019,Treatment of Small Cell Lung Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Tarveda Therapeutics, Inc.",134 Coolidge Ave.,,Watertown,Massachusetts,2472,United States,713419
NNZ-2591,2T1HU6069S,Designated,Public record,5262,Cyclo(-L-Glycyl-L-2-Allylproline),10/15/2019,Treatment of Pitt-Hopkins Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuren Pharmaceuticals, Ltd.","Ste 201, 697 Burke Rd",,Camberwel,,,Australia,706119
NNZ-2591,2T1HU6069S,Designated,Public record,5263,Cyclo(-L-Glycyl-L-2-Allylproline),10/15/2019,Treatment of Phelan-McDermid syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuren Pharmaceuticals, Ltd.","Ste 201, 697 Burke Rd",,Camberwel,,,Australia,706019
TRIBENZOIN,3LZY0X529Y,Designated,Public record,5264,glyceryl tribenzoate,10/15/2019,Treatment of nonketotic hyperglycinemia,Designated,Not FDA Approved for Orphan Indication,,,,,Liberyx Therapeutics Limited,"Unit 805, 8/F Mirror Tower","61 Mody Road, Tsim Sha Tsui",Kowloon,,,Hong Kong,705019
ABBV-383,CO86AOP337,Designated,Public record,5265,CD3 and B-cell maturation antigen T-cell engaging bispecific antibody,10/17/2019,Treatment of Multiple Myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"TeneoOne, Inc.",1 North Waukegan Road,,North Chicago,Illinois,60064,United States,706319
CRENOLANIB,LQF7I567TQ,Designated,Public record,5268,crenolanib,10/21/2019,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,Not FDA Approved for Orphan Indication,,,,,"AROG Pharmaceuticals, Inc.","5420 LBJ Freeway, Suite 410",,Dallas,Texas,75240,United States,706819
PYRONARIDINE,TD3P7Q3SG6,Designated,Public record,5269,Pyronaridine,10/21/2019,Treatment of Chagas Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,27526,United States,696919
EFLEPEDOCOKIN ALFA,ZQ9E6EX2JE,Designated,Public record,5271,recombinant human interleukin 22-human immunoglobulin Fc fusion protein,10/21/2019,Treatment of acute graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,Generon (Shanghai) Corporation Ltd.,"Building 9, 787 Kangqiao Road",,Pudong Xinqu,Shanghai Shi,,China,581117
BUTYRIC ACID,40UIR9Q29H,Designated,Public record,5272,"acetic acid, propionic acid, and butyric acid",10/22/2019,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"SFA Therapeutics, Inc.","610 Old York Rd, Suite 400",,Jenkintown,Pennsylvania,19046,United States,706219
Propionic acid,JHU490RVYR,Designated,Public record,5272,"acetic acid, propionic acid, and butyric acid",10/22/2019,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"SFA Therapeutics, Inc.","610 Old York Rd, Suite 400",,Jenkintown,Pennsylvania,19046,United States,706219
Acetic acid,Q40Q9N063P,Designated,Public record,5272,"acetic acid, propionic acid, and butyric acid",10/22/2019,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"SFA Therapeutics, Inc.","610 Old York Rd, Suite 400",,Jenkintown,Pennsylvania,19046,United States,706219
.ALPHA.1-PROTEINASE INHIBITOR HUMAN,F43I396OIS,Designated,Public record,5273,Human Alpha1-proteinase inhibitor,10/22/2019,Treatment of graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,708519
PANOBINOSTAT,9647FM7Y3Z,Designated,Public record,5274,hydroxypropyl-B-cyclodextrin-panobinostat complex,10/22/2019,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Midatech Ltd.,Oddfellows House,19 Newport Road,Cardiff,,,United Kingdom,705919
ZALSENERTANT TETRAXETAN LUTETIUM LU-177,WH9EXQ390Z,Designated,Public record,5275,"Lu-177(3+),2-[[5-(2,6-dimethoxyphenyl)-1-[2-isopropyl-4-[methyl-[3-[methyl-[3-[methyl-[2-[4,7,10- tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propyl]amino]propyl]carbamoyl]phenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid",10/28/2019,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Fusion Pharmaceuticals Inc.,"Two International Place, Ste 2310",,Boston,Massachusetts,2110,United States,708119
IMIQUIMOD,P1QW714R7M,Designated,Public record,5276,monobenzone and imiquimod,10/28/2019,Treatment of stage IIB-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Learmont Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,707519
MONOBENZONE,9L2KA76MG5,Designated,Public record,5276,monobenzone and imiquimod,10/28/2019,Treatment of stage IIB-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Learmont Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,707519
LIRENTELIMAB,SWS48LJU3T,Designated,Public record,5278,"Recombinant humanized, non-fucosylated IgG1 anti-Siglec-8 monoclonal antibody",10/30/2019,Treatment of eosinophilic esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Allakos, Inc.",75 Shoreway Road,Suite A,San Carlos,California,94070,United States,668818
SELPERCATINIB,CEGM9YBNGD,Designated,Public record,5279,selpercatinib,10/30/2019,Treatment of RET-fusion-positive non-small cell lung cancer,Designated/Approved,,RETEVMO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC),5/8/2020,5/8/2027,For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC),Loxo Oncolocy at Lilly,"701 Gateway Boulevard, Suite 420",,South San Francisco,California,94080,United States,675218
SELPERCATINIB,CEGM9YBNGD,Designated,Public record,5280,selpercatinib,10/30/2019,Treatment of RET-fusion-positive non-small cell lung cancer,Designated/Approved,,"Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test",9/21/2022,9/21/2029,"treatment of adult patients with locally advanced non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test","Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company","701 Gateway Boulevard, Suite 420",,South San Francisco,California,94080,United States,675218
SRX-246,372X2P22UY,Designated,Public record,5281,vasopressin 1a receptor antagonist,10/30/2019,Treatment of Huntington's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Azevan Pharmaceuticals, Inc.",116 Research Drive,,Bethlehem,Pennsylvania,18015,United States,532016
Tinengotinib,WZ9TJ0L9Y8,Designated,Public record,5283,"4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b] pyrido[4,3-e][1,4]diazepin-8-yl) morpholine",11/6/2019,treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TransThera Sciences (Nanjing), Inc.","F3, Bld 9, Accelerator Phase 2","Biotech and Pharmaceutical Valley, Jiangbei New Area",Nanjing,,210032,China,711719
TISLELIZUMAB,0KVO411B3N,Designated,Public record,5285,Tislelizumab,11/6/2019,Treatment of Esophageal Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,94403,United States,708919
ALPELISIB,08W5N2C97Q,Designated,Public record,5288,alpelisib,11/18/2019,Treatment of PIK3CA-related overgrowth spectrum,Designated/Approved,,Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy,4/5/2022,4/5/2029,Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,710819
NAVITOCLAX,XKJ5VVK2WD,Designated,Public record,5290,navitoclax,11/18/2019,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,"Dept #PA72, Bldg. AP30-4",North Chicago,Illinois,60064,United States,709319
PELABRESIB,306QR91I9R,Designated,Public record,5291,"2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate",11/20/2019,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Constellation Pharmaceuticals,"215 First Street, Suite 200",,Cambridge,Massachusetts,2142,United States,710219
ATELOCOLLAGEN,8WBS95X4J5,Designated,Public record,5292,Purified bovine Type V Collagen,11/20/2019,Prevention of Primary Graft Dysfunction in Lung Transplant Patients.,Designated,Not FDA Approved for Orphan Indication,,,,,Magnolia Therapeutics LLC,"605 Crescent Blvd., Suite 200",,Ridgeland,Mississippi,39157,United States,710119
TISLELIZUMAB,0KVO411B3N,Designated,Public record,5293,Tislelizumab,11/20/2019,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,709919
SELPERCATINIB,CEGM9YBNGD,Designated,Public record,5295,selpercatinib,11/21/2019,"Treatment of RET fusion-positive or RET mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid canc",Designated/Approved,,RETEVMO is indicated for the treatment of: ¿ Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; ¿ Adult and pediatric patients 12 years of age and olde,5/8/2020,5/8/2027,"For the treatment of: adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and, adult and pediatric patients 12 years of age and older with advanced or m",Loxo Oncolocy at Lilly,"701 Gateway Boulevard, Suite 420",,South San Francisco,California,94080,United States,653118
SURUFATINIB,B2K5L1L8S9,Designated,Public record,5296,surufatinib,11/21/2019,Treatment of pancreatic neuroendocrine tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Hutchison MediPharma Ltd.,"Building 4, 720 Cailun Road",Zhangjiang Hi-Tech Park,Shanghai,,,China,710319
ZOTIRACICLIB,40D08182TT,Designated,Public record,5297,zotiraciclib,11/21/2019,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cothera Bioscience, Inc.","2929 Campus Drive, Suite 230",,San Mateo,California,94403,United States,710719
DALFAMPRIDINE,BH3B64OKL9,Designated,Public record,5298,dalfampridine,11/25/2019,Treatment of Transverse Myelitis,Designated,Not FDA Approved for Orphan Indication,,,,,Magnum Therapeutics,243 W. 259th Street,,Riverdale,New York,10471,United States,713019
BF-844,AW4QOD73S3,Designated,Public record,5299,"1-(4-Chloro-3,5-diphenyl-pyrazolo[3,4-c]pyridazin-1-yl)-2-methyl-propan-2-ol",11/26/2019,Treatment of Usher syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Usher III Initiative, Inc.","191 N. Wacker Dr., Suite 1790",,Chicago,Illinois,60606,United States,711419
HYPOCHLOROUS ACID,712K4CDC10,Designated,Public record,5301,"Hypotonic, acid oxidizing solution containing hypochlorous acid (HClO)",11/26/2019,Treatment of Epidermolysis Bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,APR Applied Pharma Research s.a.,Via Corti 5,,Balerna,,,Switzerland,711819
NICARDIPINE,CZ5312222S,Designated,Public record,5302,nicardipine,11/26/2019,Treatment of Pitt-Hopkins Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,27526,United States,712819
APVO-436,DNP8BBW84R,Designated,Public record,5304,Recombinant Bispecific antibody targeting CD123 and CD3,11/26/2019,Treatment of acute myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Aptevo Research and Development,2401 Fourth Avenue,Suite 1050,Seattle,Washington,98121,United States,711019
DRONABINOL,7J8897W37S,Designated,Public record,5305,delta-9-tetrahydrocannabinol,11/27/2019,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,,Canada,652218
ROMIPLOSTIM,GN5XU2DXKV,Designated,Public record,5307,Romiplostim,11/27/2019,Treatment of aplastic anemia,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,91320,United States,712019
BRIVARACETAM,U863JGG2IA,Designated,Public record,5308,brivaracetam,12/3/2019,Treatment of Juvenile Absence Epilepsy,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive,Building 2100,Smyrna,Georgia,30080,United States,724019
BRIVARACETAM,U863JGG2IA,Designated,Public record,5309,brivaracetam,12/3/2019,Treatment of Childhood Absence Epilepsy,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive,Building 2100,Smyrna,Georgia,30080,United States,711119
NANDROLONE,6PG9VR430D,Designated,Public record,5310,nandrolone,12/4/2019,Treatment of limb-girdle muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,25 Störtloppsvägen,,Hägersten-Liljeholmen,Stockholms län,,Sweden,712219
NIPOCALIMAB,87M90CV8NC,Designated,Public record,5311,nipocalimab,12/5/2019,Treatment of autoimmune hemolytic anemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.",301 Binney Street,,Cambridge,Massachusetts,2142,United States,711519
RELDESEMTIV,4S0HBYW6QE,Designated,Public record,5315,Reldesemtiv,12/11/2019,Treatment of Amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Cytokinetics, Inc.",280 East Grand Avenue,,South San Francisco,California,94080,United States,712519
DANTROLENE,F64QU97QCR,Designated,Public record,5316,dantrolene,12/12/2019,Treatment of organophosphate exposure,Designated,Not FDA Approved for Orphan Indication,,,,,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,7677,United States,713319
PIOGLITAZONE,X4OV71U42S,Designated,Public record,5317,pioglitazone,12/12/2019,Treatment of sudden sensorineural hearing loss,Designated,Not FDA Approved for Orphan Indication,,,,,Strekin AG,60C Hochbergerstrasse,,Basel,Basel-Stadt,,Switzerland,583017
SALINOMYCIN,62UXS86T64,Designated,Public record,5318,Salinomycin,12/12/2019,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Hillstream Biopharma, Inc.",245 Main Street,Suite 204,Chester,New Jersey,7930,United States,713219
MOBOCERTINIB,39HBQ4A67L,Designated,Public record,5319,mobocertinib,12/17/2019,"Treatment of non-small cell lung cancer with genetic alterations in EGFR including EGFR mutations and/or EGFR gene amplifications, HER2 mutations, or BRAF G466V mutations",Designated/Approved,,"Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after plat",9/15/2021,9/15/2028,"Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after plat","Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,653018
ZANIDATAMAB,Z20OC92TDI,Designated,Public record,5322,"humanized, bispecific IgG1-like antibody directed against HER2",12/18/2019,Treatment of Biliary Tract Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Zymeworks Inc.,"1385 West 8th Street, Suite 540",,Vancouver,BC,,Canada,715119
MAGROLIMAB,90YIEHRFJ9,Designated,Public record,5323,Magrolimab,12/18/2019,Treatment of Myelodysplastic Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,716319
AVATROMBOPAG MALEATE,GDW7M2P1IS,Designated,Public record,5324,avatrombopag maleate,12/19/2019,Treatment of chemotherapy-induced thrombocytopenia,Designated,Not FDA Approved for Orphan Indication,,,,,"Sobi, Inc.",240 Leigh Farm Road,Suite 245,Durham,North Carolina,27707,United States,699419
IOPOFOSINE I-131,R048696O9L,Designated,Public record,5327,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,12/23/2019,Treatment of Lymphoplasmacytic Lymphoma/Waldenstrom macroglobulinemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.","100 Campus Drive, Suite 207",,Florham Park,New Jersey,7932,United States,716119
MP-0250,UGI01OSA4N,Designated,Public record,5328,"Anti-vascular endothelial growth factor, anti-hepatocyte growth factor Designed Ankyrin Repeat Protein",12/23/2019,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Molecular Partners AG,Wagistrasse 14,,Zürich,Schlieren,,Switzerland,716519
MAFTIVIMAB,KOP95331M4,Designated,Public record,5329,"atoltivimab, odesivimab and maftivimab",12/23/2019,Post-exposure prophylaxis against Ebola virus infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,714619
ATOLTIVIMAB,FJZ07Q63VY,Designated,Public record,5329,"atoltivimab, odesivimab and maftivimab",12/23/2019,Post-exposure prophylaxis against Ebola virus infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,714619
ODESIVIMAB,UY9LQ8P6HW,Designated,Public record,5329,"atoltivimab, odesivimab and maftivimab",12/23/2019,Post-exposure prophylaxis against Ebola virus infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,714619
MYCOBACTERIUM VACCAE,I639ME27W5,Designated,Public record,5331,Mycobacterium vaccae,12/23/2019,Treatment of Tuberculosis,Designated,Not FDA Approved for Orphan Indication,,,,,Immunitor Inc.,365-2912 West Broadway,,Vancouver,,,Canada,714519
UPADACITINIB,4RA0KN46E0,Designated,Public record,5334,upadacitinib,12/30/2019,Treatment of pediatric ulcerative colitis,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie,1 North Waukegan Road,,North Chicago,Illinois,60044,United States,524116
CIPROFLOXACIN,5E8K9I0O4U,Designated,Public record,5337,fixed-dose combination of celecoxib and ciprofloxacin.,1/8/2020,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,NeuroSense Therapeutics,85 Medinat Ha-Yehudim,,Herzliya,,,Israel,718519
CELECOXIB,JCX84Q7J1L,Designated,Public record,5337,fixed-dose combination of celecoxib and ciprofloxacin.,1/8/2020,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,NeuroSense Therapeutics,85 Medinat Ha-Yehudim,,Herzliya,,,Israel,718519
BMX-001,MIJ02RO47F,Designated,Public record,5338,Manganese butoxyethyl pyridyl porphyrin,1/9/2020,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"BioMimetix JV, LLC",5340 South Quebec Street,Suite 345N,Greenwood Village,Colorado,80111,United States,717419
Rifaquizinone,W2P7EF7O6O,Designated,Public record,5340,(R)-3-[(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-ylimino)-methylenyl]-rifamycin,1/14/2020,Treatment of prosthetic joint infection,Designated,Not FDA Approved for Orphan Indication,,,,,TenNor Therapeutics Limited,"218 Xinghu Street, Building B2, Suite 711",Suzhou Industrial Park,Suzhou,,,China,704419
"""5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE""",X4D0G881CN,Designated,Public record,5341,"5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",1/14/2020,Treatment of sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,Molecure S.A. (previously OncoArendi S.A.),"101 Zwirki i Wigury street,",,Warsaw,,,Poland,706419
DURVALUMAB,28X28X9OKV,Designated,Public record,5344,durvalumab,1/15/2020,Treatment of hepatocellular carcinoma,Designated/Approved,,In combination with tremelimumab-actl for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),10/21/2022,10/21/2029,treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,19803,United States,721519
FASUDIL,Q0CH43PGXS,Designated,Public record,5345,Fasudil,1/15/2020,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,719119
Olorofim,T34SH2H9HI,Designated,Public record,5347,Olorofim,1/15/2020,Treatment of lomentospora/scedosporium infections,Designated,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way,Eccles,Manchester,,,United Kingdom,704219
TREMELIMUMAB,QEN1X95CIX,Designated,Public record,5348,tremelimumab-actl,1/15/2020,Treatment of hepatocellular carcinoma,Designated/Approved,,In combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),10/21/2022,10/21/2029,treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,19803,United States,721419
ENVAFOLIMAB,ES1M06M6QH,Designated,Public record,5351,Envafolimab,1/16/2020,Treatment of biliary tract cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"3D Medicines (Sichuan) Co., Ltd","64-66, Jiaogui Second Lane, Jinniu District",,Chengdu,Sichuan,,China,718819
LUSPATERCEPT,AQK7UBA1LS,Designated,Public record,5352,luspatercept,1/16/2020,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,718419
Olorofim,T34SH2H9HI,Designated,Public record,5353,olorofim,1/16/2020,Treatment of invasive aspergillosis,Designated,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way,Eccles,Manchester,,,United Kingdom,702219
MELATONIN,JL5DK93RCL,Designated,Public record,5354,Melatonin,1/22/2020,Treatment of primary intracerebral hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,719519
EMVODODSTAT,053QD2I96A,Designated,Public record,5356,"(1S)-6-chloro-1,3,4,9-tetrahydro-1-(4-methoxyphenyl)-2H-pyrido[3,4-b]indole-2-carboxylic acid, 4-chlorophenyl ester",1/27/2020,Treatment of Acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,720919
LOSMAPIMOD,F2DQF16BXE,Designated,Public record,5358,losmapimod,1/27/2020,Treatment of Facioscapulohumeral muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Fulcrum Therapeutics, Inc.",26 Landsdowne Street,5th Floor,Cambridge,Massachusetts,2139,United States,721919
ZIRITAXESTAT,I02418V13W,Designated,Public record,5361,Ziritaxestat,1/27/2020,Treatment of systemic sclerosis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Galapagos NV,Generaal De Wittelaan,L11 A3,Mechelen,,,Belgium,723919
DEULINOLEATE ETHYL,24B102R86P,Designated,Public record,5363,di-deuterated linoleic acid,1/28/2020,Treatment of Progressive Supranuclear Palsy,Designated,Not FDA Approved for Orphan Indication,,,,,"Retrotope, Inc.",4300 El Camino Real,Suite 201,Los Altos,California,94022,United States,721019
IMMUNE GLOBULIN INTRAVENOUS (HUMAN),,Designated,Public record,5364,Immune Globulin Intravenous (Human),1/28/2020,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,720719
WHARTON JELLY DERIVED UMBILICAL CORD MESENCHYMAL STEM CELLS,3FXW1IW7WT,Designated,Public record,5365,Umbilical Cord Mesenchymal Stem Cells,1/28/2020,Treatment of Huntington’s disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Acen Regenerative Medicine Sci-Tech Co., Ltd.","No.8 Building, No. 14 Jinhui Road, Pingshan District",,Shenzhen,Guangdong,,China,720619
AK-01,1WX8O5XV4R,Designated,Public record,5366,"(2R,4R)-1-(3-chloro-2-fluorobenzyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid; 2- methylpropan-2-amine",1/29/2020,Treatment of Neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,724119
Pegtarazimod,7AUD376O4W,Designated,Public record,5367,Peptide Inhibitor of Complement C1,1/29/2020,Treatment of neonatal hypoxic-ischemic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"ReAlta Life Sciences, Inc.","4211 Monarch Way, Suite 102",,Norfolk,Virginia,23508,United States,722719
ST-101 (D-AMINO ACID PEPTIDE),CT77XS2YLT,Designated,Public record,5370,cell-penetrating CCAAT-enhancer-binding protein ß antagonist,2/5/2020,Treatment of Glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Sapience Therapeutics, Inc",500 Mamaroneck Avenue,Suite 320,Harrison,New York,10528,United States,723419
Progerinin,426P9HSR8I,Designated,Public record,5371,Progerinin,2/5/2020,Treatment of Werner syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"PRG S&T Co., Ltd.",306 Hyowon Industry-Cooperation Bldg.,Pusan National University,Geumjeong-gu,Busan,,South Korea,661818
PROGRANULIN,T2LF50ID3Y,Designated,Public record,5373,Progranulin,2/10/2020,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Alpha Cognition, Inc.",439 Helmcken Street,,Vancouver,BC,,Canada,725319
PYRONARIDINE TETRAPHOSPHATE,2T289F9ACO,Designated,Public record,5374,Pyronaridine tetraphosphate,2/11/2020,Treatment of Malaria,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,27526,United States,723819
UNESBULIN,Z4HZ70S62Q,Designated,Public record,5375,"5-fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazole-1-yl)-N4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine",2/13/2020,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,724319
TAGITANLIMAB,GUY458P83P,Designated,Public record,5376,A recombinant humanized IgG1 monoclonal antibody targeting programmed death-ligand 1,2/13/2020,Treatment of Nasopharyngeal carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Harbour BioMed US, Inc.","1 Broadway, 14th Floor, Cambridge, MA, 02142",,Cambridge,Massachusetts,2142,United States,723119
FUSIDATE SODIUM,J7P3696BCQ,Designated,Public record,5377,sodium fusidate,2/13/2020,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Aceragen, Inc.",15 TW Alexander Drive,,Durham,North Carolina,27709,United States,723519
ETAVOPIVAT,V4E0A9M44Q,Designated,Public record,5378,etavopivat,2/19/2020,Treatment of Sickle Cell Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"FORMA Therapeutics, Inc.",300 North Beacon Street,Suite 501,Watertown,Massachusetts,2472,United States,728919
SEPIAPTERIN,CJQ26KO7HP,Designated,Public record,5380,sepiapterin,2/19/2020,Treatment of primary tetrahydrobiopterin deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc. (PTC)","65 William Street, Suite 200",,Wellesley,Massachusetts,2481,United States,729519
PHENOBARBITAL,YQE403BP4D,Designated,Public record,5386,Phenobarbital,2/26/2020,Treatment of Neonatal seizures,Designated,Not FDA Approved for Orphan Indication,,,,,Accord Healthcare Inc.,"1009 Slater Road, Suite 210-B",,Durham,North Carolina,27703,United States,725519
PHENOBARBITAL SODIUM,SW9M9BB5K3,Designated,Public record,5387,phenobarbital sodium,2/26/2020,Treatment of status epilepticus,Designated,Not FDA Approved for Orphan Indication,,,,,Accord Healthcare Inc.,"1009 Slater Road, Suite 210-B",,Durham,North Carolina,27703,United States,725419
PHENOBARBITAL SODIUM,SW9M9BB5K3,Designated,Public record,5389,phenobarbital sodium,2/27/2020,Treatment of neonatal seizures,Designated,Not FDA Approved for Orphan Indication,,,,,"Nivagen Pharmaceuticals, Inc.","3050 Fite Circle, Suite 100",,Sacramento,California,95827,United States,725819
EFOCIPEGTRUTIDE,TUI1MDD9F6,Designated,Public record,5391,Glucagon-like peptide-1/Glucagon/Gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment,3/4/2020,Treatment of primary sclerosing cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Company, Ltd.","14, Wiryeseong-daero",,Seoul,Songpa-gu,,South Korea,728019
SETMELANOTIDE,N7T15V1FUY,Designated,Public record,5393,setmelanotide,3/4/2020,Treatment of Alstrom syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Rhythm Pharmaceuticals, Inc",222 Berkeley Street,Suite 1200,Boston,Massachusetts,2116,United States,726419
UMBRALISIB,38073MQB2A,Designated,Public record,5394,umbralisib,3/4/2020,Treatment of Follicular Lymphoma,Designated/Approved,,Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy (Indication withdrawn),"TG Therapeutics, Inc.",3020 Carrington Mill Blvd. Suite 475,,Morrisville,North Carolina,27560,United States,726819
EFOCIPEGTRUTIDE,TUI1MDD9F6,Designated,Public record,5397,Glucagon-like peptide-1/Glucagon/Gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment,3/9/2020,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Company, Ltd.","14, Wiryeseong-daero",,Seoul,Songpa-gu,,South Korea,727919
SOTIGALIMAB,JEA93WJ5DG,Designated,Public record,5398,humanized immunoglobulin (Ig)G1k-agonistic monoclonal antibody (mAb) that binds to CD40,3/9/2020,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Apexigen, Inc.","75 Shoreway Road, Suite C",,San Carlos,California,94070,United States,726619
FOBREPODACIN SODIUM,JX82N6UWU3,Designated,Public record,5400,Sodium (R)-2-(5-(2-(3-ethylureido)-5-fluoro-4-(tetrahydrofuran-2-yl)-1H¿benzo[d]imidazole-6-yl)pyrimidin-2-yl)propan-2-yl hydrogen phosphate,3/9/2020,Treatment of Nontuberculous mycobacteria infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Spero Therapeutics, Inc.","675 Massachusetts Ave., 14th Floor",,Cambridge,Massachusetts,2139,United States,727819
VALPROATE SODIUM,5VOM6GYJ0D,Designated,Public record,5401,sodium valproate,3/9/2020,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Cereno Scientific AB,Pepparedsleden 1,,Mölndal,,,Sweden,729920
Olorofim,T34SH2H9HI,Designated,Public record,5402,olorofim,3/11/2020,Treatment of coccidioidomycosis,Designated,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way,Eccles,Manchester,,,United Kingdom,721719
PIRFENIDONE,D7NLD2JX7U,Designated,Public record,5403,pirfenidone,3/11/2020,Treatment of Unclassifiable-interstitial lung disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., A Member of the Roche Group",1 DNA Way,MS# 355F,South San Francisco,California,94080,United States,727219
HYMECROMONE,3T5NG4Q468,Designated,Public record,5404,4-Methylumbelliferone,3/13/2020,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,732620
ACAZICOLCEPT,W507556HV0,Designated,Public record,5408,Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways,3/16/2020,Treatment of Acute Graft versus Host Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Alpine Immune Sciences,201 Elliott Ave. West,Suite 230,Seattle,Washington,98119,United States,712619
ACAZICOLCEPT,W507556HV0,Designated,Public record,5409,Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways,3/16/2020,Prevention of acute graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,Alpine Immune Sciences,201 Elliott Ave. West,Suite 230,Seattle,Washington,98119,United States,738919
MEXILETINE,1U511HHV4Z,Designated,Public record,5410,mexiletine,3/16/2020,Treatment of myotonic disorders,Designated,Not FDA Approved for Orphan Indication,,,,,Lupin Europe GmbH,Hanauer Landstr. 139 -143,,Frankfurt am Main,,,Germany,728219
ELEZANUMAB,SK1LVT23A1,Designated,Public record,5412,elezanumab,3/17/2020,Treatment of acute spinal cord injury,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60044,United States,729419
COLISTIMETHATE SODIUM,XW0E5YS77G,Designated,Public record,5413,colistimethate sodium,3/19/2020,Treatment of respiratory infection in patients with Cystic Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"EnBiotix, Inc.",197 W. Springfield St.,,Boston,Massachusetts,2118,United States,672418
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated,Public record,5414,axicabtagene ciloleucel,3/23/2020,Treatment of extranodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,90404,United States,735920
Narmafotinib,16T7U12J7U,Designated,Public record,5415,"benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-",3/23/2020,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Amplia Therapeutics,55 Flemington Road,Suite 226,North Melbourne,VIC,,Australia,730620
EFAVALEUKIN ALFA,YNH9K62UXU,Designated,Public record,5416,interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker,3/23/2020,Treatment of Graft-Versus-Host-Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,91320,United States,620217
REMDESIVIR,3QKI37EEHE,Designated/Withdrawn,Public record,5418,remdesivir,3/23/2020,Treatment of coronavirus disease 2019 (COVID-19),Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,739020
AXICABTAGENE CILOLEUCEL,U2I8T43Y7R,Designated,Public record,5419,axicabtagene ciloleucel,3/24/2020,Treatment of nodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,90404,United States,740320
RETIFANLIMAB,2Y3T5IF01Z,Designated,Public record,5420,retifanlimab,3/24/2020,Treatment of anal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,691419
SINTILIMAB,8FU7FQ8UPK,Designated,Public record,5421,sintilimab,3/24/2020,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Innovent Biologics (Suzhou) Co. Ltd,168 Dongping Street,,Suzhou Industrial Park,Jiangsu Province,,China,733120
Sodium nitrite,M0KG633D4F,Designated,Public record,5422,Sodium Nitrite,3/25/2020,Treatment of Sickle Cell Disease,Designated,Not FDA Approved for Orphan Indication,,,,,AdimaBio LLC,19 Garrison Road,,Wellesley,Massachusetts,2482,United States,729719
TORIPALIMAB,8JXN261VVA,Designated,Public record,5424,toripalimab in combination with axitinib,3/25/2020,Treatment of mucosal melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.","9430 Key West Ave, Suite 125",,Rockville,Maryland,20850,United States,730120
AXITINIB,C9LVQ0YUXG,Designated,Public record,5424,toripalimab in combination with axitinib,3/25/2020,Treatment of mucosal melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.","9430 Key West Ave, Suite 125",,Rockville,Maryland,20850,United States,730120
SEL-120,SDM3M518PJ,Designated,Public record,5425,"7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4H-imidazo[4,5,1-ij] quinoline hydrochloride",3/26/2020,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Ryvu Therapeutics S.A.,Bobrzynskiego 14,,Krakow,,,Poland,733220
CERIC OXIDE,619G5K328Y,Designated,Public record,5426,Cerium dioxide nanoparticles,3/26/2020,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Cerion Nanomaterials,1 Blossom Road,,Rochester,New York,14610,United States,731920
EPALRESTAT,424DV0807X,Designated,Public record,5427,epalrestat,3/26/2020,"Treatment of phosphomannomutase-2 deficiency, a congenital disorder of glycosylation",Designated,Not FDA Approved for Orphan Indication,,,,,Maggie's Pearl,903 Independence Street,,Sturgis,Michigan,49091,United States,735820
HYMECROMONE,3T5NG4Q468,Designated,Public record,5428,4-Methylumbelliferone,3/30/2020,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,733820
ANSUVIMAB,TG8IQ19NG2,Designated,Public record,5429,ansuvimab,3/30/2020,Post-exposure prophylaxis against Ebola virus infection,Designated,Not FDA Approved for Orphan Indication,,,,,Emergent Manufacturing Operations Baltimore LLC,5901 East Lombard Street,,Baltimore,Maryland,21224,United States,730820
2-(P-TOLYL)ETHYL NICOTINATE,V94EB48QDC,Designated,Public record,5430,combination of p-Tolylmethylcarbinol nicotinic acid ester and a-naphthylacetic acid,3/30/2020,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,731020
1-NAPHTHALENEACETIC ACID,33T7G7757C,Designated,Public record,5430,combination of p-Tolylmethylcarbinol nicotinic acid ester and a-naphthylacetic acid,3/30/2020,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,731020
AP-001 SODIUM,Q34CI1V0J6,Designated,Public record,5432,"Sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z) 10,17-dihydroxy-docosa-4,7,11,13,15,19-hexaenoate",3/30/2020,Prevention of retinopathy of prematurity,Designated,Not FDA Approved for Orphan Indication,,,,,Anida Pharma Inc.,"155 Brookline Street, Suite 005",,Cambridge,Massachusetts,2139,United States,731720
DOTANOC GALLIUM GA-68,8AHG0Z4Z5M,Designated,Public record,5434,Gallium-68 DOTANOC,4/1/2020,Diagnostic for the management of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",3651 FAU Blvd.,,Boca Raton,Florida,33467,United States,734120
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,5435,lisocabtagene maraleucel,4/1/2020,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc.",400 Dexter Avenue N,400 Dexter Avenue N,Seattle,Washington,98109,United States,730920
Acimtamig,ND470TT8Y3,Designated,Public record,5436,tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct,4/1/2020,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Affimed GmbH,Im Neuenheimer Feld 582,,Heidelberg,,,Germany,736120
DEXEPICATECHIN,LD6B6TT8Q5,Designated,Public record,5437,(+)-Epicatechin,4/6/2020,Treatment of Duchenne and Becker muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Epirium Bio Inc.,"9171 Towne Centre Dr.,",Suite 270,San Diego,California,92122,United States,732020
TIOMOLIBDATE CHOLINE,FD57A79R4P,Designated,Public record,5438,bis-choline tetrathiomolybdate,4/6/2020,Treatment of primary biliary cholangitis,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,733720
DIROXIMEL FUMARATE,K0N0Z40J3W,Designated,Public record,5439,fixed combination of diroximel fumarate and aspirin,4/6/2020,Treatment of patients with multiple sclerosis who experience the fumarate flush,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,10003,United States,724719
ASPIRIN,R16CO5Y76E,Designated,Public record,5439,fixed combination of diroximel fumarate and aspirin,4/6/2020,Treatment of patients with multiple sclerosis who experience the fumarate flush,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,10003,United States,724719
ASPIRIN,R16CO5Y76E,Designated,Public record,5440,Fixed combination of monomethyl fumarate and aspirin,4/6/2020,Treatment of patients with multiple sclerosis who experience the fumarate flush,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,10003,United States,724619
MONOMETHYL FUMARATE,45IUB1PX8R,Designated,Public record,5440,Fixed combination of monomethyl fumarate and aspirin,4/6/2020,Treatment of patients with multiple sclerosis who experience the fumarate flush,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,10003,United States,724619
TIPIFARNIB,MAT637500A,Designated,Public record,5442,tipifarnib,4/6/2020,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Kura Oncology, Inc.","12730 High Bluff Drive, Suite 400",,San Diego,California,92130,United States,730720
FLORBETABEN F-18,TLA7312TOI,Designated,Public record,5443,florbetaben F18,4/7/2020,Diagnostic for the management of amyloid light chain (AL) amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"First Floor, The Woods, Opus 40 Business Park",,Warwick,,,United Kingdom,732420
NAVTEMADLIN,7R7G6EH5UL,Designated,Public record,5444,"{(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2S)-3-methyl-1-(propan-2- ylsulfonyl)butan-2-yl]-2-oxopiperidin-3-yl}acetic acid",4/8/2020,Treatment of Merkel cell carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Kartos Therapeutics, Inc.",275 Shoreline Drive,,Redwood City,California,94065,United States,735120
LONAPEGSOMATROPIN,OP35X9610Y,Designated,Public record,5445,lonapegsomatropin-tcgd,4/13/2020,Treatment of growth hormone deficiency,Designated/Approved,,Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH),8/25/2021,,,Ascendis Pharma Endocrinology Division A/S,12 Tuborg Boulevard,,Hellerup,,,Denmark,654718
POZELIMAB,0JJ21K6L2I,Designated,Public record,5446,pozelimab,4/13/2020,Treatment of CD55-deficient protein-losing enteropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,736820
RACECADOTRIL,76K53XP4TO,Designated,Public record,5447,racecadotril,4/13/2020,Treatment of Microvillus inclusion disease,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,732920
ONTERNABEZ,8I5L034D55,Designated,Public record,5448,"[(1S,2S,5S)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol",4/13/2020,Prevention of proliferative vitreoretinopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,,Canada,734920
CARBON MONOXIDE,7U1EE4V452,Designated,Public record,5449,carbon monoxide,4/14/2020,Prevention of Primary Graft Dysfunction in transplant recipients receiving a lung or heart+ lung transplant.,Designated,Not FDA Approved for Orphan Indication,,,,,"Proterris, Inc.",197 West Springfield Street,,Boston,Massachusetts,2118,United States,733620
DRONABINOL,7J8897W37S,Designated,Public record,5450,delta-9-tetrahydrocannabinol and cannabidiol,4/14/2020,Treatment of Epidermolysis Bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,,Canada,734820
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5450,delta-9-tetrahydrocannabinol and cannabidiol,4/14/2020,Treatment of Epidermolysis Bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,,Canada,734820
DOCARPAMINE,RPQ57D8S72,Designated,Public record,5451,docarpamine,4/14/2020,Treatment of ascites due to all etiologies except cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Martin Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,701519
SINTILIMAB,8FU7FQ8UPK,Designated,Public record,5452,Sintilimab,4/14/2020,Treatment of esophageal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Innovent Biologics (Suzhou) Co. Ltd,168 Dongping Street,,Suzhou Industrial Park,Jiangsu Province,,China,737320
SARTATE CU-67,Y6WKJ2X9X8,Designated,Public record,5453,[67Cu]Cu-[MeCOSar0-Tyr3]-octreotate,4/14/2020,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Clarity Pharmaceuticals Ltd.,National Innovation Centre,4 Cornwallis Street,Eveleigh Sydney,NSW,,Australia,718619
4A10,3TA456TL87,Designated,Public record,5454,Monoclonal anti-IL-7R alpha antibody,4/15/2020,Treatment of Acute Lymphoblastic Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Allterum Therapeutics,"3900 Essex Lane, Suite 575",,Houston,Texas,77027,United States,656018
RRX-001,7RPW6SU9SC,Designated,Public record,5455,"N-(bromoacetyl)-3,3-dinitroazetidine",4/15/2020,Prevention of acute radiation syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"EpicentRx, Inc.",11099 North Torrey Pines Rd,Suite 160,La Jolla,California,92037,United States,737520
BEMPEGALDESLEUKIN,BNO1JG5MZC,Designated,Public record,5458,bempegaldesleukin,4/17/2020,Treatment of Stage IIb to Stage IV melanoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Nektar Therapeutics,"455 Mission Bay Blvd, South",,San Francisco,California,94158,United States,732720
HYMECROMONE,3T5NG4Q468,Designated,Public record,5459,4-Methylumbelliferone,4/20/2020,Treatment of Esophageal Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,735220
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5460,cannabidiol,4/20/2020,Treatment of Epidermolysis Bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,,Canada,734620
EPOPROSTENOL,DCR9Z582X0,Designated,Public record,5461,epoprostenol,4/20/2020,Treatment of Frostbite,Designated,Not FDA Approved for Orphan Indication,,,,,"Thrake Therapeutics, LLC","102 N Water St, Suite 612",,Milwaukee,Wisconsin,53202,United States,705119
BACLOFEN,H789N3FKE8,Designated,Public record,5462,intravenous baclofen,4/20/2020,Prevention of baclofen withdrawal syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Allaysis, LLC",525 Route 73 North,Suite 104,Marlton,New Jersey,8503,United States,480215
MELATONIN,JL5DK93RCL,Designated,Public record,5463,Melatonin,4/20/2020,Prevention of retinopathy of prematurity,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,734420
MELATONIN,JL5DK93RCL,Designated,Public record,5464,Melatonin,4/20/2020,Treatment of retinopathy of prematurity,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,,Italy,734320
REVUMENIB SESQUIFUMARATE,75HI05N8HS,Designated,Public record,5466,"trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide sesquifumarate salt",4/20/2020,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Syndax Pharmaceuticals, Inc.",35 Gatehouse Drive,,Waltham,Massachusetts,2451,United States,734520
PENTAGASTRIN,EF0NX91490,Designated,Public record,5467,pentagastrin,4/21/2020,Diagnostic for the management of medullary thyroid cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Exela Pharma Sciences, LLC",1245 Blowing Rock Blvd.,,Lenoir,North Carolina,28645,United States,689719
ALDESLEUKIN,M89N0Q7EQR,Designated,Public record,5468,Aldesleukin,4/22/2020,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Melanie-Rose Brown,45 Great Valley Parkway,Malvern,Pennsylvania,19355,United States,742920
OLVEREMBATINIB,KV1M7Q3CBP,Designated,Public record,5469,olverembatinib,4/22/2020,Treatment of chronic myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,735620
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5473,cannabidiol,4/28/2020,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Diverse Biotech, Inc.","3805 Old Easton Road, Suite 111",,Doylestown,Pennsylvania,18902,United States,736020
SAPOSIN C (NON-GLYCOSYLATED),2N62LTC861,Designated,Public record,5474,nanovesicle containing Saposin C and dioleoylphosphatidylserine,4/28/2020,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Bexion Pharmaceuticals, Inc",632 Russell St,,Covington,Kentucky,41011,United States,735720
PENTOSAN POLYSULFATE,F59P8B75R4,Designated,Public record,5475,pentosan polysulfate,4/28/2020,Treatment of mucopolysaccharidosis type 1,Designated,Not FDA Approved for Orphan Indication,,,,,Paradigm Biopharmaceuticals Ltd.,"Level 2, 517 Flinders Lane",,Melbourne,Victoria,,Australia,741920
TREHALOSE,B8WCK70T7I,Designated,Public record,5476,Trehalose,4/29/2020,"Treatment of mucopolysaccharidosis type III (MPS III), or Sanfilippo syndrome",Designated,Not FDA Approved for Orphan Indication,,,,,"Seelos Therapeutics, Inc.","300 Park Avenue, 12th Floor",,New York,New York,10022,United States,740920
GARADACIMAB,32W6AJL0DY,Designated,Public record,5477,garadacimab,4/30/2020,Treatment of bradykinin-mediated angioedema,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,19406,United States,715419
BROMOPYRUVATE,63JMV04GRK,Designated,Public record,5478,3-bromo-2-oxopropanoic acid,5/1/2020,Treatment of stage IIb-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"NewG Lab Pharma, Inc.",701 E Pratt St.,,Baltimore,Maryland,21202,United States,736920
CIPARGAMIN,Z7Q4FWA04P,Designated,Public record,5479,cipargamin,5/1/2020,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Bldg. 315 / 1650D,East Hanover,New Jersey,7936,United States,746820
Fostroxacitabine Bralpamide,Q1I6YZ0NGF,Designated,Public record,5480,"1-((2S,4S)-2-((((S) -(4-bromophenoxy)(((S)-1-oxo-1-(((S)- pentan-2-yl)oxy)propan-2-yl)amino)phosphoryl)oxy)methyl)-1,3-dioxolan-4-yl)-2-oxo-1,2-dihydropyrimidin-4- aminium chloride",5/4/2020,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Medivir AB,Box 1086s,,Huddinge,,,Sweden,745020
IDREVLORIDE,NY2J56S3YA,Designated,Public record,5481,"3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide",5/5/2020,Treatment of Primary Ciliary Dyskinesia,Designated,Not FDA Approved for Orphan Indication,,,,,"Parion Sciences, Inc.",2800 Meridian Parkway Suite 195,,Durham,North Carolina,27713,United States,746320
ARM-210 HEMIFUMARATE,ZHR6WM1ADJ,Designated,Public record,5482,"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate",5/5/2020,Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia,Designated,Not FDA Approved for Orphan Indication,,,,,"ARMGO Pharma, Inc.",PMB #260,923 Saw Mill River Road,Ardsley,New York,10502,United States,736220
SARTATE CU-64,UJY48W6ADC,Designated,Public record,5484,[64Cu]Cu-[MeCOSar0-Tyr3]-octreotate,5/6/2020,Diagnostic for the clinical management of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Clarity Pharmaceuticals Ltd.,National Innovation Centre,4 Cornwallis Street,Eveleigh Sydney,NSW,,Australia,737720
BENZNIDAZOLE,YC42NRJ1ZD,Designated,Public record,5488,fixed dose combination of Pyronaridine and Benznidazole,5/11/2020,Treatment of Chagas Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.",840 Main Campus Drive,Lab 3510,Raleigh,North Carolina,27606,United States,719219
PYRONARIDINE,TD3P7Q3SG6,Designated,Public record,5488,fixed dose combination of Pyronaridine and Benznidazole,5/11/2020,Treatment of Chagas Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.",840 Main Campus Drive,Lab 3510,Raleigh,North Carolina,27606,United States,719219
NAFAMOSTAT,Y25LQ0H97D,Designated,Public record,5489,Nafamostat,5/11/2020,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,742120
AZERCABTAGENE ZAPRELEUCEL,PFZ3AP93TA,Designated,Public record,5490,Allogeneic gene-edited CD19-directed CAR T cells/azercabtagene zapreleucel,5/13/2020,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Precision BioSciences, Inc.",302 East Pettigrew Street,Suite A-100,Durham,North Carolina,27701,United States,738020
HYDROCORTISONE,WI4X0X7BPJ,Designated,Public record,5491,hydrocortisone,5/13/2020,Prevention of bronchopulmonary dysplasia,Designated,Not FDA Approved for Orphan Indication,,,,,LABORATOIRE AGUETTANT,"1, rue Alexander Fleming",,Lyon,,,France,716719
NAVTEMADLIN,7R7G6EH5UL,Designated,Public record,5492,"{(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[ (2S)-3 -methyl-1-(propan-2- ylsulfonyl)butan-2-yl]-2-oxopiperidin-3-yl}acetic acid",5/13/2020,Treatment of myelofibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Kartos Therapeutics, Inc.",275 Shoreline Drive,,Redwood City,California,94065,United States,737220
DEFIBROTIDE SODIUM,L7CHH2B2J0,Designated,Public record,5493,defibrotide,5/14/2020,Prevention of acute graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin,,,Ireland,738720
TISLELIZUMAB,0KVO411B3N,Designated,Public record,5496,tislelizumab,5/14/2020,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,738120
IPTACOPAN,8E05T07Z6W,Designated,Public record,5497,"4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl) benzoic acid",5/18/2020,Treatment of C3 glomerulopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,692819
Narmafotinib,16T7U12J7U,Designated,Public record,5498,"Benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-",5/18/2020,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Amplia Therapeutics,55 Flemington Road,Suite 226,North Melbourne,VIC,,Australia,742020
GEMCITABINE,B76N6SBZ8R,Designated,Public record,5499,Gemcitabine,5/18/2020,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,RenovoRx,4546 El Camino Real,Suite 203,Los Altos,California,94022,United States,737820
TORIPALIMAB,8JXN261VVA,Designated,Public record,5501,Toripalimab,5/18/2020,Treatment of nasopharyngeal carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Coherus BioSciences, Inc.","333 Twin Dolphin Drive, Suite 600",,Redwood City,California,94065,United States,738620
TRASTUZUMAB DERUXTECAN,5384HK7574,Designated,Public record,5502,fam-trastuzumab deruxtecan-nxki,5/20/2020,"Treatment of gastric cancer, including gastroesophageal junction cancer",Designated/Approved,,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,1/15/2021,1/15/2028,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,7920,United States,738420
IVOSIDENIB,Q2PCN8MAM6,Designated,Public record,5503,ivosidenib,5/20/2020,Treatment of myelodysplastic syndromes,Designated,Not FDA Approved for Orphan Indication,,,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,2210,United States,739720
TLY-012,S4LKC378SN,Designated,Public record,5504,PEGylated recombinant human tumor necrosis factor-related apoptosis inducing ligand,5/20/2020,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Theraly Fibrosis, Inc.","20271 Goldenrod Lane, Suite 2046",,Germantown,Maryland,20876,United States,737920
PRALSETINIB,1WPE73O1WV,Designated,Public record,5505,pralsetinib,5/26/2020,"Treatment of RET-fusion, RET-mutation, and TRKC-positive poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid cancer",Designated/Approved,,Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or me,12/1/2020,12/1/2027,Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or me,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,728519
AMITRIPTYLINE,1806D8D52K,Designated,Public record,5506,Amitriptyline,5/27/2020,Treatment of Erythromelalgia,Designated,Not FDA Approved for Orphan Indication,,,,,Algo Therapeutix S.A.S,49 rue des Nouvelles,,Suresnes,,,France,739620
NILOTINIB,F41401512X,Designated,Public record,5508,nilotinib oral tablets,5/28/2020,Treatment of chronic myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Nanocopoeia, LLC",1246 West University Avenue,Suite 463,St. Paul,Minnesota,55104,United States,743720
VEPSITAMAB,ZR1EEO1ZLS,Designated,Public record,5510,half-life extended bispecific T-cell engager antibody construct targeting MUC17 and CD3,6/2/2020,"Treatment of gastric cancer, including cancer of gastroesophageal junction",Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,91320,United States,741120
Mavodelpar sodium,XRP79L5C2X,Designated,Public record,5511,Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop-1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate,6/2/2020,Treatment of primary mitochondrial myopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Reneo Pharmaceuticals Inc.,12230 El Camino Real,Suite 230,San Diego,California,92130,United States,740220
MARGETUXIMAB,K911R84KEW,Designated,Public record,5513,margetuximab,6/3/2020,Treatment of gastric and gastroesophageal junction cancer.,Designated,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.",9704 Medical Center Drive,,Rockville,Maryland,20850,United States,739820
Progesterone,4G7DS2Q64Y,Designated,Public record,5514,progesterone,6/3/2020,Treatment of ocular graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"GLIA, LLC",134 Saint Botolph Street,,Boston,Massachusetts,2115,United States,664818
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,5515,Tacrolimus,6/3/2020,Treatment of vernal keratoconjunctivitis,Designated,Not FDA Approved for Orphan Indication,,,,,"CN2 Therapeutics, Inc.",2764 Treasure Cove Circle,,Fort Lauderdale,Florida,33312,United States,753620
SIVELESTAT,DWI62G0P59,Designated,Public record,5516,sivelestat,6/5/2020,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,746220
DERSIMELAGON PHOSPHATE,7GHY3N4EDN,Designated,Public record,5517,"(1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-caroxylic acid-phosphoric acid (1/1)",6/8/2020,treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease),Designated,Not FDA Approved for Orphan Indication,,,,,"Mitsubishi Tanabe Pharma Development America, Inc.",525 Washington Blvd,Suite 400,Jersey City,New Jersey,7310,United States,645518
Elfucose,28RYY2IV3F,Designated,Public record,5518,L-fucose,6/8/2020,Treatment of Leukocyte Adhesion Deficiency Type- II,Designated,Not FDA Approved for Orphan Indication,,,,,"Orpha Labs, AG",Haldenstrasse 5,,Baar,Zug,,Switzerland,753120
MITAPIVAT,2WTV10SIKH,Designated,Public record,5519,Mitapivat,6/8/2020,Treatment of thalassemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Agios Pharmaceuticals, Inc.",88 Sidney Street,,Cambridge,Massachusetts,2139,United States,739920
OBINUTUZUMAB,O43472U9X8,Designated,Public record,5520,obinutuzumab,6/8/2020,Treatment of Membranous Nephropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group",1 DNA Way,MS# 241B,South San Francisco,California,94080,United States,727719
TREPROSTINIL,RUM6K67ESG,Designated,Public record,5521,treprostinil,6/8/2020,Treatment of Systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"LutaFlo Therapeutics, LLC","102 N Water St, Suite 612",,Milwaukee,Wisconsin,53202,United States,711319
BERUBICIN,6QPN83HK2M,Designated,Public record,5522,Berubicin,6/9/2020,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"CNS Pharmaceuticals, Inc.",2100 West Loop South,Suite 900,Houston,Texas,77027,United States,748420
TEPRENONE,S8S8451A4O,Designated,Public record,5523,geranylgeranylacetone,6/10/2020,Prevention of Acute Radiation Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,743920
GUADECITABINE,2KT4YN1DP7,Designated,Public record,5524,guadecitabine SC,6/10/2020,Treatment of myelodysplastic syndromes including chronic myelomonocytic leukemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,94588,United States,627818
Sirexatamab,RM898LZ4SI,Designated,Public record,5525,"humanized IgG4 monoclonal antibody optimized for neutralizing activity against DKK1, a secreted modulator of Wnt signaling",6/10/2020,Treatment of gastric and gastroesophageal junction cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Leap Therapeutics, Inc",47 Thorndike Street,Suite B-1,Cambridge,Massachusetts,2141,United States,744020
EFINEPTAKIN ALFA,3K3WC6MT6P,Designated,Public record,5526,Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc).,6/11/2020,Treatment of progressive multifocal leukoencephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"NeoImmuneTech, Inc.",2400 Research Boulevard,Suite 250,Rockville,Maryland,20850,United States,741620
RUSFERTIDE,XM71MYX0IQ,Designated,Public record,5527,Hepcidin mimetic peptide,6/12/2020,Treatment of Polycythemia vera,Designated,Not FDA Approved for Orphan Indication,,,,,"Protagonist Therapeutics, Inc.","7707 Gateway Blvd, Suite 140",,Newark,California,94560,United States,715819
UBENIMEX,I0J33N5627,Designated,Public record,5528,Ubenimex,6/12/2020,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,749020
ULINASTATIN,OR3S9IF86U,Designated,Public record,5529,Ulinastatin,6/12/2020,Treatment of Kawasaki Disease,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,742320
HUPERZINE A,0111871I23,Designated,Public record,5530,(-)-huperzine A,6/15/2020,Treatment of Lennox-Gastaut Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Supernus Pharmaceuticals, Inc.",9715 Key West Avenue,,Rockville,Maryland,20850,United States,744420
IMATINIB MESYLATE,8A1O1M485B,Designated,Public record,5531,imatinib mesylate,6/15/2020,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"PHPrecisionMed, LLC",3621 Grove Street,,Skokie,Illinois,60076,United States,741420
TEPRENONE,S8S8451A4O,Designated,Public record,5532,Geranylgeranylacetone,6/16/2020,Prevention of post-hepatectomy liver failure,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,742220
PROGLUMIDE,EPL8W5565D,Designated,Public record,5534,Proglumide,6/16/2020,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Jill P Smith, MD","Department of Medicine, Georgetown University",Building D Room 338,Washington,District of Columbia,20007,United States,743020
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,5535,tacrolimus,6/16/2020,Prophylaxis of lung allograft rejection,Designated,Not FDA Approved for Orphan Indication,,,,,"TFF Pharmaceuticals, Inc.","2600 Via Fortuna, Suite 360",,Austin,Texas,78746,United States,743220
TOVINONTRINE,W248Y1AKOR,Designated,Public record,5536,"6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3- tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one",6/22/2020,Treatment of Eszett-thalassemia,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"IMARA, Inc.",116 Huntington Avenue,6th Floor,Boston,Massachusetts,2116,United States,748620
ZILOVERTAMAB,FEH7RQ7B3J,Designated,Public record,5538,cirmtuzumab,6/22/2020,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc.",12230 El Camino Real,Suite 300,SanDiego,California,92130,United States,744220
ZILOVERTAMAB,FEH7RQ7B3J,Designated,Public record,5539,cirmtuzumab,6/22/2020,Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc.",12230 El Camino Real,Suite 300,SanDiego,California,92130,United States,744120
VALGANCICLOVIR,GCU97FKN3R,Designated,Public record,5540,nanatinostat and valganciclovir,6/22/2020,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,92007,United States,733420
NANATINOSTAT,YTL7A418KQ,Designated,Public record,5540,nanatinostat and valganciclovir,6/22/2020,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,92007,United States,733420
BELZUTIFAN,7K28NB895L,Designated,Public record,5541,belzutifan,6/24/2020,Treatment of von Hippel-Lindau disease,Designated/Approved,,"Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery",8/13/2021,8/13/2028,"Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery","Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,745820
ULENISTAMAB,HX998WER5A,Designated,Public record,5542,Humanized immunoglobulin G1 kappa monoclonal antibody targeting PAUF,6/24/2020,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Prestige Biopharma Ltd,2 Science Park #04-13/14,Ascent Tower B,Science Park,,,Singapore,749620
TEPRENONE,S8S8451A4O,Designated,Public record,5544,geranylgeranylacetone,6/26/2020,Treatment of spinal and bulbar muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,744620
NIPOCALIMAB,87M90CV8NC,Designated,Public record,5545,nipocalimab,6/26/2020,Prevention of hemolytic disease of the fetus and newborn,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.",301 Binney Street,,Cambridge,Massachusetts,2142,United States,712419
ANAKINRA,9013DUQ28K,Designated,Public record,5547,anakinra,6/29/2020,Treatment of Deficiency of IL-1 Receptor Antagonist,Designated/Approved,,treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA),12/18/2020,12/18/2027,treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA),Swedish Orphan Biovitrum AB (PUBL),Tomtebodavägen 23A,,Stockholm,,,Sweden,745420
PLG-0206,C8ECW4KP2L,Designated,Public record,5548,Engineered cationic antibiotic peptide,7/1/2020,Treatment of prosthetic joint infections,Designated,Not FDA Approved for Orphan Indication,,,,,"Peptilogics, Inc.","2730 Sidney Street, Suite 300",,Pittsburgh,Pennsylvania,15203,United States,723219
ALRIZOMADLIN,15QAU0SI9J,Designated,Public record,5551,"[6-(4-Chlorophenyl)-spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",7/1/2020,Treatment of Waldenstrom macroglobulinemia,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,745620
UNESBULIN,Z4HZ70S62Q,Designated,Public record,5552,"5-fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazole-1-yl)-N4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine",7/7/2020,Treatment of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,755420
Xaluritamig,ODG03B9M4U,Designated,Public record,5553,a novel humanized bispecific XmAb® T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3,7/7/2020,Treatment of Ewing Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,Mail Stop: 27-3-F,Thousand Oaks,California,91320,United States,760020
Ulviprubart,QT44II3WZP,Designated,Public record,5554,Humanized afucosylated IgG1 monoclonal antibody binding to KLRG1,7/7/2020,Treatment of inclusion body myositis,Designated,Not FDA Approved for Orphan Indication,,,,,"Abcuro, Inc.",90 Bridge Street,Suite 100,Newton,Massachusetts,2458,United States,681119
IMSIDOLIMAB,KX89J0DFZ8,Designated,Public record,5555,imsidolimab,7/7/2020,Treatment of generalized pustular psoriasis,Designated,Not FDA Approved for Orphan Indication,,,,,"AnaptysBio, Inc.",10421 Pacific Center Court,Suite 200,San Diego,California,92121,United States,673918
"""N,N-DIMETHYL-N-(2-(((2R,3R,4S,5R,6R)-3,4,5-TRIS(ACETYLOXY)-6-((ACETYLOXY)METHYL)OXAN-2-YL)OXY)ETHYL)CYCLOPROPYLAMMONIUM""",J6QN4FZ2UG,Designated,Public record,5556,"N,N-dimethyl-N-(2-{[(2R,3R,4S,5R,6R)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}ethyl)cyclopropylammonium",7/7/2020,Treatment of Trimethylaminuria,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Kintai Therapeutics, Inc.",26 Landsdowne St,Suite 450,Cambridge,Massachusetts,2139,United States,761020
EMLENOFLAST,SC4RYG0M76,Designated,Public record,5557,"N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl) amino]carbonyl]-1-(1-methylethyl)-1H-Pyrazole-3-sulfonamide",7/7/2020,Treatment of cryopyrin-associated periodic syndromes,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., a Member of the Roche Group",1 DNA Way,,South San Francisco,California,,United States,757720
Nadofaragene Firadenovec,0OOS09O1FH,Designated,Public record,5558,Nadofaragene firadenovec,7/7/2020,Treatment of malignant mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,Trizell Ltd,Sanderum House,"Oakley Road, Chinnor",Oxon,,,United Kingdom,748120
Paltusotine,F2IBD1GMD3,Designated,Public record,5559,Paltusotine,7/7/2020,Treatment of acromegaly,Designated,Not FDA Approved for Orphan Indication,,,,,"Crinetics Pharmaceuticals, Inc.",6197 Cornerstone Court East,,San Diego,California,92121,United States,576617
ANDROSTANOLONE,08J2K08A3Y,Designated,Public record,5560,Dihydrotestosterone Gel,7/9/2020,Treatment of micropenis,Designated,Not FDA Approved for Orphan Indication,,,,,Besins Healthcare Ireland Ltd.,16 Pembroke Street Upper,DO2HE63,Dublin 2,,,Ireland,747120
PXS-5505,DO94E28WYW,Designated,Public record,5561,(Z)-3-fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amine,7/10/2020,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Pharmaxis Ltd.,20 Rodborough Rd.,,Frenchs Forest,NSW,,Australia,747520
ALCOHOL,3K9958V90M,Designated,Public record,5562,Dehydrated alcohol,7/10/2020,Treatment of methanol poisoning,Designated,Not FDA Approved for Orphan Indication,,,,,Eton Pharmaceuticals,21925 W. Field Pkwy,Suite 235,Deer Park,Illinois,60010,United States,746720
SUGEMALIMAB,90IQR2I6TR,Designated,Public record,5564,Humanized Recombinant IgG4 Anti-PD-1 Monoclonal Antibody,7/14/2020,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"CStone Pharmaceuticals (Suzhou) Co., Ltd.",1000 Zhangheng Road,Building 25,Shanghai,,201203,China,722919
RILONACEPT,8K80YB5GMG,Designated,Public record,5565,rilonacept,7/14/2020,Treatment of pericarditis,Designated/Approved,,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older,3/18/2021,3/18/2028,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older,"Kiniksa Pharmaceuticals, Ltd.",c/o Kiniksa Pharmaceuticals Corp.,100 Hayden Avenue,Lexington,Massachusetts,2421,United States,649718
Zilurgisertib Fumarate,1R349830SB,Designated,Public record,5568,"2-Amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide fumarate dihydrate",7/21/2020,Treatment of fibrodysplasia ossificans progressiva,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,750320
ALIDORNASE ALFA,D4W5757EP4,Designated,Public record,5569,Alidornase alfa,7/21/2020,Treatment of sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"SarcoMed USA, Inc.",1300 Post Oak Boulevard,Suite 760,Houston,Texas,77056,United States,754820
COBOMARSEN,3JKW7CI9IU,Designated,Public record,5570,cobomarsen,7/21/2020,Treatment of adult T-cell leukemia/lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Viridian Therapeutics, Inc.",6200 Lookout Road,Suite 100,Boulder,Colorado,80301,United States,748520
ZENOCUTUZUMAB,AE72RB1W1X,Designated,Public record,5572,Zenocutuzumab,7/22/2020,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Merus N.V.,139 Main Street,,Cambridge,Massachusetts,2142,United States,750020
AVIPTADIL,A67JUW790C,Designated,Public record,5574,Aviptadil,7/23/2020,Treatment of sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,AdVita Lifescience GmbH,Alte Bundesstraße 20,,Gundelfingen,,79194,Germany,751520
PROGLUMIDE,EPL8W5565D,Designated,Public record,5575,Proglumide,7/23/2020,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,756620
"""3,5-DIIODOTHYROPROPIONIC ACID""",1HTO2X0SJ9,Designated,Public record,5577,"3,5-diiodothyropropionic acid",7/28/2020,Treatment of monocarboxylate transporter (MCT) 8 deficiency (Allan-Herndon-Dudley syndrome),Designated,Not FDA Approved for Orphan Indication,,,,,"Prizm, LLC","3377 S. Price Road, Suite 3031",,Chandler,Arizona,85248,United States,764420
RGLS-4326,UCH3QQH1C0,Designated,Public record,5578,a chemically modified full phosphorothioate-backboned anti-miR-17 oligonucleotide.,7/28/2020,Treatment of autosomal dominant polycystic kidney disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Regulus Therapeutics, Inc.",10628 Science Center Drive,Suite 225,San Diego,California,92121,United States,750820
DEXTRAN SULFATE SODIUM (5000 MW),V5LWP0C2L5,Designated,Public record,5579,Low molecular weight dextran sulfate,7/28/2020,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,TikoMed AB,79 T.W. Alexander Drive,"4401 Research Commons, Suite 300",Durham,North Carolina,27709,United States,752220
PARSACLISIB,OS7097575K,Designated,Public record,5580,parsaclisib,7/28/2020,Treatment of autoimmune hemolytic anemia,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,758420
CELECOXIB,JCX84Q7J1L,Designated,Public record,5581,Celecoxib,7/30/2020,Treatment of hemophilic arthropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Upex-Med Co., Ltd.","Rm1117, Geumgangpenterium IT Tower B","Hagui-ro 282, Dongan-gu, Anyang-si,",Gyeonggi-do,,,South Korea,751420
OSI-027,25MKH1SZ0M,Designated,Public record,5582,"trans-4-[4-Amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazine-7-yl]-cyclohexanecarboxylic acid, tromethamine salt",7/30/2020,Treatment of lymphatic malformation (LM),Designated,Not FDA Approved for Orphan Indication,,,,,"Avalo Therapeutics, Inc.",1500 Liberty Ridge Drive,Suite 321,Wayne,Pennsylvania,19087,United States,759820
GRESONITAMAB,0SIB91V6TP,Designated,Public record,5583,half-life extended bispecific T cell engager (BiTE®) antibody construct designed to target both CLDN18.2 and CD3,7/31/2020,"Treatment of gastric cancer, including cancer of gastroesophageal junction",Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,91320,United States,752720
IPTACOPAN HYDROCHLORIDE ANHYDROUS,O9HY4W0ZW7,Designated,Public record,5584,iptacopan,7/31/2020,Treatment of paroxysmal nocturnal hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Bldg. 315/5150A,East Hanover,New Jersey,7936,United States,751920
EXALUREN,TP732M43NA,Designated,Public record,5585,"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate",7/31/2020,Treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"ELOXX Pharmaceuticals, Inc.",950 Winter Street,,Waltham,Massachusetts,2451,United States,751820
RACEMETYROSINE,X88TTO174Z,Designated,Public record,5588,Racemetyrosine,7/31/2020,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Tyme Technologies, Inc.",17 State Street,7th Floor,New York,New York,10004,United States,677819
SULINDAC,184SNS8VUH,Designated,Public record,5590,sulindac,8/4/2020,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Prolindox, Inc.",8008 Desmond Dr.,,Boynton Beach,Florida,33472,United States,752620
NEDAPLATIN,8UQ3W6JXAN,Designated,Public record,5592,Nedaplatin,8/5/2020,Treatment of Small Cell Lung Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,753320
UBENIMEX,I0J33N5627,Designated,Public record,5594,Ubenimex,8/7/2020,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenafly,New Jersey,7670,United States,755720
TREHALOSE,B8WCK70T7I,Designated,Public record,5596,Trehalose + miglustat,8/10/2020,Treatment of CLN Batten disease,Designated,Not FDA Approved for Orphan Indication,,,,,Beyond Batten Disease Foundation,P.O. Box 50221,,Austin,Texas,78763,United States,756020
MIGLUSTAT,ADN3S497AZ,Designated,Public record,5596,Trehalose + miglustat,8/10/2020,Treatment of CLN Batten disease,Designated,Not FDA Approved for Orphan Indication,,,,,Beyond Batten Disease Foundation,P.O. Box 50221,,Austin,Texas,78763,United States,756020
VATIQUINONE,6O85FK9I0X,Designated,Public record,5597,vatiquinone,8/10/2020,Treatment of mitochondrial disease,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,759620
BORNEOL,M89NIB437X,Designated,Public record,5599,Edaravone and (+)-Borneol,8/11/2020,Treatment of Amyotrophic Lateral Sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Yantai Yenepharma. Co., Ltd","Inner No. 2, No.32 Zhujiang Road",Yantai Economic and Technological Development Zone,Yantai,Shandong Province,264006,China,754420
EDARAVONE,S798V6YJRP,Designated,Public record,5599,Edaravone and (+)-Borneol,8/11/2020,Treatment of Amyotrophic Lateral Sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Yantai Yenepharma. Co., Ltd","Inner No. 2, No.32 Zhujiang Road",Yantai Economic and Technological Development Zone,Yantai,Shandong Province,264006,China,754420
VENGLUSTAT MALATE,94855LQZ8D,Designated,Public record,5601,venglustat malate,8/13/2020,Treatment of GM2 gangliosidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Genzyme Corporation, a SANOFI COMPANY",50 Binney Street,,Cambridge,Massachusetts,2142,United States,755820
DISUFENTON SODIUM,7M1J3HN9VO,Designated,Public record,5603,Disufenton sodium,8/14/2020,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Oblato, Inc.",116 Village Boulevard,Suite 200,Princeton,New Jersey,8540,United States,757820
Dazucorilant,HR4RD5RBJ6,Designated,Public record,5606,"(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone",8/18/2020,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,94025,United States,756420
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5607,cannabidiol,8/21/2020,Treatment of Prader Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",950 Winter Street,,Waltham,Massachusetts,2451,United States,538916
IVALTINOSTAT,4I8MLM7L2H,Designated,Public record,5608,Ivaltinostat,8/21/2020,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"CG Pharmaceuticals, Inc.","100-D, Bldg. D, Pine Grove Business Center",4 Orinda Way,Orinda,California,94563,United States,760420
PAXALISIB,P5DKZ70636,Designated,Public record,5609,Paxalisib,8/21/2020,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Kazia Therapeutics Limited,ACN 063 259 754,"Level 24, 300 Barangaroo Avenue",Sydney,NSW,2000,Australia,759220
ZANUBRUTINIB,AG9MHG098Z,Designated,Public record,5610,zanubrutinib,8/24/2020,Treatment of nodal marginal zone lymphoma,Designated/Approved,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,9/14/2021,9/14/2028,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,94403,United States,757120
ZANUBRUTINIB,AG9MHG098Z,Designated,Public record,5611,zanubrutinib,8/24/2020,Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,Designated/Approved,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,9/14/2021,9/14/2028,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,94403,United States,756920
ZANUBRUTINIB,AG9MHG098Z,Designated,Public record,5612,zanubrutinib,8/24/2020,Treatment of splenic marginal zone lymphoma,Designated/Approved,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,9/14/2021,9/14/2028,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,94403,United States,757020
OLITIGALTIN,60Y0GUO72B,Designated,Public record,5614,"Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-B-D-galactopyranosyl) sulfane",8/25/2020,Treatment of idiopathic pulmonary fibrosis (IPF),Designated,Not FDA Approved for Orphan Indication,,,,,Galecto Biotech AB,Ole Maaloes Vej 3,,Copenhagen N,,,Denmark,757320
FASUDIL HYDROCHLORIDE,SQ04N8S7BR,Designated,Public record,5615,fasudil HCL,8/25/2020,Treatment of Huntington’s Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,715919
ZILOVERTAMAB VEDOTIN,IZY9ZSI6FI,Designated,Public record,5617,"Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.",8/26/2020,Treatment of mantle cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,7065,United States,757520
RHENIUM (<sup>186</sup>RE) OBISBEMEDA,O5L8T4LD4L,Designated,Public record,5618,BMEDA-chelated Rhenium-186 nanoliposomes,8/26/2020,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,University of Texas Health Science Center at San Antonio,7979 Wurzbach Rd.,Suite Z416,San Antonio,Texas,78229,United States,757420
TOLINAPANT L-LACTATE,VT4WU0MY57,Designated,Public record,5620,"1-{6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl}-2-[(2R,5R)-5-methyl-2-{[(3R)-3-methylmorpholin-4-yl]methyl}piperazin-1-yl]ethan-1-one, L-(+)-lactic acid salt",8/28/2020,Treatment of T-Cell Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,94588,United States,758020
"""2-(4-(4-((1-(107-(4-(guanidinomethyl)phenoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid""",,Designated,Public record,5621,"2-(4-(4-((1-(107-(4-(fluorophenyl)methoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid",8/28/2020,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,12144,United States,759420
"""2-(4-(4-((1-(107-(4-(guanidinomethyl)phenoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid""",,Designated,Public record,5622,"2-(4-(4-((1-(107-(4-(fluorophenyl)methoxy)-polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid",8/28/2020,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,12144,United States,759520
"""2-(4-(4-((1-(107-(4-(guanidinomethyl)phenoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid""",,Designated,Public record,5623,"2-(4-(4-((1-(107-(4-(guanidinomethyl)phenoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid",8/28/2020,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,12144,United States,759320
TLX-102,8VR3346X18,Designated,Public record,5624,211At-4-astato-L-phenylalanine (4-[211At]APA),8/28/2020,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Telix Pharmaceuticals Limited (Telix),55 Flemington Road,Suite 401,North Melbourne,Victoria,3015,Australia,758520
PIRTOBRUTINIB,JNA39I7ZVB,Designated,Public record,5625,pirtobrutinib,8/28/2020,Treatment of mantle cell lymphoma,Designated/Approved,,"treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor",1/27/2023,1/27/2030,"treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor","Loxo Oncology, Inc.","201 Haskins Way, Suite 400",,South San Francisco,California,94080,United States,758120
LISAFTOCLAX,OSL3FEZ1IF,Designated,Public record,5626,"[6-(4-Chlorophenyl)-spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",8/28/2020,Treatment of Chronic Lymphocytic Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,757920
20.ALPHA.-HYDROXYCHOLESTEROL,30060WAL99,Designated,Public record,5627,20-alphaHydroxycholesterol,8/31/2020,Prevention of White Matter Injury in Preterm Infants less than or equal to 32 Weeks Gestational Age,Designated,Not FDA Approved for Orphan Indication,,,,,"Tellus Therapeutics, Inc.",517 Summit Trail Drive,,Hillsborough,North Carolina,27278,United States,761620
FIROLIMOGENE AUTOTEMCEL,XH2XT2GQS6,Designated,Public record,5629,firolimogene autotemcel,8/31/2020,treatment X-linked severe combined immunodeficiency.,Designated,Not FDA Approved for Orphan Indication,,,,,"Mustang Bio, Inc.",377 Plantation Street,,Worcester,Massachusetts,1605,United States,759720
LORCASERIN,637E494O0Z,Designated,Public record,5630,Lorcaserin,8/31/2020,Treatment of Dravet syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,100 Tice Boulevard,,Woodcliff Lake,New Jersey,7677,United States,758920
NEDAPLATIN,8UQ3W6JXAN,Designated,Public record,5631,nedaplatin,8/31/2020,Treatment of esophageal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenafly,New Jersey,7670,United States,747220
ALRIZOMADLIN,15QAU0SI9J,Designated,Public record,5632,"APG-115, a novel orally available small molecule MDM2 inhibitor",9/2/2020,Treatment of Gastric Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,762520
ERFONRILIMAB,9NP50O6YSA,Designated,Public record,5633,humanized bispecific IgG1 antibody that can simultaneously bind to both programmed death-ligand 1 and cytotoxic T-lymphocyte-associated protein 4,9/2/2020,Treatment of Thymic Epithelial Tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd.","Bldg. C23, 218 Xinghu Street,",SIP,SuZhou,Jiangsu,,China,759120
Belumosudil,834YJF89WO,Designated,Public record,5635,Belumosudil,9/4/2020,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Kadmon Corporation,450 East 29th Street,,New York,New York,10016,United States,760520
"""2,4-DINITROPHENOL""",Q13SKS21MN,Designated,Public record,5636,"2,4 dinitrophenol",9/8/2020,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Mitochon Phannaceuticals, Inc.",970 Cross Lane,,Blue Bell,Pennsylvania,19422,United States,764820
BIOTIN,6SO6U10H04,Designated,Public record,5639,Biotin,9/8/2020,Treatment of Charcot-Marie-Tooth disease,Designated,Not FDA Approved for Orphan Indication,,,,,MedDay Pharmaceuticals,6880 Commerce Blvd.,,Canton,Michigan,48187,United States,760720
POZELIMAB,0JJ21K6L2I,Designated,Public record,5641,Pozelimab/Cemdisiran Combination,9/8/2020,Treatment of Paroxysmal Nocturnal Hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,760920
CEMDISIRAN,S66Z65E10T,Designated,Public record,5641,Pozelimab/Cemdisiran Combination,9/8/2020,Treatment of Paroxysmal Nocturnal Hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,760920
AMINOLEVULINIC ACID HYDROCHLORIDE,V35KBM8JGR,Designated,Public record,5642,Aminolevulinic acid hydrochloride,9/9/2020,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"SonALAsense, Inc.",2600 Tenth Street,Suite 435,Berkeley,California,94710,United States,761520
LTI-03,JE7G34JYW4,Designated,Public record,5644,Caveolin-1 Scaffolding Domain 7-Mer,9/9/2020,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Lung Therapeutics, Inc.","2801 Via Fortuna, Suite 425",,Austin,Texas,78746,United States,761920
FASUDIL,Q0CH43PGXS,Designated,Public record,5646,Fasudil,9/9/2020,Treatment of Frontotemporal Dementia,Designated,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,761320
LUMACAFTOR,EGP8L81APK,Designated,Public record,5647,Lumacaftor,9/9/2020,Treatment of Non-Traumatic Subarachnoid Hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,Qanatpharma AG,Alter Postplatz 2,,Stans,,6370,Switzerland,761720
PROGLUMIDE,EPL8W5565D,Designated,Public record,5648,Proglumide,9/9/2020,Treatment of Chronic Pancreatitis,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,7670,United States,762120
Golidocitinib hemi-ethyl acetate solvate,NS94P621A0,Designated,Public record,5649,(R)-N-(3-(2-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propenamide hemi ethyl acetate solvate,9/10/2020,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Dizal (Jiangsu) Pharmaceutical Co., Ltd.",199 Liangjing Road,Zhangjiang High-Tec Park,Shanghai,,,China,763220
Zandatrigine,SV2WPA4R4J,Designated,Public record,5650,(S)-4-((1-Benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide,9/10/2020,"Treatment of Sodium channel, voltage-gated, type VIII, alpha subunit (SCN8A) developmental and epileptic encephalopathy syndrome '||CHR(13)||CHR(10)||CHR(13)||CHR(10)||'",Designated,Not FDA Approved for Orphan Indication,,,,,Neurocrine Biosciences Inc.,12780 El Camino Real,,San Diego,California,92130,United States,762220
TW-37,FQ8NY4LUO5,Designated,Public record,5652,"N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]benzamide",9/14/2020,Treatment of retinoblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Oxular Ltd,Magadalen Centre,1 Robert Robinson Avenue,Oxford,,,United Kingdom,764020
PIRTOBRUTINIB,JNA39I7ZVB,Designated,Public record,5653,"(S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl) -1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide",9/14/2020,Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company",701 Gateway Boulevard,Suite 420,South San Francisco,California,94080,United States,763420
ALRIZOMADLIN,15QAU0SI9J,Designated,Public record,5654,"APG-115, an orally bioavailable small molecule.",9/14/2020,Treatment of acute myeloid leukemia (AML).,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,763020
MAVRILIMUMAB,1158JD1P9A,Designated,Public record,5657,mavrilimumab,9/14/2020,Treatment of Giant Cell Arteritis,Designated,Not FDA Approved for Orphan Indication,,,,,"Kiniksa Pharmaceuticals, Ltd.",c/o Kiniksa Pharmaceuticals Corp.,100 Hayden Avenue,Lexington,Massachusetts,2421,United States,764620
PEXASTIMOGENE DEVACIREPVEC,K82DG47I0G,Designated,Public record,5658,Pexastimogene Devacirepvec,9/14/2020,Treatment of stage IIB-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"SillaJen, Inc.","6F, 111, Hyoyeol-ro",Suite 200,Buk-gu,Busan,,South Korea,762820
TORIPALIMAB,8JXN261VVA,Designated,Public record,5659,Toripalimab,9/15/2020,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.",9430 Key West Ave,Suite 125,Rockville,Maryland,20850,United States,762720
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5660,Cannabidiol,9/16/2020,Treatment of 22q.11.2 deletion syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Zynerba Pharmaceuticals, Inc.",80 West Lancaster Avenue,Suite 300,Devon,Pennsylvania,19333,United States,763820
TISAGENLECLEUCEL,Q6C9WHR03O,Designated,Public record,5661,tisagenlecleucel,9/16/2020,Treatment of follicular lymphoma,Designated/Approved,,Treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy,5/27/2022,5/27/2029,Treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7936,United States,765120
PF-07059013,FXK42BP3GL,Designated,Public record,5663,6-{(1S)-1-[(2-Amino-6-fluoroquinolin-3-yl)oxy]ethyl}-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one,9/18/2020,Treatment for Sickle Cell Disease.,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",500 Arcola Road,,Collegeville,Pennsylvania,19426,United States,766020
ASPIRIN,R16CO5Y76E,Designated,Public record,5665,aspirin for injection (acetylsalicylic acid),9/18/2020,Treatment of Kawasaki Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Rhoshan Pharmaceuticals Inc.,"225 Wilmington-West Chester Pike, Suite 200",,Chadds Ford,Pennsylvania,19317,United States,764120
GABEXATE,4V7M9137X9,Designated,Public record,5666,Gabexate,9/18/2020,Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenafly,New Jersey,7670,United States,764320
GOVORESTAT,6JLQ8K35KK,Designated,Public record,5669,"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",9/21/2020,Treatment of phosphomannomutase 2 deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Applied Therapeutics Inc.,340 Madison Avenue,19th Floor,New York,New York,10173,United States,765620
CEPHARANTHINE,7592YJ0J6T,Designated,Public record,5671,Cepharanthine,9/22/2020,Treatment of immune thrombocytopenia (ITP),Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenafly,New Jersey,7670,United States,766520
5-METHYL CROMOLYN SODIUM,E86W7MDO4M,Designated,Public record,5673,Excindogen,9/23/2020,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,CarcinEx Inc.,820 Grape St.,,Denver,Colorado,80220,United States,768020
N-ACETYLGLUCOSAMINE,V956696549,Designated,Public record,5675,N-Acetylglucosamine,9/23/2020,Treatment for Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Wellesley Therapeutics, Inc.","200 Gerrard St., East",,Toronto,Ontario,,Canada,767420
PELCITOCLAX,317UBD60ML,Designated,Public record,5676,Pelcitoclax,9/23/2020,Treatment of Small Cell Lung Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,766320
Tovorafenib,ZN90E4027M,Designated,Public record,5677,"DAY101, 6-amino-5-chloro-N-[(1R)-1-(5-{[5-chloro-4-(trifluoromethyl)pyridin-2- yl]carbamoyl}-1,3-thiazol-2-yl)ethyl]pyrimidine-4-carboxamide is the chemical name.",9/24/2020,Treatment of Patients with Low-Grade Glioma Harboring an Activating RAF Alteration,Designated,Not FDA Approved for Orphan Indication,,,,,"Day One Biopharmaceuticals, Inc.",2000 Sierra Point Parkway,Suite 501,Brisbane,California,94005,United States,768320
EMAPALUMAB,3S252O2Z4X,Designated,Public record,5680,Emapalumab,9/25/2020,Prevention of graft failure following hematopoietic stem cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Sobi AG,12 Chemin des Aulx,Plan-Les-Ouates,Geneva,,1228,Switzerland,766720
NIVATROTAMAB,8RV18E4A94,Designated,Public record,5681,Nivatrotamab,9/25/2020,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Y-mAbs Therapeutics, Inc.","230 Park Avenue, Suite 3350",,New York,New York,10169,United States,767020
APADAMTASE ALFA,U5SFU33XUX,Designated,Public record,5683,apadamtase alfa,9/28/2020,Treatment of Sickle Cell Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Baxalta US Inc.,300 Shire Way,,Lexington,Massachusetts,2421,United States,768720
VACTOSERTIB,6T4O391P5Y,Designated,Public record,5684,Vactosertib,9/28/2020,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"MedPacto, Inc",145 Gwanggyo-ro,"Advanced Institutes of Convergence Technology, Building C, Room 506",Suwon,Gyeonggi-do,16229,Republic of Korea,767320
PHENOBARBITAL SODIUM,SW9M9BB5K3,Designated,Public record,5688,Phenobarbital Sodium,9/30/2020,Treatment of neonatal seizures,Designated,Not FDA Approved for Orphan Indication,,,,,"Hikma Pharmaceuticals USA, Inc.",2 Esterbrook Lane,,Cherry Hill,New Jersey,8003,United States,768420
TAURURSODIOL DIHYDRATE,U7XRV7RZ1I,Designated,Public record,5689,Sodium phenylbutyrate and tauroursodeoxycholic acid dihydrate,9/30/2020,Treatment of Wolfram syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Amylyx Pharmaceuticals Inc.,43 Thorndike Street,,Cambridge,Massachusetts,2139,United States,767720
SODIUM PHENYLBUTYRATE,NT6K61736T,Designated,Public record,5689,Sodium phenylbutyrate and tauroursodeoxycholic acid dihydrate,9/30/2020,Treatment of Wolfram syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Amylyx Pharmaceuticals Inc.,43 Thorndike Street,,Cambridge,Massachusetts,2139,United States,767720
O-(2-FLUOROETHYL)-L-TYROSINE F-18,1326R5J1IA,Designated,Public record,5690,O-(2-[18F]fluoroethyl)-L-tyrosine,10/5/2020,Diagnostic for the management of glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Telix Pharmaceuticals Limited (Telix),55 Flemington Road,Suite 401,North Melbourne,Victoria,3015,Australia,767920
SOTIGALIMAB,JEA93WJ5DG,Designated,Public record,5691,Humanized IgG1K-agonistic monoclonal antibody that binds to CD40,10/5/2020,Treatment of esophageal and gastroesophageal junction cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Apexigen, Inc.",75 Shoreway Road,Suite C,San Carlos,California,94070,United States,768220
HYALURONIDASE (BOVINE),8KOG53Z5EM,Designated,Public record,5692,daratumumab and hyaluronidase-fihj,10/6/2020,treatment of light-chain (AL) amyloidosis,Designated/Approved,,"in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis",1/15/2021,1/15/2028,treatment of adult patients with newly diagnosed light chain (AL) amyloidosis,"Janssen Research & Development, LLC",1400 McKean Road,PO Box 776,Spring House,Pennsylvania,19477,United States,769220
DARATUMUMAB,4Z63YK6E0E,Designated,Public record,5692,daratumumab and hyaluronidase-fihj,10/6/2020,treatment of light-chain (AL) amyloidosis,Designated/Approved,,"in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis",1/15/2021,1/15/2028,treatment of adult patients with newly diagnosed light chain (AL) amyloidosis,"Janssen Research & Development, LLC",1400 McKean Road,PO Box 776,Spring House,Pennsylvania,19477,United States,769220
ONFEKAFUSP ALFA,6HXC0O6JMV,Designated,Public record,5694,Fibromun / Onfekafusp alfa,10/7/2020,treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Philogen S.p.A.,Località Bellaria 35,,Sovicille,,,Italy,771020
CITRULLINE,29VT07BGDA,Designated,Public record,5695,L-citrulline,10/7/2020,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Asklepion Pharmaceuticals, LLC",729 E. Pratt Street,Suite 360,Baltimore,Maryland,21202,United States,769820
ATEZOLIZUMAB,52CMI0WC3Y,Designated,Public record,5698,atezolizumab,10/8/2020,treatment of soft tissue sarcoma,Designated/Approved,,as a single agent for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS),12/9/2022,12/9/2029,treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS),"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,769320
CUPRIC CATION,8CBV67279L,Designated,Public record,5699,Disulfiram and Copper,10/8/2020,treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cantex Pharmaceuticals, Inc.",1792 Bell Tower Lane,,Weston,Florida,33326,United States,771520
DISULFIRAM,TR3MLJ1UAI,Designated,Public record,5699,Disulfiram and Copper,10/8/2020,treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Cantex Pharmaceuticals, Inc.",1792 Bell Tower Lane,,Weston,Florida,33326,United States,771520
Casdozokitug,AL6I5N2HTN,Designated,Public record,5700,"fully human, antagonistic IgG1 monoclonal antibody targeting IL-27 subunit alpha (p28)",10/8/2020,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Surface Oncology,"50 Hampshire Street, 8th Floor",,Cambridge,Massachusetts,2139,United States,771820
BGP-15,RLN2GTG4YS,Designated,Public record,5701,O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride,10/8/2020,Treatment of familial dysautonomia,Designated,Not FDA Approved for Orphan Indication,,,,,Mitochon Technologies Kft.,Rizling út 3,,,Balatonvilágos,8171,Hungary,769720
SACITUZUMAB GOVITECAN,M9BYU8XDQ6,Designated,Public record,5703,sacituzumab govitecan (SG),10/8/2020,Treatment for adult and pediatric patients with glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,94404,United States,769520
SUGEMALIMAB,90IQR2I6TR,Designated,Public record,5704,sugemalimab,10/8/2020,treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"CStone Pharmaceuticals (Suzhou) Co., Ltd.","399 West Haiyang Road, New Bund Times Square, 21/F",,Shanghai,,200126,China,772220
BETADEX SULFOBUTYL ETHER SODIUM,2PP9364507,Designated,Public record,5705,sulfo butyl ether beta-cyclodextrin,10/8/2020,treatment of Stargardt disease,Designated,Not FDA Approved for Orphan Indication,,,,,"reVision Therapeutics, Inc.",Attention: Paul Fehlner,125 Brookside Avenue,Ridgewood,New Jersey,7450,United States,771720
VOLASERTIB,6EM57086EA,Designated,Public record,5706,Volasertib,10/8/2020,treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Oncoheroes Biosciences Inc.,"43 Kent Street, #1",,Brookline,Massachusetts,2445,United States,771420
CLOFAZIMINE,D959AE5USF,Designated,Public record,5707,"an antibiotic combination product consisting of 3 antimicrobial agents (clarithromycin, rifabutin, and clofazimine).",10/13/2020,Treatment for Nontuberculous Mycobacteria Disease,Designated,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a St.,,Tel-Aviv,,64739,Israel,770820
CLARITHROMYCIN,H1250JIK0A,Designated,Public record,5707,"an antibiotic combination product consisting of 3 antimicrobial agents (clarithromycin, rifabutin, and clofazimine).",10/13/2020,Treatment for Nontuberculous Mycobacteria Disease,Designated,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a St.,,Tel-Aviv,,64739,Israel,770820
RIFABUTIN,1W306TDA6S,Designated,Public record,5707,"an antibiotic combination product consisting of 3 antimicrobial agents (clarithromycin, rifabutin, and clofazimine).",10/13/2020,Treatment for Nontuberculous Mycobacteria Disease,Designated,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a St.,,Tel-Aviv,,64739,Israel,770820
Azenosertib,9J13XU96Z1,Designated,Public record,5708,"(R)-2-allyl-1-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one",10/14/2020,Treatment of osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"K-Group Beta, Inc.","10835 Road to the Cure, Suite #205",,San Diego,California,92121,United States,772420
LISAFTOCLAX,OSL3FEZ1IF,Designated,Public record,5709,"APG-2575, a novel, orally active, selective and potent BCL-2 inhibitor",10/14/2020,Treatment for multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,772320
SETANAXIB,45II35329V,Designated,Public record,5716,Setanaxib,10/16/2020,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics Suisse SA,Chemin des Aulx 16,,Plan-les-Ouates,,1228,Switzerland,773220
BRANAPLAM,P12R69543A,Designated,Public record,5717,Branaplam,10/19/2020,treatment of Huntington’s disease,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,773320
DABRAFENIB,QGP4HA4G1B,Designated,Public record,5719,Dabrafenib,10/19/2020,treatment of Kabuki Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Rescindo Therapeutics Inc.,1034 Kennicott Ave,,Cary,North Carolina,27513,United States,775820
Zetomipzomib Maleate,N0CK0R203F,Designated,Public record,5722,"(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate",10/21/2020,treatment of polymyositis,Designated,Not FDA Approved for Orphan Indication,,,,,"Kezar Life Sciences, Inc.","4000 Shoreline Court, Suite 300",,South San Francisco,California,94080,United States,663518
MARALIXIBAT,UYB6UOF69L,Designated,Public record,5728,maralixibat,10/21/2020,treatment of biliary atresia,Designated,Not FDA Approved for Orphan Indication,,,,,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,94404,United States,705519
TREHALOSE,B8WCK70T7I,Designated,Public record,5729,Trehalose,10/21/2020,Treatment of CLN Batten disease,Designated,Not FDA Approved for Orphan Indication,,,,,Beyond Batten Disease Foundation,P.O. Box 50221,,Austin,Texas,78763,United States,774620
Zetomipzomib Maleate,N0CK0R203F,Designated,Public record,5730,"(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate",10/22/2020,treatment of dermatomyositis,Designated,Not FDA Approved for Orphan Indication,,,,,"Kezar Life Sciences, Inc.","4000 Shoreline Court, Suite 300",,South San Francisco,California,94080,United States,672018
METHOXYAMINE HYDROCHLORIDE,203546OLMF,Designated,Public record,5734,Methoxyamine hydrochloride,10/22/2020,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"TRACON Pharmaceuticals, Inc.","4350 La Jolla Village Dr., Suite 800",,San Diego,California,92122,United States,777120
DASATINIB,RBZ1571X5H,Designated,Public record,5738,Dasatinib,10/26/2020,Treatment of Noonan syndrome-associated hypertrophic cardiomyopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"IGIA Pharmaceuticals, Inc.",1125 Boone Aire Road,,Florence,Kentucky,41042,United States,775320
DEVIMISTAT,E76113IR49,Designated,Public record,5739,Devimistat,10/26/2020,Treatment of relapsed or refractory clear cell sarcoma of the soft tissues.,Designated,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,8512,United States,777920
RETIFANLIMAB,2Y3T5IF01Z,Designated,Public record,5741,retifanlimab-dlwr,10/26/2020,Treatment of Merkel cell carcinoma,Designated/Approved,,treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC),3/22/2023,3/22/2030,treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC),Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,695719
TEPOTINIB,1IJV77EI07,Designated/Approved,Public record,5742,tepotinib,10/26/2020,Treatment of non-small cell lung cancer with MET genomic tumor aberrations,Designated/Approved,,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations,2/3/2021,2/3/2028,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,2370,United States,679719
VENETOCLAX,N54AIC43PW,Designated,Public record,5743,Venetoclax,10/26/2020,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,60064,United States,777520
TEZACAFTOR,8RW88Y506K,Designated,Public record,5744,VX-121/tezacaftor/deutivacaftor,10/26/2020,treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Incorporated,50 Northern Avenue,,Boston,Massachusetts,2210,United States,777220
DEUTIVACAFTOR,SHA6U5FJZL,Designated,Public record,5744,VX-121/tezacaftor/deutivacaftor,10/26/2020,treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Incorporated,50 Northern Avenue,,Boston,Massachusetts,2210,United States,777220
VANZACAFTOR,COM1POP492,Designated,Public record,5744,VX-121/tezacaftor/deutivacaftor,10/26/2020,treatment of cystic fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Incorporated,50 Northern Avenue,,Boston,Massachusetts,2210,United States,777220
TRICAPRILIN,6P92858988,Designated,Public record,5745,tricaprilin,10/27/2020,Treatment of infantile spasms also known as West's syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Cerecin, Inc.","44 Cook Street, Suite 100-71",,Denver,Colorado,80206,United States,777020
ALRIZOMADLIN,15QAU0SI9J,Designated,Public record,5746,"4-((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamido)bicyclo [2.2.2]octane-1-carboxylic acid",10/28/2020,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,778720
RIFAXIMIN,L36O5T016N,Designated,Public record,5747,Rifaximin,10/28/2020,treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)",400 Somerset Corporate Boulevard,,Bridgewater,New Jersey,8807,United States,778520
PIRARUBICIN,D58G680W0G,Designated,Public record,5748,Pirarubicin,10/29/2020,Treatment of osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Hillstream BioPharma, Inc.",245 Main Street,Suite 204,Chester,New Jersey,7930,United States,778820
"""CARBAMIC ACID, N-((2-(5-(1H-IMIDAZOL-1-YLMETHYL)-2-PYRIDINYL)-4-(TRIFLUOROMETHOXY)PHENYL)SULFONYL)-, BUTYL ESTER""",L43AL5NCG7,Designated,Public record,5749,butyl ((2-(5-((1H-imidazol-1-yl)methyl)pyridin-2-yl)-4-(trifluoromethoxy)phenyl)sulfonyl) carbamate,11/2/2020,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Capacity Bio Inc.,"231 Bonetti Dr., Suite 240",,San Luis Obispo,California,93401,United States,779020
Lactobacillus acidophilus DSM 24735,L3C1ZMN2IT,Designated,Public record,5750,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",11/2/2020,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,20850,United States,778120
BIFIDOBACTERIUM INFANTIS DSM 24737,FZ8OP402EJ,Designated,Public record,5750,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",11/2/2020,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,20850,United States,778120
Lacticaseibacillus paracasei DSM 24733,AY6CSB9UQM,Designated,Public record,5750,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",11/2/2020,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,20850,United States,778120
Lactiplantibacillus plantarum DSM 24730,8FK1F8U7QM,Designated,Public record,5750,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",11/2/2020,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,20850,United States,778120
Streptococcus thermophilus DSM 24731,BV48L04N5Z,Designated,Public record,5750,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",11/2/2020,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,20850,United States,778120
Lactobacillus delbrueckii bulgaricus DSM 24734,MP0P0ASH3M,Designated,Public record,5750,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",11/2/2020,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,20850,United States,778120
Bifidobacterium breve DSM 24732,JSL2VUW7D3,Designated,Public record,5750,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",11/2/2020,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,20850,United States,778120
Bifidobacterium longum DSM 24736,787QS83XR3,Designated,Public record,5750,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",11/2/2020,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,20850,United States,778120
3-HYDROXYBUTYRATE,FG2UN5EP9V,Designated,Public record,5752,"D,L-3-hydroxybutyrate",11/3/2020,Treatment of multiple acyl-CoA dehydrogenase deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Orpha Labs, AG",Haldenstrasse 5,,Baar,,,Switzerland,779220
CITRULLINE,29VT07BGDA,Designated,Public record,5753,L-Citrulline,11/3/2020,Treatment of Ornithine Transcarbamylase deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Orpha Labs, AG",Haldenstrasse 5,,Baar,,,Switzerland,779420
"""2-(4-(4-((1-(107-(4-(guanidinomethyl)phenoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid""",,Designated,Public record,5754,"2-(4-(4-((1-(107- (4-(fluorophenyl)methoxy)-polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5- diiodophenoxy)-3,5-diiodophenyl)acetic acid",11/5/2020,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,NanoPharmaceuticals LLC,1 Discovery Drive,,Rensselaer,New York,12144,United States,780420
Dazukibart,K2Q0JXS9B4,Designated,Public record,5757,"Recombinant humanized monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1kappa) directed against human soluble cytokine interferon beta.",11/5/2020,Ttreatment of DM (including improvements in cutaneous and muscle manifestations of the disease) in adult and adolescent (aged >/=12 to,Designated,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,66 Hudson Boulevard East,,New York,New York,10001,United States,779620
VENETOCLAX,N54AIC43PW,Designated,Public record,5758,Venetoclax,11/5/2020,Treatment for small cell lung cancer,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,780920
MIZORIBINE,4JR41A10VP,Designated,Public record,5759,Mizoribine,11/9/2020,Treatment of membranous nephropathy,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,161 Jefferson Avenue,,Tenafly,New Jersey,7670,United States,780820
Xylitol,VCQ006KQ1E,Designated,Public record,5760,"peritoneal dialysis solution containing combination of D-xylitol, D-glucose, L-carnitine",11/9/2020,Treatment of patients with end stage renal disease who are undergoing peritoneal dialysis,Designated,Not FDA Approved for Orphan Indication,,,,,CoreQuest Sagl,"Stabile Suglio, Via Cantonale 18",,Manno,,,Switzerland,780220
CARNITINE,S7UI8SM58A,Designated,Public record,5760,"peritoneal dialysis solution containing combination of D-xylitol, D-glucose, L-carnitine",11/9/2020,Treatment of patients with end stage renal disease who are undergoing peritoneal dialysis,Designated,Not FDA Approved for Orphan Indication,,,,,CoreQuest Sagl,"Stabile Suglio, Via Cantonale 18",,Manno,,,Switzerland,780220
ANHYDROUS DEXTROSE,5SL0G7R0OK,Designated,Public record,5760,"peritoneal dialysis solution containing combination of D-xylitol, D-glucose, L-carnitine",11/9/2020,Treatment of patients with end stage renal disease who are undergoing peritoneal dialysis,Designated,Not FDA Approved for Orphan Indication,,,,,CoreQuest Sagl,"Stabile Suglio, Via Cantonale 18",,Manno,,,Switzerland,780220
AMINOLEVULINIC ACID,88755TAZ87,Designated,Public record,5761,5-aminolevulinic acid,11/12/2020,Diagnostic for the visualization of tumor tissue in patients undergoing surgical resection for meningioma,Designated,Not FDA Approved for Orphan Indication,,,,,NX Development Corp.,870 Corporate Drive,Suite 403,Lexington,Kentucky,40503,United States,710519
AFATINIB,41UD74L59M,Designated,Public record,5762,afatanib and palbociclib,11/12/2020,Treatment of chordoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc",5616 Hilltop Needmore Rd,,Fuquay Varina,North Carolina,27526,United States,781420
PALBOCICLIB,G9ZF61LE7G,Designated,Public record,5762,afatanib and palbociclib,11/12/2020,Treatment of chordoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc",5616 Hilltop Needmore Rd,,Fuquay Varina,North Carolina,27526,United States,781420
MITAPIVAT,2WTV10SIKH,Designated,Public record,5763,mitapivat,11/12/2020,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Agios Pharmaceuticals, Inc.",88 Sidney Street,,Cambridge,Massachusetts,2139,United States,781120
RITUXIMAB,4F4X42SYQ6,Designated,Public record,5765,rituximab,11/12/2020,Treatment of autoimmune hemolytic anemia,Designated,Not FDA Approved for Orphan Indication,,,,,Taxon Therapeutics Ltd.,"122 Bar Kokhva St,",,Herzliya,,4600728,Israel,781520
NP-10679,125EX732LG,Designated,Public record,5766,"(R)-6-(2-hydroxy-3-(4-(4-(trifluoromethyl)phenyl)piperazin- 1-yl)propoxy)-3,4-dihydroquinolin-2(1H)-one",11/17/2020,treatment of subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,NeurOp Inc.,58 Edgewood Ave,,Atlanta,Georgia,30303,United States,781020
Mirvetuximab Soravtansine,98DE7VN88D,Designated,Public record,5767,Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A),11/17/2020,Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,2451,United States,781620
ITRACONAZOLE,304NUG5GF4,Designated,Public record,5768,itraconazole,11/17/2020,Treatment of coccidioidomycosis,Designated,Not FDA Approved for Orphan Indication,,,,,Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.,1240 Sugg Parkway,,Greenville,North Carolina,27834,United States,781320
SACITUZUMAB GOVITECAN-HZIY,,Designated,Public record,5769,Antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker,11/18/2020,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 The American Rd,,Morris Plains,New Jersey,7950,United States,781720
TREHALOSE,B8WCK70T7I,Designated,Public record,5771,trehalose,11/18/2020,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Seelos Therapeutics, Inc.","300 Park Avenue, 12th Floor",,New York,New York,10022,United States,781920
EO-3021,CBF5R8TXD9,Designated,Public record,5773,"Anti-Claudin 18.2 antibody drug conjugate comprised of a Claudin 18.2 targeting monoclonal IgG1 antibody, a linker LND1002, and monomethyl auristatin E",11/19/2020,Treatment for gastric cancer including cancer of gastroesophageal junction,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.","888 7th Avenue, 12th Floor",,New York,New York,10106,United States,782320
ENCALERET SULFATE,7CKZ1Y8K70,Designated,Public record,5774,Encaleret sulfate,11/24/2020,Treatment for Autosomal Dominant Hypocalcemia Type 1 (ADH1),Designated,Not FDA Approved for Orphan Indication,,,,,"Calcilytix Therapeutics, Inc.","1800 Owens Street, Suite C-1200",,San Francisco,California,94014,United States,782120
ALRIZOMADLIN,15QAU0SI9J,Designated,Public record,5776,Murine double minute-2 (MDM2) or Human double minute-2 (HDM2),11/24/2020,Treatment of Retinoblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,784720
Teclistamab,54534MX6Z9,Designated,Public record,5778,teclistamab-cqyv,11/24/2020,Treatment of multiple myeloma,Designated/Approved,,"Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody",10/25/2022,10/25/2029,"Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody","Janssen Biotech, Inc.",920 Route 202,,Raritan,New Jersey,8869,United States,782920
CINNAMIC ACID,U14A832J8D,Designated,Public record,5779,Trans-Cinnamic Acid,11/24/2020,treatment for Niemann-Pick disease Type A and Type B,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.",140 E. Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,7652,United States,783920
CINNAMIC ACID,U14A832J8D,Designated,Public record,5780,Trans-Cinnamic Acid,11/24/2020,Treatment of GM2 gangliosidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.","140 E. Ridgewood Avenue, Suite 415, South Tower",,Paramus,New Jersey,7652,United States,782820
MK-2225,YGR6AY6YL8,Designated,Public record,5782,Homodimeric fragment crystallizable fusion protein comprised of the extracellular domain of the human transforming growth factor beta receptor type II linked to a human IgG1 Fc domain,11/25/2020,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.",126 East Lincoln Avenue,P.O. Box 2000,Rahway,New Jersey,7065,United States,782620
RAVULIZUMAB,C3VX249T6L,Designated,Public record,5783,Ravulizumab,11/25/2020,Treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,2210,United States,783320
CPZEN-45,LLP2Z9Z2EK,Designated,Public record,5784,"5-{[(5-amino-3,3-dihydroxyoxolan-2-yl)oxy][5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}-N-(4-butylphenyl)-4,7-dimethyl-6-oxocyclohept-1-ene-1-carboxamide",12/1/2020,Treatment of Tuberculosis,Designated,Not FDA Approved for Orphan Indication,,,,,PAI Life Sciences Inc.,"1616 Eastlake Ave E, Suite 550",Attn: Darrick Carter,Seattle,Washington,98102,United States,783820
NBL-015,7EM2VXC85Q,Designated,Public record,5785,Anti-Claudin 18.2 Antibody consisting of a fully human monoclonal IgG1 antibody to the type 2 isoform of human Claudin 18 protein,12/1/2020,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Leap Therapeutics, Inc.","47 Thorndike Street, Suite B-1",,Cambridge,Massachusetts,2141,United States,784020
Nemtabrutinib,JTZ51LIXN4,Designated,Public record,5788,"ARQ 531, a reversible non-covalent ATP competitive inhibitor of BTK",12/7/2020,Treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),Designated,Not FDA Approved for Orphan Indication,,,,,"ArQule, Inc., a wholly owned subsidiary of Merck Sharp & Dohme, LLC",126 East Lincoln Ave,P.O. Box 2000,Rahway,New Jersey,7065,United States,787120
TREPROSTINIL,RUM6K67ESG,Designated,Public record,5789,Treprostinil,12/7/2020,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,United Therapeutics Corporation,55 T.W. Alexander Drive,PO Box 14186,Research Triangle Park,North Carolina,27709,United States,787620
TEDUGLUTIDE,7M19191IKG,Designated,Public record,5790,Teduglutide,12/8/2020,Prevention of acute graft versus host disease,Designated,Not FDA Approved for Orphan Indication,,,,,9 Meters Biopharma Inc.,"8480 Honeycutt Road, Suite 120",,Raleigh,North Carolina,27615,United States,784820
Dimebutic Acid,AY606CN05O,Designated,Public record,5791,"2,2-dimethylbutanoic acid",12/10/2020,Treatment of propionic acidemia,Designated,Not FDA Approved for Orphan Indication,,,,,"HemoShear Therapeutics, LLC",501 Locust Avenue,,Charlottesville,Virginia,22902,United States,746120
Dimebutic Acid,AY606CN05O,Designated,Public record,5792,"2,2-dimethylbutanoic acid",12/10/2020,Treatment of methylmalonic acidemia,Designated,Not FDA Approved for Orphan Indication,,,,,"HemoShear Therapeutics, LLC",501 Locust Avenue,,Charlottesville,Virginia,22902,United States,751020
DURVALUMAB,28X28X9OKV,Designated,Public record,5793,durvalumab,12/10/2020,Treatment of biliary tract cancer,Designated/Approved,,"In combination with gemcitabine and cisplatin, for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)",9/2/2022,9/2/2029,treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC),AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,19803,United States,785220
Eneboparatide,K6E9SY8U8D,Designated,Public record,5795,H-Ala-Val-Ala-Glu-Ile-Gln-Leu-Met-His-Gln-Arg-Ala-Lys-Trp-Ile-Gln-Asp-Ala-Arg-Arg-Arg-Ala-Phe-Leu-His-Lys-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile-OH,12/14/2020,Treatment of Hypoparathyroidism,Designated,Not FDA Approved for Orphan Indication,,,,,Amolyt Pharma SAS (formerly Alize Pharma III SAS),"15, chemin du Saquin, Espace Europeen",Building G,Ecully,,,France,786220
RINTATOLIMOD,94325AJ25N,Designated,Public record,5797,Rintatolimod,12/17/2020,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,2117 SW Highway 484,,Ocala,Florida,34473,United States,785520
FASUDIL,Q0CH43PGXS,Designated,Public record,5799,Fasudil,12/21/2020,Treatment of progressive supranuclear palsy,Designated,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.","233 Broadway, Suite 1750",,New York,New York,10279,United States,787220
ANBENITAMAB,RHS90QRF9E,Designated,Public record,5800,FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific IgG1 antibody inhibiting PD-L1 and CTLA-4,12/21/2020,"Treatment of Gastric Cancer, including Cancer of the Gastroesophageal Junction",Designated,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd.","Bldg. C23, 218 Xinghu Street",SIP,SuZhou,,,China,786920
IMATINIB,BKJ8M8G5HI,Designated,Public record,5802,Imatinib,12/21/2020,Treatment of Pulmonary Arterial Hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,"Aerovate Therapeutics, Inc","200 Berkeley Street, Floor 18",,Boston,Massachusetts,2116,United States,787520
NILOTINIB,F41401512X,Designated,Public record,5803,Nilotinib ONCORE,12/23/2020,Treatment of Chronic Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Handa Oncology, LLC","1732 N. First Street, Suite 200",,San Jose,California,95112,United States,786820
LISAFTOCLAX,OSL3FEZ1IF,Designated,Public record,5804,"4-{4-{[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",12/28/2020,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,787920
ANNAMYCIN,SNU299M83Q,Designated,Public record,5805,liposomal annamycin,12/28/2020,Treatment of soft tissue sarcomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.","5300 Memorial Drive, Suite 950",,Houston,Texas,77007,United States,787720
NILOTINIB,F41401512X,Designated,Public record,5806,nilotinib oral formulation,12/28/2020,Treatment of chronic myeloid leukemia (CML).,Designated,Not FDA Approved for Orphan Indication,,,,,Xspray Pharma AB,Råsundavägen 12,,Solna,,16967,Sweden,788520
Froniglutide,3V0J65M6J3,Designated,Public record,5808,Glucagon like peptide-1 Elastin like peptide-120 fusion protein,12/30/2020,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunoForge Co., Ltd.","307-1, 105 Bldg., Seoul National University","1 Gwanak-ro, Gwanak-gu",Seoul,,,South Korea,789220
ILIXADENCEL,PY29292DVJ,Designated,Public record,5809,Ilixadencel,12/30/2020,Treatment of hepatocellular carcinoma (HCC).,Designated,Not FDA Approved for Orphan Indication,,,,,Mendus AB,Östermalmstorg 5,,Stockholm,,,Sweden,788320
VLX-1005,JKU4XCC48Y,Designated,Public record,5810,N-Benzothiazol-2-yl-4-(2-hydroxy-3-methoxy-benzylamino)-bezenesulfonamide,12/30/2020,Prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia,Designated,Not FDA Approved for Orphan Indication,,,,,Veralox Therapeutics,4539 Metropolitan Ct.,,Frederick,Maryland,21704,United States,736720
ORELABRUTINIB,WJA5UO9E10,Designated,Public record,5811,Orelabrutinib,12/30/2020,Treatment of Mantle Cell Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,InnoCare Pharma Inc.,"103 Carnegie Center, Suite 209",,Princeton,New Jersey,8540,United States,788920
BACLOFEN,H789N3FKE8,Designated,Public record,5812,baclofen,12/31/2020,Prevention of baclofen withdrawal syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Saol Therapeutics Research Limited,"Peter Street, Unit G04",Adelaide Chambers,Dublin,,8,Ireland,685619
AFICAMTEN,B1I77MH6K1,Designated,Public record,5814,cardiac sarcomere inhibitor,1/5/2021,Treatment of symptomatic hypertrophic cardiomyopathy,Designated,Not FDA Approved for Orphan Indication,,,,,Cytokinetics Inc.,280 East Grand Avenue,,South San Francisco,California,94080,United States,688819
IZAFLORTAUCIPIR F-18,U796G75A7P,Designated,Public record,5816,izaflortaucipir (proposed INN),1/5/2021,1) In the initial diagnosis of progressive supranuclear palsy (PSP) and 2) Diagnostic in the clinical management of PSP.,Designated,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"First Floor, The Woods, Opus 40 Business Park",,Warwick,,,United Kingdom,755520
ATEZOLIZUMAB,52CMI0WC3Y,Designated,Public record,5819,Atezolizumab,1/7/2021,Treatment of esophageal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Genentech Inc.,"1 DNA Way, MS #45-1A",,South San Francisco,California,,United States,792320
FASUDIL HYDROCHLORIDE,SQ04N8S7BR,Designated,Public record,5820,Fasudil hydrochloride,1/7/2021,Treatment of Corticobasal Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,792720
COBIMETINIB,ER29L26N1X,Designated,Public record,5822,cobimetinib,4/26/2021,Treatment for histiocytic neoplasms,Designated/Approved,,as a single agent for the treatment of adult patients with histiocytic neoplasms,10/28/2022,10/28/2029,treatment of adult patients with histiocytic neoplasms,"Genentech, Inc.",1 DNA Way MS#451b,,South San Francisco,California,94080,United States,752820
CAMRELIZUMAB,73096E137E,Designated,Public record,5824,camrelizumab,4/27/2021,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Hengrui Medicine Co., Ltd",7 Kunlunshan Road,Economic and Technological Development Zone,Lianyungang,Jiangsu,,China,675718
DIMETHYLTRYPTAMINE,WUB601BHAA,Designated,Public record,5825,dimethyltryptamine,4/27/2021,Prevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,Sairiyo Therapeutics Inc.,"77 King Street West, Suite 2905",,Toronto,Ontario,,Canada,813521
Olorofim,T34SH2H9HI,Designated,Public record,5826,olorofim,4/27/2021,Treatment of invasive scopulariopsis/microascus,Designated,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way Eccles,,Manchester,Manchester,,United Kingdom,814021
Relutrigine,AW5C5XHM4W,Designated,Public record,5827,"Small molecule, non-isoform selective NaV persistent current inhibitor",4/27/2021,Treatment of SCN2A Developmental and Epileptic Encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Praxis Precision Medicines, Inc.","One Broadway, 16th Floor",,Cambridge,Massachusetts,2142,United States,789420
IT-139,7OSJ9KS483,Designated,Public record,5828,Sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)],4/27/2021,Treatment of Gastric Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Bold Therapeutics, Inc.","170 - 422 Richards Street,",,Vancouver,BC,,Canada,813421
COPANLISIB,WI6V529FZ9,Designated,Public record,5829,copanlisib,5/3/2021,Treatment of patients with Lymphoplasmacytoid lymphoma/ Waldenström macroglobulinemia,Designated,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare Pharmaceuticals Inc.,100 Bayer Blvd,P.O.Box 915,Whippany,New Jersey,,United States,811421
TALQUETAMAB,4W3KFI3TN3,Designated,Public record,5830,Talquetamab,5/3/2021,Treatment of Multiple Myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202,,Raritan,New Jersey,8869,United States,814921
EO-3021,CBF5R8TXD9,Designated,Public record,5831,Anti-Claudin 18.2 Antibody Drug Conjugate with MMAE and LND1002 linker,5/5/2021,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.","888 7th Avenue, 12th Floor",,New York,New York,10106,United States,814521
"""6-FLUORO-9-METHYL-9H-PYRIDO(3,4-B)-INDOLE""",KT2RT2HH65,Designated,Public record,5832,"6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole",5/10/2021,Treatment of Sudden Sensorineural Hearing Loss,Designated,Not FDA Approved for Orphan Indication,,,,,AudioCure Pharma GmbH,Schlegelstr 9,,Berlin,,10115,Germany,797920
EFOCIPEGTRUTIDE,TUI1MDD9F6,Designated,Public record,5834,glucagon-like peptide-1/glucagon/gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment,5/10/2021,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Co., Ltd.",14 Wiryeseong-daero,Songpa-gu,Seoul,,5545,South Korea,815521
KETAMINE,690G0D6V8H,Designated,Public record,5835,ketamine,5/10/2021,Treatment of Complex Regional Pain Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,iX Biopharma Ltd.,1 Kim Seng Promenade #14-01,Great World City East Tower,Singapore,,237994,Singapore,812221
MELATONIN,JL5DK93RCL,Designated,Public record,5836,Melatonin,5/10/2021,Treatment of Retinitis Pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,Via Malachia Marchesi de Taddei 21,,Milan,,,Italy,816621
Denecimig,EUV85RR8DJ,Designated,Public record,5838,recombinant bispecific human IgG4 antibody which functionally mimics the procoagulant properties of activated FVIII,5/10/2021,Treatment of Hemophilia A,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",800 Scudders Mill Rd.,,Plainsboro,New Jersey,8536,United States,814121
ROMOSOZUMAB,3VHF2ZD92J,Designated,Public record,5839,romosozumab,5/10/2021,Treatment of Osteogenesis Imperfecta,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,,United States,816321
SULINDAC,184SNS8VUH,Designated,Public record,5840,Sulindac,5/10/2021,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Healx Limited,"Charter House, 66-68 Hills Rd",,Cambridge,,,United Kingdom,818421
FLUNARIZINE,R7PLA2DM0J,Designated,Public record,5842,flunarizine,5/12/2021,Treatment of Childhood Absence Epilepsy,Designated,Not FDA Approved for Orphan Indication,,,,,Xenon Pharmaceuticals Inc.,200-3650 Gilmore Way,,Burnaby,BC,,Canada,823521
BERSIPOROCIN HYDROCHLORIDE,Q1X50E5QJL,Designated,Public record,5847,"(2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol hydrogen chloride",5/20/2021,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Daewoong Pharmaceutical Co., Ltd.","12, Bongeunsa-ro 114 gil, Gangnam-gu",,Seoul,,,South Korea,817121
SPG-302,CMJ4GT6MRD,Designated,Public record,5848,2-(2-{2-(2-{4-Benzothiazol-2- y1-phenoxy}-ethoxy]-ethoxy}-ethoxy}-ethanol,5/24/2021,Treatment of Amyotrophic Lateral Sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,"Spinogenix, Inc","10210 Campus Point Drive, Suite 150",,San Diego,California,92121,United States,802820
TAFASITAMAB-CXIX,,Designated,Public record,5851,tafasitamab-cxix,1/7/2021,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,MorphoSys US Inc.,"470 Atlantic Avenue 14th Floor, Suite 1401",,Boston,Massachusetts,2210,United States,790920
TIRAGOLUMAB,6XG22YQM2Z,Designated,Public record,5852,Tiragolumab,1/7/2021,Treatment of Esophageal Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Genentech Inc.,"1 DNA Way, MS #45-1A",,South San Francisco,California,,United States,792420
IVALTINOSTAT,4I8MLM7L2H,Designated,Public record,5855,Ivaltinostat,1/8/2021,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"CG Pharmaceuticals, Inc.","100-D, Bldg. D, Pine Grove Business Center",4 Orinda Way,Orinda,California,94563,United States,793520
ATIBUCLIMAB,23IQ3PO968,Designated,Public record,5857,chimeric IgG4 monoclonal antibody targeting CD14,1/11/2021,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Implicit Bioscience Ltd.,32 Logan Rd,Woolloongabba,,Queensland,,Australia,650418
SITAXENTAN,J9QH779MEM,Designated,Public record,5858,Sitaxentan (also known as sitaxsentan),1/11/2021,Treatment of Systemic Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Timber Pharmaceuticals, Inc.","50 Tice Boulevard, Suite A26",,Woodcliff Lake,New Jersey,7677,United States,793420
SPARSENTAN,9242RO5URM,Designated,Public record,5859,sparsentan,1/11/2021,Treatment of immunoglobulin A (IgA) nephropathy,Designated/Approved,,"to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g",2/17/2023,2/17/2030,"to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g","Travere Therapeutics, Inc.","3611 Valley Centre Drive, Suite 300",,San Diego,California,92130,United States,614417
ALITRETINOIN,1UA8E65KDZ,Designated,Public record,5860,alitretinoin,1/12/2021,Treatment of systemic (non-cutaneous) kaposi sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Galephar Pharmaceutical Research, Inc.",Carr 925 Km 6.1 Bo. Junquito,HC-04 BOX 4540,Humacao,Puerto Rico,791,United States,708819
TELACEBEC,55G92WGH3X,Designated,Public record,5861,Telacebec,1/13/2021,Treatment of Buruli ulcer,Designated,Not FDA Approved for Orphan Indication,,,,,"The Global Alliance for TB Drug Development, Inc.","80 Pine Street, 20th Floor",,New York,New York,10005,United States,793920
CEPHARANTHINE,7592YJ0J6T,Designated,Public record,5862,Cepharanthine,1/14/2021,Treatment of Esophageal Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Sairiyo Therapeutics Inc.,"77 King Street West, Suite 2905",,Toronto,Ontario,,Canada,794320
Anvatabart Opadotin,B2KH16FA7H,Designated,Public record,5863,humanized HER2 targeting monoclonal antibody conjugated to a cytotoxic tubulin inhibitor amberstatin,1/14/2021,Treatment of gastric cancer including cancer at the gastroesophageal junction,Designated,Not FDA Approved for Orphan Indication,,,,,"Ambrx, Inc.",10975 N. Torrey Pines Road,,La Jolla,California,92037,United States,794820
AVR-48,GVY9AA7Y5C,Designated,Public record,5864,"N-((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(4-nitrophenoxy)tetrahydro-2H-pyran-3-yl)acetamide",1/18/2021,Prevention of bronchopulmonary dysplasia.,Designated,Not FDA Approved for Orphan Indication,,,,,"AyuVis Research, Inc.","1120 South Fwy, #121",,Fort Worth,Texas,76104,United States,723619
LISAFTOCLAX,OSL3FEZ1IF,Designated,Public record,5865,"4-{4-{[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",1/19/2021,Treatment of follicular lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,796420
TRYPTOPHAN,8DUH1N11BX,Designated,Public record,5867,L-pyroglutamyl-L-asparaginyl-L-prolyl-D-tyrosyl-D-tryptophan amide,1/19/2021,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Neuropath Therapeutics Limited,26 Upper Pembroke Street,Suite 2006,Dublin,,2,Ireland,796220
MIGLUSTAT,ADN3S497AZ,Designated,Public record,5868,miglustat,1/19/2021,Treatment of CLN Batten Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Beyond Batten Disease Foundation,P.O. Box 50221,,Austin,Texas,78763,United States,795420
UTTROSIDE B,QK6VN86E3T,Designated,Public record,5869,uttroside B,1/19/2021,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Q BioMed,366 Madison Ave,,New York,New York,10017,United States,795820
Zunsemetinib,AX2VWG0ZCR,Designated,Public record,5870,"(P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one",1/21/2021,Treatment of cryopyrin-associated periodic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Aclaris Theapeutics Inc.,"640 Lee Road, Suite 200",,Wayne,Pennsylvania,19087,United States,795720
CARFILZOMIB,72X6E3J5AR,Designated,Public record,5872,carfilzomib,1/21/2021,Treatment of Acute Lymphoblastic Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,,United States,795120
VAMIFEPORT HYDROCHLORIDE,9DV8VO33JX,Designated,Public record,5873,ferroportin inhibitor,1/25/2021,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Vifor Pharma, Inc.",200 Cardinal Way,,Redwood City,California,94063,United States,796320
ILIXADENCEL,PY29292DVJ,Designated,Public record,5874,ilixadencel,1/25/2021,Treatment of soft tissue sarcoma (STS),Designated,Not FDA Approved for Orphan Indication,,,,,Mendus AB,Östermalmstorg 5,,Stockholm,,,Sweden,796120
ROMIPLOSTIM,GN5XU2DXKV,Designated,Public record,5875,romiplostim,1/25/2021,Treatment of chemotherapy-induced thrombocytopenia,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,91320,United States,751320
SURAMIN,6032D45BEM,Designated,Public record,5876,suramin,1/25/2021,Treatment of human African trypanosomiasis,Designated,Not FDA Approved for Orphan Indication,,,,,"PaxMedica, Inc.","50 Tice Blvd., Suite A26",,Woodcliff Lake,New Jersey,7677,United States,797220
DEXAMETHASONE,7S5I7G3JQL,Designated,Public record,5877,dexamethasone,1/26/2021,Prevention of Proliferative Vitreoretinopathy (PVR),Designated,Not FDA Approved for Orphan Indication,,,,,"TherOptix, Inc.","689 Main Street, #305",,Walpole,Massachusetts,2081,United States,795620
SAROGLITAZAR MAGNESIUM,K8V5DLS63R,Designated,Public record,5878,saroglitazar magnesium,1/26/2021,Treatment of Primary Biliary Cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,Zydus Discovery DMCC,"Unit no 909, Armada 2","Plot no : JLT-PH2-P2A,",Dubai,,,United Arab Emirates,686819
TALABOSTAT,KZ1O2SH88Z,Designated,Public record,5879,Talabostat,1/26/2021,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,BioXcel Therapeutics,"555 Long Wharf Drive, 5th Floor",,New Haven,Connecticut,6511,United States,796720
SIVELESTAT,DWI62G0P59,Designated,Public record,5880,Sivelestat,1/27/2021,Treatment of Acute Radiation Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical,c/o Noa Avtalion,161 Jefferson Avenue,Tenafly,New Jersey,,United States,796020
LJ-2698,L4A6E7Q76T,Designated,Public record,5881,"(2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol",2/1/2021,Treatment of Primary Biliary Cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Future Medicine Co., Ltd.","Rm616, LH Business Growth Center, 54 Changeop-ro, Sujeong-gu",,Seongnam,Gyeonggi-do,,South Korea,796620
IM-156,8MS59W493C,Designated,Public record,5882,N-(N-(4-(trifluoromethoxy)phenyl) carbamimidoyl)pyrrolidine-1-carboximidamide acetate (Or N1-(4-trifluoromethoxy)phenyl-N5-pyrrolidine biguanide acetate),2/1/2021,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,ImmunoMet Therapeutics Inc.,2450 Holcombe,,Houston,Texas,77021,United States,796920
DENOSUMAB,4EQZ6YO2HI,Designated,Public record,5884,denosumab,2/2/2021,Treatment of osteogenesis imperfecta,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,,United States,798920
MIGLUSTAT,ADN3S497AZ,Designated,Public record,5885,Miglustat,2/2/2021,Treatment of Niemann-Pick Disease Type C,Designated,Not FDA Approved for Orphan Indication,,,,,Edenbridge Pharmaceuticals LLC,"169 Lackawanna Ave, Suite 110",,Parsippany,New Jersey,7054,United States,798620
RIVOCERANIB,5S371K6132,Designated,Public record,5886,Rivoceranib,2/2/2021,Treatment of Adenoid Cystic Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevar Therapeutics, Inc.","2825 E Cottonwood Pkwy, Suite 180",,Salt Lake City,Utah,84121,United States,798720
CEVOSTAMAB,P86BHN01VE,Designated,Public record,5887,cevostamab,2/3/2021,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,94080,United States,799220
CINNAMIC ACID,U14A832J8D,Designated,Public record,5888,Trans-Cinnamic Acid,2/3/2021,Treatment of Krabbe disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.","140 E. Ridgewood Avenue, Suite 415, South Tower",,Paramus,New Jersey,7652,United States,802320
INZ-701,8ZH1P9LXW1,Designated,Public record,5889,Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1,2/4/2021,Treatment of adenosine triphosphate binding cassette subfamily C member 6 deficiency (ABCC6 deficiency),Designated,Not FDA Approved for Orphan Indication,,,,,"Inozyme Pharma, Inc.","321 Summer Street, Suite 400",,Boston,Massachusetts,2210,United States,660118
Vemircopan,HN6I4K50QB,Designated,Public record,5890,"(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide",2/8/2021,Treatment of paroxysmal nocturnal hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,Alexion Pharmaceuticals Inc.,121 Seaport Blvd,,Boston,Massachusetts,2210,United States,722519
HEXASODIUM PHYTATE,ZBX50UG81V,Designated,Public record,5892,"hexasodium salt of myo-inositol hexaphosphate (IP6, phytate) hexasodium phytate",2/8/2021,Treatment of peripheral arterial disease in patients with end-stage kidney disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Vifor Pharma, Inc.",200 Cardinal Way,,Redwood City,California,94063,United States,799020
IADADEMSTAT,54T74394F8,Designated,Public record,5896,iadademstat,2/10/2021,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Oryzon Genomics S.A.,"Carrera de San Jeronimo 15, 2ª planta",,Madrid,Spain,28014,Spain,800020
NIPOCALIMAB,87M90CV8NC,Designated,Public record,5897,nipocalimab,2/11/2021,Treatment of myasthenia gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.",301 Binney Street,,Cambridge,Massachusetts,2142,United States,799320
PF-06842874,AX8OYB2MWW,Designated,Public record,5900,"3-Acetyl-1-cyclopentyl-7-{[(3S,4R)-3-hydroxyoxan-4-yl]amino }-4-methyl-1,6-naphthyridin-2(1H)-one",2/18/2021,Treatment of pulmonary arterial hypertension,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",235 East 42nd Street,,New York,New York,10017,United States,800720
CARMUSTINE,U68WG3173Y,Designated,Public record,5901,Carmustine,2/18/2021,Conditioning treatment prior to hematopoietic cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Emcure Pharmaceuticals Ltd.,"T-184, M.I.D.C. Bhosari",,Pune,Maharashtra,411026,India,801420
LNS-8801,TFS4QE36ZG,Designated,Public record,5904,"1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone",2/19/2021,Treatment of uveal melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Linnaeus Therapeutics, Inc.",30 Washington Avenue,Suite F,Haddonfield,New Jersey,8033,United States,801620
TRODUSQUEMINE HYDROCHLORIDE,7VON0S1S42,Designated,Public record,5905,Trodusquemine HCl,2/19/2021,Treatment of Dystrophinopathies,Designated,Not FDA Approved for Orphan Indication,,,,,Novo Biosciences,415 Water Street,,Ellsworth,Maine,4605,United States,800120
AD-214,UA96NQU2PH,Designated,Public record,5906,Fc-fusion protein comprised of an anti-CXCR4 i-body tethered at its C-terminus to constant domains 2 and 3 of the Fc region of a mutated human IgG1,2/22/2021,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,AdAlta Limited,15/2 Park Drive,,Bundoora,Victoria,3083,Australia,800420
STIRIPENTOL,R02XOT8V8I,Designated,Public record,5907,Stiripentol,2/22/2021,Treatment of Primary Hyperoxaluria,Designated,Not FDA Approved for Orphan Indication,,,,,Biocodex,7 avenue Gallieni,,Gentilly,Gentilly,94250,France,800820
ISPECTAMAB DEBOTANSINE,WY39ZX6NZU,Designated,Public record,5908,antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead,2/23/2021,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,802520
PENPULIMAB,IBS1BZ4E4I,Designated,Public record,5909,Penpulimab,2/23/2021,Treatment of nasopharyngeal carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Akeso Biopharma, Inc.","6 Shennong Road, Torch Development Zone",,Zhongshan,Guangdong,528437,China,802020
SATRALIZUMAB-MWGE,,Designated,Public record,5910,satralizumab-mwge,2/23/2021,Treatment of myasthenia gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,802720
Cudetaxestat sodium,6FZL38CMV9,Designated,Public record,5911,"Sodium-3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoate",2/23/2021,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Blade Therapeutics, Inc.",442 Littlefield Avenue,,South San Francisco,California,94080,United States,801820
CAVROTOLIMOD,2Z5JOV1PPN,Designated,Public record,5914,cavrotolimod,3/1/2021,Treatment of merkel cell carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Exicure, Inc.","2430 N. Halsted Street, 4th Floor",,Chicago,Illinois,60614,United States,677419
MECBOTAMAB VEDOTIN,VF40YVX65F,Designated,Public record,5915,humanized IgG1anti-AXL-antibody conjugated to monomethyl auristatin E,3/1/2021,Treatment of Soft Tissue Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"BioAtla, Inc.",11085 Torreyana Road,Suite 100,San Diego,California,92121,United States,802920
NESUPARIB MONOCITRATE,5GB5K3SD5Y,Designated,Public record,5916,"6-(4-((5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-yl)methyl)piperazin-1-yl)nicotinonitrile mono citrate",3/2/2021,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Onconic Therapeutics,"1F, 12 Tehranro-26-gil",,Gangnam,Seoul,6236,South Korea,802220
FOMEPIZOLE,83LCM6L2BY,Designated,Public record,5918,Fomepizole,3/2/2021,Treatment of acetaminophen overdose,Designated,Not FDA Approved for Orphan Indication,,,,,Denver Health - Rocky Mountain Poison & Drug Safety,777 Bannock St. MC 0180,,Denver,Colorado,80204,United States,801320
PADELIPORFIN,EEO29FZT86,Designated,Public record,5919,padeliporfin,3/2/2021,Treatment of upper tract urothelial cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Steba Biotech S.A,7 Place du Théâtre,,,Luxembourg,,Luxembourg,803320
TESOFENSINE,BLH9UKX9V1,Designated,Public record,5920,Tesofensine plus metoprolol in a fixed-dose combination,3/2/2021,Treatment of Prader-Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Saniona S/A,Smedeland 26B,,Glostrup,,,Denmark,804320
METOPROLOL,GEB06NHM23,Designated,Public record,5920,Tesofensine plus metoprolol in a fixed-dose combination,3/2/2021,Treatment of Prader-Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Saniona S/A,Smedeland 26B,,Glostrup,,,Denmark,804320
Inixaciclib,Q6460P4C0B,Designated,Public record,5921,CDK inhibitor (CDKI) of CDK2/4/6,3/3/2021,"Treatment of patients with malignant gliomas (including glioblastoma, astrocytoma, and oligodendroglioma)",Designated,Not FDA Approved for Orphan Indication,,,,,"Nuvation Bio, Inc.","1500 Broadway, Suite 1401",,New York,New York,10036,United States,805820
SEPIAPTERIN,CJQ26KO7HP,Designated,Public record,5923,sepiapterin,3/4/2021,Treatment of hyperphenylalaninemia,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,805320
UBENIMEX,I0J33N5627,Designated,Public record,5924,Ubenimex,3/8/2021,Treatment of Chronic Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical inc,161 Jefferson Ave.,,tenafly,New Jersey,7670,United States,806720
DODECYL CREATINE ESTER,Z7DW5UW9UD,Designated,Public record,5925,Dodecyl Creatine Ester,3/9/2021,Treatment of Creatine Transporter Deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,CERES BRAIN Therapeutics,Paris Biotech Santé,"24, rue du Faubourg Saint Jacques",Paris,,75014,France,803720
NEMVALEUKIN ALFA,7ZX1Q9SJ1F,Designated,Public record,5926,fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha,3/9/2021,Treatment of mucosal melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Alkermes, Inc.",852 Winter Street,,Waltham,Massachusetts,,United States,806020
VEDOLIZUMAB,9RV78Q2002,Designated,Public record,5928,vedolizumab,3/15/2021,Treatment of Pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,804920
MC-16,9P2K5CXC5F,Designated,Public record,5929,(+)-5-chloro-1-ethyl-3-(2-hydroxy-3-methoxybenzyl)-2-oxoindolin-3-yl dimethylcarbamate,3/16/2021,Treatment of Retinitis Pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"MitoChem Therapeutics, Inc.",645 Meeting Street,,Charleston,South Carolina,29403,United States,806520
VITAMIN A PALMITATE,1D1K0N0VVC,Designated,Public record,5931,"Retinyl Palmitate, Alisitol (herbal extract), Zn Gluconate",3/18/2021,Treatment of Microvillus Inclusion Disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Dmitry V. Kravtsov, M.D.","925 Sherman Avenue, Hamden, CT 06514, USA",,Hamden,Connecticut,6514,United States,805420
ZINC GLUCONATE,U6WSN5SQ1Z,Designated,Public record,5931,"Retinyl Palmitate, Alisitol (herbal extract), Zn Gluconate",3/18/2021,Treatment of Microvillus Inclusion Disease.,Designated,Not FDA Approved for Orphan Indication,,,,,"Dmitry V. Kravtsov, M.D.","925 Sherman Avenue, Hamden, CT 06514, USA",,Hamden,Connecticut,6514,United States,805420
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5932,Cannabidiol,3/22/2021,Treatment of Angelman syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Biom Therapeutics,2203 Industrial Blvd.,,Sarasota,Florida,34239,United States,806620
CANAKINUMAB,37CQ2C7X93,Designated,Public record,5933,canakinumab,3/24/2021,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,805920
SPARTALIZUMAB,QOG25L6Z8Z,Designated,Public record,5934,spartalizumab,3/24/2021,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,819321
ERAGIDOMIDE,R76M2Z6366,Designated,Public record,5935,cereblon enzyme 3 (E3) ligase modulating agent,3/25/2021,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation (a Bristol-Myers Squibb Company),86 Morris Avenue,,Summit,New Jersey,7901,United States,808421
AMINOLEVULINIC ACID,88755TAZ87,Designated,Public record,5936,5-Aminolevulinic Acid,3/29/2021,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Hemerion Therapeutics,12 rue Denis Papin,NEO 2 - Building A,Villeneuve d’Ascq,,59650,France,811521
Perenostobart,O84ZK2F68E,Designated,Public record,5937,?-CD39 IgG4 monoclonal antibody,3/29/2021,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Surface Oncology, Inc.",50 Hampshire Street,8th Floor,Cambridge,Massachusetts,2139,United States,808821
AXATILIMAB,R96Z451BMC,Designated,Public record,5938,axatilimab,3/29/2021,Treatment of chronic graft versus host disease.,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,732320
LITHIUM CARBONATE,2BMD2GNA4V,Designated,Public record,5939,lithium carbonate,3/29/2021,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Lispiro LLC,4 Betsy Lane,,Dover,Massachusetts,2030,United States,808921
GLUTAMIC ACID,3KX376GY7L,Designated,Public record,5940,"(5-(3-(2-amino-4-oxo-4,7-dihydro-3 H-pyrrolo[2,3- d]pyrimidin-6-yl)propyl)thiophene-2-carbonyl)- L-glutamic acid)",3/30/2021,Treatment of Mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,"FLAG Therapeutics, Inc.",9168 Wooden Road,,Raleigh,North Carolina,,United States,806920
Emavusertib,MH5DMF9JKY,Designated,Public record,5942,"(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide",4/5/2021,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.","128 Spring Street, Building C, Suite 500",,Lexington,Massachusetts,2421,United States,810321
BEMPEDOIC ACID,1EJ6Z6Q368,Designated,Public record,5943,bempedoic acid,4/5/2021,Treatment of homozygous familial hypercholesterolemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Esperion Therapeutics, Inc.","3891 Ranchero Drive, Suite 150",,Ann Arbor,Michigan,48108,United States,812621
NBL-015,7EM2VXC85Q,Designated,Public record,5944,fully human monoclonal IgG1 antibody against the type 2 isoform of human Claudin 18 protein (Claudin 18.2).,4/6/2021,"Treatment of gastric cancer, including cancer of gastroesophageal junction",Designated,Not FDA Approved for Orphan Indication,,,,,"Leap Therapeutics, Inc.","47 Thorndike Street, Suite B-1",,Cambridge,Massachusetts,2141,United States,810021
Taniraleucel,XO25H8E4QP,Designated,Public record,5945,taniraleucel,4/6/2021,Treatment of Malignant Glioma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celularity Inc.,170 Park Avenue,,Florham Park,New Jersey,7932,United States,809021
AXATILIMAB,R96Z451BMC,Designated,Public record,5947,axatilimab,4/7/2021,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Syndax Pharmaceuticals, Inc.",35 Gatehouse Drive,"Building D, Floor 3",Waltham,Massachusetts,2451,United States,807821
EPRENETAPOPT,Z41TGB4080,Designated,Public record,5948,eprenetapopt,4/7/2021,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Aprea Therapeutics, Inc.",535 Boylston Street,2nd Floor,Boston,Massachusetts,2116,United States,797420
GLY-ARG-ARG-ALA-ALA-PRO-GLY-ARG-AIB-GLY-GLY-NH2,4SS6E3D7MH,Designated,Public record,5949,a peptidomimetic protein peptide with sequence H-Gly-Arg-Arg-Ala-Ala-Pro-Gly-Arg-Aib-Gly-Gly-NH2,4/8/2021,Treatment of Lennox- Gastaut Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,CuroNZ Ltd,173 Cames Road,,Mangawhai,,975,New Zealand,810621
Apinocaltamide,3Z7U1U8Z9E,Designated,Public record,5950,N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl-phenyl]-acetamide,4/8/2021,Treatment of epileptic encephalopathy with continuous spike-wave discharges during sleep (EECSWS),Designated,Not FDA Approved for Orphan Indication,,,,,Neurocrine Biosciences Inc.,12780 El Camino Real,,San Diego,California,92130,United States,808621
Relutrigine,AW5C5XHM4W,Designated,Public record,5951,"Small molecule, non-isoform selective NaV persistent current inhibitor",4/8/2021,Treatment of SCN8A Developmental and Epileptic Encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Praxis Precision Medicines, Inc.","One Broadway, 16th Floor",,Cambridge,Massachusetts,2142,United States,789620
IZAFLORTAUCIPIR F-18,U796G75A7P,Designated,Public record,5953,Izaflortaucipir (proposed INN),4/12/2021,Diagnosis of Corticobasal Degeneration,Designated,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"First Floor, The Woods, Opus 40 Business Park",,Warwick,,,United Kingdom,763320
Emavusertib,MH5DMF9JKY,Designated,Public record,5954,"(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide",4/16/2021,Treatment of myelodysplastic syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.","128 Spring Street, Building C, Suite 500",,Lexington,Massachusetts,2421,United States,810221
COPANLISIB,WI6V529FZ9,Designated,Public record,5955,copanlisib,4/16/2021,Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare Pharmaceuticals Inc.,100 Bayer Blvd,P.O.Box 915,Whippany,New Jersey,,United States,811321
Elzovantinib,TTY12Q00LY,Designated,Public record,5958,"(7S)-3-Amino-14-ethyl-11-fluoro-7-methyl-4-oxo-4,5,6,7,13,14-hexahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecine-12-carbonitrile",5/25/2021,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated,Not FDA Approved for Orphan Indication,,,,,Bristol Myers Squibb,3401 Princeton Pike,,Lawrenceville,New Jersey,8648,United States,817821
APRAGLUTIDE,CVQ1IAY2G6,Designated,Public record,5959,apraglutide,5/25/2021,Prevention of acute graft-versus-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,VectivBio AG,Aeschenvorstadt 36,,Basel,,4051,Switzerland,817021
TPX-4589,9GK5GYD8DQ,Designated,Public record,5961,an antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE,5/26/2021,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol Myers Squibb,3401 Princeton Pike,,Lawrenceville,New Jersey,8648,United States,819021
TPX-4589,9GK5GYD8DQ,Designated,Public record,5962,an antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE,5/26/2021,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,Not FDA Approved for Orphan Indication,,,,,Bristol Myers Squibb,3401 Princeton Pike,,Lawrenceville,New Jersey,8648,United States,819121
DIAZOXIDE CHOLINE,2U8NRZ7P8L,Designated,Public record,5963,Diazoxide choline,5/26/2021,Treatment of Glycogen Storage Disease Type 1,Designated,Not FDA Approved for Orphan Indication,,,,,"Soleno Therapeutics, Inc.",203 Redwood Shores Parkway,Suite 500,Redwood City,California,94065,United States,818621
LINPERLISIB,05HYK3CV9N,Designated,Public record,5964,linperlisib,5/26/2021,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Shanghai Yingli Pharmaceutical Co., Ltd.","Room 01, 4th Floor, Building A","2829 Jinke Road, Zhangjiang Hi-Tech Park, Pudong New Area",Shanghai,,,China,818221
TESEVATINIB,F6XM2TN5A1,Designated,Public record,5965,tesevatinib,5/26/2021,Treatment of autosomal dominant polycystic kidney disease,Designated,Not FDA Approved for Orphan Indication,,,,,Kadmon Corporation,450 East 29th Street,,New York,New York,10016,United States,802420
Briquilimab,QWX84D0DRC,Designated,Public record,5967,a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit),6/7/2021,Conditioning treatment prior to hematopoietic stem cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Jasper Therapeutics, Inc.","2200 Bridge Parkway, Suite #102",,Redwood City,California,94065,United States,820121
ADAGRASIB,8EOO6HQF8Y,Designated,Public record,5968,adagrasib,6/7/2021,Treatment for KRAS G12C Positive non-small cell lung cancer,Designated/Approved,,"Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy",12/12/2022,12/12/2029,"Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy","Mirati Therapeutics, Inc.",3545 Cray Court,,San Diego,California,92121,United States,756320
CANNABIDIOL,19GBJ60SN5,Designated,Public record,5970,cannabidiol oral solution (CBD-OS),6/7/2021,Treatment of epilepsy with myoclonic-atonic seizures,Designated,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd,5750 Fleet Street Suite 200,Sovereign House,Histon,Cambridge,,United Kingdom,819221
GUNAGRATINIB,9D589FD91A,Designated,Public record,5971,gunagratinib,6/7/2021,Treatment of Cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,InnoCare Pharma Inc.,"103 Carnegie Center, Suite 209",,Princeton,New Jersey,8540,United States,820521
QUINACRINE,H0C805XYDE,Designated,Public record,5972,quinacrine,6/7/2021,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Pulmosim Therapeutics,1 Sansome Street,Suite 3500,San Francisco,California,94104,United States,820321
DOXORUBICIN,80168379AG,Designated,Public record,5974,Doxorubicin,6/8/2021,Treatment of Malignant Glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Bionaut Labs,"3767 Overland Avenue, Suite 114",,Los Angeles,California,90046,United States,820821
ETRASIMOD ARGININE,MXE5EMA09L,Designated,Public record,5975,Etrasimod L-arginine,6/8/2021,Treatment of Eosinophilic Esophagitis (EoE),Designated,Not FDA Approved for Orphan Indication,,,,,"Arena Pharmaceuticals, Inc.",6154 Nancy Ridge Drive,,San Diego,California,92121,United States,723019
SIVELESTAT,DWI62G0P59,Designated,Public record,5976,Sivelestat,6/9/2021,Treatment of ELANE gene related neutropenia,Designated,Not FDA Approved for Orphan Indication,,,,,RNR Biomedical inc,161 Jefferson Ave.,,tenafly,New Jersey,7670,United States,812921
NALTREXONE,5S6W795CQM,Designated,Public record,5978,Naltrexone,6/14/2021,Treatment of Complex Regional Pain Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Soin Theraputics,10601 Sunderland Woods CT,,Dayton,Ohio,45458,United States,819621
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN,D733ET3F9O,Designated/Approved,Public record,5980,asparaginase erwinia chrysanthemi (recombinant)-rywn,6/22/2021,Treatment of Acute lymphoblastic leukemia,Designated/Approved,,As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived aspar,6/30/2021,,,Jazz Pharmaceuticals Ireland Limited,"Waterloo Exchange, Waterloo Road",Fifth floor,Dublin,,,Ireland,773420
CINREBAFUSP ALFA,21Z359Z1CV,Designated,Public record,5981,cinrebafusp,6/22/2021,Treatment of gastric cancer including cancer of the gastroesophageal junction,Designated,Not FDA Approved for Orphan Indication,,,,,"Pieris Pharmaceuticals, Inc.",255 State Street,9th Floor,Boston,Massachusetts,2109,United States,821221
BGS-005,U6D4B3K4P8,Designated,Public record,5982,"(1S,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E)-33-(((2S,3S,4S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,4,7,9,11,17,37-octahydroxy-15,16,18,36-tetramethyl-14,39-dioxabicyclo[33. 3.1] nonatriaconta-19,21,23,25,27,29,31-heptaen-1",6/24/2021,Treatment of invasive aspergillosis,Designated,Not FDA Approved for Orphan Indication,,,,,Biosergen AS,7092 Tiller,,Trondheim,,,Norway,803420
BEVANTOLOL,34ZXW6ZV21,Designated,Public record,5984,Bevantolol,6/24/2021,Treatment of Huntington's Disease,Designated,Not FDA Approved for Orphan Indication,,,,,SOM Innovation Biotech S.A.,"Baldiri Reixac, 4",,Barcelona,Barcelona,8028,Spain,822821
DEVIMISTAT,E76113IR49,Designated,Public record,5985,devimistat,6/24/2021,Treatment of liver and intrahepatic bile duct cancer (also known as biliary tract cancer; cholangiocarcinomas of the bile duct and the gall bladder),Designated,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,8512,United States,808021
BATOCLIMAB,C98V9UMX3D,Designated,Public record,5986,Fully human anti-human neonatal Fc receptor (hFcRn) IgG1 monoclonal antibody,6/24/2021,Treatment of Myasthenia Gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunovant Sciences, GmbH",Viaduktstrasse 8,4051 Basel,Basel,Basel-Stadt,4501,Switzerland,809421
NORUCHOLIC ACID,8A5G600D9V,Designated,Public record,5988,Norucholic acid,6/24/2021,Treatment of Primary Sclerosing Cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,Dr. Falk Pharma GmbH,Leinenweberstrasse 5,79108 Freiburg,Freiburg,,,Germany,821121
UBIDECARENONE,EJ27X76M46,Designated,Public record,5989,Ubidecarenone,6/24/2021,Treatment of Malignant Glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Berg LLC,500 Old Connecticut Path,Building B,Framingham,Massachusetts,1701,United States,822521
ENVAFOLIMAB,ES1M06M6QH,Designated,Public record,5990,envafolimab,6/28/2021,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Tracon Pharmaceuticals, Inc.",4350 LaJolla Village Dr.,Suite 800,San Diego,California,92122,United States,745320
ULINASTATIN,OR3S9IF86U,Designated,Public record,5991,Ulinastatin,6/28/2021,Treatment of Acute Radiation Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,RNR Biomedical inc,161 Jefferson Ave.,,tenafly,New Jersey,7670,United States,822421
INIPARIB,2ZWI7KHK8F,Designated,Public record,5993,Iniparib,7/1/2021,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,TriAct Therapeutics,2717 Baker Street,,San Francisco,California,94123,United States,823921
OPELCONAZOLE,45LU8Q6ASU,Designated,Public record,5994,opelconazole,7/1/2021,Treatment of invasive aspergillosis,Designated,Not FDA Approved for Orphan Indication,,,,,Pulmocide Inc.,177 Huntington Ave Ste 1703,PBM 58659,Boston,Massachusetts,,United States,824121
SODIUM ARSENITE,48OVY2OC72,Designated,Public record,5995,Sodium meta-arsenite,7/1/2021,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Komipharm International Australia Pty Ltd.,11 Monterey Road,Dandenong South,Victoria,,3175,Australia,823621
MECASERMIN RINFABATE,NZ8M50KKRG,Designated,Public record,5997,mecasermin rinfabate,7/7/2021,Prevention of bronchopulmonary dysplasia,Designated,Not FDA Approved for Orphan Indication,,,,,OHB Neonatology Ltd,"3rd Floor, 1 Ashley Road",,Altrincham,Cheshire,,United Kingdom,824321
PRIDOPIDINE,HD4TW8S2VK,Designated,Public record,5998,Pridopidine,7/7/2021,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Prilenia Neurotherapeutics LTD,"10 Hamenofim St, #317-318",,Herzliya,Merkaz,4672561,Israel,824621
ALRIZOMADLIN,15QAU0SI9J,Designated,Public record,6000,Alrizomadlin,7/14/2021,Treatment of Stage III-IV Melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,826021
Lefleuganan,3F27DMT92U,Designated,Public record,6001,(2S)-2-[(2S)-4-cyclohexyl-2-{[(2S)-1-(4-fluorobenzoyl)pyrrolidin-2-yl]formamido}butanamido]-N-(1-{[(1S)-1-{[(1S)-1-({1-[(1-{[2-({1-[(dimethylamino)methyl]cyclobutyl}carbamoyl)ethyl]carbamoyl}-1-methylethyl)carbamoyl]-1-methylethyl}carbamoyl)-3-methylbutyl,7/19/2021,Treatment of cutaneous leishmaniasis (Old World and New World),Designated,Not FDA Approved for Orphan Indication,,,,,Bacoba AG,Schloss Buonas 1,,Buonas,,6343,Switzerland,825621
METHOTREXATE,YL5FZ2Y5U1,Designated,Public record,6002,methotrexate (intravitreal),7/19/2021,Treatment of Primary Vitreoretinal Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Aldeyra Therapeutics, Inc.",131 Hartwell Avenue,Suite 320,Lexington,Massachusetts,2421,United States,754320
OCTREOTIDE ACETATE,75R0U2568I,Designated,Public record,6003,Octreotide Acetate,7/19/2021,Treatment of Idiopathic Intracranial Hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,NBO Pharma LLC,64 Quarry Lane,,Bedford,New York,10506,United States,826221
TP-317,AH6WA47YR3,Designated,Public record,6004,magnesium lysinate-bis-resolvin E1,7/20/2021,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Thetis Pharmaceuticals,"54 Danbury Rd., Suite 285",,Ridgefield,Connecticut,6877,United States,826721
VACTOSERTIB,6T4O391P5Y,Designated,Public record,6005,Vactosertib,7/20/2021,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"MedPacto, Inc.","92 Myeongdal-ro, Seocho-Gu",,Seoul,,6668,South Korea,827321
Bezuclastinib,2ROQ545LAG,Designated,Public record,6006,"3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5- carboxamide",7/21/2021,Treatment of gastrointestinal stromal tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Cogent Biosciences, Inc.",200 Cambridge Park Drive,Suite 2500,Cambridge,Massachusetts,2140,United States,827121
Riliprubart,I31869XDP8,Designated,Public record,6009,Anti-C1s Humanized IgG4 Monoclonal Antibody,7/21/2021,Treatment of chronic inflammatory demyelinating polyneuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,Sanofi Genzyme,50 Binney Street,,Cambridge,Massachusetts,2124,United States,810521
LORCASERIN,637E494O0Z,Designated,Public record,6010,Lorcaserin,7/21/2021,Treatment of Lennox-Gastaut syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 E Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,7652,United States,828021
METHOTREXATE,YL5FZ2Y5U1,Designated,Public record,6011,Methotrexate,7/21/2021,Treatment of retinitis pigmentosa,Designated,Not FDA Approved for Orphan Indication,,,,,"Aldeyra Therapeutics, Inc.","131 Hartwell Avenue, Suite 320",,Lexington,Massachusetts,2421,United States,829121
TEMPOL,U78ZX2F65X,Designated,Public record,6013,Tempol,7/21/2021,Treatment of Ataxia Telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,"Matrix Biomed, Inc.",2600 Michelson Dr.,Suite 1700,Irvine,California,92612,United States,827721
METOPROLOL,GEB06NHM23,Designated,Public record,6014,Tesofensine plus metoprolol in a fixed-dose combination,7/21/2021,Treatment of Hypothalamic Obesity,Designated,Not FDA Approved for Orphan Indication,,,,,Saniona S/A,Smedeland 26B,,Glostrup,,,Denmark,804220
TESOFENSINE,BLH9UKX9V1,Designated,Public record,6014,Tesofensine plus metoprolol in a fixed-dose combination,7/21/2021,Treatment of Hypothalamic Obesity,Designated,Not FDA Approved for Orphan Indication,,,,,Saniona S/A,Smedeland 26B,,Glostrup,,,Denmark,804220
ABX-002,QTW4WC4BRX,Designated,Public record,6015,"2?(3,5?dichloro?4?([4?hydroxy?3?(propan?2?yl)phenyl]methyl)phenoxy)?N?methylacetamide",7/22/2021,Treatment of X-linked Adrenoleukodystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Autobahn Therapeutics, Inc.",9880 Campus Point Drive Suite 370,,San Diego,California,92121,United States,827821
BZ-371A,9FZY7W5UNA,Designated,Public record,6016,19 amino acid synthetic peptide NOS-enhancer,7/26/2021,Treatment of anterior ischemic optic neuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,Biozeus Biopharmaceutical SA,Rua Visconde de Pirajá 623 9°,"andar, Ipanema",Rio de Janeiro,RJ,,Brazil,806120
OSEMITAMAB,H14V1A2F4D,Designated,Public record,6017,"Humanized, Low-fucose Anti-Claudin 18.2 IgG1 Antibody with Enhanced Antibody Dependent Cell-mediated Cytotoxicity",7/26/2021,Treatment of gastric cancer including cancer of gastroesophageal junction,Designated,Not FDA Approved for Orphan Indication,,,,,"Mabspace Biosciences (Suzhou) Co., Limited","218 Xinghu Street,Biobay, building B6-501",,Suzhou,Jiangsu,215123,China,824721
IMATINIB,BKJ8M8G5HI,Designated,Public record,6018,imatinib,7/26/2021,Treatment of pulmonary arterial hypertension,Designated,Not FDA Approved for Orphan Indication,,,,,Aerami Therapeutics,"2520 Meridian Parkway, Suite 400",,Durham,North Carolina,27713,United States,831721
LISAVANBULIN,5PT0QP06X5,Designated,Public record,6020,Lisavanbulin,7/27/2021,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Basilea Pharmaceutical International Ltd.,Grenzacherstrasse 487,,Basel,BS,4058,Switzerland,828321
SIROLIMUS,W36ZG6FT64,Designated,Public record,6021,Sirolimus,7/27/2021,Treatment of Sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,AI Therapeutics,530 Old Whitfield Street,,Guildord,Connecticut,6437,United States,828521
AZACITIDINE,M801H13NRU,Designated,Public record,6022,azacitidine,7/28/2021,Treatment of Juvenile myelomonocytic leukemia,Designated/Approved,,Treatment of pediatric patients aged one month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML),5/20/2022,5/20/2029,Treatment of pediatric patients aged one month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML),Celgene Corporation (a Bristol-Myers Squibb Company),86 Morris Avenue,,Summit,New Jersey,7901,United States,829021
SOTIGALIMAB,JEA93WJ5DG,Designated,Public record,6024,a humanized immunoglobulin IgG1k-agonistic monoclonal antibody that binds to CD40,8/3/2021,Treatment of Soft Tissue Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Apexigen, Inc.","75 Shoreway Road, Suite C",,San Carlos,California,94070,United States,830321
KETAMINE,690G0D6V8H,Designated,Public record,6026,ketamine,8/3/2021,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,,Canada,829921
Olorofim,T34SH2H9HI,Designated,Public record,6027,Olorofim,8/3/2021,Treatment of invasive fusariosis,Designated,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way Eccles,,Manchester,Manchester,,United Kingdom,829821
SERPLULIMAB,S3GQZ2K36V,Designated,Public record,6028,Recombinant anti-claudin 18.2 monoclonal antibody,8/3/2021,Treatment of Gastric Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Hengenix Biotech, Inc.",430 N. McCarthy Blvd.,,Milpitas,California,95035,United States,829321
SIROLIMUS,W36ZG6FT64,Designated,Public record,6029,sirolimus,8/3/2021,Treatment of Lymphatic Malformations,Designated,Not FDA Approved for Orphan Indication,,,,,"Palvella Therapeutics, Inc.","125 Stafford Ave., Suite 360",,Wayne,Pennsylvania,19087,United States,829421
"""3',3-DISELENODIPROPIONIC ACID""",2SP2QS73W9,Designated,Public record,6032,"3', 3, Diseleno Dipropionic Acid",8/9/2021,Prevention of acute radiation syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Innovative Partners, Inc.",7947 BROOKSIDE CT,,Lake Worth,Florida,33467,United States,832321
VB-309,GMN7ZX2D3A,Designated,Public record,6034,Mixture of delta 9-tetrahydrocannabinol glycosides,8/9/2021,Treatment of pediatric ulcerative colitis between the ages of 0-18 years,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitality Biopharma, Inc.",1901 Avenue of the Stars,2nd Floor,Los Angeles,California,90067,United States,627218
VB-311,2D48C7R49E,Designated,Public record,6034,Mixture of delta 9-tetrahydrocannabinol glycosides,8/9/2021,Treatment of pediatric ulcerative colitis between the ages of 0-18 years,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitality Biopharma, Inc.",1901 Avenue of the Stars,2nd Floor,Los Angeles,California,90067,United States,627218
VB-310,SH72P2DRU7,Designated,Public record,6034,Mixture of delta 9-tetrahydrocannabinol glycosides,8/9/2021,Treatment of pediatric ulcerative colitis between the ages of 0-18 years,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitality Biopharma, Inc.",1901 Avenue of the Stars,2nd Floor,Los Angeles,California,90067,United States,627218
VB-313,VFD5BFU5ZG,Designated,Public record,6034,Mixture of delta 9-tetrahydrocannabinol glycosides,8/9/2021,Treatment of pediatric ulcerative colitis between the ages of 0-18 years,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitality Biopharma, Inc.",1901 Avenue of the Stars,2nd Floor,Los Angeles,California,90067,United States,627218
VB-312,MHF3368LWJ,Designated,Public record,6034,Mixture of delta 9-tetrahydrocannabinol glycosides,8/9/2021,Treatment of pediatric ulcerative colitis between the ages of 0-18 years,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitality Biopharma, Inc.",1901 Avenue of the Stars,2nd Floor,Los Angeles,California,90067,United States,627218
LP-184,L683VC69K8,Designated,Public record,6035,N-hydroxy-N-(methylacylfulvene)urea,8/9/2021,Treatment of Pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantern Pharma, Inc.",1920 MCKINNEY AVE,7TH FLOOR,DALLAS,Texas,75201,United States,832821
Cemsidomide,D86MF5H9WJ,Designated,Public record,6038,cereblon E3 ubiquitin ligase modulating agent,8/10/2021,Treatment of Multiple Myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"C4 Therapeutics, Inc.",490 Arsenal Way,Suite 200,Watertown,Massachusetts,2742,United States,831921
DOTMP SM-153,S5NN2E9ZKF,Designated,Public record,6041,"Samarium (Sm-153) chelate of DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephophonate))",8/11/2021,Treatment of osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"QSAM Therapeutics, Inc.","9442 N Capital of Texas Hwy, Plaza One, Suite 500",,Austin,Texas,,United States,773120
NFX-179,K5T4I78IYZ,Designated,Public record,6042,"2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",8/12/2021,Treatment of Neurofibromatosis type 1,Designated,Not FDA Approved for Orphan Indication,,,,,"Nflection Therapeutics, Inc.",867 Boylston Street,5th Floor #1116,Boston,Massachusetts,2116,United States,746520
GANAXOLONE,98WI44OHIQ,Designated,Public record,6043,ganaxolone,8/12/2021,Treatment of Tuberous Sclerosis Complex,Designated,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",5 Radnor Corporate Center,,Radnor,Pennsylvania,19087,United States,833521
INFIGRATINIB,A4055ME1VK,Designated,Public record,6044,Infigratinib,8/12/2021,Treatment of achondroplasia,Designated,Not FDA Approved for Orphan Indication,,,,,"QED Therapeutics, Inc.",8000 Marina Blvd #400,,Brisbane,California,94005,United States,833221
OMADACYCLINE,090IP5RV8F,Designated,Public record,6045,omadacycline,8/18/2021,Treatment of infections caused by Nontuberculous Mycobacteria (NTM),Designated,Not FDA Approved for Orphan Indication,,,,,"Paratek Pharmaceuticals, Inc.",75 Park Plaza,4th floor,Boston,Massachusetts,2116,United States,741020
CEMIPLIMAB-RWLC,,Designated,Public record,6047,cemiplimab-rwlc,8/19/2021,Treatment of stage IA2 to stage IV cervical cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,671518
BEGELOMAB,360N6PY2A1,Designated,Public record,6048,begelomab,8/20/2021,Treatment of dermatomyositis,Designated,Not FDA Approved for Orphan Indication,,,,,ADIENNE SA,Via Zurigo 46,,Lugano,Europe,6900,Switzerland,833021
LP-184,L683VC69K8,Designated,Public record,6049,Hydroxyurea methylacylfulvene,8/20/2021,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantern Pharma, Inc.",1920 McKinney Avenue,,Dallas,Texas,75201,United States,833721
SIVELESTAT,DWI62G0P59,Designated,Public record,6050,Sivelestat,8/26/2021,Treatment of Myelodysplastic Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,RNR Biomedical inc,161 Jefferson Ave.,,tenafly,New Jersey,7670,United States,813321
GEMFIBROZIL,Q8X02027X3,Designated,Public record,6051,Gemfibrozil,8/27/2021,Treatment of GM2 gangliosidoses,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.","140 E. Ridgewood Avenue, Suite 415, South Tower",,Paramus,New Jersey,7652,United States,834821
VACTOSERTIB,6T4O391P5Y,Designated,Public record,6053,vactosertib,8/27/2021,Treatment of osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"MedPacto, Inc.",92 Myeongdal-ro Seocho-Gu,,Seoul,Republic of Korea,6668,South Korea,834121
CITRIC ACID MONOHYDRATE,2968PHW8QP,Designated,Public record,6054,citric acid,8/30/2021,Treatment of hyperammonemia in inborn errors of metabolism,Designated,Not FDA Approved for Orphan Indication,,,,,Versantis AG,Technoparkstrasse 1,,Zürich,,,Switzerland,731120
GEMFIBROZIL,Q8X02027X3,Designated,Public record,6055,Gemfibrozil,8/30/2021,Treatment of Krabbe Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.","140 E. Ridgewood Avenue, Suite 415, South Tower",,Paramus,New Jersey,7652,United States,834921
Froniglutide,3V0J65M6J3,Designated,Public record,6056,Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein,8/31/2021,Treatment of polymyositis,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunoForge Co., Ltd.","307-1, 105-1 Bldg, Seoul National University","1 Gwanak-ro, Gwanak-gu,",Seoul,,,South Korea,808321
GAVOCABTAGENE AUTOLEUCEL,NP6CFH3G8H,Designated,Public record,6057,gavocabtagene autoleucel (gavo-cel),9/1/2021,Treatment of Cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"TCR2 Therapeutics, Inc., a wholly owned","100 Binney Street, Suite 710",,Cambridge,Massachusetts,2142,United States,689519
NAFAMOSTAT,Y25LQ0H97D,Designated,Public record,6058,Nafamostat,9/1/2021,Treatment of Dengue Fever,Designated,Not FDA Approved for Orphan Indication,,,,,RNR Biomedical inc,161 Jefferson Ave.,,tenafly,New Jersey,7670,United States,835721
SULFORAPHANE,GA49J4310U,Designated,Public record,6059,Stabilized sulforaphane,9/1/2021,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Evgen Pharma plc,"Liverpool Science Park, Innovation Centre 2",146 Brownlow Hill,Liverpool,,,United Kingdom,836021
Ibcasertib,F40IRN5981,Designated,Public record,6060,chiauranib,9/2/2021,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Shenzhen Chipscreen Biosciences Co., Ltd.","2-601, BIO-Incubator, Gaoxin C, 1st Ave.,","Hi-Tech Industrial Park, Nanshan District",Shenzhen,Guangdong,518057,China,836221
ELIGLUSTAT TARTRATE,N0493335P3,Designated,Public record,6061,Eliglustat Tartrate,9/2/2021,"Treatment of Gaucher Disease Type 1 patients who are CYP2D6 ultra-rapid metabolizers and patients whose CYP2D6 genotype cannot be determined (i.e., indeterminate metabolizers).",Designated,Not FDA Approved for Orphan Indication,,,,,"Kashiv Biosciences, LLC",20 New England Avenue,,Piscataway,New Jersey,8854,United States,816821
Hypericin,7V2F1075HD,Designated,Public record,6062,Hypericin,9/2/2021,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.","29 Emmons Drive, Suite B-10",,Princeton,New Jersey,8054,United States,835521
NNZ-2591,2T1HU6069S,Designated,Public record,6063,Synthetic analogue of cyclic Glycine-Proline,9/2/2021,Treatment of Prader-Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Neuren Pharmaceuticals, Ltd.","Ste 201, 697 Burke Rd",,Camberwell,VIC3124,,Australia,835121
ACETYLCYSTEINAMIDE,4N69717RKW,Designated,Public record,6064,N-acetylcysteine amide,9/7/2021,Treatment of cystinosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Nacuity Pharmaceuticals, Inc.","306 W. 7th Street, Suite 310",,Fort Worth,Texas,76102,United States,768820
SEBETRALSTAT,O5ZD2TU2B7,Designated,Public record,6065,"N-[(3-fluoro-4-methoxypyridin-2-yl) methyl]-3-(methoxymethyl)-1-({4-[(2-oxo-1,2-dihydropyridin-1-yl) methyl]phenyl}methyl)-1H-pyrazole-4-carboxamide",9/7/2021,Treatment of bradykinin-mediated angioedema,Designated,Not FDA Approved for Orphan Indication,,,,,KalVista Pharmaceuticals Ltd,Porton Science Park Bybrook Road,Porton Down,Salisbury,,,United Kingdom,770420
ENCORAFENIB,8L7891MRB6,Designated,Public record,6066,Encorafenib,9/8/2021,Treatment of BRAF-mutant Non-Small Cell Lung Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.),3200 Walnut Street,,Boulder,Colorado,80301,United States,788820
"""ACETYLLEUCINE, L-""",E915HL7K2O,Designated,Public record,6067,N-acetyl-L-leucine,9/8/2021,"Treatment of Niemann-Pick Disease, Type C",Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,836121
ESMETHADONE HYDROCHLORIDE,1Q1YXA5GYG,Designated,Public record,6069,dextromethadone hydrochloride,9/13/2021,Treatment of Amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Relmada Therapeutics, Inc.",880 Third Avenue,12th Floor,New York,New York,10022,United States,836721
OCTREOTIDE,RWM8CCW8GP,Designated,Public record,6072,octreotide,9/15/2021,Treatment of autosomal dominant polycystic liver disease,Designated,Not FDA Approved for Orphan Indication,,,,,Camurus AB,Ideon Science Park,,Lund,NA,,Sweden,836621
LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN,D7RD81HE4W,Designated,Public record,6073,anti-thymocyte globulin (rabbit),9/21/2021,Prophylaxis of graft-versus-host-disease,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,50 Binney Street,,Cambridge,Massachusetts,2142,United States,838821
FASUDIL HYDROCHLORIDE,SQ04N8S7BR,Designated,Public record,6074,Fasudil hydrochloride,9/21/2021,Treatment of 16p11.2 Deletion Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,10279,United States,815421
LUSPATERCEPT,AQK7UBA1LS,Designated,Public record,6075,luspatercept,9/21/2021,Treatment of Alpha-thalassemia,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Ave,,Summit,New Jersey,7901,United States,837321
MELATONIN,JL5DK93RCL,Designated,Public record,6076,Melatonin,9/21/2021,Treatment of optic neuritis,Designated,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,Via Malachia Marchesi de Taddei 21,,Milan,MI,,Italy,845921
NIDANILIMAB,ND296JF21I,Designated,Public record,6077,nadunolimab,9/21/2021,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Cantargia AB,Scheelevägen 27,,Lund,,,Sweden,815221
RIBOFLAVIN 5'-PHOSPHATE SODIUM DIHYDRATE,20RD1DZH99,Designated,Public record,6078,riboflavin 5'-phosphate sodium,9/21/2021,Treatment of corneal ulcers,Designated,Not FDA Approved for Orphan Indication,,,,,Glaukos Corporation,229 Avenida Fabricante,,San Clemente,California,92672,United States,812721
MARZEPTACOG ALFA (ACTIVATED),J5LT149M79,Designated,Public record,6080,Marzeptacog alfa (activated),9/27/2021,Treatment of Factor VII Deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Biosciences, Inc",611 Gateway Blvd. Suite 710,,South San Francisco,California,94080,United States,837721
ACETYLCYSTEINAMIDE,4N69717RKW,Designated,Public record,6081,N-acetylcysteine amide,9/27/2021,"Treatment for Gain-of-Function Mutation in ACOX1, Mitchell’s Syndrome.",Designated,Not FDA Approved for Orphan Indication,,,,,"Nacuity Pharmaceuticals, Inc.","306 W 7th St., Ste 310",,Fort Worth,Texas,76102,United States,771920
TORIPALIMAB,8JXN261VVA,Designated,Public record,6083,Toripalimab,11/8/2021,Treatment of esophageal cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.","9430 Key West Ave, Suite 125",,Rockville,Maryland,20850,United States,836421
ZANDELISIB,8Z28M5SX0X,Designated,Public record,6086,Zandelisib,11/9/2021,Treatment of follicular lymphoma,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MEI Pharma, Inc.",11455 El Camino Real,Suite 250,San Diego,California,92130,United States,849021
OBINUTUZUMAB,O43472U9X8,Designated,Public record,6089,obinutuzumab,11/22/2021,"Treatment of childhood-onset idiopathic nephrotic syndrome (NS), defined as steroid dependent or frequently relapsing NS.",Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,824921
BERBAMINE,V5KM4XJ0WM,Designated,Public record,6097,berbamine,11/29/2021,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,IsoQ Therapeutics Inc.,2140 S. Dupont Hwy,,Camden,Delaware,19934,United States,848121
VALEMETOSTAT TOSYLATE,6N79I7X5II,Designated,Public record,6099,Valemetostat tosylate,12/1/2021,Treatment of Peripheral T-cell lymphoma (PTCL),Designated,Not FDA Approved for Orphan Indication,,,,,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,,United States,850021
ALLOGENIC BONE-MARROW-DERIVED MESENCHYMAL STEM CELLS,OEN4982XNW,Designated,Public record,6100,Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs),12/2/2021,Treatment of Hypoplastic Left Heart Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Longeveron, Inc.","1951 NW 7th Ave., Suite 520",,Miami,Florida,33136,United States,849521
SELINEXOR,31TZ62FO8F,Designated,Public record,6102,selinexor,12/2/2021,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.",85 Wells Avenue,,Newton,Massachusetts,2459,United States,825721
ENZASTAURIN,UC96G28EQF,Designated,Public record,6103,enzastaurin,12/7/2021,Treatment of Ehlers-Danlos Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Aytu BioPharma, Inc.","373 Inverness Parkway, Suite 206",,Englewood,Colorado,80112,United States,849821
TACROLIMUS,WM0HAQ4WNM,Designated,Public record,6105,tacrolimus,12/7/2021,"Treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis",Designated,Not FDA Approved for Orphan Indication,,,,,BioNanoSim Ltd.,Minrav Building,Hadassah ein Kerem Campus,Jerusalem,Jerusalem,9112101,Israel,849321
POSACONAZOLE,6TK1G07BHZ,Designated,Public record,6107,Posaconazole,12/13/2021,Treatment of Mucormycosis (previously called zygomycosis),Designated,Not FDA Approved for Orphan Indication,,,,,"AET Pharma US, Inc.",9841 Washingtonian Boulevard,Suite 200,Gaithersburg,Maryland,20878,United States,850521
ZY-19489,VL8W9427Y4,Designated,Public record,6108,"(R)-N2-(4-cyclopropyl-5-fluoro-6-methylpyridin-2-yl)-N4-(1, 5-dimethyl-1H-pyrazol-3-yl)-5-(3,4-dimethylpiperazin-1-yl) pyrimidine-2,4-diamine",12/14/2021,Treatment of malaria,Designated,Not FDA Approved for Orphan Indication,,,,,Cadila Healthcare Limited,"Zydus Research Centre,","Survey No. 396/403, Sharkhej-Bavla N.H. No. 8A, Village Moraiya, Changodar,",Ahmedabad,Gujarat,382213,India,853221
DORNASE ALFA,953A26OA1Y,Designated,Public record,6112,Dornase alpha,12/14/2021,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Xenetic Biosciences, Inc.","40 Speen Street, Suite 102",,Framingham,Massachusetts,1701,United States,851921
LP-184,L683VC69K8,Designated,Public record,6113,N-hydroxy-N-(methylacylfulvene)urea,12/14/2021,Treatment of Atypical Teratoid/Rhabdoid Tumor (ATRT),Designated,Not FDA Approved for Orphan Indication,,,,,Lantern Pharma Inc.,1920 MCKINNEY AVE,7TH FLOOR,Dallas,Texas,,United States,850721
OLVEREMBATINIB,KV1M7Q3CBP,Designated,Public record,6114,olverembatinib,12/14/2021,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,852921
THIOSTREPTON,HR4S203Y18,Designated,Public record,6115,thiostrepton,12/14/2021,Treatment of Mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,"RS Oncology, LLC","One Broadway, 14th Floor",,Cambridge,Massachusetts,2142,United States,851321
MARZEPTACOG ALFA (ACTIVATED),J5LT149M79,Designated,Public record,6116,Marzeptacog alfa (activated),12/15/2021,"Treatment of Bleeding Episodes in Patients with Hemophilia A or B, Including those with Inhibitors",Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Biosciences, Inc.",611 Gateway Blvd. Suite 710,,South San Francisco,California,94080,United States,820721
SILMITASERTIB,C6RWP0N0L2,Designated,Public record,6117,silmitasertib,12/15/2021,Treatment of Medulloblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Senhwa Biosciences, Inc.","10F, No. 225, Sec. 3, Peihsin Road",,Hsintien District,New Taipei City,23143,Taiwan,851021
SEA-BCMA,3C28VJ95EV,Designated,Public record,6118,Nonfucosylated humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting B-cell maturation antigen (SEA-BCMA),12/16/2021,Treatment of Multiple Myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.,21823 30th Drive SE,,Bothell,Washington,98021,United States,852321
CRIZOTINIB,53AH36668S,Designated/Approved,Public record,6120,crizotinib,12/20/2021,Treatment of inflammatory myofibroblastic tumor,Designated/Approved,,"Treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive",7/14/2022,7/14/2029,"Treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive",PF Prism C.V. (a wholly-owned subsidiary of Pfizer Inc.),10646 Science Center Drive,,San Diego,California,92121,United States,834721
SIROLIMUS,W36ZG6FT64,Designated,Public record,6122,Sirolimus,12/21/2021,Treatment of Bronchiolitis Obliterans Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"AI Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,6437,United States,833821
Zapnometinib,4RZD8LK83V,Designated,Public record,6124,zapnometinib,12/28/2021,Treatment of Hantavirus infection,Designated,Not FDA Approved for Orphan Indication,,,,,Atriva Therapeutics GmbH,Eisenbahnstr. 1,,Tübingen,,72072,Germany,853921
OM-301,X8K6U56JL4,Designated,Public record,6126,"Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-glutaminyl-L-alpha-glutamyl-L-threonyl-Lphenylalanyl- L-seryl-L-alpha-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-Llysyl- L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl",1/3/2022,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolyze, Inc.",845 UN Plaza,61b,New York City,New York,10017,United States,855021
TAK-733,5J61HSP0QJ,Designated,Public record,6129,"3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione",9/28/2021,Treatment of familial adenomatous polyposis,Designated,Not FDA Approved for Orphan Indication,,,,,"Recursion Pharmaceuticals, Inc.",41 S. Rio Grande Street,,Salt Lake City,Utah,84101,United States,817621
DASATINIB,RBZ1571X5H,Designated,Public record,6132,Dasatinib,10/5/2021,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Nanocopoeia, LLC",639 Campus Drive,,New Brighton,Minnesota,55112,United States,750520
DASATINIB,RBZ1571X5H,Designated,Public record,6133,Dasatinib,10/5/2021,Treatment of chronic myelogenous leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Nanocopoeia, LLC",639 Campus Drive,,New Brighton,Minnesota,55112,United States,750420
TEZEPELUMAB,RJ1IW3B4QX,Designated,Public record,6134,tezepelumab,10/7/2021,Treatment of Eosinophilic Esophagitis,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,19803,United States,839721
APPD,YG9BKQ6J2Z,Designated,Public record,6135,Aminouridyl phenoxypiperidinbenzyl butamide,10/12/2021,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Anviron Corporation,4 Trouville,,Newport Coast,California,92657,United States,840521
NT-102,CL92X4LP4N,Designated,Public record,6136,"2-[(3-Methylbutyl)amino]-1,4-naphthalenedione",10/12/2021,Treatment of Dravet Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Neuroene Therapeutics,"645 Meeting Street, 201-I",,Charleston,South Carolina,29403,United States,841521
SEL-24 HYDROCHLORIDE,1Z0H0278DB,Designated,Public record,6137,"5,6-dibromo-4-nitro-2-(piperidin-4-yl)-1-(propan-2-yl)-1H-1,3-benzodiazole hydrochloride",10/12/2021,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Stemline Therapeutics, Inc.","750 Lexington Avenue, 4th Floor",,New York,New York,10022,United States,840121
Cudetaxestat,6B7TYB2MJX,Designated,Public record,6138,cudetaxestat,10/12/2021,Treatment of systemic sclerosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Blade Therapeutics, Inc.",442 Littlefield Avenue,,South San Francisco,California,94080,United States,841021
ELRANATAMAB,L0HR9A577V,Designated,Public record,6140,elranatamab,10/12/2021,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,66 Hudson Boulevard East,,New York,New York,10001,United States,840721
Haptoglobulin 1/1 (Plasma Derived),4AUM9TX5RP,Designated,Public record,6142,"haptoglobin (Hp1-1), (Human)",10/12/2021,Treatment of subarachnoid hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,,United States,841121
KETAMINE,690G0D6V8H,Designated,Public record,6143,Ketamine,10/12/2021,Treatment of Complex Regional Pain Syndrome (CRPS),Designated,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,,Canada,840821
RITUXIMAB,4F4X42SYQ6,Designated,Public record,6145,Rituximab,10/12/2021,Treatment of Myasthenia Gravis,Designated,Not FDA Approved for Orphan Indication,,,,,Taxon Therapeutics Ltd.,122 Bar Kokhva St.,,Herzliya 4600728,Herzliya,4600728,Israel,840621
7-ETHYL-10-HYDROXYCAMPTOTHECIN,0H43101T0J,Designated,Public record,6147,Biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin,10/13/2021,Treatment of Soft Tissue Sarcoma (STS),Designated,Not FDA Approved for Orphan Indication,,,,,Cebiotex S.L.,"Plaça Pau Vila, 1; Block A, 3rd Floor",Barcelona Tech City,Barcelona,,8039,Spain,840021
CLEMIZOLE,T97CB3796L,Designated,Public record,6149,Clemizole,10/14/2021,Treatment of Lennox-Gastaut Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 E Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,7652,United States,841821
NIPOCALIMAB,87M90CV8NC,Designated,Public record,6150,nipocalimab,10/14/2021,Treatment of chronic inflammatory demyelinating polyneuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1125 Trenton-Harbourton Road,,Titusville,New Jersey,8560,United States,840221
ALVELESTAT,6Y5629322X,Designated,Public record,6153,Alvelestat,10/25/2021,Treatment of Alpha-1 Antitrypsin Deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,Mereo Biopharma 4 Limited,1 Cavendish Place,,London,,,United Kingdom,804020
DF-1001,7DGR11S93X,Designated,Public record,6154,Heterodimeric multi-specific IgG1 antibody targeting human epidermal growth factor receptor 2 (HER2) and NKG2D on natural killer (NK) and cytotoxic T-cells,10/25/2021,Treatment of Esophageal Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Dragonfly Therapeutics, Inc.",35 Gatehouse Drive,,Waltham,Massachusetts,2451,United States,844121
ANX-005,N5WBB45U8L,Designated,Public record,6155,humanized recombinant immunoglobulin G (IgG) 4 monoclonal antibody against C1q,10/25/2021,Treatment of Huntington's Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Annexon, Inc.",180 Kimball Way,"2nd Floor, Suite 200",South San Francisco,California,94080,United States,843121
PSILOCYBINE,2RV7212BP0,Designated,Public record,6156,Psilocybin,10/25/2021,Treatment of Fragile X Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Nova Mentis Life Science Corp.,700-838 West Hasting Street,,Vancouver,British Columbia,,Canada,843421
QUISOVALIMAB,M46KZB8QXL,Designated,Public record,6157,human anti-LIGHT monoclonal antibody,10/26/2021,Treatment of pediatric Crohn’s disease,Designated,Not FDA Approved for Orphan Indication,,,,,Cerecor Inc.,"540 Gaither Road, Suite 400",Suite 715,Rockville,Maryland,20850,United States,643018
IDROXIOLEIC ACID,OSV3KVO1BT,Designated,Public record,6158,Idroxioleic acid,10/26/2021,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Laminar Pharma Inc,"360 Massachusettes Avenue, Suite 203",,Acton,Massachusetts,1720,United States,844021
SATRALIZUMAB-MWGE,,Designated,Public record,6159,satralizumab-mwge,10/26/2021,Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD),Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,824521
MOCRAVIMOD,X71GCJ0HLI,Designated,Public record,6161,mocravimod,10/27/2021,Prevention of graft-versus-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,Priothera SAS,57 Avenue Général De Gaulle,,Saint-Louis,,68300,France,843321
BENRALIZUMAB,71492GE1FX,Designated,Public record,6162,Benralizumab,11/1/2021,Treatment of Eosinophilic Gastritis (EG),Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,19803,United States,828221
BENRALIZUMAB,71492GE1FX,Designated,Public record,6163,Benralizumab,11/1/2021,Treatment of eosinophilic gastroenteritis,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,19803,United States,838521
MILTEFOSINE,53EY29W7EC,Designated,Public record,6164,Miltefosine,11/1/2021,Treatment invasive candidiasis,Designated,Not FDA Approved for Orphan Indication,,,,,"Profounda, lnc.",10501 S. Orange Ave,STE 124,Orlando,Florida,32824,United States,843921
"""METHIONINE SULFOXIMINE, (S)-""",DE3D2PZ3TT,Designated,Public record,6165,L-S-(3-Amino-3-carboxypropyl)-S-methylsulfoximine,11/2/2021,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"William S. Brusilow, Ph.D.",30 Rivard Blvd.,,Gross Pointe,Michigan,48230,United States,844521
EDARAVONE,S798V6YJRP,Designated,Public record,6167,edaravone,11/4/2021,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Suzhou Auzone Biological Technology Co., Ltd","Room 406, A7 Building, BioBay, No. 218 Xinghu Street",Suzhou Industrial Park,Suzhou,Jiangsu,215000,China,847021
IVALTINOSTAT,4I8MLM7L2H,Designated,Public record,6168,Ivaltinostat,11/4/2021,Treatment of Alport Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Machaon Biotherapeutics, Inc.",70 Osongsaengmyeong 6-ro,,Cheongju-si,Chungcheongbuk-do,28158,South Korea,846121
RIVOCERANIB,5S371K6132,Designated,Public record,6169,rivoceranib,11/4/2021,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevar Therapeutics, Inc.",2825 E. Cottonwood Pkwy. Ste 180,,Salt Lake City,Utah,84121,United States,682618
P-42 PEPTIDE,YVN9TJV837,Designated,Public record,6170,synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein,11/4/2021,Treatment of Huntington’s disease,Designated,Not FDA Approved for Orphan Indication,,,,,centre national de la recherche scientifique,4101 Reservoir Rd NW,,Washington,District of Columbia,20007,United States,847121
SKQ-1 BROMIDE,7B14500J3E,Designated,Public record,6171,"[10-(4,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl](triphenyl)phosphonium bromide",11/4/2021,Treatment of Leber Hereditary Optic Neuropathy,Designated,Not FDA Approved for Orphan Indication,,,,,Mitotech S.A.,42 rue de la Vallee,,Luxembourg,Luxembourg,2661,Luxembourg,846221
DOTA-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2 Actinium AC-225,44S7GN2UDJ,Designated,Public record,6172,H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-225-actinium,11/5/2021,Treatment of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,NovaCurie AG,Spitalgasse 32,,Bern,N/A,3011,Switzerland,820221
PHI-501,73ET74LVY6,Designated,Public record,6176,"N-(4-methyl-3-(7-methyl-2-((6-methylpyridin-3-yl)amino)-8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide",11/8/2021,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Pharos iBio Co., Ltd.","1407 & 1408, 38, Heungan-daero 427 beon-gil",,Anyang,Gyeonggi,,South Korea,847921
ALENDRONIC ACID,X1J18R4W8P,Designated,Public record,6177,Pegylated Liposomal Alendronate with Doxorubicin,11/8/2021,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,LEVCO Pharmaceuticals Ltd.,Shlomo Momo Halevi St. 5,,Jerusalem,Israel,9777019,Israel,844921
DOXORUBICIN,80168379AG,Designated,Public record,6177,Pegylated Liposomal Alendronate with Doxorubicin,11/8/2021,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,LEVCO Pharmaceuticals Ltd.,Shlomo Momo Halevi St. 5,,Jerusalem,Israel,9777019,Israel,844921
EFZOFITIMOD,V5TNN0W368,Designated,Public record,6179,Human IgG1Fc- iMod domain (amino acids 2-60) of human HARS fusion protein,1/5/2022,Treatment of sarcoidosis,Designated,Not FDA Approved for Orphan Indication,,,,,aTyr Pharma,3545 John Hopkins Court,Suite 250,San Diego,California,92121,United States,708419
GOVORESTAT,6JLQ8K35KK,Designated,Public record,6180,"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",1/6/2022,Treatment of sorbitol dehydrogenase deficiency (SORD deficiency),Designated,Not FDA Approved for Orphan Indication,,,,,Applied Therapeutics Inc.,"545 Fifth Avenue, Suite 1400",,New York,New York,10017,United States,777720
EPLONTERSEN,0GRZ0F5XJ6,Designated,Public record,6181,eplontersen,1/6/2022,Treatment of transthyretin-mediated amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Ct,,Carlsbad,California,92010,United States,827521
NANDROLONE,6PG9VR430D,Designated,Public record,6182,nandrolone,1/6/2022,Treatment of facioscapulohumeral muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen,25,Hägersten,Select...,12947,Sweden,855521
MECASERMIN,7GR9I2683O,Designated,Public record,6183,insulin-like growth factor-1,1/10/2022,Treatment of Duchenne muscular dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,12947,Sweden,856421
"""ACETYLLEUCINE, L-""",E915HL7K2O,Designated,Public record,6185,N-acetyl-L-leucine,1/11/2022,Treatment of GM2 Gangliosidosis,Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,855721
TESTOSTERONE,3XMK78S47O,Designated,Public record,6186,testosterone,1/12/2022,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,12947,Sweden,855921
BI-1206,24S6PA0WXW,Designated,Public record,6190,Anti- FcgammaRIIB Monoclonal Antibody,1/18/2022,Treatment of Follicular Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,BioInvent International AB,Ideon Science Park SE-223 70,,Lund,Lund,,Sweden,856621
ELTANEXOR,Q59IQJ9NTK,Designated,Public record,6193,Eltanexor,1/19/2022,Treatment of Myelodysplastic Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.","85 Wells Ave,",,"Newton,",Massachusetts,2459,United States,857421
FLUNARIZINE,R7PLA2DM0J,Designated,Public record,6195,flunarizine,1/19/2022,Treatment of Juvenile Absence Epilepsy,Designated,Not FDA Approved for Orphan Indication,,,,,Xenon Pharmaceuticals Inc.,200-3650 Gilmore Way,,Burnaby,BC,,Canada,857721
RILPIVIRINE,FI96A8X663,Designated,Public record,6197,Rilpivirine,1/19/2022,Treatment of Neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Aptorum International Limited,4T.07 17 Hanover Square,,London,not applicable,,United Kingdom,858321
SILMITASERTIB,C6RWP0N0L2,Designated,Public record,6198,Silmitasertib,1/19/2022,Treatment of Biliary Tract Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Senhwa Biosciences, Inc.","10F, NO. 225, Sec. 3, Peihsin Road",,Hsintien District,New Taipei City,23143,Taiwan,856821
PINOMETOSTAT,8V9YR09EF3,Designated,Public record,6199,"Small molecule inhibitor of the enzymatic activity of Su(var), Enhancer-of-zeste, Trithorax domain containing 2 (SETD2)",1/19/2022,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Epizyme, Inc.",400 Technology Square 4th Floor,,Cambridge,Massachusetts,2139,United States,857121
CT-001,DQP38C562S,Designated,Public record,6200,"Human recombinant factor VIIa variant (P10Q, K32E, T106N, V253N), desialylated",1/20/2022,Treatment of postpartum hemorrhage,Designated,Not FDA Approved for Orphan Indication,,,,,"Coagulant Therapeutics, Corp.",117-3 Hoegi-ro; Suite 402,"Seoul BioHub, Dongdaemun-gu",Seoul,,2455,South Korea,782420
Maplirpacept,44D51T6SZH,Designated,Public record,6201,Recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG,1/20/2022,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Trillium Therapeutics Inc.,2488 Dunwin Drive,,Mississauga,Ontario,,Canada,858521
Gumarontinib,7JTT036WGX,Designated,Public record,6203,glumetinib,1/25/2022,Treatment of Non-small Cell Lung Cancer (NSCLC) with MET Genomic Aberration,Designated,Not FDA Approved for Orphan Indication,,,,,"Haihe Biopharma Co., Ltd.",No. 421 Newton Road,"Zhangjiang High-Tec Park, Pudong New District",Shanghai,,201203,China,858221
EVORPACEPT,X7K762X1IJ,Designated,Public record,6204,"A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG",1/27/2022,Treatment for gastric cancer and gastro-esophageal junction cancer,Designated,Not FDA Approved for Orphan Indication,,,,,ALX Oncology Inc.,323 Allerton Avenue,,South San Francisco,California,94080,United States,782220
Lirafugratinib Hydrochloride,4P76F4XM3B,Designated,Public record,6206,"N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride",1/27/2022,Treatment of Cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Relay Therapeutics Inc.,399 Binney Street,2nd Floor,Cambridge,Massachusetts,2139,United States,859021
Nizubaglustat,2X6NHN9RRN,Designated,Public record,6210,Biphenyl-substituted L-ido configured deoxynojirimycin derivative,1/31/2022,Treatment of GM2 gangliosidoses (Tay-Sachs disease and Sandhoff disease),Designated,Not FDA Approved for Orphan Indication,,,,,Azafaros BV,JH Oortweg 21,,Leiden,CH,2333,Netherlands,859521
KETAMINE HYDROCHLORIDE,O18YUO0I83,Designated,Public record,6212,Ketamine Hydrochloride,1/31/2022,Treatment of Status Epilepticus,Designated,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,,Canada,860021
TAMIBAROTENE,08V52GZ3H9,Designated,Public record,6213,tamibarotene,2/1/2022,Treatment of Myelodysplastic Syndrome (MDS),Designated,Not FDA Approved for Orphan Indication,,,,,Syros Pharmaceuticals,35 Cambridgepark Drive,Level 4,Cambridge,Massachusetts,2140,United States,861221
NDI-5033,5ZCW8AUX9U,Designated,Public record,6214,"1,1¿-(1, 12- Dodecanediyl)bis[cyclopropanecarboxamide]",2/3/2022,Treatment of congenital X-linked nephrogenic diabetes insipidus,Designated,Not FDA Approved for Orphan Indication,,,,,"NephroDI Therapeutics, Inc.","1606 Chestnut Street, Suite 3",,Philadelphia,Pennsylvania,19103,United States,859921
CANNABIDIOL,19GBJ60SN5,Designated,Public record,6216,Cannabidiol,2/9/2022,Treatment of Angelman Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",22 Boston Warf Road 7th Floor,,Boston,Massachusetts,2210,United States,860821
EPETRABOROLE HYDROCHLORIDE,MM0NZY12FA,Designated,Public record,6217,epetraborole hydrochloride,2/9/2022,Treatment of infections caused by nontuberculous mycobacteria (NTM),Designated,Not FDA Approved for Orphan Indication,,,,,"AN2 Therapeutics, Inc.",P.O. Box 418,,Menlo Park,California,94026,United States,860621
Pociredir,BC2SSV7WMT,Designated,Public record,6218,"(S)-12-fluoro-4-(2-methylpyridin-3-yl)-7a,8,13,14-tetrahydro-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine",2/10/2022,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Fulcrum Therapeutics, Inc.",26 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,862121
CANNABIDIOL,19GBJ60SN5,Designated,Public record,6219,Cannabidiol,2/10/2022,Treatment of chromosome 15q11.2-13.1 duplication syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",22 Boston Warf Road 7th Floor,,Boston,Massachusetts,2210,United States,860921
CEMDISIRAN,S66Z65E10T,Designated,Public record,6220,cemdisiran,2/10/2022,Treatment of paroxysmal nocturnal hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,861721
POLIHEXANIDE,322U039GMF,Designated,Public record,6222,Polihexanide,2/11/2022,Treatment of fungal keratitis infection,Designated,Not FDA Approved for Orphan Indication,,,,,SIFI SpA,"Via Ercole Patti, 36",,Aci Sat'Antonio,CT,95025,Italy,861321
BUCILLAMINE,R80LRA5WTF,Designated,Public record,6224,bucillamine,2/15/2022,Prevention of ischemia-reperfusion injury during liver transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,Revive Therapeutics Inc.,82 Richmond Street East,,Toronto,Ontario,,Canada,862021
SALINOMYCIN,62UXS86T64,Designated,Public record,6225,salinomycin,2/15/2022,Treatment of uveal melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Hillstream Biopharma, Inc.","245 Main Street, Suite 204",,Chester,New Jersey,7930,United States,862721
TIRATRICOL,29OQ9EU4R1,Designated,Public record,6228,tiratricol,2/17/2022,Treatment of Resistance to Thyroid Hormone Type Beta (RTH-Beta),Designated,Not FDA Approved for Orphan Indication,,,,,Rare Thyroid Therapeutics International AB,Klara Norra Kyrkogata 26,,Stockhholm,,,Sweden,862421
DARVADSTROCEL,31W7R94KYT,Designated,Public record,6229,darvadstrocel,2/22/2022,Treatment of anal fistulas in patients without Crohn's disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc. (Millennium)",40 Landsdowne Street,,Cambridge,Massachusetts,2139,United States,784320
GLOFITAMAB,06P3KLK2J8,Designated,Public record,6230,Glofitamab,2/22/2022,Treatment of Mantle Cell Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,864121
PRALSETINIB,1WPE73O1WV,Designated,Public record,6231,Pralsetinib,2/22/2022,Treatment of metastatic RET fusion-positive solid tumors,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc",1 DNA Way,,South San Francisco,California,94080,United States,840321
Vipoglanstat hydrogen sulfate,QAD7JW5RD8,Designated,Public record,6235,"2-{2,6-Dichloro-3-[(2,2-dimethyl-propionylamino)-methyl]-phenylamino}-6-(2,2-difluoroethoxy)-1-methyl-1H-benzoimidazole-5-carboxylic acid (trans-4-trifluoromethylcyclohexyl)-amide, hydrogensulfate",2/28/2022,Treatment for Systemic Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Gesynta Pharma AB,Fogdevreten 2A,,Solna,,,Sweden,785320
INSULIN HUMAN,1Y17CTI5SR,Designated,Public record,6236,Human Insulin (rDNA),2/28/2022,Prevention of Retinopathy of Prematurity (ROP),Designated,Not FDA Approved for Orphan Indication,,,,,"Elgan Pharma, Ltd.",Wadi El Haj 13,,Nazareth,Israel,16100,Israel,863821
NAPROXCINOD,V24GR4LI3I,Designated,Public record,6237,naproxcinod,2/28/2022,Treatment of sickle cell disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,11560,United States,742820
EPCORITAMAB,D6OMY2L0WA,Designated,Public record,6239,epcoritamab,3/1/2022,Treatment of Follicular Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Genmab US, Inc.",777 Scudders Mill Road,"Bldg. 2, 4th Floor",Plainsboro,New Jersey,8536,United States,865921
Oxytocin,1JQS135EYN,Designated,Public record,6240,Oxytocin,3/1/2022,Treatment of Prader-Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Tonix Pharmaceuticals, Inc.","26 Main Street, Suite 101",,Chatham,New Jersey,7928,United States,864421
ABSK-091,2167OG1EKJ,Designated,Public record,6241,"Small molecular inhibitor of fibroblast growth factor receptor (FGFR)-1,2 and 3 tyrosine kinases",3/1/2022,Treatment of gastric cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbisko Therapeutics Co.,Ltd","Building 3, Lane 898, Halei Road, Zhangjiang High-Tech Park",,Shanghai,Shanghai,201210,China,863921
TISLELIZUMAB,0KVO411B3N,Designated,Public record,6244,Tislelizumab,3/2/2022,Treatment of nasopharyngeal carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,7963,United States,863721
Nizubaglustat,2X6NHN9RRN,Designated,Public record,6245,biphenyl-substituted L-ido configured deoxynojirimycin derivative,3/7/2022,Treatment of Niemann Pick Disease Type C,Designated,Not FDA Approved for Orphan Indication,,,,,Azafaros BV,JH Oortweg 21,,Leiden,,2333,Netherlands,865321
SOMATORELIN,4UR7N9Z9MM,Designated,Public record,6246,Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide and Arginine,3/7/2022,Diagnosis of Growth Hormone Deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Hollenbeck Pharmaceuticals, Inc.",P.O. Box 429,,Falls Village,Connecticut,6031,United States,785420
ARGININE,94ZLA3W45F,Designated,Public record,6246,Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide and Arginine,3/7/2022,Diagnosis of Growth Hormone Deficiency,Designated,Not FDA Approved for Orphan Indication,,,,,"Hollenbeck Pharmaceuticals, Inc.",P.O. Box 429,,Falls Village,Connecticut,6031,United States,785420
APT-101 HYDROCHLORIDE,NB264L4WZU,Designated,Public record,6247,"((S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid hydrochloride)",3/8/2022,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,APIE Therapeutics,P.O. Box 13169,2 Davis Dr.,Research Triangle Park,North Carolina,27709,United States,865821
OLVEREMBATINIB,KV1M7Q3CBP,Designated,Public record,6248,olverembatinib,3/8/2022,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"800 King Farm Blvd., Suite 300",,Rockville,Maryland,20850,United States,864921
CFT-8634,AW8PEP3VZ3,Designated,Public record,6249,"small molecule composed of a ligand binding moiety to BRD9, a chemical linker, and a ligand binding moiety to the cereblon (CRBN) E3 ligase",3/8/2022,Treatment of Soft Tissue Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"C4 Therapeutics, Inc.",490 Arsenal Way,Suite 200,Watertown,Massachusetts,2742,United States,865121
DT-2216,Y8JQ9V7JAJ,Designated,Public record,6250,"(2S,4R)-1-((S)-2-(7-(4-((R)-3-((4-(N-(4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)butyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimet",3/9/2022,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Dialectic Therapeutics, Inc.",3889 Maple Ave,STE 125,Dallas,Texas,75219,United States,865621
TTI-101,KZ3DLD11RQ,Designated,Public record,6253,"(N-(1¿,2-dihydroxy-[1,2¿-binapthalen]-4¿-yl)-4-methoxybenzenesulfonamide)",3/14/2022,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Tvardi Therapeutics, Inc.",2450 Holcombe Blvd. Suite X,,Houston,Texas,77021,United States,866721
2'-DEOXYTHIOGUANOSINE,KR0RFB46DF,Designated,Public record,6254,6-thio-2¿-deoxyguanosine,3/14/2022,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"MAIA Biotechnology, Inc.","444 West Lake Street, Suite 1700",,Chicago,Illinois,60606,United States,867621
ALRIZOMADLIN,15QAU0SI9J,Designated,Public record,6257,alrizomadlin,3/17/2022,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,869522
KIO-301,57HBP7XKS9,Designated,Public record,6258,Benzyl ethyl aminoazobenzene quaternary ammonium,3/17/2022,Treatment of Retinitis Pigmentosa (RP),Designated,Not FDA Approved for Orphan Indication,,,,,"Kiora Pharmaceuticals, Inc.",1371 East 2100 South,Suite 200,Salt Lake City,Utah,84105,United States,868421
DASATINIB MONOLAURYL SULFATE,FY77PS0C4O,Designated,Public record,6259,dasatinib monolauryl sulfate,3/17/2022,Treatment of chronic myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Handa Oncology, LLC","1732 N. First Street, Suite 200",,San Jose,California,95112,United States,869722
IDRONOXIL,995FT1W541,Designated,Public record,6260,Idronoxil,3/17/2022,Treatment of soft tissue sarcomas (STS),Designated,Not FDA Approved for Orphan Indication,,,,,Noxopharm Limited,"Level 20, Tower A, The Zenith",821 Pacific Hwy,Chatswood,NSW,2067,Australia,868622
Vancomycin,6Q205EH1VU,Designated,Public record,6262,Vancomycin,3/17/2022,Treatment of periprosthetic joint infection,Designated,Not FDA Approved for Orphan Indication,,,,,"Osteal Therapeutics, Inc.",PO BOX 140740,,Dallas,Texas,75214,United States,867521
DEUCRICTIBANT,69GCA2KX22,Designated,Public record,6264,"N-[(1S)-1-[3-chloro-5-fluoro-2-({[2-methyl-4-(1-methyl-1H-1,2,4-triazol-5-yl)quinolin-8-yl]oxy}methyl)phenyl](1-2H)ethyl]-2-(difluoromethoxy)acetamide",3/18/2022,Treatment of bradykinin-mediated angioedema,Designated,Not FDA Approved for Orphan Indication,,,,,Pharvaris Inc.,"303 Wyman Street, Suite 300",,Waltham,Massachusetts,2451,United States,809521
PARPI F-18,FT8GT4M7UG,Designated,Public record,6265,F18-PARPi,3/21/2022,Diagnostic for the management of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,"Theragnostics, Inc.","150 Grossman Drive, Suite 306",,Braintree,Massachusetts,2184,United States,868221
ELAMIPRETIDE,87GWG91S09,Designated,Public record,6266,elamipretide,3/22/2022,Treatment of Friedreich’s ataxia (FRDA),Designated,Not FDA Approved for Orphan Indication,,,,,"Stealth Biotherapeutics, Inc.","275 Grove Street, Suite 3-107",,Newton,Massachusetts,2466,United States,794420
ICERGUASTAT,9M998304JB,Designated,Public record,6267,icerguastat,3/23/2022,Treatment of Amyotrophic Lateral Sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,Inflectis Bioscience,21 Rue la Noue Bras de Fer,,Nantes,,,France,868321
BESILESOMAB BARZUXETAN YTTRIUM Y-90,2N493JC4Y2,Designated,Public record,6268,besilesomab-CHX-A¿-DTPA-90Y,3/28/2022,Conditioning treatment prior to hematopoietic stem cell transplant,Designated,Not FDA Approved for Orphan Indication,,,,,"Telix Pharmaceuticals (US), Inc.","12 Municipal Drive, Suite 330",,Fishers,Indiana,46038,United States,869222
LAPACHONE,6N4FA2QQ6A,Designated,Public record,6269,Beta-Lapachone,3/28/2022,Treatment of Primary Sclerosing Cholangitis (PSC),Designated,Not FDA Approved for Orphan Indication,,,,,"Curome Biosciences Co., Ltd.","Gwanggyo Business Center 5F(#508),","156, Gwanggyo-ro, Yeongtong-Gu",Suwon-si,Gyeonggi-do,16506,South Korea,812821
AB-001,TNM7KA4LB3,Designated,Public record,6270,"(1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)- 7-(4-hydroxy-3, 5dimethoxyphenyl) hepta- 1, 4, 6-trien-3-one",3/31/2022,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Agastiya Biotech,5256 South Mission Road,Suite 132,Bonsall,California,92003,United States,870822
AB-001,TNM7KA4LB3,Designated,Public record,6271,"(1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)-7-(4-hydroxy-3, 5 dimethoxyphenyl) hepta-1, 4, 6-trien-3-one",3/31/2022,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Agastiya Biotech,5256 South Mission Road,Suite 132,Bonsall,California,92003,United States,870922
SERPLULIMAB,S3GQZ2K36V,Designated,Public record,6272,serplulimab,3/31/2022,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Hengenix Biotech, Inc.",430 N. McCarthy Blvd.,"Milpitas, CA 95035",Milpitas,California,95035,United States,869822
"""DEUTEROPIOGLITAZONE HYDROCHLORIDE, (R)-""",YJ4MVI8ETZ,Designated,Public record,6274,"(R)-5-({4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}methyl)-(5-2H)-1,3-thiazolidine-2,4-dione hydrochloride",4/11/2022,Treatment of X-Linked Adrenoleukodystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Poxel S.A.,259/261 Avenue Jean Jaures,,Lyon,,,France,871522
ECHOTHIOPHATE IODIDE,BA9QH3P00T,Designated,Public record,6275,Echothiophate iodide,4/11/2022,Treatment of Stargardt Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,11560,United States,871422
MECASERMIN,7GR9I2683O,Designated,Public record,6276,Insulin-like Growth Factor-1,4/11/2022,Treatment of Congenital Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,12947,Sweden,871322
TORIPALIMAB,8JXN261VVA,Designated,Public record,6277,Toripalimab,4/11/2022,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc","9430 Key West Ave, Suite 125",,Rockville,Maryland,20850,United States,869622
EFZOFITIMOD,V5TNN0W368,Designated,Public record,6278,efzofitimod,4/12/2022,Treatment of Systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,aTyr Pharma Inc.,"3545 John Hopkins Court, Suite 250",,San Diego,California,92121,United States,870022
"""ACETYLLEUCINE, L-""",E915HL7K2O,Designated,Public record,6279,N-Acetyl-Leucine,4/13/2022,Treatment of GM1 Gangliosidosis,Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,870222
GLYCOLIC ACID,0WT12SX38S,Designated,Public record,6280,Glycolic acid and D-lactic acid,4/19/2022,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Neurevo GmbH,Balantstr. 6,,München,Bavaria,81669,Germany,872422
"""LACTIC ACID, D-""",3Q6M5SET7W,Designated,Public record,6280,Glycolic acid and D-lactic acid,4/19/2022,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Neurevo GmbH,Balantstr. 6,,München,Bavaria,81669,Germany,872422
FENVALERATE,Z6MXZ39302,Designated,Public record,6281,"methyl (R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3- ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate",4/19/2022,Treatment of Rett Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"DepYmed, Inc.",3 Bioscience Park Drive,,Farmingdale,New York,11735,United States,872122
TTI-101,KZ3DLD11RQ,Designated,Public record,6282,"N-(1¿,2-dihydroxy-[1,2¿-binapthalen]-4¿-yl)-4-methoxybenzenesulfonamide",4/19/2022,Treatment of pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Tvardi Therapeutics, Inc.",2450 Holcombe Blvd. Suite X,,Houston,Texas,77021,United States,872022
NANVURANLAT,CEDO9QXYZK,Designated,Public record,6283,Nanvuranlat,4/19/2022,Treatment of biliary tract cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"J-Pharma Co., Ltd.",Leading Venture Plaza 1,75-1 Onocho,"Tsurumi, Yokohama",Kanagawa,,Japan,872522
Vodudeutentan sodium,AAY8R26VDX,Designated,Public record,6284,sodium bispiperidine-carboxamido-dimethylpenatnamido-methoxycarbonyl-indol-propanamidohexanoate,4/19/2022,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"ENB Therapeutics, Inc.","Alexandria Center for Life Sciences, Launch Labs","430 E 29th St, 14th Floor",New York,New York,10016,United States,871622
ST-101 (D-AMINO ACID PEPTIDE),CT77XS2YLT,Designated,Public record,6285,H-D-valyl1-D-alanyl-D-glutamyl-D-alanyl-D-arginyl5-D-glutamyl-D-glutamyl-D-leucyl-D-glutamyl-D-arginyl10-D-leucyl-D-glutamyl-D-alanyl-D-arginyl-D-leucyl15-glycyl-D-glutaminyl-D-alanyl-D-arginyl-glycyl20-D-glutamyl-D-leucyl-D-lysyl-D-lysyl-D-tryptophyl25-D,4/25/2022,Treatment of stage IIB-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Sapience Therapeutics, Inc.","500 Mamaroneck Ave, Suite 320",,Harrison,New York,10528,United States,871922
Utreloxastat,WW8KZK2PZT,Designated,Public record,6286,"2,3,5-Trimethyl-6-nonyl-2,5-cyclohexadiene-1,4-dione",4/26/2022,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,7080,United States,875722
CLEMIZOLE HYDROCHLORIDE,85W6I13D8M,Designated,Public record,6290,Clemizole Hydrochloride,4/26/2022,Treatment of Ohtahara Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 E. Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,7652,United States,852621
DAROVASERTIB,E0YF0M8O09,Designated,Public record,6292,darovasertib,4/27/2022,Treatment of Uveal Melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,IDEAYA Biosciences Inc.,7000 Shoreline Court,Suite 350,South San Francisco,California,94080,United States,873322
AGS-499,UDG33RMP94,Designated,Public record,6293,"4,4',4''-(Ethane-1,1,1- triyl)tris(2,6-diethoxyphenol)",4/29/2022,Treatment of Amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,Neuromagen Pharma Ltd.,Beer Sheva High Tech Park,P.O. Box 5316,Beer Sheva,Southern District,84561,Israel,872722
2'-DEOXYTHIOGUANOSINE,KR0RFB46DF,Designated,Public record,6294,6-thio-2'-deoxyguanosine,5/2/2022,Treatment of Small Cell Lung Cancer (SCLC),Designated,Not FDA Approved for Orphan Indication,,,,,"MAIA Biotechnology, Inc.","444 West Lake Street, Suite 1700",,Chicago,Illinois,60606,United States,872822
KUS-121 dihydrate,79A6RUR6P3,Designated,Public record,6295,Sodium 4-amino-3- [6-( 4-fluoro-2-methylphenyl)pyridine-3-ylazo] naphthalene-1-sulfonate dihydrate,5/3/2022,Treatment of retinal artery occlusion (RAO).,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyoto Drug Discovery & Development Co., Ltd.","8F, Sakaisuji Satellite Building 1-6-9",,"Awaji-Machi, Chuo-ku",,,Japan,873422
TP-3654 HYDROCHLORIDE,D7A0W431TR,Designated,Public record,6298,"2-(trans-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin6-yl)amino)cyclohexyl)propan-2-ol hydrochloride",5/10/2022,Treatment of Myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,1752,United States,874922
ALOXISTATIN,L5W337AOUR,Designated,Public record,6300,Aloxistatin,5/10/2022,Treatment of GM1-gangliosidosis,Designated,Not FDA Approved for Orphan Indication,,,,,DORPHAN SA,Chemin de l’Eglise 7,,Epalinges,Vaud,,Switzerland,874322
ELAMIPRETIDE HYDROCHLORIDE,E40WZ3BK2D,Designated,Public record,6301,Elamipretide HCl,5/10/2022,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Stealth Biotherapeutics Inc.,140 Kendrick Street,Building C-West,Needham,Massachusetts,2494,United States,874722
Valbenazine,54K37P50KH,Designated,Public record,6303,Valbenazine,5/10/2022,Treatment of Huntington disease,Designated,Not FDA Approved for Orphan Indication,,,,,Neurocrine Biosciences Inc.,12780 El Camino Real,,San Diego,California,92130,United States,875022
MESENCHYMAL STEM CELLS,,Designated,Public record,6304,Mesenchymal stem cells,5/12/2022,Treatment of acute Graft-versus-host disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Ossium Health, Inc.",80 Tehama Street,,San Francisco,California,94105,United States,874222
DPM-1001,4EA2U2RX2G,Designated,Public record,6305,"methyl (R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate",5/12/2022,Treatment of Wilson's Disease,Designated,Not FDA Approved for Orphan Indication,,,,,DepYmed Inc.,3 Bioscience Park Dr,,Farmingdale,New York,11735,United States,876122
PXL-770,414C1D1T0T,Designated,Public record,6306,"potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate",5/12/2022,Treatment of X-Linked Adrenoleukodystrophy (ALD),Designated,Not FDA Approved for Orphan Indication,,,,,Poxel S.A.,259/261 Avenue Jean Jaures,,Lyon,,,France,875822
Osivelotor,UK749B4S16,Designated,Public record,6307,(S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin- 3-yl)methoxy)benzaldehyde,5/16/2022,Treatment of Sickle Cell Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Global Blood Therapeutics, Inc.",181 Oyster Point Blvd,,South San Francisco,California,94080,United States,877122
AB-001,TNM7KA4LB3,Designated,Public record,6308,"(1E,4E,6E)-1-(3,5-dimethoxyphenyl)-7-(4-hydroxy-3,5dimethoxyphenyl)hepta-1,4,6-trien-3-one",5/16/2022,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Agastiya Biotech,"5256 South Mission Road, Suite 132",,Bonsall,California,92003,United States,876722
TASQUINIMOD,756U07KN1R,Designated,Public record,6309,Tasquinimod,5/16/2022,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Active Biotech AB,Scheelevagen 22,,Lund,Lund,,Sweden,877022
DSP-0390 DIPHOSPHATE,HH28W4F6XQ,Designated,Public record,6310,"(4'aR,10'bR)-8'-chloro-1-[2-(1H-imidazol-1-yl)ethyl]-5',5'-dimethyl-4'a,10'b-dihydro-2'H,4'H,5'H-spiro[piperidine-4,3'-pyrano[3,2-c][1]benzopyran] diphosphate",5/17/2022,Treatment of Brain Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,1752,United States,877322
Saltikva,L82BY2VM3Q,Designated,Public record,6311,Attenuated Salmonella typhimurium containing the gene for human interleukin-2 (IL-2),5/17/2022,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Salspera Inc.,3510 Hopkins Place N,,Oakdale,Minnesota,55128,United States,877922
Exarafenib hydrochloride,5RHX544GEH,Designated,Public record,6313,"N-[3-[2-[(1R)-1-Hydroxypropan-2-ylamino]-6-(4- morpholinyl)-4-pyridinyl]-4-methylphenyl]-(3S)-3-(2,2,2-trifluoroethyl)-1- pyrrolidine carboxamide hydrochloride.",5/19/2022,Treatment of Stage IIb-IV Melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,Kinnate Biopharma Inc.,3611 Valley Centre Drive,Suite 175,San Diego,California,92130,United States,854521
SELPERCATINIB,CEGM9YBNGD,Designated/Approved,Public record,6314,selpercatinib,5/19/2022,Treatment of tissue-agnostic RET fusion-positive solid tumors,Designated/Approved,,Treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options,9/21/2022,9/21/2029,Treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,46285,United States,849621
RWJ-800088,CU0FSR29BQ,Designated,Public record,6315,a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous,5/24/2022,Treatment of primary failure of platelet recovery (PFPR) or secondary failure of platelet recovery (SFPR) in patients who have undergone allogeneic hematopoietic stem cell transplant (HSCT).,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen R&D, LLC",920 Route 202 South,PO Box 300,Raritan,New Jersey,8869,United States,878122
ST-003,HSN8WK37D7,Designated,Public record,6316,Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu- Gly-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Ala-NH2,5/24/2022,Treatment of primary sclerosing cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Sterotherapeutics, LLC",805 Old Easton Road,,Doylestown,Pennsylvania,18902,United States,878622
INCLACUMAB,A6734I702L,Designated,Public record,6317,Inclacumab,5/24/2022,Treatment of Sickle Cell Disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Global Blood Therapeutics, Inc.",181 Oyster Point Blvd,,South San Francisco,California,94080,United States,875522
BUPRENORPHINE,40D3SCR4GZ,Designated,Public record,6318,buprenorphine,5/25/2022,Treatment of opioid withdrawal syndrome in the pediatric population,Designated,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,Parma,,43122,Italy,541116
NNI-351,97LG4X5P2E,Designated,Public record,6321,"4-(3-cyano-6-ethoxyquinolin-2-yl)-N- (2-fluorophenyl)-1,4-diazepane-1-carbothiomide",5/26/2022,Treatment of Fragile X syndrome (FXS),Designated,Not FDA Approved for Orphan Indication,,,,,"Neuronascent, Inc.","6030 Day Break Circle, A150 PMB244",,Clarksville,Maryland,21029,United States,880622
RWJ-800088,CU0FSR29BQ,Designated,Public record,6322,a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous TPO,5/26/2022,To treat patients undergoing myeloablative hematopoietic stem cell transplant conditioning to improve platelet recovery and reduce myeloablative bone marrow conditioning-related toxicities.,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 US Highway 202,P.O. Box 300,Raritan,New Jersey,8869,United States,878222
SELINEXOR,31TZ62FO8F,Designated,Public record,6324,Selinexor,5/26/2022,Treatment of Myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.","85 Wells Ave,",,Newton,Massachusetts,2459,United States,880222
EPELEUTON,FA9BPX1T6V,Designated,Public record,6329,"15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester (15(S)-HEPE-EE)",6/3/2022,Treatment of sickle cell disease (SCD),Designated,Not FDA Approved for Orphan Indication,,,,,Afimmune,"Trintech Building, South County Business Park",Leopardstown,Dublin 18,,,Ireland,880022
Misetionamide,489TQ24FC1,Designated,Public record,6332,"1,4Lambda6, 3-Oxathiazinane-4,4-dione",6/6/2022,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Geistlich Pharma North America,"902 Carnegie Center, Suite 360",,Princeton,New Jersey,8540,United States,883222
ICAPAMESPIB DIHYDROCHLORIDE,Y0CQ2DGP7R,Designated,Public record,6333,"8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(2-(neopentylamino)ethyl)-9H-purin-6-amine, dihydrochloride salt",6/6/2022,Treatment of Malignant Glioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Samus Therapeutics, Inc.",10 South Main Street,,Topsfield,Massachusetts,1983,United States,882822
AZITHROMYCIN,,Designated,Public record,6334,azithromycin,6/6/2022,Prevention of bronchopulmonary dysplasia in neonates.,Designated,Not FDA Approved for Orphan Indication,,,,,Iorek Pharma Limited,102 High Street,,GODALMING,England,,United Kingdom,881322
PT-217,4A6ZWS8R8E,Designated,Public record,6335,Bispecific Antibody against DLL3 and CD47,6/6/2022,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Phanes Therapeutics, Inc.","11535 Sorrento Valley Road, Suite 400",,San Diego,California,92121,United States,880922
LINVOSELTAMAB,M3CPC50MZS,Designated,Public record,6336,human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA,6/6/2022,Treatment of Multiple Myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,10591,United States,882022
IADADEMSTAT,54T74394F8,Designated,Public record,6337,iadademstat,6/6/2022,Treatment of small cell lung cancer (SCLC),Designated,Not FDA Approved for Orphan Indication,,,,,Oryzon Genomics S.A.,Sant Ferran 74,Cornellà de Llobregat,Barcelona,,8940,Spain,880122
KETAMINE,690G0D6V8H,Designated,Public record,6338,Ketamine,6/6/2022,Treatment of Complex Regional Pain Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Vitalis Analgesics, LLC",93 4th Avenue #19,,New York,New York,10003,United States,883122
HUPERZINE A,0111871I23,Designated,Public record,6340,(-)-Huperzine A,6/7/2022,Treatment of SCN8A Developmental and Epileptic Encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,"Supernus Pharmaceuticals, Inc.",9715 Key West Avenue,,Rockville,Maryland,20850,United States,885322
"""(6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyridin-2-yl)isoxazol-5-yl)methyl)-8-(quinolin-5-ylmethyl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide methane sulfonic acid""",BC3NAR7TV9,Designated,Public record,6341,"(6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyridin-2-yl)isoxazol-5-yl)methyl)-8-(quinolin-5-ylmethyl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide methane sulfonic acid",6/7/2022,Treatment of Idiopathic Pulmonary Fribrosis (IPF),Designated,Not FDA Approved for Orphan Indication,,,,,"3Plus2 Pharma, LLC",3904 Chapman Ct.,,Altadena,California,91001,United States,884022
FENFLURAMINE HYDROCHLORIDE,3KC089243P,Designated,Public record,6343,fenfluramine hydrochloride,6/7/2022,Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder,Designated,Not FDA Approved for Orphan Indication,,,,,Zogenix Inc.,"5959 Horton Street, 5th Floor",,Emeryville,California,94608,United States,880422
ILIXADENCEL,PY29292DVJ,Designated,Public record,6344,ilixadencel,6/7/2022,Treatment of gastrointestinal stromal tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Mendus AB,Västra Trädgårdsgatan 15,,Stockholm,,11153,Sweden,864821
PEGCETACOPLAN,TO3JYR3BOU,Designated,Public record,6345,pegcetacoplan,6/7/2022,Treatment of immune complex-membranoproliferative glomerulonephritis,Designated,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.",100 5th Ave,3rd floor,Waltham,Massachusetts,2451,United States,799620
Tegoprubart,EK87C62XNH,Designated,Public record,6346,tegoprubart,6/7/2022,Prevention of allograft rejection in pancreatic islet cell transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Eledon Pharmaceuticals, Inc.",19900 MacArthur Blvd.,Suite 550,Irvine,California,92612,United States,881622
ST-1535,NTK8WWM73W,Designated,Public record,6347,"2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine A triazole purine analogue",6/8/2022,Treatment of Non-24 Sleep Wake Rhythm Disorder (N24SWRD) in blind individuals without light perception,Designated,Not FDA Approved for Orphan Indication,,,,,Circadian Therapeutics Ltd.,Oxford Centre for Innovation,New Road,Oxford,,,United Kingdom,811021
"""5-[[trans-4-[4-(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid""",WC82E7HRU5,Designated,Public record,6348,"5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid",6/8/2022,Treatment of primary hyperoxaluria type 1,Designated,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,94949,United States,882922
CPO-107,65RC2F9XAB,Designated,Public record,6349,CD20-CD47 bispecific fusion protein,6/8/2022,Treatment of Burkitt Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Conjupro Biotherapeutics, Inc.","302 Carnegie Center, Ste 100",,Princeton,New Jersey,8540,United States,883922
VINBLASTINE SULFATE,N00W22YO2B,Designated,Public record,6351,"cis-diamminedichloroplatinum(II) (CDDP), vinblastine sulfate, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO-FA)",6/13/2022,Treatment of Soft Tissue Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Intensity Therapeutics, Inc.","61 Wilton Road, 3rd Floor",,Westport,Connecticut,6880,United States,867921
SALCAPROZIC ACID,X88E147FCU,Designated,Public record,6351,"cis-diamminedichloroplatinum(II) (CDDP), vinblastine sulfate, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO-FA)",6/13/2022,Treatment of Soft Tissue Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Intensity Therapeutics, Inc.","61 Wilton Road, 3rd Floor",,Westport,Connecticut,6880,United States,867921
CISPLATIN,Q20Q21Q62J,Designated,Public record,6351,"cis-diamminedichloroplatinum(II) (CDDP), vinblastine sulfate, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO-FA)",6/13/2022,Treatment of Soft Tissue Sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Intensity Therapeutics, Inc.","61 Wilton Road, 3rd Floor",,Westport,Connecticut,6880,United States,867921
rafutrombopag,9WGT51BDDL,Designated,Public record,6352,hetrombopag,6/13/2022,Treatment for chemotherapy-induced thrombocytopenia,Designated,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.",7 Kunlunshan Road,Economic & Technological Development Zone,Lianyungang,Jiangsu,222047,China,882322
PALTIMATRECTINIB,SP4MKH8Y5J,Designated,Public record,6354,"(R)-5-(2-(2,5-difluorophenyl) pyrrolidin-1-yl)-3-(4-(trifluoromethyl)-1H-pyrazol-1-yl) pyrazolo[1,5-a] pyrimidine",6/15/2022,Treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Pyramid Biosciences,330 Bear Hill Road,Suite 302,Waltham,Massachusetts,2451,United States,827621
IBUDILAST,M0TTH61XC5,Designated,Public record,6355,Ibudilast,6/15/2022,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Healx Limited,"Charter House, 66-68 Hills Rd.",,Cambridge,,,United Kingdom,889222
PAXALISIB,P5DKZ70636,Designated,Public record,6356,Paxalisib (INN and USAN),6/15/2022,Treatment of atypical teratoid/rhabdoid tumors (AT/RT),Designated,Not FDA Approved for Orphan Indication,,,,,Kazia Therapeutics Limited,ACN 063 259 754,"Level 24, 300 Barangaroo Avenue",Sydney,New South Whales,2000,Australia,892422
TQS-168,3WT26285WB,Designated,Public record,6357,2-(4-Tert-butylphenyl)-1H-benzimidazole,6/16/2022,Treatment of Amyotrophic Lateral Sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,"Tranquis Therapeutics, Inc.",3 Lagoon Dr #130,,Redwood City,California,94065,United States,884922
DASATINIB,RBZ1571X5H,Designated,Public record,6360,dasatinib,6/16/2022,Treatment of chronic myeloid leukemia (CML),Designated,Not FDA Approved for Orphan Indication,,,,,Xspray Pharma AB,Råsundavägen 12,,Solna,,16967,Sweden,809221
RENCOFILSTAT,M3H4D91AY5,Designated,Public record,6363,rencofilstat,6/17/2022,Treatment of hepatocellular carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Hepion Pharmaceuticals, Inc.","399 Thornall Street, First Floor",,Edison,New Jersey,8837,United States,885822
AMINOLEVULINIC ACID HYDROCHLORIDE,V35KBM8JGR,Designated,Public record,6365,5-aminolevulinic acid hydrochloride,6/23/2022,Treatment of malignant glioma.,Designated,Not FDA Approved for Orphan Indication,,,,,"Alpheus Medical, Inc.",3510 Hopkins Place N,,Oakdale,Minnesota,55128,United States,885522
Brigimadlin,9A934ZAN94,Designated,Public record,6367,"Spiro[3H-Indole-3,2¿-pyrrolidin]-2(1H)-one derivative",6/24/2022,Treatment of soft tissue sarcoma (STS).,Designated,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,PO Box 368,Ridgefield,Connecticut,6877,United States,885622
TRAMETINIB,33E86K87QN,Designated,Public record,6368,trametinib,6/24/2022,Treatment of malignant glioma with BRAF V600 mutation,Designated/Approved,,"in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy",3/16/2023,3/16/2030,treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,882722
VILOBELIMAB,F5T0RF9ZJA,Designated,Public record,6369,Vilobelimab,6/27/2022,Treatment of pyoderma gangrenosum,Designated,Not FDA Approved for Orphan Indication,,,,,InflaRx N.V.,Winzerlaer Str. 2,,Jena,,7745,Germany,884822
ILOPROST,JED5K35YGL,Designated,Public record,6371,Iloprost,6/29/2022,Treatment of frostbite,Designated,Not FDA Approved for Orphan Indication,,,,,Eicos Sciences,3 East 3rd Avenue,Suite 200,San Mateo,California,94401,United States,886722
DSP-5336,VW83Y2JLZ5,Designated,Public record,6372,menin inhibitor,6/29/2022,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,1752,United States,887822
OCTREOTIDE ACETATE,75R0U2568I,Designated,Public record,6373,Octreotide (acetate),6/30/2022,Treatment of carcinoid syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Amryt Pharmaceuticals DAC,45 Mespil Road,,Dublin 4,,,Ireland,886622
5-O-DESMETHYLOMEPRAZOLE,QH71GLR6GT,Designated,Public record,6374,"2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-ol or 5-O-desmethyl-omeprazole",7/1/2022,Treatment of Multiple System Atrophy (MSA),Designated,Not FDA Approved for Orphan Indication,,,,,Yoda Therapeutics Inc.,"4F-4, No. 305, Sec. 3, Zhongxiao E. Rd., Da' an Dist.",,Taipei,,106452,Taiwan,830021
MAVORIXAFOR,0G9LGB5O2W,Designated,Public record,6376,mavorixafor,7/1/2022,Treatment of Waldenstrom’s Macroglobulinemia,Designated,Not FDA Approved for Orphan Indication,,,,,"X4 Pharmaceuticals, Inc.",61 N Beacon St; 4th Floor,,Boston,Massachusetts,2134,United States,887322
Elenestinib,6FBM4CP6RK,Designated,Public record,6377,Selective KIT Inhibitor,7/1/2022,Treatment of Mastocytosis,Designated,Not FDA Approved for Orphan Indication,,,,,Blueprint Medicines,45 Sidney Street,,Cambridge,Massachusetts,2139,United States,890922
AKV-9,SSZ5C8U4KQ,Designated,Public record,6378,"5-((S)-1-(3,5-bis(trifluoromethyl)phenoxy)ethyl)-3-hydroxycyclohex-2-en-1-one",7/6/2022,Amyotrophic Lateral Sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,"Akava Therapeutics, LLC",755 Sheridan Road,,Winnetka,Illinois,60093,United States,886022
ALDESLEUKIN,M89N0Q7EQR,Designated,Public record,6379,aldesleukin,7/6/2022,Treatment of amyotrophic lateral sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,ILTOO Pharma,14 rue des Reculettes,,Paris,Ile-de-France,75013,France,854621
MELATONIN,JL5DK93RCL,Designated,Public record,6381,melatonin / ethanol,7/7/2022,Treatment of neonatal hypoxic ischemic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,ESPL Regulatory Consulting Limited,Unit 3D North Point House,North Point Business Park,New Mallow Road,Cork,,United Kingdom,888822
ALCOHOL,3K9958V90M,Designated,Public record,6381,melatonin / ethanol,7/7/2022,Treatment of neonatal hypoxic ischemic encephalopathy,Designated,Not FDA Approved for Orphan Indication,,,,,ESPL Regulatory Consulting Limited,Unit 3D North Point House,North Point Business Park,New Mallow Road,Cork,,United Kingdom,888822
TRYPAN BLUE,I2ZWO3LS3M,Designated,Public record,6382,Trypan Blue Ophthalmic Solution,7/8/2022,For use as an aid in ophthalmic surgery by staining the Descemet membrane during Descemet membrane endothelial keratoplasty (DMEK),Designated,Not FDA Approved for Orphan Indication,,,,,D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.,Scheijdelveweg 2,,Zuidland,ZUID-HOLLAND,,Netherlands,889622
EFINEPTAKIN ALFA,3K3WC6MT6P,Designated,Public record,6384,Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc),7/11/2022,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,NeoImmuneTech,2400 Research Blvd,Suite 250,Rockville,Maryland,20850,United States,890122
GGTI-2418,M67G28K74K,Designated,Public record,6385,2-{[2-benzyl-4-(5-methyl-3H-imidazol-4-ylmethyl)-3-oxo-piperazine-1-carbonyl]- amino}-4methyl-pentanoic acid,7/13/2022,Treatment of peripheral T-cell lymphomas,Designated,Not FDA Approved for Orphan Indication,,,,,"Prescient Therapeutics, LTD","Level 4, 100 Albert Road",,South Melbourne,VIC,3205,Australia,890422
CISPLATIN,Q20Q21Q62J,Designated,Public record,6386,Cisplatin transmucosal system,7/13/2022,Treatment of carcinoma in situ (CIS) of the anterior 2/3 of the oral cavity,Designated,Not FDA Approved for Orphan Indication,,,,,Privo Technologies,200 Corporate Place Suite 6b,,Peabody,Massachusetts,1960,United States,783620
PREDNISONE,VB0R961HZT,Designated,Public record,6387,Prednisone,7/13/2022,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,12947,Sweden,889122
SATRALIZUMAB-MWGE,,Designated,Public record,6392,satralizumab-mwge,7/18/2022,Treatment of N-methyl-D-asparatate receptor antibody autoimmune encephalitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,,United States,822921
DOCETAXEL,15H5577CQD,Designated,Public record,6393,Docetaxel albumin bound,7/20/2022,Treatment of gastric cancer Including cancer of gastroesophageal junction,Designated,Not FDA Approved for Orphan Indication,,,,,"Conjupro Biotherapeutics, Inc.","302 Carnegie Center, Ste 100",,Princeton,New Jersey,8540,United States,892322
PIOGLITAZONE HYDROCHLORIDE,JQT35NPK6C,Designated,Public record,6394,Pioglitazone hydrochloride,7/20/2022,Treatment of childhood onset idiopathic nephrotic syndrome (defined as steroid dependent or frequently relapsing NS).,Designated,Not FDA Approved for Orphan Indication,,,,,"NephKey Therapeutics, Inc.","15100 Weston Parkway, Suite 101",,Cary,North Carolina,27513,United States,890822
Vensobafusp alfa,G3PS38JMS8,Designated,Public record,6395,Recombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminus,7/20/2022,Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH),Designated,Not FDA Approved for Orphan Indication,,,,,"Kira Pharmaceuticals, LLC",245 Main Street,,Cambridge,Massachusetts,2142,United States,834521
ASPACYTARABINE,JL7V54Z2BR,Designated,Public record,6396,aspacytarabine,7/25/2022,Treatment of Myelodysplastic Syndromes,Designated,Not FDA Approved for Orphan Indication,,,,,"BioSight, Ltd.","3 Hayarden St., Airport City",P.O.B.1083,Lod,,7019802,Israel,835821
IDRX-42,Y6UHU32G5Z,Designated,Public record,6400,"[4-(Methyl-1H-pyrazol-4-yl)-benzyl] -(6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a] pyridin-3-yl]-pyrimidin-4-yl]-amine",7/26/2022,Treatment of gastrointestinal stromal tumors (GIST),Designated,Not FDA Approved for Orphan Indication,,,,,IDRx Incorporated,52A Court Street,,Plymouth,Massachusetts,2360,United States,892122
Iodine I-124 Evuzamitide,9DR4VH0DJP,Designated,Public record,6401,Iodine (I-124) evuzamitide,7/26/2022,Diagnostic for the management of transthyretin amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Attralus, Inc.",50 Francisco Street,Suite 450,San Francisco,California,94133,United States,891522
BROMOPYRUVATE,63JMV04GRK,Designated,Public record,6403,3-bromopyruvic acid,7/27/2022,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Ko Discovery LLC,701 East Pratt Street,Lab 4023,Baltimore,Maryland,21202,United States,894722
EFGARTIGIMOD ALFA,961YV2O515,Designated,Public record,6404,efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20),7/27/2022,Treatment of myasthenia gravis,Designated,Not FDA Approved for Orphan Indication,,,,,argenx BV,Industriepark Zwijnaarde 7,,Zwijnaarde (Ghent),,9052,Belgium,825421
HYALURONIDASE (HUMAN RECOMBINANT),743QUY4VD8,Designated,Public record,6404,efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20),7/27/2022,Treatment of myasthenia gravis,Designated,Not FDA Approved for Orphan Indication,,,,,argenx BV,Industriepark Zwijnaarde 7,,Zwijnaarde (Ghent),,9052,Belgium,825421
Iluzanebart,23Q5AU2MD5,Designated,Public record,6405,Human monoclonal IgG1 TREM2 agonist antibody,7/27/2022,Treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia,Designated,Not FDA Approved for Orphan Indication,,,,,"Vigil Neuroscience, Inc.","One Broadway, Suite 07-300",,Cambridge,Massachusetts,2142,United States,831521
OMS-906,0SOY20O318,Designated,Public record,6408,Humanized immunoglobulin G4 monoclonal antibody directed against mannan-binding lectin-associated serine protease-3 (MASP-3),7/28/2022,Treatment of Paroxysmal Nocturnal Hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Ave West,,Seattle,Washington,98119,United States,830121
TEMOZOLOMIDE,YF1K15M17Y,Designated,Public record,6413,"a fixed-dose combination containing two active ingredients, senaparib and temozolomide",8/3/2022,Treatment of Small Cell Lung Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"IMPACT Therapeutics, Inc.","12F, New Bund Times Square, 399 Haiyang West Rd.",Pudong District,Shanghai,,,China,895222
SENAPARIB,MNZ4OP95CF,Designated,Public record,6413,"a fixed-dose combination containing two active ingredients, senaparib and temozolomide",8/3/2022,Treatment of Small Cell Lung Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"IMPACT Therapeutics, Inc.","12F, New Bund Times Square, 399 Haiyang West Rd.",Pudong District,Shanghai,,,China,895222
VENADAPARIB,PUP792O0IW,Designated,Public record,6415,Venadaparib,8/5/2022,Treatment of Gastric Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Idience Co., Ltd.","2, Baumoe-ro 27-gil, Seocho-gu",,Seoul,Seoul,6752,South Korea,816221
Boditrectinib hemi-oxalate,P3TD57J553,Designated,Public record,6416,"(R,E)-3-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-1-(piperazin-1-yl)prop-2-en-1-on hemi-oxalate",8/11/2022,Treatment of Solid Tumors with the NTRK fusion gene,Designated,Not FDA Approved for Orphan Indication,,,,,AUM Biosciences Pty Ltd.,10 Anson Rd #24-16A/B,International Plaza,Singapore,,79903,Singapore,894622
BI-1015550,I5DGT51IB8,Designated,Public record,6419,A thienopyrimidine derivative that preferentially inhibits Phosphodiesterase 4B,8/15/2022,Treatment Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,,Ridgefield,Connecticut,6877,United States,896222
GANAPLACIDE,85VMN9JU7A,Designated,Public record,6422,Ganaplacide and Lumefantrine fixed-dose combination,8/15/2022,Treatment of Malaria,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,895622
LUMEFANTRINE,F38R0JR742,Designated,Public record,6422,Ganaplacide and Lumefantrine fixed-dose combination,8/15/2022,Treatment of Malaria,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,895622
ROVATIRELIN,9DL0X410PY,Designated,Public record,6424,Rovatirelin,8/15/2022,Treatment of spinocerebellar ataxia,Designated,Not FDA Approved for Orphan Indication,,,,,BioPharma Global,"1934 Old Gallows Rd., Suite 420",,Vienna,Virginia,22182,United States,895422
GARADACIMAB,32W6AJL0DY,Designated,Public record,6425,garadacimab,8/16/2022,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,19406,United States,870622
SOTULETINIB,7W3V82OQ0P,Designated,Public record,6426,sotuletinib,8/16/2022,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,897222
VEBRELTINIB,2WZP8A9VFN,Designated,Public record,6427,vebreltinib,8/16/2022,Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations,Designated,Not FDA Approved for Orphan Indication,,,,,"Apollomics, Inc.","989 E. Hillsdale Blvd, Suite 220",,Foster City,California,94404,United States,878722
TUCIDINOSTAT,87CIC980Y0,Designated,Public record,6428,tucidinostat,8/26/2022,Treatment of patients with of stage IIb-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"HUYABIO International, LLC","12531 High Bluff Drive, Suite 138",,San Diego,California,92130,United States,867121
Trastuzumab Vedotin,W95G28K44S,Designated,Public record,6432,Trastuzumab vedotin,8/29/2022,Treatment of patients with gastric cancer (GC) and gastroesophageal junction (GEJ) cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Shanghai Miracogen Inc.,"1238 Zhangjiang Road, Building 3, Suite 4E",Pudong District,Shanghai,,201203,China,898822
AVA-6000,7XPB9B6MUA,Designated,Public record,6433,"N-[(2R)-1-[(2S)-2-[(3-hydroxy-2-methyl-6-{[(3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl)carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]pyridine-4-carboxamide",9/1/2022,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Avacta Life Sciences Ltd.,"Scale Space, White City, Imperial College Campus",58 Wood Lane,London,,,United Kingdom,887022
EMRUSOLMIN,E7WRA77JET,Designated,Public record,6435,"3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole",9/1/2022,Treatment of Multiple System Atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,19380,United States,898522
AL-01211,T6GUK68SDC,Designated,Public record,6439,"N-[(1R,2R)-2-(3-chloro-4-cyclopropoxyphenyl)-2-hydroxy-1-(pyrrolidinylmethyl)ethyl]-2-(6-chloro(2-naphthyl))-2-(hydroxyimino)acetamide.",9/1/2022,Treatment of Fabry disease,Designated,Not FDA Approved for Orphan Indication,,,,,"AceLink Therapeutics, Inc.","39600 Eureka Drive, Suite 151",,Newark,California,94560,United States,898722
BR-007 Sodium,UK2SRR5EMV,Designated,Public record,6441,"Sodium (1-hydroxy-4-(((2-((4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethoxy)carbonyl)amino)butane-1,1-diyl)bis(hydrogen phosphonate)",9/1/2022,Treatment of Camurati-Engelmann disease,Designated,Not FDA Approved for Orphan Indication,,,,,"Brise Pharmaceuticals Co., Ltd.","1976 Middle Gaoke Road, Building A, Suite A108",Pudong New District,Shanghai,Shanghai,201210,China,898222
EZURPIMTROSTAT,MS6LGW5JFK,Designated,Public record,6442,ezurpimtrostat,9/7/2022,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Genfit SA,"Parc Eurasanté, 885 Avenue Eugène Avinée",,Loos,,59120,France,897522
SY-5609,TW6044C3O6,Designated,Public record,6445,"(S)-7-(dimethylphosphoryl)-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile",9/12/2022,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Syros Pharmaceuticals,35 Cambridgepark Drive,Level 4,Cambridge,Massachusetts,2140,United States,898122
PXL-770,414C1D1T0T,Designated,Public record,6450,"potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate",9/14/2022,Treatment of Autosomal Dominant Polycystic Kidney Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Poxel S.A.,259/261 Avenue Jean Jaures,,Lyon,,,France,898922
BB-1701,GGL7785YRX,Designated,Public record,6452,Humanized IgG1kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin,9/16/2022,Treatment of Gastric and Gastroesophageal Junction cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Bliss Biopharmaceutical (Hangzhou) Co., Ltd.","Building 7, Hexiang Technology Center, Qiantang New Area",,Hangzhou,Zhejiang,,China,899522
MRG-003,VHA6L8H5FM,Designated,Public record,6454,Recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E,9/20/2022,Treatment of patients with nasopharyngeal carcinoma (NPC),Designated,Not FDA Approved for Orphan Indication,,,,,Shanghai Miracogen Inc.,"Building 3, Suite 4E, No. 1238 Zhangjiang Rd.",Pudong District,Shanghai,,201203,China,899622
INSULIN HUMAN,1Y17CTI5SR,Designated,Public record,6455,recombinant human insulin,9/21/2022,Treatment of intestinal malabsorption in preterm infants,Designated,Not FDA Approved for Orphan Indication,,,,,"Elgan Pharma, Ltd.",Wadi El Haj 13,,Nazareth,Nazareth,16100,Israel,900422
ABBV-CLS-7262,BN9FN5629V,Designated,Public record,6460,"Sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2- yl}oxy)methyl hydrogen phosphate - 2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)",9/27/2022,Treatment of Vanishing White Matter Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Calico Life Sciences LLC,1170 Veterans Blvd.,,South San Francisco,California,94080,United States,901322
TELITACICEPT,1FHM3D7Z49,Designated,Public record,6461,telitacicept,9/27/2022,Treatment of Myasthenia Gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"RemeGen Co., Ltd.","58 Middle Beijing Road, Yantai Development Area",,Yantai,ShangDong,264006,China,901522
ENA-001 HYDROGEN SULFATE,T9I273EQ99,Designated,Public record,6462,"2-N,O-dimethylhydroxylamino-4,6-bispropylamino-s-triazine, hydrogen sulfate salt",9/28/2022,Treatment of Apnea of Prematurity,Designated,Not FDA Approved for Orphan Indication,,,,,Enalare Therapeutics Inc.,161 Hodge Rd,,Princeton,New Jersey,8540,United States,853721
Taldefgrobep Alfa,766C38JSAR,Designated,Public record,6468,Taldefgrobep Alfa,12/16/2022,Treatment of spinal muscular atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceuticals, Inc.",215 Church Street,,New Haven,Connecticut,6510,United States,918122
AZELIRAGON,LPU25F15UQ,Designated,Public record,6470,azeliragon,12/20/2022,Treatment of Glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Cantex Pharmaceuticals,2536 Royal Palm Way,,Weston,Florida,33327,United States,915922
TEGAVIVINT,18AP231HUP,Designated,Public record,6471,Tegavivint,12/20/2022,Treatment of Hepatocellular Carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,Iterion Therapeutics,2450 Holcombe Blvd. East,Suite X,Houston,Texas,77021,United States,923322
ADENINE,JAC85A2161,Designated,Public record,6474,Adenine,12/22/2022,Treatment of Epidermolysis Bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,Energenesis Biomedical Co. Ltd.,"6F-3, No.21, Ln.583, Ruiguang Rd.",Neihu Dist.,Taipei,,11492,Taiwan,917122
BITOPERTIN,Q8L6AN59YY,Designated,Public record,6475,bitopertin,12/22/2022,Treatment of Erythropoietic Protoporphyria,Designated,Not FDA Approved for Orphan Indication,,,,,Disc Medicine,321 Arsenal Street,Suite 101,Watertown,Massachusetts,2472,United States,916222
JBI-802,8GSV79C4QX,Designated,Public record,6476,"N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl) amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrogen bromide",12/27/2022,Treatment of small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Jubilant Therapeutics Inc.,"1430 US Highway 206, Suite 110",,Bedminster,New Jersey,7921,United States,916922
LNS-8801,TFS4QE36ZG,Designated,Public record,6480,"1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone",1/3/2023,Treatment of Stage IIB to Stage IV Melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Linnaeus Therapeutics, Inc.","30 Washington Avenue, Suite F",,Haddonfield,New Jersey,8033,United States,918622
IVALTINOSTAT,4I8MLM7L2H,Designated,Public record,6482,Ivaltinostat,1/3/2023,Treatment of Idiopathic Pulmonary Fibrosis.,Designated,Not FDA Approved for Orphan Indication,,,,,"Machaon Biotherapeutics, Inc.","70 Osongsaengmyeong 6-ro,","Osong-eup, Heungdeok-gu,",Cheongju-si,Chungcheongbuk-do,28158,South Korea,919022
GOLEXANOLONE,9C48F08TP2,Designated,Public record,6489,Golexanolone,1/12/2023,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,Umecrine Cognition AB,Fogdevreten 2,,Solna,Sweden,,Sweden,871222
KF-1601 dihydrochloride,5MWF2X9XSZ,Designated,Public record,6490,"N-(3-(2-cyanopropan-2-yl)-5-(4-methyl-1H-imidazol-1-yl)phenyl)-2-fluoro-4-methyl-5-((8-((1-methyl-1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)benzamide dihydrochloride",1/12/2023,Treatment of Chronic myeloid leukemia (CML),Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunoForge Co., Ltd.","#1701~#1711, Ace Hansol Tower, 58 Gasan Digital 1-ro",Geumcheon-gu,Seoul,,8591,South Korea,873522
EZURPIMTROSTAT,MS6LGW5JFK,Designated,Public record,6493,ezurpimtrostat,1/18/2023,Treatment of hepatocellular carcinoma (HCC),Designated,Not FDA Approved for Orphan Indication,,,,,Genoscience Pharma,"10, rue d’Iéna",,Marseille,Provence,13006,France,922922
BELIMUMAB,73B0K5S26A,Designated,Public record,6499,belimumab,1/24/2023,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,GSK LLC,"2929 Walnut St, Suite 1700",,Philadelphia,Pennsylvania,19112,United States,921522
Golcadomide hydrochloride,488383336A,Designated,Public record,6501,"2-[(3S)-2,6-dioxopiperidin-3-yl]-4-{[(2-fluoro-4-{[3-(morpholin-4-yl)azetidin-1-yl]methyl} phenyl) methyl]amino}-1H-isoindole-1,3(2H)-dione-hydrogen chloride (1/1)",1/25/2023,Treatment of Follicular Lymphoma (FL),Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Coporation,86 Morris Avenue,,Summit,New Jersey,7901,United States,921022
CBP-501 ACETATE,8HSP55450P,Designated,Public record,6503,H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt,1/26/2023,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"CanBas Co., Ltd.",2-2-1 Otemachi,,Numazu City,Shizuoka,,Japan,922322
ECULIZUMAB,A3ULP0F556,Designated,Public record,6504,eculizumab,9/28/2022,Treatment of Guillain Barre syndrome (GBS),Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Blvd.,,Boston,Massachusetts,2210,United States,902222
APT-101 HYDROCHLORIDE,NB264L4WZU,Designated,Public record,6505,"((S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid hydrochloride)",9/29/2022,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,APIE Therapeutics,"P.O. Box 13169, 2 Davis Dr.",,Research Triangle Park,North Carolina,27709,United States,903322
OLVEREMBATINIB,KV1M7Q3CBP,Designated,Public record,6506,Olverembatinib,9/29/2022,Treatment of gastrointestinal stromal tumor (GIST),Designated,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,20850,United States,903622
SBT-272 Trihydrochloride,66CG5Q6RLH,Designated,Public record,6507,"(R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, tris hydrochloride",10/3/2022,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,Stealth Biotherapeutics Inc.,140 Kendrick Street,Building C-West,Needham,Massachusetts,2494,United States,902322
VELUSETRAG,J4VNV64ARB,Designated,Public record,6509,Velusetrag,10/4/2022,Treatment of chronic intestinal pseudo-obstruction,Designated,Not FDA Approved for Orphan Indication,,,,,ALFASIGMA S.P.A.,VIA RAGAZZI DEL '99 - 5,,BOLOGNA,BO,,Italy,902622
NM-8074,P9NB0SOG5X,Designated,Public record,6510,"Recombinant, Humanized, aglycosylated, IgG1 Kappa Anti-Properdin Monoclonal Antibody",10/5/2022,Treatment of Paroxysmal Nocturnal Hemoglobinuria,Designated,Not FDA Approved for Orphan Indication,,,,,"NovelMed Therapeutics, Inc.",11000 Cedar Avenue 135,,Cleveland,Ohio,44106,United States,835921
BR-101801,FJ5CTS1VNJ,Designated,Public record,6513,"4-[[(1S)-1-(4, 8-Dichloro-1-oxo-2-phenyl-3-isoquinolyl) ethyl] amino]-8H- pyrido[2,3-d] pyrimidin-5-one]",10/11/2022,"Treatment of Peripheral T-Cell Lymphoma, Not Otherwise Specified",Designated,Not FDA Approved for Orphan Indication,,,,,"Boryung Co., LTD",Boryung Bldg,Changgyeonggung-ro 136,Seoul,Jongno-gu,,South Korea,904122
BRODALUMAB,6ZA31Y954Z,Designated,Public record,6514,brodalumab,10/11/2022,Treatment of systemic sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,Bausch Health,400 Somerset Corporate Blvd,,Bridgewater,New Jersey,8807,United States,904322
3D-185,MU088RW4I5,Designated,Public record,6515,"N-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(3,3-dimethylpiperazin-1-yl)benzamide hydrochloride",10/11/2022,Treatment of cholangiocarcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"3D Medicines (Beijing) Co., Ltd","7 Liangshuihe 1st Street, Building 3-6","Hongkun Park, BDA",Beijing,,100176,China,904422
PCLX-001,5HY8BYC3Q6,Designated,Public record,6516,"2,6-Dichloro-N-(3-isobutyl-1,5-dimethyl-1H-pyrazol-4-yl)-4-(2-(piperazin-1-yl)pyridin-4-yl)benzenesulfonamide",10/12/2022,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Pacylex Pharmaceuticals,"4560, 10230 Jasper Avenue",,Edmonton,Alberta,,Canada,904722
BEVACIZUMAB,2S9ZZM9Q9V,Designated,Public record,6518,Bevacizumab,10/12/2022,Treatment of hereditary hemorrhagic telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,Laboratoires Delbert SAS,49 rue Rouelle,,Paris,,75015,France,904822
VIGABATRIN,GR120KRT6K,Designated,Public record,6520,Ready-to-use vigabatrin oral liquid,10/12/2022,Treatment of Infantile Spasms,Designated,Not FDA Approved for Orphan Indication,,,,,"Pyros Pharmaceuticals, Inc.","2001 Route 46, Suite 310",,Parsippany,New Jersey,7054,United States,905322
Vinblastine N-Oxide,PN45E4NV2N,Designated,Public record,6521,Vinblastine N-Oxide,10/12/2022,Treatment of Pancreatic Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Cascade Prodrug, Inc.",P.O. Box 13020,,Eugene,Oregon,97440,United States,904922
IM-156,8MS59W493C,Designated,Public record,6523,"1-Pyrrolidinecarboximidamide, N-[imino[[4-(trifluoromethoxy)phenyl]amino]methyl]-, acetate (1:1)",10/17/2022,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunoMet Therapeutics, Inc.",2450 Holcombe Blvd,JLABS at TMC,Houston,Texas,77021,United States,889822
GI-101,3Y7ANB3DKG,Designated,Public record,6524,bi-specific fragment crystallizable region (Fc) fusion protein containing cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc,10/17/2022,Treatment of Merkel cell carcinoma,Designated,Not FDA Approved for Orphan Indication,,,,,"GI Innovation, Inc.","A-1116 Tera Tower, 167, Songpa-daero",,Songpa-gu,Seoul,5855,South Korea,905422
IMIQUIMOD,P1QW714R7M,Designated,Public record,6525,imiquimod (IMQ)-ferulic acid (FA) co-crystal (IMQ API and FA coformer),10/17/2022,Treatment of vulvar intraepithelial neoplasia,Designated,Not FDA Approved for Orphan Indication,,,,,Celista Pharmaceuticals LLC,5305 Kelsey Terrace,,Edina,Minnesota,55436,United States,886422
FERULIC ACID,AVM951ZWST,Designated,Public record,6525,imiquimod (IMQ)-ferulic acid (FA) co-crystal (IMQ API and FA coformer),10/17/2022,Treatment of vulvar intraepithelial neoplasia,Designated,Not FDA Approved for Orphan Indication,,,,,Celista Pharmaceuticals LLC,5305 Kelsey Terrace,,Edina,Minnesota,55436,United States,886422
MEZAGITAMAB,0XMR8L9LOL,Designated,Public record,6526,Mezagitamab,10/17/2022,Treatment of myasthenia gravis,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,2421,United States,905822
RIFAMYCIN,DU69T8ZZPA,Designated,Public record,6529,Rifamycin,10/18/2022,Treatment of Pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Cosmo Technologies, Ltd.",Riverside II,Sir John Rogerson’s Quay,Dublin,Dublin,2,Ireland,853821
VPO-227,T5WV2JH7PN,Designated,Public record,6530,"(+-)-9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid",10/19/2022,Treatment of Cholera,Designated,Not FDA Approved for Orphan Indication,,,,,Vanda Pharmaceuticals Inc.,2200 Pennsylvania Avenue NW,Suite 300E,Washington,District of Columbia,20052,United States,906322
NX-210c,8U8J5ASV94,Designated,Public record,6535,H-L-tryphophanyl-L-seryl-glycyl-L-tryptophanyl-L-seryl-L-seryl-L-cysteinyl-L-seryl-L-arginyl-L-seryl-L-cysteinyl-glycyl-OH (disulfide bond),10/20/2022,Treatment of Amyotrophic Lateral Sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,AXOLTIS Pharma,15-17 Rue du Pré la Reine,,Clermont-Ferrand,,63100,France,906122
CRISDESALAZINE,11VWK61J69,Designated,Public record,6537,Crisdesalazine,10/24/2022,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"GNT Pharma Co., Ltd.",23 Yonggu-daero 1855beon-gil,"Giheng-gu,",Yongin-si,Gyeonggi-do,17096,South Korea,907322
LISURIDE MALEATE,UV1635N8XW,Designated,Public record,6538,Lisuride Maleate,10/24/2022,Treatment of Fragile X Syndrome.,Designated,Not FDA Approved for Orphan Indication,,,,,NeuroVenti Inc.,"15, Seolleung-ro 121-gil",,Seoul,Gangnam-gu,6100,South Korea,906822
JBI-802,8GSV79C4QX,Designated,Public record,6539,"N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl) amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrogen bromide.",10/24/2022,Treatment of the acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,Jubilant Therapeutics Inc.,"1430 US Highway 206, Suite 110",,Bedminster,New Jersey,7921,United States,906522
WP-1301,28GAR3B45E,Designated,Public record,6542,H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys-OH,10/27/2022,Treatment of Hemophilia A,Designated,Not FDA Approved for Orphan Indication,,,,,Worg Pharmaceuticals (Hangzhou) Co. Ltd,"Suite 801, Building#5, JiaBao Technology Innovation Center","No. 519, 2nd Avenue, Qiantang New District",Hangzhou,Zhejiang,310000,China,906922
Imvotamab,F3HG38I0T1,Designated,Public record,6544,Imvotamab,10/31/2022,Treatment of Follicular Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"IGM Biosciences, Inc.",325 East Middlefield Road,,Mountain View,California,94043,United States,907622
MAZINDOL,C56709M5NH,Designated,Public record,6545,mazindol,10/31/2022,Treatment of idiopathic hypersomnia,Designated,Not FDA Approved for Orphan Indication,,,,,NLS Pharmaceutics AG,Alter Postplatz 2,,Stans,NIDWALDO,6370,Switzerland,876822
RINTATOLIMOD,94325AJ25N,Designated,Public record,6546,Rintatolimod,10/31/2022,Treatment of Ebola Virus Disease,Designated,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,2117 SW Highway 484,,Ocala,Florida,34473,United States,907922
MSC-2360844 hemifumarate,W8JCY5F7F3,Designated,Public record,6547,"[6-Fluoro-1-(4-morpholin-4-ylmethyl-phenyl)-5,5-dioxo-4,5-dihydro-1H-5Lambda6-thiochromeno[4,3-c]pyrazol-3-yl]-morpholin-4-yl-methanone hemi-fumarate",11/1/2022,Treatment of uveal melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,iOnctura SA,"Avenue de Sécheron, 15",,Geneva,,,Switzerland,908222
BLARCAMESINE,9T210MMZ3F,Designated,Public record,6549,blarcamesine,11/3/2022,Treatment of Fragile X syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Anavex Life Sciences Corp.,"630 5th Avenue, 20th Floor",,New York,New York,10111,United States,908022
DASATINIB MONOLAURYL SULFATE,FY77PS0C4O,Designated,Public record,6550,dasatinib monolauryl sulfate,11/3/2022,Treatment of acute lymphoblastic leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Handa Oncology, LLC","2025 Gateway Place, Suite 480",,San Jose,California,95110,United States,888722
ACT-001,580BNQ45EO,Designated,Public record,6551,dimethylaminomicheliolide Fumarate,11/3/2022,Treatment of Diffuse Midline Glioma,Designated,Not FDA Approved for Orphan Indication,,,,,Accendatech AU Pty Ltd.,"Suite 2903, 201 Elizabeth Street",,Sydney,Sydney,2000,Australia,842721
AVS-100,9EYT5CWH6E,Designated,Public record,6553,"5-[2-[(3,4-dichlorobenzoyl)amino]ethyl]-N-hydroxy-3-isoxazolecarboxamide",11/8/2022,Treatment of Stage IIb to IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,Avstera Therapeutics Corp.,365 Phoenixville Pike,,Malvern,Pennsylvania,19355,United States,910122
SGN-1,6CCT5H8PTZ,Designated,Public record,6555,a genetically modified Salmonella comprising of methioninase,11/8/2022,Treatment for osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Guangzhou Sinogen Pharmaceutical Co., Ltd.","No. 11 Kai Yuan Ave., Huangpu Dist.","Building C5, Room 101",Guangzhou,Guangdong,510530,China,910022
NITRIC OXIDE,31C4KY9ESH,Designated,Public record,6558,Nitric Oxide,11/8/2022,To selectively reduce pulmonary arterial pressures in patients at elevated risk for developing hemodynamically unstable pulmonary hypertension after cardiovascular surgery,Designated,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Pharmaceuticals,90 Washington Valley Road,,Bedminster,New Jersey,7921,United States,756820
AMT-101,QX77JY19LD,Designated,Public record,6559,recombinant human interleukin-10 fusion protein,11/8/2022,Treatment of pouchitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Applied Molecular Transport, Inc.","1 Tower Place, Suite 850",,South San Francisco,California,94080,United States,784420
PEMBROLIZUMAB,DPT0O3T46P,Designated,Public record,6560,vibostolimab and pembrolizumab,11/8/2022,Treatment of Small Cell Lung Cancer (SCLC),Designated,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.",126 East Lincoln Ave,P.O.Box 2000,Rahway,New Jersey,7065,United States,893722
VIBOSTOLIMAB,5XO3JF0FEK,Designated,Public record,6560,vibostolimab and pembrolizumab,11/8/2022,Treatment of Small Cell Lung Cancer (SCLC),Designated,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.",126 East Lincoln Ave,P.O.Box 2000,Rahway,New Jersey,7065,United States,893722
OBINUTUZUMAB,O43472U9X8,Designated,Public record,6561,Zanubrutinib in combination with Obinutuzumab,11/8/2022,Treatment of Relapsed/Refractory Follicular Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene, Ltd., c/o BeiGene USA, Inc.","1840 Gateway Drive, 3rd Floor",,San Mateo,California,94404,United States,889422
ZANUBRUTINIB,AG9MHG098Z,Designated,Public record,6561,Zanubrutinib in combination with Obinutuzumab,11/8/2022,Treatment of Relapsed/Refractory Follicular Lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene, Ltd., c/o BeiGene USA, Inc.","1840 Gateway Drive, 3rd Floor",,San Mateo,California,94404,United States,889422
Iodine I-124 Evuzamitide,9DR4VH0DJP,Designated,Public record,6562,Iodine (I124) evuzamitide,11/14/2022,Diagnostic for the management of immunoglobulin light chain amyloidosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Attralus, Inc.",50 Francisco Street,Suite 450,San Francisco,California,94133,United States,888422
Ritivixibat,3U7H6NE2KE,Designated,Public record,6563,"3-([3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1Lambda6,2,5-benzothiadiazepin-8-yl]oxy)propanoic acid",11/15/2022,Treatment of Primary Sclerosing Cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,Albireo AB,Arvid Wallgrens backe 20,,Göteborg,Göteborg,,Sweden,910222
DOXORUBICIN,80168379AG,Designated,Public record,6565,Single Protein Encapsulated Doxorubicin,11/15/2022,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Sunstate Biosciences LLC,870 S. Myrtle Ave,,Monrovia,California,91016,United States,808521
SERDEXMETHYLPHENIDATE,0H8KZ470DW,Designated,Public record,6566,serdexmethylphenidate,11/17/2022,Treatment of Idiopathic hypersomnia,Designated,Not FDA Approved for Orphan Indication,,,,,KemPharm Inc.,1180 Celebration Blvd.,,Celebration,Florida,34747,United States,878522
MEBENDAZOLE,81G6I5V05I,Designated,Public record,6571,mebendazole,11/22/2022,Treatment of Autosomal Dominant Polycystic Kidney Disease,Designated,Not FDA Approved for Orphan Indication,,,,,Healx Technology Limited,"Charter House, 66-68 Hills Road",,Cambridge,,,United Kingdom,910922
TEGAVIVINT,18AP231HUP,Designated,Public record,6573,tegavivint,11/22/2022,Treatment of Osteosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Iterion Therapeutics, Inc",2450 West Holcombe Boulevard,,Houston,Texas,77021,United States,912222
SKL-27969,NVE35UH48R,Designated,Public record,6574,"[4-[(2R)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxy-propyl]-8-[(1-methyl-4-piperidyl)oxy]-2,3-dihydro-1,4-benzoxazepin-5-one]",11/22/2022,Treatment of glioblastoma multiforme,Designated,Not FDA Approved for Orphan Indication,,,,,SK Life Science Inc.,461 From Road,5th floor,Paramus,New Jersey,7652,United States,911122
RIBOCICLIB,TK8ERE8P56,Designated,Public record,6575,ribociclib,11/25/2022,Treatment of neuroblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,912722
BOTULINUM TOXIN TYPE A,E211KPY694,Designated,Public record,6577,incobotulinumtoxinA,11/28/2022,Treatment of hemifacial spasm,Designated,Not FDA Approved for Orphan Indication,,,,,"Merz Pharmaceuticals, LLC",6601 Six Forks Road,Suite 430,Raleigh,North Carolina,27615,United States,911422
BRM-421,N9MH3WI51M,Designated,Public record,6578,Pigment Epithelium Derived Factor derived short peptide (Ac-Ser-Leu-Gly-Ala-Glu-Gln-Arg-Thr-Glu-Ser-Ile-Ile-His-Arg-Ala- Leu-Tyr-Tyr-Asp-Leu-Ile-Ser-Ser-Pro-Asp-Ile-His-Gly-Thr-NH2),11/28/2022,Treatment of Neurotrophic Keratitis,Designated,Not FDA Approved for Orphan Indication,,,,,BRIM Biotechnology,"8F, No.1, Alley 30, Lane 358,","Ruiguang Rd., Neihu Dist.",Taipei,,11492,Taiwan,838321
RADGOCITABINE,00M634HD2V,Designated,Public record,6579,radgocitabine,11/28/2022,Treatment of acute myeloid leukemia (AML),Designated,Not FDA Approved for Orphan Indication,,,,,"Delta-Fly Pharma, Inc.",37-5 Nishikino Miyajima Kawauchi-cho,,Tokushima,,,Japan,912822
IFENPRODIL,R8OE3P6O5S,Designated,Public record,6582,ifenprodil,12/1/2022,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Algernon Pharmaceuticals Inc.,Suite 400 - 601 West Broadway,,Vancouver,British Columbia,,Canada,914122
1-[12-(1 Carboxycyclopropyl)dodecyl]cyclopropane-1-carboxylic acid,WJP2HBU8UU,Designated,Public record,6589,1-[12-(1 Carboxycyclopropyl) dodecyl] cyclopropane-1-carboxylic acid,12/7/2022,Treatment of Congenital X-linked Nephrogenic Diabetes Insipidus,Designated,Not FDA Approved for Orphan Indication,,,,,"NephroDI Therapeutics, Inc.","1606 Chestnut Street, Suite 3",,Philadelphia,Pennsylvania,19103,United States,915322
VAD-044 L-TARTRATE,U9YT3F9XWE,Designated,Public record,6590,"6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl) phenyl)-1-ethyl-7- phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one L-Tartrate salt",12/7/2022,Treatment of Hereditary Hemorrhagic Telangiectasia,Designated,Not FDA Approved for Orphan Indication,,,,,Vaderis Therapeutics AG,Lichtstasse 35,Building WSJ-350,Basel,Basel,,Switzerland,914222
LUVELTAMAB TAZEVIBULIN,XDE2GOF1JT,Designated,Public record,6591,luveltamab tazevibulin,12/7/2022,Treatment of pediatric acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,"Sutro Biopharma, Inc.",111 Oyster Point Blvd,,South San Francisco,California,94080,United States,915722
ILGINATINIB MALEATE,8P0KTT2T1Z,Designated,Public record,6592,"N-[(1S)-1-(4- fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6- diamine maleate",12/7/2022,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"NS Pharma, Inc.",140 East Ridgewood Avenue,Suite 280S,Paramus,New Jersey,7652,United States,916522
IMIQUIMOD,P1QW714R7M,Designated,Public record,6594,Imiquimod,12/8/2022,Treatment of Stage IIB-IV melanoma,Designated,Not FDA Approved for Orphan Indication,,,,,Celista Pharmaceuticals LLC,5305 Kelsey Terrace,,Edina,Minnesota,55436,United States,881222
POTASSIUM CITRATE,EE90ONI6FF,Designated,Public record,6595,fixed-dose combination of potassium citrate and potassium bicarbonate,12/9/2022,Treatment of primary/inherited distal renal tubular acidosis,Designated,Not FDA Approved for Orphan Indication,,,,,Advicenne,262 rue du Faubourg Saint Honoré,,Paris,Paris,75008,France,913522
POTASSIUM BICARBONATE,HM5Z15LEBN,Designated,Public record,6595,fixed-dose combination of potassium citrate and potassium bicarbonate,12/9/2022,Treatment of primary/inherited distal renal tubular acidosis,Designated,Not FDA Approved for Orphan Indication,,,,,Advicenne,262 rue du Faubourg Saint Honoré,,Paris,Paris,75008,France,913522
CANNABIDIOL,19GBJ60SN5,Designated,Public record,6596,cannabidiol,12/12/2022,Treatment of Glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,Transpire Bio Inc.,"8201 Peters Road, Suite 1000",,Plantation,Florida,33324,United States,914322
DIANHYDROGALACTITOL,4S465RYF7M,Designated,Public record,6598,"1,2:5,6-dianhydrogalactitol",12/14/2022,Treatment of Diffuse Intrinsic Pontine Glioma (DIPG),Designated,Not FDA Approved for Orphan Indication,,,,,"Kintara Therapeutics, Inc.",9920 PACIFIC HEIGHTS BLVD.,Suite 150,San Diego,California,92121,United States,903822
ANIFROLUMAB,38RL9AE51Q,Designated,Public record,6600,anifrolumab,12/14/2022,Treatment of Idiopathic Inflammatory Myopathies,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,PO Box 8355,Wilmington,Delaware,19803,United States,876522
KETAMINE HYDROCHLORIDE,O18YUO0I83,Designated,Public record,6602,ketamine hydrochloride,12/14/2022,Prevention of ischemia/reperfusion injury during solid organ transplantation.,Designated,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,,Canada,901422
RITUXIMAB,4F4X42SYQ6,Designated,Public record,6603,rituximab,1/26/2023,Treatment of membranous nephropathy,Designated,Not FDA Approved for Orphan Indication,,,,,Mabion S.A.,Langiewicza 60 Str.,,Lodzki,Konstantynow,,Poland,922222
INS-018_055 acetate,6X7X6H7YDC,Designated,Public record,6605,"5¿-(4-fluorophenyl)-3¿-isopropyl-N-(4-(4-methylpiperazin-1-yl) phenyl)-1H,3¿H-[2,4¿-biimidazole]-4-carboxamide acetate",2/1/2023,Treatment of Idiopathic Pulmonary Fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,InSilico Medicine Hong Kong Limited,"Unit310, F3, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong",,Hong Kong,Hong Kong,999077,China,922822
KETAMINE,690G0D6V8H,Designated,Public record,6606,Ketamine,2/1/2023,Treatment of Rett Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,,Canada,922622
RITUXIMAB,4F4X42SYQ6,Designated,Public record,6608,rituximab,2/7/2023,Treatment of autoimmune hemolytic anemia,Designated,Not FDA Approved for Orphan Indication,,,,,Mabion S.A.,Langiewicza 60 Str.,,Konstantynow Lodzki,,,Poland,923822
BATIRAXCEPT,B6840JH4EB,Designated,Public record,6620,batiraxcept,2/22/2023,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Aravive, Inc.","3730 Kirby Drive, Suite 1200",,Houston,Texas,77098,United States,925522
CROFELEMER,PY79D6C8RX,Designated,Public record,6623,crofelemer,2/27/2023,Treatment of microvillus inclusion disease,Designated,Not FDA Approved for Orphan Indication,,,,,Napo Pharmaceuticals Inc.,"200 Pine Street, Suite 400",,San Francisco,California,94104,United States,897722
GALLIUM MALTOLATE,17LEI49C2G,Designated,Public record,6625,Gallium maltolate,2/27/2023,Treatment of glioblastoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Imaging Biometrics, LLC",13416 Watertown Plank Road,Suite 260,Elm Grove,Wisconsin,53122,United States,924822
MEFUPARIB,9NN2OZ1YX4,Designated,Public record,6627,Mefuparib,2/28/2023,Treatment of Biliary Tract Cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Convalife (Shanghai) Co., Ltd.","Room 41, No.780 Cailun Road","Zhangjiang Hi-Tech Park, Pudong New Area",Shanghai,,201203,China,926722
GGTI-2418,M67G28K74K,Designated,Public record,6632,2-{[2-benzyl-4-(5-methyl-3H-imidazol-4-ylmethyl)-3-oxo-piperazine-1-carbonyl]- amino}-4methyl-pentanoic acid,3/7/2023,Treatment of T-cell lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Prescient Therapeutics, LTD",Level 4,100 Albert Road,South Melbourne,VIC,3205,Australia,927422
RIFAMPIN,VJT6J7R4TR,Designated,Public record,6635,Rifampin,3/7/2023,Treatment of Frontotemporal Dementia,Designated,Not FDA Approved for Orphan Indication,,,,,"Medilabo RFP, Inc.",Sanjo CHOJU building 4F,"24 Umeda-cho, Nakagyo-ku,",Kyoto,,,Japan,928022
ARGININE BUTYRATE,IK8S1P79MU,Designated,Public record,6636,Arginine butyrate,3/9/2023,Treatment of Short Bowel Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corporation,1 Baxter Parkway,,Deerfield,Illinois,60015,United States,928222
TP-1287,7MPP85IIJ3,Designated,Public record,6637,"2-(2-chlorophenyl)-5-hydroxy-8-((3S,4R)-3-hydroxy-1-methylpiperidin-4-yl)-4-oxo-4H-chromen-7-yl dihydrogen phosphate",3/14/2023,Treatment of Ewing sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,1752,United States,928322
"""ACETYLLEUCINE, L-""",E915HL7K2O,Designated,Public record,6638,N-Acetyl-Leucine,3/14/2023,Treatment of Ataxia-oculomotor apraxia-4 (AOA4),Designated,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,7670,United States,914022
Bezuclastinib,2ROQ545LAG,Designated,Public record,6641,Bezuclastinib,3/17/2023,Treatment of Mastocytosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Cogent Biosciences, Inc.",275 Wyman Street,3rd Floor,Waltham,Massachusetts,2451,United States,929722
ZYIL-1,P9ZQS28F8C,Designated,Public record,6642,"Ethenesulfonamide, 2-[(2R)-1,2-dimethyl-2- pyrrolidinyl]-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4- yl)amino]carbonyl]-, (1E)-",3/17/2023,Treatment of Cryopyrin Associated Periodic Syndromes (CAPS),Designated,Not FDA Approved for Orphan Indication,,,,,Zydus Therapeutics Inc.,73C Route 31 North,,Pennington,New Jersey,8534,United States,929522
FLUCICLOVINE F-18,38R1Q0L1ZE,Designated,Public record,6643,fluciclovine (18F),3/17/2023,Diagnostic for the management of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,Blue Earth Diagnostics Ltd,"The Oxford Science Park, Magdalen Centre",Robert Robinson Avenue,Oxford,Oxfordshire,,United Kingdom,929022
ALPELISIB,08W5N2C97Q,Designated,Public record,6648,Alpelisib,3/21/2023,Treatment of lymphatic malformations,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,,United States,930022
GANAXOLONE,98WI44OHIQ,Designated,Public record,6649,ganaxolone,3/21/2023,Treatment of Lennox-Gastaut Syndrome (LGS),Designated,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",5 Radnor Corporate Center,"100 Matsonford Road, Suite 500",Radnor,Pennsylvania,19087,United States,929822
Tirabrutinib,LXG44NDL2T,Designated,Public record,6651,tirabrutinib,3/21/2023,Treatment of primary central nervous system lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Ono Pharma USA, Inc",One Main Street,Suite 1050,Cambridge,Massachusetts,2142,United States,930322
Zagociguat,H7KEN3O8AI,Designated,Public record,6655,zagociguat,3/23/2023,Treatment of mitochondrial disease,Designated,Not FDA Approved for Orphan Indication,,,,,Cyclerion Therapeutics,245 First Street,"Riverview II, 18th Floor",Cambridge,Massachusetts,2142,United States,931423
ABSK-012,8XDP7T5XLU,Designated,Public record,6656,3-(5-cyano-4-(cyclopropylamino)pyridin-2-yl)-1-(6-formyl-5-((4-methyl-2-oxopiperazin-1-yl)methyl)pyridin-2-yl)-1-methylurea,3/27/2023,Treatment of soft tissue sarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Wuxi Abbisko Biomedical Technology Co., Ltd.","Building E, Xingye Building, 97-1",Linghu Avenue,Wuxi,Jiangsu,214000,China,932323
D3S-001,PFW9YLB86H,Designated,Public record,6658,a multiple substituted pyrimidoheterocycle small molecule inhibitor that covalently binds to the Switch II pocket of KRAS p.G12C and locks the oncogenic protein in its GDP-bound inactive form,3/27/2023,Treatment of patients with advanced pancreatic cancer harboring KRAS p.G12C mutant protein,Designated,Not FDA Approved for Orphan Indication,,,,,"D3 Bio (Wuxi) Co., Ltd.","1101, Tower 1, No.6, Lane 38, Yuanshan Road, Pudong",,Shanghai,,200120,China,932223
RUXOLITINIB,82S8X8XX8H,Designated,Public record,6660,parsaclisib and ruxolitinib,3/27/2023,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,932023
PARSACLISIB,OS7097575K,Designated,Public record,6660,parsaclisib and ruxolitinib,3/27/2023,Treatment of myelofibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,19803,United States,932023
1-O-octadecyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolamine,6B7M56U62N,Designated,Public record,6662,1-O-octadecyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolamine,3/29/2023,Treatment of Rett Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,Institute of Rheological Functions of Food,"2241-1 Kubara, Hisayama-machi, Kasuya-gun",,Fukuoka,,,Japan,933223
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,6665,lisocabtagene maraleucel,3/30/2023,Treatment of nodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N.,Suite 1200,Seattle,Washington,98109,United States,933723
VEPAFESTINIB,LF333FK2V5,Designated,Public record,6666,vepafestinib,3/30/2023,Treatment of RET alteration-positive non-small cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Helsinn Healthcare SA,Via Pian Scairolo 9,,Pazzallo (Lugano),,6912,Switzerland,857521
PADELIPORFIN,EEO29FZT86,Designated,Public record,6668,Padeliporfin,4/5/2023,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,IMPACT Biotech Ltd,"16 Einstein St., Kiryat Weizmann Science Park",P.O. Box 4052,Ness Ziona,Ness Ziona,7403620,Israel,932523
NV-354,4GF65YYK2S,Designated,Public record,6670,Methyl 4-{[2-(acetamino)ethyl]sulfanyl}-4-oxobutanoate,4/14/2023,Treatment of mitochondrial disease,Designated,Not FDA Approved for Orphan Indication,,,,,Abliva AB,Medicon Village,,Lund,,,Sweden,933323
BN-104,L25B98F8W3,Designated,Public record,6671,"(2-(6-(2-(4-cyclopropylpyrimidin-5-yl)-4-fluorophenoxy)-1,2,4-triazin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)((1S,3aR,6aS)-octahydrocyclopenta[c]pyrrol-1-yl)methanone",4/17/2023,Treatment of Acute Myeloid Leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,BioNova Pharmaceuticals (Shanghai) Limited,"2889 Jinke Road, Chamtime Plaza, Building B, 9F Suite 901",,Shanghai,,201203,China,933923
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,6672,lisocabtagene maraleucel,4/17/2023,Treatment of splenic marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N.,Suite 1200,Seattle,Washington,98109,United States,933623
LISOCABTAGENE MARALEUCEL,7K2YOJ14X0,Designated,Public record,6673,lisocabtagene maraleucel,4/17/2023,Treatment of extranodal marginal zone lymphoma,Designated,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N.,Suite 1200,Seattle,Washington,98109,United States,933823
MRTX-1719,AY4A8WD6JS,Designated,Public record,6674,"(2M)-2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1- methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3- fluorobenzonitrile",4/20/2023,Treatment of Mesothelioma,Designated,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",3545 Cray Ct.,,San Diego,California,92121,United States,934823
O-(2-FLUOROETHYL)-L-TYROSINE F-18,1326R5J1IA,Designated,Public record,6675,O-(2-[18F]fluoroethyl)-L-tyrosine,4/20/2023,Diagnostic for the management of malignant glioma,Designated,Not FDA Approved for Orphan Indication,,,,,UCSF Radiopharmaceutical Facility,185 Berry Street,Suite 350,San Francisco,California,94107,United States,934623
OXYPURINOL,G97OZE5068,Designated,Public record,6676,oxypurinol,4/20/2023,Treatment of autosomal dominant polycystic kidney disease,Designated,Not FDA Approved for Orphan Indication,,,,,XORTX Therapeutics Inc.,3710 33rd Street NW,,Calgary,AB,,Canada,934023
PEMAFIBRATE,17VGG92R23,Designated,Public record,6677,Pemafibrate,4/20/2023,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Kowa Research Institute, Inc.","430 Davis Drive, Suite 200",,Morrisville,North Carolina,27560,United States,934223
ANAGRELIDE,K9X45X0051,Designated,Public record,6678,Anagrelide,4/24/2023,Treatment of Gastrointestinal Stromal Tumors,Designated,Not FDA Approved for Orphan Indication,,,,,Sartar Therapeutics Oy,Terkko Health Hub,"Haartmaninkatu 4, Building 14",Helsinki,,,Finland,935223
EDRALBRUTINIB,SG5I5QTR4E,Designated,Public record,6680,Edralbrutinib,4/24/2023,Treatment of neuromyelitis optica spectrum disorder,Designated,Not FDA Approved for Orphan Indication,,,,,Reistone Biopharma Company Limited,"No. 298 Xiangke Road, Youyue Plus, 2nd Floor, #203, Pudong",,Shanghai,Shanghai,21210,China,935023
PEGCETACOPLAN,TO3JYR3BOU,Designated,Public record,6682,Pegcetacoplan,4/24/2023,Treatment of Amyotrophic Lateral Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.",100 5th Ave,3rd floor,Waltham,Massachusetts,2451,United States,817321
IFINATAMAB DERUXTECAN,C6I0GC0GX5,Designated,Public record,6685,Ifinatamab deruxtecan,4/26/2023,Treatment of small-cell lung cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Daiichi Sankyo, Inc.",211 Mt. Airy Road,,Basking Ridge,New Jersey,7920,United States,935123
TRYPAN BLUE,I2ZWO3LS3M,Designated,Public record,6687,Trypan Blue and Brilliant Blue G Ophthalmic Solution,4/26/2023,To selectively stain the epiretinal membrane and internal limiting membrane,Designated,Not FDA Approved for Orphan Indication,,,,,D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.,Scheijdelveweg 2,,Zuidland,ZUID-HOLLAND,,Netherlands,876222
BRILLIANT BLUE G,M1ZRX790SI,Designated,Public record,6687,Trypan Blue and Brilliant Blue G Ophthalmic Solution,4/26/2023,To selectively stain the epiretinal membrane and internal limiting membrane,Designated,Not FDA Approved for Orphan Indication,,,,,D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.,Scheijdelveweg 2,,Zuidland,ZUID-HOLLAND,,Netherlands,876222
BM-3103,VWK5QZV94D,Designated,Public record,6688,4-Hydroxy-4'-methyoxytolan,5/1/2023,Treatment of Epidermolysis Bullosa,Designated,Not FDA Approved for Orphan Indication,,,,,"BioMendics, LLC",4209 State Route 44,,Rootstown,Ohio,44272,United States,801220
SODIUM LUMINOLATE,KFG2PZR7UX,Designated,Public record,6691,luminol monosodium,5/1/2023,Treatment of Duchenne Muscular Dystrophy,Designated,Not FDA Approved for Orphan Indication,,,,,MetrioPharm AG,Europaallee 41,,Zurich,,8004,Switzerland,935523
ASP-2138,8P2N8N28WN,Designated,Public record,6694,Bispecific antibody directed against CLDN18.2 and T cell receptor complex CD3,5/3/2023,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,60062,United States,936323
FASUDIL HYDROCHLORIDE,SQ04N8S7BR,Designated,Public record,6696,Fasudil hydrochloride,5/3/2023,Treatment of amyotrophic lateral sclerosis (ALS),Designated,Not FDA Approved for Orphan Indication,,,,,"BioPharma Global, a division of Pace® Life Sciences",1934 Old Gallows Rd Suite 420,,Vienna,Virginia,22182,United States,936123
AMPRELOXETINE,19997EZ42I,Designated,Public record,6700,Ampreloxetine,5/9/2023,Treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy,Designated,Not FDA Approved for Orphan Indication,,,,,Theravance Biopharma Ireland Limited,Ten Earlsfort Terrace,,Dublin 2,,,Ireland,936523
TSN-084,9FJ3MBL7XW,Designated,Public record,6702,"N-[3-fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-(1-methylethoxy)-2-oxo-3-pyridinecarboxamide",5/16/2023,Treatment of acute myeloid leukemia,Designated,Not FDA Approved for Orphan Indication,,,,,Tyligand Bioscience (Shanghai) Limited,"No.3728 Jinke Road, Zhangjiang Hi-Tech Park","West wing, building 1",Shanghai,Shanghai,201203,China,937623
AVASIMIBE,28LQ20T5RC,Designated,Public record,6705,avasimibe,5/16/2023,Treatment of Prader-Willi syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,EFIL BioScience Inc.,"#601, Bando Ivyvalley","686 Chenggyesan-ro, Soojeong-gu",Seongnam,Gyeonggi-do,13105,South Korea,938123
OBETICHOLIC ACID,0462Z4S4OZ,Designated,Public record,6706,"Obeticholic Acid, Bezafibrate fixed dose combination",5/16/2023,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Intercept Pharmaceuticals, Inc.",305 Madison Avenue,,Morristown,New Jersey,7960,United States,937523
BEZAFIBRATE,Y9449Q51XH,Designated,Public record,6706,"Obeticholic Acid, Bezafibrate fixed dose combination",5/16/2023,Treatment of primary biliary cholangitis,Designated,Not FDA Approved for Orphan Indication,,,,,"Intercept Pharmaceuticals, Inc.",305 Madison Avenue,,Morristown,New Jersey,7960,United States,937523
AUT-00201,QZ8ETV7QYU,Designated,Public record,6707,"(5R)-5-ethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione",5/17/2023,Treatment of progressive myoclonic epilepsy-7,Designated,Not FDA Approved for Orphan Indication,,,,,Autifony Therapeutics Ltd.,Gunnels Wood Road,,Stevenage,,,United Kingdom,939923
FELZARTAMAB,3O9FA4XC02,Designated,Public record,6709,felzartamab,5/17/2023,Treatment of membranous nephropathy,Designated,Not FDA Approved for Orphan Indication,,,,,Human Immunology Biosciences,2 Tower Place,,South San Francisco,California,94080,United States,939423
IVOSIDENIB,Q2PCN8MAM6,Designated,Public record,6710,ivosidenib,5/17/2023,Treatment of Chondrosarcoma,Designated,Not FDA Approved for Orphan Indication,,,,,Servier Pharmaceuticals,200 Pier 4 Blvd,,Boston,Massachusetts,2210,United States,938423
MITAZALIMAB,Q9J81E7VFM,Designated,Public record,6711,Mitazalimab,5/17/2023,Treatment of Pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,Alligator Biosciences AB,Medicon Village,Scheelevägen 2,Lund,Lund,,Sweden,865221
Rucosopasem Manganese,FW5T90VM32,Designated,Public record,6712,Rucosopasem manganese,5/17/2023,Treatment of pancreatic cancer,Designated,Not FDA Approved for Orphan Indication,,,,,"Galera Therapeutics, Inc.","2 West Liberty Boulevard, Suite 100",,Malvern,Pennsylvania,19355,United States,939023
YT-001,256XF8BC7R,Designated,Public record,6718,N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-Thr,5/31/2023,Prevention of ischemia/reperfusion injury in kidney transplantation,Designated,Not FDA Approved for Orphan Indication,,,,,"Young Therapeutics, LLC",1715 Stanwood Street,,Philadelphia,Pennsylvania,19152,United States,617017
KTX-1001 D-tartrate,8T4LU8M9TG,Designated,Public record,6722,"(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol D-tartrate salt (1:1)",6/8/2023,Treatment of multiple myeloma,Designated,Not FDA Approved for Orphan Indication,,,,,K36 Therapeutics Inc.,1 Main Street 13Fl,,Cambridge,Massachusetts,2142,United States,941323
DENATONIUM ACETATE MONOHYDRATE,YE84H43CRF,Designated,Public record,6723,Denatonium acetate monohydrate,6/8/2023,Treatment of Prader Willi Syndrome,Designated,Not FDA Approved for Orphan Indication,,,,,"Aardvark Therapeutics, Inc.","4747 Executive Drive, Suite 1020",,San Diego,California,92121,United States,942123
HL-001,B67NB6LLA8,Designated,Public record,6725,"(R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl] amino}thiophen-2-yl)-2'-methoxy-[1,1'-biphenyl]-4-yl]cyclopropanecarboxylic acid",6/12/2023,Treatment of idiopathic pulmonary fibrosis,Designated,Not FDA Approved for Orphan Indication,,,,,"HiLung, Inc.","46-29 Yoshida-Shimo'adachicho, Sakyo-ku",,Kyoto,Kansai,0,Japan,942923
IMMUNE GLOBULIN (HUMAN),,Designated,Public record,6726,Immune Globulin (Human),6/12/2023,Treatment of Systemic Sclerosis,Designated,Not FDA Approved for Orphan Indication,,,,,"CSL Behring, L.L.C.",1020 1st Ave,,King of Prussia,Pennsylvania,19406,United States,943023
NITISINONE,K5BN214699,Designated,Public record,6727,nitisinone,6/12/2023,Treatment of alkaptonuria,Designated,Not FDA Approved for Orphan Indication,,,,,Cycle Pharmaceuticals Ltd.,"The Broers Building, 21 JJ Thomson Ave.",,Cambridge,,,United Kingdom,942723
